<SEC-DOCUMENT>0001564590-21-010823.txt : 20210304
<SEC-HEADER>0001564590-21-010823.hdr.sgml : 20210304
<ACCEPTANCE-DATETIME>20210304130133
ACCESSION NUMBER:		0001564590-21-010823
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210304
DATE AS OF CHANGE:		20210304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		21713257

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cbio-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-04T15:52:13.4126890+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : e2a5eda4d98d48aba04c2fa8e195e2fb -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cbio="http://www.catalystbiosciences.com/20201231" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
cbio-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001124105_20200101_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001124105_20200101_20201231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001124105_20200101_20201231">0001124105</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001124105_20200101_20201231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000265" name="us-gaap:LeasePracticalExpedientsPackage" contextRef="C_0001124105_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000268" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000270" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000471" name="us-gaap:TaxCreditCarryforwardExpirationDate" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2040-12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000502" name="cbio:ResearchServicesAgreementOptionToExtend" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioLicenseAndCollaborationAgreementMember_20191218_20191218">P12M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001124105_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001124105_20191231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:PreferredStockValue" contextRef="C_0001124105_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:PreferredStockValue" contextRef="C_0001124105_20191231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000394" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001124105_20180101_20181231">P8Y8M15D</ix:nonNumeric>
			<ix:nonNumeric id="F_000395" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001124105_20190101_20191231">P8Y1M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000396" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001124105_20200101_20201231">P7Y11M15D</ix:nonNumeric>
			<ix:nonNumeric id="F_000397" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001124105_20200101_20201231">P7Y1M20D</ix:nonNumeric>
			<ix:nonNumeric id="F_000404" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P5Y9M21D</ix:nonNumeric>
			<ix:nonNumeric id="F_000405" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P5Y11M23D</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="cbio-20201231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001124105_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_20210225">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-25</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:LicenseRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCostOfLicenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CostOfLicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CostOfCollaborationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_cbioSegment">
				<xbrli:measure>cbio:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cbio:LongTermInvestmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cbio:FederalAgencySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cbio:LongTermInvestmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cbio:FederalAgencySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:AGCBiologicsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioCatalentIndianaLLCMember_srtProductOrServiceAxis_cbioDalcinonacogAlfaMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:CatalentIndianaLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:DalcinonacogAlfaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:IntravitrealAntiComplementFactor3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:IntravitrealAntiComplementFactor3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_cbioBiogenCollaborationMember_20200110">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:BiogenCollaborationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:IntravitrealAntiComplementFactor3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-01-10</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:IntravitrealAntiComplementFactor3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-05-08</xbrli:startDate>
					<xbrli:endDate>2020-05-08</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-05-08</xbrli:startDate>
					<xbrli:endDate>2020-05-08</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20200716_20200717">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-16</xbrli:startDate>
					<xbrli:endDate>2020-07-17</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20200717">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-17</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20200611_20200611">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-06-11</xbrli:startDate>
					<xbrli:endDate>2020-06-11</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20200611">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-11</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613_20180613">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-06-13</xbrli:startDate>
					<xbrli:endDate>2018-06-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-06-13</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20071231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2007-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629_20200629">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-06-29</xbrli:startDate>
					<xbrli:endDate>2020-06-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioPfizerIncMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_us-gaapCollaborativeArrangementMember_20161208">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:PfizerIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-12-08</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioPfizerIncMember_us-gaapTransactionTypeAxis_us-gaapCollaborativeArrangementMember_20180201_20180228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:PfizerIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-02-01</xbrli:startDate>
					<xbrli:endDate>2018-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioPfizerIncMember_us-gaapTransactionTypeAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:PfizerIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-12-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-12-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioLicenseAndCollaborationAgreementMember_20191218_20191218">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-12-18</xbrli:startDate>
					<xbrli:endDate>2019-12-18</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioTransferOfExclusiveLicenseAndRelatedKnowHowMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:LicenseRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbio:TransferOfExclusiveLicenseAndRelatedKnowHowMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioExclusiveLicenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbio:ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200228_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-28</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200228_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-28</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-02-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20200228_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-28</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200629_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-06-29</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20200629_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-06-29</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtStatementScenarioAxis_srtScenarioForecastMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioUnderwritersOverallotmentOptionMember_srtStatementScenarioAxis_srtScenarioForecastMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:UnderwritersOverallotmentOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtStatementScenarioAxis_srtScenarioForecastMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000000" fromRefs="F_000275 F_000276 F_000285 F_000286"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000002" fromRefs="F_000287 F_000288 F_000289 F_000290"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000001" fromRefs="F_000277 F_000278 F_000279 F_000280"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000003" fromRefs="F_000416 F_000417"></ix:relationship>
		</ix:resources>
	</ix:header>
</div>

<p style="border-bottom:none 0pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">002018 $480,800&#160;&#160; </p>
<p style="border-bottom:none 0pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40.6%;margin-right:40.6%;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form&#160;<ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001124105_20200101_20201231">10-K</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40.6%;margin-right:40.6%;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000032" name="dei:DocumentAnnualReport" contextRef="C_0001124105_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001124105_20200101_20201231" format="ixt:datemonthdayyearen">December&#160;31, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001124105_20200101_20201231">2020</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000033" name="dei:DocumentTransitionReport" contextRef="C_0001124105_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> to <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission file number: <ix:nonNumeric id="F_000022" name="dei:EntityFileNumber" contextRef="C_0001124105_20200101_20201231">000-51173</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40.6%;margin-right:40.6%;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0001124105_20200101_20201231">Catalyst Biosciences, Inc.</ix:nonNumeric></p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in its Charter)</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40.6%;margin-right:40.6%;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001124105_20200101_20201231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000024" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001124105_20200101_20201231">56-2020050</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporation or Organization)</p></td>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:EntityAddressAddressLine1" contextRef="C_0001124105_20200101_20201231">611 Gateway Blvd</ix:nonNumeric>. <ix:nonNumeric id="F_000026" name="dei:EntityAddressAddressLine2" contextRef="C_0001124105_20200101_20201231">Suite 710</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:EntityAddressCityOrTown" contextRef="C_0001124105_20200101_20201231">South San Francisco</ix:nonNumeric>, <ix:nonNumeric id="F_000028" name="dei:EntityAddressStateOrProvince" contextRef="C_0001124105_20200101_20201231" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000029" name="dei:EntityAddressPostalZipCode" contextRef="C_0001124105_20200101_20201231">94080</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Chief Executive Offices)</p></td>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000030" name="dei:CityAreaCode" contextRef="C_0001124105_20200101_20201231">650</ix:nonNumeric>) <ix:nonNumeric id="F_000031" name="dei:LocalPhoneNumber" contextRef="C_0001124105_20200101_20201231">871-0761</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s Telephone Number, Including Area Code)</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:33.24%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Title of each class</span></p></td>
<td valign="top" style="width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Trading Symbol(s)</span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.38%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Name of each exchange on which registered</span></p></td>
</tr>
<tr>
<td valign="top" style="width:33.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:Security12bTitle" contextRef="C_0001124105_20200101_20201231">Common stock</ix:nonNumeric></p></td>
<td valign="top" style="width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001124105_20200101_20201231">CBIO</ix:nonNumeric></p></td>
<td valign="top" style="width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0001124105_20200101_20201231">NASDAQ</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act:&#160;None</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40.6%;margin-right:40.6%;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000009" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001124105_20200101_20201231">No</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000011" name="dei:EntityVoluntaryFilers" contextRef="C_0001124105_20200101_20201231">No</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000010" name="dei:EntityCurrentReportingStatus" contextRef="C_0001124105_20200101_20201231">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;&#8201;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000019" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001124105_20200101_20201231">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="bottom" style="width:44.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="bottom" style="width:5.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="middle" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="middle" style="width:44.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="middle" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="middle" style="width:5.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityFilerCategory" contextRef="C_0001124105_20200101_20201231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="bottom" style="width:44.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;&#160;</p></td>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="bottom" style="width:5.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000014" name="dei:EntitySmallBusiness" contextRef="C_0001124105_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:44.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:5.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:44.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="bottom" style="width:5.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001124105_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000018" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001124105_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000013" name="dei:EntityShellCompany" contextRef="C_0001124105_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 25, 2021, the number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, was <ix:nonFraction unitRef="U_xbrlishares" id="F_000016" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001124105_20210225" decimals="INF" format="ixt:numdotdecimal">31,331,027</ix:nonFraction>. The aggregate market value of the voting stock held by non-affiliates of the registrant as of June 30, 2020, was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000017" name="dei:EntityPublicFloat" contextRef="C_0001124105_20200630" decimals="0" format="ixt:numdotdecimal">128,362,589</ix:nonFraction>.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CATALYST BIOSCIENCES, INC.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Page</span><span style="text-decoration:underline;font-weight:normal;"> </span></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><span style="text-decoration:none;">PART I</span></a><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:none;">Business</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_Risk_Factors"><span style="text-decoration:none;">Risk Factors</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:none;">Unresolved Staff Comments</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES_NEED_TO_UPDATE_WITH_SU"><span style="text-decoration:none;">Properties</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><span style="text-decoration:none;">Legal Proceedings</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:none;">Mine Safety Disclosures</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr style="height:6pt;">
<td colspan="3" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><span style="text-decoration:none;">PART II</span></a><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:none;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><span style="text-decoration:none;">Selected Financial Data</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:none;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:none;">Quantitative and Qualitative Disclosures About Market Risk</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:none;">Financial Statements and Supplementary Data</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:none;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:none;">Controls and Procedures</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:none;">Other Information</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr style="height:6pt;">
<td colspan="3" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART III </p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:none;">Directors, Executive Officers and Corporate Governance</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:none;">Executive Compensation</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:none;">Security Ownership of Certain Beneficial Owners and Management</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:none;">Certain Relationships and Related Transactions and Director Independence</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:none;">Principal Accountant Fees and Services</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr style="height:6pt;">
<td colspan="3" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><span style="text-decoration:none;">PART IV</span></a><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:none;">Exhibits and Financial Statement Schedules</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 16.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><span style="text-decoration:none;">Form 10-K Summary</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#LIST_EXHIBITS"><span style="text-decoration:none;">LIST OF EXHIBITS</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:none;">SIGNATURES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I">PART I</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements and Market Data</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K and the documents incorporated by reference herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements, other than statements of historical facts, included or incorporated by reference in this Annual Report on Form 10-K regarding our strategy, future results of operations, future financial condition, future revenues, projected costs, prospects, plans, intentions and objectives of management, as well as the assumptions that underlie these statements, are forward-looking statements. These forward-looking statements should not be relied upon as predictions of future events as we cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur. Forward-looking statements are identified by words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;pro forma,&#8221; &#8220;estimates,&#8221; or &#8220;anticipates&#8221; or the negative of these words and phrases or other variations of these words and phrases or comparable terminology, although not all forward-looking statements contain these identifying words. Such forward-looking statements are based on our management&#8217;s assumptions and assessments in light of information currently available to our management, its experience and its perception of historical trends, current conditions, expected future developments and other factors our management believes to be appropriate. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other &#8220;forward-looking&#8221; information. These statements relate to our plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. For example, forward-looking statements include any statements regarding:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the strategies, prospects, plans, expectations or objectives of management for future operations&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our focus on specific product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope, duration, progress or outcomes of the development of product candidates or programs&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the timelines, progress and potential results of our current and future clinical studies and trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the competitiveness of our products candidates against other competing products&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the benefits that may be derived from product candidates or the commercial or market opportunity in any target indication&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to protect intellectual property rights&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our anticipated operations, financial position, revenues, costs or expenses, statements regarding future economic conditions or performance, statements of belief and any statement of assumptions underlying any of the foregoing&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">potential regulatory filings for or approval of any of our product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the progress of our third-party collaborations, including estimated milestones&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our intention to seek, and the ability to enter into, strategic alliances, partnerships and collaborations&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the responsibilities of our collaborators, including the responsibility to make cost reimbursement, milestone, royalty and other payments to us, and our expectations regarding our collaborators&#8217; plans with respect to our products&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the results and timing of clinical trials and the possible commencement of future clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">conditions for obtaining regulatory approval of our product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">submission and timing of applications for regulatory approval&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the impact of the United States (U.S.) Food and Drug Administration (&#8220;FDA&#8221;) and other government regulations on our business&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-family:'Times New Roman';"></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uncertainties associated with obtaining and protecting patents and other intellectual property rights, as well as avoiding the intellectual property rights of others&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">products and companies that will compete with the products we license to third-party collaborators&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the possibility we may commercialize our own products and build up our commercial, sales and marketing capabilities and other required infrastructure&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our employees, including the number of employees and the continued service of key management, technical and scientific personnel&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our future performance and obligations under agreements we have entered into, such as our collaboration agreement with Biogen&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our future performance and our expectations regarding our ability to achieve profitability&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">requirements for us to purchase supplies and raw materials from third parties, and the ability of third parties to provide us with required supplies and raw materials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">sufficiency of our cash resources, anticipated capital requirements and capital expenditures and our need for additional financing, as well as our plans for obtaining and ability to obtain such additional financing&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the composition of future revenues&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">accounting policies and estimates, including revenue recognition policies&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">statements of belief and any statement of assumptions underlying any of the foregoing.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any such forward-looking statements are not guarantees of future performance and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in or contemplated by such forward-looking statements. Factors that might cause such a difference include, but are not limited to, the risks and uncertainties described in this Annual Report on Form 10-K, including those risks described in Part I, Item 1A, &#8220;Risk Factors,&#8221; as well as others that we may consider immaterial or do not anticipate at this time. The risks and uncertainties described in this report, including in Part I, Item 1A, &#8220;Risk Factors,&#8221; are not exclusive and further information concerning our company and our businesses, including factors that potentially could materially affect our operating results or financial condition, may emerge from time to time. All forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements considering future developments. We caution investors that our business and financial performance are subject to substantial risks and uncertainties and they should carefully consider the factors set forth in other reports or documents that we file from time to time with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business, and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless the context requires otherwise, in this Annual Report on Form 10-K the terms &#8220;Catalyst,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Catalyst Biosciences, Inc., together with our subsidiary, Catalyst Bio, Inc., which we refer to as &#8220;Catalyst Bio.&#8221; See &#8220;Item 1&#8212; Business&#8212; Business Organization.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1_BUSINESS">BUSINESS. </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in disorders of the complement and coagulation systems. Proteases are the natural regulators of these biological systems. We engineer proteases to create both improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Our protease engineering platform has generated two late-stage clinical programs including marzeptacog alfa (activated) (&#8220;MarzAA&#8221;), a subcutaneously (&#8220;SQ&#8221;) administered next-generation engineered coagulation Factor VIIa (&#8220;FVIIa&#8221;) for the treatment of episodic bleeding in subjects with rare bleeding disorders. Our complement pipeline includes a preclinical program partnered with Biogen International GmbH (&#8220;Biogen&#8221;) for dry age-related macular degeneration (&#8220;AMD&#8221;), an improved complement factor I protease for SQ prophylaxis in patients with complement factor I (&#8220;CFI&#8221;) deficiency and C4b-degraders designed to target disorders of the classical complement pathway as well as other complement programs in development.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The product candidates generated by our protease engineering platform have improved functional properties such as longer half-life, improved specificity, higher potency and increased bioavailability. These characteristics potentially allow for improved efficacy, SQ administration of recombinant coagulation factors and complement inhibitors, or less frequently dosed intravitreal therapeutics.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our most advanced product candidate is MarzAA, a next-generation SQ FVIIa that is entering a registrational Phase 3 trial (MAA-304) in patients with Hemophilia A or B with inhibitors. We also plan to initiate a Phase 1/2 trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our complement portfolio is led by the development candidates CB 4332 and CB 2782-PEG. CB 4332 is a wholly-owned first-in-class improved CFI intended for lifelong prophylactic SQ administration in individuals with CFI deficiency. CB 2782-PEG is a potential best-in-class C3 degrader product candidate in preclinical development for the treatment of dry AMD that we have licensed to Biogen. We have several engineered protease programs in discovery or early non-clinical development. These programs all target diseases caused by deficient regulation of the complement system.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our next most advanced hemophilia product candidate is dalcinonacog alfa (&#8220;DalcA&#8221;), a next-generation SQ FIX, which has shown efficacy and safety in a Phase 2b clinical trial in individuals with Hemophilia B. We have a discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B, that has demonstrated superiority compared with the Padua FIX variant in preclinical models.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our current development programs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2g5bnvu5o20000001.jpg" title="" alt="" style="width:624px;height:320px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Both MarzAA and DalcA have received orphan drug designation in the U.S. and in the European Union (&#8220;E.U.&#8221;)&#59; MarzAA, for routine prophylaxis to prevent bleeding episodes in individuals with Hemophilia A and B with inhibitors, and DalcA, for routine prophylaxis to prevent bleeding episodes for Hemophilia B patients. In addition, the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) has granted Fast Track designation for MarzAA for the treatment of episodic bleeding in patients with Hemophilia A or Hemophilia B with inhibitors. We control worldwide development, manufacturing and commercialization rights of both MarzAA and DalcA, except for the commercialization rights of DalcA in South Korea. We estimate the global market opportunity for MarzAA and DalcA to be approximately $4.0 billion: $2.2 billion for the Factor VIIa market and $1.8 billion for the Factor IX (&#8220;FIX&#8221;) market.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the CB 4332, enhanced CFI program, we intend to commence enrollment of an observational trial in mid-2021 to assess CFI activity and genotype patients who have diseases related to CFI deficiency in order to identify those who would benefit from CB 4332 treatment. This will prepare us for a P1/2 clinical study of CB 4332 in 2022. CB 4332 is intended to restore the missing physiological complement regulation in patients with absent, low or aberrant CFI. There are currently no approved options for protein replacement therapy in CFI deficiency, nor are there any in clinical development. We estimate that the market for CB 4332 in patients with atypical hemolytic uremic syndrome (&#8220;aHUS&#8221;), complement 3 glomerulopathy (&#8220;C3G&#8221;) and immune complex mediated membranoproliferative glomerulonephritis (&#8220;IC-MPGN&#8221;) is approximately $500 million, with additional potential opportunities for patients who are CFI deficient with indications outside of nephrology, such as to prevent severe infections and recurrent inflammatory histopathologies. The size of the market for these potential opportunities is estimated to be approximately $12.0 billion by 2026. This patient population is likely significantly underdiagnosed and appears to be growing as more awareness about the clinical manifestation of complete CFI deficiency emerge. There are a number of dry AMD patients who have genetic abnormalities in their CFI gene that may be an important driver of their disease.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we are currently developing a portfolio of next generation specific complement degraders based on CB 4332 and designed to target disorders of the classical or alternative pathways.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently no approved drugs for treating dry AMD. Dry AMD is estimated to have a $5.0 billion market opportunity which could grow to over $18.0 billion by 2028 with no approved drugs on the market. We entered into an exclusive worldwide license and collaboration agreement with Biogen (&#8220;Biogen Agreement&#8221;) in late 2019 for the development and commercialization of CB 2782-PEG. We received a $15.0 million upfront payment from Biogen in </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 2020 and are eligible to receive up to $340.0 million in milestone payments and tiered royalties for worldwide net sales of this product candidate up to low double-digits.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are experiencing operational and other challenges as a result of the novel coronavirus disease (&#8220;COVID-19&#8221;) global pandemic, which have delayed our enrollment in MAA-304 and MAA-202, and which may delay or halt our development in our programs. See the section entitled &#8220;Risk Factors&#8221; for further discussion of the current and expected impact on our business and development programs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Hemostasis </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Background on Hemophilia. <span style="font-style:normal;">Hemophilia is a rare and serious bleeding disorder that results from a genetic or an acquired deficiency of a factor required for normal blood coagulation. There are two major types of hemophilia: Hemophilia A and Hemophilia B, caused by abnormalities in coagulation Factor VIII or Factor IX, respectively. Deficiencies in these factors reduce the ability of the affected individuals to form clots and stop bleeding. The disease is X chromosome-linked, meaning that most people who inherit the disorder and suffer from bleeding are male&#59; however, female carriers of mutations in Factor VIII or Factor IX can also have reduced coagulation factor levels and resultant bleeding. Hemophilia A occurs in approximately 1 in 5,000 male births, and Hemophilia B in approximately 1 in 20,000 male births. The estimated number of patients with hemophilia worldwide is 1.1 million, of whom 418,000 are estimated to have severe hemophilia. The prevalence of severe Hemophilia A and Hemophilia B in the United States is approximately 20,000 patients. Patients with hemophilia suffer from spontaneous and traumatic bleeding episodes that can become limb- or life-threatening. In cases of severe hemophilia, spontaneous bleeding into muscles or joints is frequent and often results in disabling irreversible joint damage. Currently there is no cure for hemophilia.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Hemophilia Management and Opportunities for a New Paradigm with SQ Therapy. <span style="color:#000000;font-style:normal;">Current hemophilia treatments involve on-demand management of acute bleeding episodes or prophylactic treatment using factor replacement or bypassing therapy. Replacement therapy involves frequent IV administration of the missing factors to prevent or stop bleeding. IV infusion is invasive, painful, time consuming and particularly challenging to administer to children. Often times, patients must seek assistance of a health professional for the IV infusion.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Another significant challenge in managing patients with hemophilia is the risk for development of inhibitors, which are neutralizing anti-drug-antibodies (&#8220;nAbs&#8221;) that reduce the efficacy of the factor replacement. This occurs in approximately 30% of Hemophilia A and 5-10% of Hemophilia B patients. Inhibitor patients must be treated with bypassing agents to achieve coagulation in the absence of effective factor levels.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, two types of IV bypassing treatments exist: recombinant activated coagulation factor VII (rFVIIa: NovoSeven RT and SEVENFACT) and activated prothrombin complex concentrates (e.g., FEIBA). rFVIIa is currently the leading bypassing agent for on-demand treatment in inhibitor complicated hemophilia. rFVIIa has proven effective in multiple rare bleeding disorders, including Hemophilia A or B with inhibitors, Severe Factor VII Deficiency, Glanzmann Thrombasthenia, and Acquired Hemophilia A. NovoSeven RT sales for 2019 were $1.2 billion. FEIBA is also administered for acute bleeding but its effect is reduced by the need for frequent dosing and the risk of anaphylaxis and renal side effects in Hemophilia B with inhibitor patients. All of these bypassing agents are administered intravenously, making them cumbersome to administer and have relatively short half-lives, often requiring multiple infusions to treat a bleed. Although FEIBA is approved for prophylaxis, it must be administered by IV infusion every other day and the rFVIIa products are generally not used for routine prophylaxis.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe SQ dosing is the future for the treatment of hemophilia and other rare benign hematology indications. Our nonclinical and clinical studies have shown that MarzAA is nine-fold more potent than NovoSeven RT and that DalcA is 22-fold more potent than BeneFIX. The enhanced potency of MarzAA and DalcA allows for SQ dosing using a small volume, which we believe will provide for more effective, durable and convenient treatments of spontaneous bleeds with MarzAA and prophylactic protection with MarzAA and DalcA, especially for children and adults with difficult IV access. In late 2018 Hemlibra&#174;, a bispecific antibody mimicking FVIIIa, was approved for SQ prophylaxis in Hemophilia A with or without inhibitors but Hemlibra cannot treat breakthrough bleeding.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">MarzAA Clinical Development</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">. </span><span style="font-weight:normal;font-style:normal;">We are initiating a registrational Phase 3 trial (MAA-304) for our most advanced product candidate, MarzAA, a potent, subcutaneously administered, next-generation Factor VIIa variant.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development program began with a Phase 1 clinical trial evaluating the pharmacokinetics and pharmacodynamics of MarzAA administered IV in patients with severe Hemophilia A and B with and without inhibitors. In this study, we demonstrated that single IV administration of doses of MarzAA ranging from 0.5 &#181;g/kg/day to 30 &#181;g/kg/day were safe and well tolerated. Moreover, there was a dose dependent increase in MarzAA antigen and activity levels with normalization of coagulation parameters at the higher dose levels.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, we successfully completed a Phase 2 open-label SQ prophylaxis trial that met all primary and secondary end points. The Phase 2 trial was designed to evaluate the efficacy of MarzAA in preventing bleeding episodes. The primary endpoint assessed the effect of MarzAA on the annualized bleed rate (&#8220;ABR&#8221;) at a subject&#8217;s final dose level, with each patient&#8217;s prior 6-month ABR serving as his own control. The secondary endpoints included safety, tolerability and lack of anti-drug-antibody or neutralizing antibody formation. Daily SQ administration for 50 days at an individual&#8217;s final dose of MarzAA significantly reduced the mean 6-month pre-study ABR from 19.8 to 1.6 during treatment (p&#60;0.01). Additionally, the Proportion of Days with Bleeding (&#8220;PDB&#8221;), was significantly reduced from a 6-month pre-treatment mean of 12.3% to 0.8% during treatment (p&#60;0.01). The median ABR and PDB were both reduced to zero during treatment, with seven of nine subjects experiencing no bleeds, either traumatic or spontaneous, at their final dose level. Subcutaneous treatment with MarzAA demonstrated an acceptable safety profile and was well tolerated. No anti-drug antibodies or inhibitors to MarzAA or thrombotic events were detected after administration of a total of 517 SQ doses. Subcutaneous administration prolonged the half-life of MarzAA to 16.6 hours so that trough levels of MarzAA before the next SQ dose are projected to be sufficient to provide bleed prevention.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We completed a Phase 1/2 PK/PD study (MAA-102) in 2020, to evaluate the pharmacokinetics and pharmacodynamics of ascending single dose levels of MarzAA and twice and thrice dosing of 60 &#181;g/kg at 3-hourly intervals in individuals with Hemophilia A or B with or without inhibitors. The purpose of the trial was to determine if the timing and peak levels achieved were sufficient to treat episodic or breakthrough bleeding with SQ dosing and determine if increasing dose levels resulted in dose proportional pharmacokinetics. This trial, together with population pharmacokinetic simulations and preclinical studies of spontaneous joint bleeding, confirm that we have optimized dosing for the registrational Phase 3 trial (MAA-304). We reported final data from the trial at the International Society on Thrombosis and Haemostasis in July 2020, which demonstrated that MarzAA reaches target levels estimated to effectively treat episodic and breakthrough bleeds. In addition to prophylaxis efficacy in patients, multiple preclinical studies suggest that MarzAA has the potential to be used for treatment of episodic bleeding and supports further clinical testing to assess effectiveness to achieve hemostasis in the treatment of bleeding events in individuals with hemophilia with inhibitors or for other conditions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Across all clinical studies we have treated a total of 46 subjects ranging from single IV to 44-97 days of daily SQ with no MarzAA anti-drug antibodies (ADAs) detected and an ISR rate of &#60;1%.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we announced that the FDA had granted Fast Track designation for MarzAA. The Fast Track program is designed to facilitate and expedite the development and review of drug candidates that have demonstrated the potential to address an unmet medical need in treating serious diseases or conditions. A drug candidate with Fast Track designation is eligible for greater access to the FDA as well as a priority review and rolling review of the marketing application. We believe the FDA Fast Track designation validates MarzAA&#8217;s potential to improve patient care. As the only SQ delivered therapy in development for on-demand treatment of bleeding events, MarzAA is uniquely positioned to become an important addition to the treatment landscape.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 3 registration trial (MAA-304) is an open-label, global, multi-center, randomized, cross-over study, designed to evaluate the safety and efficacy of MarzAA for on-demand treatment of spontaneous or traumatic bleeding episodes, in adolescents and adults with congenital Hemophilia A or B with inhibitors, compared with Standard of Care, either IV rFVIIa or IV FEIBA. The study will enroll approximately 60 subjects to treat 244 eligible bleeding episodes with each treatment. The primary endpoint is hemostatic efficacy using a standard 4-point assessment scale at the 24-hour timepoint. The study will assess the effectiveness of SQ MarzAA, using up to three doses to treat a bleeding episode, compared with the Standard of Care. We plan to submit our first report to the Data and Safety Monitoring Board (&#8220;DSMB&#8221;) in 2021 and our final DSMB report in the middle of 2022.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also plan to initiate a Phase 1/2 trial (MAA-202) of MarzAA for treatment of bleeding in Factor VII Deficiency, Glanzmann Thrombasthenia, and in individuals with Hemophilia A with inhibitors treated with Hemlibra in 2021 and to report interim PK data mid-year.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2g5bnvu5o20000002.jpg" title="" alt="" style="width:624px;height:332px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interplay of On-demand Treatment of Bleed and Prophylaxis for Hemophilia Management. <span style="font-style:normal;">Our preclinical data has shown that SQ injections of MarzAA given one minute after injury, to mirror on-demand therapy, significantly reduced bleeding in animal models of Hemophilia A. In mice, reduction of bleeding after SQ administration of MarzAA was as efficient as NovoSeven RT administered IV. Moreover, bleeding was reduced in a dose-dependent manner when MarzAA was given 15 minutes prior to the injury. Moreover, SQ MarzAA was efficacious as a stand-alone therapy for treating spontaneous bleeding in rats and dogs with congenital Hemophilia A. Rats and dogs with hemophilia A present with spontaneous unprovoked bleeding as is seen in humans with hemophilia. These findings suggest that MarzAA has the potential to be used on-demand by SQ administration for treatment of acute bleeding episodes and supports further clinical testing for on-demand treatment of bleeds in individuals with hemophilia or Factor VII deficiency or other rare bleeding disorders.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients on prophylaxis with Hemlibra or other Factor replacement therapy may experience breakthrough bleeds &#8211; bleeding despite preventive treatment &#8211; or require additional treatments for certain procedures or surgery. Our preclinical data showed that MarzAA is expected to have a similar safety profile as NovoSeven when used in combination with Hemlibra. Specifically, when tested in vitro by the thrombin-generation assay with Hemophilia A plasma, both MarzAA and NovoSeven were equally effective at triggering blood coagulation at their respective clinically relevant concentrations without overshooting safe levels when combined with Hemlibra. Current therapies used with Hemlibra include FEIBA (a pro-coagulation complex) and NovoSeven. However, the concurrent administration of FEIBA with Hemlibra is associated with increased risk of thrombotic events (when a blood clot forms inside a blood vessel), requiring a boxed warning in the package insert. While NovoSeven is safe in patients on Hemlibra prophylaxis, it is administered by an IV infusion to treat a bleeding event. Ideally, add-on therapy for patients on SQ Hemlibra should be given subcutaneously. We believe MarzAA provides a potential SQ solution to this problem as a SQ rescue therapy for hemophilia patients experiencing breakthrough bleeds while on prophylaxis with SQ agents such as Hemlibra.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Complement</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">.</span><span style="color:#000000;font-size:12pt;font-style:normal;"> </span><span style="font-weight:normal;font-style:normal;">The complement system is a complex enzyme-based defense system depicted in the figure below, developed to protect the body from pathogens, such as viruses and bacteria. Similar to the coagulation system, the complement system employs a triggering mechanism followed by a cascading system of enzymatic proteins (proteases) that, when functioning properly, ultimately leads to the destruction and removal of the pathogen.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2g5bnvu5o20000003.jpg" title="" alt="" style="width:606px;height:606px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* <span style="font-size:8pt;">Figure adapted from Mastellos </span><span style="font-style:italic;font-size:8pt;">et</span><span style="font-size:8pt;"> </span><span style="font-style:italic;font-size:8pt;">al</span><span style="font-size:8pt;">., Clinical promise of next-generation complement therapeutics. Nature Reviews. 2019</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Complement system disorders. <span style="font-style:normal;">Deficient or excessive activation of the complement system may lead to severe disorders, including micro thrombotic, autoimmune, and severe infectious diseases. Complement system disorders can be caused either by defects in the complement system that prevent an appropriate response to threats, or by the lack of complement inhibitor activity, which can cause the complement system to become hyperactive and become self-destructive. Either imbalance can have severe or even fatal consequences in affected individuals. </span></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Complement Factor I Deficiency and CB 4332. CB 4332 is an engineered version of the CFI protease with an extended half-life that was designed for SQ use in patients with CFI deficiency. Even partial CFI deficiency can lead to several diseases including the following:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="width:21.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:76.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-top:solid 0.75pt #50748A; border-bottom:solid 0.75pt #50748A; border-left:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Atypical Hemolytic<br />Uremic Syndrome<br />(&#8220;aHUS&#8221;)</p></td>
<td valign="bottom" style="width:auto; border-top:solid 0.75pt #50748A; border-bottom:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-top:solid 0.75pt #50748A; border-bottom:solid 0.75pt #50748A; border-right:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aHUS is a severe and life-threatening, ultra-rare disease characterized by chronic uncontrolled complement activation and the formation of blood clots in small blood vessels throughout the body, causing a reduction in platelet count (thrombocytopenia) and life-threatening damage to the kidney, brain, heart and other vital organs. In aHUS, clots in small vessels are common, and the disease is diagnosed based on a combination of hemolytic anemia, thrombocytopenia, and kidney impairment followed by testing for complement protein levels and/or aberrant genes. Disease manifestation can occur at any age and is often caused by a combination of environmental and genetic factors. Not all aHUS patients are CFI deficient, however, and a definitive diagnosis of CFI deficiency requires measurement of CFI antigen and/or activity eventually supplemented by genetic testing.</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-left:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">C3 Glomerulonephritis<br />(&#8220;C3G&#8221;) and<br />Immune Complex<br />Membranoproliferative<br />Glomerulonephritis<br />(&#8220;IC-MPGN&#8221;)</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-right:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C3G, or Complement 3 Glomerulonephritis and IC-MPGN represent a group of diseases that affects the kidneys caused by a dysregulated complement system. Symptoms of glomerulonephritis are related to a loss of normal kidney function, which includes vital functions such as removing wastes from the body, balancing body fluids, regulating blood pressure, and making the hormones that help make blood platelets and red blood cells. Signs can include blood and excess protein in the urine, edema, gout, infections, high blood pressure, fatigue and reduced alertness, lack of appetite, nausea and vomiting, difficulty sleeping, dry and itchy skin and muscle cramps.</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-left:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Complete CFI<br />Deficiency (&#8220;CFID&#8221;)</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-right:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CFID may present with a variety of disease manifestations, such as recurrent invasive infections with encapsulated bacteria, but patients are also at risk for developing noninfectious diseases such as chronic inflammation of the blood vessels of the brain and/or spinal cord. Clinical presentations include invasive bacterial infections, peritonitis, meningitis, cutaneous IgA vasculitis and bacteremia. The heterogenous clinical presentation likely makes the disease significantly underdiagnosed and patients may experience life threatening emergencies that may have severe long-term impact on the quality of life. No real prophylaxis exists and patients often receive lifelong antibiotic treatment, which may cause a range of additional problems.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, there are no therapeutic options approved to specifically replace the deficient CFI protein with a well-functioning CFI to treat these disorders. While not specifically targeting CFI deficiency, eculizumab and ravulizumab are indicated for use in aHUS. Neither eculizumab nor ravulizumab address the root cause of the CFI deficiency&#59; instead, they are designed to prevent the downstream effects of uncontrolled complement activity. Patients with aberrant CFI may therefore still have uncontrolled complement activation downstream of CFI. This may cause deposition of complement proteins, for example, on red blood cells, and some CFI patients may have a worse prognosis than others even when on non-replacement therapy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CB 4332 is designed to address this unmet need by providing a therapeutic option that corrects the root problem of these diseases by simple, fast and easy SQ administration. The total US and EU5 market potential in kidney disease caused by CFI deficiency such as aHUS, C3G, and IC-MPGN is estimated to be around $500M with a potential to grow as genetic and complement-specific diagnostics gain more widespread use. Similarly, diagnosis of CFI deficiency can be expected to grow in the future. The size of the market for these potential opportunities is estimated to be approximately $10.0 billion. This would represent a further upside to the market estimate as CFI deficiency may be significantly underdiagnosed at present.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Diseases of the Classical Complement Pathway<span style="font-style:normal;">. In healthy individuals, the classical complement pathway is triggered by antibody-pathogen interactions. Specifically, antibodies bind to pathogens and mark them as targets for destruction by the complement system. This lets the complement system know that an unwanted pathogen is present and needs to be destroyed and cleared.</span></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In disease, however, the antibody mediated targeting affects an individual&#8217;s own cells, and the classical complement system triggers an uncontrolled self-destructive process, which can have dire consequences. This response involves complement proteins C1, C2, and C4, and modulating these factors could potentially treat disorders of the classical complement pathway in a way that leaves the alternative as well as common pathways intact to carry out their normal physiological functions.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Examples of disorders related to the classical complement pathway for which limited treatment options are available include the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="width:14.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:84.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-top:solid 0.75pt #50748A; border-bottom:solid 0.75pt #50748A; border-left:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Warm<br />Autoimmune<br />Hemolytic<br />Anemia<br />(&#8220;wAIHA&#8221;)</p></td>
<td valign="bottom" style="width:auto; border-top:solid 0.75pt #50748A; border-bottom:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-top:solid 0.75pt #50748A; border-bottom:solid 0.75pt #50748A; border-right:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wAIHA is a hemolytic anemia where destruction of red blood cells &#8220;tagged&#8221; by antibodies may cause fatigue, shortness of breath, dizziness chest pain, decreased alertness, confusion, transient loss of consciousness and deregulation of heart rate and blood pressure. wAIHA is also associated with an increased risk of blood clots. Even after treatment, approximately 70% are at risk of developing recurrent episodes of hemolysis. The majority of people with wAIHA survive, although mortality rates of about 5% have been reported. Children may develop wAIHA, but it is more common among adults.</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-left:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cold Agglutinin<br />Disease (&#8220;CAD&#8221;)</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-right:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to wAIHA, CAD is a hemolytic anemia with similar symptoms. CAD is, however, triggered by cold temperatures. In addition to symptoms mentioned above, patients with CAD may have cold and/or discolored feet or hands. CAD can also cause potentially fatal thrombotic events. Current treatments include blood transfusions, steroids or&#160;off-label&#160;rituximab often requiring patients to have recurring transfusions which may lead to iron overload. CAD can also be seen in association with some cancers.</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-left:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Generalized<br />Myasthenia<br />Gravis (&#8220;gMG&#8221;)</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-right:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Myasthenia gravis is a neuromuscular disease caused by an antibody-mediated autoimmune response in which the complement system inappropriately attacks receptors in muscles that receive nerve impulses. gMG patients suffer profound muscle weakness throughout the body, resulting in slurred speech, impaired swallowing and choking, double vision, upper and lower extremity weakness, disabling fatigue, shortness of breath due to respiratory muscle weakness and episodes of respiratory failure. In 2017, eculizumab was approved for gMG in patients who are anti-acetylcholine receptor antibody-positive. As described elsewhere in this prospectus supplement, eculizumab does not directly modulate the classical pathway hyperreactivity that is causing the disease.</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-left:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Guillain-Barr&#233;<br />Syndrome<br />(&#8220;GBS&#8221;)</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-right:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GBS is a severe disorder where the complement system triggered by an infection also attacks innocent bystander nerve cells resulting in muscle weakness, inability to climb stairs or walk, double vision or inability to move eyes, severe cramp-like pain, lack of bladder control or bowel function as well as impaired ability to breathe. Although most people recover from GBS, the mortality rate has been reported at about 5%.</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-left:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-right:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-left:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Amyotrophic<br />Lateral<br />Sclerosis<br />(&#8220;ALS&#8221;)</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-right:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALS is a motor neuron disease that can cause symptoms similar to those of gMG. The weakness eventually affects chewing, swallowing, speaking and breathing. People with ALS are also at increased risk for acute inflammation of the lungs, caused by the inhalation of food or stomach contents due to loss of control of the muscles normally preventing this whereas pain is uncommon as is the loss of bladder control and senses.</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-left:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Multifocal Motor<br />Neuropathy<br />(&#8220;MMN&#8221;)</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-right:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MMN is a rare disease characterized by slowly progressive muscle weakness, primarily of the arms and legs due to antibody-initiated complement activation. There is often asymmetric muscle weakness in the hands and lower arms as well as cramping, involuntary contractions or twitching, wrist or foot drop and wasting of affected muscles. Men are more frequently affected than women and men tend to be diagnosed at a younger age.</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-left:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Systemic Lupus<br />Erythematosus<br />(&#8220;SLE&#8221;)</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-right:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SLE is an autoimmune disorder causing widespread inflammation and tissue damage in the affected organs. It can affect the joints, skin, brain, lungs, kidneys, and blood vessels. Accordingly, affected individuals can present with a variety of symptoms including fatigue, skin rashes, fevers, and pain or swelling in the joints. The symptoms may wax and wane and come in &#8220;flares&#8221; that can be more or less frequent. Other symptoms of SLE can include sun sensitivity, ulcers in the mouth, joint and lung disease, heart and kidney problems, seizures, psychosis, and blood cell and immunological abnormalities.</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-top:solid 0.75pt #50748A; border-bottom:solid 0.75pt #50748A; border-left:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Lupus Nephritis</span><span style="font-style:italic;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><br />(&#8220;LN&#8221;)</span></p></td>
<td valign="bottom" style="width:auto; border-top:solid 0.75pt #50748A; border-bottom:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-top:solid 0.75pt #50748A; border-bottom:solid 0.75pt #50748A; border-right:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LN is a nephritic complication of SLE induced by autoantibody-initiated complement activation in which the symptoms share many similarities with those of other kidney disorders including blood and proteins in the urine, high blood pressure, edema and high levels of creatinine in the blood. Treatment is generally unspecific and may involve immunosuppressants, dialysis, or kidney transplantation.</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-left:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Schizophrenia</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #50748A; border-right:solid 0.75pt #50748A;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#50748A;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schizophrenia is a complex disorder. Growing evidence points to imbalances in the classical pathway, such as C4 hyperreactivity, that may be involved in aberrant pruning of nerve cell interactions.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, these disorders have large patient populations. For example, it is estimated that across the US/EU5 markets there are: 32,000 patients with ALS&#59; 76,000 with wAIHA&#59; 129,000 with gMG&#59; 13,000 with GBS&#59; 22,000 with CAD&#59; 4,000 with MMN, and 372,000 and 129,000 with SLE and LN, respectively. Taken together as a whole the classical pathway disorders either have no approved therapies or severe unmet needs exists that if addressed by successful drug candidates could significantly improve patient outcomes and become great commercial successes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Catalyst protease programs in complement. <span style="font-style:normal;">We believe that engineered proteases have a unique potential to address disorders driven by dysregulated biological processes and are differentiated by circumventing certain limitations of small molecule and antibody-based therapeutics. Two examples of biological processes/systems that can be targeted by engineered proteases are the coagulation and complement systems. In both systems one protease molecule can modulate tens, hundreds, thousands, or even more target molecules, either activating or inactivating them. This is because a protease therapeutic is not consumed in the process of cleaving or degrading its target. Therefore, smaller amounts of protease-based drug molecules can have a profound impact on biological regulatory pathways. In comparison, small molecule drugs normally only inhibit a single target molecule per drug molecule and antibodies inhibit two at best. Proteases do not have this inherent limitation. Moreover, proteases lend themselves well to half-life extension allowing infrequent and convenient administration.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have several protease programs in preclinical discovery or early non-clinical development. Common to the programs is that they target diseases caused by deficient regulation of the complement system. One ocular program for dry AMD is partnered with Biogen&#59; the remaining complement programs are focused on systemic complement disorders and are wholly owned by Catalyst. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">CB 2782-PEG for dry AMD (Biogen collaboration). <span style="font-style:normal;">CB 2782-PEG is an engineered pegylated C3 degrader that we designed with a best-in-class anti-C3 profile for dry AMD. Dry AMD is an ocular disease leading to vision loss and blindness for which there is currently no approved therapies. Complement hyperreactivity plays an important role in dry AMD. Using the protease CB 2782-PEG to degrade C3 allows for the neutralization of C3 activity. It is expected that maintaining low C3 in the eye can significantly slow disease progression in dry AMD in patients who would otherwise lose their vision over time. The global market potential in dry AMD has been estimated to be $8.6 billion which could grow to over $18.0 billion by 2028. In December 2019, we entered into a License and Collaboration Agreement with Biogen for the development and commercialization of CB2782-PEG.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">C4b degraders for classical pathway disorders. <span style="font-style:normal;">A key regulation of the classical pathway occurs at the level of C2/C4. Specifically, CFI together with co-factors, cleave and inactivate C4b to appropriately limit the downstream response. However, in diseases of the classical complement pathway, this regulatory step can be overwhelmed by too much upstream activity leading to uncontrolled downstream complement activation, even in people with normal CFI, ultimately resulting in destruction of the patient&#8217;s own cells. We are engineering specific and potent C4b degraders to counteract this imbalance to alleviate disease in disorders of classical pathway hyperactivity by engineering an existing regulatory mechanism to become more effective and thereby applicable in individuals with normal CFI levels. By taking this approach we leverage existing biological functions and aim to specifically address fundamental deficiencies in the way current and future antibody and small molecule-based therapeutics work. Our engineered C4b degrader program aims to leverage the same SQ delivery and high-yield production process used for CB 4332. Notably, although we have not chosen a disorder for our first clinical trial with a C4b degrader, the concept is designed to work across disorders of the classical pathway irrespective of the patients CFI genotype.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Future programs currently in discovery. <span style="font-style:normal;">We have additional early stage complement targeted discovery programs that have not yet been disclosed. The programs target different proteins from C3b and C4b.</span></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Complement intellectual property</span><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">. </span><span style="font-style:normal;">The United States Patent and Trademark Offices issued a patent covering Catalyst&#8217;s portfolio of engineered proteases that selectively cleave and degrade complement Factor 3 (C3), including the lead candidate CB 2782-PEG, a potential best-in-class treatment for dry AMD currently in development and under a license and collaboration agreement with Biogen. These modified proteases inhibit complement activation and have the potential to treat multiple diseases in which complement activation plays a role. The newly issued patent provides protection until at least 2038. Our portfolio encompasses additional issued IP and pending applications in the complement space across a range of targets and protease scaffolds.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DalcA Clinical Development. <span style="font-weight:normal;font-style:normal;">DalcA is a next-generation SQ Factor IX product candidate for the prophylactic treatment of individuals with Hemophilia B, which completed a Phase 2b study in 2020.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We completed a Phase 1/2 SQ dosing trial that evaluated the safety and efficacy of DalcA in patients with severe Hemophilia B in a collaboration with ISU Abxis. The study objective was to demonstrate the feasibility of increasing Factor IX activity levels from approximately 1% (severe hemophilia) to greater than 12% (mild hemophilia corresponding to a reduced risk of spontaneous joint bleeds) with daily SQ injections. DalcA maintained protective Factor IX activity levels of 12-30%. Mild to moderate injection site reactions were reported and all resolved spontaneously without sequelae. Two subjects, who were cousins with the same rare Factor IX mutation, developed nAbs, one transiently. The nAbs were specific to DalcA (did not bind to wild-type Factor IX) and therefore did not interfere with the patients&#8217; ability to resume use of their prior Factor IX therapy. Thus, the nAbs to DalcA are not referred to as inhibitors. We completed a comprehensive investigation of the root cause of the nAbs in 2018 and concluded that the immunogenic potential of DalcA was low and similar to that of commercial Factor IX products. Furthermore, the drug product quality of DalcA was shown to be comparable to commercial Factor IX products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, we completed an open-label Phase 2b study to evaluate the ability of DalcA to maintain steady state protective Factor IX levels above 12% in six individuals with severe hemophilia B. Each subject received a single intravenous dose, followed by daily SQ doses of DalcA for 28 days during which FIX activity levels, clotting parameters, half-life, safety, tolerability and anti-drug antibody formation were monitored.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the World Federation of Hemophilia Virtual Summit in June 2020, we reported that 28 days of daily SQ dosing of DalcA at 100 IU/kg achieved protective target FIX levels of &#62;12% in all participants, with FIX levels of up to 27% and a half-life of 2.5 to 5.1 days. No bleeds were reported during the 28 days of dosing and the 5 day wash-out, demonstrating effective prophylaxis and the potential for lower or less frequent dosing. Injection volumes were less than 1 mL. One subject withdrew on day 7 after reporting injection site reactions (&#8220;ISR&#8221;) from the first 3 SQ doses. No neutralizing anti-drug antibodies were detected, and no serious adverse events were reported. A single non-neutralizing anti-drug antibody to DalcA was observed at the end of study time point and had no clinical effect. Some subjects reported mild ISR of pain and/or redness, primarily with the initial injections. No thrombotic events occurred, and blood coagulation markers did not show any prothrombotic signals. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Factor IX Gene Therapy. <span style="font-weight:normal;font-style:normal;">Our Factor IX gene therapy construct CB 2679d-GT has demonstrated a 2-fold to 3-fold higher activity resulting in improved clotting time and blood loss in a preclinical Hemophilia B mouse model compared with the Padua variant of Factor IX. Fidanacogene elaparvovec (Pfizer/Spark), AMT-061 (uniQure),TAK-748 (Takeda) and FLT180A (Freeline) use the Padua FIX variant as the transgene in their AAV-based gene therapy clinical programs. Fidanacogene elaparvovec, AMT-061 and FLT180A have demonstrated encouraging Factor IX levels in their respective Phase 1/2 and Phase 2/3 studies with median Factor IX activity levels in the upper end of the mild to normal ranges. By its increased activity, CB 2679d-GT has the potential to reach higher Factor IX activity levels at lower vector doses which could improve tolerability of the vector as well as efficacy of the transgene, and ultimately lower manufacturing costs.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have licensed AAV technology from The Board of Trustees of The Leland Stanford Junior University (&#8220;Stanford&#8221;) and are currently optimizing the vector under a sponsored research agreement with Stanford. Data presented at European Association for Haemophilia and Allied disorders (&#8220;EAHAD&#8221;) in February 2020 show that the combination of our proprietary potency enhanced CB 2679d-GT Factor IX construct with a novel chimeric AAV capsid may reduce the vector dose required in gene therapy while maintaining high Factor IX levels. We reported at the World Federation of Hemophilia Virtual Summit in June 2020 that studies of CB 2679d-GT in Hemophilia B mice have demonstrated a 4-fold reduction in blood loss and an 8-fold reduction in bleeding time when compared </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with the same dose of the Padua variant of FIX. We also reported that in a non-human primate study evaluating expression and tolerability, CB 2679d-GT in the novel chimeric capsid KP1 was well tolerated with high FIX expression that stabilized to approximately 25% to 50% FIX above baseline levels at the 6-week interim data cutoff. The novel chimeric capsid had differentiated and superior response to anti-capsid neutralizing antibodies compared to that observed for the LK03 comparator during the screening of non-human primates for the study.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are building a protease medicines company. Our portfolio of engineered protease therapies is designed for individuals with disorders of the complement and coagulation systems who need new or better treatment options. Our overall strategy builds on our belief that proteases can uniquely be engineered to improve their properties as potential drugs, for example by circumventing limitations of small molecule and antibody-based therapies. We are focused on building a portfolio of closely linked, yet highly differentiated drug candidates that leverages the unique attributes of proteases. Key focus areas for us in the near and longer term include:&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Complement Therapeutics:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Invest in multiple differentiated systemic complement regulation programs with our proprietary protease engineering platform.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Initiate clinical trial(s) with CB 4332 including an observational trial and a Phase 1/2 trial.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Advance C4b-degraders and other novel complement programs into clinical development.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hemostasis Therapeutics:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Initiate and complete a registrational Phase 3 trial for the treatment of acute bleeds.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Expand clinical development of MarzAA in additional indications.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Complete formulation studies of DalcA.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leverage the protease engineering platform to develop novel differentiated therapeutics:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Focus on rare systemic disorders amenable to engagement by proteases and where clear unmet needs exist.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Engineer drug candidates that have applications across multiple indications. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Utilize existing processes across candidates and programs to achieve platform benefits.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Strategically develop candidates with a fast to clinic approach.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Develop therapeutics with infrequent, convenient SQ administration.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Collaborations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">MarzAA. <span style="font-style:normal;color:#000000;">In 2009, we licensed MarzAA to Wyeth Pharmaceuticals, Inc. (&#8220;Wyeth&#8221;). Wyeth was subsequently acquired by Pfizer, Inc. (&#8220;Pfizer&#8221;) who terminated the license and collaboration agreement after completing a Phase 1 IV trial. Pursuant to the collaboration termination agreement, in exchange for the rights to certain Pfizer technology, we agreed to make payments to Pfizer in an aggregate amount equal to up to $17.5 million, payable upon the achievement of clinical, regulatory and commercial milestones. Following commercialization of any covered product, Pfizer would also receive a single-digit royalty on net product sales on a country-by-country basis for a predefined royalty term. In February 2018, we paid Pfizer a $1.0 million milestone payment based on the dosing of the first patient in a Phase 2 study.</span></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">DalcA</span><span style="color:#000000;">. </span><span style="font-style:normal;">We collaborated with ISU Abxis (&#8220;ISU&#8221;), in the early development of DalcA. Under the collaboration agreement, ISU conducted the Phase I clinical trial of DalcA and was responsible for all manufacturing activities for the Phase 1 clinical trial. Pursuant to the agreement, as amended in December 2018, ISU is entitled to a low single-digit royalty payment, on a country-by-country basis, for net product sales of DalcA by the Company or its affiliates in each country other than South Korea. ISU is also entitled up to $19.5 million in milestone payments, of which $2.5 million are regulatory and development milestone payments and up to $17.0 million in commercial milestone payments.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">CB2782-PEG. <span style="font-style:normal;">In 2019, we agreed to collaborate with Biogen to develop and commercialize CB 2782-PEG and our other anti-C3 proteases for potential treatment of dry AMD and other disorders. We will perform preclinical and manufacturing activities, and Biogen will be solely responsible for funding the preclinical and manufacturing activities and performing investigational new drug (&#8220;IND&#8221;)-enabling activities, worldwide clinical development, and commercialization. We received a $15.0 million upfront payment from Biogen in January 2020 and are eligible to receive up to $340.0 million in milestone payments, along with tiered royalties for worldwide net sales of this product candidate up to low double-digits.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also collaborated with Mosaic Biosciences (&#8220;Mosaic&#8221;) in the development of our Complement product candidates including CB 2782-PEG. Under the collaboration agreement, as amended in December 2019, Mosaic will perform all future services for an FTE-based fee. Pursuant to a subsequent amendment in May 2020, Mosaic received a one-time cash payment of $0.8 million and is eligible to receive up to $4.0 million in potential future milestone payments for regulatory and clinical development milestones resulting from the development of CB 2782-PEG and an additional anti-complement product candidate payable in cash or common stock at the Company&#8217;s election. As a result, we now own one hundred percent of all future payment streams related to these product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Competition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates will face competition from approved therapeutics. Competition for our product candidate pipeline comes primarily from large, well-established pharmaceutical companies, who have greater financial resources and expertise in research and development, manufacturing, conducting clinical trials, and marketing approved products. Mergers and acquisitions within the pharmaceutical and biotechnology industries may further concentrate competitors&#8217; resources. We are not only competing with these companies in terms of technology, but also in recruiting and retaining qualified scientists and management personnel, in establishing partnerships with clinical trial sites, and in enrolling individuals into clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to current Standard of Care for individuals, clinical trials are being pursued by several parties in the field of biologics and in our lead indications. These products in development may provide efficacy, safety, convenience, and other benefits that are not provided by currently marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we obtain marketing approval. Based on publicly available information, the following are some of the products currently on market or being developed by competitors in indications overlapping with those of our programs.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">Factor VIIa Competition:</span> </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Approved products</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Novo Nordisk&#8217;s NovoSeven RT is an intravenous recombinant Factor VIIa indicated for treatment of bleeding episodes in individuals with Hemophilia A or B with an inhibitor to Factor VIII or Factor IX. NovoSeven was approved in 1999 and was approved as a room temperature formulation &#8220;NovoSeven RT&#8221; in 2008. The treatment has since been approved for on demand use in individuals with Factor VII deficiency and Glanzmann thrombasthenia, but not for prophylaxis. It is also approved for treatment of bleeding episodes and peri-operative management in adults with Acquired Hemophilia.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Takeda&#8217;s FEIBA is a plasma-based composition of coagulation factors indicated for intravenous on-demand and prophylactic use in the treatment of individuals with Hemophilia A or B with inhibitors. FEIBA has been on the market for more than 30 years.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Roche&#8217;s Hemlibra (emicizumab-kxwh), a bispecific Factor IXa-Factor X monoclonal antibody is indicated for routine SQ prophylaxis in adults and children with Hemophilia A with a Factor VIII inhibitor. Emicizumab received approval from the FDA in 2017. Emicizumab cannot treat episodic bleeding.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">HEMA Biologics&#8217; SEVENFACT is an intravenous recombinant Factor VIIa indicated for treatment of bleeding episodes in individuals with Hemophilia A or B with or without an inhibitor to Factor VIII or Factor IX approved in 2020.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In addition to currently approved products, several other companies including Novo Nordisk, Pfizer, Genzyme and others are developing SQ agents for the treatment of Hemophilia A or B with or without inhibitors or Hemophilia B with inhibitors using a variety of technologies.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">Factor IX Competition: </span> BeneFIX, a recombinant Factor IX indicated for treatment of individuals with Hemophilia B, was approved in 1997 and is marketed by Pfizer. In addition, Alprolix, a Factor IX-Fc fusion product was approved in 2014 and is marketed by Sanofi Aventis and Swedish Orphan Biovitrum (&#8220;SOBI&#8221;) in Europe, Russia, North Africa and the Middle East. Idelvion, a Factor IX-albumin fusion product marketed by CSL Behring was approved by the FDA in 2016. Idelvion is approved for weekly dosing for adolescents and adults and bi-weekly at a higher dose for those same patients if well controlled on the original regimen. It is approved for weekly in patients &#60;12 years of age. Novo Nordisk&#8217;s glycopegylated-Factor IX product Rebinyn&#174; was approved by the FDA in 2017 but is not indicated for routine prophylaxis in the U.S. Rebinyn is approved for on-demand treatment and control of bleeding episodes as well as Perioperative management of bleeding.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">Factor IX Gene Therapy Competition: </span>While there are no currently approved Factor IX gene therapy treatments for Hemophilia B, several companies, are developing Factor IX gene therapy treatments in clinical studies.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Dry AMD Competition:</span><span style="color:#000000;"> While there are no currently approved treatments for dry AMD, several companies are developing cyclic peptide, aptamer, antibody or gene therapy based anti-complement product candidates for the treatment of dry AMD that are currently in clinical studies:</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Apellis is conducting two Phase 3 studies to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients aged 60 years and older with GA secondary to AMD, which is scheduled to be completed in 2021.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Iveric Bio (formerly Ophthotech) is developing two therapies to treat GA secondary to dry AMD. Iveric Bio completed its Phase 2b clinical of Zimura&#174; (avacincaptad pegol) with positive data in patients with dry AMD.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Gemini Therapeutics is developing &#8220;GEM103&#8221; a recombinant human complement factor H (&#8220;FH&#8221;) for patients with genetically well-defined dry AMD and &#8220;GEM104,&#8221; a recombinant human complement factor I as well as additional molecules in preclinical development for other genetically defined subpopulations of patients with dry AMD.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Gyroscope Therapeutics is developing &#8220;GT005&#8221; a gene therapeutic approach to expressing additional CFI in the patient&#8217;s eye after subretinal delivery. GT005 is being developed for a genetically well-defined subpopulation of patients with dry AMD. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">Systemic Complement Factor I Deficiency Competition: There are currently no approved agents</span> specifically targeting systemic factor I deficiency patients irrespective of the resultant disease phenotype being aHUS, C3G, IC-MPGN, invasive infections or any other. There are no approved therapies for C3G and IC-MPGN. There are, however, less specific treatment options on the market or in clinical development which may be applicable to some disease manifestations of systemic CFI deficiency, for instance aHUS and C3G. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:Courier New;"></span><span style="color:#000000;"></span><span style="color:#000000;">Alexion Pharmaceuticals (to be acquired by AstraZeneca) markets eculizumab and ravulizumab for use in aHUS irrespective of the patients&#8217; CFI status.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Apellis is conducting clinical development for APL-2 (pegcetacoplan), a pegylated peptide based C3 inhibitor, in IgA Nephropathy (&#8220;IgAN&#8221;), LN, Membranous Nephropathy (&#8220;MN&#8221;), C3G, and Dense Deposit Disease irrespective of the patients&#8217; CFI status.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ChemoCentryx is developing CCX168 (avacopan), a twice daily oral small molecule inhibitor of the complement 5a receptor (&#8220;C5aR&#8221;) in C3G &#8211; currently in phase 2.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Novartis is conducting clinical development for iptacopan (&#8220;LNP023&#8221;), a small peptide complement factor B inhibitor. Iptacopan is in development for PNH, as well as C3G and several other rare renal diseases including IgAN, aHUS, and membranous nephropathy. Novartis expect first FDA filings in 2023. Iptacopan has received Rare Pediatric Disease Designation in C3G.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Omeros is developing OMS721 (&#8220;narsoplimab&#8221;). Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (&#8220;MASP-2&#8221;), the effector enzyme of the lectin pathway of the complement system. Clinical activities have been initiated in IgAN, LN, MN, &#38; C3G and a phase 3 clinical program is underway in aHUS.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity in different indications could be reduced or eliminated if our competitors develop and market products that are safer, more effective, more convenient to use, or less expensive to use than our products. Furthermore, if competitors gain FDA approval faster than we do, we may be unable to establish a strong market presence or to gain market share. The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition, and the availability of reimbursement from government and other third-party payors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have established a broad intellectual property portfolio including patents and patent applications covering the identification, selection, optimization, and manufacture of human proteases, the composition of matter and methods of use of our product candidates and related technology, and other inventions that are important to our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to protect the proprietary technologies that we believe are important to our business by seeking, maintaining and defending patent rights, whether developed internally or in conjunction with or in-licensed from third parties. We also rely on trade secrets relating to our proprietary technology platform and know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the field of human protease engineering.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As more fully described below, as of December 31, 2020, our patent portfolio included approximately 72 patents&#894; including 3 issued U.S. patents and 69 foreign granted and accepted patents, and 7 U.S. patent applications, plus an additional 5 pending foreign patent applications. We also rely on trade secrets and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success will depend significantly on our ability to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Defend and enforce our patents&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Maintain our licenses to use intellectual property owned by third parties&#894; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, a third-party may hold intellectual property, including patent rights that are important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be third party patents or patent applications with claims to compositions of matter, materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. There is a patent family pending in the U.S. and Europe in which claims that may read on MarzAA have been filed. We, however, do not believe such claims are patentable. If they were to issue, we would take appropriate action to challenge their enforceability and/or validity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware of a patent family that includes issued patents in the United States, Australia, Israel, Malaysia, New Zealand, and Japan, and pending applications in Europe and Canada.&#160;&#160;The patents and pending applications may include claims that may read on a contemplated Factor Xa (&#8220;FXa&#8221;) clinical candidate. There is prior art that we believe discloses subject matter on which a challenge to the patentability of such claims can be based. In the event that development of the FXa candidate is pursued we would, if necessary, consider appropriate action to challenge such claims.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific, and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented, or invalidated by third parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18 months, and since publication of discoveries in the scientific or patent literature often lags actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the United States Patent and Trademark Office, or USPTO, or a foreign patent office to determine priority of invention or in post-grant challenge proceedings, such as oppositions, that challenge priority of invention or other features of patentability. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All our patents and applications were internally developed and assigned to us, except for two granted South Korean patents that are co-owned. Members of the 4902 family, directed to screening methods (4 patents, including 2 of the issued U.S. patents) are jointly owned with the Torrey Pines Institute for Molecular Studies, which licensed its interest to us. Our current patents and patent applications include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">72 patents, including 3 issued U.S. patents, and 9 patent applications, including 4 pending U.S. patent applications, covering modified Factor VII polypeptides, including our lead product candidate, MarzAA, and methods of production of modified Factor VII polypeptides. The U.S. patents, with patent term adjustment, expire in 2029 and 2031. The foreign patents expire in 2029.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">30 patents, including 4 issued U.S. patents, and 9 patent applications, including 1 U.S. patent application, covering modified Factor IX polypeptides, such as our clinical candidate DalcA, nucleic acid molecules encoding modified Factor IX polypeptides, or therapeutic uses. The U.S. patents and patent applications, including patent term adjustment, expire, or are expected to expire, respectively, in 2030-2031 and 2038, and the foreign patents and patent applications, if granted, expire, or are expected to expire, respectively, in 2031. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">1 PCT patent application filed and 1 U.S. patent application in progress, covering adeno-associated viral vectors that have increased tropism for hepatocytes and encode modified factor IX polypeptides. The applications, if granted, are expected to expire in 2040.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">63 patents, including 6 issued U.S. patents, and 33 patent applications, including 3 U.S. patent applications, covering novel proteases, nucleic acid molecules encoding novel proteases, or therapeutic uses. The U.S. patents and patent applications, including patent term adjustment, expire, or are expected to expire, respectively in 2025-2029 and 2038-2039, and the foreign patents and foreign patent applications, if granted, expire, or are expected to expire, respectively, in 2025-2027 and 2038-2039.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term for individual patents depends upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of a non-provisional patent application in that country or the international filing date. In the United States, a patent&#8217;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration date of a U.S. patent as partial compensation for the length of time the drug is under regulatory review while the patent is in force. The regulatory review period that occurs after the patent to be extended was issued is eligible to be counted for extension. The extension is calculated as one-half of the time of the testing phase added to time in the approval phase. The testing phase is the period between the effective date of an investigational product exemption (Investigational New Drug Application) and the initial submission of the marketing application (New Drug Application or Biologic License Application). The approval phase is the period between the submission and approval of the marketing application. Extensions can be reduced by any time that the applicant did act not with due diligence as determined by the FDA. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent applicable to each regulatory review period may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar provisions are available in the European Union and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, to the extent our product candidates including MarzAA, DalcA, Anti-C3 and systemic complement proteases receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those products, depending upon the length of the clinical trials for each drug and other factors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Manufacturing">Manufacturing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our team has in-depth knowledge on biologics development, manufacturing and CMC regulatory requirements. We do not have any manufacturing facilities and we currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for clinical or commercial uses. We own or have rights to all intellectual property developed in such manufacturing development activities that are specifically related to our product candidates and have a royalty-free and perpetual license to use the intellectual property to the extent reasonably necessary to make our product candidates, including commercial manufacturing. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Drug Substance manufacturing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a long-term development and manufacturing services agreement with AGC Biologics, Inc. (&#8220;AGC&#8221;). AGC has global manufacturing sites and we use their facilities in the U.S. and Europe for drug substance manufacturing of MarzAA, DalcA, and CB 2782-PEG. We have successfully manufactured MarzAA to support our global Phase 3 (MAA-304) clinical trial to evaluate the safety and efficacy of MarzAA for on-demand treatment and control of bleeding episodes in subjects with Hemophilia A or Hemophilia B with inhibitors. As of December 2020, we have successfully completed two large-scale GMP batches of MarzAA that will be sufficient to support the Phase 3 clinical trial (MAA-304) through its completion. Additionally, we have entered into a firm purchase commitment, </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with AGC, to validate the MarzAA manufacturing process including production of three Process Performance Qualification batches.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, we completed a successful CMC Scientific Advice meeting with the Paul Ehrlich Institute in the EU which endorsed our current CMC strategy and manufacturing activities required for registration filing for the MarzAA program.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Drug Product manufacturing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a long-term clinical supply services agreement with Catalent Indiana, LLC (&#8220;Catalent&#8221;). Catalent has facilities in the U.S. and Europe and conducts drug product development and manufacturing for MarzAA and DalcA. We successfully completed development work for a variety of vial sizes which supports flexible dosing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also work with Symbiosis Pharmaceutical Services Limited on drug product manufacturing for MarzAA on a fee-for-services basis. Symbiosis has a facility in the United Kingdom.&#160;&#160;In 2020, two drug product manufacturing batches were successfully completed at Symbiosis to support MarzAA pivotal trials.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The two MarzAA drug product batches manufactured at Symbiosis in 2020, were also successfully packaged and labeled at Catalent to support MarzAA clinical trials.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercialization</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have yet to establish a sales, marketing, or product distribution infrastructure for our product candidates, which are still in clinical development. We expect to retain commercial rights for our product candidates in the United States except for our anti-C3 dry AMD program, for which we entered into a license and collaboration agreement with Biogen to develop and commercialize CB 2782-PEG and other products or compounds that target complement Factor 3 globally. We have also granted ISU rights to commercialize DalcA in South Korea. We believe that it may be possible to access the United States hemophilia market through a focused, specialized sales force. We have not yet developed a commercial hemophilia strategy outside of the United States. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a clinical-stage biopharmaceutical company that operates in the United States, we are subject to extensive regulation. Our engineered human protease products will be regulated as biological products. Biological products, including engineered human proteases, are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FD&#38;C Act, and the Public Health Service Act, or PHS Act, and other federal, state, local, and foreign statutes and regulations. The FD&#38;C Act and the PHS Act and their implementing regulations govern, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biological products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA approval must be obtained before clinical testing of a biological product begins and before the marketing of biological products. The process of obtaining regulatory approvals and the subsequent compliance with federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development, the approval process, or after product approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning or untitled letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">US Biological Products Development Process</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">submission to the FDA of an investigational new drug application or IND, which must become effective before human clinical trials may begin&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations, commonly referred to as good clinical practices, or GCPs, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">submission to the FDA of a biologics license application or BLA for marketing approval that includes substantial evidence of safety, purity and potency from results of nonclinical testing and clinical trials&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with good manufacturing practices or GMP, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, the FDA&#8217;s current good tissue practices, or GTPs, for the use of human cellular and tissue products&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA&#894; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">FDA review and approval, or licensure, of the BLA.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before testing any biological product candidate, including an engineered human protease, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements, including GLPs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical trial sponsor must submit the results of the preclinical tests, together with the manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after an IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the clinical study on a clinical hold within that 30-day period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research patients provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Clinical trials also may be reviewed by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Phase 1:</span><span style="font-family:Times New Roman;"> The product candidate is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Phase 2:</span><span style="font-family:Times New Roman;"> The product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Phase 3:</span><span style="font-family:Times New Roman;"> Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product candidate and provide an adequate basis for product labeling.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3 trial with other confirmatory evidence may be sufficient in instances where the study is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible such as in rare or orphan diseases like hemophilia. In the case of hemophilia, almost all clinical trials are conducted as open-label single arm trials, in which both the researchers and participants know which treatment is being administered and there is no placebo or blinded portion of the trial because there are too few subjects available in these orphan populations to perform statistically powered placebo or active comparator trials. Endpoints for on-demand therapies are the number of treatments required to control bleeding episodes and for prophylaxis therapies are the calculated annualized bleeding rates. Bleeding rates during the trial are compared to historic bleeding rates for participating individuals. Patients are often studied for at least 50 treatment days to see if neutralizing anti-drug antibodies (inhibitors) develop.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the 21st Century Cures Act, which was enacted on December 13, 2016, the manufacturer of an investigational drug for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access to such investigational drug. This requirement applies on the later of 60 calendar days after the date of enactment of the law or the initiation of a Phase 2 or Phase 3 trial of the investigational drug.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrently with clinical trials, companies usually complete additional animal studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with GMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">US Review and Approval Processes</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual product fee for biological products and an annual establishment fee on facilities used to manufacture prescription biological products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. No user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. MarzAA has been granted orphan drug designation for routine prophylaxis to prevent bleeding episodes in individuals with Hemophilia A and B with inhibitors and DalcA has received orphan designation for routine prophylaxis to prevent bleeding episodes for Hemophilia B patients.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe and potent, or effective, for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with GMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to assure the safe use of the biological product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving a BLA, the FDA will generally inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To assure GMP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than how we interpret the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that describes all the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all the deficiencies identified in the letter, or withdraw the application.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a REMS, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biological product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has agreed to certain review goals under PDUFA and aims to complete its review of 90% of standard BLAs within ten months from filing and 90% of priority BLAs within six months from filing. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs and its review goals are subject to change from time to time. The review process and the PDUFA goal date may be extended by three months if the FDA requests, or the BLA sponsor otherwise provides, additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fast Track Designation, Accelerated Approval, Priority Review, Orphan Drug Designation, and Breakthrough Therapy Programs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fast Track</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are several FDA programs intended to help facilitate the development of new drugs and biologics that meet certain criteria. Specifically, new drugs and biological products are eligible for Fast Track designation if they are intended to treat a serious or life- threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biological product may request the FDA to designate the drug or biological product as a Fast Track product at any time during the clinical development of the product. Under a Fast Track designation, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Priority Review</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review to facilitate the review. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accelerated Approval</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product that is being studied for safety and effectiveness in treating serious or life-threatening illnesses and provides meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that it may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Orphan Drug Designation</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. If a product that has orphan drug designation subsequently receives FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, for seven years. These circumstances are an inability to supply the drug in sufficient quantities or a situation in which a new formulation of the drug has shown superior safety or efficacy or a major contribution to patient care. This exclusivity, however, could also block the approval of our product for seven years if a competitor obtains earlier approval of the same drug for the same indication.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MarzAA has been granted orphan drug designation in the U.S. for routine prophylaxis to prevent bleeding episodes in individuals with Hemophilia A and B with inhibitors and for routine prophylaxis to prevent bleeding episodes in individuals with Hemophilia B with inhibitors in the E.U. DalcA has been granted orphan drug designation in the U.S. and the E.U. for routine prophylaxis to prevent bleeding episodes for Hemophilia B patients. We may seek orphan drug designation for MarzAA and DalcA for a different indication, or other product candidates, but the FDA may disagree with our analysis of the prevalence of the particular disease or condition or other criteria for designation and refuse to grant orphan status. We cannot guarantee that we will obtain orphan drug designation or approval for any product candidate, or that we will be able to secure orphan drug exclusivity if we do obtain approval.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Break Through Designation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product may also be eligible for receipt of a Breakthrough Therapy designation. The Breakthrough Therapy designation is intended to expedite the FDA&#8217;s review of a potential new drug for serious or life-threatening diseases where &#8220;preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.&#8221; The designation of a drug as a Breakthrough Therapy provides the same benefits as are available under the Fast Track program, as well as intensive FDA guidance on the product&#8217;s development program. Fast Track designation, priority review, accelerated approval and Breakthrough Therapy designation do not change the standards for approval, but they may expedite the development or approval process.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Post-approval Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maintaining substantial compliance with applicable federal, state and local statutes and regulations requires the expenditure of substantial time and financial resources. Rigorous and extensive FDA regulation of biological products continues after approval, particularly with respect to GMP. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the GMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements applicable to biological products include reporting of GMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all the manufacturer&#8217;s tests performed on the lot. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biological products.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also must comply with the FDA&#8217;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in-patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biological product manufacturers and other entities involved in the manufacturing and distribution of approved biological products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMPs and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain GMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Marketing Exclusivity and U.S. Patent Term Restoration</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Biologics Price Competition and Innovation Act, or BPCIA, amended the PHS Act to authorize the FDA to approve similar versions of innovative biologics, commonly known as biosimilars. A competitor seeking approval of a biosimilar must file an application to establish its molecule as highly similar to an approved innovator biologic, among other requirements. The BPCIA, however, bars the FDA from accepting biosimilar applications for four years after an innovator biological product receives initial marketing approval and from approving biosimilar applications for 12 years after an innovator biological product receives initial marketing approval. As innovative biological products, we believe that our products would receive this data protection if the FDA approves them for marketing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of regulatory market exclusivity that may apply to biological products approved in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods, include the 4- and 12-year periods discussed. This six-month exclusivity, which runs from the end of other exclusivity protection, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents, if granted, may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years, as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Disclosure of clinical trial information</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sponsors of clinical trials of FDA-regulated products, including biological products, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;" id="Commercialization">Other U.S. Healthcare Laws and Compliance Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, sales, marketing and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the privacy provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws, each as amended.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Our practices may not in all cases meet all the criteria for protection under a statutory exception or regulatory safe harbor.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the intent standard under the Anti-Kickback Statute was amended by the Affordable Care Act (&#8220;ACA&#8221; to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIPAA created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for healthcare benefits, items or services.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All our activities are potentially subject to federal and state consumer protection and unfair competition laws.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Coverage, Pricing and Reimbursement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products. In the United States, third-party </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payors include federal and state healthcare programs, private</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ly</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list,&#160;&#160;also known as a formulary, which might not include all the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product.&#160;&#160;This is also true of Medicare reimbursement, where different vendors process payments, so that coverage by one vendor does not assure that all other vendors will provide coverage. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.&#160;&#160;In addition, the United States federal government position on matters related to drug pricing is evolving and uncertain, and any changes could have a material impact on drug pricing generally in the United States, including for our product candidates if approved</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The National Institute for Health and Care Excellence (NICE) in the United Kingdom also requires consideration of cost-benefit analysis. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third- party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The Foreign Corrupt Practices Act</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Additional Regulation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and that continued compliance therewith will not have a material adverse effect on its business. We cannot predict, however, how changes in these laws may affect its future operations.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Government Regulation Outside of the United States</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we must submit a marketing authorization application. The application used to file the BLA in the United States is similar to that required in the EU, with the exception of, among other things, country-specific document requirements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Employees</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consider our ability to recruit, retain and motivate our employees to be critical to our success. We are an equal opportunity employer and we are fundamentally committed to creating and maintaining a work environment in which employees are treated with respect and dignity. All&#160;&#160;human resources policies, practices and actions related to hiring, promotion, compensation, benefits and termination are administered in accordance with the principal of equal employment opportunity, meaning that they are made on the basis of individual skills, knowledge, abilities, job performance and other legitimate criteria and without regard to race, color, religion, sex, sexual orientation, gender expression or identity, ethnicity, national origin, ancestry, age, mental or physical disability, genetic information, any veteran status, any military status or application for military service, or membership in any other category protected under applicable law.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 56 full-time employees. Of the full-time employees, 36 employees are engaged in manufacturing and clinical development activities and 20 employees are engaged in finance, business development, facilities and general management. Of our employees, 52% are male and 48% are female.&#160;&#160;We have no collective bargaining agreements with our employees, and we have not experienced any work stoppages. We consider our relations with our employees to be good.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We aim to provide our employees with competitive salary and benefits that enable them to achieve a good quality of life and plan for the future. Our benefits are based on local norms and market preferences, but include all salary and </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">social benefits required by local law (including </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">paid time off for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vacation and sick leave) and many additional benefits that go beyond legal requirements.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To maintain and enhance the safety of our employees, we promote a culture of continuous improvement and individual accountability to provide safe workplaces. The safety of our employees has been a priority throughout our response to the COVID-19 pandemic. Our management team guided our operations in the processes and procedures to comply with applicable government-imposed health and safety-related operating restrictions, and to enhance the safety of our facilities to protect the health of our employees. The management team continues to operate, updating guidance as the pandemic has continued and the medical science and government guidance and orders have evolved. We continue to enforce COVID-19 health and safety protocols and have implemented protocols to address actual and suspected cases of COVID-19 and resulting contact tracing and quarantine requirements. Throughout the pandemic, we have been communicating regularly with our employees and monitoring their views on issues related to COVID-19 and the workplace as well as general levels of engagement. In addition, management has regularly updated our Board of Directors on our COVID-19 status and response, including with respect to employee safety.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Business Organization</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced operations in 2002 and are a Delaware corporation. On August 20, 2015, we merged with Targacept, Inc. Our corporate headquarters are in South San Francisco, California. We conduct our research and development activities and general and administrative functions primarily from our South San Francisco, California location. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports, are available for free at www.catalystbiosciences.com as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. They are also available for free on the SEC&#8217;s website at www.sec.gov. The information in or accessible through the SEC and our website are not incorporated into, and are not considered part of, this filing.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.46%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1A_Risk_Factors">RISK FACTORS<span style="font-style:italic;"> </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following section includes the most significant factors that may adversely affect our business and operations. You should carefully consider the risks and uncertainties described below and all information contained in this Annual Report on Form 10-K before deciding to invest in our common stock. If any of the following risks actually occur, our business, financial condition, results of operations and growth prospects may be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could lose all or part of your investment. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Summary of Risk Factors </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our securities involves a high degree of risk. Below please find a summary of the principal risks we face. These risks are discussed more fully below. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We are experiencing operational and other challenges as a result of the COVID-19 global pandemic, which have delayed our enrollment in MAA-304 and MAA-202 and which may delay or halt our development in these or other programs. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">CB 4332, one of our complement product candidates, is in the early stages of development and its commercial viability remains subject to preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable to advance or develop our complement product candidates, our business may be materially harmed. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">All of our product candidates will require additional clinical testing before they can be sold.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our regulatory approvals could be delayed or prevented. Competitive products or products that reduce the frequency of bleeding among patients treated with our drugs have reduced the likelihood that patients will enroll in our clinical trials. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">The operations of our third-party manufacturers may be requisitioned by government orders such as under emergency, disaster and civil defense declarations in connection with the COVID-19 pandemic. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">COVID-19 may impact our third-party supply of the raw materials needed for our product candidates, which increases the risk that we will not have sufficient quantities of such product candidates or quantities at an acceptable cost, which could delay, prevent or impair our development efforts. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We have incurred significant losses since our inception and are expected to continue to incur significant losses for the foreseeable future. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We will need additional capital. If we are unable to raise sufficient capital, we will be forced to delay, reduce or eliminate product development programs. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Raising additional funds by issuing securities or through licensing arrangements may cause dilution to stockholders, restrict our operations or require us to relinquish proprietary rights. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We are focused on the clinical development of MarzAA and our complement product candidates. Any adverse events, trial failures or material delays in these programs could materially harm our business. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">DalcA has caused and MarzAA or our complement product candidates may cause the generation of neutralizing antibodies, which could prevent their further development. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">MarzAA and DalcA are in late-stage clinical trials, and all of our other product candidates are still in preclinical development. If we are unable to obtain regulatory clearance and commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Results from our trials may not be confirmed, and if serious adverse side effects are identified during development of product candidates, we may need to abandon or limit development of some product candidates. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Fast Track designation by the FDA may not actually lead to a faster development or regulatory review or approval process. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Our collaboration with Biogen may not result in successful product development or payments to us. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We expect to seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We contract with third parties for the manufacture of our product candidates. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We and our contract manufacturers will be subject to significant regulation with respect to manufacturing our products. The manufacturing facilities on which we will rely may not continue to meet regulatory requirements and have limited capacity. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Our employees, principal investigators and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and insider trading. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">If we are unable to obtain, protect or enforce intellectual property rights related to our product candidates, we may not be able to compete effectively in our markets. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Third-party claims of intellectual property infringement or challenging the inventorship or ownership of our patents may prevent or delay our development and commercialization efforts. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our products, and our ability to generate revenue will be materially impaired. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Our results of operations may be adversely affected by current and potential future healthcare legislative and regulatory actions. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">If we fail to protect personal information or comply with existing or future data protection regulations, our business, financial condition, results of operations and prospects may be materially adversely affected. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Even if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance necessary for commercial success. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Our product candidates are years away from regulatory approval. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">If we are unable to establish sales, marketing and distribution capabilities, we may not be successful in commercializing our product candidates if they are approved. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We face substantial competition that may result in others discovering, developing or commercializing products before or more successfully than we do. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">If the market opportunities for our product candidates are smaller than expected, our revenues may be adversely affected and our business may suffer. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock. </span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to our financial condition and capital requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The outbreak of the novel coronavirus disease, COVID-19, could adversely impact our business, including our preclinical studies and clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global coronavirus pandemic has resulted in widespread requirements for individuals to work from their homes, strained medical facilities worldwide and is causing disruptions to certain pharmaceutical manufacturing and product supply chains. We are experiencing operational and other challenges as a result of the COVID-19 global pandemic, which have delayed our enrollment in MAA-304 and MAA-202, and which may delay or halt our development in these or other programs. In particular, as a result of the COVID-19 pandemic, we may experience disruptions that could severely impact our business, preclinical studies, drug manufacturing and clinical trials including: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>additional delays or difficulties in enrolling potential trial participants in our clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays in manufacturing of our product candidates as third-party manufacturing capacity is shifted towards the production of COVID-19 vaccines&#59;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>interruption or delays in the operations of the FDA, European Medicines Agency (the &#8220;EMA&#8221;) or other regulatory authorities, which may impact review and approval timelines&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>interruptions in preclinical studies due to restricted or limited operations at laboratory facilities&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">suspension or termination of our clinical trials for various reasons, such as a finding that the participants are being exposed to infectious diseases like COVID-19 or the participants involved in our clinical trials have become infected with COVID-19&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">material delays and complications with respect to our research and development programs.</span> </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. Furthermore, a recession or market correction resulting from the spread of COVID-19 could materially affect our operations and the value of our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CB 4332, one of our complement product candidates, is in the early stages of development and its commercial viability remains subject to current and future preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable to successfully advance or develop our complement product candidates, our business may be materially harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to successfully advance the development of our complement product candidates, including CB 4332, may have a material adverse effect on us. To date, we have not successfully commercially marketed, distributed or sold any product candidate. The success of our business depends primarily upon our ability to successfully advance the development of our product candidates through preclinical studies and clinical trials, have the product candidates approved for sale by the FDA or regulatory authorities in other countries, and ultimately have the product candidates successfully commercialized by us or a strategic partner. We cannot assure you that the results of our ongoing preclinical studies or future clinical trials will support or justify the continued development of CB 4332, or that we will receive approval from the FDA, or similar regulatory authorities in other countries, to advance the development of CB 4332.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">All of our product candidates will require additional clinical testing before they can be sold.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates, including MarzAA, CB 4332 and DalcA, must satisfy rigorous regulatory standards of safety and efficacy before we can advance or complete their clinical development or they can be approved for sale. To satisfy these standards, we must engage in expensive and lengthy preclinical studies and clinical trials, develop acceptable manufacturing processes, and obtain regulatory approval of our complement product candidates. Despite these efforts, our complement product candidates, including MarzAA, CB 4332 and DalcA, may not:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>offer therapeutic or other medical benefits over existing drugs or other product candidates in development to treat the same patient population&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>be proven to be safe and effective in current and future preclinical studies or clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>have the desired effects&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>be free from undesirable or unexpected effects&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>meet applicable regulatory standards&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>be capable of being formulated and manufactured in commercially suitable quantities and at an acceptable cost&#59; or</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>be successfully commercialized by us or by collaborators.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we demonstrate favorable results in preclinical studies and early-stage clinical trials, we cannot assure you that the results of late-stage clinical trials will be favorable enough to support the continued development of our product candidates. A number of companies in the pharmaceutical and biopharmaceutical industries have experienced significant delays, setbacks and failures in all stages of development, including late-stage clinical trials, even after achieving promising results in preclinical testing or early-stage clinical trials. Accordingly, results from completed preclinical studies and early-stage clinical trials of our complement product candidates, including MarzAA, CB 4332 and DalcA, may not be predictive of the results we may obtain in later-stage trials. Furthermore, even if the data collected from preclinical studies and clinical trials involving our complement product candidates, demonstrate a favorable safety and efficacy profile, such results may not be sufficient to support the submission of a new drug application or biologics license application (&#8220;BLA&#8221;) to obtain regulatory approval from the FDA in the United States or other similar regulatory agencies in other jurisdictions, which is required to market and sell the products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MarzAA, CB 4332 and DalcA will require significant additional research and development efforts, the commitment of substantial financial resources, and regulatory approvals prior to advancing into clinical development or being commercialized by us or collaborators. We cannot assure you that CB 4332 will successfully progress into clinical development or that CB 4332, MarzAA or DalcA will progress through the drug development process or will result in a commercially viable product. We do not expect CB 4332 or any of our other complement product candidates to be commercialized by us or collaborators for at least several years.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our regulatory approvals could be delayed or prevented.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our collaborators may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate, enroll and maintain enrollment of a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. In particular, there is a relatively small number of individuals with hemophilia, which may cause delays in enrollment of clinical trials of MarzAA in individuals with hemophilia A and B with an inhibitor, and there are a limited number of individuals with CFI deficiency for whom CB 4332 can be used in clinical trials. Competitive products or products that reduce the frequency of bleeding among patients treated with our drugs have reduced the likelihood that patients will enroll in our clinical trials. Some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates and thus compete with us to enroll patients in their clinical trials. The availability of other approved products and other products in clinical trials may limit the number of patients willing to participate in our clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient enrollment is affected by other factors including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the severity of the disease under investigation&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the eligibility criteria for the study in question&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the perceived risks and benefits of the product candidate under study&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the efforts to facilitate timely enrollment in clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>laboratory testing and turnaround time for samples needed for eligibility assessments&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the patient referral practices of physicians&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the ability to monitor patients adequately during and after treatment&#59; and</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the proximity and availability of clinical trial sites for prospective patients.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our inability to enroll a sufficient number of patients for our clinical trials will result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in clinical trials conducted by us may also result in increased development costs for our product candidates, which would cause the value of the Company to decline and limit our ability to obtain additional financing.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The operations of our third-party manufacturers may be requisitioned, diverted or allocated by U.S. or foreign government orders such as under emergency, disaster and civil defense declarations in connection with the COVID-19 pandemic or otherwise.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our third-party manufacturers of MarzAA have advised us that they could be required under orders of the U.S. government to allocate manufacturing capacity to the manufacture or distribution of COVID-19 vaccines. If any of our third-party manufacturers become subject to acts or orders of U.S. or foreign government entities to allocate manufacturing capacity to the manufacture or distribution of COVID-19 vaccines or medical supplies needed to treat COVID-19 patients, this could delay or interrupt, perhaps substantially, our supply of clinical trial material for MarzAA which could materially and adversely affect our business. Refer to the risk factor entitled &#8220;The outbreak of the novel coronavirus disease, COVID-19, could adversely impact our business, including our preclinical studies and clinical trials.&#8221;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The coronavirus disease, COVID-19, may impact our third-party supply of the raw materials and components needed for our product candidates, which increases the risk that we will not have sufficient quantities of such product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If supplies of the raw materials for our product candidates are significantly delayed, or if the third parties that we engage to supply any materials or to manufacture any products for our preclinical tests and clinical trials should cease to continue to do so for any reason, including due to the effects of the COVID-19 pandemic and the actions undertaken by governments and private enterprises to contain COVID-19, we likely would experience delays in advancing these tests and trials while we identify and qualify replacement suppliers or manufacturers and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our product candidates or the substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and anticipated dependence upon third-party suppliers may adversely affect our ability to develop product candidates and could delay our clinical trials and development programs, and otherwise harm our operations and financial condition and increase our costs and expenses.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant losses since our inception and are expected to continue to incur significant losses for the foreseeable future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biotechnology company, and we have not yet generated significant revenues. We have incurred net losses in each year since our inception in August 2002, including net losses of $56.2 million and $55.2 million for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated deficit of $314.8 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are still in the early stages of development of our product candidates, and have no products approved for commercial sale. To date, we have financed our operations primarily through issuances of shares of common stock, from private placements of convertible preferred stock, and from payments under collaboration agreements.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have devoted most of our financial resources to research and development, including our preclinical and clinical development activities. We expect to continue to incur significant expenses and operating losses over the next several years as we continue clinical development of MarzAA, our complement product candidates and DalcA. Our operating losses may fluctuate significantly from quarter to quarter and year to year. We are expected to continue to incur significant expenses and increasing operating losses for at least the next several years, and our expenses will increase substantially if and as we:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>continue clinical development of MarzAA and DalcA&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>continue preclinical development and begin clinical development of CB 4332 and our other complement product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>further develop the manufacturing process for our product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>attract and retain skilled personnel&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical studies&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>acquire or in-license other product candidates and technologies&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>make milestone or other payments under collaboration agreements, or any in-license agreements we may enter&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>maintain, protect and expand our intellectual property portfolio&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>create additional infrastructure to support operations as a public company and our product development and planned future commercialization efforts&#894; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>experience any delays or other issues with any of the above.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the license granted to us by Pfizer, we agreed to make contingent cash payments to Pfizer in an aggregate amount equal to up to $17.5 million, payable upon the achievement of clinical, regulatory and commercial milestones, the timing of which is uncertain. Following commercialization of any Factor VIIa products, Pfizer would also receive a single-digit royalty on net product sales on a country-by-country basis for a predefined royalty term. See the section entitled &#8220;Collaborations&#8221; in this prospectus supplement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the license agreement with ISU, the Company will also make up to an aggregate of $19.5 million in milestone payments to ISU, inclusive of $2.5 million in regulatory and development milestone payment and up to $17.0 million in commercial milestone payment, if the applicable milestones are met. See the section entitled &#8220;Collaborations&#8221; in this prospectus supplement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, in connection with the development and manufacturing agreement that we have with AGC, we have firm work orders with AGC to manufacture MarzAA and DalcA to support our clinical trials totaling $11.2 million and the payment obligations remaining for the year ended December 31, 2020 was $2.3 million. Furthermore, in connection with the clinical supply services agreement we have with Catalent, we have firm work orders with Catalent to manufacture DalcA to support clinical trials totaling $0.5 million and all outstanding amounts were paid the year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which regulatory approval is obtained. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, we may never generate revenues that are significant enough to achieve profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Failure to become and remain profitable would depress the value of our common stock and </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could impair our ability to raise capital, expand our business, maintain research and development efforts, diversify product offerings or even continue operations. A decline in the value of our common stock could also cause you to lose all or part of your investment.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We will need additional capital. If we are unable to raise sufficient capital, we will be forced to delay, reduce or eliminate product development programs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We expect our research and development expenses to increase with our ongoing activities, particularly activities related to the continued clinical development of MarzAA, the preclinical and clinical development of our complement product candidates, and the clinical development of DalcA. We believe that our available cash, cash equivalents and investments will be sufficient to fund our operations for at least the next 12 months. However, we may need to raise substantial additional capital to complete the development and commercialization of MarzAA, DalcA, or other product candidates, and depending on the availability of capital, may need to delay or cease development of some of our product candidates. Even if we raise additional capital, we may elect to focus our efforts on one or more development programs and delay or cease other development programs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until we can generate sufficient revenue from our product candidates, if ever, we expect to finance future cash needs through public or private equity offerings, debt financings, corporate collaborations and/or licensing arrangements. Additional funds may not be available when we need them on terms that are acceptable, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or development programs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds required to complete research and development and commercialize our products under development. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the initiation, progress, timing, costs and results of clinical trials for our product candidates in hemophilia, including MarzAA and DalcA&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs and results of preclinical studies or clinical trials of CB 4332 or our other complement product candidates, and expenses related to potential clinical development of such candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the number and characteristics of product candidates that we pursue&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the terms and timing of any future collaboration, licensing or other arrangements that we may establish&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the outcome, timing and cost of regulatory approvals&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the cost of obtaining, maintaining, defending and enforcing intellectual property rights, including patent rights&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the effect of competing technological and market developments&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the cost and timing of completing outsourced manufacturing activities&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>market acceptance of any product candidates for which we may receive regulatory approval&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the extent to which we acquire, license or invest in businesses, products or technologies.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Raising additional funds by issuing securities or through licensing arrangements may cause dilution to stockholders, restrict our operations or require us to relinquish proprietary rights.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of common stockholders.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We may also seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time. There can be no assurance that we will be able to obtain additional funding if, and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, curtail or eliminate one or more, or all, of our development programs or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have effective registration statements on Form S-3 that allows us to offer up to $170.0 million of securities in one or more offerings. Any additional sales in the public market of our common stock or other securities under these shelf registration statements could adversely affect prevailing market prices for our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We have no history of commercialization of pharmaceutical products, which may make it difficult to evaluate the Company&#8217;s prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We began operations in August 2002. Our operations to date have been limited to financing and staffing the Company, developing our technology and product candidates, establishing collaborations and conducting Phase 2 clinical trials on small numbers of patients. We have not yet demonstrated an ability to successfully conduct a Phase 3 clinical trial, obtain marketing approvals, manufacture a product at commercial scale repeatedly, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about the Company&#8217;s future product development timelines, clinical trial plans, expenses, success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to the discovery, development and commercialization of our product candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We are focused on the clinical development of MarzAA and our complement product candidates. Any adverse events, trial failures or material delays in these programs could materially harm our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The failure of MarzAA to achieve successful clinical trial endpoints, delays in clinical development, unanticipated adverse side effects, the cessation of clinical development or any other adverse developments or information related to MarzAA, CB 4332 or our other product candidates would significantly harm our business, its prospects and the value of the Company&#8217;s common stock. There is no guarantee that the results of further clinical trials of MarzAA will be positive or will not generate unanticipated safety concerns. If neutralizing antibodies or other adverse events in patients receiving either MarzAA lead to concerns about patient safety, the long-term efficacy, or commercial viability of MarzAA could be halted. Depending on the availability of additional capital, we may also delay or terminate clinical development of MarzAA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MarzAA is not expected to be commercially available in the near term, if at all. Further, its commercial success will depend upon its acceptance by physicians, patients, third-party payors and other key decision-makers as a therapeutic and cost-effective alternative to currently available products. If we are unable to successfully develop, obtain regulatory approval for and commercialize MarzAA, our ability to generate revenue from product sales will be significantly delayed and our business will be materially and adversely affected, and we may not be able to earn sufficient revenues to continue as a going concern.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the FDA or other regulatory agency approves MarzAA or our other product candidates, the approval may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product and may impose ongoing commitments or requirements for post-approval studies, including additional research and development and clinical trials. The FDA and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. Regulatory approval from authorities in foreign countries will be needed to market MarzAA or our other product candidates in those countries. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions. If we fail to obtain approvals from foreign jurisdictions, the geographic market for MarzAA or our other product candidates would be limited.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">DalcA has caused and MarzAA or our complement product candidates may cause the generation of neutralizing antibodies, which could prevent their further development.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MarzAA, CB 4332 and DalcA are protein molecules which may cause the generation of antibodies in individuals who receive them. Two patients who received DalcA subcutaneously following intravenous dosing developed neutralizing antibodies that inhibit the activity of DalcA. There can be no assurance that such antibodies will not be observed in the future, either in the patients who have already received DalcA or MarzAA, or in new patients with those products or CB 4332 or our other complement product candidates. If clinical trials demonstrate a treatment-related neutralizing immunological response in individuals that causes safety concerns or would limit the efficacy of either product candidate, development of the product candidate could be halted.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">MarzAA and DalcA are in late-stage clinical trials, and all of our other product candidates are still in preclinical development. The regulatory path for MarzAA and DalcA is uncertain. If we are unable to obtain regulatory clearance and commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MarzAA and DalcA have completed Phase 2 clinical trials. All our other product candidates are still in preclinical development. Engineered protease biopharmaceuticals are a relatively new class of therapeutics. There can be no assurance as to the length of the trial period, the number of individuals the FDA or EMA will require to be enrolled in the trials to establish the safety, efficacy, purity and potency of the engineered protease products, or that the data generated in these trials will be acceptable to the FDA, EMA or other foreign regulatory agencies to support marketing approval. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on several factors, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>successful completion of preclinical studies and clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>receipt of marketing approvals from applicable regulatory authorities&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>making arrangements with third-party manufacturers for, or establishing, commercial manufacturing capabilities&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>launching commercial sales of the products, if and when approved, whether alone or in collaboration with others&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>acceptance of the products, if and when approved, by patients, the medical community and third-party payors&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>effectively competing with other therapies&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>obtaining and maintaining healthcare coverage and adequate reimbursement&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>protecting our rights in our intellectual property portfolio&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>maintaining a continued acceptable safety profile of the products following approval.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome. Results from our successful Phase 1 or Phase 2 trials may not be confirmed in later trials, and if serious adverse or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive, time consuming and uncertain as to outcome. We cannot guarantee that any preclinical studies and clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of our product candidates is susceptible to the risk of failure at any stage of drug development, including failure to demonstrate efficacy in a clinical trial or across a suitable population of patients, the occurrence of severe or medically or commercially unacceptable adverse events, failure to comply with protocols or applicable regulatory requirements and determination by the FDA or any comparable foreign regulatory authority that a drug product is not approvable. It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials we may fail to detect toxicity of or intolerability caused by our product candidates, or mistakenly believe that our product candidates are toxic or not well tolerated when that is not in fact the case.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials. Our Phase 2 trial of MarzAA was conducted in eleven patients, and DalcA has been dosed repeatedly in a subcutaneous prophylaxis trial in only six patients. Trials of these product candidates in larger numbers of patients may not have similar efficacy results and could result in adverse effects that were not observed in the earlier trials with smaller numbers of patients.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we may face similar setbacks. The design of a clinical trial can determine whether our results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Any Phase 2, Phase 3 or other clinical trials that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may need to abandon development or limit development of the product candidate to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Any such limitations could adversely affect the value of our product candidates or common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fast Track designation by the FDA may not actually lead to a faster development or regulatory review or approval process.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA grants Fast Track designation to therapies that are considered capable of addressing unmet medical needs and possess the potential to treat serious or life-threatening disease conditions in order to facilitate its development and expedite the review procedure. The FDA has broad discretion in granting Fast Track designation, so even if we believe that a particular product candidate is eligible for such designation, the FDA could decide not to grant it. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even though Marzeptacog alfa (activated)&#8212;or MarzAA has received Fast Track designation in certain indications, we may not experience a faster development process, review or approval, or receive FDA approval at all, in any of those indications compared to conventional FDA procedures. A Fast Track designation does not change the standards for approval. The FDA may also withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to our reliance on third parties</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our collaboration with Biogen may not result in successful product development or payments to us. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into a collaboration and license agreement with Biogen to develop and commercialize CB 2782-PEG and our other anti-C3 proteases for potential treatment of dry AMD and other disorders. We will perform preclinical and manufacturing activities, and Biogen will be solely responsible for funding the preclinical and manufacturing activities and performing IND-enabling activities, worldwide clinical development, and commercialization. Future revenues from this collaboration depend upon the achievement of milestones and payment of royalties based on product sales after successful product development and regulatory approval. Biogen can terminate this agreement on 60 days&#8217; prior written notice. If Biogen terminates the agreement, our reputation in the business and scientific community may suffer and we will not receive payments from them after termination. If milestones are not achieved or Biogen is unable to successfully develop and commercialize products from which milestones and royalties are payable, we will not earn the revenues contemplated by the collaboration.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited or no control over the resources that Biogen may devote to the development and commercialization of products under our agreement. Biogen may not perform its obligations as expected or may breach or terminate the agreement with us or otherwise fail to conduct research, development or commercialization activities successfully or in a timely manner. Further, Biogen may elect not to develop pharmaceutical products arising out of our collaborative arrangement or may not devote sufficient resources to the development, regulatory approval, manufacture, marketing or sale of these products. If any of these events occurs, we may not receive collaboration revenue or otherwise realize anticipated benefits from such collaborations, our product development efforts may be delayed and our business, operating results and financial condition could be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We expect to seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We have previously relied on collaborators, such as Pfizer and ISU, to contribute to the development of our product candidates, and we are currently working with Biogen and Mosaic to support the development of our dry AMD product candidates. We may seek one or more additional collaborators for the development and commercialization of one or more of our product candidates. For example, we may seek a new collaborator to develop MarzAA and might also seek collaborators for DalcA or our earlier stage programs. In addition, full development efforts on the use of our novel proteases for the treatment of other complement mediated diseases will likely involve significant cost, and we do not expect to conduct any such efforts except in collaboration with one or more partners who are willing to pay for such costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face significant competition in seeking appropriate collaborators. Whether we can reach a definitive agreement with a collaborator will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of preclinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and the potential of competing products. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the one with us. There can also be no assurance that any collaboration agreements will be on favorable terms.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations are complex and time consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay our development program or one or more of our other development programs, delay our potential commercialization or reduce the scope of any sales or marketing activities, and increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We contract with third parties for the manufacture of our product candidates for preclinical testing and expect to continue to do so for clinical testing and commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no internal capabilities to manufacture our product candidates for clinical use or for preclinical trials following good manufacturing practices (&#8220;GMP&#8221;), or good laboratory practices (&#8220;GLP&#8221;). We expect to rely on one or more third-party contractors to manufacture, package, label and distribute clinical supplies and commercial quantities of any product candidate that we commercialize following approval for marketing by applicable regulatory authorities. We also expect to rely on one or more third-party contractors to manufacture our product candidates for use in our clinical trials. Reliance on such third-party contractors entails risks, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our inability to identify and negotiate manufacturing and supply agreements with suitable manufacturers&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>manufacturing delays if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the possible termination or nonrenewal of agreements by our third-party contractors at a time that is costly or inconvenient for us&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the possible breach by the third-party contractors of our agreements with them&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the failure of third-party contractors to comply with applicable regulatory requirements&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the possible mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the possible misappropriation of our proprietary information, including our trade secrets and know-how.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may incur delays in product development resulting from the need to identify or qualify manufacturers for our product candidates. Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We are subject to many manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates and any future products.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, our product candidates have been manufactured by third-party manufacturers solely for preclinical studies and relatively small clinical trials. The process of manufacturing MarzAA, DalcA, CB 4332 and our other Complement associated therapeutic product candidates is complex, highly regulated and subject to several risks, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the process of manufacturing biologics is susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error and improper storage conditions. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, the manufacturing facilities may need to be closed for an extended period of time to investigate and eliminate the contamination&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the manufacturing facilities in which our products are made could be adversely affected by equipment failures, labor and raw material shortages, financial difficulties of our contract manufacturers, including as a result of the evolving effects of the COVID-19 pandemic, natural disasters, power failures, local political unrest and numerous other factors&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>any adverse developments affecting manufacturing operations or the scale up of manufacturing operations for our products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the supply of our product candidates. We may also have to record inventory write-offs and incur other charges and expenses for product candidates or drug substances that fail to meet specifications, undertake costly remediation efforts or seek costlier manufacturing alternatives.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, we have entered into various development, manufacturing and clinical supply services agreements with third-party manufacturers for drug substance and drug product manufacturing of MarzAA, DalcA and CB 4332. If any of our third-party manufacturers is not able to provide us with sufficient quantities of (i) MarzAA or DalcA for our clinical trials or (ii) CB 4332 for our preclinical trials on a timely basis, or at all, whether due to production shortages or other supply delays or interruptions resulting from the ongoing COVID-19 pandemic or otherwise, our preclinical trials, clinical trials or regulatory approval, as applicable, may be delayed. Significant portions of our research and development resources are focused on manufacturing. If any of our third-party manufacturers experiences difficulties in scaling production or experiences product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error or improper storage conditions, the potential trials of the affected product candidate would be delayed, perhaps substantially, which could materially and adversely affect our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have minimal process development capabilities and have access only to external manufacturing capabilities. We do not have, and we do not currently plan to acquire or develop, the facilities or capabilities to manufacture bulk drug substance or filled drug product for use in clinical trials or commercialization. Any delay or interruption in the supply of clinical trial material or preclinical trial material could delay the completion of clinical trials or preclinical trials, increase the costs associated with maintaining such trial programs and, depending upon the period of delay, require us to commence new clinical trials or preclinical trials at additional expense or terminate the trials completely.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We and our contract manufacturers will be subject to significant regulation with respect to manufacturing our products. The manufacturing facilities on which we will rely may not continue to meet regulatory requirements and have limited capacity.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including any contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with GMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#8217;s GLP and GMP regulations enforced by the FDA through its facilities inspection program. Our facilities and quality systems and the facilities and quality systems of some or all our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If these facilities do not pass a pre-approval plant inspection or do not have a GMP compliance status acceptable for the FDA, FDA approval of the products will not be granted.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulatory authorities also may, at any time following approval of a product for sale, audit our manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third-party to implement and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, or revocation of a pre-existing approval. As a result, our business, financial condition and results of operations may be materially harmed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. An alternative manufacturer would need to be qualified through a BLA supplement which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These factors could cause the delay of clinical studies, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed, or we could lose potential revenue.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third parties such as contract research organizations (&#8220;CROs&#8221;), medical institutions and clinical investigators to enroll qualified patients and conduct, supervise and monitor clinical trials. Our reliance on these third parties for clinical development activities will reduce our control over these activities. Our reliance on these third parties, however, will not relieve us of our regulatory responsibilities, including ensuring that our clinical studies are conducted in accordance with good clinical practices, and the investigational plan and protocols contained in the relevant regulatory application, such as an investigational new drug application, or IND. In addition, the CROs with whom we contract may not complete activities on schedule or may not conduct our preclinical studies or clinical studies in accordance with regulatory requirements or our clinical study design. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, our efforts to obtain regulatory approvals for, and to commercialize, our product candidates may be delayed or prevented.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to employee matters, managing growth and our business operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on our executive management and scientific personnel. We do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. In addition, we will need to add personnel to achieve our business objectives. The loss of the services of any of our executive officers, other key employees, and our inability to find suitable replacements, or our inability to hire new clinical development and manufacturing personnel, could result in delays in product development and harm our business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conduct operations at our facility in the San Francisco Bay Area. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To induce valuable employees to remain at Catalyst, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in the Company&#8217;s stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of management and scientific and development teams may terminate their employment with the Company on short notice. Our employees are under at-will employment arrangements, which means that any of our employees can leave employment with Catalyst at any time, with or without notice. Failure to retain, replace or recruit personnel could harm our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and collaborators. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-US regulators, to provide accurate information to the FDA and non-US regulators, to comply with healthcare fraud and abuse laws and regulations in the United States and abroad, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained during clinical studies that could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We will continue to incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we have and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company, including costs associated with public company reporting and corporate governance requirements, in order to comply with the rules and regulations imposed by the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection (the &#8220;Dodd-Frank Act&#8221;), as well as rules implemented by the SEC and Nasdaq. Stockholder activism, the political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways that are not currently anticipated. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. In addition, these rules and regulations make it difficult and expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain our current levels of such coverage. We expect that we will annually incur significant expenses to comply with the requirements imposed on us as a public company.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our offices are located in the San Francisco Bay Area, which is prone to earthquakes. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans that, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to our intellectual property</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to obtain, protect or enforce intellectual property rights related to our product candidates, we may not be able to compete effectively in our markets.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. Third parties may challenge the validity, enforceability or scope of our patents, which may result in those patents being narrowed or invalidated. The patent applications that we own may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. Certain of our patents also cover processes, for which enforcement can be difficult. Any of these outcomes could impair our ability to prevent competition from third parties that may have an adverse impact on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the patents or patent applications we hold or have in-licensed for our programs or product candidates are invalidated or fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates, it could threaten our ability to commercialize future products. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available&#59; however the life of a patent, and the protection it affords, is limited. Once the patent life has expired for a product, we may be open to competition from generic medications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent and other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Third-party claims of intellectual property infringement or challenging the inventorship or ownership of our patents may prevent or delay our development and commercialization efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter partes reexamination proceedings before the USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert that the manufacture, use or sale of our product candidates infringes patents held by such third parties, or that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to compositions of matter, materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. There is a patent family pending in the U.S. and Europe in which claims that may read on MarzAA have been filed. We, however, do not believe such claims are patentable. If they were to issue, we would take appropriate action to challenge their enforceability and/or validity. We are also aware of additional patents that have been issued in the United States and Europe that have claims related to Factor VII. We do not believe that MarzAA does or will infringe any valid claims in such patents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware of a patent family that includes issued patents in the United States, Australia, Israel, Malaysia, New Zealand and Japan, and pending applications in Europe and Canada. The patents and pending applications may include claims that may read on a contemplated FXa clinical candidate. There is prior art that we believe discloses subject matter on which a challenge to the patentability of such claims can be based. In the event that development of the FXa candidate is pursued we would, if necessary, consider appropriate action to challenge such claims.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have received confidential and proprietary information from third parties, and we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may obtain injunctive or other equitable relief that could effectively block our ability to further develop and commercialize one or more of our product candidates unless we redesigned infringing products (which may be impossible) or obtained a license under the applicable patents (which may not be available on commercially reasonable terms or at all), or until such patents expire.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We may be involved in lawsuits to protect or enforce our patents.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our patents. To counter infringement or unauthorized use, we or our collaborators may be required to file infringement claims that can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one of our patents is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims, regardless of their merit, would cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, in addition to paying royalties, redesign infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A third-party may hold intellectual property, including patent rights, that is important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to regulatory approval of our product candidates and other legal compliance matters</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we have multiple drug candidates in clinical and advanced preclinical development for a range of diseases, we have not yet submitted BLAs for our engineered human proteases to the FDA, or similar approval filings to comparable foreign authorities. Submission of a BLA requires extensive preclinical and clinical data and supporting information that demonstrates the product candidate&#8217;s safety, purity, and potency, also known as safety and effectiveness, for each desired indication. A BLA must also include significant information regarding the chemistry, manufacturing and controls for the product. MarzAA has completed a Phase 2 clinical trial, and DalcA is completing a Phase 2 clinical trial. However, failure of one or more clinical trials can occur at any stage in the clinical trial process. Accordingly, the regulatory pathway for our product candidates is still uncertain, complex, and lengthy, and ultimately, approval may not be obtained.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the availability of financial resources to commence and complete the planned trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>inability to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>obtaining approval at each clinical trial site by an independent institutional review board (&#8220;IRB&#8221;)&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>recruiting suitable patients to participate in trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>having patients complete a trial or return for post-treatment follow-up&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>clinical trial sites deviating from trial protocol or dropping out of a trial&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>adding new clinical trial sites&#894; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>manufacturing sufficient quantities of qualified materials under Current Good Manufacturing Practice (&#8220;cGMPs&#8221;) regulations and applying them on a subject-by-subject basis for use in clinical trials.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could also experience delays in obtaining approval if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles given the serious nature of the diseases for the core indications for our product candidates. Additionally, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which the trials are being conducted, the Data Monitoring Committee for the trial, or by the FDA or other regulatory authorities for a number of reasons, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues, or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, the FDA review and approval process could be delayed by any future shutdown of the U.S. government, and our development activities could be harmed or delayed as a result. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, our ability to commercialize our product candidates will be harmed and our ability to generate revenue will be materially impaired. Additionally, delays in completing trials will increase costs, slow down our product development and approval process, and impair our ability to commence product sales and generate revenue. Many of the factors that could create or lead to a delay in the commencement or completion of clinical trials may lead to the denial of regulatory approval for our product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of clinical trials we conduct may not support regulatory approval of our product candidates. Our product candidates could fail to receive regulatory approval for many reasons, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>We may be unable to demonstrate to the satisfaction of the FDA or comparable foreign authorities that our product candidates are safe and effective for any of their proposed indications&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>We may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute our products. As a pharmaceutical company, even though we do not and may not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. These regulations include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the Federal Healthcare Anti-Kickback Statute that prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid, and which will constrain our marketing practices and the marketing practices of our licensees, educational programs, pricing policies, and relationships with healthcare providers or other entities&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the federal physician self-referral prohibition, commonly known as the Stark Law, which prohibits physicians from referring Medicare or Medicaid patients to providers of &#8220;designated health services&#8221; with whom the physician or a member of the physician&#8217;s immediate family has an ownership interest or compensation arrangement, unless a statutory or regulatory exception applies&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">federal false claims laws that prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other government reimbursement programs that are false or fraudulent, and which may expose entities that provide coding and billing advice to customers to potential criminal and civil penalties, including through civil whistleblower or qui tam actions, and including as a result of claims presented in violation of the Federal Healthcare Anti-Kickback Statute, the Stark Law or other healthcare-related laws, including laws enforced by the FDA&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services that, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>federal physician sunshine requirements under the ACA, which requires manufacturers of approved drugs, devices, biologics and medical supplies to report annually to the U.S. Department of Health and Human Services or HHS, information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the Federal Food, Drug, and Cosmetic Act, which, among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, state laws requiring pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and which may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state and foreign laws governing the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws such as HIPAA, thus complicating compliance efforts.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our results of operations may be adversely affected by current and potential future healthcare legislative and regulatory actions.&#160;&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legislative and regulatory actions affecting government prescription drug procurement and reimbursement programs occur relatively frequently. In the United States, the ACA was enacted in 2010 to expand healthcare coverage. Since then, numerous efforts have been made to repeal, amend or administratively limit the ACA in whole or in part. For example, the Tax Cuts and Jobs Act, signed into law by President Trump in 2017, repealed the individual health insurance mandate, which is considered a key component of the ACA. In December 2018, a Texas federal district court struck down the ACA on the grounds that the individual health insurance mandate is unconstitutional, although this ruling has been stayed pending appeal. The ongoing challenges to the ACA and new legislative proposals have </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resulted in uncertainty regarding the ACA&#8217;s future viability and destabilization of the health insurance market. The resulting impact on our business is uncertain and could be material.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to control prescription drug prices could also have a material adverse effect on our business. For example, in 2018, President Trump and the Secretary of the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) released the &#8220;American Patients First Blueprint&#8221; and have begun implementing certain portions. The initiative includes proposals to increase generic drug and biosimilar competition, enable the Medicare program to negotiate drug prices more directly and improve transparency regarding drug prices and ways to lower consumers&#8217; out-of-pocket costs. The Trump administration also proposed to establish an &#8220;international pricing index&#8221; that would be used as a benchmark to determine the costs and potentially limit the reimbursement of drugs under Medicare Part B. Among other pharmaceutical manufacturer industry-related proposals, Congress has proposed bills to change the Medicare Part D benefit to impose an inflation-based rebate in Medicare Part D and to alter the benefit structure to increase manufacturer contributions in the catastrophic phase. The volume of drug pricing-related bills has dramatically increased under the current Congress, and the resulting impact on our business is uncertain and could be material.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, many states have proposed or enacted legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as by requiring biopharmaceutical manufacturers to publicly report proprietary pricing information or to place a maximum price ceiling on pharmaceutical products purchased by state agencies. For example, in 2017, California&#8217;s governor signed a prescription drug price transparency state bill into law, requiring prescription drug manufacturers to provide advance notice and explanation for price increases of certain drugs that exceed a specified threshold. Both Congress and state legislatures are considering various bills that would reform drug purchasing and price negotiations, allow greater use of utilization management tools to limit Medicare Part D coverage, facilitate the import of lower-priced drugs from outside the United States and encourage the use of generic drugs. Such initiatives and legislation may cause added pricing pressures on our products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes to the Medicaid program at the federal or state level could also have a material adverse effect on our business. Proposals that could impact coverage and reimbursement of our products, including giving states more flexibility to manage drugs covered under the Medicaid program and permitting the re-importation of prescription medications from Canada or other countries, could have a material adverse effect by limiting our products&#8217; use and coverage. Furthermore, state Medicaid programs could request additional supplemental rebates on our products as a result of an increase in the federal base Medicaid rebate. To the extent that private insurers or managed care programs follow Medicaid coverage and payment developments, they could use the enactment of these increased rebates to exert pricing pressure on our products, and the adverse effects may be magnified by their adoption of lower payment schedules.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other proposed regulatory actions affecting manufacturers could have a material adverse effect on our business. It is difficult to predict the impact, if any, of any such proposed legislative and regulatory actions or resulting state actions on the use and reimbursement of our products in the United States, but our results of operations may be adversely affected.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We are subject to evolving privacy and data protection laws, including HIPAA and the EU General Data Protection Regulation (&#8220;GDPR&#8221;). If we fail to protect personal information or comply with existing or future data protection regulations, our business, financial condition, results of operations and prospects may be materially adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability, integrity, and other processing of personal information. HIPAA establishes a set of national privacy and security standards for the protection of protected health information (as defined in HIPAA) (&#8220;PHI&#8221;) by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. HIPAA requires covered entities and business associates, such as us, to develop and maintain policies with respect to the protection of, use and disclosure of electronic PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and certain notification requirements in the event of a data breach.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By virtue of our clinical trial activities in Europe, we are also subject to European data protection laws, including the GDPR (as implemented in the European Economic Area (the &#8220;EEA&#8221;) and the United Kingdom). The GDPR which came into effect on May 25, 2018, establishes stringent requirements applicable to the processing of personal data (i.e., data which identifies an individual or from which an individual is identifiable), affords various data protection rights to individuals (e.g., the right to erasure of personal data) and imposes potential penalties for serious breaches of up to 4.0% annual worldwide turnover or &#8364;20 million, whichever is greater. Individuals (e.g., study subjects) also have a right to compensation for financial or non-financial losses (e.g., distress). There may be circumstances under which a failure to comply with the GDPR, or the exercise of individual rights under the GDPR, would limit our ability to utilize clinical trial data collected on study subjects. The GDPR imposes additional responsibility and liability in relation to our processing of personal data. This may be onerous and materially adversely affect our business, financial condition, results of operations and prospects. The GDPR also prohibits the international transfer of personal data from the EEA/UK to countries outside of the EEA/United Kingdom unless made to a country deemed to have adequate data privacy laws by the European Commission or a data transfer mechanism has been put in place.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the interpretation and application of consumer, health-related and data protection laws in the United States, Europe and elsewhere are often uncertain, contradictory and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are subject to various U.S. state laws which may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts that could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients or is perceived to harm patients even when such harm is unrelated to our product candidates, regulatory approvals could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>impairment of our business reputation&#894;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>withdrawal of clinical trial participants&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>costs due to related litigation&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>distraction of management&#8217;s attention from our primary business&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>substantial monetary awards to patients or other claimants&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the inability to commercialize our product candidates&#894; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>decreased demand for our product candidates, if approved for commercial sale.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We carry product liability insurance of $10,000,000 per occurrence and $10,000,000 aggregate limit. We believe our product liability insurance coverage is sufficient for our current clinical programs&#59; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products&#59; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed insurance coverage, could adversely affect our results of operations and business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with the diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition, results of operations, or cash flows.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to commercialization of our product candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Even if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates receives marketing approval, we may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current hemophilia treatments like intravenous NovoSeven RT are well established in the medical community, and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on several factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the subcutaneous efficacy and potential advantages compared with alternative treatments&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our ability to offer our products for sale at competitive prices&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the convenience and ease of subcutaneous administration compared with alternative treatments&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the strength of marketing and distribution support&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the availability of third-party coverage and adequate reimbursement&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the prevalence and severity of any side effects&#894; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>any restrictions on the use of our products together with other medications.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates are years away from regulatory approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MarzAA and DalcA are not expected to be commercially available for several years, if at all. Further, the commercial success of either product candidate will depend upon its acceptance by physicians, individuals, third-party payors and other key decision-makers as a therapeutic and cost-effective alternative to products available at the time, which may include competing products currently under development by others. See &#8220;We face substantial competition that may result in others discovering, developing or commercializing products before or more successfully than we do.&#8221; If we are unable to successfully develop, obtain regulatory approval in a timely manner (including due to reasons that are beyond our control, such as changes in regulations or a shutdown of the federal government, including the FDA) for and commercialize MarzAA or DalcA, our ability to generate revenue from product sales will be significantly delayed and our business will be materially and adversely affected, and we may not be able to earn sufficient revenues to continue as a going concern.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the FDA or other regulatory agency approves MarzAA or DalcA, the approval may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product and may impose ongoing commitments or requirements for post-approval studies, including additional research and development and clinical trials. The FDA and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. Regulatory approval from authorities in foreign countries will be needed to market MarzAA or DalcA in those countries. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions. If we fail to obtain approvals from foreign jurisdictions, the geographic market for MarzAA or DalcA would be limited.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to establish sales, marketing and distribution capabilities, we may not be successful in commercializing our product candidates if they are approved.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet established a sales, marketing or product distribution infrastructure for our other product candidates, which are still in preclinical or early clinical development. Except for ISU Abxis&#8217; rights to commercialize DalcA in South Korea, we generally expect to retain commercial rights for the Company&#8217;s hemophilia product candidates. We believe that it will be possible to access the United States hemophilia market through a focused, specialized sales force. However, we have not yet developed a commercial strategy for hemophilia products outside of the United States, or for any other of our product candidates. To achieve commercial success for any product for which we obtain marketing approval, we will need to establish a sales and marketing organization within the United States and to develop a strategy for sales outside of the United States.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are risks involved with establishing internal sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. If we are unable to establish sales, marketing and distribution capabilities and enter into additional arrangements with third parties to perform these services, then our product revenues and profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We face substantial competition that may result in others discovering, developing or commercializing products before or more successfully than we do.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, there are a large number of companies developing or marketing treatments for hemophilia, including many major pharmaceutical and biotechnology companies, including Novo Nordisk, which has developed </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NovoSeven RT, an intravenous recombinant Factor VIIa indicated for treatment of bleeding episodes that has been approved for use in treatment of (i) hemophilia A or B individuals with inhibitors to Factor VIII or Factor IX and in individuals with Factor VII deficiency and Glanzmann&#8217;s thrombasthenia but not for prophylaxis and (ii) peri-operative management in adults with Acquired Hemophilia&#59; HEMA Biologics, which has developed SEVENFACT, an intravenous recombinant Factor VIIa indicated for treatment of bleeding episodes in individuals with Hemophilia A or B with an inhibitor to Factor VIII or Factor IX&#59; Takeda&#8217;s FEIBA, a plasma-based composition of coagulation factors indicated for intravenous on-demand and prophylactic use in the treatment of individuals with Hemophilia A or B inhibitors&#59; Roche, which is marketing Hemlibra (emicizumab-kxwh), a recombinant humanized bispecific antibody that binds to activated Factor IX and Factor X mimicking the cofactor function of Factor VIIIa, that has been approved by the FDA to treat hemophilia A with inhibitors and is administered subcutaneously&#59; several companies including Novo Nordisk, Pfizer and Genzyme are developing SQ agents for the treatment of Hemophilia A or B with or without inhibitors or Hemophilia with inhibitors using a variety of technologies. There are numerous marketed factor IX-based products that are used to replace Factor IX intravenously. BeneFIX, a recombinant Factor IX indicated for treatment of individuals with Hemophilia B, was approved in 1997 and is marketed by Pfizer. In addition, Alprolix, a Factor IX-Fc fusion product was approved in 2014 and is marketed by Sanofi Aventis and Swedish Orphan Biovitrum (SOBI&#8212;in Europe, Russia, North Africa and the Middle East). Idelvion, a Factor IX-albumin fusion product marketed by</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CSL Behring was approved by the FDA in 2016. Idelvion is approved for weekly dosing for adolescents and adults and bi-weekly at a higher dose for those same patients if well controlled on the original regimen. It is approved for weekly in patients &#60;12 years of age. Novo Nordisk&#8217;s glycopegylated-Factor IX product Rebinyn was approved by the FDA in 2017 but is not indicated for routine prophylaxis in the U.S. Rebinyn is approved for on-demand treatment and control of bleeding episodes as well as Perioperative management of bleeding. CSL Behring is developing its marketed product Idelvion an albumin-linked Factor IX for subcutaneous administration. We are also aware of many companies focused on developing gene therapies that may compete with our planned hemophilia B indication, as well as several companies addressing other methods for modifying genes and regulating gene expression. Although there are no currently approved treatments for dry AMD, several companies are developing cyclic peptide, aptamer, antibody or gene therapy based anti-complement product candidates in clinical studies. Apellis is conducting two Phase 3 studies to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients aged 60 years and older with GA secondary to AMD&#59; Iveric Bio (formerly Ophthotech) is developing two therapies to treat GA secondary to dry AMD, iveric Bio completed its Phase 2b clinical of Zimura&#174; (avacincaptad pegol) with positive data in patients with dry AMD&#59; Gemini Therapeutics is developing &#8220;GEM103&#8221; a recombinant human complement factor H (&#8220;FH&#8221;) for patients with genetically well-defined dry AMD and &#8220;GEM104,&#8221; a recombinant human complement factor I as well as additional molecules in preclinical development for other genetically defined subpopulations of patients with dry AMD and Gyroscope Therapeutics is developing &#8220;GT005&#8221; a gene therapeutic approach to expressing additional CFI in the patient&#8217;s eye after subretinal delivery. In addition, there are currently no approved agents specifically targeting systemic factor I deficiency patients irrespective of the resultant disease phenotype being aHUS, C3G, IC-MPGN, invasive infections or any other or any approved therapies for C3G and IC-MPGN. However, there are less specific treatment options on the market or in clinical development which may be applicable to some disease manifestations of systemic CFI deficiency, for instance aHUS and C3G. These treatment options include: eculizumab and ravulizumab marketed by Alexion Pharmaceuticals (to be acquired by AstraZeneca) for use in aHUS irrespective of the patients&#8217; CFI status&#59; APL-2 (pegcetacoplan), a pegylated peptide based C3 inhibitor, in IgA Nephropathy (&#8220;IgAN&#8221;), LN, Membranous Nephropathy (&#8220;MN&#8221;), C3G, and Dense Deposit Disease which is in clinical development by Apellis&#59; CCX168 (avacopan), a twice daily oral small molecule inhibitor of the complement 5a receptor (&#8220;C5aR&#8221;) in C3G&#8212;currently in phase 2 being developed by ChemoCentryx&#59; iptacopan (&#8220;LNP023&#8221;), a small peptide complement factor B inhibitor which is currently in development by Novartis for PNH, C3G and several other rare renal diseases including IgAN, aHUS, and membranous nephropathy&#59; and Omeros has initiated clinical activities in igAN, LN, MN, &#38; C3G and a phase 3 clinical program in aHUS with OMS721 (&#8220;narsoplimab&#8221;), a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (&#8220;MASP-2&#8221;), the effector enzyme of the lectin pathway of the complement system.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity in different indications could be reduced or eliminated if competitors develop and market products or therapies that are more convenient to use, more effective, less expensive, and safer to use than our products. Furthermore, if competitors gain FDA approval earlier than we do, we may be unable to establish a strong market presence or to gain market share. The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition, and the availability of reimbursement from government and other third-party payors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and individual registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we believe that MarzAA could be a SQ rescue therapy for hemophilia A (congenital factor VIII deficiency) patients with inhibitors experiencing breakthrough bleeds while on prophylaxis with other agents such as Hemlibra, nevertheless, branded products such as Hemlibra, present a potentially significant competitive risk to the wide-spread use of MarzAA, due to bleeding prophylaxis with Hemlibra requiring less frequent administration while decreasing the risk of breakthrough bleeds. Consequently, MarzAA, if approved, may compete with existing drugs such as Hemlibra, NovoSeven RT, and other therapies, and to the extent it is ultimately used in combination with or as an adjunct to these therapies, MarzAA may not be competitive. The FDA first approved Hemlibra in 2017 for patients with hemophilia A with factor VIII (&#8220;FVIII&#8221;) inhibitors and in 2018, the FDA approved Hemlibra for prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A with or without FVIII inhibitors. As a result, obtaining market acceptance of, and gaining significant market share for MarzAA may pose challenges.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Even if we commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives that would harm our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we may obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for certain medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we or our collaborators commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate that receives marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmaco-economic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, ability to raise capital needed to commercialize products and overall financial condition.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">If the market opportunities for our product candidates are smaller than expected, our revenues may be adversely affected and our business may suffer.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We focus our research and product development on hemostasis and inflammation treatment. Our projections of both the number of people who suffer from related conditions, as well as the subset of people with these conditions who have the potential to benefit from treatment with our product candidates, are based on estimates. These estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of these diseases. The number of patients in the United States, Europe and elsewhere may turn out to be lower than expected or may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to our common stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The market price of our common stock has historically been highly volatile.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading price of our common stock has historically been highly volatile and there have been significant periods of time in which the trading volume of our common stock has been low, which can contribute to volatility in price. Additionally, the stock market in general has experienced extreme price and volume fluctuations. The market prices of securities of pharmaceutical, biopharmaceutical and biotechnology companies in particular have been extremely volatile and have experienced fluctuations that have often been unrelated or disproportionate to operating performance. Factors giving rise to this volatility may include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>disclosure of clinical trial results&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>regulatory or political developments in both the United States and abroad&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>developments concerning proprietary rights, including patents and litigation matters&#894;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>disclosure of new collaborations or other strategic transactions&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>public concern about the safety or efficacy of product candidates or technology, their components, or related technology or new technologies generally&#894;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>public announcements by competitors or others regarding new products or new product candidates&#894; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>general market conditions and comments by securities analysts and investors.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fluctuations in operating results could adversely affect the price of our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operating results are likely to fluctuate significantly from quarter to quarter and year to year. These fluctuations could cause our stock price to decline. Some of the factors that may cause operating results to fluctuate on a period-to-period basis include the scope, progress, duration results and costs of preclinical and clinical development programs, as well as non-clinical studies and assessments of product candidates and programs, restructuring costs, implementation or termination of collaboration, licensing, manufacturing or other material agreements with third parties, non-recurring revenue or expenses under any such agreement, the cost, timing and outcomes of regulatory compliance, approvals or other regulatory actions and general and industry-specific economic conditions, particularly as affects the pharmaceutical, biopharmaceutical or biotechnology industries in the United States. Period-to-period comparisons of our historical and future financial results may not be meaningful, and investors should not rely on them as an indication of future performance. Fluctuating losses may fail to meet the expectations of securities analysts or investors. Failure to meet these expectations may cause the price of our common stock to decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current trading volumes are modest, and sales of a substantial number of shares of our common stock in the public market, or the perception that these sales could occur, could cause the market price to decline. We have effective registration statements on Form S-3 that enables us to sell up to $170.0 million in securities. Any additional sales in the public market of our common stock or other securities under these shelf registration statements could adversely affect prevailing market prices for our common stock. In addition, we have outstanding options to purchase 2,355,615 shares of common stock at a weighted average exercise price of $8.59 for the year ended December 31, 2020. If such options are exercised and the shares are sold into the open market, such sales also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. Conversion or exercise of these securities into shares of our common stock will cause dilution to the other holders of our common stock, and all such stock may be sold in the public market after conversion or exercise, subject to restrictions under the securities laws, which may lead to a decline in the market price of our common stock.\</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Anti-takeover provisions in our charter documents and provisions of Delaware law may make an acquisition more difficult and could result in the entrenchment of management.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are incorporated in Delaware. Anti-takeover provisions of Delaware law and our charter documents may make a change in control or efforts to remove management more difficult. Also, under Delaware law, our board of directors may adopt additional anti-takeover measures. The existence of the following provisions of Delaware law and our restated certificate of incorporation and amended and restated bylaws could limit the price that investors might be willing to pay in the future for shares of our common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation authorizes our board of directors to issue up to 5,000,000 shares of preferred stock and to determine the terms of those shares of stock without any further action by our stockholders. If the board of directors exercises this power to issue preferred stock, it could be more difficult for a third-party to acquire a majority of our outstanding voting stock and vote the stock they acquire to remove management or directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate also provides staggered terms for the members of our board of directors, and that directors may be removed by stockholders only by vote of the holders of 66 2/3% of voting shares then outstanding. In addition, our amended and restated bylaws do not permit stockholders to call special or annual meetings of stockholders, or to act by written consent without a meeting. These provisions may prevent stockholders from </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">replacing the entire board in a single proxy contest, making it more difficult for a third party to acquire control without the consent of our board of directors. These provisions could also delay the removal of management by the board of directors with or without cause.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a Delaware corporation, we are also subject to certain Delaware anti-takeover provisions. Under Delaware law, a publicly-held corporation may not engage in a business combination with any holder of 15% or more of our voting stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Our board of directors could rely on Delaware law to prevent or delay an acquisition.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two of our stockholders have requested that we add one or more individuals to our board of directors. Although we have entered into a cooperation agreement with one such stockholder and appointed two new members to our board of directors, one or more other stockholders could engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Such an activist campaign could conflict with our strategic direction or seek changes in the composition of our board of directors and could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs, and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategy, or limit our ability to attract and retain qualified personnel, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We are a smaller reporting company, and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and thus have been allowed to provide simplified executive compensation disclosures in our filings. We have also had certain other decreased disclosure obligations in our SEC filings. We cannot predict whether investors find our common stock less attractive because of our reliance on any of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">UNRESOLVED STAFF COMMENTS</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_2_PROPERTIES_NEED_TO_UPDATE_WITH_SU">PROPERTIES</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters is in South San Francisco, California, where we lease approximately 16,208 rentable square feet of space. The term of the leases will expire on April 30, 2023. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our existing facilities are adequate for our current needs. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_3_LEGAL_PROCEEDINGS">LEGAL PROCEEDINGS</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that in the opinion of our management, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition or cash flows.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 4</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">MINE SAFETY DISCLOSURES</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART II</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 5.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. is listed on the Nasdaq Capital Market under the symbol &#8220;CBIO.&#8221; </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders of Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 25, 2021, there were approximately 65 holders of record of our common stock. In addition, a substantially greater number of stockholders may be &#8220;street name&#8221; or beneficial holders, whose shares are held of record by banks, brokers and other financial institutions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Securities Authorized for Issuance Under Equity Compensation Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The response to this item is incorporated by reference from the discussion responsive thereto under the caption &#8220;Equity Compensation Plan Information&#8221; in Item 12. Security Ownership Of Certain Beneficial Owners And Management.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unregistered Sales of Securities&#59; Use of Proceeds from Registered Securities&#59; Issuer Purchases of Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 6. </span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_6_SELECTED_FINANCIAL_DATA">SELECTED FINANCIAL DATA.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information requested by this Item is not applicable as we are electing to adopt recently implemented regulations regarding this Item.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;7.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties, including those set forth under the heading &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. Our actual results and the timing of selected events discussed below could differ materially from those expressed in, or implied by, these forward-looking statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in disorders of the complement and coagulation systems. Proteases are the natural regulators of these biological systems. We engineer proteases to create both improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Our protease engineering platform has generated two late-stage clinical programs including marzeptacog alfa (activated) (&#8220;MarzAA&#8221;), a subcutaneously (&#8220;SQ&#8221;) administered next-generation engineered coagulation Factor VIIa (&#8220;FVIIa&#8221;) for the treatment of episodic bleeding in subjects with rare bleeding disorders. Our complement pipeline includes a preclinical program partnered with Biogen International GmbH (&#8220;Biogen&#8221;) for dry age-related macular degeneration (&#8220;AMD&#8221;), an improved complement factor I protease for SQ prophylaxis in patients with complement factor I (&#8220;CFI&#8221;) deficiency and C4b-degraders designed to target disorders of the classical complement pathway as well as other complement programs in development.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The product candidates generated by our protease engineering platform have improved functional properties such as longer half-life, improved specificity, higher potency and increased bioavailability. These characteristics potentially allow for improved efficacy, SQ administration of recombinant coagulation factors and complement inhibitors, or less frequently dosed intravitreal therapeutics.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our most advanced product candidate is MarzAA, a next-generation SQ FVIIa that is entering a registrational Phase 3 trial (MAA-304) in patients with Hemophilia A or B with inhibitors. We also plan to initiate a Phase 1/2 trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our complement portfolio is led by the development candidates CB 4332 and CB 2782-PEG. CB 4332 is a wholly owned first-in-class improved CFI intended for lifelong prophylactic SQ administration in individuals with CFI deficiency. CB 2782-PEG is a potential best-in-class C3 degrader product candidate in preclinical development for the treatment of dry AMD that we have licensed to Biogen. We have several engineered protease programs in discovery or early non-clinical development. These programs all target diseases caused by deficient regulation of the complement system.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our next most advanced hemophilia product candidate is dalcinonacog alfa (&#8220;DalcA&#8221;), a next-generation SQ FIX, which has shown efficacy and safety in a Phase 2b clinical trial in individuals with Hemophilia B. We have a discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B, that has demonstrated superiority compared with the Padua FIX variant in preclinical models.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our current development programs.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2g5bnvu5o20000004.jpg" title="" alt="" style="width:624px;height:320px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are experiencing operational and other challenges as a result of the COVID-19 global pandemic, which could delay or halt our development programs. See Recent Other Developments and Item 1A - Risk Factors for further discussion of the current and expected impact on our business and development programs.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Development Program Updates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">MarzAA</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are initiating a registrational Phase 3 trial (MAA-304) for our most advanced product candidate, MarzAA, a potent, subcutaneously administered, next-generation Factor VIIa variant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 3 registration trial &#8211; MAA-304 &#8211; is an open-label, global, multi-center, randomized, cross-over study, designed to evaluate the safety and efficacy of MarzAA for on-demand treatment of spontaneous or traumatic bleeding episodes, in adolescents and adults with congenital Hemophilia A or B with inhibitors, compared with Standard of Care, either IV rFVIIa or IV FEIBA. The study will enroll approximately 60 subjects to treat 244 eligible bleeding episodes with each treatment. The primary endpoint is hemostatic efficacy using a standard 4-point assessment scale at the 24-hour timepoint. The study will assess the effectiveness of SQ MarzAA, using up to three doses to treat a bleeding episode, compared with the Standard of Care. We plan to submit our first report to the Data and Safety Monitoring Board (&#8220;DSMB&#8221;) in 2021 and our final DSMB report in the middle of 2022.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also plan to initiate a Phase 1/2 trial (MAA-202) of MarzAA for treatment of bleeding in Factor VII Deficiency, Glanzmann Thrombasthenia, and in individuals with Hemophilia A with inhibitors treated with Hemlibra in 2021 and to report interim PK data mid-year.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Complement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have several protease programs in preclinical discovery or early non-clinical development. Common to the programs is that they target diseases caused by deficient regulation of the complement system. One ocular program for dry AMD is partnered with Biogen&#59; the remaining complement programs are focused on systemic complement disorders and are wholly owned by Catalyst.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our complement portfolio is led by the development candidates CB 4332 and CB 2782-PEG. CB 4332 is a wholly owned first-in-class improved CFI intended for lifelong prophylactic SQ administration in individuals with CFI </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deficiency. CB 2782-PEG is a potential best-in-class C3 degrader product candidate in preclinical development for the treatment of dry AMD that we have licensed to Biogen. We have several engineered protease programs in discovery or early non-clinical development. These programs all target diseases caused by deficient regulation of the complement system.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CB 2782-PEG is an engineered pegylated C3 degrader that we designed with a best-in-class anti-C3 profile for dry AMD. Dry AMD is an ocular disease leading to vision loss and blindness for which there is currently no approved therapies. Complement hyperreactivity plays an important role in dry AMD. Using the protease CB 2782-PEG to degrade C3 allows for the neutralization of C3 activity. It is expected that maintaining low C3 in the eye can significantly slow disease progression in dry AMD in patients who would otherwise lose their vision over time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, there are no therapeutic options approved to specifically replace the deficient CFI protein with a well-functioning CFI to treat these disorders. While not specifically targeting CFI deficiency, eculizumab and ravulizumab are indicated for use in aHUS. Neither eculizumab nor ravulizumab address the root cause of the CFI deficiency&#59; instead, they are designed to prevent the downstream effects of uncontrolled complement activity. Patients with aberrant CFI may therefore still have uncontrolled complement activation downstream of CFI. This may cause deposition of complement proteins, for example, on red blood cells, and some CFI patients may have a worse prognosis than others even when on non-replacement therapy. CB 4332 is designed to address this unmet need by providing a therapeutic option that corrects the root problem of these diseases by simple, fast and easy SQ administration.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have additional early stage complement targeted discovery programs that have not yet been disclosed. The programs target different proteins from C3b and C4b.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">DalcA<span style="font-weight:bold;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DalcA is a next-generation SQ Factor IX product candidate for the prophylactic treatment of individuals with Hemophilia B. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, we completed an open-label Phase 2b study to evaluate the ability of DalcA to maintain steady state protective <span style="color:#000000;">Factor IX</span> levels above 12% in six individuals with severe hemophilia B. Each subject received a single intravenous dose, followed by daily SQ doses of DalcA for 28 days during which FIX activity levels, clotting parameters, half-life, safety, tolerability and anti-drug antibody formation were monitored.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the World Federation of Hemophilia Virtual Summit in June 2020, we reported that 28 days of daily SQ dosing of DalcA at 100 IU/kg achieved protective target FIX levels of &#62;12% in all participants, with FIX levels of up to 27% and a half-life of 2.5 to 5.1 days.&#160;&#160;No bleeds were reported during the 28 days of dosing and the 5 day wash-out, demonstrating effective prophylaxis and the potential for lower or less frequent dosing. Injection volumes were less than 1 mL. One subject withdrew on day 7 after reporting injection site reactions (&#8220;ISR&#8221;) from the first 3 SQ doses. No neutralizing anti-drug antibodies were detected, and no serious adverse events were reported. A single non-neutralizing anti-drug antibody to DalcA was observed at the end of study time point and had no clinical effect. Some subjects reported mild ISR of pain and/or redness, primarily with the initial injections. No thrombotic events occurred, and blood coagulation markers did not show any prothrombotic signals.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Factor IX Gene Therapy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Factor IX gene therapy construct CB 2679d-GT has demonstrated a 2-fold to 3-fold higher activity resulting in improved clotting time and blood loss in a preclinical Hemophilia B mouse model compared with the Padua variant of Factor IX. Fidanacogene elaparvovec (Pfizer/Spark), AMT-061 (uniQure),TAK-748 (Takeda) and FLT180A (Freeline) use the Padua FIX variant as the transgene in their AAV-based gene therapy clinical programs. Fidanacogene elaparvovec, AMT-061 and FLT180A have demonstrated encouraging Factor IX levels in their respective Phase 1/2 and Phase 2/3 studies with median Factor IX activity levels in the upper end of the mild to normal ranges. By its increased activity, CB 2679d-GT has the potential to reach higher Factor IX activity levels at lower vector doses which could improve tolerability of the vector as well as efficacy of the transgene, and ultimately lower manufacturing costs. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have licensed AAV technology from The Board of Trustees of The Leland Stanford Junior University (&#8220;Stanford&#8221;) and are currently optimizing the vector under a sponsored research agreement with Stanford. Data presented at </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">European Association for Haemophilia and Allied Disorders (&#8220;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EAHAD</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> show that the combination of</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our proprietary potency enhanced CB 2679d-GT Factor IX construct with a novel chimeric AAV capsid may reduce the vector dose required in gene therapy while maintaining high Factor IX levels.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We reported at the World Federation of Hemophilia Virtual Summit in June 2020 that studies of CB 2679d-GT in Hemophilia B mice have demonstrated a 4-fold reduction in blood loss and an 8-fold reduction in bleeding time when compared with the same dose of the Padua variant of FIX. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also reported that in a non-human primate study evaluating expression and tolerability, CB 2679d-GT in the novel chimeric capsid KP1 was well tolerated with high FIX expression that stabilized to approximately 25% to 50% FIX above baseline levels at the 6-week interim data cutoff. The novel chimeric capsid had differentiated and superior response to anti-capsid neutralizing antibodies compared to that observed for the LK03 comparator during the screening of non-human primates for the study.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Collaborations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;2019, we entered into a license and collaboration agreement with Biogen to develop and commercialize CB 2782-PEG and our other anti-C3 proteases for the potential treatment of dry AMD and other disorders. Under the collaboration agreement, we will perform pre-clinical and manufacturing activities, and Biogen is solely responsible for funding the pre-clinical and manufacturing activities and performing IND-enabling activities, worldwide clinical development, and commercialization. We received a $15.0 million upfront payment from Biogen in January 2020 for the grant of an exclusive license and the related know-how, and we are eligible to receive up to $340.0 million in milestone payments, along with tiered royalties for worldwide net sales of this product candidate up to low double-digits. For the year ended December 31, 2020, we recorded $5.8 million in collaboration revenue. Unless earlier terminated, the agreement will remain in effect until the expiry of all royalty obligations. Biogen has the right to terminate the agreement at will, on a product-by-product basis or in its entirety at any time upon 60 days prior written notice. In addition, either party has the right to terminate the agreement following a material breach that remains uncured for 90 days, or in connection with an insolvency event involving the other party.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also collaborated with Mosaic Biosciences (&#8220;Mosaic&#8221;) in the development of our Complement product candidates including CB 2782-PEG. Under the collaboration agreement, as amended in December 2019, Mosaic will perform all future services for a fee, and pursuant to a subsequent amendment in May 2020, Mosaic received a one-time cash payment of $0.8 million and is eligible to receive up to $4.0 million in potential future milestone payments related to regulatory and clinical development events for CB 2782-PEG and an additional anti-complement product candidate<span style="color:#000000;"> in cash, or in common stock if the Company elects</span>, in lieu of our obligations to pay Mosaic a double-digit percentage of funds we receive from Biogen or any other amounts we receive related to sublicense fees, research and development payments, or any other research, regulatory, clinical or commercial milestones and royalties on any other development candidates. We now own one hundred percent of all future payment streams related to these product candidates.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Manufacturing Updates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Drug Substance manufacturing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a long-term development and manufacturing services agreement with AGC Biologics, Inc. (&#8220;AGC&#8221;). AGC has global manufacturing sites and we use their facilities in the U.S. and Europe for drug substance manufacturing of MarzAA, DalcA, and CB 2782-PEG. We have successfully manufactured MarzAA to support our global Phase 3 clinical trial to evaluate the safety and efficacy of MarzAA for on-demand treatment and control of bleeding episodes in subjects with Hemophilia A or Hemophilia B with inhibitors. As of December 2020, we have successfully completed two large-scale GMP batches of MarzAA that will be sufficient to support the Phase 3 clinical trial through its completion. Additionally, we have entered into a firm purchase commitment, with AGC, to validate the MarzAA manufacturing process including production of three Process Performance Qualification batches.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, we completed a successful CMC Scientific Advice meeting with the Paul Ehrlich Institute in the EU which endorsed our current CMC strategy and manufacturing activities required for registration filing for the MarzAA program.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Drug Product manufacturing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a long-term clinical supply services agreement with Catalent Indiana, LLC (&#8220;Catalent&#8221;). Catalent has facilities in the U.S. and Europe and conducts drug product development and manufacturing for MarzAA and DalcA. We successfully completed development work for a variety of vial sizes which supports flexible dosing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also work with Symbiosis Pharmaceutical Services Limited on drug product manufacturing for MarzAA on a fee-for-services basis. Symbiosis has a facility in the United Kingdom.&#160;&#160;In 2020, two drug product manufacturing batches were successfully completed at Symbiosis to support MarzAA pivotal trials.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The two MarzAA drug product batches manufactured at Symbiosis in 2020, were also successfully packaged and labeled at Catalent to support MarzAA pivotal trials.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Recent Developments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">COVID-19 business impact</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global coronavirus pandemic has resulted in widespread requirements for individuals to work from their homes, strained medical facilities worldwide and is causing disruptions to certain pharmaceutical manufacturing and product supply chains. We are experiencing operational and other challenges as a result of the COVID-19 global pandemic, which have delayed our enrollment in MAA-304 and MAA-202, and which may delay or halt our development in these or other programs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recent Financing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2021, we sold an aggregate of 9,185,000 shares of common stock (including 485,000 shares sold pursuant to the exercise of the underwriters&#8217; overallotment option) at a price of $5.75 per share. The net proceeds, after deducting $3.5 million in underwriting discounts and commissions and offering expenses, were approximately $49.3 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, we completed an underwritten public offering of 4,615,384 shares of common stock at a price of $6.50 per share. The net proceeds, after deducting $2.0 million in underwriting discounts and commissions and offering expenses payable by us, were approximately $28.0 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020,<span style="font-style:italic;"> </span>we completed an underwritten public offering of 5,307,692 shares of common stock (including 692,307 shares sold pursuant to the exercise of the underwriters&#8217; overallotment option)&#160;at a price of $6.50 per share. The net proceeds, after deducting $2.5 million in underwriting discounts and commissions and offering expenses payable by us, were $32.0 million.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no products approved for commercial sale and have not generated any revenue from product sales. From inception to December 31, 2020, we have raised net proceeds of approximately $452.9 million, primarily from private placements of convertible preferred stock, proceeds from our merger with Targacept, issuances of shares of common stock and warrants, including $76.4 million in total revenue received from our license and collaboration agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never been profitable and have incurred significant operating losses in each year since inception. Our net losses were $56.2 million and $55.2 million for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated deficit of $314.8 million. As of December 31, 2020, our cash, cash equivalents and investments balance were $81.9 million. Substantially all our operating losses were incurred in our research and development programs and in our general and administrative operations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to incur significant expenses and increasing operating losses for at least the next several years as we continue the preclinical, manufacturing and clinical development, and seek regulatory approval for our drug candidates. Our operating losses may fluctuate significantly from quarter to quarter and year to year due to timing of preclinical, manufacturing, clinical development programs and regulatory guidance spending.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License and Collaboration Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenue consist of revenue earned for performance obligations satisfied pursuant to our Biogen Agreement. In December 2019, we entered into a license and collaboration agreement with Biogen. In consideration for the grant of an exclusive license and related know-how, we received an up-front license payment of $15.0 million in January 2020, which was recorded in license revenue during the year ended December 31, 2020.  We also recognized collaboration revenue for reimbursable third-party vendor, out-of-pocket and personnel costs pertaining to the Biogen Agreement of $5.8 million during the year ended December 31, 2020. There can be no assurance when any future milestone or royalty payments under the Biogen agreement may occur, if at all.<span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not generated any revenue from the sale of any drugs, and we do not expect to generate any revenue from the sale of drugs until we obtain regulatory approval of and commercialize our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of License and Collaboration Revenue</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license and collaboration revenue consists of sublicense fees and fees for research and development services payable to Mosaic, fees for research and development services payable to third-party vendors, and personnel costs, corresponding to the recognition of license and collaboration revenue from Biogen. Cost of license and collaboration revenue does not include any allocated overhead costs. In connection with the license revenue recognized from Biogen as discussed above, we paid<span style="color:#000000;"> Mosaic a $3.0 million sublicense fee and recorded such payment as cost of license. We </span>recognized third-party vendor, out-of-pocket and personnel costs, most of which were reimbursable, pertaining to the Biogen Agreement of $6.1 million and recorded such costs as cost of collaboration revenue during the year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses represent costs incurred to conduct research, such as the discovery and development of our product candidates. We recognize all research and development costs as they are incurred. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">employee-related expenses, which include salaries, benefits and stock-based compensation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">laboratory and vendor expenses, including payments to consultants and third parties, related to the execution of preclinical, non-clinical, and clinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the cost of acquiring and manufacturing preclinical and clinical materials and developing manufacturing processes&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">clinical trial expenses, including costs of third-party clinical research organizations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">performing toxicity and other preclinical studies&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation and amortization expense and other supplies. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the periods presented </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-style:italic;">in&#160;thousands</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,546</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,284</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical research</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,437</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,484</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical manufacturing</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,524</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,137</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility and overhead</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,468</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">954</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,975</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,859</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The largest component of our total operating expenses has historically been our investment in research and development activities, including the clinical and manufacturing development of our product candidates. We are currently focusing substantially all our resources and development efforts on MarzAA, our complement program and DalcA. Our internal resources, employees and infrastructure are not directly tied to individual product candidates or development programs. As such, we do not maintain information regarding these costs incurred for these research and development programs on a project-specific basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our aggregate research and development expenses will increase during the next year as we advance the clinical and manufacturing development of our programs. The global coronavirus pandemic may also delay and increase costs of our current development plans.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 20, 2016, we signed a development and manufacturing services agreement with AGC, formerly known as CMC ICOS Biologics, Inc., pursuant to which AGC will conduct manufacturing development of agreed upon product candidates. We will own all intellectual property developed in such manufacturing development activities that are specifically related to our product candidates and will have a royalty-free and perpetual license to use AGC&#8217;s intellectual property to the extent reasonably necessary to make these product candidates, including commercial manufacturing. In 2016 we commenced manufacturing activities for MarzAA and as of December 31, 2020, six GMP batches have been manufactured at AGC in addition to an engineering batch to support the planned clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial term of the agreement is ten years or, if later, until all stages under outstanding statements of work have been completed. Either party may terminate the agreement in its entirety upon written notice of a material uncured breach or upon the other party&#8217;s bankruptcy, and we may terminate the agreement upon prior notice for any reason. In addition, each party may terminate the agreement in the event that the manufacturing development activities cannot be completed for technical or scientific reasons. We have firm work orders with AGC to manufacture MarzAA and DalcA to support clinical trials totaling $11.2 million. The payment obligations remaining for the year ended December 31, 2020 were $2.3 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 9, 2019, we signed a clinical supply services agreement with Catalent, effective Oct 4, 2019, pursuant to which Catalent will conduct drug product development of agreed upon product candidates. We will own, and Catalent assigns to us, the intellectual property that is specifically related to our products including the products&#8217; composition and use, and Catalent will own, and we assign to Catalent, the intellectual property that result from Catalent&#8217;s performance of its services under the clinical supply agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial term of the clinical supply agreement is three years, although the term may be extended for successive twelve-month periods, unless either party gives the other party written notice of its intent not to extend the term at least ninety (90) days prior to the expiration of the initial term or the then-current extension.&#160;&#160;Either party may terminate the clinical supply agreement in its entirety upon written notice of a material uncured breach or upon the other party&#8217;s bankruptcy, and we may terminate the clinical supply agreement for its convenience upon thirty (30) days prior written notice. In addition, each party may terminate the clinical supply agreement in the event that the other party fails to perform its obligations under the agreement for reasons beyond the reasonable control of such party, such as technical or scientific reasons. If we cancel or reschedule a project plan or purchase order outside the parameters set in the clinical supply agreement, we would be obligated to pay for a portion of Catalent&#8217;s costs less certain fees that Catalent is able to mitigate. We have committed to a total of $0.5 million in payments to Catalent pursuant to the statements of work for DalcA and zero of those payments are outstanding as of December 31, 2020. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving marketing approval for our product candidates. The probability of success of each product candidate may be affected by numerous factors, including clinical data, competition, manufacturing capability and commercial viability. As a result, we are unable to determine the duration of and costs to complete our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Successful development of current and future product candidates is highly uncertain. Completion dates and costs for our research programs can vary significantly for each current and future product candidate and are difficult to predict. Thus, we cannot estimate with any degree of certainty the costs we will incur in the development of our product candidates. We anticipate we will make determinations as to which programs and product candidates to pursue and how much funding to direct to each program and product candidate on an ongoing basis in response to the scientific success of early research programs, results of ongoing and future clinical trials, our ability to enter into collaborative agreements with respect to programs or potential product candidates, as well as ongoing assessments as to each current or future product candidate&#8217;s commercial potential. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist of personnel costs, allocated expenses and other expenses for outside professional services, including legal, human resources, audit and accounting services. Personnel costs consist of salaries, bonus, benefits and stock-based compensation. We incur expenses associated with operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), insurance expenses, audit expenses, investor relations activities, Sarbanes-Oxley compliance expenses and other administrative expenses and professional services. We expect such expenses to increase as we advance our programs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest and Other Income, Net</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income consist primarily of interest income on our investment portfolio and a payment received in the first quarter of 2020 under an agreement associated with neuronal nicotinic receptor assets sold in 2016.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables set forth our results of operations data for the periods presented <span style="font-style:italic;">(in thousands, except percentages)</span>: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change ($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change&#160;(%)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,848</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,848</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,948</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,948</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,102</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,102</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of collaboration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,061</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,061</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,975</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,859</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,116</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,180</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,418</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,762</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,318</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,277</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,041</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,370</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,277</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,129</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,099</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(970</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,241</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,178</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,063</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;text-indent:7.69%;"><span style="font-weight:normal;font-style:normal;">*<sup style="font-size:85%;line-height:120%;vertical-align:top">Not meaningful</sup></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License and Collaboration Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenue of $20.9 million generated in the year ended December 31, 2020 consisted primarily of a license payment of $15.0 million and reimbursable collaboration expenses of $5.8 million from our Biogen Agreement, which was entered into on December 18, 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of License and Collaboration Revenue</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license and collaboration revenue were $9.2 million during the year ended December 31, 2020. Cost of license revenue for the year ended December 31, 2020 primarily include the $3.0 million sublicense fee we paid to Mosaic in connection with the recognition of the license revenue from Biogen. Cost of collaboration revenue for the year ended December 31, 2020 was primarily reimbursable third-party vendor, out-of-pocket and personnel related costs we incurred pertaining to the Biogen Agreement. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $53.0 million and $43.9 million during the years ended December 31, 2020 and 2019, respectively, an increase of approximately $9.1 million, or 21%. The increase was due primarily to an increase of $2.3 million in personnel-related costs, an increase of $7.0 million in preclinical research and an increase of $0.5 million in facilities costs, partially offset by a decrease of $0.7 million in clinical manufacturing costs. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $16.2 million and $13.4 million during the years ended December 31, 2020 and 2019, respectively, an increase of approximately $2.8 million, or 21%. The increase was due primarily to an increase of $2.8 million in professional services and an increase of $0.3 million in personnel-related costs, partially offset by a decrease of $0.3 million in indirect employee and facilities costs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest and Other Income, Net</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net was $1.1 million and $2.1 million during the years ended December 31, 2020 and 2019, respectively, a decrease of $1.0 million. The decrease was primarily due to a $1.6 million decrease in interest income on investments, partially offset by a $0.6 million increase in miscellaneous and other income.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refer to Note 3 to our consolidated financial statements included within Item 8 of this Annual Report on Form 10-K for a description of recent accounting pronouncements adopted and not yet adopted for the year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had $81.9 million of cash, cash equivalents and investments. During the year ended December 31, 2020, we had a $56.2 million net loss and $55.0 million cash used in operating activities. We have an accumulated deficit of $314.8 million as of December 31, 2020. Our primary uses of cash are to fund operating expenses, including research and development expenditures and general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our existing capital resources, including cash, cash equivalents and investments will be sufficient to meet our projected operating requirements for at least the next 12 months from the date of this filing. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We plan to continue to fund losses from operations and capital funding needs through future equity and/or debt financings, as well as potential additional asset sales, licensing transactions, collaborations or strategic partnerships with other companies. At the year ended December 31, 2020, we had effective registration statements on Form S-3 that enable us to sell up to $170.0 million in securities. The sale of additional equity or </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">convertible debt could result in additional dilution to our stockholders. The incurrence of indebtedness would result in debt service obligations and could result in operating and financing covenants that would restrict our operations. Licensing transactions, collaborations or strategic partnerships may result in us relinquishing valuable rights. We can provide no assurance that financing will be available in the amounts we need or on terms acceptable to us, if at all. If we are not able to secure adequate additional funding we may be forced to delay, make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm our business.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the first quarter 2021, we sold additional equity receiving approximately $49.3 million in cash proceeds. See Note 16.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cash flows for the periods presented <span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,048</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,613</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,663</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,392</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,376</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">327</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,991</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,894</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows from Operating Activities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities for the year ended December 31, 2020 was $55.0 million, due primarily to a net loss of $56.2 million and a net change in our operating assets and liabilities of $2.6 million, due primarily to a $11.7 million decrease in accounts receivable and a $1.7 million increase in accounts payable, partially offset by a $13.0 million decrease in deferred revenue related to the Biogen Agreement and a $3.0 million increase in prepaid and other assets. This is partially offset by non-cash charges of $3.8 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities for the year ended December 31, 2019 was $43.6 million, primarily due to a net loss of $55.2 million, partially offset by non-cash charges of $3.4 million and a net change in our operating assets and liabilities of $8.2 million: primarily due to a $15.0 million increase in deferred revenue related to the upfront payment from Biogen, a $5.6 million increase in accrued compensation and other accrued liabilities, and a $3.0 million increase in accounts payable, partially offset by a $15.0 million increase in accounts receivable related to the upfront payment from Biogen, and a $0.5 million increase in prepaid and other assets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows from Investing Activities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by investing activities for the year ended December 31, 2020 was $9.7 million, due primarily to $107.6 million in proceeds from maturities of investments, partially offset by $97.6 million in purchases of short-term and long-term investments. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by investing activities for the year ended December 31, 2019 was $27.4 million, primarily due to $157.4 million in proceeds from maturities of investments, partially offset by $130.0 million in purchases of investments.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash flows from Financing Activities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities for the year ended December 31, 2020 was $60.4 million, due to $32.0 million in net proceeds from the issuance of common stock related to our public offering in February 2020, $28.0 million in net proceeds from the issuance of common stock related to our public offering in June 2020, and $0.4 million in proceeds from ESPP purchases of common stock and stock option exercises.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities for the year ended December 31, 2019 was $0.3 million due to proceeds from the </span><span style="color:#000000;">issuance of common stock from </span><span style="color:#000000;">proceeds from ESPP purchases </span><span style="color:#000000;">stock grants and </span><span style="color:#000000;">stock </span><span style="color:#000000;">option</span><span style="color:#000000;font-family:Calibri;"> </span><span style="color:#000000;">exercises</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any off-balance sheet arrangements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Polices and Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and the Company&#8217;s discussion and analysis of its financial condition and operating results require the Company&#8217;s management to make judgments, assumptions and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Our significant accounting policies and methods used in preparation of the Company&#8217;s consolidated financial statements are described in Note 3 &#8220;Summary of Significant Accounting Policies&#8221; of the Notes to the Consolidated Financial Statements of this Annual Report on Form 10-K. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management believes the Company&#8217;s critical accounting policies and estimates discussed below are critical to understanding its historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Collaboration Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may enter into collaboration arrangements that fall under the scope Collaborative Arrangements (Topic 808) (&#8220;ASC 808&#8221;). We analyze collaboration arrangements to assess whether they are within the scope of ASC 808 to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. The accounting for some of the activities under collaboration arrangements may be analogized to ASC 606 for distinct units of accounting that are reflective of a vendor-customer relationship.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, in determining the appropriate amount of revenue to be recognized as we fulfill our obligations under its agreements, we perform the following steps: (i) identification of the promised goods or services in the contract&#59; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract&#59; (iii) measurement of the transaction price, including the constraint on variable consideration&#59; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices&#59; and (v) recognition of revenue when we satisfy each performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues attributed to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we use our judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that contains development milestones, we evaluate whether the development milestones included are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not generally considered probable of being achieved until those approvals are received. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the end of each reporting period, we re-evaluate the probability of achievement of any development milestones, and if necessary, adjust its estimate of the transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For research and development services, the Company elected the practical expedient to recognize revenue as the research and development services are invoiced.&#160;&#160;As the Company has a right to consideration from the collaboration agreement with Biogen, in an amount that corresponds directly with the value of the Company&#8217;s performance completed to date for the research services, the Company recognized revenue related to the research services as invoiced, in line with the practical expedient in ASC 606-10-55-18.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is allocated to each performance obligation on a relative stand-alone selling price (&#8220;SSP&#8221;) basis. We recognize revenue as or when the performance obligations under the contract are satisfied. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the timing of recognition and the SSP for each performance obligation identified in the contract.&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SSP for licenses are calculated using the residual approach if we have not yet established a price for such license and the license has not previously been sold on a standalone basis.&#160;Otherwise, selling prices for licenses are determined using an income approach model and include key assumptions such as: development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success. To estimate the SSP for research and development services, we use a cost-plus margin approach. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accrued expenses for estimated costs of our research and development activities conducted by external service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. We record the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in other accrued liabilities in the consolidated balance sheet and within research and development expense in the consolidated statement of operations. These costs are a significant component of our research and development expenses. We record accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these external service providers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the amount of work completed through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust its accrued estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure the cost of employee and director services received in exchange for an award of equity instruments based on the fair value-based measurement of the award on the date of grant and recognize the related expense over the period during which an employee or director is required to provide service in exchange for the award on a straight-line basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Determining the fair value of stock-based awards at the grant date requires judgment. We use the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option-pricing model is affected by our assumptions regarding a number of variables including the fair value of our common stock, our expected common stock price volatility over the expected life of the options, expected term of the stock option, risk-free interest rates and expected dividends. We record stock-based compensation as a compensation expense, net of the forfeited awards. We elected to account for forfeitures when they occur. As such, we recognize stock-based compensation expense only for those stock-based awards that are expected to vest, over their requisite service period, based on the vesting provisions of the individual grants.&#160;See Note 10,<span style="font-style:italic;"> </span>to our consolidated financial statements included in this Annual Report on Form 10-K for more information.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">Item&#160;7A.<span style="margin-left:36pt;">QUANTITATIVE AND QUALITAT</span>IVE DISCLOSURES ABOUT MARKET RISK</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.47%;text-indent:-10.47%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CATALYST BIOSCIENCES, INC.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Index to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:none;">Report of Independent Registered Public Accounting Firm</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Financial Statements</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36.75pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:none;">Consolidated Balance Sheets</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
</tr>
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36.75pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><span style="text-decoration:none;">Consolidated Statements of Operations</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
</tr>
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36.75pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"><span style="text-decoration:none;">Consolidated Statements of Comprehensive Loss</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
</tr>
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36.75pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"><span style="text-decoration:none;">Consolidated Statements of Stockholders&#8217; Equity</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></td>
</tr>
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36.75pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:none;">Consolidated Statements of Cash Flows</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
</tr>
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36.75pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:none;">Notes to the Consolidated Financial Statements</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Board of Directors and Stockholders of</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Opinion on the Financial Statements </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) as of December 31, 2020 and 2019, and the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).&#160;&#160;In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2020 and 2019, and the consolidated results of their operations and their cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis for Opinion </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management.&#160;&#160;Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits.&#160;&#160;We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB.&#160;&#160;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.&#160;&#160;The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.&#160;&#160;As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.&#160;&#160;Accordingly, we express no such opinion.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.&#160;&#160;Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.&#160;&#160;Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.&#160;&#160;We believe that our audits provide a reasonable basis for our opinion.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Critical Audit Matter</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved especially challenging, subjective, or complex judgments.&#160;&#160;The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in Note 3 to the consolidated financial statements, the Company is required to estimate their expenses resulting from their research and development activities conducted by external service providers, which include the performance of preclinical studies and clinical trials and contract manufacturing activities. The Company recorded accrued expenses related to research and development activities of $5.9 million, which are included in other accrued liabilities on the December 31, 2020 consolidated balance sheet and also recorded prepaid research and development expenses of $5.6 million, which are included in prepaid and other current assets on the December 31, 2020 consolidated balance sheet. The amounts recorded for research and development accruals and for prepaid research and development expenses, within the aforementioned balance sheet captions represent the Company&#8217;s estimate of the unpaid and prepaid research and development expenses based on the progress of the research and development activities for clinical trials compared to the amounts paid for clinical trials through December 31, 2020.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s estimate of research and development expenses is based on the estimated amount of services provided but not yet invoiced, the estimated amount of work completed and estimates to completion and in accordance with agreements established with these external service providers.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We identified management&#8217;s estimate of the research and development expenses as a critical audit matter. There was significant judgment required by management with respect to the estimate of the amount of work completed, as the calculation includes estimates of the progress or stage of completion of the services.&#160;&#160;This in turn led to a high degree of auditor judgment, subjectivity and effort in applying the procedures related to those estimates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements.&#160;&#160;We obtained an understanding and evaluated the design of the controls over the Company&#8217;s process of estimation and assumptions used in the estimation of the research and development expenses.&#160;&#160;We performed procedures to test the research and development accruals and prepaid balances that included, among others, reading agreements with external service providers and evaluating the significant assumptions described above and methods used in developing the research and development estimates and calculating the amounts that were unpaid and prepaid at the balance sheet date. We made direct inquiries of financial and clinical personnel on the status of the research and development activities, progress towards completion, and status of any change orders. We compared the current estimate of expenses incurred to estimates previously made by management. We also assessed the historical accuracy of management&#8217;s estimates and examined invoices issued and payments made to services providers after the consolidated balance sheet date.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ EisnerAmper LLP</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2014.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EISNERAMPER LLP</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Iselin, New Jersey </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_BALANCE_SHEETS">Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except shares and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:ShortTermInvestments" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">48,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:ShortTermInvestments" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,496</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,843</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,201</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:AssetsCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,510</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:AssetsCurrent" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">96,066</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:LongTermInvestments" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,543</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets, noncurrent</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001124105_20201231" decimals="-3" scale="3">528</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001124105_20191231" decimals="-3" scale="3">257</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,832</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,927</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001124105_20201231" decimals="-3" scale="3">433</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001124105_20191231" decimals="-3" scale="3">304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:Assets" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">94,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:Assets" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">98,554</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,279</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,106</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:DeferredRevenueCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,983</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:DeferredRevenueCurrent" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,031</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001124105_20201231" decimals="-3" scale="3">663</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001124105_20191231" decimals="-3" scale="3">483</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,796</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,899</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, noncurrent</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001124105_20201231" decimals="-3" scale="3">981</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,319</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:Liabilities" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,777</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:Liabilities" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,218</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and Contingencies (Note 7)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000069">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000070">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000085" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001124105_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000086" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001124105_20191231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000087" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001124105_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000088" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001124105_20191231" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000089" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001124105_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000090" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001124105_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000091" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001124105_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000092" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001124105_20191231" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; shares issued and outstanding</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000071">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000072">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000093" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001124105_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000094" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001124105_20191231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000095" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001124105_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000096" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001124105_20191231" decimals="INF" format="ixt:numdotdecimal">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; <ix:nonFraction unitRef="U_xbrlishares" id="F_000097" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001124105_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000099" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001124105_20201231" decimals="INF" format="ixt:numdotdecimal">22,097,820</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000098" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001124105_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000100" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001124105_20191231" decimals="INF" format="ixt:numdotdecimal">12,040,835</ix:nonFraction></ix:nonFraction> shares issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:CommonStockValue" contextRef="C_0001124105_20201231" decimals="-3" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:CommonStockValue" contextRef="C_0001124105_20191231" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">390,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">326,810</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001124105_20201231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001124105_20191231" decimals="-3" scale="3">34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001124105_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">314,761</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001124105_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">258,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,069</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">94,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">98,554</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_OPERATIONS">Consolidated Statements of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,948</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCostOfLicenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,102</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of collaboration</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,061</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,975</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">43,859</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,418</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:OperatingExpenses" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">78,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:OperatingExpenses" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">57,277</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">57,370</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001124105_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">57,277</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="cbio:InterestAndOtherIncomeExpenseNet" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="cbio:InterestAndOtherIncomeExpenseNet" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,099</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">56,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,178</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000118" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001124105_20200101_20201231" decimals="2" sign="-">2.93</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000119" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001124105_20190101_20191231" decimals="2" sign="-">4.60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares used to compute net loss per share attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stockholders, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000120" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001124105_20200101_20201231" decimals="0" format="ixt:numdotdecimal">19,179,299</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000121" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001124105_20190101_20191231" decimals="0" format="ixt:numdotdecimal">12,004,489</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO">Consolidated Statements of Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">56,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,178</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income (loss):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized (loss) gain on available-for-sale debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" scale="3">29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001124105_20190101_20191231" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">56,270</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001124105_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU">Consolidated Statements of Stockholders&#8217; Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000128" name="us-gaap:SharesOutstanding" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" format="ixt:numdotdecimal">11,954,528</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">323,279</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" sign="-" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">203,342</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">119,945</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000134" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">24,235</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from ESPP purchases and stock option exercises</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000137" name="cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">62,072</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" contextRef="C_0001124105_20190101_20191231" decimals="-3" scale="3">327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on available-for-sale debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001124105_20190101_20191231" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,178</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,178</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000144" name="us-gaap:SharesOutstanding" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">12,040,835</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">326,810</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" scale="3">34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">258,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000150" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">51,056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from ESPP purchases and stock option exercises</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000153" name="cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">82,853</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for public offering, net of issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,559</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000156" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">9,923,076</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,941</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on available-for-sale debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" sign="-" scale="3">29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" scale="3">29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">56,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">56,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000164" name="us-gaap:SharesOutstanding" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">22,097,820</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">390,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">314,761</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,069</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:21.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">Consolidated Statements of Cash Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:ProfitLoss" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">56,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:ProfitLoss" contextRef="C_0001124105_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,178</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:ShareBasedCompensation" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:ShareBasedCompensation" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001124105_20190101_20191231" decimals="-3" scale="3">146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">11,687</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001124105_20190101_20191231" decimals="-3" scale="3">490</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,652</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,031</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and other accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">82</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,599</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability and right-of-use asset</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">67</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" contextRef="C_0001124105_20190101_20191231" decimals="-3" scale="3">75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,048</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001124105_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">43,613</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investing Activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities of short-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">107,565</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">157,433</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of short-term and long-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="cbio:PaymentsToAcquireShortTermAndLongInvestments" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">97,635</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="cbio:PaymentsToAcquireShortTermAndLongInvestments" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">129,977</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">267</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_0001124105_20190101_20191231" decimals="-3" scale="3">64</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows provided by investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,663</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,392</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing Activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for public offering, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="cbio:ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,941</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from ESPP purchase and stock option exercises</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="cbio:ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="cbio:ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" contextRef="C_0001124105_20190101_20191231" decimals="-3" scale="3">327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">60,376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001124105_20190101_20191231" decimals="-3" scale="3">327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,991</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001124105_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">15,894</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at beginning of the period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001124105_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,263</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of the period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental Disclosure of Non-Cash Investing and Financing Activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use asset and operating lease liability recorded upon the adoption of ASC 842</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="cbio:NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,052</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="cbio:NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN">Notes to the Consolidated Financial Statements</p><ix:nonNumeric id="F_000212" name="us-gaap:NatureOfOperations" contextRef="C_0001124105_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="NOTES_TO_CONSOLIDATED">Nature of Operations</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. and its subsidiary (the &#8220;Company&#8221; or &#8220;Catalyst&#8221;) is a <span style="color:#000000;">fully integrated research and clinical development biopharmaceutical company with expertise in protease engineering, discovery, translational research, clinical development, and manufacturing. The Company is focused on advancing its protease product candidates in the fields of hemostasis and complement regulation.</span> <span style="color:#000000;">The Company is located in South San Francisco, California and operates in</span> <ix:nonFraction unitRef="U_cbioSegment" id="F_000261" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001124105_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> segment. </p></ix:nonNumeric><ix:nonNumeric id="F_000213" name="us-gaap:LiquidationBasisOfAccountingTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Liquidity<span style="font-weight:normal;"> </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had a net loss of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20200101_20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">56.2</ix:nonFraction> million for the year ended December 31, 2020 and an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001124105_20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">314.8</ix:nonFraction> million as of December 31, 2020. The Company expects to continue to incur losses for the next several years. As of December 31, 2020, the Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="C_0001124105_20201231" decimals="-5" scale="6">81.9</ix:nonFraction> million of cash, cash equivalents and investments. Its primary uses of cash are to fund operating expenses, including research and development expenditures and general and administrative expenditures. Based on the current status of its research and development plans, the Company believes that its existing cash, cash equivalents and investments as of December 31, 2020 will be sufficient to fund its cash requirements for at least the next 12 months from the date of the filing of this report. If, at any time, the Company&#8217;s prospects for financing its research and development programs decline, the Company may decide to reduce research and development expenses by delaying, discontinuing or reducing its funding of one or more of its research or development programs. Alternatively, the Company might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The Company will continue to evaluate the impact of the COVID-19 pandemic on our business, operations, and cash requirements. For recent financing, see Note 16.</p></ix:nonNumeric><ix:nonNumeric id="F_000214" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000214_dcnt_79bd21fe-9341-4854-b5d2-dc3b600e9266">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies</p></td></tr></table></div><ix:nonNumeric id="F_000228" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation. The Company&#8217;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). &#160;&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000229" name="us-gaap:UseOfEstimates" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, operating lease right-of-use assets and liabilities, accrued expenses, income taxes and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric id="F_000230" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000230_dcnt_0fa3fc36-9d07-4e60-84b1-b18a8c243c22">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Pronouncements Recently Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-18,&#160;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606 (&#8220;ASU 2018-18&#8221;). The amended guidance precludes presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The new guidance is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2018-18 as of January 1, 2020. The adoption of ASU 2018-18 did not have a material impact on the Company&#8217;s consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement (&#8220;ASU 2018-13&#8221;). The </p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000214_dcnt_79bd21fe-9341-4854-b5d2-dc3b600e9266" continuedAt="F_000214_dcnt_cd81d71f-adca-494b-9d6f-db65ba357680"><ix:continuation id="F_000230_dcnt_0fa3fc36-9d07-4e60-84b1-b18a8c243c22">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">guidance removes, modifies, and adds certain disclosure requirements for fair value measurements. Entities no longer have to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The guidance is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2018-13 as of January 1, 2020. The adoption of ASU 2018-13 did not have a material impact on the Company&#8217;s consolidated financial statements. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,<span style="font-style:italic;">&#160;</span>Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to adopt ASU 2016-13&#160;and related updates&#160;as of January 1, 2023.&#160;The Company will assess the impact of adoption of this standard on its consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued&#160;ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes<span style="font-style:italic;">. </span>The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes.&#160;ASU 2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning January 1, 2021. The adoption of this standard will not have a material impact on the Company&#8217;s consolidated financial statements<span style="color:#000000;">.</span></p></ix:continuation><ix:nonNumeric id="F_000231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.</p></ix:nonNumeric><ix:nonNumeric id="F_000232" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000232_dcnt_d559f26b-4cc6-47ae-a713-466d373ba7c4">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 1<span style="font-style:normal;"> &#8211; Quoted prices in active markets for identical assets or liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 2<span style="font-style:normal;"> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 3<span style="font-style:normal;"> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000214_dcnt_cd81d71f-adca-494b-9d6f-db65ba357680" continuedAt="F_000214_dcnt_abc11f64-65de-4a5b-83a0-fba4f7ecb169"><ix:continuation id="F_000232_dcnt_d559f26b-4cc6-47ae-a713-466d373ba7c4">
</ix:continuation><ix:nonNumeric id="F_000233" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, which are <ix:nonNumeric id="F_000266" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001124105_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_000267" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001124105_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20200101_20201231" format="ixt-sec:durwordsen">three years</ix:nonNumeric></ix:nonNumeric> for computer equipment and software, and three to <ix:nonNumeric id="F_000269" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_000271" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231" format="ixt-sec:durwordsen">seven years</ix:nonNumeric></ix:nonNumeric> for furniture and leasehold improvements.</p></ix:nonNumeric><ix:nonNumeric id="F_000234" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash in investment grade, short to intermediate-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#8220;available-for-sale&#8221; and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation as of each consolidated balance sheet date. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value determined to be other-than-temporary, if any, on available-for-sale debt securities are included in interest and other income, net. The cost of securities sold is based on the specific-identification method. Interest on short-term investments is included in interest and other income, net.</p></ix:nonNumeric><ix:nonNumeric id="F_000235" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000235_dcnt_d9990dc1-be6d-4798-ba6c-40957ac2be16">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Collaboration Arrangements </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.21%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may enter into collaboration arrangements that fall under the scope Collaborative Arrangements (Topic 808). The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808 to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. The accounting for some of the activities under collaboration arrangements may be analogized to ASC 606 for distinct units of account that are reflective of a vendor-customer relationship.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract&#59; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract&#59; (iii) measurement of the transaction price, including the constraint on variable consideration&#59; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices&#59; and (v) recognition of revenue when the Company satisfies each performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues attributed to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that contain development milestones, the Company evaluates whether the development milestones included are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not generally considered probable of being achieved until those approvals are received.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the end of each reporting period, the Company re-evaluates the probability of achievement of any development milestones, and if necessary, adjusts its estimate of the transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For research and development services, the Company elected the practical expedient to recognize revenue as the research and development services are invoiced.&#160;&#160;As the Company has a right to consideration from the </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000214_dcnt_abc11f64-65de-4a5b-83a0-fba4f7ecb169" continuedAt="F_000214_dcnt_9c0e6e94-0733-47b1-99e2-2b4b42ae21fa"><ix:continuation id="F_000235_dcnt_d9990dc1-be6d-4798-ba6c-40957ac2be16">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaboration agreement with Biogen, in an amount that corresponds directly with the value of the Company&#8217;s performance completed to date for the research services, the Company recognized revenue related to the research services as invoiced, in line with the practical expedient in ASC 606-10-55-18.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is allocated to each performance obligation on a relative stand-alone selling price (&#8220;SSP&#8221;) basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the timing of recognition and the SSP for each performance obligation identified in the contract.&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SSP for licenses are calculated using the residual approach if the Company has not yet established a price for such license and the license has not previously been sold on a standalone basis.&#160;Otherwise, selling prices for licenses are determined using an income approach model and include key assumptions such as: development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success. To estimate the SSP for research and development services, the Company uses a cost-plus margin approach. </p></ix:continuation><ix:nonNumeric id="F_000236" name="cbio:CostOfLicenseAndCollaborationRevenuePolicyTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of License and Collaboration Revenue</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license revenue includes sublicense fees paid or payable to Mosaic Biosciences, Inc. (&#8220;Mosaic&#8221;), incurred in the period, under the terms of the Mosaic collaboration agreement, and fees for patent development and protection paid or payable to other third-party vendors corresponding to the recognition of license revenue from the Company&#8217;s collaboration agreement with Biogen International GmbH (&#8220;Biogen&#8221;). See<span style="color:#000000;"> Notes 8 and 12. Cost of license revenue does not include any allocated overhead costs.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of collaboration revenue includes fees for research and development services paid or payable to Mosaic and other third-party vendors and personnel cost, incurred in the period pertaining to the Biogen Agreement. See<span style="color:#000000;"> Notes 8 and 12. Cost of collaboration revenue does not include any allocated overhead costs.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000237" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, and consulting costs, as well as allocations of facilities and other overhead costs. Under the Company&#8217;s collaboration agreement with Biogen, certain specific expenditures are reimbursed by third parties. During the year ended December 31, 2020, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="cbio:CostOfCollaborationRevenue" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-5" scale="6">5.4</ix:nonFraction> million of research and development expense was recorded as cost of collaboration revenue related to the collaboration agreement with Biogen signed in December 2019.</p></ix:nonNumeric><ix:nonNumeric id="F_000238" name="cbio:AccruedResearchAndDevelopmentExpensesPolicyTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000238_dcnt_39670fb2-adcd-4b20-8a82-71ea62c61c4f">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses include estimated costs of research and development activities conducted by external service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in other accrued liabilities in the consolidated balance sheet and within research and development expense in the consolidated statement of operations. These costs are a significant component of the research and development expenses. The Company records accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these external service providers.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000214_dcnt_9c0e6e94-0733-47b1-99e2-2b4b42ae21fa" continuedAt="F_000214_dcnt_99d86fa2-b865-4b30-bbf0-4f109dc66468"><ix:continuation id="F_000238_dcnt_39670fb2-adcd-4b20-8a82-71ea62c61c4f">
</ix:continuation><ix:nonNumeric id="F_000239" name="cbio:ConcentrationRiskCreditRiskPolicyTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, investments and accounts receivable. The Company&#8217;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company believes that it has established guidelines for investment of its excess cash that maintain safety and liquidity through its policies on high quality of investment and investment duration. The Company is exposed to credit risk in the event of default by the institutions holding the cash and cash equivalents to the extent beyond the amount insured by the federal depository insurance corporation. The Company&#8217;s accounts receivable as of December 31, 2020 of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:AccountsReceivableGrossCurrent" contextRef="C_0001124105_20201231" decimals="-5" scale="6">3.3</ix:nonFraction> million as well as its total license and collaboration revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_20200101_20201231" decimals="-5" scale="6">20.9</ix:nonFraction> million for the year ended December 31, 2020 is from one party, see Note 12.&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000240" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounts Receivable, net and Allowance for Doubtful Accounts</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under the arrangements. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time balances are past due, the Company&#8217;s previous loss history, the customer&#8217;s current ability to pay its obligations to the Company and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are determined to be uncollectible. For the years ended December 31, 2020 and 2019, there were no allowance for doubtful accounts deemed necessary.</p></ix:nonNumeric><ix:nonNumeric id="F_000241" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are computed using the liability method. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the authoritative guidance on accounting for uncertainty in income taxes. This guidance prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company&#8217;s income tax returns. This interpretation also provides guidance on accounting for interest and penalties and associated with tax positions, accounting for income taxes in interim periods and income tax disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary.</p></ix:nonNumeric><ix:nonNumeric id="F_000242" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000242_dcnt_e13525a5-bcd8-41c6-a420-5d842080a9bb">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant and recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option-pricing valuation model to estimate the grant-date fair value of stock-based awards. The determination of fair value for stock-based awards on the date of grant using an option-pricing model requires management to make certain assumptions regarding a number of variables. The Company elected to account for forfeitures when they occur. As such, the Company recognizes stock-based compensation expense, over their requisite service period, based on the vesting provisions of the individual grants.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000214_dcnt_99d86fa2-b865-4b30-bbf0-4f109dc66468"><ix:continuation id="F_000242_dcnt_e13525a5-bcd8-41c6-a420-5d842080a9bb">
</ix:continuation><ix:nonNumeric id="F_000243" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected to combine lease and non-lease components as a single component. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the consolidated balance sheet as right-of-use assets, operating lease liabilities, current and operating lease liabilities, non-current. </p></ix:nonNumeric><ix:nonNumeric id="F_000244" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss of the Company for all periods presented.</p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000215" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000215_dcnt_3778d338-7300-4f79-aacb-a9af3517fc1d">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value Measurements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a description of the fair value hierarchy and fair value methodology, see &#8220;<span style="font-style:italic;">Note 3 &#8211; Summary of Significant Accounting Policies</span>&#8221;. As of December 31, 2020 and 2019, the Company&#8217;s highly liquid money market funds included within cash equivalents and U.S. government agency securities are valued using Level&#160;1 inputs. The Company classifies its federal agency securities as Level 2. There were no transfers in or out of Level 1 and Level 2 during the periods presented. U.S. government agency securities are bonds issued by the U.S. government and are fully backed by the U.S. government. Given the frequency at which U.S. government agency securities trade and the accessibility of observable, quoted prices for such assets in active markets, they are recognized as Level 1 assets. Federal agency securities are bonds and notes issued by government-sponsored enterprises, including Fannie Mae, Freddie Mac and the Federal Home Loan Bank. Since Federal agency securities typically do not trade as U.S. government agency securities and no exchange exists to price such investments, they are recognized as Level 2 assets. </p><ix:nonNumeric id="F_000245" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000245_dcnt_4c81766c-2025-4e9b-bd99-22f597e11192"></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000215_dcnt_3778d338-7300-4f79-aacb-a9af3517fc1d"><ix:continuation id="F_000245_dcnt_4c81766c-2025-4e9b-bd99-22f597e11192">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present the fair value hierarchy for assets measured at fair value on a recurring basis as of December 31, 2020 and 2019 <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,837</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,837</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">81,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><ix:footnote id="FNT_000000" xml:lang="en-US">Included in cash and cash equivalents on accompanying consolidated balance sheet.</ix:footnote></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><ix:footnote id="FNT_000001" xml:lang="en-US">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. $<ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20201231" decimals="-5" scale="6">2.5</ix:nonFraction> million of U.S. government agency securities are included in long-term investments on the accompanying consolidated balance sheets due to the maturity being more than 12 months.</ix:footnote></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,490</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,490</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,006</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,006</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">66,859</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,006</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><ix:footnote id="FNT_000002" xml:lang="en-US">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities.</ix:footnote> &#160;</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-0.43%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000216" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000216_dcnt_4b451086-ee1a-45ad-8c9d-1147ea6e6b8b">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Instruments</p></td></tr></table></div><ix:nonNumeric id="F_000246" name="us-gaap:AvailableForSaleSecuritiesTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000246_dcnt_7e466d20-b2fe-4ae8-88ca-dbd61a939e72">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents and investments (debt securities) which are classified as available-for-sale securities, consisted of the following <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,835</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,837</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">81,892</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001124105_20201231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">81,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">48,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,543</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">81,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000216_dcnt_4b451086-ee1a-45ad-8c9d-1147ea6e6b8b"><ix:continuation id="F_000246_dcnt_7e466d20-b2fe-4ae8-88ca-dbd61a939e72">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,467</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" scale="3">23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,490</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,995</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20191231" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,006</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,831</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001124105_20191231" decimals="-3" scale="3">34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,496</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been <ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet" contextRef="C_0001124105_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> material realized gains or losses on available-for-sale debt securities for the periods presented. As of December 31, 2020, the remaining contractual maturities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001124105_20201231" decimals="-5" scale="6">49.0</ix:nonFraction> million of available-for-sale debt securities was less than one year and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="C_0001124105_20201231" decimals="-5" scale="6">2.5</ix:nonFraction> million of available-for-sale debt securities were less than two years. </p></ix:continuation><ix:nonNumeric id="F_000217" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Other Accrued Liabilities </p></td></tr></table></div><ix:nonNumeric id="F_000247" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities consisted of the following <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional and consulting services</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,979</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,026</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="cbio:AccruedManufacturingExpensesCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="cbio:AccruedManufacturingExpensesCurrent" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,320</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="cbio:AccruedClinicalExpensesCurrent" contextRef="C_0001124105_20201231" decimals="-3" scale="3">291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="cbio:AccruedClinicalExpensesCurrent" contextRef="C_0001124105_20191231" decimals="-3" scale="3">435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="cbio:AccruedAndOtherCurrentLiabilities" contextRef="C_0001124105_20201231" decimals="-3" scale="3">235</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="cbio:AccruedAndOtherCurrentLiabilities" contextRef="C_0001124105_20191231" decimals="-3" scale="3">250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,031</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000218" name="us-gaap:CommitmentsDisclosureTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000218_dcnt_f12ad1df-2dc5-464f-b8d9-eaac1aede5fc">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing Agreements</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 20, 2016, the Company signed a development and manufacturing services agreement with AGC Biologics, Inc. (&#8220;AGC&#8221;), formerly known as CMC ICOS Biologics, Inc., pursuant to which AGC will conduct manufacturing development of agreed upon product candidates. The Company has firm work orders with AGC to manufacture MarzAA and DalcA to support its clinical trials totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="cbio:ClinicalTrials" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_20201231" decimals="-5" scale="6">11.2</ix:nonFraction> million and the payment obligations remaining at the year ended December 31, 2020 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="us-gaap:ContractualObligation" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_20201231" decimals="-5" scale="6">2.3</ix:nonFraction> million.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 9, 2019, the Company and Catalent Indiana, LLC (&#8220;Catalent&#8221;) signed a clinical supply services agreement, effective October 4, 2019, pursuant to which Catalent will conduct drug product development of agreed upon product candidates. The Company had firm work orders with Catalent to manufacture DalcA to support its clinical trial totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="cbio:ClinicalTrials" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioCatalentIndianaLLCMember_srtProductOrServiceAxis_cbioDalcinonacogAlfaMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="cbio:ClinicalTrialsPaid" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioCatalentIndianaLLCMember_srtProductOrServiceAxis_cbioDalcinonacogAlfaMember_20201231" decimals="-5" scale="6">0.5</ix:nonFraction></ix:nonFraction> million and all outstanding amounts were paid during the year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, potential trial participants and business operations. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national, and international markets. The COVID-19 pandemic may disrupt the operations of the Company&#8217;s manufacturers or disrupt supply logistics, which could impact the timing of deliveries and potentially increase expenses under our agreements. All required MarzAA supplies for the MAA-304 and MAA-202 studies have been manufactured.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000218_dcnt_f12ad1df-2dc5-464f-b8d9-eaac1aede5fc">
</ix:continuation><ix:nonNumeric id="F_000219" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Related Parties</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 24, 2017, the Company announced a strategic research collaboration with Mosaic to develop intravitreal anti-complement factor 3 (C3) products for the treatment of dry Age-related Macular Degeneration (AMD) and other retinal diseases. Dr. Usman, the Company&#8217;s Chief Executive Officer and a member of the Company&#8217;s board of directors, and Mr. Lawlor, a member of the Company&#8217;s board of directors, were also members of the board of directors of Mosaic. On December 21, 2018, the Company amended its collaboration agreement with Mosaic to, among other things, include certain additional products. Pursuant to the Mosaic collaboration agreement, as amended, the Company and Mosaic co-funded certain research. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 18, 2019, the Company entered into the second amendment to the Mosaic collaboration agreement following completion of the co-funded research. Pursuant to the second amendment, any future services provided by Mosaic will be performed on a fee-for-service basis. In connection with the Biogen Agreement, the Company received a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="cbio:UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" contextRef="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_cbioBiogenCollaborationMember_20200110" decimals="-5" scale="6">15.0</ix:nonFraction> million upfront license fee on January 10, 2020, see Note 12. The Company paid Mosaic a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="cbio:SublicenseFee" contextRef="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200101_20201231" decimals="-5" scale="6">3.0</ix:nonFraction> million sublicense fee and recorded such payment as cost of license revenue for the year ended December 31, 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 8, 2020, the Company entered into a subsequent amendment to the Mosaic collaboration agreement. As part of this amendment, the Company paid a one-time $<ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508" decimals="-5" scale="6">0.8</ix:nonFraction> million cash payment to Mosaic, and Mosaic is eligible to receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="cbio:MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508" decimals="-5" scale="6">4.0</ix:nonFraction> million in potential future milestone payments related to regulatory and clinical development events for CB 2782-PEG and an additional anti-complement product candidate in lieu of the Company&#8217;s obligations to pay Mosaic a double-digit percentage of funds the Company receives from Biogen or any other amounts the Company receives related to sublicense fees, research and development payments, or any other research, regulatory, clinical or commercial milestones and royalties on any other development candidates. The Company now owns one hundred percent of all future payment streams related to these product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The one-time $<ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200101_20201231" decimals="-5" scale="6">0.8</ix:nonFraction> million cash payment was recorded to research and development expenses for the year ended December 31, 2020.<span style="color:#000000;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2020, Mosaic was no longer a related party. Total expense related to the collaboration with Mosaic were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="cbio:TotalTransactionExpensesRelatedToCollaboration" contextRef="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231" decimals="-5" scale="6">1.6</ix:nonFraction> million for the year ended December 31, 2020, of which expense recognized while Mosaic was a related party were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231" decimals="-5" scale="6">1.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231" decimals="-5" scale="6">1.1</ix:nonFraction> million for the year ended December 31, 2019. The amount incurred in 2020 is fully reimbursable under the Biogen Agreement, see Note 12.</p></ix:nonNumeric><ix:nonNumeric id="F_000220" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000220_dcnt_165bd708-49f0-4641-8c94-f046465016c1">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space for its corporate headquarters, located in South San Francisco, CA. The lease term is through <ix:nonNumeric id="F_000348" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001124105_20200101_20201231" format="ixt:datemonthdayyearen">April 30, 2023</ix:nonNumeric> and there are <ix:nonNumeric id="F_000349" name="cbio:LesseeOperatingLeaseRenewalTermDescription" contextRef="C_0001124105_20200101_20201231">no stated renewal options</ix:nonNumeric>. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not the remaining lease term. The lease includes non-lease components (<span style="font-style:italic;">e.g.</span>, common area maintenance) that are paid separately from rent based on actual costs incurred and therefore were not included in the right-of-use asset and lease liability but are reflected as an expense in the period incurred.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 17, 2020, the Company entered into an amendment to the existing lease agreement to lease additional office space for an aggregated undiscounted future monthly payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001124105_20200717" decimals="-5" scale="6">0.5</ix:nonFraction> million. This amendment is treated as a separate lease with a lease term of <ix:nonNumeric id="F_000351" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001124105_20200717" format="ixt-sec:duryear">2.6</ix:nonNumeric> years and <ix:nonNumeric id="F_000350" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedDescription" contextRef="C_0001124105_20200716_20200717">commenced during the fourth quarter of 2020.</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2020 and 2019, the Company&#8217;s operating lease expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001124105_20200101_20201231" decimals="-5" scale="6">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001124105_20190101_20191231" decimals="-5" scale="6">0.6</ix:nonFraction> million, respectively. <ix:nonNumeric id="F_000248" name="cbio:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000248_cnt_1">The present value assumptions used in calculating the present value of the lease payments were as follows:</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000248_cnt_1" continuedAt="F_000248_dcnt_1e546a57-e39a-44c4-a6ea-62144840d849">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000355" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001124105_20201231" format="ixt-sec:duryear">2.33</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000356" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001124105_20191231" format="ixt-sec:duryear">3.33</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000357" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001124105_20201231" decimals="3" scale="-2">5.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000358" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001124105_20191231" decimals="3" scale="-2">6.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p></ix:continuation></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000220_dcnt_165bd708-49f0-4641-8c94-f046465016c1"><ix:continuation id="F_000248_dcnt_1e546a57-e39a-44c4-a6ea-62144840d849">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000249" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity of the Company&#8217;s operating lease liabilities as of&#160;December&#160;31, 2020 were as follows&#160;<span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Undiscounted lease payments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001124105_20201231" decimals="-3" scale="3">739</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001124105_20201231" decimals="-3" scale="3">762</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001124105_20201231" decimals="-3" scale="3">259</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,760</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001124105_20201231" decimals="-3" scale="3">116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000250" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. The Company did not incur significant variable lease costs for the years ended December 31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information for the years ended December 31, 2020 and 2019 related to operating leases was as follows&#160;<span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for leases that were included in operating cash</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; outflows</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:OperatingLeasePayments" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:OperatingLeasePayments" contextRef="C_0001124105_20190101_20191231" decimals="-3" scale="3">562</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000221" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000221_dcnt_6a2159aa-92b7-42eb-a302-fc42c501102f">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock Based Compensation</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2018 Omnibus Incentive Plan </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, stockholders of the Company approved the Company&#8217;s 2018 Omnibus Incentive Plan (the &#8220;2018 Plan&#8221;). The 2018 Plan had previously been approved by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and the Compensation Committee of the Board, subject to stockholder approval. The 2018 Plan became effective on June 13, 2018. On June 11, 2020, the stockholders of the Company approved an amendment previously approved by the Board to increase the number of shares of common stock reserved for issuance under the 2018 Plan by <ix:nonFraction unitRef="U_xbrlishares" id="F_000367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20200611_20200611" decimals="INF" format="ixt:numdotdecimal">1,300,000</ix:nonFraction> to a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000368" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20200611" decimals="INF" format="ixt:numdotdecimal">2,800,000</ix:nonFraction> shares. The amendment became effective immediately upon stockholder approval. </p><ix:nonNumeric id="F_000251" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000251_dcnt_809ab317-e5e8-4e6c-87ee-d82e336adb10"></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000221_dcnt_6a2159aa-92b7-42eb-a302-fc42c501102f" continuedAt="F_000221_dcnt_03795116-b020-48eb-840a-6f3891e4fccb"><ix:continuation id="F_000251_dcnt_809ab317-e5e8-4e6c-87ee-d82e336adb10">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under the Company&#8217;s equity incentive plans and related information:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000369" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001124105_20181231" decimals="INF" format="ixt:numdotdecimal">1,361,977</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000382" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001124105_20181231" decimals="2">12.04</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000394">8.71</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001124105_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000370" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001124105_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">450,900</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000383" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20190101_20191231" decimals="2">7.85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000371" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001124105_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">41,219</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000384" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20190101_20191231" decimals="2">4.57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001124105_20190101_20191231" decimals="-3" scale="3">159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000372" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001124105_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">182,722</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000385" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20190101_20191231" decimals="2">8.36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000373" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_0001124105_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">11,395</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000386" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20190101_20191231" decimals="2">96.49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000374" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001124105_20191231" decimals="INF" format="ixt:numdotdecimal">1,577,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000387" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001124105_20191231" decimals="2">10.85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000395">8.15</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,350</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000375" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001124105_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,091,250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000388" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20200101_20201231" decimals="2">6.26</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000376" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001124105_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">44,605</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000389" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20200101_20201231" decimals="2">5.04</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000377" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001124105_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">250,641</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000390" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20200101_20201231" decimals="2">10.32</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000378" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_0001124105_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">17,930</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000391" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20200101_20201231" decimals="2">51.12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000379" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001124105_20201231" decimals="INF" format="ixt:numdotdecimal">2,355,615</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000392" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001124105_20201231" decimals="2">8.59</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000396">7.96</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable &#8212; December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000380" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001124105_20201231" decimals="INF" format="ixt:numdotdecimal">1,113,791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000393" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001124105_20201231" decimals="2">10.45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000397">7.14</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001124105_20201231" decimals="-3" scale="3">823</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available to be granted &#8212; December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000381" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001124105_20201231" decimals="INF" format="ixt:numdotdecimal">1,255,302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Valuation Assumptions</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited history as a public company and limited number of sales of its common stock, the Company estimated its volatility considering a number of factors including the use of the volatility of comparable public companies. The expected term of options granted under the Plan, all of which qualify as &#8220;plain vanilla&#8221; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#8217;s limited operating history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000252" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000252_cnt_1">The fair value of employee stock options was estimated using the following&#160;weighted-average assumptions for the&#160;years ended&#160;December&#160;31, 2020&#160;and 2019:</ix:nonNumeric><span style="color:#000000;"> </span></p><ix:continuation id="F_000252_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Options:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000404">5.81</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000405">5.98</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000406" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="4" scale="-2">0.91</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000407" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="4" scale="-2">2.35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000408" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000409" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000410" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="4" scale="-2">113.36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000411" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="4" scale="-2">90.81</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average fair value of stock options</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000412" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="2">5.20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000413" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="2">5.85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000253" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000253_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation recognized was as follows <span style="font-style:italic;">(in thousands):</span></p></ix:nonNumeric><ix:continuation id="F_000253_cnt_1" continuedAt="F_000253_dcnt_0bf4fefc-b34d-4d6d-afb5-a49193b64e17">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,487</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,052</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000416" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,152</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000221_dcnt_03795116-b020-48eb-840a-6f3891e4fccb"><ix:continuation id="F_000253_dcnt_0bf4fefc-b34d-4d6d-afb5-a49193b64e17">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top"><ix:footnote id="FNT_000003" xml:lang="en-US">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Included in general and administrative stock-based compensation for the years ended December 31, 2020 and 2019 is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-5" scale="6">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-5" scale="6">0.2</ix:nonFraction> million in expense related to <ix:nonFraction unitRef="U_xbrlishares" id="F_000420" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="C_0001124105_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">51,056</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000421" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="C_0001124105_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">24,235</ix:nonFraction> shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.</span></p></ix:footnote></td></tr></table></div></ix:continuation>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.19%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, <ix:nonFraction unitRef="U_xbrlishares" id="F_000426" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001124105_20201231" decimals="INF" format="ixt:numdotdecimal">1,255,302</ix:nonFraction> shares of common stock were available for future grant and <ix:nonFraction unitRef="U_xbrlishares" id="F_000427" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001124105_20201231" decimals="INF" format="ixt:numdotdecimal">2,355,615</ix:nonFraction> options to purchase shares of common stock were outstanding.&#160;<span style="color:#000000;">As of December 31, 2020, the Company had unrecognized employee stock-based compensation expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="-5" scale="6">6.5</ix:nonFraction> million, related to unvested stock option awards, which is expected to be recognized</span> over an estimated weighted-average period of <ix:nonNumeric id="F_000425" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" format="ixt-sec:duryear">2.63</ix:nonNumeric> years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company&#8217;s stockholders approved the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP had previously been approved by the Board and the Compensation Committee of the Board, subject to stockholder approval which became effective as of June 13, 2018. Under the ESPP, employees meeting certain specific employment qualifications are eligible to participate and can purchase shares of common stock semi-annually on February 9<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> and August 9<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> of each year, through payroll deductions. The purchase price is <ix:nonFraction unitRef="U_xbrlipure" id="F_000428" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613_20180613" decimals="INF" scale="-2">85</ix:nonFraction>% of the lower of the fair market value of the stock at the commencement or end of the offering period. The ESPP permits eligible employees to purchase shares of common stock through payroll deductions for up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000429" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613" decimals="INF" scale="-2">15</ix:nonFraction>% of qualified compensation.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s ESPP is subject to an Evergreen provision which shares may be added to the pool as needed. As of December 31, 2020, a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000431" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">359,545</ix:nonFraction> shares of common stock may be granted in accordance with the terms of the ESPP as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000432" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">38,248</ix:nonFraction> shares of common stock for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million have been issued to employees participating in the two ESPP purchases of 2020 and <ix:nonFraction unitRef="U_xbrlishares" id="F_000430" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">300,444</ix:nonFraction> shares are available for issuance under the ESPP as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for the ESPP was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20190101_20191231" decimals="-5" scale="6">0.1</ix:nonFraction> million for the years ended December 31, 2020 and 2019, respectively, and is included in total stock-based compensation recognized.</p></ix:continuation><ix:nonNumeric id="F_000222" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000222_dcnt_2bb44b52-de78-40da-80bd-5760bd9dfea8">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred cumulative net operating losses since inception and, consequently, has not recorded any income tax expense for the years ended December 31, 2020 and 2019 due to its net operating loss position. </p><ix:nonNumeric id="F_000254" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate for the years ended December 31, 2020 and 2019 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax at statutory federal rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000436" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001124105_20200101_20201231" decimals="INF" scale="-2">21.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000437" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001124105_20190101_20191231" decimals="INF" scale="-2">21.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State Tax (benefit)&#8212;net of federal benefit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000438" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001124105_20200101_20201231" decimals="4" scale="-2">0.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000439" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001124105_20190101_20191231" decimals="4" scale="-2">0.06</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000440" name="cbio:EffectiveIncomeTaxRateReconciliationPermanentDifferences" contextRef="C_0001124105_20200101_20201231" decimals="4" sign="-" format="ixt:numdotdecimal" scale="-2">0.58</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000441" name="cbio:EffectiveIncomeTaxRateReconciliationPermanentDifferences" contextRef="C_0001124105_20190101_20191231" decimals="4" sign="-" format="ixt:numdotdecimal" scale="-2">0.43</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000442" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001124105_20200101_20201231" decimals="4" scale="-2">12.26</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000443" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001124105_20190101_20191231" decimals="4" scale="-2">11.20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition due to Sec. 382 and 383 limitations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000444" name="cbio:EffectiveIncomeTaxRateReconciliationDerecognition" contextRef="C_0001124105_20200101_20201231" decimals="4" sign="-" format="ixt:numdotdecimal" scale="-2">44.55</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000445" name="cbio:EffectiveIncomeTaxRateReconciliationDerecognition" contextRef="C_0001124105_20190101_20191231" decimals="4" scale="-2">0.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000446" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001124105_20200101_20201231" decimals="4" scale="-2">12.25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000447" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001124105_20190101_20191231" decimals="4" sign="-" format="ixt:numdotdecimal" scale="-2">31.20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000448" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="C_0001124105_20200101_20201231" decimals="4" sign="-" format="ixt:numdotdecimal" scale="-2">0.38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000449" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="C_0001124105_20190101_20191231" decimals="4" sign="-" format="ixt:numdotdecimal" scale="-2">0.63</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective tax rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000450" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001124105_20200101_20201231" decimals="4" scale="-2">0.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000451" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001124105_20190101_20191231" decimals="4" scale="-2">0.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000255" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000255_dcnt_5f2f65ff-b64b-4e06-97dc-9c1af48338c3">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000222_dcnt_2bb44b52-de78-40da-80bd-5760bd9dfea8" continuedAt="F_000222_dcnt_c1525161-004f-4384-9510-fa98d322e961"><ix:continuation id="F_000255_dcnt_5f2f65ff-b64b-4e06-97dc-9c1af48338c3">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets as of December 31, 2020 and 2019 consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,095</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_0001124105_20191231" decimals="-3" scale="3">936</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carry forwards</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,505</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,392</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carry forwards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,945</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed and intangible assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="cbio:DeferredTaxAssetsFixedAssetsAndIntangibles" contextRef="C_0001124105_20201231" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="cbio:DeferredTaxAssetsFixedAssetsAndIntangibles" contextRef="C_0001124105_20191231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,396</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">45,283</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the available objective evidence at December 31, 2020, the Company does not believe it is more likely than not that the net deferred tax assets will be realizable. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets at December 31, 2020 and 2019. The net valuation allowance decreased by approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" contextRef="C_0001124105_20200101_20201231" decimals="-5" sign="-" scale="6">6.9</ix:nonFraction> million and increased by approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" contextRef="C_0001124105_20190101_20191231" decimals="-5" scale="6">17.2</ix:nonFraction> million during the years ended December 31, 2020 and 2019, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, after consideration of certain limitations (see below), the Company had approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">140.4</ix:nonFraction> million federal and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" scale="6">8.0</ix:nonFraction> million state net operating loss carryforwards (&#8220;NOL&#8221;) available to reduce future taxable income which, if unused, will begin to expire in <ix:nonNumeric id="F_000466" name="cbio:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2037</ix:nonNumeric> for federal and <ix:nonNumeric id="F_000467" name="cbio:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2032</ix:nonNumeric> for state tax purposes. The federal net operating loss carryforward includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="cbio:OperatingLossCarryforwardsWithIndefiniteLife" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">132.9</ix:nonFraction> million that have an indefinite life.&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company also had tax credit carry forwards available to offset future tax liabilities of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">5.0</ix:nonFraction> million for federal and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" scale="6">6.8</ix:nonFraction> million for state. If unused, the federal credit will begin to expire in 2040 and the state tax credit does not expire. &#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Company experiences a greater than 50 percent aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carryforwards are subject to annual limitation under Section 382 of the Internal Revenue Code (California has similar provisions). The annual limitation is determined by multiplying the value of the Company's stock at the time of such ownership change by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company determined that ownership changes occurred December 31, 2007, August 20, 2015, April 13, 2017, February 15, 2018, and February 18, 2020. Approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20071231" decimals="-5" scale="6">156.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20201231" decimals="-5" scale="6">70.8</ix:nonFraction> million of the NOLs will expire unutilized for federal and California purposes, respectively. The Company has derecognized NOL related deferred tax assets in the tax affected amounts of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="cbio:DeferredTaxAssetsStateNetOperatingLossCarryForwards" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">32.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="cbio:DeferredTaxAssetsStateNetOperatingLossCarryForwards" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20201231" decimals="-6" scale="6">0</ix:nonFraction> for federal and California purposes, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the federal R&#38;D credits could expire unutilized, whereas none of the California R&#38;D credits are subject to expiration. Approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="cbio:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" contextRef="C_0001124105_20200101_20201231" decimals="-5" scale="6">15.2</ix:nonFraction> million of gross federal R&#38;D credit-related deferred tax assets were derecognized due to the Section 383 limitation. The ability of the Company to use its remaining NOL carryforwards may be further limited if the Company experiences a Section 382 ownership change as a result of future changes in its stock ownership. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 27, 2020, the &#8220;Coronavirus Aid, Relief and Economic Security (CARES) Act&#8221; (the &#8220;Act&#8221;) was signed into law. The Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll taxes, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company analyzed the provisions of the Act and determined there was no significant impact to its 2020 tax provision.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 29, 2020, the California Governor signed Assembly Bill 85 (&#8220;A.B. 85&#8221;), which now becomes California law. A.B. 85, which includes several tax measures, provides for a three-year suspension of the use of net operating losses for medium and large businesses and a three-year cap on the use of business incentive tax credits to offset no more than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="cbio:MaximumAmountOfTaxOffsetPerYear" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629_20200629" decimals="-6" scale="6">5</ix:nonFraction> million of tax per year. Generally, A.B. 85 suspends the use of net operating losses for taxable years 2020, 2021, and 2022 for taxpayers with taxable income of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="cbio:RequiredMinimumTaxableIncome" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629" decimals="-6" scale="6">1</ix:nonFraction> million or </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000222_dcnt_c1525161-004f-4384-9510-fa98d322e961">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more. Since the Company is not expected to generate California source taxable income of more than $1 million, no material impact is anticipated at this time.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 27, 2020, the &#8220;Consolidated Appropriations Act, 2021&#8221; (the &#8220;CAA&#8221;) was signed into law. The CAA includes provisions meant to clarify and modify certain items put forth in CARES Act, while providing aid to businesses affected by the pandemic.&#160;&#160;The CAA allows deductions for expenses paid for by Paycheck Protection Program (&#8220;PPP&#8221;) and Economic Injury Disaster Loan (&#8220;EIDL&#8221;) Program, clarifies forgiveness of EIDL advances, and other business provisions.&#160;&#160;The Company analyzed the provisions of the CAA and determined there was no significant impact to its 2020 tax provision.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting for Uncertainty in Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company only recognizes tax benefits if it is more likely than not that they will be sustained upon audit by the relevant tax authority based upon their technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001124105_20201231" decimals="-5" scale="6">3.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001124105_20191231" decimals="-5" scale="6">1.9</ix:nonFraction> million of unrecognized tax benefits as of December 31, 2020 and 2019, respectively. As the Company has a full valuation allowance on its deferred tax assets, the unrecognized tax benefits have reduced the deferred tax assets and the valuation allowance in the same amount. The Company does not expect the amount of unrecognized tax benefits to materially change in the next twelve months.</p><ix:nonNumeric id="F_000256" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Beginning Balance at January&#160;1, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001124105_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,573</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits taken</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; in prior years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="cbio:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" contextRef="C_0001124105_20190101_20191231" decimals="-3" scale="3">45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related to current year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001124105_20190101_20191231" decimals="-3" scale="3">253</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ending Balance at December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,871</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits taken</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; in prior years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="cbio:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" scale="3">295</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related to current year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ending Balance at December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,955</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and penalties related to unrecognized tax benefits would be included as income tax expense in the Company&#8217;s consolidated statements of operations. As of December 31, 2020 and 2019, the Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="C_0001124105_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="C_0001124105_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t recognized any tax-related penalties or interest in its consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the United States federal, California, Kansas, Missouri and New Jersey state jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. As of December 31, 2020 and 2019, the Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextRef="C_0001124105_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextRef="C_0001124105_20191231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction></ix:nonFraction> uncertain tax positions which affected its financial position as its results of operations or its cash flow, and will continue to evaluate for uncertain tax positions in the future. The Company is subject to United States federal and state income tax examinations by authorities for all tax years due to accumulated net operating losses that are being carried forward for tax purposes.</p></ix:continuation><ix:nonNumeric id="F_000223" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true" continuedAt="F_000223_dcnt_865b689c-054f-4d06-af24-5a56b70ce63e">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaborations</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pfizer</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.2pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the termination agreement entered into on December 8, 2016, in connection with the termination of a prior license and development agreement, Pfizer granted the Company an exclusive license to Pfizer&#8217;s proprietary rights for manufacturing materials and processes that apply to Factor VIIa variants, CB 813a and marzeptacog alfa (activated) - MarzAA. Pfizer also transferred to the Company the IND application and documentation related to the development, manufacturing and testing of the Factor VIIa products as well as </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000223_dcnt_865b689c-054f-4d06-af24-5a56b70ce63e" continuedAt="F_000223_dcnt_155e9c1c-69fc-4e48-bba6-4e5f3ddb2e17">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;letter-spacing:-0.2pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the orphan drug designation</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Company agreed to make contingent cash payments to Pfizer in an aggregate amount up to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="cbio:MilestoneContingentCashPaymentsObligation" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioPfizerIncMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_us-gaapCollaborativeArrangementMember_20161208" decimals="-5" scale="6">17.5</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, payable upon the achievement of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> certain</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and commercial milestones. Following commercialization of any covered product, Pfizer w</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ill</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> also receive a single-digit royalty on net product sales on a country-by-country basis for a predefined royalty term. In February 2018, the Company paid Pfizer a $</span><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="cbio:MilestonePayments" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioPfizerIncMember_us-gaapTransactionTypeAxis_us-gaapCollaborativeArrangementMember_20180201_20180228" decimals="-5" scale="6">1.0</ix:nonFraction><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million milestone payment based on the dosing of the first patient in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 2 study</span><span style="color:#000000;">&#59; the amount was recorded as a research and development expens</span><span style="color:#000000;">e</span><span style="color:#000000;">. </span><span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="cbio:MilestonePayments" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioPfizerIncMember_us-gaapTransactionTypeAxis_us-gaapCollaborativeArrangementMember_20200101_20201231" decimals="-6" format="ixt-sec:numwordsen" scale="6">No</ix:nonFraction></span><span style="color:#000000;"> payments were made to Pfizer </span><span style="color:#000000;">in </span><span style="color:#000000;">the year ended</span><span style="color:#000000;"> December 31, 20</span><span style="color:#000000;">20</span><span style="color:#000000;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ISU Abxis</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, the Company entered into an amended and restated license agreement with ISU Abxis (the &#8220;A&#38;R ISU Abxis Agreement&#8221;), which amended and restated its previous license and collaboration agreement with ISU Abxis previously entered into in September 2013, as subsequently amended in October 2014 and December 2016 <span style="color:#000000;">(the &#8220;Original ISU Abxis Agreement&#8221;)</span>. Under the A&#38;R ISU Abxis Agreement, <span style="color:#000000;">ISU Abxis will receive commercialization rights in South Korea to the Company&#8217;s engineered Factor IX dalcinonacog alfa - DalcA and the Company will receive clinical development and commercialization rights in the rest of world (excluding South Korea) and manufacturing development and manufacturing rights worldwide (including South Korea)</span>. <span style="color:#000000;">The </span>A&#38;R ISU Abxis Agreement <span style="color:#000000;">eliminates the profit-sharing arrangement in the Original ISU Abxis Agreement and</span> p<span style="color:#000000;">rovides for a low single-digit royalty payment to ISU Abxis, on a country-by-country basis, for net product sales of DalcA by the Company or its affiliates in each country other than South Korea. Pursuant to the A&#38;R </span>ISU Abxis Agreement<span style="color:#000000;">, the Company will also pay up to an aggregate of</span> <span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="cbio:MilestonePayments" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231" decimals="-5" scale="6">19.5</ix:nonFraction> million in milestone payments to ISU Abxis, including $<ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="cbio:RegulatoryAndDevelopmentMilestonePayment" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231" decimals="-5" scale="6">2.5</ix:nonFraction>&#160;million in regulatory and development milestone payments and up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="cbio:CommercialMilestonePayments" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231" decimals="-5" scale="6">17.0</ix:nonFraction>&#160;million in commercial milestone payments, if the applicable milestones are met. As of December 31, 2020, <ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="cbio:MilestonePayments" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20200101_20201231" decimals="-6" format="ixt-sec:numwordsen" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="cbio:RegulatoryAndDevelopmentMilestonePayment" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20200101_20201231" decimals="-6" format="ixt-sec:numwordsen" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="cbio:CommercialMilestonePayments" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20200101_20201231" decimals="-6" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> milestones have been met.</span><span style="letter-spacing:-0.2pt;"> </span>&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Biogen</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 18, 2019, the Company and Biogen International GmbH (&#8220;Biogen&#8221;) entered into a License and Collaboration Agreement (the &#8220;Biogen Agreement&#8221;), under which the Company granted Biogen a worldwide, royalty-bearing, exclusive, with the right to sublicense, license (&#8220;Exclusive License&#8221;) to develop and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders. Pursuant to the Biogen Agreement, the Company will perform certain pre-clinical and manufacturing activities (&#8220;Research Services&#8221;), and Biogen will be solely responsible for funding the pre-clinical and manufacturing activities and performing IND-enabling activities, worldwide clinical development, and commercialization. The Company will provide the Research Services over a term of <span style="color:#000000;"><ix:nonNumeric id="F_000501" name="cbio:ResearchServicesAgreementTerm" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioLicenseAndCollaborationAgreementMember_20191218_20191218" format="ixt-sec:durwordsen">thirty months</ix:nonNumeric></span> with Biogen having the option to extend the term for two additional <span style="color:#000000;"><span style="-sec-ix-hidden:F_000502">twelve-month</span></span> periods.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Biogen Agreement, the Company received an up-front payment for the transfer of the Exclusive License (inclusive of certain know-how) of <span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131" decimals="-5" scale="6">15.0</ix:nonFraction></span> million in January 2020. The Company is eligible to receive development milestones and sales milestones of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="cbio:DevelopmentMilestonesPaymentReceivable" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131" decimals="-5" scale="6">340.0</ix:nonFraction> million. In addition, the Company is eligible to receive royalties in the range of single-digit to low double-digit percentage rates of annual net sales on a product-by-product and country-by-country basis. The Company will also receive reimbursements for costs associated with the performance of the Research Services.<span style="color:#000000;">   </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the performance obligations under the Biogen Agreement were the Exclusive License and the Research Services. For the Exclusive License, the Company used the residual approach in determining the standalone selling price, or SSP, which includes the upfront payments, milestones and royalties. For the Research Services, the Company used the historical pricing approach for determining the SSP, which includes the reimbursement of personnel and out-of-pocket costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Biogen Agreement will continue on a product-by-product and country-by-country basis until the tenth anniversary of the first commercial sale of the first product in a country, unless terminated earlier by either party as specified under the agreement. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000223_dcnt_155e9c1c-69fc-4e48-bba6-4e5f3ddb2e17">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, the Company recognized the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioTransferOfExclusiveLicenseAndRelatedKnowHowMember_20200101_20201231" decimals="-5" scale="6">15.0</ix:nonFraction> million in license revenue upon the transfer of the Exclusive License and the related know-how, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioExclusiveLicenseMember_20200101_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million in license revenue for reimbursable out-of-pocket costs incurred.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, the Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20200101_20201231" decimals="-5" scale="6">5.8</ix:nonFraction> million in collaboration revenue for reimbursable out-of-pocket and personnel costs incurred related to research services.</p></ix:continuation><ix:nonNumeric id="F_000224" name="us-gaap:InterestAndOtherIncomeTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Interest and Other Income, Net </p></td></tr></table></div><ix:nonNumeric id="F_000257" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows the detail of interest and other income, net for the years ended December 31, 2020 and 2019 <span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">561</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,145</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Miscellaneous income (expense)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">659</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001124105_20190101_20191231" decimals="-3" sign="-" scale="3">39</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="us-gaap:OtherNonoperatingExpense" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">91</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:OtherNonoperatingExpense" contextRef="C_0001124105_20190101_20191231" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="cbio:InterestAndOtherIncomeExpenseNet" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="cbio:InterestAndOtherIncomeExpenseNet" contextRef="C_0001124105_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,099</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000225" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14.</span></p></td>
<td valign="top">
<p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020,<span style="font-style:italic;"> </span>the Company completed an underwritten public offering of <ix:nonFraction unitRef="U_xbrlishares" id="F_000516" name="cbio:FirmCommitmentUnderwrittenPublicOfferingShares" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200228_20200229" decimals="INF" format="ixt:numdotdecimal">5,307,692</ix:nonFraction> shares of its common stock (including <ix:nonFraction unitRef="U_xbrlishares" id="F_000517" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200228_20200229" decimals="INF" format="ixt:numdotdecimal">692,307</ix:nonFraction> shares sold pursuant to the exercise of the underwriters&#8217; overallotment option)&#160;at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000518" name="us-gaap:SharePrice" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200229" decimals="2">6.50</ix:nonFraction> per share. The net proceeds to the Company, after deducting $<ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="cbio:UnderwritingCommissionsAndOfferingExpensesPayable" contextRef="C_0001124105_20200228_20200229" decimals="-5" scale="6">2.5</ix:nonFraction> million in underwriting discounts and commissions and offering expenses payable by the Company, were approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="cbio:NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable" contextRef="C_0001124105_20200228_20200229" decimals="-5" scale="6">32.0</ix:nonFraction> million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, the Company completed an underwritten public offering of <ix:nonFraction unitRef="U_xbrlishares" id="F_000521" name="cbio:FirmCommitmentUnderwrittenPublicOfferingShares" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200629_20200630" decimals="INF" format="ixt:numdotdecimal">4,615,384</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000522" name="us-gaap:SharePrice" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630" decimals="2">6.50</ix:nonFraction> per share. The net proceeds to the Company, after deducting $<ix:nonFraction unitRef="U_iso4217USD" id="F_000524" name="cbio:UnderwritingCommissionsAndOfferingExpensesPayable" contextRef="C_0001124105_20200629_20200630" decimals="-5" scale="6">2.0</ix:nonFraction> million in underwriting discounts and commissions and offering expenses payable by the Company, were approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="cbio:NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable" contextRef="C_0001124105_20200629_20200630" decimals="-5" scale="6">28.0</ix:nonFraction> million.</p><ix:nonNumeric id="F_000258" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had issued and outstanding common stock warrants as follows:</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000525" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001124105_20181231" decimals="INF" format="ixt:numdotdecimal">10,194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000530" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001124105_20181231" decimals="INF">155.73</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000526" name="cbio:ClassOfWarrantOrRightForfeitedDuringPeriod" contextRef="C_0001124105_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">2,337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000531" name="cbio:ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited" contextRef="C_0001124105_20190101_20191231" decimals="INF">499.50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000527" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001124105_20191231" decimals="INF" format="ixt:numdotdecimal">7,857</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000532" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001124105_20191231" decimals="INF">53.61</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000528" name="cbio:ClassOfWarrantOrRightForfeitedDuringPeriod" contextRef="C_0001124105_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">7,772</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000533" name="cbio:ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited" contextRef="C_0001124105_20200101_20201231" decimals="INF">49.91</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000529" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001124105_20201231" decimals="INF">85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000534" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001124105_20201231" decimals="INF">392.70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000226" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss per Share Attributable to Common Stockholders</p></td></tr></table></div><ix:nonNumeric id="F_000259" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per common share during the years ended December 31, 2020 and 2019 <span style="font-style:italic;">(in thousands, except share and per share data)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">56,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001124105_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,178</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of shares used in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; computing net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000537" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001124105_20200101_20201231" decimals="0" format="ixt:numdotdecimal">19,179,299</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000538" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001124105_20190101_20191231" decimals="0" format="ixt:numdotdecimal">12,004,489</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000539" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001124105_20200101_20201231" decimals="2" sign="-">2.93</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000540" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001124105_20190101_20191231" decimals="2" sign="-">4.60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000260" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000541" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,355,615</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000542" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">1,577,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000543" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20200101_20201231" decimals="INF">85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000544" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">7,857</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000545" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,355,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000546" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">1,585,398</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000227" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001124105_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subsequent Event</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2021, we sold an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000547" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001124105_srtStatementScenarioAxis_srtScenarioForecastMember_20210331" decimals="INF" format="ixt:numdotdecimal">9,185,000</ix:nonFraction> registered shares of common stock (including <ix:nonFraction unitRef="U_xbrlishares" id="F_000548" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioUnderwritersOverallotmentOptionMember_srtStatementScenarioAxis_srtScenarioForecastMember_20210331" decimals="INF" format="ixt:numdotdecimal">485,000</ix:nonFraction> shares sold pursuant to the exercise of the underwriters&#8217; overallotment option) at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000549" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001124105_srtStatementScenarioAxis_srtScenarioForecastMember_20210331" decimals="INF">5.75</ix:nonFraction> per share. The net proceeds, after deducting $<ix:nonFraction unitRef="U_iso4217USD" id="F_000550" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001124105_srtStatementScenarioAxis_srtScenarioForecastMember_20210101_20210331" decimals="-5" scale="6">3.5</ix:nonFraction> million underwriting discounts and offering expenses, were approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000551" name="cbio:UnderwritingDiscountsAndOfferingExpenses" contextRef="C_0001124105_srtStatementScenarioAxis_srtScenarioForecastMember_20210101_20210331" decimals="-5" scale="6">49.3</ix:nonFraction> million. </p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.46%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9A_CONTROLS_PROCEDURES">CONTROLS AND PROCEDURES</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;Evaluation of disclosure controls and procedures</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management maintains disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) that are designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC's rules and forms, and </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that such information is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial officer, respectively), as appropriate, to allow for timely decisions regarding required disclosure.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, including the Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that the information required to be disclosed in the reports filed or submitted by us under the Exchange Act was recorded, processed, summarized and reported within the requisite time periods and that such information was accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow for timely decisions regarding required disclosure.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Management&#8217;s Annual Report on Internal Control Over Financial Reporting</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Because of its inherent limitations, internal control over financial reporting may not prevent or detect all misstatements. Our internal control system was designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation of published financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2020. Our assessment was based on the framework in the updated <span style="font-style:italic;">Internal Control - Integrated Framework (2013) </span>issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our assessment we believe that as of December 31, 2020, our internal control over financial reporting is effective based on those criteria.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;Changes in internal control over financial reporting</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, including our Chief Executive Officer and Chief Financial Officer, evaluated our &#8220;internal control over financial reporting&#8221; as defined in Exchange Act Rule 13a-15(f) to determine whether any changes in our internal control over financial reporting occurred during the fiscal year ended December 31, 2020 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Based on that evaluation, there were no changes in our internal control over financial reporting during the fiscal quarter ended December 31, 2020 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9B_OR_INFORMATION">Other Information</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;" id="Item_9B_Other">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE&#160;&#160;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item is incorporated by reference to the information set forth in the sections titled &#8220;Information About Our Board of Directors&#8221; and &#8220;Information About Our Executive Officers Who Are Not Directors,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Corporate Governance &#8211; Code of Business Conduct and Ethics,&#8221; &#8220;Delinquent Section 16(a) Reports,&#8221; &#8220;Corporate Governance &#8211; Committees of the Board of Directors &#8211; Nominating and Corporate Governance Committee,&#8221; &#8220;Corporate Governance &#8211; Committees of the Board of Directors &#8211; Audit Committee&#8221; and &#8220;Corporate Governance &#8211; Committees of the Board of Directors &#8211; Compensation Committee&#8221; in our definitive proxy statement to be filed with the SEC on Schedule 14A in connection with our 2020 Annual Meeting of Shareholders, or the Proxy Statement, which is expected to be filed not later than 120 days after December 31, 2020.&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_11_EXECUTIVE_COMPENSATION">EXECUTIVE COMPENSATION</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item is incorporated by reference to the information set forth in the sections titled &#8220;Executive Compensation,&#8221; &#8220;Director Compensation&#8221; and &#8220;Committees of the Board of Directors &#8212; Compensation Committee Interlocks and Insider Participation&#8221; in the Proxy Statement and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item is included in the sections titled &#8220;Securities Authorized For Issuance Under Equity Compensation Plans&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in the Proxy Statement and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item is included in the sections titled &#8220;Corporate Governance &#8211; Board of Directors Independence&#8221; and &#8220;Transactions With Related Persons&#8221; in the Proxy Statement and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC">PRINCIPAL ACCOUNTING FEES AND SERVICES</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item is included in the sections titled &#8220;Independent Registered Public Accounting Firm Fees and Services&#8221; in the Proxy Statement and is incorporated herein by reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IV">PART IV</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES&#160;&#160;</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The following documents are filed as part of this Annual Report on Form 10-K:</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. Consolidated Financial Statements</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:10.47%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Index to Consolidated Financial Statements at Part II, Item&#160;8 Financial Statements and Supplementary Data, herein.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Consolidated Financial Statement Schedules</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:10.47%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All schedules are omitted because they are not applicable or the required information is shown under Item 8. &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. See LIST OF EXHIBITS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) See LIST OF EXHIBITS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 16.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_16_FORM_10K_SUMMARY">FORM 10-K SUMMARY</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="LIST_EXHIBITS"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIST OF </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBITS</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.04%;">
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="7" valign="bottom" style="width:41.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by reference</p></td>
<td colspan="2" valign="bottom" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit title</p></td>
<td valign="bottom" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="bottom" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filed or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Furnished</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">herewith</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1(a)</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312515079787/d887299dex21.htm"><span style="text-decoration:none;">Agreement and Plan of Merger dated as of March 5, 2015, by and among Targacept, Catalyst Biosciences, Inc. and Talos Merger Sub, Inc.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mar. 6, 2015</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1(b)</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312515183156/d924437dex101.htm"><span style="text-decoration:none;">Amendment No. 1 to Agreement and Plan of Merger by and among Targacept, Talos Merger Sub, Inc., and Catalyst dated May 6, 2015.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 12, 2015</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1(c)</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312515186989/d925981dex101.htm"><span style="text-decoration:none;">Amendment No. 2 to Agreement and Plan of Merger by and among Targacept, Talos Merger Sub, Inc., and Catalyst dated May 13, 2015.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 14, 2015</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312506103288/dex41.htm"><span style="text-decoration:none;">Fourth Amended and Restated Certificate of Incorporation of the Company.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-8</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-133881</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 8, 2006</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312515297752/d24322dex31.htm"><span style="text-decoration:none;">Certificate of Amendment to Fourth the Amended and Restated Certificate of Incorporation of the Company.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aug. 20, 2015</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312517037156/d326649dex31.htm"><span style="text-decoration:none;">Second Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Company.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Feb. 10, 2017</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312515079787/d887299dex31.htm"><span style="text-decoration:none;">Bylaws of the Company, as amended.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jun. 6, 2020</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312517121994/d375894dex31.htm"><span style="text-decoration:none;">Certificate of Designation of Preferences, Rights and Limitations, filed with the Delaware Secretary of State on April 10, 2017, with respect to the Series A Preferred Stock.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Apr. 13, 2017</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020005546/cbio-ex41_709.htm"><span style="text-decoration:none;">Description of Securities.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Feb. 20, 2020</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001124105/000119312516498295/d117011dex43.htm"><span style="text-decoration:none;">Warrant to Purchase Stock of Catalyst Biosciences, Inc., issued to Silicon Valley Bank on March 3, 2005.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mar. 9, 2016</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001124105/000119312516498295/d117011dex45.htm"><span style="text-decoration:none;">Form of Warrant to Purchase Stock of Catalyst Biosciences, Inc., issued to purchasers of convertible promissory notes.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mar. 9, 2016</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1**</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312516554394/d165946ddef14a.htm"><span style="text-decoration:none;">Catalyst Biosciences, Inc. (formerly Targacept, Inc.) 2015 Stock Incentive Plan (as Amended and Restated Effective June 9, 2016).</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEF 14A</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Apr. 25, 2016</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2**</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312516548415/d149784dex101.htm"><span style="text-decoration:none;">Catalyst Biosciences, Inc. 2016 Inducement Stock Incentive Plan.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Apr. 20, 2016</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3**</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312515198706/d899628dex1031a.htm"><span style="text-decoration:none;">Catalyst's 2004 Stock Plan.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-204423</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31(a)</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 22, 2015</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.04%;">
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="7" valign="bottom" style="width:41.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by reference</p></td>
<td colspan="2" valign="bottom" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit title</p></td>
<td valign="bottom" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="bottom" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filed or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Furnished</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">herewith</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4**</span></p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459017013442/cbio-ex101_24.htm"><span style="text-decoration:none;">Form of Incentive Stock Option Award Notice.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 14, 2017</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5**</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459017013442/cbio-ex102_25.htm"><span style="text-decoration:none;">Form of Non-qualified Stock Option Award Notice.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 14, 2017</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6**</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020020531/cbio-def14a_20200611.htm"><span style="text-decoration:none;">Catalyst Biosciences, Inc. 2018 Omnibus Incentive Plan.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEF 14A</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 1, 2020</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7**</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312518160813/d581034ddef14a.htm#toc581034_35"><span style="text-decoration:none;">Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEF 14A</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix B</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 11, 2018</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8**</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex108_383.htm"><span style="text-decoration:none;">Form of Stock Option Award Agreement.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9**</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312518265035/d612321dex101.htm"><span style="text-decoration:none;">Amended and Restated Employment Agreement, dated as of August 28, 2018, by and between Catalyst Biosciences, Inc. and Dr. Nassim Usman, Ph.D.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aug. 31, 2018</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10**</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312518265035/d612321dex102.htm"><span style="text-decoration:none;">Amended and Restated Employment Agreement, dated as of August 29, 2018, by and between Catalyst Biosciences, Inc. and Dr. Howard Levy, M.B.B.Ch., Ph.D., M.M.M.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aug. 31, 2018</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12++</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459019013422/cbio-ex1016b_9.htm"><span style="text-decoration:none;">Amended and Restated License Agreement, dated December 17, 2018, by and between Catalyst Biosciences, Inc. and ISU Abxis.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K/A</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 29, 2019</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13+</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459016022517/cbio-ex101_419.htm"><span style="text-decoration:none;">Development and Manufacturing Services Agreement, by and between CMC ICOS Biologics, Inc. and Biosciences, Inc., dated as of May 20, 2016.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aug. 4, 2016</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14+</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459017003722/cbio-ex1016_464.htm"><span style="text-decoration:none;">Termination Agreement, dated December 8, 2016, between Catalyst Biosciences, Inc. and Wyeth LLC, a wholly-owned subsidiary of Pfizer Inc.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mar. 8, 2017</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15(a)</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312517347025/d465134dex101.htm"><span style="text-decoration:none;">Lease Agreement, dated November 8, 2017 by and between BXP 611 Gateway Center, LP and Catalyst Biosciences, Inc..</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nov. 17, 2017</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15(b)</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312518249889/d610054dex101.htm"><span style="text-decoration:none;">First Amendment to Office Lease, dated as of August 9, 2018, by and between BXP 611 Gateway Center, LP and Catalyst Biosciences, Inc.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aug. 15, 2018</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16++</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312519267593/d820794dex101.htm"><span style="text-decoration:none;">Clinical Supply Agreement, effective as of October 4, 2019, by and between Catalyst Biosciences, Inc. and Catalent Indiana, LLC.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October&#160;15,&#160;2019</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17++</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020005546/cbio-ex1017_708.htm"><span style="text-decoration:none;">License and Collaboration Agreement, dated December 18, 2019, by and between Biogen International GMBH and Catalyst Biosciences, Inc.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 20, 2020</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.04%;">
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="7" valign="bottom" style="width:41.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by reference</p></td>
<td colspan="2" valign="bottom" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit title</p></td>
<td valign="bottom" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="bottom" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filed or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Furnished</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">herewith</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18++</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020005546/cbio-ex1018_773.htm"><span style="text-decoration:none;">Amended and Restated Collaboration Agreement, dated December 18, 2019, by and between Mosaic Biosciences, Inc. and Catalyst Biosciences, Inc.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 20, 2020</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312520009556/d847025dex101.htm"><span style="text-decoration:none;">Cooperation Agreement, dated January 13, 2020, by and between CCUR Holdings, Inc. and certain of its affiliates and Catalyst Biosciences, Inc</span><span style="text-decoration:none;">.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 10, 2020</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020005546/cbio-ex1020_631.htm"><span style="text-decoration:none;">Description of Annual Cash Incentive Program</span><span style="text-decoration:none;">.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 20, 2020</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21**</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001124105/000119312518265035/d612321dex103.htm"><span style="text-decoration:none;">Form of Indemnification Agreement between the Company and each of its directors and members of executive management.</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August&#160;31,&#160;2018</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22++</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020037483/cbio-ex101_66.htm"><span style="text-decoration:none;">Amended and Restated Collaboration Agreement, dated May 8, 2020, by and between Mosaic Biosciences, Inc. and Catalyst Biosciences, Inc.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 6, 2020</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020051083/cbio-ex101_33.htm"><span style="text-decoration:none;">Second Amendment to Office Lease, dated July 17, 2020, by and between 611 Gateway Center, L.P. and Catalyst Biosciences, Inc.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November&#160;5,&#160;2020</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020051083/cbio-ex102_126.htm"><span style="text-decoration:none;">Offer Letter by and between Clinton Musil and Catalyst Biosciences, Inc. dated June 9, 2020.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 5, 2020</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312516498295/d117011dex211.htm"><span style="text-decoration:none;">List of subsidiaries of Catalyst Biosciences, Inc.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2016</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex231_10.htm"><span style="text-decoration:none;">Consent of EisnerAmper LLP, Independent Registered Public Accounting Fir</span><span style="text-decoration:none;">m</span><span style="text-decoration:none;">.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POWER_ATTORNEY"><span style="text-decoration:none;">Power of Attorney </span><span style="text-decoration:none;">(included as part of the signature page hereto)</span><span style="text-decoration:none;">.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex311_9.htm"><span style="text-decoration:none;">Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex312_151.htm"><span style="text-decoration:none;">Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex321_12.htm"><span style="text-decoration:none;">Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.04%;">
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="7" valign="bottom" style="width:41.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by reference</p></td>
<td colspan="2" valign="bottom" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit title</p></td>
<td valign="bottom" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="bottom" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filed or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Furnished</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">herewith</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:3.85pt;">
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex322_152.htm"><span style="text-decoration:none;">Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following materials from the Company's Annual Report on Form 10-K for the year ended December 31, 2020, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets as of December 31, 2020 and December 31, 2019&#59; (ii) the Consolidated Statement of Operations for the years ended December 31, 2020 and 2019&#59; (iii) the Consolidated Statements of Comprehensive Loss for the years ended December 31, 2020 and 2019&#59; (iv) the Consolidated Statements of Stockholders' Equity as of December 31, 2020&#59; (v) the Consolidated Statements of Cash Flows for the twelve months ended December 31, 2020 and 2019&#59; and (vi) the Notes to the Consolidated Financial Statements.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:14.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Denotes management contract, compensatory plan or arrangement.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Confidential treatment has been granted with respect to certain portions of this Exhibit, which portions have been omitted and filed separately with the SEC as part of an application for confidential treatment.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">++</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:12.4pt;">
<td colspan="2" valign="top" style="width:46.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CATALYST BIOSCIENCES, INC</p></td>
<td colspan="2" valign="top" style="width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CATALYST BIOSCIENCES, INC.</p></td>
</tr>
<tr style="height:12.4pt;">
<td colspan="2" valign="top" style="width:46.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Nassim Usman, Ph.D.</p></td>
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:48.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <span style="color:#000000;">Clinton Musil</span>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Nassim Usman, Ph.D.</p></td>
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinton Musil</p></td>
</tr>
<tr style="height:24.75pt;">
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr style="height:9pt;">
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top" style="width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021</p></td>
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top" style="width:48.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="POWER_ATTORNEY">POWER OF ATTORNEY</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each person whose individual signature appears below hereby authorizes and appoints Nassim Usman and Clinton Musil, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="middle" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:38.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:19.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Nassim Usman, Ph.D.</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:38.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer<br />(<span style="font-style:italic;">Principal Executive Officer</span>)</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Nassim Usman, Ph.D.</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="middle" style="width:39.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:19.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Clinton Musil</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:38.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer (Principal Financial and Accounting Officer)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinton Musil</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="middle" style="width:39.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Augustine Lawlor</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board of Directors</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Augustine Lawlor</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="middle" style="width:39.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:38.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Errol B. De Souza, Ph.D.</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Errol B. De Souza, Ph.D.</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="middle" style="width:39.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Andrea Hunt</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Andrea Hunt</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="middle" style="width:39.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Geoffrey Ling, M.D., Ph.D.</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Geoffrey Ling, M.D., Ph.D.</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom" style="width:39.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sharon Tetlow</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sharon Tetlow</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="middle" style="width:39.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Eddie Williams</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Eddie Williams</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>2
<FILENAME>cbio-ex108_383.htm
<DESCRIPTION>EX-10.8
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex108_383.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;font-variant: normal;">Exhibit 10.8</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Arial;font-size:10pt;font-style:normal;font-variant: normal;">CATALYST BIOSCIENCES INC. 2018 OMNIBUS INCENTIVE PLAN</p>
<p style="margin-bottom:24pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Arial;font-size:10pt;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">NOTICE OF STOCK OPTION AWARD</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grantee&#8217;s Name and Address:</p></td>
<td valign="top"  style="width:17.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.54%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You (the &#8220;Grantee&#8221;) have been granted an option to purchase shares of Common Stock (the &#8220;Option&#8221;), subject to the terms and conditions of this Notice of Stock Option Award (the &#8220;Notice&#8221;), the Catalyst Biosciences, Inc. 2018 Omnibus Incentive Plan, as amended from time to time (the &#8220;Plan&#8221;) and the Stock Option Award Agreement (the &#8220;Option Agreement&#8221;) attached hereto, as follows.  Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Notice.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting Commencement Date</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price per Share</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  style="width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Number of Shares Subject <br />to the Option (the &#8220;Shares&#8221;)</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Exercise Price</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  style="width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Type of Option:</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incentive Stock Option</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Qualified Stock Option</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expiration Date:</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Ten (10)&#160;Year Anniversary of Grant Date]</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-Termination Exercise Period:</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Ninety (90)&#160;Days]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Vesting Schedule:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the Grantee&#8217;s Continuous Service and other limitations set forth in this Notice, the Plan and the Option Agreement, the Option may be exercised, in whole or in part, in accordance with the following schedule (the &#8220;Vesting Schedule&#8221;):</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Vesting Schedule]</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During any authorized leave of absence, the vesting of the Option as provided in this schedule shall be suspended after the leave of absence exceeds a period of [three (3)&#160;months].  Vesting of the Option shall resume upon the Grantee&#8217;s termination of the leave of absence and return to service to the Company or a Related Entity.  The Vesting Schedule of the Option shall be extended by the length of the suspension.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4145-7952-3365.2</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Company and the Grantee have executed this Notice and agree that the Option is to be governed by the terms and conditions of this Notice, the Plan, and the Option Agreement.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.,</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware corporation</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THE GRANTEE ACKNOWLEDGES AND AGREES THAT THE SHARES SUBJECT TO THE OPTION SHALL VEST, IF AT ALL, ONLY DURING THE PERIOD OF THE GRANTEE&#8217;S CONTINUOUS SERVICE (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THE OPTION OR ACQUIRING SHARES HEREUNDER).  THE GRANTEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS NOTICE, THE OPTION AGREEMENT, OR THE PLAN SHALL CONFER UPON THE GRANTEE ANY RIGHT WITH RESPECT TO FUTURE AWARDS OR CONTINUATION OF THE GRANTEE&#8217;S CONTINUOUS SERVICE, NOR SHALL IT INTERFERE IN ANY WAY WITH THE GRANTEE&#8217;S RIGHT OR THE RIGHT OF THE COMPANY OR RELATED ENTITY TO WHICH THE GRANTEE PROVIDES SERVICES TO TERMINATE THE GRANTEE&#8217;S CONTINUOUS SERVICE, WITH OR WITHOUT CAUSE, AND WITH OR WITHOUT NOTICE.  THE GRANTEE ACKNOWLEDGES THAT UNLESS THE GRANTEE HAS A WRITTEN EMPLOYMENT AGREEMENT WITH THE COMPANY TO THE CONTRARY, THE GRANTEE&#8217;S STATUS IS AT WILL.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By clicking &#8220;Accept&#8221; on the button below, the Grantee acknowledges receipt of a copy of the Plan and the Option Agreement, and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts the Option subject to all of the terms and provisions hereof and thereof.  The Grantee has reviewed this Notice, the Plan, and the Option Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Notice, and fully understands all provisions of this Notice, the Plan and the Option Agreement.  The Grantee hereby agrees that all questions of interpretation and administration relating to this Notice, the Plan and the Option Agreement shall be resolved by the Administrator in accordance with Section&#160;13 of the Option Agreement.  The Grantee further agrees to the venue selection in accordance with Section&#160;12 of the Option Agreement.  The Grantee further agrees to notify the Company upon any change in the residence address indicated in this Notice.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4145-7952-3365.2</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Arial;font-size:10pt;font-style:normal;font-variant: normal;">CATALYST BIOSCIENCES INC. 2018 OMNIBUS INCENTIVE PLAN</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Arial;font-size:10pt;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">STOCK OPTION AWARD AGREEMENT</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Grant of Option</font><font style="color:#000000;">.&nbsp;&nbsp;Catalyst Biosciences, Inc., a Delaware corporation (the &#8220;Company&#8221;), hereby grants to the Grantee (the &#8220;Grantee&#8221;) named in the Notice of Stock Option Award (the &#8220;Notice&#8221;), an option (the &#8220;Option&#8221;) to purchase the Total Number of Shares of Common Stock subject to the Option (the &#8220;Shares&#8221;) set forth in the Notice, at the Exercise Price per Share set forth in the Notice (the &#8220;Exercise Price&#8221;) subject to the terms and provisions of the Notice, this Stock Option Award Agreement (the &#8220;Option Agreement&#8221;) and the Company&#8217;s 2018 Omnibus Incentive Plan, as amended from time to time (the &#8220;Plan&#8221;), which are incorporated herein by reference.&nbsp;&nbsp;Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Option Agreement.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If designated in the Notice as an Incentive Stock Option, the Option is intended to qualify as an Incentive Stock Option as defined in Section&#160;422 of the Code.&nbsp;&nbsp;However, notwithstanding such designation, the Option will qualify as an Incentive Stock Option under the Code only to the extent the $100,000 limitation of Section&#160;422(d) of the Code is not exceeded.&nbsp;&nbsp;The $100,000 limitation of Section&#160;422(d) of the Code is calculated based on the aggregate Fair Market Value of the Shares subject to options designated as Incentive Stock Options which become exercisable for the first time by the Grantee during any calendar year (under all plans of the Company or any Parent or Subsidiary of the Company).&nbsp;&nbsp;For purposes of this calculation, Incentive Stock Options shall be taken into account in the order in which they were granted, and the Fair Market Value of the shares subject to such options shall be determined as of the grant date of the relevant option.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Exercise of Option</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Right to Exercise</font><font style="color:#000000;">.&nbsp;&nbsp;The Option shall be exercisable during its term in accordance with the Vesting Schedule set out in the Notice and with the applicable provisions of the Plan and this Option Agreement.&nbsp;&nbsp;The Grantee shall be subject to reasonable limitations on the number of requested exercises during any monthly or weekly period as determined by the Administrator.&nbsp;&nbsp;In no event shall the Company issue fractional Shares.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Method of Exercise</font><font style="color:#000000;">.&nbsp;&nbsp;The Option shall be exercisable by delivery of an exercise notice (a form of which is attached as Exhibit&#160;A) or by such other procedure as specified from time to time by the Administrator which shall state the election to exercise the Option, the whole number of Shares in respect of which the Option is being exercised, and such other provisions as may be required by the Administrator.&nbsp;&nbsp;The exercise notice shall be delivered in person, by certified mail, or by such other method (including electronic transmission) as determined from time to time by the Administrator to the Company accompanied by payment of the Exercise Price.&nbsp;&nbsp;As a condition to the exercise of the Option, the Grantee must also make arrangements with the Company for payment of any tax withholding obligations.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Taxes</font><font style="color:#000000;">.&nbsp;&nbsp;The Company or any Related Entity shall be entitled, if necessary or desirable, to deduct and withhold (or, in the sole discretion of the Company, secure payment from the Grantee in lieu of withholding) the amount of any tax withholding due with respect to this Option.&nbsp;&nbsp;In the [Company&#8217;s] [Grantee&#8217;s] sole discretion, such tax withholding may be accomplished by the withholding of Shares which would otherwise be issued upon Option exercise to the Grantee in an amount whose Fair Market Value equal to the amount required to be withheld (provided the amount withheld does not exceed the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4145-7952-3365.2</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">maximum statutory tax rate for an employee in the applicable jurisdictions or such lesser amount as is necessary to avoid adverse accounting treatment).</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Method of Payment</font><font style="color:#000000;">.&nbsp;&nbsp;Payment of the Exercise Price shall be made by any of the following, or a combination thereof, at the election of the Grantee; provided, however, that such exercise method does not then violate any Applicable Law and, provided further, that the portion of the Exercise Price equal to the par value of the Shares must be paid in cash or other legal consideration permitted by the Delaware General Corporation Law:</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">cash;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">check;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">surrender of Shares held for the requisite period, if any, necessary to avoid a charge to the Company&#8217;s earnings for financial reporting purposes, or delivery of a properly executed form of attestation of ownership of Shares as the Administrator may require which have a Fair Market Value on the date of surrender or attestation equal to the aggregate Exercise Price of the Shares as to which the Option is being exercised;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">payment through a &#8220;net exercise&#8221; such that, without the payment of any funds, the Grantee may exercise the Option and receive the net number of Shares equal to (i)&#160;the number of Shares as to which the Option is being exercised, multiplied by (ii)&#160;a fraction, the numerator of which is the Fair Market Value per Share (on such date as is determined by the Administrator) less the Exercise Price per Share, and the denominator of which is such Fair Market Value per Share (the number of net Shares to be received shall be rounded down to the nearest whole number of Shares); or</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">while the Common Stock is listed on a national stock exchange or a national market system, payment through a broker-dealer sale and remittance procedure pursuant to which the Grantee (i)&#160;shall provide written instructions to a Company-designated brokerage firm to effect the immediate sale of some or all of the purchased Shares and remit to the Company sufficient funds to cover the aggregate exercise price payable for the purchased Shares and (ii)&#160;shall provide written directives to the Company to deliver the certificates for the purchased Shares directly to such brokerage firm in order to complete the sale transaction.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Restrictions on Exercise</font><font style="color:#000000;">.&nbsp;&nbsp;The Option may not be exercised if the issuance of the Shares subject to the Option upon such exercise would constitute a violation of any Applicable Laws.&nbsp;&nbsp;If the exercise of the Option within the applicable time periods set forth in Section&#160;5, 6 and 7 of this Option Agreement is prevented by the provisions of this Section&#160;4, the Option shall remain exercisable until one (1)&#160;month after the date the Grantee is notified by the Company that the Option is exercisable, but in any event no later than the Expiration Date set forth in the Notice.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination or Change of Continuous Service</font><font style="color:#000000;">.&nbsp;&nbsp;In the event the Grantee&#8217;s Continuous Service terminates, the Grantee may, but only during the Post-Termination Exercise Period, exercise the portion of the Option that was vested at the date of such termination (the &#8220;Termination Date&#8221;).&nbsp;&nbsp;The Post-Termination Exercise Period shall commence on the Termination Date.&nbsp;&nbsp;In no event, however, shall the Option be exercised later than the Expiration Date set forth in the Notice.&nbsp;&nbsp;[In the event of the Grantee&#8217;s change in status from Employee, Director or Consultant to any other status of Employee, Director or Consultant, the Option shall remain in effect and the Option shall continue to vest in accordance with the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4145-7952-3365.2</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Vesting Schedule set forth in the Notice; provided, however, that with respect to any Incentive Stock Option that shall remain in effect after a change in status from Employee to Director or Consultant, such Incentive Stock Option shall cease to be treated as an Incentive Stock Option and shall be treated as a Non-Qualified Stock Option on the day three (3</font><font style="color:#000000;">)&#160;</font><font style="color:#000000;">months and one (1</font><font style="color:#000000;">)&#160;</font><font style="color:#000000;">day following such change in status</font><font style="color:#000000;">.</font><font style="color:#000000;">]</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">Except as provided in Sections 6 and 7 below, to the extent that the Option was unvested on the Termination Date, or if the Grantee does not exercise the vested portion of the Option within the Post-Termination Exercise Period, the Option shall terminate.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Disability of Grantee</font><font style="color:#000000;">.&nbsp;&nbsp;In the event the Grantee&#8217;s Continuous Service terminates as a result of his or her Disability, the Grantee may, but only within twelve (12)&#160;months commencing on the Termination Date (but in no event later than the Expiration Date), exercise the portion of the Option that was vested on the Termination Date; provided, however, that if such Disability is not a &#8220;disability&#8221; as such term is defined in Section&#160;22(e)(3) of the Code and the Option is an Incentive Stock Option, such Incentive Stock Option shall cease to be treated as an Incentive Stock Option and shall be treated as a Non-Qualified Stock Option on the day three (3)&#160;months and one (1)&#160;day following the Termination Date.&nbsp;&nbsp;To the extent that the Option was unvested on the Termination Date, or if the Grantee does not exercise the vested portion of the Option within the time specified herein, the Option shall terminate.&nbsp;&nbsp;Section&#160;22(e)(3) of the Code provides that an individual is permanently and totally disabled if he or she is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than twelve (12)&#160;months.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Death of Grantee</font><font style="color:#000000;">.&nbsp;&nbsp;In the event of the termination of the Grantee&#8217;s Continuous Service as a result of his or her death, or in the event of the Grantee&#8217;s death during the Post-Termination Exercise Period, the person who acquired the right to exercise the Option pursuant to Section&#160;8 may exercise the portion of the Option that was vested at the date of termination within twelve (12)&#160;months commencing on the date of death (but in no event later than the Expiration Date).&nbsp;&nbsp;To the extent that the Option was unvested on the date of death, or if the vested portion of the Option is not exercised within the time specified herein, the Option shall terminate.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Transferability of Option</font><font style="color:#000000;">.&nbsp;&nbsp;The Option, if an Incentive Stock Option, may not be transferred in any manner other than by will or by the laws of descent and distribution and may be exercised during the lifetime of the Grantee only by the Grantee.&nbsp;&nbsp;The Option, if a Non-Qualified Stock Option, may not be transferred in any manner other than by will or by the laws of descent and distribution, provided, however, that a Non-Qualified Stock Option may be transferred during the lifetime of the Grantee to the extent and in the manner authorized by the Administrator.&nbsp;&nbsp;Notwithstanding the foregoing, the Grantee may designate one or more beneficiaries of the Grantee&#8217;s Incentive Stock Option or Non-Qualified Stock Option in the event of the Grantee&#8217;s death on a beneficiary designation form provided by the Administrator.&nbsp;&nbsp;Following the death of the Grantee, the Option, to the extent provided in Section&#160;7, may be exercised (a)&#160;by the person or persons designated under the deceased Grantee&#8217;s beneficiary designation or (b)&#160;in the absence of an effectively designated beneficiary, by the Grantee&#8217;s legal representative or by any person empowered to do so under the deceased Grantee&#8217;s will or under the then applicable laws of descent and distribution.&nbsp;&nbsp;The terms of the Option shall be binding upon the executors, administrators, heirs, successors and transferees of the Grantee.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4145-7952-3365.2</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">9.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Term of Option</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">The Option must be exercised no later than the Expiration Date set forth in the Notice or such earlier date as otherwise provided herein</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">After the Expiration Date or such earlier date, the Option shall be of no further force or effect and may not be exercised.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Tax Consequences</font><font style="color:#000000;">.&nbsp;&nbsp;The Grantee may incur tax liability as a result of the Grantee&#8217;s purchase or disposition of the Shares.&nbsp;&nbsp;THE GRANTEE SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THE OPTION OR DISPOSING OF THE SHARES.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Entire Agreement:&nbsp;&nbsp;Governing Law</font><font style="color:#000000;">.&nbsp;&nbsp;The Notice, the Plan and this Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Grantee with respect to the subject matter hereof, and may not be modified adversely to the Grantee&#8217;s interest except by means of a writing signed by the Company and the Grantee.&nbsp;&nbsp;Nothing in the Notice, the Plan and this Option Agreement (except as expressly provided therein) is intended to confer any rights or remedies on any persons other than the parties.&nbsp;&nbsp;The Notice, the Plan and this Option Agreement are to be construed in accordance with and governed by the internal laws of the State of Delaware without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of Delaware to the rights and duties of the parties.&nbsp;&nbsp;Should any provision of the Notice, the Plan or this Option Agreement be determined to be illegal or unenforceable, such provision shall be enforced to the fullest extent allowed by law and the other provisions shall nevertheless remain effective and shall remain enforceable.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Venue and Jurisdiction</font><font style="color:#000000;">.&nbsp;&nbsp;The parties agree that any suit, action, or proceeding arising out of or relating to the Notice, the Plan or this Option Agreement shall be brought exclusively in the United States District Court for Delaware (or should such court lack jurisdiction to hear such action, suit or proceeding, in a Delaware state court) and that the parties shall submit to the jurisdiction of such court.&nbsp;&nbsp;The parties irrevocably waive, to the fullest extent permitted by law, any objection the party may have to the laying of venue for any such suit, action or proceeding brought in such court.&nbsp;&nbsp;If any one or more provisions of this Section&#160;12 shall for any reason be held invalid or unenforceable, it is the specific intent of the parties that such provisions shall be modified to the minimum extent necessary to make it or its application valid and enforceable.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Construction</font><font style="color:#000000;">.&nbsp;&nbsp;The captions used in the Notice and this Option Agreement are inserted for convenience and shall not be deemed a part of the Option for construction or interpretation.&nbsp;&nbsp;Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular.&nbsp;&nbsp;Use of the term &#8220;or&#8221; is not intended to be exclusive, unless the context clearly requires otherwise.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Administration and Interpretation</font><font style="color:#000000;">.&nbsp;&nbsp;Any question or dispute regarding the administration or interpretation of the Notice, the Plan or this Option Agreement shall be submitted by the Grantee or by the Company to the Administrator.&nbsp;&nbsp;The resolution of such question or dispute by the Administrator shall be final and binding on all persons.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notices</font><font style="color:#000000;">.&nbsp;&nbsp;Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery, upon deposit for delivery by an internationally recognized express mail courier service or upon deposit in the United States mail by certified mail (if the parties are within the United States), with postage and fees prepaid, addressed to the other party at its </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4145-7952-3365.2</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">address as shown in these instruments, or to such other address as such party may designate in writing from time to time to the other party.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">END OF AGREEMENT</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4145-7952-3365.2</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Arial;font-size:10pt;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT&#160;A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Arial;font-size:10pt;font-style:normal;font-variant: normal;">CATALYST BIOSCIENCES INC. 2018 OMNIBUS INCENTIVE PLAN</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Arial;font-size:10pt;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">EXERCISE NOTICE</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[COMPANY<br />ADDRESS]<br /><font style="font-weight:normal;">Attention:&nbsp;&nbsp;Secretary</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Exercise of Option</font><font style="color:#000000;">.&nbsp;&nbsp;Effective as of today, [DATE], the undersigned (the &#8220;Grantee&#8221;) hereby elects to exercise the Grantee&#8217;s option to purchase shares of the Common Stock (the &#8220;Shares&#8221;) of Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) under and pursuant to the Company&#8217;s 2018 Omnibus Incentive Plan, as amended from time to time (the &#8220;Plan&#8221;) and the Stock Option Award Agreement (the &#8220;Option Agreement&#8221;) and Notice of Stock Option Award (the &#8220;Notice&#8221;) dated [&#160;&#160;], 20[&#160;&#160;] and this Exercise Notice (the &#8220;Exercise Notice&#8221;).&nbsp;&nbsp;Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Exercise Notice.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Representations of the Grantee</font><font style="color:#000000;">.&nbsp;&nbsp;The Grantee acknowledges that the Grantee has received, read and understood the Notice, the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Rights as Stockholder</font><font style="color:#000000;">.&nbsp;&nbsp;Until the stock certificate evidencing such Shares is issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall exist with respect to the Shares, notwithstanding the exercise of the Option.&nbsp;&nbsp;The Company shall issue (or cause to be issued) such stock certificate promptly after the Option is exercised.&nbsp;&nbsp;No adjustment will be made for a dividend or other right for which the record date is prior to the date the stock certificate is issued, except as provided in Section&#160;10 of the Plan.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Delivery of Payment</font><font style="color:#000000;">.&nbsp;&nbsp;The Grantee herewith delivers to the Company the full Exercise Price for the Shares, which, to the extent selected, shall be deemed to be satisfied by use of the broker-dealer sale and remittance procedure to pay the Exercise Price provided in Section&#160;3(e) of the Option Agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Tax Consultation</font><font style="color:#000000;">.&nbsp;&nbsp;The Grantee understands that the Grantee may suffer adverse tax consequences as a result of the Grantee&#8217;s purchase or disposition of the Shares.&nbsp;&nbsp;The Grantee represents that the Grantee has consulted with any tax consultants the Grantee deems advisable in connection with the purchase or disposition of the Shares and that the Grantee is not relying on the Company for any tax advice.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Taxes</font><font style="color:#000000;">.&nbsp;&nbsp;The Grantee agrees to satisfy all applicable foreign, federal, state and local income and employment tax withholding obligations and herewith delivers to the Company the full amount of such obligations or has made arrangements acceptable to the Company to satisfy such obligations.&nbsp;&nbsp;In the case of an Incentive Stock Option, the Grantee also agrees, as partial consideration for the designation of the Option as an Incentive Stock Option, to notify the Company in writing within thirty (30)&#160;days of any disposition of any shares acquired by exercise of the Option if such disposition occurs within two (2)&#160;years from the Grant Date or within one (1)&#160;year from the date the Shares were transferred to the Grantee.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4145-7952-3365.2</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">7.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Successors and Assigns</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">The Company may assign any of its rights under this Exercise Notice to single or multiple assignees, and this Exercise Notice shall inure to the benefit of the successors and assigns of the Company</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">This Exercise Notice shall be binding upon the Grantee and his or her heirs, executors, administrators, successors and assigns.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Construction</font><font style="color:#000000;">.&nbsp;&nbsp;The captions used in this Exercise Notice are inserted for convenience and shall not be deemed a part of this Exercise Notice for construction or interpretation.&nbsp;&nbsp;Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular.&nbsp;&nbsp;Use of the term &#8220;or&#8221; is not intended to be exclusive, unless the context clearly requires otherwise.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Administration and Interpretation</font><font style="color:#000000;">.&nbsp;&nbsp;The Grantee hereby agrees that any question or dispute regarding the administration or interpretation of this Exercise Notice shall be submitted by the Grantee or by the Company to the Administrator.&nbsp;&nbsp;The resolution of such question or dispute by the Administrator shall be final and binding on all persons.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Governing Law; Severability</font><font style="color:#000000;">.&nbsp;&nbsp;This Exercise Notice is to be construed in accordance with and governed by the internal laws of the State of Delaware without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of Delaware to the rights and duties of the parties.&nbsp;&nbsp;Should any provision of this Exercise Notice be determined by a court of law to be illegal or unenforceable, such provision shall be enforced to the fullest extent allowed by law and the other provisions shall nevertheless remain effective and shall remain enforceable.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notices</font><font style="color:#000000;">.&nbsp;&nbsp;Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery, upon deposit for delivery by an internationally recognized express mail courier service or upon deposit in the United States mail by certified mail (if the parties are within the United States), with postage and fees prepaid, addressed to the other party at its address as shown below beneath its signature, or to such other address as such party may designate in writing from time to time to the other party.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Further Instruments</font><font style="color:#000000;">.&nbsp;&nbsp;The parties agree to execute such further instruments and to take such further action as may be reasonably necessary to carry out the purposes and intent of this agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Entire Agreement</font><font style="color:#000000;">.&nbsp;&nbsp;The Notice, the Plan and the Option Agreement are incorporated herein by reference and together with this Exercise Notice constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Grantee with respect to the subject matter hereof, and may not be modified adversely to the Grantee&#8217;s interest except by means of a writing signed by the Company and the Grantee.&nbsp;&nbsp;Nothing in the Notice, the Plan, the Option Agreement and this Exercise Notice (except as expressly provided therein) is intended to confer any rights or remedies on any persons other than the parties.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4145-7952-3365.2</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Submitted by:</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accepted by:</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GRANTEE:</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Signature)</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:12pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Address</font>:</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:12pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:12pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Address</font>:</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[COMPANY ADDRESS]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4145-7952-3365.2</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>cbio-ex231_10.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex231_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Segoe UI;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Segoe UI;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the Registration Statements of Catalyst Biosciences, Inc. on Form S-8 (Nos. 333-133881, 333-133882, 333-160331, 333-185888,<font style="font-weight:bold;font-size:12pt;font-family:Arial;"> </font>333-189143, 333-206523, 333-206526, 333-212345, 333-219301, 333-225902, and 333-239712), and Form S-3 (No. 333-228970) of our report dated March 4, 2021, on our audits of the consolidated financial statements as of December 31, 2020 and December 31, 2019, and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March 4, 2021.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Segoe UI;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ EisnerAmper LLP</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Segoe UI;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EISNERAMPER LLP</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Segoe UI;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Iselin, New Jersey</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Segoe UI;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021 </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>cbio-ex311_9.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex311_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">Rule 13<font style="text-transform:none;">a</font>-14(<font style="text-transform:none;">a</font>) or 15<font style="text-transform:none;">d</font>-14(<font style="text-transform:none;">a</font>) of the Securities Exchange Act of 1934<font style="text-transform:none;">,</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Nassim Usman, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this report on Form 10-K of Catalyst Biosciences, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 4, 2021</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td style="width:40%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Nassim Usman, Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nassim Usman, Ph.D.</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>cbio-ex312_151.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex312_151.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">Rule 13<font style="text-transform:none;">a</font>-14(<font style="text-transform:none;">a</font>) or 15<font style="text-transform:none;">d</font>-14(<font style="text-transform:none;">a</font>) of the Securities Exchange Act of 1934<font style="text-transform:none;">,</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Clinton Musil, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this report on Form 10-K of Catalyst Biosciences, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 4, 2021</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td style="width:40%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Clinton Musil&#160;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinton Musil&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer (Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>cbio-ex321_12.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex321_12.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;"><br />Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Nassim Usman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 4, 2021</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="middle"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Nassim Usman, Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nassim Usman, Ph.D.</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>cbio-ex322_152.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex322_152.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;"><br />Exhibit 32.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Clinton Musil, Chief Financial Officer (Principal Financial Officer) of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 4, 2021</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="middle"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ &#160;Clinton Musil</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;Clinton Musil</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer (Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g2g5bnvu5o20000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2g5bnvu5o20000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0.!YX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)-0^(.O6^HW
M,$<L&R.5E7,0Z U':_$77&NHQ-+ 8RV&Q$!Q7-:O_P AF]_Z[O\ ^A&JI1D"
ML1P>13$?1<+B6%) 0=R@\5#?W2V=C-<,<;$)!/KCBLGP;?"^\-VS;LNBX;VJ
ME\0-0%GX>>(?ZR4@+^?-(9Q+_$?7][;)8 N>/W0K0T#QUK>H:U;6MQ)"8I'
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M,MU(%]!W-<WH/C237?$WV.*,):^4S<CDD8KF?B#J]AJD]N;&Z2<*.=N>*SO
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M.<4#,G2/"FJZY#YULJ^7G&Z1L"FZKX5U714\RXC!3/WHSD4S2/$^IZ(-EK*
MF<[6&1736WQ*=QLU&RCG0^PQ^6*!$7@35=3M=06V:.62UDZY&=IKU>N=T#Q%
MH^K +:K'%-W38%KHJ0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /GO5_\ D,WO_7=__0C7J_A"TCF\&B%LE95Y_*O*-7_Y
M#-[_ -=W_P#0C7L'@?GPO;C_ &:8CQN[C>SU"5 <,CG!JSHELU]K=O&<DF0,
M??!S6AXVLA9^);C:,(YRM:'PYLO/U_SRN5A4Y_$4 =9\1%5/#J*H 4,0 /I7
MG?A/_D9;+_KH*]&^(_\ R %_WC_*O.?"?_(RV7_704(9[!XF_P"0!=?[IKPF
MW_X^8O\ ?'\Z]V\3?\@"Z_W37A-O_P ?,7^^/YT(#Z*A_P!1'_NC^5>#^)/^
M0]=?[YKWB'_41_[H_E7@_B3_ )#UU_OFA >G?#\;O">WU=A^@KR[Q#;/::]>
M0N,%9*]2^'G_ "*Z_P#71OZ53\;^$FU0?;K)?](4?,@_B_\ KT 0^!['0]4T
M11-8V\ES&2'+KS[5OWFC>&=/A,MU8V<48[LE>.QOJ>B7!9#+;2*?3%/N]6U;
M6F"W$\MP>PQ_A0(]9M+/PE=2*+:WLG8GC"5H:OKECH,"&Y8*",(HK@O!GA"[
M>]COKY'CB0[E1L@DUV_B30(M<TMK<C;(HS&WICM0,YI=6\->)]26T>QV2R=)
MCBGWOPSL9?FM+AH\_P!\Y%<!?:+J>CW)$D,B%3PX'%2KXKUU(?LXU"4)C&W
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M[N[V.[O(FB@C.X!ARQKUM5"*%48 & *&,6BBBD 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "JVH7L6GV,MU,P5(U)R:LUY!\3_
M !4+B<:1:2?NTYE(/4^E &/J/Q+U^6_F:TN_*MRQV+L!P*J_\+'\4?\ 01_\
MAK7*44Q'5_\ "Q_%'_01_P#(:T?\+'\4?]!'_P AK7*44 =7_P +'\4?]!'_
M ,AK1_PL?Q1_T$?_ "&M<I10!U?_  L?Q1_T$?\ R&M'_"Q_%'_01_\ (:UR
ME% '5_\ "Q_%'_01_P#(:T?\+'\4?]!'_P AK7*44 =7_P +'\4?]!'_ ,AK
M1_PL?Q1_T$?_ "&M<I10!U?_  L?Q1_T$?\ R&M'_"Q_%'_01_\ (:URE% '
M5_\ "Q_%'_01_P#(:T?\+'\4?]!'_P AK7*44 =7_P +'\4?]!'_ ,AK1_PL
M?Q1_T$?_ "&M<I10!U?_  L?Q1_T$?\ R&M'_"Q_%'_01_\ (:URE% '5_\
M"Q_%'_01_P#(:T?\+'\4?]!'_P AK7*44 =7_P +'\4?]!'_ ,AK1_PL?Q1_
MT$?_ "&M<I10!U?_  L?Q1_T$?\ R&M'_"Q_%'_01_\ (:URE% '5_\ "Q_%
M'_01_P#(:T?\+'\4?]!'_P AK7*44 =7_P +'\4?]!'_ ,AK1_PL?Q1_T$?_
M "&M<I10!U?_  L?Q1_T$?\ R&M'_"Q_%'_01_\ (:URE% '5_\ "Q_%'_01
M_P#(:T?\+'\4?]!'_P AK7*44 =7_P +'\4?]!'_ ,AK1_PL?Q1_T$?_ "&M
M<I10!U?_  L?Q1_T$?\ R&M'_"Q_%'_01_\ (:URE% '5_\ "Q_%'_01_P#(
M:T?\+'\4?]!'_P AK7*44 =7_P +'\4?]!'_ ,AK1_PL?Q1_T$?_ "&M<I10
M!U?_  L?Q1_T$?\ R&M'_"Q_%'_01_\ (:URE% '5_\ "Q_%'_01_P#(:T?\
M+'\4?]!'_P AK7*44 =7_P +'\4?]!'_ ,AK1_PL?Q1_T$?_ "&M<I10!U?_
M  L?Q1_T$?\ R&M'_"Q_%'_01_\ (:URE% '5_\ "Q_%'_01_P#(:T?\+'\4
M?]!'_P AK7*44 =7_P +'\4?]!'_ ,AK1_PL?Q1_T$?_ "&M<I10!U?_  L?
MQ1_T$?\ R&M'_"Q_%'_01_\ (:URE% '5_\ "Q_%'_01_P#(:T?\+'\4?]!'
M_P AK7*44 =7_P +'\4?]!'_ ,AK1_PL?Q1_T$?_ "&M<I10!U?_  L?Q1_T
M$?\ R&M'_"Q_%'_01_\ (:URE% '5_\ "Q_%'_01_P#(:T?\+'\4?]!'_P A
MK7*44 =7_P +'\4?]!'_ ,AK1_PL?Q1_T$?_ "&M<I10!U?_  L?Q1_T$?\
MR&M'_"Q_%'_01_\ (:URE% '5_\ "Q_%'_01_P#(:T?\+'\4?]!'_P AK7*4
M4 =7_P +'\4?]!'_ ,AK1_PL?Q1_T$?_ "&M<I10!U?_  L?Q1_T$?\ R&M'
M_"Q_%'_01_\ (:URE% '5_\ "Q_%'_01_P#(:T?\+'\4?]!'_P AK7*44 =7
M_P +'\4?]!'_ ,AK1_PL?Q1_T$?_ "&M<I10!U?_  L?Q1_T$?\ R&M'_"Q_
M%'_01_\ (:URE% '5_\ "Q_%'_01_P#(:T?\+'\4?]!'_P AK7*44 =7_P +
M'\4?]!'_ ,AK1_PL?Q1_T$?_ "&M<I10!U?_  L?Q1_T$?\ R&M'_"Q_%'_0
M1_\ (:URE% '5_\ "Q_%'_01_P#(:T?\+'\4?]!'_P AK7*44 =7_P +'\4?
M]!'_ ,AK1_PL?Q1_T$?_ "&M<I10!U?_  L?Q1_T$?\ R&M'_"Q_%'_01_\
M(:URE% '5_\ "Q_%'_01_P#(:T?\+'\4?]!'_P AK7*44 =7_P +'\4?]!'_
M ,AK1_PL?Q1_T$?_ "&M<I10!U?_  L?Q1_T$?\ R&M'_"Q_%'_01_\ (:UR
ME% '5_\ "Q_%'_01_P#(:T?\+'\4?]!'_P AK7*44 =7_P +'\4?]!'_ ,AK
M1_PL?Q1_T$?_ "&M<I10!U?_  L?Q1_T$?\ R&M'_"Q_%'_01_\ (:URE% '
M5_\ "Q_%'_01_P#(:T?\+'\4?]!'_P AK7*44 =7_P +'\4?]!'_ ,AK1_PL
M?Q1_T$?_ "&M<I10!U?_  L?Q1_T$?\ R&M'_"Q_%'_01_\ (:URE% '5_\
M"Q_%'_01_P#(:T?\+'\4?]!'_P AK7*44 =7_P +'\4?]!'_ ,AK1_PL?Q1_
MT$?_ "&M<I10!U?_  L?Q1_T$?\ R&M'_"Q_%'_01_\ (:URE% '5_\ "Q_%
M'_01_P#(:T?\+'\4?]!'_P AK7*44 =7_P +'\4?]!'_ ,AK1_PL?Q1_T$?_
M "&M<I10!U?_  L?Q1_T$?\ R&M'_"Q_%'_01_\ (:URE% '5_\ "Q_%'_01
M_P#(:T?\+'\4?]!'_P AK7*44 =7_P +'\4?]!'_ ,AK1_PL?Q1_T$?_ "&M
M<I10!U?_  L?Q1_T$?\ R&M'_"Q_%'_01_\ (:URE% '5_\ "Q_%'_01_P#(
M:T?\+'\4?]!'_P AK7*44 =7_P +'\4?]!'_ ,AK1_PL?Q1_T$?_ "&M<I10
M!U?_  L?Q1_T$?\ R&M'_"Q_%'_01_\ (:URE% '5_\ "Q_%'_01_P#(:T?\
M+'\4?]!'_P AK7*4JJ78*H))Z 4 =]X?\7>+=<U>&TCOB59OG/EC@=^U>U1!
MEB17;<X4!F]37&?#OPP-'TD74Z?Z5.,G/517;4AA1110 4444 %%%% !1110
M 5#=W,=G:R7$S!4C7))J:O*/BAXJS_Q)[23WF(/Z4 86K?$K79-3G-C=^5;;
MOD78#Q5+_A8_BC_H(_\ D-:Y2BF(ZO\ X6/XH_Z"/_D-:/\ A8_BC_H(_P#D
M-:Y2B@#J_P#A8_BC_H(_^0UH_P"%C^*/^@C_ .0UKE** .K_ .%C^*/^@C_Y
M#6C_ (6/XH_Z"/\ Y#6N4HH ZO\ X6/XH_Z"/_D-:/\ A8_BC_H(_P#D-:Y2
MB@#J_P#A8_BC_H(_^0UH_P"%C^*/^@C_ .0UKE** .K_ .%C^*/^@C_Y#6C_
M (6/XH_Z"/\ Y#6N4HH ZO\ X6/XH_Z"/_D-:/\ A8_BC_H(_P#D-:Y2B@#J
M_P#A8_BC_H(_^0UH_P"%C^*/^@C_ .0UKE** .K_ .%C^*/^@C_Y#6C_ (6/
MXH_Z"/\ Y#6N4HH ZO\ X6/XH_Z"/_D-:/\ A8_BC_H(_P#D-:Y2B@#J_P#A
M8_BC_H(_^0UH_P"%C^*/^@C_ .0UKE** .K_ .%C^*/^@C_Y#6C_ (6/XH_Z
M"/\ Y#6N4HH ZO\ X6/XH_Z"/_D-:/\ A8_BC_H(_P#D-:Y2B@#J_P#A8_BC
M_H(_^0UH_P"%C^*/^@C_ .0UKE** .K_ .%C^*/^@C_Y#6C_ (6/XH_Z"/\
MY#6N4HH ZO\ X6/XH_Z"/_D-:/\ A8_BC_H(_P#D-:Y2B@#J_P#A8_BC_H(_
M^0UH_P"%C^*/^@C_ .0UKE** .K_ .%C^*/^@C_Y#6C_ (6/XH_Z"/\ Y#6N
M4HH ZO\ X6/XH_Z"/_D-:/\ A8_BC_H(_P#D-:Y2B@#J_P#A8_BC_H(_^0UH
M_P"%C^*/^@C_ .0UKE** .K_ .%C^*/^@C_Y#6C_ (6/XH_Z"/\ Y#6N4HH
MZO\ X6/XH_Z"/_D-:/\ A8_BC_H(_P#D-:Y2B@#J_P#A8_BC_H(_^0UH_P"%
MC^*/^@C_ .0UKE** .K_ .%C^*/^@C_Y#6C_ (6/XH_Z"/\ Y#6N4HH ZO\
MX6/XH_Z"/_D-:/\ A8_BC_H(_P#D-:Y2B@#J_P#A8_BC_H(_^0UH_P"%C^*/
M^@C_ .0UKE** .K_ .%C^*/^@C_Y#6C_ (6/XH_Z"/\ Y#6N4HH ZO\ X6/X
MH_Z"/_D-:/\ A8_BC_H(_P#D-:Y2B@#J_P#A8_BC_H(_^0UH_P"%C^*/^@C_
M .0UKE** .K_ .%C^*/^@C_Y#6C_ (6/XH_Z"/\ Y#6N4HH ZO\ X6/XH_Z"
M/_D-:/\ A8_BC_H(_P#D-:Y2B@#J_P#A8_BC_H(_^0UH_P"%C^*/^@C_ .0U
MKE** .K_ .%C^*/^@C_Y#6C_ (6/XH_Z"/\ Y#6N4HH ZO\ X6/XH_Z"/_D-
M:/\ A8_BC_H(_P#D-:Y2B@#J_P#A8_BC_H(_^0UH_P"%C^*/^@C_ .0UKE**
M .K_ .%C^*/^@C_Y#6C_ (6/XH_Z"/\ Y#6N4HH ZO\ X6/XH_Z"/_D-:/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%6;"-);^!)&"H7&XL>,9H W=
M\#:MX@C\Z%!#"1Q)(.#6U<?"36886=+FWE(&=B Y-=UJ7BO2=%\-2?V7=6TD
ML4>(XPXR37.> O'&K:OK_P!AOI!+&Z,X/3;CM0,\QOK&YTZZ:VNHFBE7JK5J
M^'?">I>))&^R)MB7@RL/E!KN?BUI\/VG3)U4"6>0QL1W''^-== L7A'P.9D0
M%K>#<>,%C0(\YNOA-K-O;M(EQ;S,!G8@.37#75K-9W#P7$;1R(<%6ZBO5? _
MCS4=7\0-8WQ#Q2*S(W=<=JH_%?2;>#4[*\50C7+;'/L,?XT <?X?\*:GXB<_
M9(L1 X,K#Y0:Z9_A#K"Q[A>6K'^Z V:[32-;T/0_"J16][;--##RN\ L:Y#0
M/B)K-WXFAMYW$EO/*$"?W030,X;5M&O=%NVM[V%HW'3(Z^]4*]M^*MA!+X=^
MUL@\Z)@%;ZFN3\$?#]=:BCU&]EQ;!LB->=WU]*!&9X=^'VI^(K$W<4L4$><+
MYH/S>XQ7+7,#6UU-;L06B=D)'<@XKZ>LHK:WMUM[4*(X_E 7M7S1J_\ R&K[
M_KXD_P#0C0!3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCH<K^= &-16YX?\ ">I^)1(=/$/[LX;S'VUJ1?#/Q%-<20K' "G5C)P?H<4
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MT'>@#@_'OB=]=U=H8SBV@)50#U/0FN0I223DG)/4TE,04444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** )[*SFO[R*U@7=+*VU17T3X5T&+0-&BME&9"
M,NV.2:X?X7^%MH_MBZCY/^I!_G7JE(84444 %%%% !1110 4444 %(S!5+,<
M #)-+7#?$7Q0-(TLV=N_^DS#''8=Z .#^(GB=]8U9K.%O]&MV(&#PQ]:XBE)
M+,2Q))ZDTE,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOQK96&1:@Y9B,;JX&@#J_!_C2X\,S&,KYMK(<NA/3W%>@CXI>&G >2"?S/\
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MGBB*.*:_F@C0YVQJ""?QKEO^%-Z=_P!!6Z_[]K0!X]17L/\ PIO3O^@K=?\
M?M:/^%-Z=_T%;K_OVM,1X]17L/\ PIO3O^@K=?\ ?M:/^%-Z=_T%;K_OVM '
MCU%>P_\ "F]._P"@K=?]^UH_X4WIW_05NO\ OVM 'CU%>P_\*;T[_H*W7_?M
M:/\ A3>G?]!6Z_[]K0!X]17L/_"F]._Z"MU_W[6C_A3>G?\ 05NO^_:T >/4
M5[#_ ,*;T[_H*W7_ '[6C_A3>G?]!6Z_[]K0!X]17L/_  IO3O\ H*W7_?M:
M/^%-Z=_T%;K_ +]K0!X]17L/_"F]._Z"MU_W[6C_ (4WIW_05NO^_:T >/45
M[#_PIO3O^@K=?]^UH_X4WIW_ $%;K_OVM 'CU%>P_P#"F]._Z"MU_P!^UH_X
M4WIW_05NO^_:T >/45[#_P *;T[_ *"MU_W[6C_A3>G?]!6Z_P"_:T >/45[
M#_PIO3O^@K=?]^UH_P"%-Z=_T%;K_OVM 'CU%>P_\*;T[_H*W7_?M:/^%-Z=
M_P!!6Z_[]K0!X]17L/\ PIO3O^@K=?\ ?M:/^%-Z=_T%;K_OVM 'CU%>P_\
M"F]._P"@K=?]^UK@8O#<,GCC^P#<2"+SS%YN!NP,\XH YRBO8?\ A3>G?]!6
MZ_[]K1_PIO3O^@K=?]^UH \>HKV'_A3>G?\ 05NO^_:T?\*;T[_H*W7_ '[6
M@#QZBO8?^%-Z=_T%;K_OVM'_  IO3O\ H*W7_?M: /'J*]A_X4WIW_05NO\
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MMU_W[6@#QZBO8?\ A3>G?]!6Z_[]K1_PIO3O^@K=?]^UH \>HKV'_A3>G?\
M05NO^_:T?\*;T[_H*W7_ '[6@#QZBO8?^%-Z=_T%;K_OVM'_  IO3O\ H*W7
M_?M: /'J*]A_X4WIW_05NO\ OVM'_"F]._Z"MU_W[6@#QZBO8?\ A3>G?]!6
MZ_[]K1_PIO3O^@K=?]^UH \>HKV'_A3>G?\ 05NO^_:T?\*;T[_H*W7_ '[6
M@#QZBO8?^%-Z=_T%;K_OVM'_  IO3O\ H*W7_?M: /'J*]A_X4WIW_05NO\
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MMU_W[6@#QZBO8?\ A3>G?]!6Z_[]K1_PIO3O^@K=?]^UH \>HKV'_A3>G?\
M05NO^_:T?\*;T[_H*W7_ '[6@#QZBO8?^%-Z=_T%;K_OVM'_  IO3O\ H*W7
M_?M: /'J*]A_X4WIW_05NO\ OVM'_"F]._Z"MU_W[6@#QZBO8?\ A3>G?]!6
MZ_[]K1_PIO3O^@K=?]^UH \>HKV'_A3>G?\ 05NO^_:T?\*;T[_H*W7_ '[6
M@#QZBO8?^%-Z=_T%;K_OVM'_  IO3O\ H*W7_?M: /'J*]A_X4WIW_05NO\
MOVM'_"F]._Z"MU_W[6@#QZBO8?\ A3>G?]!6Z_[]K1_PIO3O^@K=?]^UH \>
MHKV'_A3>G?\ 05NO^_:T?\*;T[_H*W7_ '[6@#QZBO8?^%-Z=_T%;K_OVM'_
M  IO3O\ H*W7_?M: /'J*]A_X4WIW_05NO\ OVM'_"F]._Z"MU_W[6@#QZBO
M8?\ A3>G?]!6Z_[]K1_PIO3O^@K=?]^UH \>HKV'_A3>G?\ 05NO^_:T?\*;
MT[_H*W7_ '[6@#QZBO8?^%-Z=_T%;K_OVM'_  IO3O\ H*W7_?M: /'J*]A_
MX4WIW_05NO\ OVM'_"F]._Z"MU_W[6@#QZN@\(>'Y/$&M1PA3Y*'=(W8"O0?
M^%-Z=_T%;K_OVM==X9\+6?ABS:"W9I68Y:5P 3[4 :]K;16=M';PJ%CC&% J
M:BBD,**** "BBB@ HHHH **** *6JZE!I.G2WEPP5(US]3Z5\YZ_K$VMZM-=
MS,3N;"CT':O>_$_AE?$UHEM+>S6\2G)$:@Y/XUR7_"F]._Z"MU_W[6@#QZBO
M8?\ A3>G?]!6Z_[]K1_PIO3O^@K=?]^UIB/'J*]A_P"%-Z=_T%;K_OVM'_"F
M]._Z"MU_W[6@#QZBO8?^%-Z=_P!!6Z_[]K1_PIO3O^@K=?\ ?M: /'J*]A_X
M4WIW_05NO^_:T?\ "F]._P"@K=?]^UH \>HKV'_A3>G?]!6Z_P"_:T?\*;T[
M_H*W7_?M: /'J*]A_P"%-Z=_T%;K_OVM'_"F]._Z"MU_W[6@#QZBO8?^%-Z=
M_P!!6Z_[]K1_PIO3O^@K=?\ ?M: /'J*]A_X4WIW_05NO^_:T?\ "F]._P"@
MK=?]^UH \>HKV!_@[IZHS?VK=<#/W%K@_"GAJ'Q#XDDTN:XDB1%=MZ $_*:
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M]K1_PIO3O^@K=?\ ?M: /'J*]A_X4WIW_05NO^_:T?\ "F]._P"@K=?]^UH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5XA:_P#)8O\ M\;^1KV^O$+7_DL7_;XW
M\C0![?VHH[44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ,E_U3_[IKQ;X9_\E N/^N<O\Z]IE_U3_P"Z:\6^&?\ R4"X_P"N<O\
M.@#VRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\0M?^2Q?]OC?
MR->WUXA:_P#)8O\ M\;^1H ]O[44=J* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** &2_ZI_\ =->+?#/_ )*!<?\ 7.7^=>TR_P"J
M?_=->+?#/_DH%Q_USE_G0![91110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %>(6O_ "6+_M\;^1KVQI8T^_(B_5@*\2MG3_A;^_<NW[8WS9XZ&@#W
M#M135=7&58,/8YIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMJ,/]E7I/VF$84MU8>E>A4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:6N=C1117H'E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH+&_83V;U.BUKP+I4NDRK:6YBG1<QLA.<U2\$ZK/?>&M1M+AR\EHK)D]>_\
MA74ZOK=KINE37?VB+*KE?F!R:XSP!:R+H>LWSJ0+HNRY[]:N$I3H2=3HU8B<
M80Q$53ZIW,GP-X9M]7U&\NKS+PQN=L>>"<U?\;:-%X9%KK.D@P,D@#(&X-/^
M&^IVT5Q?V<LBH_F%AN.,\U8^)M]#=:?;:9;L);F63(5#GUKHE.H\6HO;\+'-
M&%-8-R6_XW&^.[ZYNO"]E<0>8;=]IF*CGW_K4>E1^"]3TN.WW)%,R ,TC;2&
MQ]:V=2U6W\-:#86U[9FYAD55<]ESZYJG?>#?#.IV!O8'6"1DWJ5E  XSTK*$
MXJFHNZ5W9HUG"3J.2LW973_0V=!TJ'PSHTQ2_:Z@'SAF'2N'\-VUMXHUJ]U'
M6;E?+BDVI$SX!_SBK/@?[7>6VK:89WFM@I6-V)]NE9_A'0='O;N]LM5DN(+M
M)#M59B@(YK51]G[1REKIJEK8S<_:>R48^[KHWI<T_%^FZ;H\$6K:+.D4L+C>
ML<F=P^E:7BF^.I_#>.]/6>+?46J>%/!VG0!KZ\NMC'  N2V?P%3^*X;2V^':
M0V.[[*D6(M_7;[U"G&3I[MWW:+<)1539*VR8WP7X3TV;P];7=W"99Y/F)8GC
M!K/U"(>%OB#;7,2;;2Y4)CL3C_Z]=EX2_P"18LO]RLGXB::;O0ENX_\ 6VKA
MUQ]16<*SEB'&;T=T:3HJ.'C*"U5F0_$K43;Z+'8Q-^\NW\LJ.N*LR:+>6G@2
M/3M/=(Y@GS.S;1@\GG\:Y+2;E_&/B?3';+Q6D2M*#W/(_K72_$N\NK+PV$M2
MR*[JK.O8<\53@X.G06][LE5%-5,0]K61DV-MX2TBQ6'4YX[F[ZR.C[N3VZUF
M>'+ZTB^(*Q:29%LISM*-D>M=1X=\.^&X=(@NW\F9R@=VD8'G&3UKF+"YM+GX
MI0-9(J0*^U=JX!ZUM&2E[1:O1[[?<82BX>S>BU6V_P!Y;\:Z79IX[T*-80%N
M6_>C^]\V*VOB!8V^G> +BWM8Q'$)4(4>[51\<D+X]\-,QPH/)/0?-6K\2W5_
M ]PR,&7S$Y!SWK*,I-T+O^KFLHQ2KV7]6,[4M8FTGX::7]G.V6>!8U;TXJYX
M9\%::VCQ7%]&;BXG&YV8GBLC7[*:Z^&>CRQ*6%O$KL!Z8KKO"NL6=]H%LR3H
M&1<.K-@@U-5RC1;A_,[ETE&59*I_*K'&7$+>"_&ULMHS"RNSMV,>,G _K1\1
MH3<>)M/B#%2^!D?C3_%%P/$/C?3;&U(E6U<.2O;D$\_A3_'G_(WZ7]1_6MZ;
M?M(2E\7*[_H<]1+V=2,?AYE;]3=N_!&C)H,B"W_>+'D29.<^M4/AE=3R:;?6
MQ<N()"J;C[FNSOO^03-_URK@/AT[1Z?KCI]]68K]?FKFA.53#SYG?5'7.$:>
M(ARJVC$;2+2#Q#=WWB:\A92?W,(E!(Y]*P_%MYX<%K%+H7F1W:/G<H.,?G5[
MP?I]AK^K7]SK+[YU;A'?&.?>I?B,VC6.DPV%A! )]VXF-1G'N179!VKQ@[M_
M@<,U>A*:22^]F_X@N7N_AT)I/O%%S^5:O@G_ )%6S_W?Z"L35O\ DF2_[JUM
M^"?^15L_]W^@KAJJU!K^\=])WKIO^4WY$62-D<95A@BO*K;1;"7XM7-@\ -L
M(2VSWP*]7KS:U=8_C1=-(P5?(/+' ^Z*6#DTJEOY6/&13=._\R#XHVRK;:%;
M1 JGG%% [# %=5I?A/2],2"1(,W$0SYA)R3ZU@?$<@W&@D'(-R>1^%=[_!^%
M%2I)8>"3WO\ F%*G!XBI)K:WY'F7@G_D=]2^K5)-I%M%XDN[[Q->0F'/[B$2
MY)'/4=N*K>%)'B\6:O)&,NJN5'OBJ_A.QL?$&O:E-K<F^9'^1';&.3ZUVS34
MY3O966VYQ0:<(PM=MO?8J>+;OPR;2)]%$B7:/G<@.,?G78:M=27GPW\^4Y=H
MN3^!K$^(?]C:?I$-E8PP"<MR8U&0/4D5JW?_ "2Y?^N1_K42M*%.6N_4J*<:
ME2.GP]-C7\!_\BG;?4UTM<UX#_Y%.V^IKI:\[$?Q9>IZ>'_@Q]$%%%%8FP44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?/X5KRJ=6+I0:MN[6T,N9TZ,U6J*5UHKWU.FHHHKTCQPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@/'O@;^V
M%.H:>H%VG+*!]_\ ^O7->&/B!<Z!C3-8BD9(SM#'JM>R5S^N>#M*UY#Y\(24
M])%'(H LZ?XFT?4T#6M]$Y(Y4'D5HM=VZ)N:9 OKFO*KWX37L$A_LV_9E/\
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M371'S2,.GTH L^#O#L?AW14AP/.DPTI]370T44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>(6O_)8O^WQOY&O;Z\0M?^2Q?]OC?R- 'M_:BCM10 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!3N=-L9D=I+2!S@
M\M&#7C?PW@BE\>3QR1HZ".7"L,@<U[;+_JG_ -TUXM\,_P#DH%Q_USE_G0![
M6JJB[54*!V I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ"U_Y
M+%_V^-_(U[?7B%K_ ,EB_P"WQOY&@#V_M11VHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH 9+_JG_P!TUXM\,_\ DH%Q_P!<Y?YU
M[3+_ *I_]TUXM\,_^2@7'_7.7^= 'ME%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%!.!D]!0 A8*I+$ #J37"^(_B58:4S6]D/M-P#C*] :Q/'_C.>>Z_L32
M7;=G;(R=6/I5OP?\.8$@2_UA#).WS"-NU '.MXN\8ZXY:RBD5>PA&/YFLH:!
MXO@U$:H=/NA<[M_FY&<^O6O?8K:"! D42(H&  M28'H* /&+3XB^(='E$6I6
MQ=1][>/F_.O1O#OC'3?$2!8)!'/CF)CS6IJ&CV&IV[0W=M'(C=>*\D\6>#KO
MPO=KJ6CM)Y .?E_@H ]IHKD/ WBZ/Q#IXAG8"]B'SC^][UU] !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MS7XO6YDTRSF )$;')],XKTJL'Q?I']M>'+FU ^?&]?PYH K^ ;I;GPC9!3GR
MD"'\*Z:O(OAAKO\ 9U[-HEX?+W-E-Q_B]*]=H **** "BBHYYX[:!YI6"HBD
MDDXH \N^+URLC6%F#\RONQ]1BN[\)0&V\*:="PP5BQC\37DUR\WC?Q\!&"84
M?:".@49P:]PBC$4*1J,!1C% #Z*** "LKQ'_ ,@.X_W:U:R_$",^BW"HI9BO
M  R:SK?PY>AMA_XL?5'*6]G]J\"!Q_K(9"R_I5R[UKS/!<>QLS2KY1]<UH>%
M+=_^$9\F6,JS,PVNN.WO7,Z=I-T/$*V$T4GV6&;<3@[3^->6U.$(./VE8]E2
MA4G-3?P2YBWK]G]A\-64)QG<"<>YS761W*6GA^*9S@+ .?PK&\:P226$"0Q.
M^UAPJD]ZB\137 \/65E#%*S3*JOM0G'2M;^QG-KHD86^L4Z:;WD[F/HUYJT=
MW<:C;:<+DSGEFS_2DUVXU>ZDAO;G31;^0<AUS]>]=UHMI]ATBV@QAE0!OK4F
MI6PO-.G@(SN0@?6A8.;HVYGWMY@\P@L1S*"[7UVV(]-OTN])CN@<_)EOJ!S7
M#I>WUUXBGU*RL_M2H^$SG _*BPO+W3]%OK#[/<;E;$9$9.<GFNI\(V#6.B1^
M8I5Y?G((Y%)2EB7".UM7ZE.$<&JD][NR]-SG-=N=:U2Q*W&D"(1G=YBYR,5T
MWA;4?[0T>,L?WD?R$?3BMB6-98FC;[K#!KB_#BW.E^(KFT:*3R)6)5MAP.O>
MM.25"O&3=U+3_(R]I'$8:4%%1<=5^IV]4=4U6VTJV,T[@''RKW-72<*3Z"O,
MM2NKJ\UYI[JRN)+>-OEC"-C^5;8K$.C'3=G/@L*J\WS;(UK6TO?%=^MW>J8K
M*,Y1/6M[Q)"L?A6\BB3"K'A5'U%9$?B^6*-8X]&G55&  C?X5NVTQUO2'\V!
MH?,&"K#FL:/LY0E&+O)K5G17]M"<)SC:$6K(A\)L#X:LP#DJF#[<FL?QN0US
MIL0^\TG]15>QN]0\,2RVDUI)/#NRC(I/\JFL[6\\0ZVE_=P-#;1?=1NN:S=3
MVE%4$O>T7W&L:7LL1+$-^[JUYW.M0K:VB^:P"HO)-<CJ6L76OW)TW2U/DDXD
ME%/\;7=X1'9VT,S(>79%)R/3BJ>E:[_9-JL,.C3Y_B;8V3^E.O73G[)NT5OY
M^1.&PKC3]NES2>R[>9UNCZ1!I%F(8AESR[=R:T:PM'U^75+DQ/8RP #.YU(_
MF*W:[J,H."]GL>;B(U(U'[7<Y/X@?\@.+_KL/Y5!;Z7XH:VB*:KA"@*C(X&/
MI5KQW#+-HL2Q1O(WF@X523TKH[,$65N",$1KD'Z5R.BJF)E=M:+;0[E7=+"0
MLD]7NK]CE8O"=[=W22ZM>F8*<[1CFK_BR-8O#<L:#"JN *Z&L/Q9&\N@S+&C
M.Q'11DUI4H0IT9\N[1E2Q,ZU>'.]$_1'->&?"T-_I9N[AMWF*RQKV'O4V@7\
MNA:L^DWAQ$Q^1CVK>\(1O%X;MTD1D8%LAA@]:K^+-$^W6HNK=?\ 28N1CJ:Y
MHX?DHPJTE[R7W]SKEBO:8B=&L_=;LO+L=+17/^%=2GO+#R;J*5)HN,NA&1^-
M=!7I4ZBJ04EU/)K4G2FX2Z'#Z+^]\9W;2<LIPN?QKI?$$:2Z%>*X!'E]ZP=8
MT^[TK61JUA&75N'0<FJ^K:Y?ZOITEO;6$T8(^<LI''MQ7G1FJ5.=.:UU^=SU
M94W7JTZM-Z:?*Q>\*/##X9E:;F)<[A[<U0LM1O[G>FAV$<-N'/[P$_-5O0-/
MEN/"DUJZ/'(X( 8$<\U1T;5+SP_ UA/I\LFUB59$)S^0J$VHTU+16W-'%2G5
M<5S2OLWIZ^91U^'5([JT;4IE<E_E53G%=)XP_P"177ZK_*L#7%U3498+^:V=
M8=^U8U!) ]:Z?Q':2WWAORX5)8!6QCG@40C=54KZKJ.I)*5!RMH];;(ET>6*
M'PW&\Q C$?S9[\5S]GJ-_<+(FA:>D-MO^_SR:LZ5/)J6COI3VTL+JF S*0"<
M54T;4[SP_"]C/I\LF&R&120?R%5*I?DUM&V_GV(C2<74TO*^S>EN_F4M?@U6
M.ZM&U*=7)8;54YQS7HEM_P >D/\ N+_*O/\ 7!JFI307\ULZ0JP"1J"2![UZ
M!:_\>D/!'[M>#]*UP:_>SM>VFYCCV_8T[VOKL2T445Z!Y04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU.7^Q-+;S$8[9&7^+VK-OO%OB7QC+]DT^!HHFX*0Y((]\UU_@WX>Q:24OM2
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M"BBBM#$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *\0M?^2Q?]OC?R->WUXA:_P#)8O\
MM\;^1H ]O[44=J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *CE@BG7;-$DB^C*#4E% '.7W@G0;L222V0W$$_*<?RKRGP#I5GJ/C.6TN
MHM\*)(0I/H>*]VE_U3_[IKQ;X9_\E N/^N<O\Z /8[73[2R0+;V\<>.ZJ :L
MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7B%K_R6+_M\;^1KV^O
M$+7_ )+%_P!OC?R- 'M_:BCM10 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 R7_5/_NFO%OAG_P E N/^N<O\Z]IE_P!4_P#NFO%O
MAG_R4"X_ZYR_SH ]LHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y_7/&
M.DZ"A\^8/+VC4\FN?\>^.?['4Z?I[@W;<.P/W/\ Z]<WX8^']SK^-3UB5U20
M[@IZM0!9O?BQ>SR'^S;!E4?WUW_RKBX]4U.+Q(-<-J_VCS#)_JCC)KWC3_#.
MCZ8@6UL8D('+ <FM%K6!TVM$A7TQ0!YKIGQ:3<L6IV3HQZN#@#\*]!TS6;'5
MX!+9SK(".@/(K(UCP+HFK1,#:I#,>DJ#YJ\QU+2]8^'FK)<VLKM;L>&'1AZ&
M@#W2BL+PMXEM_$FF+.A43J/WD8[&MV@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M230!XI=?N_B[B+I]J0?AQ7M]>(>%U;7OB-)=@':KF0GZ$5[?0 4444 %%%%
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MREI^DV>F(5M8@N>I/)J[116T8J*LD82G*;YI.["BBBF2%%%% !1110 4444
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M5U;6PVXMO$;]6/J: -SX:^&VTO2VOKE"+BXY&>H%=Y2* JA1T P*6@ HHHH
M**** "N;\<_\BS)_UT3^==)4-U:6][ 8;F)98R<E6'%95H.I3E!=4;8>HJ56
M-1]&84EE]N\%0Q 9;R%*^U<[X?DFUC5;&*0?+9)SGO@__7KT*.&.*%840+&H
MVA1T J"VTZSLY&>WMHXF;[Q4=:YYX5RG&5]M_.QU4\:H0G&VK;:\KG*^,O\
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M72V\8G;K)CDU9K;#4G2ARMW,,77C7J<\5;1?@%%%%;G,%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ,:*-_OQHWU7->)6R)_PM_9M7;]L;Y<<=#7N%>(6O_)8O^WQOY&@#
MVU45!A5"CV&*=1VHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K/U+1-.U:+R[VU20?3!K0HH \_OOA3H\N]X9I(!@D*JYQ^=>=^#O#UM
MKGBF33KEV$2*[9 Z[37T#+_JG_W37BWPS_Y*!<?]<Y?YT >H:3X1T;1B&M;1
M/,'\9YS6X  , 8HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O$+7
M_DL7_;XW\C7M]>(6O_)8O^WQOY&@#V_M11VHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH 9+_JG_ -TUXM\,_P#DH%Q_USE_G7M,
MO^J?_=->+?#/_DH%Q_USE_G0![91110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%9^KZS9Z+9O<WDJHJC@9Y8^E>4:IX]UWQ#=?9=
M&BDCC)PNS[Q_&@#UZXO;6.-P]S"IVGAI *\9^&TL<?CV=WD55,<N"3@=:FA^
M'OBC55\R^NC$[=1-DG]*<_PJUNR)EMKZ)Y ./+4@T >S!@PRI!'J*6O#XM=\
M7>$+E5OUF>('[LOS CVYKTSPOXPL?$EL-C".X ^:)CS0!TE%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 52U74(],TR>[E.%13CZ]JNUP'Q7OGM_#\=LIP)VY_ B@#C/
M#^FS^._%4UW>%S;*V]L],9Z5[7:6D%E;);V\82-!@ 5R?PTTY;+PO'+@;ISO
MS[&NSH **** "L;Q%X>L_$&GO!<1@R 'RWQR#6S10!XGX0U.X\)^+)-*NV80
M.^PYZ?6O:P<@$=#7D'Q5L!::U::E&-ID(4X]1S7I^@79O]!L[INLD>30!HT4
M44 %%%8_B?6UT#1)KT@%A\J#W/2JA%SDHK=DSFH1<I;(NW>J6-A_Q]W44/\
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MHW5E/0J<BFTUN)-/8=114<T\-NF^>6.)?5V"C]:0R2BJ?]K:;_T$+3_O\O\
MC3X]0LIFVQ7=NY/99 ?ZU7++L3S1[EFBBD9E12S,%4=23@"I*%HID4L<Z;XI
M$D0_Q(P(I] !14<=Q#,S+%-&Y4X8*P.*BEU"RA;;+=V\;>CR '^=.S%=;EFB
MHXKB&<9AFCD'JC _RJ2D.]PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *YG7O VCZ[EWA$,QZRQCDUTU% 'D5W\)+
MN,L;.^!0<C><']*X_P .:!/X@UUM,$Y1E5F+$^AKZ*E_U3_[IKQ;X9_\E N/
M^N<O\Z .TT3X9:3IDBS7):[D'.) , _A7:QQ)#&L<:A448 ':GT4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7B%K_ ,EB_P"WQOY&O;Z\0M?^2Q?]
MOC?R- 'M_:BCM10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 R7_5/_NFO%OAG_R4"X_ZYR_SKVF7_5/_ +IKQ;X9_P#)0+C_ *YR
M_P Z /;**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ***P-=\7Z5H$9^T3!I>T:GDT ;DO^J?_=->+?#/_DH%Q_US
ME_G5^^^*U]<LRZ;8LJ=/F7?7'Z'JFJ:!J[:G;VDGF,&!W1$C!ZT ?1M%>8Z7
M\68F=8M3M'C8GEQP!^%>A:?JEGJMN)[.=94/H>?RH N4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8)()5W1R*58>H-2453E)VUV)48J]EN8+>#-!:V6W-@OEJ<@!C_.KNFZ#IND
MBRM5BSWZG]:T:*IU:C5FV2J5.+NHH****S-#$OO"6B:C<&>YLE:0]6!(_E2#
MPAH8FMYA8H)+<YB.3\O.:W**T]M4M;F9E[&G>_*ON(YH8[B)HY4#HPP016$_
M@?P]))O:P7)]'/\ C70T4HU)P^%V*G3A/XE<JV.G6FFP^3:0K$GH*X?6?$%C
M)J\EAXCTD+ G^KF7)S^/%>A5!/96MR<W%M%+_OH#_.M*551DY3U^>IG5I.45
M&#M\M#RG6+CPY-ITFG^'K%Y+FY^0M@G:/S->A:!I M?"MMIERFY1$5=?7-:,
M6FV,#;H;.WC8=TC -6JNMB.>*C&_?5W9G1PW))SE;MHK(J:=IMII-F+6RB$4
M(8L%!SR>M,U+1[#5XA'?6ZRJ#D9J]17/SRYN:^IT\D>7EMH8EEX2T33IA+;6
M2JX.022?YU:T[0].TJ::6RMQ$\QW2$$\FM&BFZLY;MDQI0CLD9FI^'],U<@W
MMJLI'?.#^E4O^$)\/_9S!_9ZF,G)!8UT%%-5:D5928.C3D[N*(;:UAM+9;>%
M L2C 7VK(N_!^A7TQFGL59R<DAB/Y5NT4HU)Q=TQRIPDK25S-TW0-,TDDV5J
ML1/?J?UI]]HMAJ-U;W-U ))K<YB8D_+5^BCVDK\U]0]G#EY;:!1114%E6_TZ
MTU.W,%Y"LL9[&LRU\'Z%9R>9!8J&(QRQ/\ZW:*M5)Q5D]")4X2=VM2AIVD6.
MCV\L5C (DD;>P!)R:\V\%Z99ZKK&K07L(EC\TG!_&O6*AAL[:W=GAMXHV;[Q
M1 ":VIXAPC)=7U,:F&4Y0:V70S=/\+Z/I<WFVEFJ/ZDD_P ZUR RD, 0>H-+
M16$IRD[R=S>,(Q5HJQ@3>"] N)S/)8*9"<DAB*L6_AG2+344U""S5+E%VJX)
MX&,5KT53K5&K.3)5&FG=11GZGHFGZP@2^MEE Z9X-5+/PEHE@^^WLE5O4DG^
M=;=%)59I<J>@W2@WS-*YGZ;HFGZ0TS6-N(C,=SX).35:^\*:-J5U]INK-7FS
MG=N(_E6S10JLT^:^H.E!QY6E8JSZ=:7-H+6:%7A QM:L<>!O#P??_9XS_OM_
MC71441JSC\+:%*E3E\23(;:U@LX%AMXU2->  *S-0\+:-J<WFW=DKN>X)'\J
MV:*49RB[IZCE",E9K0RM.\.:3I4GF6=HL;>I))_6M6BBB4I2=Y.XXQC%6BK!
M1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 51U+2+'5[<PWMNDJXP-PSCZ5>HH \VU+X264SEK&Y:+/9^@_(5DCX.WWF
M<ZE;;/HV:]?HH \YTSX36$#![ZX:8CLO0_G7=V&FV>F0"&S@2% .BC&:MT4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'-#'<0M%,@>-A
M@J>AKS+Q)\,"97O=%DV/G=Y7O[5ZC10!XA'K7C;PZ?*N(YW5> )>0/UIR_$_
MQ'<GR8H(2_\ LJ<_SKVB>.-XGW(K?*>HKQ;X:HK>/IPR@CRY>"/>@!O]G>,_
M%L@6Y^T+;,?XS\@_"N_\*^ +'P_B>;;<7?\ ?(X7Z5V"JJC"J /84M !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% #)?\ 5/\ [IKQ;X9_\E N/^N<
MO\Z]IE_U3_[IKQ;X9_\ )0+C_KG+_.@#VRBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **9YL?/SKQUYJG)K.G0OMDNXU;TH;MN*Z+]%007E
MM<C,,RN/8U/1>XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\$,,@@CU%<!:_#F*>P6:ZOYVO'7<6!Z$TSP3JU]:ZW=:#>3&98C^[<GGJ?\
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M6L%4<;IJ_8GZY!2LT[=SURBFHP=%<=&&13JXSK"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-XBT>*T-Q]JC* 9'O6N+:YT^2_F985/D:Y['E.@0ZC'XMMKH6,\2/,"P\LX
M_*I/'J^9XQ93_$$'Z"NR\/\ C*?6]9-M%:?N0?O@=!7(>.?^1W/U3^E:4YR=
M?WE9I$5(Q5#W7=7/5=!M(K31;6.- !Y8)P.IQ7DGC>-8?%TQC4+E\G%>Q:9_
MR"[7_KFO\J\?\>?\C;)_O5RX%MUI?,Z<:DJ*/8[$YT^W/_3-?Y58JK8LJV%L
M"P!,2]_:K5>?+<[UL%%%%(84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 R6))HVCD4,C#!!'!KS?Q
M+\,$GE>\T>3RI,Y\L]S[>E>ET4 >'K<^-_#C&-A*RCIO^<?SI_\ PG?C*?\
M="%01QQ 17MA /4 TFQ?[H_*@#Q&/P_XP\42 W;RI QY+M\H_#->B^%_ MAX
M=42,!/==Y".!]/2NKP!T%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M15#5=9LM%@6:^E\M&.!@9S6/_P + \._\_;_ /?LT =/17,?\+ \._\ /V__
M '[-'_"P/#O_ #]O_P!^S0!T]%<Q_P + \._\_;_ /?LT?\ "P/#O_/V_P#W
M[- '3T5S'_"P/#O_ #]O_P!^S1_PL#P[_P _;_\ ?LT =/17,?\ "P/#O_/V
M_P#W[-'_  L#P[_S]O\ ]^S0!T]%<Q_PL#P[_P _;_\ ?LT?\+ \._\ /V__
M '[- '3T5S'_  L#P[_S]O\ ]^S1_P + \._\_;_ /?LT =/17,?\+ \._\
M/V__ '[-'_"P/#O_ #]O_P!^S0!T]%<Q_P + \._\_;_ /?LT?\ "P/#O_/V
M_P#W[- '3T5S'_"P/#O_ #]O_P!^S1_PL#P[_P _;_\ ?LT =/17,?\ "P/#
MO_/V_P#W[-'_  L#P[_S]O\ ]^S0!T]%<Q_PL#P[_P _;_\ ?LT?\+ \._\
M/V__ '[- '3T5S'_  L#P[_S]O\ ]^S1_P + \._\_;_ /?LT =/17,?\+ \
M._\ /V__ '[-'_"P/#O_ #]O_P!^S0!T]%<Q_P + \._\_;_ /?LT?\ "P/#
MO_/V_P#W[- '3T5S'_"P/#O_ #]O_P!^S1_PL#P[_P _;_\ ?LT =/17,?\
M"P/#O_/V_P#W[-'_  L#P[_S]O\ ]^S0!T]%<Q_PL#P[_P _;_\ ?LT?\+ \
M._\ /V__ '[- '3T5S'_  L#P[_S]O\ ]^S1_P + \._\_;_ /?LT =/17,?
M\+ \._\ /V__ '[-'_"P/#O_ #]O_P!^S0!T]%<Q_P + \._\_;_ /?LT?\
M"P/#O_/V_P#W[- '3T5S'_"P/#O_ #]O_P!^S1_PL#P[_P _;_\ ?LT =/17
M,?\ "P/#O_/V_P#W[-'_  L#P[_S]O\ ]^S0!T]%<Q_PL#P[_P _;_\ ?LT?
M\+ \._\ /V__ '[- '3T5S'_  L#P[_S]O\ ]^S1_P + \._\_;_ /?LT =/
M17,?\+ \._\ /V__ '[-'_"P/#O_ #]O_P!^S0!T]%<Q_P + \._\_;_ /?L
MT?\ "P/#O_/V_P#W[- '3T5S'_"P/#O_ #]O_P!^S1_PL#P[_P _;_\ ?LT
M=/17,?\ "P/#O_/V_P#W[-'_  L#P[_S]O\ ]^S0!T]%<Q_PL#P[_P _;_\
M?LT?\+ \._\ /V__ '[- '3T5S'_  L#P[_S]O\ ]^S1_P + \._\_;_ /?L
MT =/17,?\+ \._\ /V__ '[-'_"P/#O_ #]O_P!^S0!T]%<Q_P + \._\_;_
M /?LT?\ "P/#O_/V_P#W[- '3T5S'_"P/#O_ #]O_P!^S1_PL#P[_P _;_\
M?LT =/17,?\ "P/#O_/V_P#W[-'_  L#P[_S]O\ ]^S0!T]%<Q_PL#P[_P _
M;_\ ?LT?\+ \._\ /V__ '[- '3T5S'_  L#P[_S]O\ ]^S1_P + \._\_;_
M /?LT =/17,?\+ \._\ /V__ '[-'_"P/#O_ #]O_P!^S0!T]%<Q_P + \._
M\_;_ /?LT?\ "P/#O_/V_P#W[- '3T5S'_"P/#O_ #]O_P!^S1_PL#P[_P _
M;_\ ?LT =/17,?\ "P/#O_/V_P#W[-'_  L#P[_S]O\ ]^S0!T]%<Q_PL#P[
M_P _;_\ ?LT?\+ \._\ /V__ '[- '3T5S'_  L#P[_S]O\ ]^S1_P + \._
M\_;_ /?LT =/17,?\+ \._\ /V__ '[-'_"P/#O_ #]O_P!^S0!T]%<Q_P +
M \._\_;_ /?LT?\ "P/#O_/V_P#W[- '3T5S'_"P/#O_ #]O_P!^S1_PL#P[
M_P _;_\ ?LT =/17,?\ "P/#O_/V_P#W[-'_  L#P[_S]O\ ]^S0!T]%<Q_P
ML#P[_P _;_\ ?LT?\+ \._\ /V__ '[- '3T5S'_  L#P[_S]O\ ]^S1_P +
M \._\_;_ /?LT =/17,?\+ \._\ /V__ '[-'_"P/#O_ #]O_P!^S0!T]%<Q
M_P + \._\_;_ /?LT?\ "P/#O_/V_P#W[- '3T5S'_"P/#O_ #]O_P!^S1_P
ML#P[_P _;_\ ?LT =/17,?\ "P/#O_/V_P#W[-'_  L#P[_S]O\ ]^S0!T]%
M<Q_PL#P[_P _;_\ ?LT?\+ \._\ /V__ '[- '3T5S'_  L#P[_S]O\ ]^S1
M_P + \._\_;_ /?LT =/17,?\+ \._\ /V__ '[-'_"P/#O_ #]O_P!^S0!T
M]%<Q_P + \._\_;_ /?LT?\ "P/#O_/V_P#W[- '3T5S'_"P/#O_ #]O_P!^
MS1_PL#P[_P _;_\ ?LT =/17,?\ "P/#O_/V_P#W[-'_  L#P[_S]O\ ]^S0
M!T]%<Q_PL#P[_P _;_\ ?LT?\+ \._\ /V__ '[- '3T5S'_  L#P[_S]O\
M]^S1_P + \._\_;_ /?LT =/17,?\+ \._\ /V__ '[-'_"P/#O_ #]O_P!^
MS0!T]%<Q_P + \._\_;_ /?LT?\ "P/#O_/V_P#W[- '3T5S'_"P/#O_ #]O
M_P!^S1_PL#P[_P _;_\ ?LT =/17,?\ "P/#O_/V_P#W[-'_  L#P[_S]O\
M]^S0!T]%<Q_PL#P[_P _;_\ ?LT?\+ \._\ /V__ '[- '3T5S'_  L#P[_S
M]O\ ]^S1_P + \._\_;_ /?LT =/17,?\+ \._\ /V__ '[-'_"P/#O_ #]O
M_P!^S0!T]%<Q_P + \._\_;_ /?LT?\ "P/#O_/V_P#W[- '3T5S'_"P/#O_
M #]O_P!^S1_PL#P[_P _;_\ ?LT =/17,?\ "P/#O_/V_P#W[-'_  L#P[_S
M]O\ ]^S0!T]%<Q_PL#P[_P _;_\ ?LT?\+ \._\ /V__ '[- '3T5S'_  L#
MP[_S]O\ ]^S1_P + \._\_;_ /?LT =/17,?\+ \._\ /V__ '[-'_"P/#O_
M #]O_P!^S0!T]%<Q_P + \._\_;_ /?LT?\ "P/#O_/V_P#W[- '3T5S'_"P
M/#O_ #]O_P!^S1_PL#P[_P _;_\ ?LT =/17,?\ "P/#O_/V_P#W[-'_  L#
MP[_S]O\ ]^S0!T]%<Q_PL#P[_P _;_\ ?LT?\+ \._\ /V__ '[- '3T5S'_
M  L#P[_S]O\ ]^S1_P + \._\_;_ /?LT =/17,?\+ \._\ /V__ '[-'_"P
M/#O_ #]O_P!^S0!T]%<Q_P + \._\_;_ /?LT?\ "P/#O_/V_P#W[- '3T5S
M'_"P/#O_ #]O_P!^S1_PL#P[_P _;_\ ?LT =/17,?\ "P/#O_/V_P#W[-'_
M  L#P[_S]O\ ]^S0!T]%<Q_PL#P[_P _;_\ ?LT?\+ \._\ /V__ '[- '3T
M5S'_  L#P[_S]O\ ]^S1_P + \._\_;_ /?LT =/17,?\+ \._\ /V__ '[-
M*OC[P\[!1=MDG'^K- '344R*19HDE0Y1P&4^HI] !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M +XK8HH Q_\ A%=!_P"@5;?]\4?\(KH/_0*MO^^*V** ,?\ X170?^@5;?\
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MW_?%'_"*Z#_T"K;_ +XK8HH Q_\ A%=!_P"@5;?]\4?\(KH/_0*MO^^*V**
M,?\ X170?^@5;?\ ?%'_  BN@_\ 0*MO^^*V** ,?_A%=!_Z!5M_WQ1_PBN@
M_P#0*MO^^*V** ,?_A%=!_Z!5M_WQ1_PBN@_] JV_P"^*V** ,?_ (170?\
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M%'_"*Z#_ - JV_[XK8HH Q_^$5T'_H%6W_?%'_"*Z#_T"K;_ +XK8HH Q_\
MA%=!_P"@5;?]\4?\(KH/_0*MO^^*V** ,?\ X170?^@5;?\ ?%'_  BN@_\
M0*MO^^*V** ,?_A%=!_Z!5M_WQ1_PBN@_P#0*MO^^*V** ,?_A%=!_Z!5M_W
MQ1_PBN@_] JV_P"^*V** ,?_ (170?\ H%6W_?%'_"*Z#_T"K;_OBMBB@#'_
M .$5T'_H%6W_ 'Q1_P (KH/_ $"K;_OBMBB@#'_X170?^@5;?]\4?\(KH/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJCJVJ0:182
M74[ *HX'J?2@"W)+'"NZ1U1?5CBL2Z\8Z)9N4ENLD?W1N_E7GD^HZWXTU P6
MV];?/W1T ]ZW[+X86XC'VVZ9F[^6<?SI@=';>,]#NW"1W6"?[RXK;BFBG3=%
M(KJ>ZG-<'>?#"U,9^R7+J_;S#FN:-WK?@:]"3,Q@)X!^ZWTIJ+D[(3DHJ[/5
M]6U:UT>Q>ZNI JJ,@=S7DW_"R;__ (2$7?\ RZ [?*Q_#6%XE\47?B.[WR$K
M I^2/TK9\$^"9=9F6\O$*6:G(!'W_P#ZU>Q2PM.A2<ZVYXM7%5<154*.R/8-
M,U"+5+"*[A#!''1AC%6ZC@@CMH$AA0)&@P *DKQI6OH>U&]M=PHHHI#"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD/B3_R*3?]=T_K77UR'Q)_
MY%)O^NZ?UH Z'1O^0)8_]<$_D*O51T;_ ) EC_UP3^0J]0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '"?$K[F
MC_\ 7R?Z5W2?<7Z5POQ*^YH__7R?Z5W2?<7Z4 +1110 4444 %%%% !6)XJU
M7^R-"GG4_.1M4?7BMNO/_BC,4L;.,9P[-G]* ,[P'H*:A-)JU^-ZHWR[NY]:
M] AUBRDO/L<4@+@<8Z5AZ)IK3>![:.!BDDD0?(.,FN5#36=WG)61&KR\?CYX
M:<4HZ/J>C@L'#$1DV]3U>L37=<BTZ%HDP\[# 7TJA+XLC7249!FX8;<?UKD9
M))KVY+,2\CFL,;FD5!1HN[?X?\$UPF72<N:KHD0R2 EI&P,\DUUO@NTM+JU-
M\#ODW%0#VQ52Z\."V\+WES/_ *X1%@,].*@^%LQ:WO8B3A"I'XYHR[+N7]]6
MW'CL=S?NJ6QZ'1117MGD&#J?BS3]*OFM+A93(H!.U<CFM>VNXKJS2ZC)\MEW
M#/I7G'BN 7'BV>,_\\@1^5:FDZMY'@ZZ5GQ/#D8/IP*\RGC)>UG&>RO;Y'L5
M<OA["G.GN[7^9KKXTTQ[P6JB8N6V@[>*Z)2&4,.A&:\@MK4P:AILI_Y;_/\
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M%M.\4W&GJ<Q2CS%'IQDU7MKN,E\+)^KV4X2^*.OR.HHHHKH.0**** "BBB@
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MS;T6WG<ZH8QSY(I:N]_*QW]WKVDV%P8+O4+>&8#)1WP14\6HV=Q:-=07$<D
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M8I)S@'-<A9M!<V3O<:)>WMTS$_:4D?'Y 44\O3E+F>B=OZN%3,6HQY5JU?\
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M_D*O51T;_D"6/_7!/Y"KU !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 <)\2ON:/_U\G^E=TGW%^E<+\2ON:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!PGQ*^YH__ %\G^E=TGW%^E<+\2ON:/_U\G^E=TGW%^E "T444
M %%%% !1110 4444 8^N^'+/7;<I.H60#Y9 .17GEQX5\0Z!,9;&1GB'3:__
M ++7K=% 'D/_  D'C'_4[)?_  '/\\4ZW\+^(O$$PDO9&2(]2S8Q_P !KURB
MG<#%T'PW9Z%;A85#2G[TA')K:HHI %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!'<01W,#PRJ&1P0017E&M^&M1\,ZC
M_:&F[VAW97;R1[$5ZW2.BNI5P"IZ@T >>:;\2XO+$>I0%6'!8#.?PK2E^).B
M+'F(RLV.AC(K3OO!NC7[%GMA&3U,>!5&/X=Z'&V[;,WLSY_I3 X_5_%FJ>)G
M^Q6,#I"QP0H)S^/:NO\ !WA$:+']INL-=./KMKH+#1[#35Q:VT<9_O <FKU(
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *1E5U*LH93U!'6EHH I:=I5KI:R+:JRK(VX@L2,^WI5VBBFVV[
ML222L@HHHI#"BBB@ HHHH **** &R()(V1L[6!!P<=:JZ=I=KI<)BM4(#')+
M'))]S5RBG=VL*RO<****0PHHHH **** "BBB@ HHHH **** "FNBR(4=0RD8
M((IU% ' >(/A]YTS76E/Y<A.?+SC]:Y]9_%^A_NE$K;?]DR5Z_13N!Y UYXO
MUD>2PE7=_L%/UK;T'X>R"9;K5Y-[#GR]V<_C7HE%%P&11)#&L<:A448  I]%
M%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD/B3
M_P BDW_7=/ZUU]<A\2?^12;_ *[I_6@#H=&_Y EC_P!<$_D*O51T;_D"6/\
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M/X>_YZW'_?DT =;17)?\+'\/?\];C_OR:/\ A8_A[_GK<?\ ?DT =;17)?\
M"Q_#W_/6X_[\FC_A8_A[_GK<?]^30!UM%<E_PL?P]_SUN/\ OR:/^%C^'O\
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M/X>_YZW'_?DT =;17)?\+'\/?\];C_OR:/\ A8_A[_GK<?\ ?DT =;17)?\
M"Q_#W_/6X_[\FC_A8_A[_GK<?]^30!UM%<E_PL?P]_SUN/\ OR:/^%C^'O\
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M/X>_YZW'_?DT =;17)?\+'\/?\];C_OR:/\ A8_A[_GK<?\ ?DT =;17)?\
M"Q_#W_/6X_[\FC_A8_A[_GK<?]^30!UM%<E_PL?P]_SUN/\ OR:/^%C^'O\
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M VV_[]BM*B@#-_X1_2/^@;;?]^Q1_P (_I'_ $#;;_OV*TJ* ,W_ (1_2/\
MH&VW_?L4?\(_I'_0-MO^_8K2HH S?^$?TC_H&VW_ '[%'_"/Z1_T#;;_ +]B
MM*B@#-_X1_2/^@;;?]^Q1_PC^D?] VV_[]BM*B@#-_X1_2/^@;;?]^Q1_P (
M_I'_ $#;;_OV*TJ* ,W_ (1_2/\ H&VW_?L4?\(_I'_0-MO^_8K2HH S?^$?
MTC_H&VW_ '[%'_"/Z1_T#;;_ +]BM*B@#-_X1_2/^@;;?]^Q1_PC^D?] VV_
M[]BM*B@#-_X1_2/^@;;?]^Q1_P (_I'_ $#;;_OV*TJ* ,W_ (1_2/\ H&VW
M_?L4?\(_I'_0-MO^_8K2HH S?^$?TC_H&VW_ '[%'_"/Z1_T#;;_ +]BM*B@
M#-_X1_2/^@;;?]^Q1_PC^D?] VV_[]BM*B@#-_X1_2/^@;;?]^Q1_P (_I'_
M $#;;_OV*TJ* ,W_ (1_2/\ H&VW_?L4?\(_I'_0-MO^_8K2HH S?^$?TC_H
M&VW_ '[%'_"/Z1_T#;;_ +]BM*B@#-_X1_2/^@;;?]^Q1_PC^D?] VV_[]BM
M*B@#-_X1_2/^@;;?]^Q1_P (_I'_ $#;;_OV*TJ* ,W_ (1_2/\ H&VW_?L4
M?\(_I'_0-MO^_8K2HH S?^$?TC_H&VW_ '[%'_"/Z1_T#;;_ +]BM*B@#-_X
M1_2/^@;;?]^Q1_PC^D?] VV_[]BM*B@#-_X1_2/^@;;?]^Q1_P (_I'_ $#;
M;_OV*TJ* ,W_ (1_2/\ H&VW_?L4?\(_I'_0-MO^_8K2HH S?^$?TC_H&VW_
M '[%'_"/Z1_T#;;_ +]BM*B@#-_X1_2/^@;;?]^Q1_PC^D?] VV_[]BM*B@#
M-_X1_2/^@;;?]^Q1_P (_I'_ $#;;_OV*TJ* ,W_ (1_2/\ H&VW_?L4?\(_
MI'_0-MO^_8K2HH S?^$?TC_H&VW_ '[%'_"/Z1_T#;;_ +]BM*B@#-_X1_2/
M^@;;?]^Q1_PC^D?] VV_[]BM*B@#-_X1_2/^@;;?]^Q1_P (_I'_ $#;;_OV
M*TJ* ,W_ (1_2/\ H&VW_?L4?\(_I'_0-MO^_8K2HH S?^$?TC_H&VW_ '[%
M'_"/Z1_T#;;_ +]BM*B@#-_X1_2/^@;;?]^Q1_PC^D?] VV_[]BM*B@#-_X1
M_2/^@;;?]^Q1_P (_I'_ $#;;_OV*TJ* ,W_ (1_2/\ H&VW_?L4?\(_I'_0
M-MO^_8K2HH S?^$?TC_H&VW_ '[%'_"/Z1_T#;;_ +]BM*B@#-_X1_2/^@;;
M?]^Q1_PC^D?] VV_[]BM*B@#-_X1_2/^@;;?]^Q1_P (_I'_ $#;;_OV*TJ*
M ,W_ (1_2/\ H&VW_?L4?\(_I'_0-MO^_8K2HH S?^$?TC_H&VW_ '[%'_"/
MZ1_T#;;_ +]BM*B@#-_X1_2/^@;;?]^Q1_PC^D?] VV_[]BM*B@#-_X1_2/^
M@;;?]^Q1_P (_I'_ $#;;_OV*TJ* ,W_ (1_2/\ H&VW_?L4?\(_I'_0-MO^
M_8K2HH S?^$?TC_H&VW_ '[%'_"/Z1_T#;;_ +]BM*B@#-_X1_2/^@;;?]^Q
M1_PC^D?] VV_[]BM*B@#-_X1_2/^@;;?]^Q1_P (_I'_ $#;;_OV*TJ* ,W_
M (1_2/\ H&VW_?L4?\(_I'_0-MO^_8K2HH S?^$?TC_H&VW_ '[%'_"/Z1_T
M#;;_ +]BM*B@#-_X1_2/^@;;?]^Q2C0=)4@C3K8$=#Y8K1HH 15"*%4 *!@
M=J6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g2g5bnvu5o20000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2g5bnvu5o20000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /H!YX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TK,LKR:;4)XG8%$/
MQ6D>AK&TW_D+77UH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#,-Y-_;7V?</+VYQBM.L4_\ (R?\!K:H **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>S6WP8\&VLHD2TN"P[/.2*S_  5\++[PMXLDUB?4K>>-RY\M$8'G/K]:]1H
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MAMC&<DR*3GGVH M?#3_D1K'Z?T%</<*?$7QUA;.Z/30 R]AC(_K7I7AC0YM
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MKL,,T2N":WM,^'WCNTU2UN+KQJ9[>*56DBR_SJ#R* /5:*** "BBB@ HHHH
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MK&&(IS3:>VYT3PM6#BI+66Q<HKB(O'-Y<N?L^E&5 >64DX_2NTB9GB1V7:6
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M1110 4444 %%%% !1110 4444 %%%% !1110 AZ&L;3?^0M=?6MD]#6-IO\
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MY=+G!AZ5&CAGB*D>9WLD4=&\;7$MZEOJ**-QQN"[<&NLU35K?2[(W,IR"/E
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MF)A%EKP%9>7ILEV<;I&*_E65\0/^0G;_ .X*Z?PB OA^' QR:Y?X@\ZE /\
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MLS8Z;#;L<LJ\_6KM%%=$8J*21RRDY2<GU"BBBF2%%%% !1110 4444 %%%%
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M?V[+^3\?^ ']CK^?\#UG[5;_ //>+_OL4?:K?_GO%_WV*\FHH_MV7\GX_P#
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M*=*K>2?GL34445VGG!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %07G_'C<?]<V_E4]07G_ !XW'_7-OY4 >*:9_KG_ -VM
M2LO3/]<_^[6I7R6;_P"]/Y'TV6?[NOF%%%%>8>@%%%% !1110 4444 %%%%
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M=''1@>AIEW=V]A:275U*L4$0W.[=%% $]%5-.U2QU>T6ZT^Y2X@;I(AX-6Z
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MHHKS#T HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBMGP_I!U*[#2 ^2G)/K[5I1I2JS4([LBK4C3@YRV1M>%=&V+]MF7YC]P&
MNKIJ(L:*BC"@8%.K[3#8>.'IJ$3Y/$5Y5JCG(****Z# **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ JCJ__ "#)O]VKU4=7_P"09-_NT .TK_D&
MP_2KE4]*_P"0;#]*N4 %%%% !7*^-_\ CTM/^NC?RKJJY7QO_P >EI_UT;^5
M<.9?[K/^NIV9?_O,?ZZ'%UVG@C_CUN_]]?Y5Q==IX(_X];O_ 'U_E7S^4_[U
M'Y_D>WF?^[2^7YG54445]<?,!7FWQR_Y)O+_ -?47\S7I->;?'+_ ))O+_U]
M1?S- '9>%?\ D4](_P"O2+_T$53\>_\ (BZO_P!</ZBN!T1/BI_85A]BN+ 6
MOD)Y0:-,[<#&?PJ#Q.GQ/'AJ_.IW%B;+R_WH2- <9'3% '5_"'_D0[3\?YFM
M+6_B)H&A7GV.>66>X'6*W7>P_#-<QX%OVTOX/2WX.&@@9\X[@FN9^&&J>&K9
M+S5M9N$>^N)6(\X;MHR?6@#U'0?'NA^(;G[-:RR17'_/&==C'\,U=\2^*-/\
M*:>M[J7F^2S;1Y:[CFO)OB+K/A^2?3=4T"XCCOX9QO\ ) 7<O [?C6S\6[HZ
MA\.]/N6&#+(&(_"@#HKWXJ^'+-\?Z5.H +/!%N5<C/)S5L_$CPY_9<=^EV9%
MD)"Q( 9#CVS3_"GAW2XO"5K;_8X762(;V9 2<^]>;_!_1[*Z\5^(WGA606=R
MRPHXRJ@LPZ?A0!Z'HGQ(T#7=2&GPM<073?=CN8]A;Z<UTNH:C::79R7=Y,L4
M*#+,QQ7DWQ1MH--\5Z!>VD*0S-/M+(H7(Q[5)\39)-6\9>&O#$DCK:WNUI K
M$9Y(H Z(_%WPV)& 2^:,''G"#Y/SS77:3K%CK=DMW83K-"W=3G%0P>'=*ATU
M;$6%N80FT@QKSQ]*\R\!E_#GQ+U70$<_9IAYD<><A>IX]* .QG^)GAVVOK^S
MFFE2>R<I(K)]XCLO/-,TWXG^'M2U".RS<VTTAPGVF+8&^G-</X1\.VFL?%_Q
M-=7L8D6UN&>-&Y&[=CD=ZZ;XL:!8R^#Y[V.%(+BU'F1R1*%(P/44 :_Q*(;P
M)?$'(*Y!_ UR7@KX@Z)H7A"TM)S//.BY9+>/>5&!UYJQ>ZC-JGP3^TSG,ACV
MD_0$5?\ A-H&FV_@JWG^RQ22S,2SN@8]N.: .C\-^-=&\4[UT^9A*@RT4HVN
M/PK)UN\\*1^.=-AU"TE?6&_X]Y0IVKR/?UKDG@CTKXZ6\=D@ACN1F54& >3V
MI_C#_DLN@?Y_B% %[Q!_R6;2_P#KBW_H(K>\4W?A6'Q-IT>L6DLNH,W^CNJD
MA3CZU@^(/^2S:7_UQ;_T$53^)/\ R4+0?]\?R- 'IFM>(--\/6/VK4+A8H_X
M03R?I7*GXN>'5.7@U%(\_P"L:WPOYYJG\1K+11J>E:IKFHLEM;X_T-4+F7KV
M'^%9.J>/](OM(N+.P\,S3HT156:T*@#'7.WB@#U33-3M-8L([VQF66!^C*<_
MA5RO*O@?/(^@WD395$G8JA/W<L>*]5H KW]Y%I]C-=SG$4*EF/M7SG)I=]J^
MEZEXU +7$5ZC0G/6-2<_R%>E_&;7O[,\)-91,?.O#Y94==ISS6-I/COP5I_@
MM=",UT0T)5_]$;[S#GMZF@#TKPMK$6N^'+.^C;=OC ?_ 'L#-;%>-?!7Q%%]
MHU#00[>1'(9+;>,%@2?7V%>RT ,EECAB:65PD:C+,3P!7$W7Q7\.6UR\""[N
M?+.&>WBWJ/QS6?\ &74[FT\+16MK(8WNIE1F!_A.<UTOA3PQI>D^';2".TA?
M?$KNTB!BQ89.2?K0!:T#Q5I/B6%I-.N Y7[R'AE^HJGKWCS1/#>KPZ;J4DD<
MTL?F*P7Y<9QR<UY]J=LOA#XP64UC^YL[T 21+T)P3T_&G>/=.35?C-X:MI4#
MPM$/,4]QN- '?>'_ !SI?B2^:TLH;M752VZ6+:I ]#FNGJO;V-K:A?(MXHR!
M@%$ .*L4 >#7.EV>K_'!K6^A$T+'E3WZUZ7-\,_"<T3(=*C&1U#'C]:\IUH:
MT?C+(-!:);[^ R $=_6NLN[;XNSVSI]HL"2. J(I/XT 5OAE+<:3XUU7P]%,
MTUBA+*2<A<#@?K7L->-_"C4+72]9O-%U.V>'796+R2.Q8/CT/;K7LE '/7_C
M+2]-\36F@7(G6[NO]6VSY._4_A5S7_$%CX;TI]1ORX@3KL&2:X#XOVCVDFCZ
M] /WEK<?.0.BX(_K3/B7<KK]KX>T*%SC4948D>G(- 'H7A[Q!8^)M)CU+3V<
MP2$@;Q@\>U9]MXRTC5-6U#1XA.\UI&3/\GR@<@\Y]C7"_#"_;1- U_3+AMKZ
M;O903U'S'^E6OA?8^=H>M^()%/F7[S#)ZX&2/YT ;'A36/"D&EZK>:#9W$4<
M#$W V'<S<=!GZ5P'@;QG:6GCC4Y[B*]D6YDP@6/<5XQSSQ6_\&55[76E90RF
M=L@C(Z"H/AO;POX_UX-#&P60X!4<<"@"#Q/J=K8_&:TO[J010"U#$MQ_ ./K
M77GXN>&UFC1UO420X65H<(?QS7'^+M,MM5^-=E:W*;HO*5MOT4$5WWCC1-,D
M\&7T9LH%"1Y4I& 5^G% '46MU#>VL=S;R+)#(-R.IR"*FK@?A!<2S>!K=9'+
M"/Y5SV%=]0!Q%I>>%&^(LEO#:2C71'EIBIV[<'W_ *5<OOB)H&FZI=:==321
MSVR[GW+@'G'!SR:XG3/^2]7'_7#_ -E-4CI=MJGQPD2Z021Q_-L/(/)ZB@#L
MXOBUX;>[2"07EOO.%DFAVH?QS71>(Y4G\':I+$P9'LI"I'<;37,?%31]/;P)
M>R"TA1X4+(R( 00/:F^'[B6Y^#4\DK%F^Q3#)]E- '*?"SQOH_ASP##:W;2R
M7)N96\F!-S8XYQ7HOA[Q]H?B6Z>ULY9([A>L4Z[&_+-<9\#="L'\'MJ<MO')
M<2SO&2ZAL 'C&?K5/QE:PZ3\7_#US8QK \C#>$& WWNH% '9>,;OPM;ZYI*:
M[:2S7CL/LK("0ISWY]:XOXSRQ0Z]X0F8[84G#$GLH935OXJ'/B_PL3W=?_0J
MK_%ZQ74M;\(VCG"2-AOIE<T =;+\6/#D5P8_]+:,'!G6+,?_ 'UFNNT_4K35
M;)+NSF6:!QD,IS5#_A&=)BT1M.6R@\D1E>8QGIUSBO//A1*^G^(->T!'9K:V
MD+1[FSCIP* .AT'5/"46NZM)I=G.E] "URVT_-@=N:\]\/>-;2V^)E]?3Q7S
MPR_(BK'EAU'(SQ6]\.@&^(>O!@""QR#]*B\(V\#?%W54:&,J%X!48'6@#U*^
M\0:=IFE+J-[,((&7<-_!/MCUKE4^+OAMG&Y+Z.,G E>#"'\<URWBQ#XD^+>F
MZ#<,PTZ)0S1 X!//^%>HW7AS2;O36L)+"W\EDV\1J"/IQ0!:M-3M+[3Q>VLR
MRP%=P9#FN0?XL^&D$H!NGDBD:-HDBRY(.#@9Z5S'PQN9M/N]?T"60M'"Y:$$
MYVK@FH_A)HMM/KVOW]Q;QRGSV5"X#8^8YX- 'H/_  G.C+H"ZS-))!;M]U9E
MVN3Z 9K&'Q<\.[P)(K^*,G ED@PGYYK$^+FD7J+INH65EY]G:2[Y+>->HP>P
M^M1P?$'P5K=A_9.L:>;,RIL9#;[<?CCB@#U.PO[;4[..[M)5EA<95E.:LUC>
M&;#2M.T:*#1I-]GU4^9OZ^];#NL:EG8*HZDG % "T5G_ -NZ1_T%;'_P(3_&
MC^W=(_Z"MC_X$)_C0!H5'/#'<0M#*NZ-QAAZU';7]G>[OLMW!/M^]Y4@;'UQ
M5B@#E6^'/A0Y)TF+/U->9_"+PKHNM-XA_M"R2;[/>!(\D_*/FXKW4]#7D?P-
M^]XI_P"OX?\ LU 'HFD^%M&T*5Y=.LD@=QAB">:R]:^(N@:'>FSFDFGN <&.
MV3>1]1FM/Q7J$FF>&;ZZB^^L1 /ID5Q'PAT*TE\/MK-Y&MS?73Y:24;L#@]Z
M .HT'X@:%X@NOLMM-)%<?\\IUV,?PS7&_'-0VDV"D9!E4'_OH4?%_28=)L[+
MQ'IL207EO, 3& N1R><=:H?%R[-]X/T6YC.7D$9R1_%Q_6@#L-#^'WA>XT&Q
MFETJ-I'@1F.3R2*XCQAHUOX%\8:/>Z 6@\^4*]NK$@]:T]*C^*QTBT^RW%@+
M?R5\L&-,[<<5S=V^LZ!XVLM5\>6WVB,.!!)"WR(>>2HX_"@#WZ!B]O&[=64$
M_E4E16TT=Q;1S1$&-U!4CTJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@O/^/&X_
MZYM_*IZ@O/\ CQN/^N;?RH \4TS_ %S_ .[6I2>$=(_M>^GB\WR]D>[.,YYK
ML/\ A"#_ ,_O_CE?.YC@:];$.<(W6G8]W XRC2HJ,W9G(45U_P#PA!_Y_?\
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M_/[_ ..4?\(0?^?W_P <H_LO%?R_B@_M'#?S?F<A177_ /"$'_G]_P#'*/\
MA"#_ ,_O_CE']EXK^7\4']HX;^;\SD**Z_\ X0@_\_O_ (Y1_P (0?\ G]_\
M<H_LO%?R_B@_M'#?S?F<A177_P#"$'_G]_\ '*/^$(/_ #^_^.4?V7BOY?Q0
M?VCAOYOS.0HKK_\ A"#_ ,_O_CE'_"$'_G]_\<H_LO%?R_B@_M'#?S?F<A17
M7_\ "$'_ )_?_'*/^$(/_/[_ ..4?V7BOY?Q0?VCAOYOS.0HKK_^$(/_ #^_
M^.4?\(0?^?W_ ,<H_LO%?R_B@_M'#?S?F<A177_\(0?^?W_QRC_A"#_S^_\
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MS?F<A177_P#"$'_G]_\ '*/^$(/_ #^_^.4?V7BOY?Q0?VCAOYOS.0HKK_\
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MX,_Z%ZT_\>_QK2TSPGH.C.'T[2X+=AW0'^M $^@6;Z?H5G:R'+QQ@&M*BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *@O/^/&X_ZYM_*IZ@O/^/&X_P"N;?RH \[^
M&W_(6O/^N(_G7I=>:?#;_D+7G_7$?SKTN@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH 0]#6-IO_ "%KKZULGH:QM-_Y"UU]: -J
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q3
M_P C)_P&MJL4_P#(R?\  :VJ "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K%U;_ (_[7_>K:K%U;_C_ +7_ 'J -JBBB@ HHHH
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M?_GO%_WV*.>/<.678EHJ+[5;_P#/>+_OL4?:K?\ Y[Q?]]BCGCW#EEV,H_\
M(R?\!K:K!,\/_"1;O-CV[>NX8K9^U6__ #WB_P"^Q1SQ[ARR[$M%1?:K?_GO
M%_WV*/M5N3@3Q?\ ?8HYX]PY9=B6BBBJ)"BBB@ HHHH **** "BBB@ HHHH
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MHP>=9W$<\9_B0Y% %FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"7O9F6/=V .?ZUF?'S_CRTO_ *[C^1H ] \2_P#)-;__ +!Q_P#0*Y#X)?\
M(@2_[\G\S77^)?\ DFM__P!@X_\ H%<A\$O^1 E_WY/YF@# \!^%M)\1^+_$
M8U.V\[RY25^;&/FKN[SX2^%;FV:.*T>&3'RR)(05-<Y\)_\ D</$_P#UT/\
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M\+Q70@>:Z&6VB3R#L/\ P+I6MXFNH;SP)JMQ;N'B>SD*L#U^4UE>,?#>D)X
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MH **** "H+S_ (\;C_KFW\JGJ"\_X\;C_KFW\J /%-,_US_[M:E9>F?ZY_\
M=K4KY+-_]Z?R/ILL_P!W7S"BBBO,/0"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "G(C2.$0$L3@ 4VNM\*Z-N;[;.O ^X#71A</+$
M5%")AB*\:%-S9L>'])73K0.Z_OG&6]JV:**^TI4HTH*$=D?*5:DJDW.6["BB
MBM#,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%U;_ (_[7_>K
M:K%U;_C_ +7_ 'J -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH R=>_X]XO]^M*'_4I]*S=>_X]XO\ ?K2A_P!2GTH DHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZO\ \@R;
M_=J]5'5_^09-_NT .TK_ )!L/TJY5/2O^0;#]*N4 %%%% !7*^-_^/2T_P"N
MC?RKJJY7QO\ \>EI_P!=&_E7#F7^ZS_KJ=F7_P"\Q_KH<77:>"/^/6[_ -]?
MY5Q==IX(_P"/6[_WU_E7S^4_[U'Y_D>WF?\ NTOE^9U5%%%?7'S 5X[\:_\
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M!K#T]?B>Y\OCL4Z]339;!1117><04444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRC_A"/\ I]_\<KKZ*/[+PO\ +^+#^T<3_-^".0_X0C_I]_\ '*/^$(_Z??\
MQRNOHH_LO"_R_BP_M'$_S?@CD/\ A"/^GW_QRC_A"/\ I]_\<KKZ*/[+PO\
M+^+#^T<3_-^".0_X0C_I]_\ '*/^$(_Z??\ QRNOHH_LO"_R_BP_M'$_S?@C
MD/\ A"/^GW_QRC_A"/\ I]_\<KKZ*/[+PO\ +^+#^T<3_-^".0_X0C_I]_\
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M6ABG_D9/^ UM5BG_ )&3_@-;5=AR!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5BZM_Q_P!K_O5M5BZM_P ?]K_O4 ;5%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!DZ]_Q[Q?[]
M:4/^I3Z5FZ]_Q[Q?[]:4/^I3Z4 24444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %4=7_Y!DW^[5ZJ.K_\ (,F_W: ':5_R#8?I5RJ>
ME?\ (-A^E7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** ,G7O^/>+_ 'ZTH?\ 4I]*S=>_X]XO]^M*'_4I]* )**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "J.K_\ (,F_W:O51U?_ )!D
MW^[0 [2O^0;#]*N53TK_ )!L/TJY0 4444 %%-9U099@OU.*;]HA_P">T?\
MWT* )**C^T0_\]H_^^A1]HA_Y[1_]]"@"2BH_M$/_/:/_OH4?:(?^>T?_?0H
M DHJ/[1#_P ]H_\ OH4?:(?^>T?_ 'T* )**C^T0_P#/:/\ [Z%'VB'_ )[1
M_P#?0H DHJ/[1#_SVC_[Z%'VB'_GM'_WT* )**C^T0_\]H_^^A1]HA_Y[1_]
M]"@"2BH_M$/_ #VC_P"^A1]HA_Y[1_\ ?0H DHJ/[1#_ ,]H_P#OH4?:(?\
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M**C^T0_\]H_^^A1]HA_Y[1_]]"@"2BH_M$/_ #VC_P"^A1]HA_Y[1_\ ?0H
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M**C^T0_\]H_^^A1]HA_Y[1_]]"@"2BH_M$/_ #VC_P"^A1]HA_Y[1_\ ?0H
MDHJ/[1#_ ,]H_P#OH4?:(?\ GM'_ -]"@"2BH_M$/_/:/_OH4?:(?^>T?_?0
MH DHJ/[1#_SVC_[Z%'VB'_GM'_WT* 'GH:QM-_Y"UU]:U3<0X/[Z/_OH5CZ;
M-$-6NB94Z_WA0!NT5']HA_Y[1_\ ?0H^T0_\]H_^^A0!)14?VB'_ )[1_P#?
M0H^T0_\ /:/_ +Z% $E%1_:(?^>T?_?0H^T0_P#/:/\ [Z% $E%1_:(?^>T?
M_?0H^T0_\]H_^^A0!)14?VB'_GM'_P!]"C[1#_SVC_[Z% $E%1_:(?\ GM'_
M -]"C[1#_P ]H_\ OH4 245']HA_Y[1_]]"C[1#_ ,]H_P#OH4 245']HA_Y
M[1_]]"C[1#_SVC_[Z% $E%1_:(?^>T?_ 'T*/M$/_/:/_OH4 245']HA_P">
MT?\ WT*/M$/_ #VC_P"^A0!)14?VB'_GM'_WT*/M$/\ SVC_ .^A0!DG_D9/
M^ UM5@F:+_A(\^:F-O7<*VOM$/\ SVC_ .^A0!)14?VB'_GM'_WT*/M$/_/:
M/_OH4 245']HA_Y[1_\ ?0H^T0_\]H_^^A0!)14?VB'_ )[1_P#?0H^T0_\
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M-_C1_P (GH7_ $#H_P#OIO\ &MJB@#%_X1/0O^@='_WTW^-'_")Z%_T#H_\
MOIO\:VJ* ,7_ (1/0O\ H'1_]]-_C1_PB>A?] Z/_OIO\:VJ* ,7_A$]"_Z!
MT?\ WTW^-'_")Z%_T#H_^^F_QK:HH Q?^$3T+_H'1_\ ?3?XT?\ ")Z%_P!
MZ/\ [Z;_ !K:HH Q?^$3T+_H'1_]]-_C1_PB>A?] Z/_ +Z;_&MJB@#%_P"$
M3T+_ *!T?_?3?XT?\(GH7_0.C_[Z;_&MJB@#%_X1/0O^@='_ -]-_C1_PB>A
M?] Z/_OIO\:VJ* ,7_A$]"_Z!T?_ 'TW^-'_  B>A?\ 0.C_ .^F_P :VJ*
M,7_A$]"_Z!T?_?3?XT?\(GH7_0.C_P"^F_QK:HH Q?\ A$]"_P"@='_WTW^-
M'_")Z%_T#H_^^F_QK:HH Q?^$3T+_H'1_P#?3?XT?\(GH7_0.C_[Z;_&MJB@
M#%_X1/0O^@='_P!]-_C1_P (GH7_ $#H_P#OIO\ &MJB@#%_X1/0O^@='_WT
MW^-'_")Z%_T#H_\ OIO\:VJ* ,7_ (1/0O\ H'1_]]-_C1_PB>A?] Z/_OIO
M\:VJ* ,7_A$]"_Z!T?\ WTW^-'_")Z%_T#H_^^F_QK:HH Q?^$3T+_H'1_\
M?3?XT?\ ")Z%_P! Z/\ [Z;_ !K:HH Q?^$3T+_H'1_]]-_C1_PB>A?] Z/_
M +Z;_&MJB@#%_P"$3T+_ *!T?_?3?XT?\(GH7_0.C_[Z;_&MJB@#%_X1/0O^
M@='_ -]-_C1_PB>A?] Z/_OIO\:VJ* ,7_A$]"_Z!T?_ 'TW^-'_  B>A?\
M0.C_ .^F_P :VJ* ,7_A$]"_Z!T?_?3?XT?\(GH7_0.C_P"^F_QK:HH Q?\
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M_OIO\:/^$3T+_H'1_P#?3?XUM44 8O\ PB>A?] Z/_OIO\:/^$3T+_H'1_\
M?3?XUM44 8O_  B>A?\ 0.C_ .^F_P :/^$3T+_H'1_]]-_C6U10!B_\(GH7
M_0.C_P"^F_QH_P"$3T+_ *!T?_?3?XUM44 8O_")Z%_T#H_^^F_QH_X1/0O^
M@='_ -]-_C6U10!B_P#")Z%_T#H_^^F_QH_X1/0O^@='_P!]-_C6U10!B_\
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M +Z;_&C_ (1/0O\ H'1_]]-_C6U10!B_\(GH7_0.C_[Z;_&C_A$]"_Z!T?\
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MGH7_ $#H_P#OIO\ &C_A$]"_Z!T?_?3?XUM44 8O_")Z%_T#H_\ OIO\:/\
MA$]"_P"@='_WTW^-;5% &+_PB>A?] Z/_OIO\:/^$3T+_H'1_P#?3?XUM44
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M +Z;_&C_ (1/0O\ H'1_]]-_C6U10!B_\(GH7_0.C_[Z;_&C_A$]"_Z!T?\
MWTW^-;5% &+_ ,(GH7_0.C_[Z;_&C_A$]"_Z!T?_ 'TW^-;5% &+_P (GH7_
M $#H_P#OIO\ &C_A$]"_Z!T?_?3?XUM44 8O_")Z%_T#H_\ OIO\:/\ A$]"
M_P"@='_WTW^-;5% &+_PB>A?] Z/_OIO\:/^$3T+_H'1_P#?3?XUM44 8O\
MPB>A?] Z/_OIO\:/^$3T+_H'1_\ ?3?XUM44 8O_  B>A?\ 0.C_ .^F_P :
M/^$3T+_H'1_]]-_C6U10!R>L^&M'@@C,5BBDM@_,W^-7XO"FAF)2=/CR1_>;
M_&I]>_X]XO\ ?K2A_P!2GTH R?\ A$]"_P"@='_WTW^-'_")Z%_T#H_^^F_Q
MK:HH Q?^$3T+_H'1_P#?3?XT?\(GH7_0.C_[Z;_&MJB@#%_X1/0O^@='_P!]
M-_C1_P (GH7_ $#H_P#OIO\ &MJB@#%_X1/0O^@='_WTW^-'_")Z%_T#H_\
MOIO\:VJ* ,7_ (1/0O\ H'1_]]-_C1_PB>A?] Z/_OIO\:VJ* ,7_A$]"_Z!
MT?\ WTW^-'_")Z%_T#H_^^F_QK:HH Q?^$3T+_H'1_\ ?3?XT?\ ")Z%_P!
MZ/\ [Z;_ !K:HH Q?^$3T+_H'1_]]-_C1_PB>A?] Z/_ +Z;_&MJB@#%_P"$
M3T+_ *!T?_?3?XT?\(GH7_0.C_[Z;_&MJB@#%_X1/0O^@='_ -]-_C1_PB>A
M?] Z/_OIO\:VJ* ,7_A$]"_Z!T?_ 'TW^-5-3\+Z+%82NE@BL!P=S?XUTM4=
M7_Y!DW^[0!1T+1--M8(KJ"U5)BI&\$_XUN53TK_D&P_2KE !1110 5P_CKXD
M:=X.C$.W[1>L.(E/3W-=G=3?9[2:?_GG&S_D,U\L6D)\;?%;R+IRZ7%PW7^Z
M,G% &]-\9?'%PYELK-! >F;0M^M=%X7^-\LVH1V6OVOEER%\U1M"GW%>P6&E
MV6FV*V=I;I% HQL48%<OJ?PN\-:IJXU&>T ?^)% VM]: .QBE2>%)8V#(ZAE
M([@T^LS4;VS\-:$]PX$=M;1X51QT' KP&]^(WC;QAJ<L/AT7,2 _(EL<-CMG
MG% 'TC17S9:?$/QQX.U../Q$+J53]Z.Y.3CVYKV76?$/VWX>W&L:9<-&S0%D
M=#RIP?ZT ==17RYX>^(WCBX:XL;6[NM1NKA0(][99,=2*F'C[QWX2UM$UV>[
M)^\;>Y;(Q^% 'T[17SQK7C;Q[XFCDO\ 08+RVTV(9\V XXQWYK?^$?Q#U76M
M8;0]7E:>8JS)(YRWRCG- 'M%%>*_&;Q1K>@ZI9II>IW%JC %EB; /%<I#XM^
M)/B:Q1]'^W&*!=KS0-@M[G)H ^E:X'XI^+=4\):+%=:6T2RLV#YB;AU%>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@#)U[_CWB_P!^M*'_ %*?2LW7O^/>+_?K2A_U*?2@"2BBB@ HHHH
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M'XFO+_%VDZE+\5Q/'I]T\/FJ?,6%BO4]\4 >Z>(8(AX1O8A&OEB#&W'%>(_
M\8\<78'9)*]TU]'D\,WB(K,YAP% R37BWP9TO4+/QI=R75C<P1E),-)$R@_B
M10!%\=/^1IL?HO\ 2O:?"/\ R*.E?]>Z_P J\N^-GA75-1NK74["!IT0894&
M6' ["IOA+J_BNYO!9:M!-'801!(A) 4(Q[D<T >RT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5!>?\>-Q_P!<V_E4]07G
M_'C<?]<V_E0!YW\-O^0M>?\ 7$?SKTNO-/AM_P A:\_ZXC^=>ET %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'H:QM-_P"0M=?6
MMD]#6-IO_(6NOK0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% &*?\ D9/^ UM5BG_D9/\ @-;5 !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5BZM_Q_VO^]6U6+JW_'_:_P"]
M0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M &3KW_'O%_OUI0_ZE/I6;KW_ ![Q?[]:4/\ J4^E $E%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !5'5_^09-_NU>JCJ__(,F_P!V
M@!VE?\@V'Z5<JGI7_(-A^E7* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#P3X\6MQ/JMF88)9 %YV(3V]J]3^'"/'\.]"2165A:J"K#!'6NG*J>J@_4
M4H  P!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<?\ \+-\,?\ /U+_ -^6H_X6;X8_Y^I?^_+4?5:_\C^X/K=#^=?>=A17'_\
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M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J.K_\
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MWJ9U"\+);%L[CTQZ"LJ'/4M6K.T8[&V(]G3O1HQO*6YT7PDLIH[*[NG^6-G
M4'OQUKTNLI=/&E>'WM-.0J\<9$>T<YKRV6;XD><^P:GMW'&$'3\JR</K=251
M22]36,_J=*--Q;]#O_B'_P B3?\ T7^8KE?A++'';W>^15^;^)L>E3WK:PWP
MIOSKGG?;/,_Y;##;<C%<-X:\)ZCXC25K*>.,1G!WL1_*NJA2C]6G3G*ROO\
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M*M[5;WN1##QC1]B]5:Q\Y6GAG5I[Z*!]/NE1GVEC&0!7T)I]JEGI\%NBA0B
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M+ZD\5[E7+BJ'L9V6QU8:O[:%WN%%%%<QT!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !4%Y_QXW'_7-OY5/4%Y_P >-Q_US;^5 'SMJW^I
MC_WJR*U]6_U,?^]617TN6?[NOF?+YI_O+^04445WGGA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7J_PV\(F-1J]Z
M@RP_=*?YUR?@?PP^O:JKR*?LL)W,<=3Z5[S#"D$*Q1*%1!A0.PKR,RQ?*O90
MWZGLY9A.9^VGMT'T445X1[X4444 %%%% !1110 4444 %%%% !1110 4444
M8I_Y&3_@-;58I_Y&3_@-;5 !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5BZM_Q_VO\ O5M5BZM_Q_VO^]0!M4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &3KW_ ![Q?[]:4/\
MJ4^E9NO?\>\7^_6E#_J4^E $E%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !5'5_\ D&3?[M7JHZO_ ,@R;_=H =I7_(-A^E7*IZ5_
MR#8?I5R@ HHHH *\U^,/_(,TS_KL_P#Z"*]*KS7XP_\ (,TS_KL__H(KLP'^
M\Q_KH<>8?[M/^NIY%7;_  J_Y'(?]>[_ -*XBNW^%7_(Y#_KW?\ I7T&,_@3
M]#YS!_[Q#U/<****^3/KPI"P526( '4FEKS_ .+>OW6C^%_(LFVW-TXC!'H>
M#0!8UGXH:/IE\UG:0S:E<+PR6V.#^-5+3XMZ8UVD&IZ==Z7O/#W)&/TS6GX
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M&03[U[3+JUKHGA:&_O'"0Q6Z$^_R]* -FBO+K?XC>)]85[K1/#:3V*DXDE+
ML!Z8KIO"/C>V\3--:RPM:ZC;G$UNXP5H ZNBO-O$?Q,O-$\6-HD.EI<LRGR=
MI)9G[#%=#X6UGQ%JDLPUK2(K%%P4*%CNS]: .HKCO%7Q$T_PO?PZ>;::]O91
MD00$;L?C76SM(EO(T2AI%0E5/<XX%?/\VJ^)I?B='=RZ):G45C&+<LQ7&3SZ
MT >V>'==.OZ=]K:PGLCG'ESD;OTK8KCM8\;1^&O#]M<ZI;)'J,X^6TBYR>>G
M?%8#>/O&<-M]OF\*(+'&XE2^\+ZX^E 'J%%87AKQ39>)]'^W69Y7(>,]5(KA
MC\5-7N-?U#1=/T2.YN[>4I&%+8(]6]* /5J:[;(V<\[036/X9U#5]2TXRZS8
M)97 ./+0DC]:UKC_ (]I?]P_RH \SN?C390:G=6,6@ZC.]NY1FC9,''XTB_&
MNQ5A]IT'4K:,_P <A7'Z51^%<<<GC'Q/O16Q(>HS_%7JT^GV=U \,UM$\;C#
M*4'- %70]?T[Q#8K=Z=<)-&>NT]#Z5IUXEHJMX'^+LFEPL5TV\4E8\\;CC'\
MZZWQI\19_">OVNGK8)<1SK]X$[MV. !]: /0**\]M_%WC%[&]NKCPY!"(H?,
MA#,_S'/0_A6YX&\5_P#"7:$+UXHXKA3MEC0DA6].: .FHKB_%/C6ZT;Q'IFC
M:?9Q7,UVW[S>Q&Q<C)X]C79KG:-V,]\4 #,%4L>@&:X/2_BKI.J>*3H26L\;
MY*K.S#8Q'8=ZU?B!K@T'P?>W"MB=D*P^[5Y+?>%KC0_ NE>)HT)U""82R#VR
M30!]!5PWC'XG:?X,U2*QN["YG:10V^-E &?K73Z!JD>L:':7T3;A)&I;_>P,
M_K7CGQ7TY-5^(NGV;\K)#_)2: /:=*U*'5]+M]0M_P#4SIO7Z4:KJ,.D:7<7
M\^3'!&7('4X'2N#^#NI/+X<ETJ?*SZ?)Y6T^F,_UJ?XJ7Y;3+/0H7Q<:A.BX
M'79G#?SH M>"_B78>-;VXMK2QN(#" 2TK*0?RJ/Q=\3[/PEKT6D2Z7=W<\D8
MD4PE<<YXY^E<5\([%=-\:ZO9H,"%50_49%7/%*AOV@_#RL 08ER"/9J -+_A
M=5N.7\,ZHJCJQ*<?K75>%_'NC>*28[27R[D#)@D^\*Z/[-;_ //"+_O@5XW\
M4-'C\,:YIOB73!]F(E47&S@-DB@#VFBJFF78OM+M;L=)HE?\QFK= !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 <UX]_P"13N?]Y?YUY7X1T*WU
M[5&MKAW50,Y4UZIX]_Y%.Y_WE_G7GGPXFCAUYFE=4&WJ37JX63CAI..YY>)2
MEB8I['5_\*LTK_GXG_,?X5@>)_A^='LS>V$K.B?>4]1[UZE_:5E_S\Q_]]5S
MWC#Q#I]MH=Q")TDEE4JJ \\]ZQHXC$.:5[F];#T%!NUCBO _BZZMM1CL;N5I
M+>3@;C]TU;^*O_'[;?[O^-<7H,4D^MVJ1C+>8#@?6NS^*?%Y;#_9']:[I0C'
M%1:ZIG#&<I8:2?1HN^ )&A\(ZI(OWE;(_*O/;<>=K\8;^.X&?Q:O2?AI"+CP
M[?0MT>0 _E7G5_#)I7B!Q(I#1S;@/QR**+7MJBZA63]E3?0^@K5!':Q(O15
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M?#_PDNCV*WMRN;J89Y'W17-B\2J%._7H=>#PSQ%3EZ=3H] T6WT+2XK6! "
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M !1110 4444 %%%% !1110 4444 %%%% !6+JW_'_:_[U;58NK?\?]K_ +U
M&U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M9.O?\>\7^_6E#_J4^E9NO?\ 'O%_OUI0_P"I3Z4 24444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %4=7_Y!DW^[5ZJ.K_\@R;_ ':
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M44 %%%% !1110 4444 %%%% &*?^1D_X#6U6*?\ D9/^ UM4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+JW_ !_VO^]6U6+J
MW_'_ &O^]0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &3KW_'O%_OUI0_ZE/I6;KW_'O%_OUI0_ZE/I0!)1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51U?\ Y!DW^[5ZJ.K_
M /(,F_W: ':5_P @V'Z5<JGI7_(-A^E7* "BBB@ KS7XP_\ (,TS_KL__H(K
MTJO-?C#_ ,@S3/\ KL__ *"*[,!_O,?ZZ''F'^[3_KJ>15ZY\'?^09JG_79/
MY&O(Z]<^#O\ R#-4_P"NR?R->UF7^[/Y?F>'EG^\Q^?Y'I=%%%?,GU 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %07G_'C<?]<V_E4]07G_ !XW'_7-OY4 >3^$O$.G^';V>?49'2.2/8I5
M"W.<]JZ[_A9_AC_GYF_[\M7D&K?ZF/\ WJR*]C!X"E6I*<KW/%QN85:-9PC:
MQ[M_PL_PQ_S\S?\ ?EJ/^%G^&/\ GYF_[\M7A-%=7]E4.[.7^UJ_9?U\SW;_
M (6?X8_Y^9O^_+4?\+/\,?\ /S-_WY:O":*/[*H=V']K5^R_KYGNW_"S_#'_
M #\S?]^6H_X6?X8_Y^9O^_+5X311_95#NP_M:OV7]?,]V_X6?X8_Y^9O^_+4
M?\+/\,?\_,W_ 'Y:O":*/[*H=V']K5^R_KYGNW_"S_#'_/S-_P!^6H_X6?X8
M_P"?F;_ORU>$T4?V50[L/[6K]E_7S/=O^%G^&/\ GYF_[\M1_P +/\,?\_,W
M_?EJ\)HH_LJAW8?VM7[+^OF>[?\ "S_#'_/S-_WY:C_A9_AC_GYF_P"_+5X3
M11_95#NP_M:OV7]?,]V_X6?X8_Y^9O\ ORU'_"S_  Q_S\S?]^6KPFBC^RJ'
M=A_:U?LOZ^9[M_PL_P ,?\_,W_?EJ/\ A9_AC_GYF_[\M7A-%']E4.[#^UJ_
M9?U\SW;_ (6?X8_Y^9O^_+4?\+/\,?\ /S-_WY:O":*/[*H=V']K5^R_KYGN
MQ^)WAC'_ !\S?]^6K-LOB%X>AU">9[B4(YX_=&O&Z*/[*H=V']K5^R_KYGNW
M_"S_  Q_S\S?]^6H_P"%G^&/^?F;_ORU>$T4?V50[L/[6K]E_7S/=O\ A9_A
MC_GYF_[\M1_PL_PQ_P _,W_?EJ\)HH_LJAW8?VM7[+^OF>[?\+/\,?\ /S-_
MWY:C_A9_AC_GYF_[\M7A-%']E4.[#^UJ_9?U\SW;_A9_AC_GYF_[\M70:/K5
MGKEJ;FR,C1 XRZ%<_G7@7AK0)O$&JQVT8/EYS(W]T5]":=80Z;8Q6D"A4C7&
M!7G8[#T*%HPO<]+ 8BO7O*:5BU1117G'I!1110 4444 %%%% !1110 4444
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ME%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'5_\
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M62]^<(ZQ[EZXG2VMY)Y#A$&2:\7N;I_''C )+.D5E$W1W"C:.O6O8=4LVO\
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M )&3_@-;58I_Y&3_ (#6U0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %8NK?\?]K_O5M5BZM_Q_VO\ O4 ;5%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!DZ]_Q[Q?[]:4/^I3Z
M5FZ]_P >\7^_6E#_ *E/I0!)1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 51U?_D&3?[M7JHZO_R#)O\ =H =I7_(-A^E7*IZ5_R#
M8?I5R@ HHHH *Q]?\-:?XEAABU 2E86+)Y;[>36Q151G*#YHNS)G",URR5T<
M5_PJOPU_<NO^_P!_]:MW0/#6G^&H9HM/$H69@S^8^[D5L45I/$59KEE)M&<,
M-1@^:,4F%%%%8FP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %07G_'C<?]<V_E4]07G_ !XW'_7-OY4 >=_#
M;_D+7G_7$?SKTNO-/AM_R%KS_KB/YUZ70 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 (>AK&TW_D+77UK9/0UC:;_P A:Z^M &U1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8I_
MY&3_ (#6U6*?^1D_X#6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %8NK?\?\ :_[U;58NK?\ '_:_[U &U1110 4444 %%%%
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M1110 4444 %%%% !1110 5!>?\>-Q_US;^53U!>?\>-Q_P!<V_E0!YW\-O\
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M@YX]SHJ***DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_@-;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5BZM_P ?]K_O5M5BZM_Q_P!K_O4 ;5%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!DZ]_Q[Q?[]:4/^I3Z5FZ]_Q[Q?[]:4/^
MI3Z4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M4=7_ .09-_NU>JCJ_P#R#)O]V@!VE?\ (-A^E7*IZ5_R#8?I5R@ HHHH *\U
M^,/_ "#-,_Z[/_Z"*]*KS7XP_P#(,TS_ *[/_P"@BNS ?[S'^NAQYA_NT_ZZ
MGD5=O\*O^1R'_7N_]*XBNW^%7_(Y#_KW?^E?08S^!/T/G,'_ +Q#U/<****^
M3/KPKDOB!KSZ+X?80,5N)B%7Z'K76UYA\75<P63#[@!S]<UU8."G7BI'+C9R
MA0E*.YA>!_!Z^)9)+_4'8P!O^^SWKL]6^&.CW-JPL(C;S ?+@D@G\:=\*W0^
M#U0$;Q,Y(_&NWK?%8NM&NU%VL<^$PE&5!.2NV<+X)\&ZCX=NI);FZ^1@1Y:G
M(^M=?J>H0Z7I\MW.P"1KGGN>PJW7C_CO7GUW7(]&M)@MNK .Q.T$Y_I6=.,\
M76O/YFE24,'1M#Y'(>(=2NM:OWU*8-Y4CE8_0 =OUKUKX:?\BF/K_2N.\=6%
MCI?A?1[.TFAD=)7,AC<,<[1Z5UOPUN(/^$9$7G1^9G[FX9Z>E=^+DIX5.*TN
M>?@X.&+:D[NWYGF<]U'8^.5NI<^7%<AVQZ UV-Q\7G2Y*V^G1O"#]YG(./I7
M(262:CXY^RR'Y)+@*WTS7KFJ>$-';P_-;K:(OE1,RN% ;('K58J5!."JQOH3
MA88AJ;I2MJ6O#7BBS\2VID@RLJ#]XA[5NUX?\-YY+7Q:+=6.V3Y6P>N,U[A7
MF8V@J-7ECL>I@<1*O2YI;G(?$K_D3YO^NJ_UKCOAUX9TG7+.XDU"U\UD/!W$
M=Z['XE?\B?-_UU7^M8OPD_Y!]U]?ZUU4I2C@I.+MJ<M:$9XZ*DKJQ-XD^&NE
MG3II],C:&:-,JB\[OSKFOAEK,UEKC:=(Y,,O 4GHW2O8[D@6LI) &P]?I7@G
M@T,WC:UV]I\G\ZO"U)5J%2-1WL1BJ<:&(IRIJUSUWQ/XPLO#<0$A\RX;[L8_
MK7%Q?&"8S8ETR)8\_>60DURWBR^>]\92RSQM*JR*/+7N!V'UK7U#6K6\TK[%
M'X1GB('RR!#N'U.WFM*>#IPA'FCS-^>QE4QM6<Y<LN5+;3<]4T'7K/Q!8+<V
MC_[RGJ#6)XJ\>VGAV3[-''Y]V.J'@#ZFN3^%GVNSU&\AN()XHVARN^,@;LUS
MUO ->\>>7=DLCS_.">HS6,,%35:7-K&*N;3QU5T(..DI.QV.F?%E+F5UOK)(
M $)4HQ.3C@5?\+_$&X\0:U]A>QBB3^^KDUI>(/"&DS^'IXX[9(C!$SJZJ >!
MGD_A7G'PQ_Y&E?I_C3C3PU6C.I"-FA2J8FE6A3G*Z9V/B/XC7&A:X]@MA%)&
MIQO9R#5&'XKSW6I16UOID;K(P4'><Y/M7*_$7GQ=./>O6_#WAW3M-TNU"VT+
MR; _F,@+9//6BI##T:,9RC=M!3GB:U><(SLDS-\2>.X-!\J!8/.O'4,8O3(K
M ?XH:I:,AOM"$$3]&+-S].*L^)4\':9K!O+YIIM0!#!!(6%<SXR\90^(;".W
MATYHEC;(E(X_E3P^'IS45[-M/=O3[@Q&(J0<G[1)K9+7[SUK0]:MM=TY+NV)
MVGJ".AKFO%'Q$M="N?LMM$MS.OW@3@#\15'X93&#PI>RCG9)D#\*X?PY8)XA
M\;-#=G<I=W.3UP>E12PE)5:CG\,2ZN+JNE34/BD;U[\2UUG2+BSNK-8'D'RE
M&+"F_!__ )#>H?\ 7N/_ $(5U_B_PMI<GAV5HK6.*2%?E9%"]/7UKCOA&<:O
MJ1]+7_V:ME*E+"5'25C%QJPQ=-57<[?Q3XYLO#A\A1YUW_SS[#ZFN6MOB_(\
MX%SIL<<>>61R3BN+O;TW/BV6ZN;>2Z'G9,2GEL=JV]<U>#5=-%K#X4GMI%^[
M(J'/XX7FJA@J4(QC*-[[N^Q$\=5G*4HRM;96W/7;#6;75-*-_:-O3:3@^H'2
MO/A\6Y4N98YM-B54Z%7))I?AE]KBL=3MKB*:-%A+*)$(&3GUKB] T^+4_&,%
MK-S$\V&'J*SHX2C&=135U$UK8NM*%-P=G(]'\+?$&Z\1:O\ 8SIJ1I@G>KDX
M%=]52TTRRL5 MK6&(@8W(@!/XU;KS*TZ<I7IQLCU*$*D(VJ2NPHHHK$V"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "H+S_CQN/^N;?RJ>H+S_ (\;C_KFW\J /G;5
MO]3'_O5D5KZM_J8_]ZLBOI<L_P!W7S/E\T_WE_(****[SSPHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "M#1M)N-9U**UMT+%B-Q'851C1I9%1
M2S'  KW/P#X671--%S,O^E3C))[#M7+C,2J%._7H=>#PKQ%2W1;F_HFCP:)I
M<=I H^4?,V.IJ#3?^0M=?6MD]#6-IO\ R%KKZU\M*3D[L^LC%17*MC:HHHI#
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%/_(R?
M\!K:K%/_ ",G_ :VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K%U;_C_M?]ZMJL75O^/^U_WJ -JBBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\7^_6E#_ *E/I6;KW_'O%_OUI0_ZE/I0!)1110 4444 %%%% !1110 4444
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M&/\ GQ;_ +^M7644?6:W\[^\/JM#^1?<<G_PK?PQ_P ^+?\ ?UJ/^%;^&/\
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M0 4444 %4=7_ .09-_NU>JCJ_P#R#)O]V@!VE?\ (-A^E7*IZ5_R#8?I5R@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *@O/^/&X_ZYM_*IZ@O/\ CQN/^N;?
MRH \[^&W_(6O/^N(_G7I=>:?#;_D+7G_ %Q'\Z]+H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** $/0UC:;_R%KKZULGH:QM-_P"0
MM=?6@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@0O_ ']_^M7EM%']GX;^7\P_M'$_S?D>I?\ "XG_ .@0O_?W_P"M1_PN)_\
MH$+_ -_?_K5Y;11_9^&_E_,/[1Q/\WY'J7_"XG_Z!"_]_?\ ZU'_  N)_P#H
M$+_W]_\ K5Y;11_9^&_E_,/[1Q/\WY'J7_"XG_Z!"_\ ?W_ZU'_"XG_Z!"_]
M_?\ ZU>6T4?V?AOY?S#^T<3_ #?D>I?\+B?_ *!"_P#?W_ZU'_"XG_Z!"_\
M?W_ZU>6T4?V?AOY?S#^T<3_-^1ZC_P +A?'_ ""%_P"_O_UJJV7Q/E2_=X]*
M#O*<!1)_]:O.*]#^&GAM;O4/[0NDRD7,:D=3ZUC7PN%HP<Y1_%FV'Q>+K5%"
M,OP1ZWI\\US8Q37$(AD==Q0-G%6: ,# Z"BOGF[L^C2L@HHHI#"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** ,4_P#(R?\  :VJQ3_R,G_
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MN[W-JBBBN([@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[3+BY\6"YMP\=O$6._V[5[A7%F$%&MH[G;ETW*CJK:A1117"=X4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_?K2A_U*?2@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ JCJ_\ R#)O]VKU4=7_ .09-_NT .TK_D&P_2KE4]*_Y!L/TJY0 444
M4 %07-E:WJJMU;Q3!3E1(@;'YU/133:U0FD]&9_]A:3_ - RT_[\K_A4MOI=
MA:2^;;6<$4F,;DC .*MT4W.3ZB4(K9!1114E!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!>?\ 'C<?]<V_
ME4]07G_'C<?]<V_E0!YW\-O^0M>?]<1_.O2Z\T^&W_(6O/\ KB/YUZ70 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>AK&TW_D+
M77UK9/0UC:;_ ,A:Z^M &U1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 8I_Y&3_@-;58I_Y&3_@-;5 !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5BZM_Q_VO\ O5M5BZM_Q_VO
M^]0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% &3KW_ ![Q?[]:4/\ J4^E9NO?\>\7^_6E#_J4^E $E%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5'5_\ D&3?[M7JHZO_ ,@R
M;_=H =I7_(-A^E7*IZ5_R#8?I5R@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MH+S_ (\;C_KFW\JGJ"\_X\;C_KFW\J /._AM_P A:\_ZXC^=>EUYI\-O^0M>
M?]<1_.O2Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!#T-8VF_\A:Z^M;)Z&L;3?^0M=?6@#:HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,4_\C)_P&MJL4_\ (R?\!K:H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L75O^/^U_
MWJVJQ=6_X_[7_>H VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#)U[_ (]XO]^M*'_4I]*S=>_X]XO]^M*'_4I]* )****
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M $+L_P#W_2MZB@#!_MG5_P#H79_^_P"E']LZO_T+L_\ W_2MZB@#!_MG5_\
MH79_^_Z4?VSJ_P#T+L__ '_2MZB@#!_MG5_^A=G_ ._Z4?VSJ_\ T+L__?\
M2MZB@#!_MG5_^A=G_P"_Z4?VSJ__ $+L_P#W_2MZB@#!_MG5_P#H79_^_P"E
M']LZO_T+L_\ W_2MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T+L__ '_2MZB@#!_M
MG5_^A=G_ ._Z4?VSJ_\ T+L__?\ 2MZB@#!_MG5_^A=G_P"_Z4?VSJ__ $+L
M_P#W_2MZB@#!_MG5_P#H79_^_P"E']LZO_T+L_\ W_2MZB@#!_MG5_\ H79_
M^_Z4?VSJ_P#T+L__ '_2MZB@#!_MG5_^A=G_ ._Z4?VSJ_\ T+L__?\ 2MZB
M@#!_MG5_^A=G_P"_Z4?VSJ__ $+L_P#W_2MZB@#!_MG5_P#H79_^_P"E']LZ
MO_T+L_\ W_2MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T+L__ '_2MZB@#!_MG5_^
MA=G_ ._Z4?VSJ_\ T+L__?\ 2MZB@#!_MG5_^A=G_P"_Z4?VSJ__ $+L_P#W
M_2MZB@#!_MG5_P#H79_^_P"E']LZO_T+L_\ W_2MZB@#!_MG5_\ H79_^_Z4
M?VSJ_P#T+L__ '_2MZB@#!_MG5_^A=G_ ._Z4?VSJ_\ T+L__?\ 2MZB@#!_
MMG5_^A=G_P"_Z4?VSJ__ $+L_P#W_2MZB@#!_MG5_P#H79_^_P"E']LZO_T+
ML_\ W_2MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T+L__ '_2MZB@#!_MG5_^A=G_
M ._Z4?VSJ_\ T+L__?\ 2MZB@#!_MG5_^A=G_P"_Z4?VSJ__ $+L_P#W_2MZ
MB@#!_MG5_P#H79_^_P"E']LZO_T+L_\ W_2MZB@#!_MG5_\ H79_^_Z4?VSJ
M_P#T+L__ '_2MZB@#!_MG5_^A=G_ ._Z4?VSJ_\ T+L__?\ 2MZB@#!_MG5_
M^A=G_P"_Z4?VSJ__ $+L_P#W_2MZB@#!_MG5_P#H79_^_P"E']LZO_T+L_\
MW_2MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T+L__ '_2MZB@#!_MG5_^A=G_ ._Z
M4?VSJ_\ T+L__?\ 2MZB@#!_MG5_^A=G_P"_Z4?VSJ__ $+L_P#W_2MZB@#!
M_MG5_P#H79_^_P"E']LZO_T+L_\ W_2MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T
M+L__ '_2MZB@#!_MG5_^A=G_ ._Z4?VSJ_\ T+L__?\ 2MZB@#!_MG5_^A=G
M_P"_Z4?VSJ__ $+L_P#W_2MZB@#!_MG5_P#H79_^_P"E']LZO_T+L_\ W_2M
MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T+L__ '_2MZB@#!_MG5_^A=G_ ._Z4?VS
MJ_\ T+L__?\ 2MZB@#!_MG5_^A=G_P"_Z4?VSJ__ $+L_P#W_2MZB@#!_MG5
M_P#H79_^_P"E']LZO_T+L_\ W_2MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T+L__
M '_2MZB@#!_MG5_^A=G_ ._Z4?VSJ_\ T+L__?\ 2MZB@#!_MG5_^A=G_P"_
MZ4?VSJ__ $+L_P#W_2MZB@#!_MG5_P#H79_^_P"E']LZO_T+L_\ W_2MZB@#
M!_MG5_\ H79_^_Z4?VSJ_P#T+L__ '_2MZB@#!_MG5_^A=G_ ._Z4?VSJ_\
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M '_2C^V=7_Z%V?\ [_I6]10!QAU74_[<W_V'+OV_<\Y:U?[9U?\ Z%V?_O\
MI4A_Y&3_ (#6U0!@_P!LZO\ ]"[/_P!_TH_MG5_^A=G_ ._Z5O44 8/]LZO_
M -"[/_W_ $H_MG5_^A=G_P"_Z5O44 8/]LZO_P!"[/\ ]_TH_MG5_P#H79_^
M_P"E;U% &#_;.K_]"[/_ -_TH_MG5_\ H79_^_Z5O44 8/\ ;.K_ /0NS_\
M?]*/[9U?_H79_P#O^E;U% &#_;.K_P#0NS_]_P!*/[9U?_H79_\ O^E;U% &
M#_;.K_\ 0NS_ /?]*/[9U?\ Z%V?_O\ I6]10!@_VSJ__0NS_P#?]*/[9U?_
M *%V?_O^E;U% &#_ &SJ_P#T+L__ '_2C^V=7_Z%V?\ [_I6]10!@_VSJ_\
MT+L__?\ 2C^V=7_Z%V?_ +_I6]10!@_VSJ__ $+L_P#W_2LO4M5U-[RW+Z'*
MA!X!F4YKLJQ=6_X_[7_>H C_ +9U?_H79_\ O^E']LZO_P!"[/\ ]_TK>HH
MP?[9U?\ Z%V?_O\ I1_;.K_]"[/_ -_TK>HH P?[9U?_ *%V?_O^E']LZO\
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ME#_J4^E &+_;.K_]"[/_ -_TH_MG5_\ H79_^_Z5O44 8/\ ;.K_ /0NS_\
M?]*/[9U?_H79_P#O^E;U% &#_;.K_P#0NS_]_P!*/[9U?_H79_\ O^E;U% &
M#_;.K_\ 0NS_ /?]*/[9U?\ Z%V?_O\ I6]10!@_VSJ__0NS_P#?]*/[9U?_
M *%V?_O^E;U% &#_ &SJ_P#T+L__ '_2C^V=7_Z%V?\ [_I6]10!@_VSJ_\
MT+L__?\ 2C^V=7_Z%V?_ +_I6]10!@_VSJ__ $+L_P#W_2C^V=7_ .A=G_[_
M *5O44 8/]LZO_T+L_\ W_2C^V=7_P"A=G_[_I6]10!@_P!LZO\ ]"[/_P!_
MTH_MG5_^A=G_ ._Z5O44 8/]LZO_ -"[/_W_ $JIJ6KZJ]A*KZ!,BD<L9U.*
MZFJ.K_\ (,F_W: ,[0=0OIH8HIM*DABVG]Z95(_*M^J>E?\ (-A^E7* "BBB
M@ K*;Q-HB7WV%M4M1=9V^49!NS]*U:^8[_\ Y+2W_7T?YF@#Z<K+NO$FBV-Y
M]DNM3M8;@G'E/( WY5IK]T?2OFSXF_\ )68_^NJ?TH ^DU970,I!5AD$=Z6J
MNGD+I=J20 (5))^@KF-9^*'A70KHVUY?,9 <'R4+C\Q0!V-%8.@^,=$\2#_B
M6WBNW]QOE;\C2^)?%VD>$[=)]6EDCC<X4I&6_E0!NT5QTOQ0\*PZ5'J+W[>3
M(2% 0E^/]GK5[0/'7A_Q*DC:=>@[!EA*-AQ]#0!T=%<3>_%?PE8:A]BFOW,N
M<92,LOYCBNML-0M=3M$NK.9987&0RG- %FBLS6-?TS0;8SZC=)$OH2-Q^@KE
M[;XO^#KJZ%O'?2AR<9:$@?G0!W=%0VMU!>0+/;2I+&PR&1@16/K_ (QT3PT/
M^)E=A&_N*-S?D* -ZBN%L/B]X/U&Y6WAOI0[' ,D)4?F:ZO4-9LM-T6?5YYL
MV4,9E:2/YOE]1CK0!:GNH+;;Y\J1[V"KN.,D]!4M?+FO^/SJWQ!M=0^VS'28
M+B-PH!7Y01GY:^AO#GB[2/%5K)<Z7,[Q1_>,B%,?G0!NT5QVL_%#PKH5T;>\
MOF,@.#Y*%Q^E6M!^('ASQ)*(M/O<R'HLB["?SH Z>BJ][?6VGVK7-U,D42C)
M9B!7$S_&3P;;SF%[V<L#C*P,1^= '?51U'6=-TA5;4;Z"U5NAE<+FH-$\1Z7
MXBMO/TVZ65>ZYPP^HZUP/QEL]'N[&T&K:I)8J#\I2 R9Y]J /3+.]MM0MEN+
M2>.>%NCQG(-3URGP[BL;;P7:K8W9N;92Q$SILSSSP>E5]7^*7A31+HV]W?,9
M <'RHRX_,4 =G17+Z!\0?#GB27RM/O<R'HLJ["?IFNHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+S_CQN/^
MN;?RJ>H+S_CQN/\ KFW\J /._AM_R%KS_KB/YUZ77FGPV_Y"UY_UQ'\Z]+H
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M[4?$?C*VO]4C6.Y:5<A4*CMV-?72PQ;1^[3I_=%?-WQ,4+\6(PH 'FIT'TH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *@O/^/&X_P"N;?RJ>H+S_CQN/^N;?RH \[^&W_(6O/\ KB/YUZ77
MFGPV_P"0M>?]<1_.O2Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@!#T-8VF_P#(6NOK6R>AK&TW_D+77UH VJ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%/\ R,G_  &MJL4_
M\C)_P&MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *Q=6_X_[7_>K:K%U;_C_M?]Z@#:HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ,G7O^/>+_?K2A_U*?2LW7O\ CWB_WZTH
M?]2GTH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *HZO_R#)O\ =J]5'5_^09-_NT .TK_D&P_2KE4]*_Y!L/TJY0 4444 %><3
M_"2TG\8'Q"=5F$AD,GD^4,?3.:]'HH 0#  ]*\]\1_"BU\1>*%UR35)H7#!O
M*6($<8[Y]J]#HH KBSB-@MG*HDC$8C(8=1C%>8ZS\"M%U.\:XMKZ:R#-DHD8
M8?J:]6HH X+PE\*=%\*70NU=KNY7[LDBXQ^%:/CCP-!XVLHK::]DM1&<@H@;
M/YUUE% '/>#/"L7@WP\ND0W3W*+*TGF.H4_-VP*Y6[^#UG=>,I?$9U>=9)+@
MSF$1# )[9S7I=% &'XG\-Q^)= ?2I+AX$<8\Q5R>F.E9W@;P+!X'M+BW@O9+
MH3$$ET"XQ]*ZVB@#E?%G@#1O%T8-Y%LG7[LR#D?XUQ-O^S_I,5R))=6N)8\_
MZLQ #\\U[!10!FZ+H=AH%@MG80K'&OIU-<]XL^&NC>*K@74NZVNP,>=$.:[.
MB@#R2/X%VGF+]J\0WUS"#_JI%X_G7I.B:%8>'].2RT^$1Q*.W>M*B@#SSQA\
M(]*\6:D^H&ZDL[A\;VC0-NQ]35WP_P##32]$T&YTB29[N"X'S&1<<^M=M10!
MY(OP)L(KHR6^NWD,)/,*+@$>F<U-J'P-TFYGMIK/4I[-X5P2J!RYSU.37JM%
M &/?^'++5M"32M147,:H%WL,'(&,UY[+\#+3S2;3Q!?6L1_Y91KQ_.O6J* .
M*\)_#31_"LYNHRUU=_\ /:4<U-XY\!0>-[>&&>^DM1$>"B!L_G77T4 8GAWP
MU!H'AV/1O--S"NX%G4#.?:N,U7X*Z3>WDES8:A<Z:TAR1"/_ *]>G44 >9Z-
M\%])T^^2[O[^XU)T.5\\8_K7I4<:Q1K&BA548 ':G44 %%%% !1110 4444
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M (3+Q#_T%)OR'^%'_"9>(?\ H*3?D/\ "C^SJG=!_9E3NCW*BO#?^$R\0_\
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M^$R\0_\ 04F_(?X4?\)EXA_Z"DWY#_"C^SJG=!_9E3NCU@_\C)_P&MJO!_\
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MSFO"?$L=I'KUTMD<PA^*,(U6@Z4]D&#:K0=&>R+=O%=>+_$N6R0[98]@H_\
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M'8F,CWKIOAJ[/X;?<2=LQ ^F!45L/%4O:1NO4SK8>$:7M(W7J<9K7_)1I_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M663YI-O8UUE<IX0\*RZ 9WN'#NQPFTYXKJZX,0TZC:=SS\2XNJW%W. ^*?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]+\ >&0B?VG=QC<?\
M5 CI[US/@_P[)K6HK(Z_Z-$V7/K[5[/%$D$2Q1J JC  KS<=B++V<3R\?B>5
M>SCOU,S7O^/>+_?K2A_U*?2LW7O^/>+_ 'ZTH?\ 4I]*\D\<DHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZO\ \@R;_=J]5'5_
M^09-_NT .TK_ )!L/TJY5/2O^0;#]*N4 %%%% !7G_Q3_P"0?I__ %U;^0KT
M"O/_ (I_\@_3_P#KJW\A73@_X\3JP7\>)YA7I_PL_P"0?J/_ %U7^1KS"O3_
M (6?\@_4?^NJ_P C7J8[^ SUL?\ P'\CT"BBBO"/GPHHK@/C'J-YI?@"2YL;
MF6VG%S$HDB;:<$G(S0!W]%9?AN62?PQI<LKL\CVL;,S'))*CFJOC6XFM/!NJ
M3V\C12I#E74X(.10!O45Q7PMOKK4/!=M/>7$D\S9R\C9)Y-=C)<0P_ZV:./_
M 'F H DHJ**X@G_U4T<G^XP-.DFBA7=+(D:^K,!0 ^BH'O+6,X>YA4^C2 4\
MW$(C\PS1A/[VX8_.@"2BHHKJWG.(IXI#Z(X-2].M !15<WUHK;3=0!O0R#-3
MJRNN58$'N#0 M%1?:8-S+YT>Y.6&\9'UI$O+65ML=S"[>BN": )J*P?&=Q-:
M^$]0F@D:.5(F*NIP0<&L/X7ZM)=>!K>XU*^WS-(P+SR<GIZT =U14<4\,XS%
M*D@]48&N8\4Z+J6I:MIL]EKJZ?% P,D)8CSN>G6@#JZ*\Q^*.IW^FW?AQ+2\
MFA$EU&DGEN1O&]0<UT?C?1=2UB/3AIVNKI)AGWR$L1YHX^7@T =7131\J#<>
M@Y-0F_LU;:;N 'T,@H L44U'61=R,&4]P<BG4 %%>5?&[5]1TG1;.33[V:V=
MI0"T3E2>M0V?PZ\475E;W'_"9W8\V-7QYC\9&: /6Z*\7CU;Q+\._$UG8ZWJ
M/]HZ?>/L61@<Y^I/N*]HH **** "BBB@ HHHH **** "BBB@ KE=>\#66LW)
MN5<P3-]Y@,@_A7545<*DJ;O%V+IU)4W>+L>=+\+$#9;4B5]/+_\ KUV&AZ#:
MZ%:^3;C+'[S'J:U:*NIB*E16DS2IB:M16DPHHHK$P"BBB@ HHHH **** "BB
MB@ HHHH P?$OAB#Q##&#)Y,R'Y9 ,\>E:FGVTEG8Q6\LOFM&-N_&,BK5%6ZD
MG%1>R+=23BH/9!1114$!1110 4444 %9^LZ=)JFFR6D<_DE^KXS6A133<7=#
MC)Q=T8WASP]#X?LC C^8['+/C&:V:**<I.3YGN.<G-\TMPHHHJ20HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+S_C
MQN/^N;?RJ>H+S_CQN/\ KFW\J / +C[@^M5JU[32+[6':*Q@,KH-S $# JW_
M ,(/XA_Z![?]]#_&O9P=6$:*39[>!JPC12DTCG:*Z+_A!_$/_0/;_OH?XT?\
M(/XA_P"@>W_?0_QKJ]M3_F7WG7[>E_,OO.=HKHO^$'\0_P#0/;_OH?XT?\(/
MXA_Z![?]]#_&CVU/^9?>'MZ7\R^\YVBNB_X0?Q#_ - ]O^^A_C1_P@_B'_H'
MM_WT/\:/;4_YE]X>WI?S+[SG:*Z+_A!_$/\ T#V_[Z'^-'_"#^(?^@>W_?0_
MQH]M3_F7WA[>E_,OO.=HKHO^$'\0_P#0/;_OH?XT?\(/XA_Z![?]]#_&CVU/
M^9?>'MZ7\R^\YVBNB_X0?Q#_ - ]O^^A_C1_P@_B'_H'M_WT/\:/;4_YE]X>
MWI?S+[SG:*Z+_A!_$/\ T#V_[Z'^-'_"#^(?^@>W_?0_QH]M3_F7WA[>E_,O
MO.=HKHO^$'\0_P#0/;_OH?XT?\(/XA_Z![?]]#_&CVU/^9?>'MZ7\R^\YVBN
MB_X0?Q#_ - ]O^^A_C1_P@_B'_H'M_WT/\:/;4_YE]X>WI?S+[SG:*Z+_A!_
M$/\ T#V_[Z'^-'_"#^(?^@>W_?0_QH]M3_F7WA[>E_,OO.=HKH?^$'\0_P#0
M/;_OH?XU#'X1UN65HDLF+KU&X<4>VI_S+[P]O2_F7WF)171?\(/XA_Z![?\
M?0_QH_X0?Q#_ - ]O^^A_C1[:G_,OO#V]+^9?><[171?\(/XA_Z![?\ ?0_Q
MH_X0?Q#_ - ]O^^A_C1[:G_,OO#V]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0
M?Q#_ - ]O^^A_C1[:G_,OO#V]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_
M - ]O^^A_C1[:G_,OO#V]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_ - ]
MO^^A_C1[:G_,OO#V]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_ - ]O^^A
M_C1[:G_,OO#V]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_ - ]O^^A_C1[
M:G_,OO#V]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_ - ]O^^A_C1[:G_,
MOO#V]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_ - ]O^^A_C1[:G_,OO#V
M]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_ - ]O^^A_C1[:G_,OO#V]+^9
M?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_ - ]O^^A_C1[:G_,OO#V]+^9?><[
M16W_ ,(CK?VC[/\ 8F\S&=NX5/\ \(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO
M.=HKHO\ A!_$/_0/;_OH?XT?\(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HK
MHO\ A!_$/_0/;_OH?XT?\(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\
MA!_$/_0/;_OH?XT?\(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\ A!_$
M/_0/;_OH?XT?\(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\ A!_$/_0/
M;_OH?XT?\(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\ A!_$/_0/;_OH
M?XT?\(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\ A!_$/_0/;_OH?XT?
M\(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\ A!_$/_0/;_OH?XT?\(/X
MA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\ A!_$/_0/;_OH?XT?\(/XA_Z!
M[?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\ A!_$/_0/;_OH?XT?\(/XA_Z![?\
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MA"\7=FWH>DPZ/IL=M$HR!\Q]36E117A2DY.[/GY2<G=F3KW_ ![Q?[]:4/\
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MY!\9[/3K6UT^YMTBAU 3#R_+^5CR/2O2_#DEQ+X<L'NL^>T(+Y]: -2BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"\_X\;C_KFW\JGJ
M"\_X\;C_ *YM_*@#SOX;?\A:\_ZXC^=>EUYI\-O^0M>?]<1_.O2Z "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#T-8VF_\ (6NO
MK6R>AK&TW_D+77UH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#%/_ ",G_ :VJQ3_ ,C)_P !K:H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L75O\ C_M?]ZMJL75O^/\
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MN:M/J<D3;D#LP /T)->E@!5"J  .@%+10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %07G_ !XW'_7-OY5/4%Y_QXW'_7-OY4 >=_#;
M_D+7G_7$?SKTNO-/AM_R%KS_ *XC^=>ET %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% "'H:QM-_Y"UU]:V3T-8VF_P#(6NOK0!M4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &*?
M^1D_X#6U6*?^1D_X#6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %8NK?\?]K_ +U;58NK?\?]K_O4 ;5%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!DZ]_P >\7^_6E#_ *E/
MI6;KW_'O%_OUI0_ZE/I0!)1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 51U?_ )!DW^[5ZJ.K_P#(,F_W: ':5_R#8?I5RJ>E?\@V
M'Z5<H **** "BBN0\?:W?Z)9V<EA*(VDD96)4'( JZ=-U)**ZFE*FZDU!=3K
MZ*\5_P"$]\0_\_@_[]BNC\$^*=6U?Q +6]N!)#Y3-C8!R,5TSP-2$7)M:'34
MP%2$7)M:'H]%%%<9Q!1110 45#/=VUM_KYXX_P#?8"H%U?37.$OK=CZ"04U%
MOH4HR>J1=HI%8,H92"#T(JO<:A9VK!;BZAB8] [@4)-["2;T19HJA_;6E_\
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M3_\ KJW\A73@_P"/$ZL%_'B>85U_PW_Y&L?]<'_I7(5U_P -_P#D:Q_UP?\
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MQ6EVMSI\-UPJR('Y/2O$_$NN'7M2-UY1C3&%!ZUU]_J\]G\/;54<AY1Y8;N
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MX-Z7"BBBN0XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_/2W_P"_(H_X6/X@_P">EO\ ]^17)44?5Z7\J#ZM1_E1UO\ PL?Q!_STM_\
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MS<?<'UJM7N8'^"CW\!_ 04445V':%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7IG@#PP8@-4NE^8C]VI'3WKFO!OAQM9U%995/V
M6(Y8^I[5[+%$D,2QQJ%11@ 5YN.Q%E[./S/+Q^)Y5[./S'T445Y)XX4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!BG_D9/^ UM5BG_ )&3
M_@-;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJC"_4ZS1=)AT?3H[:)0"!\Q]36C117@2DY.[/G92<G=A1112$%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 8I_Y&3_ (#6U6*?^1D_X#6U
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8NK?
M\?\ :_[U;58NK?\ '_:_[U &U1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 9.O?\>\7^_6E#_J4^E9NO?\>\7^_6E#_J4^E
M$E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'5_^
M09-_NU>JCJ__ "#)O]V@!VE?\@V'Z5<JGI7_ "#8?I5R@ HHHH *\_\ BG_R
M#]/_ .NK?R%>@5Y_\4_^0?I__75OY"NG!_QXG5@OX\3S"NO^&_\ R-8_ZX/_
M $KD*Z_X;_\ (UC_ *X/_2O8Q/\ !EZ'M8K^#+T/8****^>/FPKS;XY?\DWE
M_P"OJ+^9KTFO-OCE_P DWE_Z^HOYF@"GH7Q=\.V.@:?:2P:B9(;=(V*V^1D
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MQ]A^%>ZUXO\ %_3;#2;W1[_342UOFG"D083(R.PKUW2Y99]+MI9QB5D!8>]
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M.34)@2PAERS =3BN)\8:WJOB7QQ#X2TBX:WMU4-/*O7OD?I67X9TO3]&^/\
M)9:6 +5+1MN'W<E!GFL]]$O;CXN:A;1:K_9T\@WQR.F=P)/ YH ZG6OAS<^'
MM*EU70]8N_MULN_#G(D^N2:Z+P]XF;Q-X!N+Q\+<QQ,DH4]&Y_PK(N/A_P")
M#;N)_&($1'S%H<#'YU=\,>%HO"W@W5;>+4XM0$RES)'C X/H30!PGP_\/:AX
MNBO(KS5+B+3X)WVHC9+$L>_6KFHV=Y\-?&.F_8]0GGT^[?8T4ASSBMSX*_\
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M8 2&,(,>PH M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !4%Y_QXW'_ %S;^53U!>?\>-Q_US;^5 '@ZV-U??):V\DS
M+R0BYP*=_P (]K'_ $#;G_OV:[+X;?\ (6O/^N(_G7I==E'&2I0Y$CMH8V5*
M'(D>!?\ "/:Q_P! VY_[]FC_ (1[6/\ H&W/_?LU[[16O]HS_E-O[3G_ "G@
M7_"/:Q_T#;G_ +]FC_A'M8_Z!MS_ -^S7OM%']HS_E#^TY_RG@7_  CVL?\
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M@ HHHH **** "L75O^/^U_WJVJQ=6_X_[7_>H VJ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)U[_CWB_WZTH?]2GTK-U[_
M (]XO]^M*'_4I]* )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "J.K_\@R;_ ':O51U?_D&3?[M #M*_Y!L/TJY5/2O^0;#]*N4
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M?X4^'FF>&+LWZO)<:@RD-/*V3SUQ1XO\!V_B6>*^@G:TU*'[EPAP?H<5V%%
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MQ[Q?[]:4/^I3Z5FZ]_Q[Q?[]:4/^I3Z4 24444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %4=7_ .09-_NU>JCJ_P#R#)O]V@!VE?\
M(-A^E7*IZ5_R#8?I5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:7VO>>F,5=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "L75O\ C_M?]ZMJJ5W8"YN(I=Y&PYQ0!=HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** ,G7O^/>+_?K2A_U*?2H+^S%[
M$J[BNTYJRB[$"^@H =1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 51U?_ )!DW^[5ZH+NW^U6KPYQN&,T 1:5_P @V'Z5<J&U@^S6
MR19SM'6IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BN$:2UEC7[S(0/J111
M0!R'@WPWJ.B7]Q->)&$>/:NU\\YKM*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g2g5bnvu5o20000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2g5bnvu5o20000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /H!YX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TK,LKR:;4)XG8%$/
MQ6D>AK&TW_D+77UH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#,-Y-_;7V?</+VYQBM.L4_\ (R?\!K:H **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>S6WP8\&VLHD2TN"P[/.2*S_  5\++[PMXLDUB?4K>>-RY\M$8'G/K]:]1H
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MAMC&<DR*3GGVH M?#3_D1K'Z?T%</<*?$7QUA;.Z/30 R]AC(_K7I7AC0YM
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MKL,,T2N":WM,^'WCNTU2UN+KQJ9[>*56DBR_SJ#R* /5:*** "BBB@ HHHH
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MK&&(IS3:>VYT3PM6#BI+66Q<HKB(O'-Y<N?L^E&5 >64DX_2NTB9GB1V7:6
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M1110 4444 %%%% !1110 4444 %%%% !1110 AZ&L;3?^0M=?6MD]#6-IO\
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MY=+G!AZ5&CAGB*D>9WLD4=&\;7$MZEOJ**-QQN"[<&NLU35K?2[(W,IR"/E
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MF)A%EKP%9>7ILEV<;I&*_E65\0/^0G;_ .X*Z?PB OA^' QR:Y?X@\ZE /\
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MLS8Z;#;L<LJ\_6KM%%=$8J*21RRDY2<GU"BBBF2%%%% !1110 4444 %%%%
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M?V[+^3\?^ ']CK^?\#UG[5;_ //>+_OL4?:K?_GO%_WV*\FHH_MV7\GX_P#
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M*=*K>2?GL34445VGG!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %07G_'C<?]<V_E4]07G_ !XW'_7-OY4 >*:9_KG_ -VM
M2LO3/]<_^[6I7R6;_P"]/Y'TV6?[NOF%%%%>8>@%%%% !1110 4444 %%%%
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M=''1@>AIEW=V]A:275U*L4$0W.[=%% $]%5-.U2QU>T6ZT^Y2X@;I(AX-6Z
M"BBB@ HHHH **** "BBB@ HHHH **K7U_:Z;:/=7LZ00)]YWZ"BPU"TU2T2Z
ML9TG@?[LB=#0!9HHK-N?$&DV>IPZ;<7\4=Y-_JX6/S-]* -*BL^;7-,M]3CT
MV6]B2]D&4A)^8BFWVOZ3IMY#9WE]%#<3'$<;'EOI0!I44=110 A 92",@C!%
M5HM-L8)1+%:PI(.C*@!JU12<4]T4I22LF%%%8\_BO0K;5_[)FU.!+\D#R"?F
MYZ4R38HHHH **** "BBB@ HHHH **Y_4/''AC2;QK2_UFUM[A?O1N3D?I59?
MB1X.=@J^(+,D]!N/^% '4U4DTNPF;=)9PNWJ4%2VMW;WMNL]M*LL3?=93P:F
MI.*>Z*C*4=G8K0Z?9V[;H;:*-AW50*LT44));"<G)W;"BBD=UC1G<X51DD]A
M3$+16=I>O:7K0D.FWL5R(FVOY9^Z:L)?VDEXUHDZ-<*,M&#R* +-%9LNOZ3!
MJRZ5+?1+?L-RP$_,16E0 4444 %%9L?B#29=7;24OHFOU&XP _,!6E0 445'
M//%:V\EQ.XCBC4N[GHH'4T 1K8VJ3^>MO&)3_&%YJQ5'2M8T_7+(7NF7<=U;
M%BHDC/&1U%7J226PW)O<**SM0U[2M*N8+:_OHK>:X.(D<\O]*;J7B+2-(FM8
M=0OX;>2Z.V!7/,A]OS%,1IT444 %%9MEK^DZC>S6=G?137$)Q)&IY7ZU:^WV
MOVW['YZ?:,9\O/.* +%%%% !1110 5!<6=M=8^T01RXZ;USBIZ*32>C&FT[H
M0 *H4#  P *6BBF(**** "BBHYIH[>%IIG"1H,LQZ 4 245RI^)/@T'!\0V>
M1_M'_"D_X67X,_Z&*R_[Z/\ A0!U=%8VD>*]"UZ5XM*U."[=!EEC)XK9H **
M*S=7U_2=!A675;Z*TC8X#2'@T :5%<K_ ,+*\&?]##9_]]'_  K7TKQ%I&N*
M6TS4(;H#D^6: -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@O/^/&X_ZYM_*I
MZ@O/^/&X_P"N;?RH \4TS_7/_NUJ5EZ9_KG_ -VM2ODLW_WI_(^FRS_=U\PH
MHHKS#T HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBMGP_I!U*[#2 ^2G)/K[5I1I2JS4([LBK4C3@YRV1M>%=&V+]MF7YC]P&
MNKIJ(L:*BC"@8%.K[3#8>.'IJ$3Y/$5Y5JCG(****Z# **** "BBB@ HHHH
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ML/\ A"#_ ,_O_CE?.YC@:];$.<(W6G8]W XRC2HJ,W9G(45U_P#PA!_Y_?\
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M_/[_ ..4?\(0?^?W_P <H_LO%?R_B@_M'#?S?F<A177_ /"$'_G]_P#'*/\
MA"#_ ,_O_CE']EXK^7\4']HX;^;\SD**Z_\ X0@_\_O_ (Y1_P (0?\ G]_\
M<H_LO%?R_B@_M'#?S?F<A177_P#"$'_G]_\ '*/^$(/_ #^_^.4?V7BOY?Q0
M?VCAOYOS.0HKK_\ A"#_ ,_O_CE'_"$'_G]_\<H_LO%?R_B@_M'#?S?F<A17
M7_\ "$'_ )_?_'*/^$(/_/[_ ..4?V7BOY?Q0?VCAOYOS.0HKK_^$(/_ #^_
M^.4?\(0?^?W_ ,<H_LO%?R_B@_M'#?S?F<A177_\(0?^?W_QRC_A"#_S^_\
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MS?F<A177_P#"$'_G]_\ '*/^$(/_ #^_^.4?V7BOY?Q0?VCAOYOS.0HKK_\
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MX,_Z%ZT_\>_QK2TSPGH.C.'T[2X+=AW0'^M $^@6;Z?H5G:R'+QQ@&M*BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *@O/^/&X_ZYM_*IZ@O/^/&X_P"N;?RH \[^
M&W_(6O/^N(_G7I=>:?#;_D+7G_7$?SKTN@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH 0]#6-IO_ "%KKZULGH:QM-_Y"UU]: -J
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q3
M_P C)_P&MJL4_P#(R?\  :VJ "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K%U;_ (_[7_>K:K%U;_C_ +7_ 'J -JBBB@ HHHH
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M?_GO%_WV*.>/<.678EHJ+[5;_P#/>+_OL4?:K?\ Y[Q?]]BCGCW#EEV,H_\
M(R?\!K:K!,\/_"1;O-CV[>NX8K9^U6__ #WB_P"^Q1SQ[ARR[$M%1?:K?_GO
M%_WV*/M5N3@3Q?\ ?8HYX]PY9=B6BBBJ)"BBB@ HHHH **** "BBB@ HHHH
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MHP>=9W$<\9_B0Y% %FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"7O9F6/=V .?ZUF?'S_CRTO_ *[C^1H ] \2_P#)-;__ +!Q_P#0*Y#X)?\
M(@2_[\G\S77^)?\ DFM__P!@X_\ H%<A\$O^1 E_WY/YF@# \!^%M)\1^+_$
M8U.V\[RY25^;&/FKN[SX2^%;FV:.*T>&3'RR)(05-<Y\)_\ D</$_P#UT/\
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M\+Q70@>:Z&6VB3R#L/\ P+I6MXFNH;SP)JMQ;N'B>SD*L#U^4UE>,?#>D)X
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MH **** "H+S_ (\;C_KFW\JGJ"\_X\;C_KFW\J /%-,_US_[M:E9>F?ZY_\
M=K4KY+-_]Z?R/ILL_P!W7S"BBBO,/0"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "G(C2.$0$L3@ 4VNM\*Z-N;[;.O ^X#71A</+$
M5%")AB*\:%-S9L>'])73K0.Z_OG&6]JV:**^TI4HTH*$=D?*5:DJDW.6["BB
MBM#,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%U;_ (_[7_>K
M:K%U;_C_ +7_ 'J -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH R=>_X]XO]^M*'_4I]*S=>_X]XO\ ?K2A_P!2GTH DHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZO\ \@R;
M_=J]5'5_^09-_NT .TK_ )!L/TJY5/2O^0;#]*N4 %%%% !7*^-_^/2T_P"N
MC?RKJJY7QO\ \>EI_P!=&_E7#F7^ZS_KJ=F7_P"\Q_KH<77:>"/^/6[_ -]?
MY5Q==IX(_P"/6[_WU_E7S^4_[U'Y_D>WF?\ NTOE^9U5%%%?7'S 5X[\:_\
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M!K#T]?B>Y\OCL4Z]339;!1117><04444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRC_A"/\ I]_\<KKZ*/[+PO\ +^+#^T<3_-^".0_X0C_I]_\ '*/^$(_Z??\
MQRNOHH_LO"_R_BP_M'$_S?@CD/\ A"/^GW_QRC_A"/\ I]_\<KKZ*/[+PO\
M+^+#^T<3_-^".0_X0C_I]_\ '*/^$(_Z??\ QRNOHH_LO"_R_BP_M'$_S?@C
MD/\ A"/^GW_QRC_A"/\ I]_\<KKZ*/[+PO\ +^+#^T<3_-^".0_X0C_I]_\
M'*/^$(_Z??\ QRNOHH_LO"_R_BP_M'$_S?@CD/\ A"/^GW_QRC_A"/\ I]_\
M<KKZ*/[+PO\ +^+#^T<3_-^".0_X0C_I]_\ '*/^$(_Z??\ QRNOHH_LO"_R
M_BP_M'$_S?@CD/\ A"/^GW_QRC_A"/\ I]_\<KKZ*/[+PO\ +^+#^T<3_-^"
M.0_X0CC_ (_?_'*I6WA?[1=RP?:<>7WV]:[L]#6-IO\ R%KKZT?V7A?Y?Q8?
MVCB?YOP1E?\ "$?]/O\ XY1_PA'_ $^_^.5U]%']EX7^7\6']HXG^;\$<A_P
MA'_3[_XY1_PA'_3[_P".5U]%']EX7^7\6']HXG^;\$<A_P (1_T^_P#CE'_"
M$?\ 3[_XY77T4?V7A?Y?Q8?VCB?YOP1R'_"$?]/O_CE'_"$?]/O_ (Y77T4?
MV7A?Y?Q8?VCB?YOP1R'_  A'_3[_ ..4?\(1_P!/O_CE=?11_9>%_E_%A_:.
M)_F_!'(?\(1_T^_^.4?\(1_T^_\ CE=?11_9>%_E_%A_:.)_F_!'(?\ "$?]
M/O\ XY1_PA'_ $^_^.5U]%']EX7^7\6']HXG^;\$<A_PA'_3[_XY1_PA'_3[
M_P".5U]%']EX7^7\6']HXG^;\$<A_P (1_T^_P#CE'_"$?\ 3[_XY77T4?V7
MA?Y?Q8?VCB?YOP1R'_"$?]/O_CE'_"$?]/O_ (Y77T4?V7A?Y?Q8?VCB?YOP
M1R'_  A'_3[_ ..5JZ/X>BTJ1I#)YLAZ'&,5M45I3R_#TY*<8ZHBIC:]2/+*
M6ABG_D9/^ UM5BG_ )&3_@-;5=AR!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5BZM_Q_P!K_O5M5BZM_P ?]K_O4 ;5%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!DZ]_Q[Q?[]
M:4/^I3Z5FZ]_Q[Q?[]:4/^I3Z4 24444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %4=7_Y!DW^[5ZJ.K_\ (,F_W: ':5_R#8?I5RJ>
ME?\ (-A^E7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** ,G7O^/>+_ 'ZTH?\ 4I]*S=>_X]XO]^M*'_4I]* )**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "J.K_\ (,F_W:O51U?_ )!D
MW^[0 [2O^0;#]*N53TK_ )!L/TJY0 4444 %%-9U099@OU.*;]HA_P">T?\
MWT* )**C^T0_\]H_^^A1]HA_Y[1_]]"@"2BH_M$/_/:/_OH4?:(?^>T?_?0H
M DHJ/[1#_P ]H_\ OH4?:(?^>T?_ 'T* )**C^T0_P#/:/\ [Z%'VB'_ )[1
M_P#?0H DHJ/[1#_SVC_[Z%'VB'_GM'_WT* )**C^T0_\]H_^^A1]HA_Y[1_]
M]"@"2BH_M$/_ #VC_P"^A1]HA_Y[1_\ ?0H DHJ/[1#_ ,]H_P#OH4?:(?\
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M**C^T0_\]H_^^A1]HA_Y[1_]]"@"2BH_M$/_ #VC_P"^A1]HA_Y[1_\ ?0H
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M**C^T0_\]H_^^A1]HA_Y[1_]]"@"2BH_M$/_ #VC_P"^A1]HA_Y[1_\ ?0H
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M/_OH4 245']HA_Y[1_\ ?0H^T0_\]H_^^A0!)14?VB'_ )[1_P#?0H^T0_\
M/:/_ +Z% $E%1_:(?^>T?_?0H^T0_P#/:/\ [Z% $E%1_:(?^>T?_?0H^T0_
M\]H_^^A0!)14?VB'_GM'_P!]"C[1#_SVC_[Z% $E%1_:(?\ GM'_ -]"C[1#
M_P ]H_\ OH4 245']HA_Y[1_]]"C[1#_ ,]H_P#OH4 245']HA_Y[1_]]"C[
M1#_SVC_[Z% $E%1_:(?^>T?_ 'T*/M$/_/:/_OH4 25BZM_Q_P!K_O5K?:(?
M^>T?_?0K&U::(W]KB5#\W]X4 ;M%1_:(?^>T?_?0H^T0_P#/:/\ [Z% $E%1
M_:(?^>T?_?0H^T0_\]H_^^A0!)14?VB'_GM'_P!]"C[1#_SVC_[Z% $E%1_:
M(?\ GM'_ -]"C[1#_P ]H_\ OH4 245']HA_Y[1_]]"C[1#_ ,]H_P#OH4 2
M45']HA_Y[1_]]"C[1#_SVC_[Z% $E%1_:(?^>T?_ 'T*/M$/_/:/_OH4 245
M']HA_P">T?\ WT*/M$/_ #VC_P"^A0!)14?VB'_GM'_WT*/M$/\ SVC_ .^A
M0!)14?VB'_GM'_WT*/M$/_/:/_OH4 245']HA_Y[1_\ ?0H^T0_\]H_^^A0!
MFZ]_Q[Q?[]:4/^I3Z5DZ[-$;>+$J'Y_[PK2AGA\E/WL?3^\* +%%1_:(?^>T
M?_?0H^T0_P#/:/\ [Z% $E%1_:(?^>T?_?0H^T0_\]H_^^A0!)14?VB'_GM'
M_P!]"C[1#_SVC_[Z% $E%1_:(?\ GM'_ -]"C[1#_P ]H_\ OH4 245']HA_
MY[1_]]"C[1#_ ,]H_P#OH4 245']HA_Y[1_]]"C[1#_SVC_[Z% $E%1_:(?^
M>T?_ 'T*/M$/_/:/_OH4 245']HA_P">T?\ WT*/M$/_ #VC_P"^A0!)14?V
MB'_GM'_WT*/M$/\ SVC_ .^A0!)14?VB'_GM'_WT*/M$/_/:/_OH4 251U?_
M )!DW^[5K[1#_P ]H_\ OH51U:>$Z;,!*A^7^\* )M*_Y!L/TJY5#298VT^%
M0ZDXZ U?H **** *M]IMGJ48CO(!*HZ DC^59_\ PB>A?] Z/_OIO\:VJ* ,
M7_A$]"_Z!T?_ 'TW^-'_  B>A?\ 0.C_ .^F_P :VJ* ,7_A$]"_Z!T?_?3?
MXT?\(GH7_0.C_P"^F_QK:HH Q?\ A$]"_P"@='_WTW^-'_")Z%_T#H_^^F_Q
MK:HH Q?^$3T+_H'1_P#?3?XT?\(GH7_0.C_[Z;_&MJB@#%_X1/0O^@='_P!]
M-_C1_P (GH7_ $#H_P#OIO\ &MJB@#%_X1/0O^@='_WTW^-'_")Z%_T#H_\
MOIO\:VJ* ,7_ (1/0O\ H'1_]]-_C1_PB>A?] Z/_OIO\:VJ* ,7_A$]"_Z!
MT?\ WTW^-'_")Z%_T#H_^^F_QK:HH Q?^$3T+_H'1_\ ?3?XT?\ ")Z%_P!
MZ/\ [Z;_ !K:HH Q?^$3T+_H'1_]]-_C1_PB>A?] Z/_ +Z;_&MJB@#%_P"$
M3T+_ *!T?_?3?XT?\(GH7_0.C_[Z;_&MJB@#%_X1/0O^@='_ -]-_C1_PB>A
M?] Z/_OIO\:VJ* ,7_A$]"_Z!T?_ 'TW^-'_  B>A?\ 0.C_ .^F_P :VJ*
M,7_A$]"_Z!T?_?3?XT?\(GH7_0.C_P"^F_QK:HH Q?\ A$]"_P"@='_WTW^-
M'_")Z%_T#H_^^F_QK:HH Q?^$3T+_H'1_P#?3?XT?\(GH7_0.C_[Z;_&MJB@
M#%_X1/0O^@='_P!]-_C1_P (GH7_ $#H_P#OIO\ &MJB@#%_X1/0O^@='_WT
MW^-'_")Z%_T#H_\ OIO\:VJ* ,7_ (1/0O\ H'1_]]-_C1_PB>A?] Z/_OIO
M\:VJ* ,7_A$]"_Z!T?\ WTW^-'_")Z%_T#H_^^F_QK:HH Q?^$3T+_H'1_\
M?3?XT?\ ")Z%_P! Z/\ [Z;_ !K:HH Q?^$3T+_H'1_]]-_C1_PB>A?] Z/_
M +Z;_&MJB@#%_P"$3T+_ *!T?_?3?XT?\(GH7_0.C_[Z;_&MJB@#%_X1/0O^
M@='_ -]-_C1_PB>A?] Z/_OIO\:VJ* ,7_A$]"_Z!T?_ 'TW^-'_  B>A?\
M0.C_ .^F_P :VJ* ,7_A$]"_Z!T?_?3?XT?\(GH7_0.C_P"^F_QK:HH Q?\
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M_OIO\:/^$3T+_H'1_P#?3?XUM44 8O\ PB>A?] Z/_OIO\:/^$3T+_H'1_\
M?3?XUM44 8O_  B>A?\ 0.C_ .^F_P :/^$3T+_H'1_]]-_C6U10!B_\(GH7
M_0.C_P"^F_QH_P"$3T+_ *!T?_?3?XUM44 8O_")Z%_T#H_^^F_QH_X1/0O^
M@='_ -]-_C6U10!B_P#")Z%_T#H_^^F_QH_X1/0O^@='_P!]-_C6U10!B_\
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M +Z;_&C_ (1/0O\ H'1_]]-_C6U10!B_\(GH7_0.C_[Z;_&C_A$]"_Z!T?\
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MGH7_ $#H_P#OIO\ &C_A$]"_Z!T?_?3?XUM44 8O_")Z%_T#H_\ OIO\:/\
MA$]"_P"@='_WTW^-;5% &+_PB>A?] Z/_OIO\:/^$3T+_H'1_P#?3?XUM44
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M +Z;_&C_ (1/0O\ H'1_]]-_C6U10!B_\(GH7_0.C_[Z;_&C_A$]"_Z!T?\
MWTW^-;5% &+_ ,(GH7_0.C_[Z;_&C_A$]"_Z!T?_ 'TW^-;5% &+_P (GH7_
M $#H_P#OIO\ &C_A$]"_Z!T?_?3?XUM44 8O_")Z%_T#H_\ OIO\:/\ A$]"
M_P"@='_WTW^-;5% &+_PB>A?] Z/_OIO\:/^$3T+_H'1_P#?3?XUM44 8O\
MPB>A?] Z/_OIO\:/^$3T+_H'1_\ ?3?XUM44 8O_  B>A?\ 0.C_ .^F_P :
M/^$3T+_H'1_]]-_C6U10!R>L^&M'@@C,5BBDM@_,W^-7XO"FAF)2=/CR1_>;
M_&I]>_X]XO\ ?K2A_P!2GTH R?\ A$]"_P"@='_WTW^-'_")Z%_T#H_^^F_Q
MK:HH Q?^$3T+_H'1_P#?3?XT?\(GH7_0.C_[Z;_&MJB@#%_X1/0O^@='_P!]
M-_C1_P (GH7_ $#H_P#OIO\ &MJB@#%_X1/0O^@='_WTW^-'_")Z%_T#H_\
MOIO\:VJ* ,7_ (1/0O\ H'1_]]-_C1_PB>A?] Z/_OIO\:VJ* ,7_A$]"_Z!
MT?\ WTW^-'_")Z%_T#H_^^F_QK:HH Q?^$3T+_H'1_\ ?3?XT?\ ")Z%_P!
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M)/B:Q1]'^W&*!=KS0-@M[G)H ^E:X'XI^+=4\):+%=:6T2RLV#YB;AU%>?\
M@#XIZS;Z_'H_B*62997\O?*?G5N@_"NC^/!#>%[9@<@N"#^(H ZWX<^(;_Q-
MX534-1,9N&D*DQIM&..U==7FGPGO(M/^&9NYFQ'$[,3^ KSS4_B-XS\7ZS+;
M>&5N8D4D(EN<,1[\XH ^CJ*^<=.^(OC3PAJT-OXE%Q)&Q^9;DY;'<CFO4?B'
MXAN8?AC+K&D74EO*XB9)8SA@&(XH [VBOF+0O'WCW5;233--FNKZ[8[O,W9=
M1[&I-*^)?B_PKX@^S^()[J=5?$T-PV64>U 'TS17SCK?B_XBZO"^LV$=[9Z6
MI.'A;"X]^:[CX0^/[[Q,MSIVIL9+BW4,)2>6R?\ ZU 'JU%>2_%'XF76@72Z
M-HX_TMQ\\G]WV'O7 OKGQ3TR :K=2:E]CQNS(XV8_.@#Z8HK@_AIX]_X3+3)
M%N55+VWP) O0^A_2O,_&_CWQ#H?Q FBM]3NOLD9XMU?Y3U[4 ?1%%?-.J>)?
MB==6AUI3?VFGD;MT380#\\UW/PL^(&I>)8KK3;]C)=QH6BDS\QP.] '1^/?B
M+;^#_+MEA,UW*1M&>![UU6A7LFI:%97LN/,FB#M@=S7RMX[3Q,OB&3^WOM6\
MRM]G\Y@?ESQC\,5ZI\(X_&JW8;63??V28%^S^:P*8SV_"@#V6BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@#)U[_CWB_P!^M*'_ %*?2LW7O^/>+_?K2A_U*?2@"2BBB@ HHHH
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M'XFO+_%VDZE+\5Q/'I]T\/FJ?,6%BO4]\4 >Z>(8(AX1O8A&OEB#&W'%>(_
M\8\<78'9)*]TU]'D\,WB(K,YAP% R37BWP9TO4+/QI=R75C<P1E),-)$R@_B
M10!%\=/^1IL?HO\ 2O:?"/\ R*.E?]>Z_P J\N^-GA75-1NK74["!IT0894&
M6' ["IOA+J_BNYO!9:M!-'801!(A) 4(Q[D<T >RT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5!>?\>-Q_P!<V_E4]07G
M_'C<?]<V_E0!YW\-O^0M>?\ 7$?SKTNO-/AM_P A:\_ZXC^=>ET %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'H:QM-_P"0M=?6
MMD]#6-IO_(6NOK0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% &*?\ D9/^ UM5BG_D9/\ @-;5 !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5BZM_Q_VO^]6U6+JW_'_:_P"]
M0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M &3KW_'O%_OUI0_ZE/I6;KW_ ![Q?[]:4/\ J4^E $E%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !5'5_^09-_NU>JCJ__(,F_P!V
M@!VE?\@V'Z5<JGI7_(-A^E7* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#P3X\6MQ/JMF88)9 %YV(3V]J]3^'"/'\.]"2165A:J"K#!'6NG*J>J@_4
M4H  P!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<?\ \+-\,?\ /U+_ -^6H_X6;X8_Y^I?^_+4?5:_\C^X/K=#^=?>=A17'_\
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M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J.K_\
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MWJ9U"\+);%L[CTQZ"LJ'/4M6K.T8[&V(]G3O1HQO*6YT7PDLIH[*[NG^6-G
M4'OQUKTNLI=/&E>'WM-.0J\<9$>T<YKRV6;XD><^P:GMW'&$'3\JR</K=251
M22]36,_J=*--Q;]#O_B'_P B3?\ T7^8KE?A++'';W>^15^;^)L>E3WK:PWP
MIOSKGG?;/,_Y;##;<C%<-X:\)ZCXC25K*>.,1G!WL1_*NJA2C]6G3G*ROO\
M<<M>M+ZU"I"-W;;[ST;XD76DMH3HS0O=EAMQR:P_A$D_VJ^9<^3A=WZU!#\)
M]6>0?:;R'9GG:Q)_45Z5X=\/6GAW3Q;6XRQY=SU8UE5JT:6'=&$N9LTI4JU7
M$JM./*D>-7-S#9_$FYN)W"1)=L68]J]77Q]X9"C_ (FL73^ZW^%>1ZE8IJ7Q
M!O+.1V19;I@67J*[H?"#2R ?[2N^?]E:WQ4<.U#VK:=NAAA)8A.?L4FK]3J[
M'Q?H.I72VUIJ$<LS=% /^%<%\6-3D>[M]-5L(OS,/7-=)HGPVL-$U..^AOKB
M1T& KA<5ROQ8LY(M7M[TK\D@"@_05AA(T%B5[-W5NO<Z,7*N\*_:*SOT['7^
M!?#=E8:#;731(]Q,@<N1R/:N@U&UTW48'M[SR74C;AF&169X+U&WU'PO:+"X
M+Q1!''H:XO6/AMK=_JUS=0WD"QR/E07.16/+[2O+VL^5HVYO9T(^RAS)G9:-
MX5T'1[OS[/8TW."S@D9]*Z6OGSPL)H?%T$#R,3'*4/)QD'%?0=3CJ,J<US2Y
MKE8"M&K!\L>6P4445Q'<%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %0W;^7:R,.RFIJBN4\RVD7U4TUN)['(V5THB9FZD5AZK*&9L4YYF
MMW>(\%3@UE7MTO)9L5Z<(>]<\Z4]+&-K"AK4MW!&*S]/)WK[FI;Z=KH[%&$!
M_.M/0]%GN7$OED1+R6Q17E",&Y[$13>B-ZTT_:H9_P JV],D\B]AV\#<!57[
MHQV%3Z<AFU&%5[,":^.BVYJQVQ5MCO <@&EK"\6WUQIOAR:XMI"DJE0&%>4+
MXY\0L<+?2D_A7T]#"3K1YHL5;%0I2Y9(]THKP[_A-/$O_/Y-^E/M_B%KEO)F
M2<R@'HYK;^SJO1HQ_M"GV9[=17.>%?%4/B*U/ 2X3[Z"L'X@>(-2T>[@2RN7
MB5ADA>]<T,/.53V>S.B6(A&G[3='H-%<AX U>]U?3+B6]F:5UD !;TQ77UG4
MING-P?0TIS52*DNH4445!84444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%Y_P >
M-Q_US;^53U!>?\>-Q_US;^5 'SMJW^IC_P!ZLBM?5O\ 4Q_[U9%?2Y9_NZ^9
M\OFG^\OY!1117>>>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%2V\$ES<)#$I9W. !1>P)7-3PUH,_B#58[6,'R
M\_O&_NBOH33K"'3+"*T@4*D:XP*Q/!GAJ+P_I*!D'VJ09D;'?TKI:^:Q^*]M
M.T=D?49?A/80YI?$PHHHK@/0"BBB@ HHHH **** "BBB@ HHHH **** ,4_\
MC)_P&MJL4_\ (R?\!K:H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "L75O^/^U_WJVJQ=6_X_[7_>H VJ*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)U[_ (]XO]^M*'_4I]*S
M=>_X]XO]^M*'_4I]* )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "J.K_P#(,F_W:O51U?\ Y!DW^[0 [2O^0;#]*N53TK_D&P_2
MKE !1110 5YK\8?^09IG_79__017I5>:_&'_ )!FF?\ 79__ $$5V8#_ 'F/
M]=#CS#_=I_UU/(J[?X5?\CD/^O=_Z5Q%=O\ "K_D<A_U[O\ TKZ#&?P)^A\Y
M@_\ >(>I[A1117R9]>%<'\3[*ZO='B2UMY)F#C(C4D]:[RBM:-5TIJ:Z&5:D
MJM-P?4X3X865U9:-*EU;R0L7/$BD'K6WXSTD:OX;N80A:95W1X'.:Z"BJG7E
M*M[5;WN1##QC1]B]5:Q\Y6GAG5I[Z*!]/NE1GVEC&0!7T)I]JEGI\%NBA0B
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M+ZD\5[E7+BJ'L9V6QU8:O[:%WN%%%%<QT!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !4%Y_QXW'_7-OY5/4%Y_P >-Q_US;^5 'SMJW^I
MC_WJR*U]6_U,?^]617TN6?[NOF?+YI_O+^04445WGGA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7J_PV\(F-1J]Z
M@RP_=*?YUR?@?PP^O:JKR*?LL)W,<=3Z5[S#"D$*Q1*%1!A0.PKR,RQ?*O90
MWZGLY9A.9^VGMT'T445X1[X4444 %%%% !1110 4444 %%%% !1110 4444
M8I_Y&3_@-;58I_Y&3_@-;5 !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5BZM_Q_VO\ O5M5BZM_Q_VO^]0!M4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &3KW_ ![Q?[]:4/\
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M#0!8UGXH:/IE\UG:0S:E<+PR6V.#^-5+3XMZ8UVD&IZ==Z7O/#W)&/TS6GX
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M&03[U[3+JUKHGA:&_O'"0Q6Z$^_R]* -FBO+K?XC>)]85[K1/#:3V*DXDE+
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M[?0MT>0 _E7G5_#)I7B!Q(I#1S;@/QR**+7MJBZA63]E3?0^@K5!':Q(O15
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M?#_PDNCV*WMRN;J89Y'W17-B\2J%._7H=>#PSQ%3EZ=3H] T6WT+2XK6! "
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M !1110 4444 %%%% !1110 4444 %%%% !6+JW_'_:_[U;58NK?\?]K_ +U
M&U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M9.O?\>\7^_6E#_J4^E9NO?\ 'O%_OUI0_P"I3Z4 24444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %4=7_Y!DW^[5ZJ.K_\@R;_ ':
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M44 %%%% !1110 4444 %%%% &*?^1D_X#6U6*?\ D9/^ UM4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+JW_ !_VO^]6U6+J
MW_'_ &O^]0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &3KW_'O%_OUI0_ZE/I6;KW_'O%_OUI0_ZE/I0!)1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51U?\ Y!DW^[5ZJ.K_
M /(,F_W: ':5_P @V'Z5<JGI7_(-A^E7* "BBB@ KS7XP_\ (,TS_KL__H(K
MTJO-?C#_ ,@S3/\ KL__ *"*[,!_O,?ZZ''F'^[3_KJ>15ZY\'?^09JG_79/
MY&O(Z]<^#O\ R#-4_P"NR?R->UF7^[/Y?F>'EG^\Q^?Y'I=%%%?,GU 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!7G8[#T*%HPO<]+ 8BO7O*:5BU1117G'I!1110 4444 %%%% !1110 4444
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ME%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'5_\
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M62]^<(ZQ[EZXG2VMY)Y#A$&2:\7N;I_''C )+.D5E$W1W"C:.O6O8=4LVO\
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M )&3_@-;58I_Y&3_ (#6U0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %8NK?\?]K_O5M5BZM_Q_VO\ O4 ;5%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!DZ]_Q[Q?[]:4/^I3Z
M5FZ]_P >\7^_6E#_ *E/I0!)1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 51U?_D&3?[M7JHZO_R#)O\ =H =I7_(-A^E7*IZ5_R#
M8?I5R@ HHHH *Q]?\-:?XEAABU 2E86+)Y;[>36Q151G*#YHNS)G",URR5T<
M5_PJOPU_<NO^_P!_]:MW0/#6G^&H9HM/$H69@S^8^[D5L45I/$59KEE)M&<,
M-1@^:,4F%%%%8FP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %07G_'C<?]<V_E4]07G_ !XW'_7-OY4 >=_#
M;_D+7G_7$?SKTNO-/AM_R%KS_KB/YUZ70 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 (>AK&TW_D+77UK9/0UC:;_P A:Z^M &U1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8I_
MY&3_ (#6U6*?^1D_X#6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %8NK?\?\ :_[U;58NK?\ '_:_[U &U1110 4444 %%%%
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M1110 4444 %%%% !1110 5!>?\>-Q_US;^53U!>?\>-Q_P!<V_E0!YW\-O\
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M@YX]SHJ***DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_@-;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "H+S_CQN/^N;?RJ>H+S_ (\;C_KFW\J /G;5
MO]3'_O5D5KZM_J8_]ZLBOI<L_P!W7S/E\T_WE_(****[SSPHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "M#1M)N-9U**UMT+%B-Q'851C1I9%1
M2S'  KW/P#X671--%S,O^E3C))[#M7+C,2J%._7H=>#PKQ%2W1;F_HFCP:)I
M<=I H^4?,V.IJ#3?^0M=?6MD]#6-IO\ R%KKZU\M*3D[L^LC%17*MC:HHHI#
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%/_(R?
M\!K:K%/_ ",G_ :VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K%U;_C_M?]ZMJL75O^/^U_WJ -JBBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\7^_6E#_ *E/I6;KW_'O%_OUI0_ZE/I0!)1110 4444 %%%% !1110 4444
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M&/\ GQ;_ +^M7644?6:W\[^\/JM#^1?<<G_PK?PQ_P ^+?\ ?UJ/^%;^&/\
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M0 4444 %4=7_ .09-_NU>JCJ_P#R#)O]V@!VE?\ (-A^E7*IZ5_R#8?I5R@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *@O/^/&X_ZYM_*IZ@O/\ CQN/^N;?
MRH \[^&W_(6O/^N(_G7I=>:?#;_D+7G_ %Q'\Z]+H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** $/0UC:;_R%KKZULGH:QM-_P"0
MM=?6@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@0O_ ']_^M7EM%']GX;^7\P_M'$_S?D>I?\ "XG_ .@0O_?W_P"M1_PN)_\
MH$+_ -_?_K5Y;11_9^&_E_,/[1Q/\WY'J7_"XG_Z!"_]_?\ ZU'_  N)_P#H
M$+_W]_\ K5Y;11_9^&_E_,/[1Q/\WY'J7_"XG_Z!"_\ ?W_ZU'_"XG_Z!"_]
M_?\ ZU>6T4?V?AOY?S#^T<3_ #?D>I?\+B?_ *!"_P#?W_ZU'_"XG_Z!"_\
M?W_ZU>6T4?V?AOY?S#^T<3_-^1ZC_P +A?'_ ""%_P"_O_UJJV7Q/E2_=X]*
M#O*<!1)_]:O.*]#^&GAM;O4/[0NDRD7,:D=3ZUC7PN%HP<Y1_%FV'Q>+K5%"
M,OP1ZWI\\US8Q37$(AD==Q0-G%6: ,# Z"BOGF[L^C2L@HHHI#"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** ,4_P#(R?\  :VJQ3_R,G_
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MN[W-JBBBN([@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[3+BY\6"YMP\=O$6._V[5[A7%F$%&MH[G;ETW*CJK:A1117"=X4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_?K2A_U*?2@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ JCJ_\ R#)O]VKU4=7_ .09-_NT .TK_D&P_2KE4]*_Y!L/TJY0 444
M4 %07-E:WJJMU;Q3!3E1(@;'YU/133:U0FD]&9_]A:3_ - RT_[\K_A4MOI=
MA:2^;;6<$4F,;DC .*MT4W.3ZB4(K9!1114E!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!>?\ 'C<?]<V_
ME4]07G_'C<?]<V_E0!YW\-O^0M>?]<1_.O2Z\T^&W_(6O/\ KB/YUZ70 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>AK&TW_D+
M77UK9/0UC:;_ ,A:Z^M &U1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 8I_Y&3_@-;58I_Y&3_@-;5 !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5BZM_Q_VO\ O5M5BZM_Q_VO
M^]0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% &3KW_ ![Q?[]:4/\ J4^E9NO?\>\7^_6E#_J4^E $E%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5'5_\ D&3?[M7JHZO_ ,@R
M;_=H =I7_(-A^E7*IZ5_R#8?I5R@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MH+S_ (\;C_KFW\JGJ"\_X\;C_KFW\J /._AM_P A:\_ZXC^=>EUYI\-O^0M>
M?]<1_.O2Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!#T-8VF_\A:Z^M;)Z&L;3?^0M=?6@#:HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,4_\C)_P&MJL4_\ (R?\!K:H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L75O^/^U_
MWJVJQ=6_X_[7_>H VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#)U[_ (]XO]^M*'_4I]*S=>_X]XO]^M*'_4I]* )****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J.K_P#(,F_W
M:O51U?\ Y!DW^[0 [2O^0;#]*N53TK_D&P_2KE !1110!3U"ZN;6(-;6+W;'
MJJN%Q^=9O]LZO_T+L_\ W_2MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T+L__ '_2
MMZB@#!_MG5_^A=G_ ._Z4?VSJ_\ T+L__?\ 2MZB@#!_MG5_^A=G_P"_Z4?V
MSJ__ $+L_P#W_2MZB@#!_MG5_P#H79_^_P"E']LZO_T+L_\ W_2MZB@#!_MG
M5_\ H79_^_Z4?VSJ_P#T+L__ '_2MZB@#!_MG5_^A=G_ ._Z4?VSJ_\ T+L_
M_?\ 2MZB@#!_MG5_^A=G_P"_Z4?VSJ__ $+L_P#W_2MZB@#!_MG5_P#H79_^
M_P"E']LZO_T+L_\ W_2MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T+L__ '_2MZB@
M#!_MG5_^A=G_ ._Z4?VSJ_\ T+L__?\ 2MZB@#!_MG5_^A=G_P"_Z4?VSJ__
M $+L_P#W_2MZB@#!_MG5_P#H79_^_P"E']LZO_T+L_\ W_2MZB@#!_MG5_\
MH79_^_Z4?VSJ_P#T+L__ '_2MZB@#!_MG5_^A=G_ ._Z4?VSJ_\ T+L__?\
M2MZB@#!_MG5_^A=G_P"_Z4?VSJ__ $+L_P#W_2MZB@#!_MG5_P#H79_^_P"E
M']LZO_T+L_\ W_2MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T+L__ '_2MZB@#!_M
MG5_^A=G_ ._Z4?VSJ_\ T+L__?\ 2MZB@#!_MG5_^A=G_P"_Z4?VSJ__ $+L
M_P#W_2MZB@#!_MG5_P#H79_^_P"E']LZO_T+L_\ W_2MZB@#!_MG5_\ H79_
M^_Z4?VSJ_P#T+L__ '_2MZB@#!_MG5_^A=G_ ._Z4?VSJ_\ T+L__?\ 2MZB
M@#!_MG5_^A=G_P"_Z4?VSJ__ $+L_P#W_2MZB@#!_MG5_P#H79_^_P"E']LZ
MO_T+L_\ W_2MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T+L__ '_2MZB@#!_MG5_^
MA=G_ ._Z4?VSJ_\ T+L__?\ 2MZB@#!_MG5_^A=G_P"_Z4?VSJ__ $+L_P#W
M_2MZB@#!_MG5_P#H79_^_P"E']LZO_T+L_\ W_2MZB@#!_MG5_\ H79_^_Z4
M?VSJ_P#T+L__ '_2MZB@#!_MG5_^A=G_ ._Z4?VSJ_\ T+L__?\ 2MZB@#!_
MMG5_^A=G_P"_Z4?VSJ__ $+L_P#W_2MZB@#!_MG5_P#H79_^_P"E']LZO_T+
ML_\ W_2MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T+L__ '_2MZB@#!_MG5_^A=G_
M ._Z4?VSJ_\ T+L__?\ 2MZB@#!_MG5_^A=G_P"_Z4?VSJ__ $+L_P#W_2MZ
MB@#!_MG5_P#H79_^_P"E']LZO_T+L_\ W_2MZB@#!_MG5_\ H79_^_Z4?VSJ
M_P#T+L__ '_2MZB@#!_MG5_^A=G_ ._Z4?VSJ_\ T+L__?\ 2MZB@#!_MG5_
M^A=G_P"_Z4?VSJ__ $+L_P#W_2MZB@#!_MG5_P#H79_^_P"E']LZO_T+L_\
MW_2MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T+L__ '_2MZB@#!_MG5_^A=G_ ._Z
M4?VSJ_\ T+L__?\ 2MZB@#!_MG5_^A=G_P"_Z4?VSJ__ $+L_P#W_2MZB@#!
M_MG5_P#H79_^_P"E']LZO_T+L_\ W_2MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T
M+L__ '_2MZB@#!_MG5_^A=G_ ._Z4?VSJ_\ T+L__?\ 2MZB@#!_MG5_^A=G
M_P"_Z4?VSJ__ $+L_P#W_2MZB@#!_MG5_P#H79_^_P"E']LZO_T+L_\ W_2M
MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T+L__ '_2MZB@#!_MG5_^A=G_ ._Z4?VS
MJ_\ T+L__?\ 2MZB@#!_MG5_^A=G_P"_Z4?VSJ__ $+L_P#W_2MZB@#!_MG5
M_P#H79_^_P"E']LZO_T+L_\ W_2MZB@#!_MG5_\ H79_^_Z4?VSJ_P#T+L__
M '_2MZB@#!_MG5_^A=G_ ._Z4?VSJ_\ T+L__?\ 2MZB@#!_MG5_^A=G_P"_
MZ4?VSJ__ $+L_P#W_2MZB@#!_MG5_P#H79_^_P"E']LZO_T+L_\ W_2MZB@#
M!_MG5_\ H79_^_Z4?VSJ_P#T+L__ '_2MZB@#!_MG5_^A=G_ ._Z4?VSJ_\
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M '_2C^V=7_Z%V?\ [_I6]10!QAU74_[<W_V'+OV_<\Y:U?[9U?\ Z%V?_O\
MI4A_Y&3_ (#6U0!@_P!LZO\ ]"[/_P!_TH_MG5_^A=G_ ._Z5O44 8/]LZO_
M -"[/_W_ $H_MG5_^A=G_P"_Z5O44 8/]LZO_P!"[/\ ]_TH_MG5_P#H79_^
M_P"E;U% &#_;.K_]"[/_ -_TH_MG5_\ H79_^_Z5O44 8/\ ;.K_ /0NS_\
M?]*/[9U?_H79_P#O^E;U% &#_;.K_P#0NS_]_P!*/[9U?_H79_\ O^E;U% &
M#_;.K_\ 0NS_ /?]*/[9U?\ Z%V?_O\ I6]10!@_VSJ__0NS_P#?]*/[9U?_
M *%V?_O^E;U% &#_ &SJ_P#T+L__ '_2C^V=7_Z%V?\ [_I6]10!@_VSJ_\
MT+L__?\ 2C^V=7_Z%V?_ +_I6]10!@_VSJ__ $+L_P#W_2LO4M5U-[RW+Z'*
MA!X!F4YKLJQ=6_X_[7_>H C_ +9U?_H79_\ O^E']LZO_P!"[/\ ]_TK>HH
MP?[9U?\ Z%V?_O\ I1_;.K_]"[/_ -_TK>HH P?[9U?_ *%V?_O^E']LZO\
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ME#_J4^E &+_;.K_]"[/_ -_TH_MG5_\ H79_^_Z5O44 8/\ ;.K_ /0NS_\
M?]*/[9U?_H79_P#O^E;U% &#_;.K_P#0NS_]_P!*/[9U?_H79_\ O^E;U% &
M#_;.K_\ 0NS_ /?]*/[9U?\ Z%V?_O\ I6]10!@_VSJ__0NS_P#?]*/[9U?_
M *%V?_O^E;U% &#_ &SJ_P#T+L__ '_2C^V=7_Z%V?\ [_I6]10!@_VSJ_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+S_CQN/^
MN;?RJ>H+S_CQN/\ KFW\J /._AM_R%KS_KB/YUZ77FGPV_Y"UY_UQ'\Z]+H
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M[4?$?C*VO]4C6.Y:5<A4*CMV-?72PQ;1^[3I_=%?-WQ,4+\6(PH 'FIT'TH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\%])T^^2[O[^XU)T.5\\8_K7I4<:Q1K&BA548 ':G44 %%%% !1110 4444
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M (3+Q#_T%)OR'^%'_"9>(?\ H*3?D/\ "C^SJG=!_9E3NCW*BO#?^$R\0_\
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M^$R\0_\ 04F_(?X4?\)EXA_Z"DWY#_"C^SJG=!_9E3NCU@_\C)_P&MJO!_\
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MSFO"?$L=I'KUTMD<PA^*,(U6@Z4]D&#:K0=&>R+=O%=>+_$N6R0[98]@H_\
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M'8F,CWKIOAJ[/X;?<2=LQ ^F!45L/%4O:1NO4SK8>$:7M(W7J<9K7_)1I_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***D@A>XG2&-26<
M@ "@1:TK3Y-1O$C4?*"-Q]!7NNEV<5AIT-O"H5$7%<I8>'TT/1( P_TB1LN?
MRXKLX?\ 4I]*\+%XCVLK+9'@XS$>UG9;(DHHHKD.(**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *HZO_R#)O\ =J]5'5_^09-_NT .TK_D
M&P_2KE4]*_Y!L/TJY0 4444 %>?_ !3_ .0?I_\ UU;^0KT"O/\ XI_\@_3_
M /KJW\A73@_X\3JP7\>)YA7I_P +/^0?J/\ UU7^1KS"O3_A9_R#]1_ZZK_(
MUZF._@,];'_P'\CT"BBBO"/GPKC_ ![/JMG8Q76G7$T*H</Y9QUKL*CG@BN8
M6BF0/&PP0:TI34)J35S2E-0FI-7.#\*^.[<V@M]7N2LP)_?2'@BJ7CCQ%H^I
MV@AM=D\P/$J]JV+WX:Z9<S,\5Q+;@G.U%! _.DM/AIIMO(K2W,LX!SM90,_E
M7:IX93]HF[]CO53"J?M$W?L1?#:T<:'>><IV32 KGN,5Q>I6]UX9\2F78R@2
M;U/J,YQ7M5O;16D"PP($C48 %4]5T6QUB'R[N$-CHW<5G#%I592:T9G3QB56
M4I+21QNK>-TO='C>PO5M;H<NA)R?IBN3UCQ9?:WI\-I<[<1G)8=6^M=I)\+[
M!WW+?3H/0(*)OAE8_9&2*ZD\WLQ45T4ZN%A:QT4ZV$A:WY%_P'!9VNC;+>Y2
M663YI-O8UUE<IX0\*RZ 9WN'#NQPFTYXKJZX,0TZC:=SS\2XNJW%W. ^*?\
MR#=/_P"NS?RI_@WQ'I&GZ#%!=W\44HZJV<UT/B3PW#XDMX(9KAX1"Y8% #G(
MQWKF_P#A5EE_T$KC_OA:Z85*,J"IS=CIIU*$J"IU'8A\8^,[&YT][&PD$Q<C
M,B],4SX=:7+#;W6INA VD1D]R,YK3L_AKIMM,KR7$LX!SM=0 ?RKL8+>*VA6
M&% D:C 44JE:G"G[.EU%4KTH4O94NNYXK,S:[XL\F_N#'&\I!+'[HK2\7Z1H
MVCV44%DV^Z+ LV1P*[#5_ 5AJMZUTL\EM(QRWEJ.35<?#C3_ +.T;W<SR,.)
M& R*W6*IWB[M)=#H6+I7B^9I+H+\-_\ D G_ 'OZUQ=G_P E D_Z^7_F:],\
M.^'8_#L$L,5U).KD'YP!C\JS8O =K%KC:H+V8NTADV;1CFLHUZ:G-WW,8XBF
MJE25]]CG?B;:2#4+:\VGR]FS/OR:V= \:Z5%H<:74XCFB3!1CRWTKK+_ $ZV
MU.U:WNHP\;#H:XZ7X8:>\I9;Z=%)^Z$%3"K2G24*NEB85J-2DJ=72PW2/'T^
MI:P+06FY&8A2G7'J:ROB7_R%H/\ =%=KH?A6PT(EX07E/'F,.:@\0^#[?Q#=
M)/+=2PE!C"*#3A6HPK*4=$.%:C"NI15D0#_DFO\ VZ?UKE_AK_R&)_\ =->@
M?V-'_P (_P#V1YK>7Y7E^9CGZUF^'_!]OX?NWN(KJ64L",.H%3&M!4YQZLF-
M>"I5(]6S$^*'_'G9?[S?TJ?P_:-??#^:V3[S@X_2MWQ'X:A\1Q0QS7$D(C)(
M* '.:M:)I$>B:<MG'*TJ@YW,,&E[:*H1BMTQ>WBJ$8+=.YY9X1UI/#NLR+>*
M5C;*M_LFNB\9>+]-N](:SLI1.\A!W+T%;VM^"M-UF8S',$K?>=!UK-L_AIIM
MM.LDEU+. <[64 5LZV'G)597N;NOAIR565[KH5_AGITMO:W-XZE5FPJY]C7,
MWG_)2)O^OLU[#!!%;0K%"@2-1@**Y>7P+;2^('U<WLPD:4R>7M&,^E13Q,?:
M3G+JC.GBHNI.<]+HU?$7_(JW_P#U[G^5<%\-6*7ETP&2$R!^!KTJ_LEO]-GL
MF<HLL90L!R*Q?#O@^W\.SR2Q74DQ<8(=0*SI58QHR@]V9TJT(T)P>[/-KR1]
M;\6M#?7!2,RE<L?NCTK3\7Z+HVBV,45F^^Y9N<D9 Q77ZQX#T_5KQKI9I+:1
MOO>6 <GUJNOPYT_[-)')=322,,"1AROO72L53]UW:2Z'4L72]U\S270C^'<8
MF\/7$;'AF ./H:XJVN7\->,'FE5@%D;_ +Y)_P *]0\.>&T\.Q2Q17<LR2$'
M#J!BDUSPII^ND/,/+E'_ "T4<UE'$0565]8R,HXFFJL[ZQD9FK>/]-MM/\RQ
ME2>X8<)_=^M+I6LS^+M OHFMFC9E*!Q]TFJ<7PPT^.0,]]/(/[I05V.GZ?;:
M9:K;VL82->PK.I*A&-J>K[F=26'A&U+5]SR#PUJH\-^(7^UHPCRR-[>]=7XL
M\9:9<:,]M9S+/)*!]WHOUK<USP=IVMR>:X,,QZN@Y-9-M\,M.@F#R7<TR@YV
MLH K=UL/.2J3O=&[KX>I)5)W310^&FG2I'>7C(0DL?EJ?7O7-+,WA[QB9+A&
MVQ2Y8=R*]FMK:"RMUA@C"1J.%%>>>*-0\,ZC?O!=BYAN8SM:1(P?ZT4:[J59
M-K1A1KNI5DVM&:FN>.=+;19$M91--,A4H.JY&.:Y/X=_\C&/]W_&KPTSPKI>
MG37 U#[9*\1$:'&5)''2HOAI SZQ-*%RJ(.?SK11A"A/DO\ ,U4:<*$^2_S/
M6*X?XCW]S;:=%#"S*LARQ'\J[BJ&K:3;:S9-:W*Y4\@XY!KSJ,U"HI2V/+H3
MC"HI2V/./#'AW1[S1WU'4+G+*3N3/2L32_(_X3"/[,,0><=@]J[B+X:64;Y_
MM"X*9Y3  J;_ (5U9)?1W,%Y-$4((55&*]#ZU3O*\F[_ ('I?6J5Y7DW?RV#
MXC_\B['_ -=/Z4SX:?\ (%F_WQ_6M_7M!BU[3UM)9WB56SN4 FD\/:!%X?M'
MMXIWE#'.7 %<GM8_5_9];G)[:'U;V?6YY3-_R.K?]?/_ +-7H/Q OKBRT)1;
MLR^:Q5B/2F/\/[5]7.H?;IMYD\S9M&.N:Z74M.M]4LWMKE=R,/RK6KB*;G!K
M6QI5Q%.4X26J6YY?X1\/:7JMK/=ZA<X:-N5SV]ZQD%LOBVW6T $"W"!?SKNU
M^&=DDA9=0N A/W H J67X<:>US'-#=S0%"" J@\BMUBJ?,VY/7\#H6+I<S;D
M]?+8[2F2?ZI_]TTD,?DP)&6+;5 W'J:>1D$>M>5U/(ZGC?A#]UXRP_!WL/UK
MUK5/^01>_P#7!_\ T$UY=J=N?#_CR.8@B%I0RGU'>O59$6]L'3)"SQ$9'8,/
M_KUW8MWE&?1H[\:TY0J=&CRKX;_\AV3_ '!_6O7*Y?P_X*MM O6N8KR65B,8
M90*ZBL<74C4J<T3'&58U:G-'8H:U_P @2]_ZXM_*O+_A]_R-8_W7_D:]9N[<
M7=G-;LQ42H5)';-<WH?@BVT/4OML5Y+(V"-K* .:JC5C&E.+W95"M"%&<7NQ
MGCCQ&-)T\VT+?Z1,,<=5'K7%^%?";Z_'<SSY1-N$8_WO6NQU3P##JVH/=W&I
M7&YCG;M& /2NFTZPATRRCM8!A$&/K5JO"E2Y:>[W+6(A1H\M)^\]SQW2KVY\
M)^(RDH(4-M=3W'K7L]M<1W=M'/$<HZA@:Y_Q!X,LM?N$G>9X)%&"44'=5K3=
M+'AW1IH3>R31HK,ID &.*G$5*=:*DOB%B*M.M%27Q'FNK_O?B!*J<G[01Q7L
M<?\ JD_W17E/@ZS?6/%\NHD96)_-)/?M7K%/&O6,.R'CG9QAV04445Q' %<%
M\3?^0=!_O"N]K$\1>'(?$4"12W#PA#G* &ML/-0J*4MC?#3C"JI2V.<\$>(M
M(T[PS%;WE_%#,)')1LYP33?%OC6PETR6SL)!.THP77H*7_A5EE_T$KC_ +X6
MK%K\,]-@D#274LP!SM90*ZW+"^T]I=L['+"^T]HVV]S+^&NER?:)]1D0A=NQ
M21^.:Y[499-9\5&&^G*1F7;ECT&:]GMK:&TMT@@C"1H, "N9UGP)8:O=FY$T
MEO(W),8!S2IXJ+JRG+2XJ>+BZLISTOMY'(>+=$T;1=/CCM'\RY?G)/.*Z;X9
M_P#(N2_]=S_(4J?#G3Q Z274TKGI(PY6M7PYX9C\.K(D5W+,C_PNH&#15KPE
M1Y.:[%6KTY4>3FNSSC6O^2C3_P#7R/Y"N@^)%G)+86%TJDI$FUB.V<5LW?@6
MVN]??5FO9ED>0/Y848KI+BR@NK3[-.@DC*X(-*6)BI0E'H@EBH*5.4=;+4XC
MPCXPTRVT5;:]G$,D><;N])!\0Y+G6A:PVOF0N^U-OWB*GN/AEITTQ>.[FA4G
M[BJ"!6MHG@S3M%E\Y,RS#H[CD43GAM9+5L)SPNLE=MG'_$C5?M%Y!9)D!%RX
M]ZKV?PWU*[M([C[5!'YBA@K YP:ZN^\ 6^H:J]_/J$Y=VW%=@Q]*ZV*,0PI$
MO1%"C\*;Q2ITXQI/U!XM4Z<847ZGC6N^";[0K(74L\4J9P=@/%=E\.=4^U:2
MUF[9>$X4?[-=5JFG1:KI\MG,2$D&"0.16'H'@R+P_>M<07\TFX8*,H -*6)5
M6BXU-Q3Q4:U%QJ/WNAU%%%%<!YX4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%Y_QXW'_7-OY5/4%Y
M_P >-Q_US;^5 '@%Q]P?6JU6;C[@^M5J]S _P4>_@/X""BBBNP[0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]+\ >&0B?VG=QC<?\
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M/;_OH?XU#'X1UN65HDLF+KU&X<4>VI_S+[P]O2_F7WF)171?\(/XA_Z![?\
M?0_QH_X0?Q#_ - ]O^^A_C1[:G_,OO#V]+^9?><[171?\(/XA_Z![?\ ?0_Q
MH_X0?Q#_ - ]O^^A_C1[:G_,OO#V]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0
M?Q#_ - ]O^^A_C1[:G_,OO#V]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_
M - ]O^^A_C1[:G_,OO#V]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_ - ]
MO^^A_C1[:G_,OO#V]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_ - ]O^^A
M_C1[:G_,OO#V]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_ - ]O^^A_C1[
M:G_,OO#V]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_ - ]O^^A_C1[:G_,
MOO#V]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_ - ]O^^A_C1[:G_,OO#V
M]+^9?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_ - ]O^^A_C1[:G_,OO#V]+^9
M?><[171?\(/XA_Z![?\ ?0_QH_X0?Q#_ - ]O^^A_C1[:G_,OO#V]+^9?><[
M16W_ ,(CK?VC[/\ 8F\S&=NX5/\ \(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO
M.=HKHO\ A!_$/_0/;_OH?XT?\(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HK
MHO\ A!_$/_0/;_OH?XT?\(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\
MA!_$/_0/;_OH?XT?\(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\ A!_$
M/_0/;_OH?XT?\(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\ A!_$/_0/
M;_OH?XT?\(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\ A!_$/_0/;_OH
M?XT?\(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\ A!_$/_0/;_OH?XT?
M\(/XA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\ A!_$/_0/;_OH?XT?\(/X
MA_Z![?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\ A!_$/_0/;_OH?XT?\(/XA_Z!
M[?\ ?0_QH]M3_F7WA[>E_,OO.=HKHO\ A!_$/_0/;_OH?XT?\(/XA_Z![?\
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MA"\7=FWH>DPZ/IL=M$HR!\Q]36E117A2DY.[/GY2<G=F3KW_ ![Q?[]:4/\
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MY!\9[/3K6UT^YMTBAU 3#R_+^5CR/2O2_#DEQ+X<L'NL^>T(+Y]: -2BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"\_X\;C_KFW\JGJ
M"\_X\;C_ *YM_*@#SOX;?\A:\_ZXC^=>EUYI\-O^0M>?]<1_.O2Z "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#T-8VF_\ (6NO
MK6R>AK&TW_D+77UH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#%/_ ",G_ :VJQ3_ ,C)_P !K:H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L75O\ C_M?]ZMJL75O^/\
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MN:M/J<D3;D#LP /T)->E@!5"J  .@%+10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %07G_ !XW'_7-OY5/4%Y_QXW'_7-OY4 >=_#;
M_D+7G_7$?SKTNO-/AM_R%KS_ *XC^=>ET %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% "'H:QM-_Y"UU]:V3T-8VF_P#(6NOK0!M4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &*?
M^1D_X#6U6*?^1D_X#6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %8NK?\?]K_ +U;58NK?\?]K_O4 ;5%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!DZ]_P >\7^_6E#_ *E/
MI6;KW_'O%_OUI0_ZE/I0!)1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 51U?_ )!DW^[5ZJ.K_P#(,F_W: ':5_R#8?I5RJ>E?\@V
M'Z5<H **** "BBN0\?:W?Z)9V<EA*(VDD96)4'( JZ=-U)**ZFE*FZDU!=3K
MZ*\5_P"$]\0_\_@_[]BNC\$^*=6U?Q +6]N!)#Y3-C8!R,5TSP-2$7)M:'34
MP%2$7)M:'H]%%%<9Q!1110 45#/=VUM_KYXX_P#?8"H%U?37.$OK=CZ"04U%
MOH4HR>J1=HI%8,H92"#T(JO<:A9VK!;BZAB8] [@4)-["2;T19HJA_;6E_\
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M3_\ KJW\A73@_P"/$ZL%_'B>85U_PW_Y&L?]<'_I7(5U_P -_P#D:Q_UP?\
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MQ6EVMSI\-UPJR('Y/2O$_$NN'7M2-UY1C3&%!ZUU]_J\]G\/;54<AY1Y8;N
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MX-Z7"BBBN0XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_/2W_P"_(H_X6/X@_P">EO\ ]^17)44?5Z7\J#ZM1_E1UO\ PL?Q!_STM_\
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MS<?<'UJM7N8'^"CW\!_ 04445V':%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7IG@#PP8@-4NE^8C]VI'3WKFO!OAQM9U%995/V
M6(Y8^I[5[+%$D,2QQJ%11@ 5YN.Q%E[./S/+Q^)Y5[./S'T445Y)XX4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!BG_D9/^ UM5BG_ )&3
M_@-;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJC"_4ZS1=)AT?3H[:)0"!\Q]36C117@2DY.[/G92<G=A1112$%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 8I_Y&3_ (#6U6*?^1D_X#6U
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8NK?
M\?\ :_[U;58NK?\ '_:_[U &U1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 9.O?\>\7^_6E#_J4^E9NO?\>\7^_6E#_J4^E
M$E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'5_^
M09-_NU>JCJ__ "#)O]V@!VE?\@V'Z5<JGI7_ "#8?I5R@ HHHH *\_\ BG_R
M#]/_ .NK?R%>@5Y_\4_^0?I__75OY"NG!_QXG5@OX\3S"NO^&_\ R-8_ZX/_
M $KD*Z_X;_\ (UC_ *X/_2O8Q/\ !EZ'M8K^#+T/8****^>/FPKS;XY?\DWE
M_P"OJ+^9KTFO-OCE_P DWE_Z^HOYF@"GH7Q=\.V.@:?:2P:B9(;=(V*V^1D
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MQ]A^%>ZUXO\ %_3;#2;W1[_342UOFG"D083(R.PKUW2Y99]+MI9QB5D!8>]
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M.34)@2PAERS =3BN)\8:WJOB7QQ#X2TBX:WMU4-/*O7OD?I67X9TO3]&^/\
M)9:6 +5+1MN'W<E!GFL]]$O;CXN:A;1:K_9T\@WQR.F=P)/ YH ZG6OAS<^'
MM*EU70]8N_MULN_#G(D^N2:Z+P]XF;Q-X!N+Q\+<QQ,DH4]&Y_PK(N/A_P")
M#;N)_&($1'S%H<#'YU=\,>%HO"W@W5;>+4XM0$RES)'C X/H30!PGP_\/:AX
MNBO(KS5+B+3X)WVHC9+$L>_6KFHV=Y\-?&.F_8]0GGT^[?8T4ASSBMSX*_\
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M8 2&,(,>PH M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !4%Y_QXW'_ %S;^53U!>?\>-Q_US;^5 '@ZV-U??):V\DS
M+R0BYP*=_P (]K'_ $#;G_OV:[+X;?\ (6O/^N(_G7I==E'&2I0Y$CMH8V5*
M'(D>!?\ "/:Q_P! VY_[]FC_ (1[6/\ H&W/_?LU[[16O]HS_E-O[3G_ "G@
M7_"/:Q_T#;G_ +]FC_A'M8_Z!MS_ -^S7OM%']HS_E#^TY_RG@7_  CVL?\
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M@ HHHH **** "L75O^/^U_WJVJQ=6_X_[7_>H VJ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)U[_CWB_WZTH?]2GTK-U[_
M (]XO]^M*'_4I]* )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "J.K_\@R;_ ':O51U?_D&3?[M #M*_Y!L/TJY5/2O^0;#]*N4
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M?X4^'FF>&+LWZO)<:@RD-/*V3SUQ1XO\!V_B6>*^@G:TU*'[EPAP?H<5V%%
M'F$_@'QAJ$7V74/%,;V9X=8E<,P]":['3?"]KH_AE]'L3M5HRN]N<D]S6]10
M!R'@/P?<>$;.ZAGNHK@S2M(#&I&,DGO]:A\:^"+GQ3J.F7,%Y% MG+O8.I.[
MCMBNUHH QO$/ANR\2Z,VFWZ;D(^5AU4^HKBHO /C"QA^R:?XIC2T'"B17+*/
M8UZ=10!R'@_P+!X9EFO)KA[O4)_]9,YSGZ9^M=?110 5P_B7P-<Z[XNTS68K
MR**.S.6C922W(/'Y5W%% !7$^)O ]SKOB_2M:BO(HH[(@M&RDENO3\Z[:B@"
MK?6C7>F36BL%:2,H&/05S?@3P?/X2L;JWN+J*X,TK."BD8!)..?K7744 >>:
MQ\-ICK4NK^'=2_LVZF_UH.=K?@*JCX:ZSJUY"_B?7A>V\3;A#"&4'ZYKTVB@
M#E/&?A!O$GAF'2+.>.U$4\<@9U)&%SQQ71V-N;73[>V9@QBB6,D=#@8JQ10!
MYOK7PTO&\12ZUX<U5=.N9CF8."0Y_"H;WX7W^MZ=<+KNM&[O&C*PL-WEQMZX
M->G44 <3'H=SX<^%M_IEU<1SR0VDWSQJ0""#ZUYQ\,O!^KW_ (135M$UHV-Q
M)-)'(KY*,!TX%>YZE8IJ>F75C(S(EQ$T;,O4 C%9?A#PM;>#]!72;6>6>)9&
MDWR@9RWTH PO#?P\:PU<:SK=\=1U)?N2<[4^@/2NVGF@BC/GR(J8YWD#BI:Y
M;Q=X)M_%WD^??W-L(AC$./F'OF@#@/AKX=MI_'>JZO;_ #VEO(ZQ$]"6SG'X
MU[165H'A^Q\-Z8EA81A8UY)[L?4UJT %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5!>?\ 'C<?]<V_E4]5[_\ Y!]Q
M_P!<V_E0!YY\-O\ D+7G_7$?SKTNO-/AM_R%KS_KB/YUZ70 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 (>AK&TW_D+77UK9/0UC
M:;_R%KKZT ;5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!BG_D9/^ UM5BG_ )&3_@-;5 !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5BZM_P ?]K_O5M5BZM_Q_P!K_O4 ;5%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!DZ]_
MQ[Q?[]:4/^I3Z5FZ]_Q[Q?[]:4/^I3Z4 24444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %4=7_ .09-_NU>JCJ_P#R#)O]V@!VE?\
M(-A^E7*IZ5_R#8?I5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:7VO>>F,5=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "L75O\ C_M?]ZMJJ5W8"YN(I=Y&PYQ0!=HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** ,G7O^/>+_?K2A_U*?2H+^S%[
M$J[BNTYJRB[$"^@H =1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 51U?_ )!DW^[5ZH+NW^U6KPYQN&,T 1:5_P @V'Z5<J&U@^S6
MR19SM'6IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BN$:2UEC7[S(0/J111
M0!R'@WPWJ.B7]Q->)&$>/:NU\\YKM*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g2g5bnvu5o20000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2g5bnvu5o20000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" =F!V8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4]* *M68.E+Y*>E/50O2D,?13:* '44VB@!U%-HH =13:* '44VB@!U%-HH
M=13:* '44VB@!U%-HH =13:* '44VB@!U%-HH =13:* '44VB@!U%-HH JR_
M?-1U;,:D\BD\E/2F(JT58>)0.!5>@ HHHH ***GCB!7)% $%*OWA5GR4]*7R
MDSG% $@Z4M-HI#'44VB@!U%-HH =13:* '44VB@!U%-HH =13:* '44VB@!U
M%-HH =13:* '44VB@!U%-HH =13:* '44VB@!U(W2BDZT 4F^\:2K?E)Z4GD
MIZ4Q%6BII(PO05#0 4444 %%*!DU8$*XY% %:I8?O"I?)3TI1&JG@4 2T4VB
MD,=13:* '44VB@!U%-HH =13:* '44VB@!XZT^HAUJ4=* "BBB@ HHHH ***
M* "BBF/*D?WG4?4T /HI 0PR.0:@NKN*UB,DC  >] $DLR01EY&"J.I-<G>>
M-88;_P"SQ[67<!N_&N:\4>,GN6:WM'(3HP]:XGS6,RR$\@@UU4Z%U>1VTL-=
M7D?0UO*LT*.ISN -2UR'@G6OMMCLD;+*<"NOKGE'E=CDG%QE9A1114DA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8'C"?R?#T[ \BO
M&&O)Q,765QSV->I>/KG;I<L.>HKR2NW#KW3T<+'W#H-.\67E@1R7Q_>-=AIG
MQ $V%N0J#UKR^BKE2C(UG0A+H>]V6OZ?>X$4X9CV%:8((R.AKQ'PI.4U, R!
M5QW->R6]Y;&!!Y\9./[PKDJT^1Z'!6I<CLBW13!-$W213]#3@0>AK(P%HHHH
M **** "BBB@!#TJ$]:GICJ,9H CI"P7J:HW=Z(CL7D^U4\W,W(? H$;'FI_>
MIP(/2L7[/<#GS*!// ?G)(H V\T9JI;W:3#T/O5GK0,=13:* '44VB@!U%-H
MH =13:* '44VB@!U%-HH =13:* '44VB@!U%-HH =13:* '44VB@!U%-HH =
M13:* '44VB@!U%-HH =13:* '44VB@!DHRM5ZM$9%5V&#3$-HHI5&3B@">)<
M#-2TP# Q2TACJ*;10 ZBFT4 .HIM% #J*;10 ZBFT4 .HIM% #J*;10 ZBFT
M4 .HIM% #J*;10 ZBFT4 .HIM% #J*;10 ZBFT4 .HIM% #J*;10 ZBFT4 *
M>E5I!AJL5'*O&: (****8AR#+"K0X&*AB7O4M(8ZBFT4 .HIM% #J*;10 ZB
MFT4 .HIM% #J*;10 ZBFT4 .HIM% #J*;10 ZBFT4 .HIM% #J*;10 ZBFT4
M .HIM% #J*;10 ZBFT4 .HIM%  XRM53P:M5!(,'- $=%%'>F(DB7YJLU%&,
M"GTACJ*;10 ZBFT4 .HIM% #J*;10 [-%-) ZU1NKT)\J\GVH MR7$<?WFQ5
M9M1C!X(-45BEG.YSQ[U86TB Y6F(G34(B?F8"K22I)]TYK->TC(^5<5#^]M7
M!!^7/:@#=5>:EJM:7*SQ@BK-(84444 %%%075U':Q&21@ .Q- $]%8VF^(;;
M4KN2"/@H,YS3=<\06^E6[,6#,.P-5RN]BN25[%K5-6M]-@9Y9 K8X![UY9K?
MBZXO;L^6Q5<_PFLW6M?N-4G8LY,>?E![5C5UTZ*CJST*.'4=7N>P:/XKMCI.
M990'C3OWKB?$GBJ;4I6CC8A/537,K/(BE5; /6HZJ-**=RH4(QES"EBQR3DT
ME%%:FYO>%]4:PU2++8CSSS7M5I<+=6R3*<AJ^>58JV5ZUZWX'U9KNU6V8'Y%
MZFN;$0TYCCQ5/3F1V5%%%<AP!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ<*() #WQ4VIZ#<::,N"1C.<5K[M_,W]SF\S(HJW;:?<W3A8XG()Z@5VNB>
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MLKCC@U7666U?G+"@#8HJ"&Y251R ?2IZ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **C>>*/[[@?6D6YA<X612: ):*** "BBB@ HHHH ****
M "BBB@ HHHH 9M^;-/HHH ***0D 9- "T4@96Z$&D=U098@#WH =10"",CI1
M0 444T.K-M# D=J '4444 %%%% !1110 4444 %%%-+JO4@4 .HH!!&13?,3
M?LW#=Z4 .HJ.2:*(C>X7/3-.5U==RD$>M #J*** "BBB@ HHHH **:'4MM##
M/I3J "BBB@ HHHH **** "BBB@!K#(H1<"G44 %%-,B*P4L 3T%#.J?>(&:
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M5?055GGS\B#)/'% "(//OP!TK>0;4 ]!6?IMH47S'^][U:N@[1,B9!88R.U
MT96N^((-*A;+XDKS"^N=1\171VY*@_+7HH\+&:;S+F?S1_=:MFWTBRME 2W0
M$=P*VC.,-MSIA4A36FK/,-.\!WTQ#7$6$-=AIW@;3[8!F5MX]:ZQ5"C"C I:
MF5:3)GB)R*UO906R!41>/:JNJZ+;:I T<R\'T%:=%9IM.YBI-.YE:;H-IIJ
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MD53EAT/%2_#;S&AOS*<DRG^=+'I%]!$+00ET'_+0]371Z!HJ:1 X4G,AW'-
M',W^DRZ9KT^IE=T<IQA1S3X'N=1U6)[,-'"!A@P[UW+QI(,.BM]134@BC^Y&
MJ_04 86O:/)?6<)X+P_-FL*35+Q].:PP_P!HSPVTXQ7?$ C!J+[-!G/E)GUQ
M0!R_A^VN+6TNI)/OE<]*MZ+9O)<_;I!\YXY%= (T P% !]J5551A0 /:@#F/
M%FGSW021#F)!\PQUK 15GTY;6RA>.9>264XQ7HS*K## $>]1K;PJ<K$@/L*
M.8\(V<UM87"RCYBWI2:%82P>)[R=Q\C#CBNK5%0850/H* B@Y"@$]\4 <3XB
MM)XO%5OJ: F.-,$ <]O\*VM2LCK&DI(!\P7(S6X\2/\ ?16^HI0JA=H  ]*
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M)'?%#(K_ 'E!^HH S)XKK^Q/+M7"3[  3]*Y*YN/,B>UOXI)9R-H8*<9KT+
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M 2A=*N%'03$#\S12^ _^09<_]=C_ #-% $_@;_D6+?\ SVKI*YOP-_R+%O\
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MKJUATK/MK:2.7+#BM#M7;AXM1U.>JTWH%%%%;F04444 %%%% !1110 4444
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M_OU<HH I_8W_ +]'V-_[]7** *?V-_[]'V-_[]7** *?V-_[]'V-_P"_5LG
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M,=**.U%>F<84444 %%%% !1110 4444 %%%% !5>_P#^/"X_ZYG^56*KW_\
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MB@ HHHH **** "BBB@"G?3F, #O64SLW4DUK7EN90".U93(RG!% #:*7%)0
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M\!_\@RY_Z['^9HH G\#?\BQ;_P">U=)7-^!O^18M_P#/:NDH **** "BBB@
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M% $?DQ_W%_*CR8_[B_E4E% $?DQ_W%_*CR8_[B_E4E% $?DQ_P!Q?RH\F/\
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M%_*CR8_[B_E4E% $?DQ_W%_*CR8_[B_E4E% $?DQ_P!Q?RH\F/\ N+^5244
M1^3'_<7\J/)C_N+^5250U34DTV%9'&03B@"YY,?]Q?RIP51T 'X52L-4M[^/
M<CKGTS5Z@ HHHH **** "BBB@ I&&1BEHH QM,T86.IW%T'8F7L36S110 44
M44 %%%% !1110 4444 %%%% !112,P5<GM0!!=W26L)=SCTKD;N_FOI3U"@X
MX-3:S>-<730*?E!JLB!%XIB&I"%Y//UJ3 ]!33-$IPTB@^YI//A_YZ+^= #\
M#TI"BD=!2-+&H!+@ ^])]HA/_+1?SH 8T3(=R,01Z&MC2=88,(9N .YK-!##
M@YJ&9"IWKUS0!WBL&4,.AI:R-$O?M,)5CRO%:](84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !5>_\ ^/"X_P"N9_E5BJ]__P >%Q_US/\ *@#G/ ?_ "#+G_KL
M?YFBCP'_ ,@RY_Z['^9HH G\#?\ (L6_^>U=)7-^!O\ D6+?_/:NDH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "J4NK6D,GEO)ALXIFM*S:7*$F\EL??\ 2N)FA\NS=S>B:0*><T >AQ2I
M,FY#D4T3QE]N>17%> ;ZXFM'2>1G/F'!/U-/@NICKTR&0[0_2@#LWF1#AC5/
M5]173]-FN ?F5<C-<_XCN9HKD!)".E6==@:X\)R.6Y$/- %KPQKG]M:7'<.1
MYC=0*UI[J*V7=(V!7'_#RV,7AF.XW?PGC\*J*;KQ!JS;)VCCB<JR^M '<VU]
M!=?ZILU8)P,FO/-:CNO#,\-R+@M'+($"#MS_ /7K8\4:K)!H0$3%)'C#!AVX
MH WSJMH)O*+_ #9QBK@((R*\OMS-)I2SF<F7;G/<UTW@B^N;K2W^T[BX? +4
M =$]] F[<WW>M%O>P70S$V:\\L[>]U7Q%>QK=,L<<GW:N745SHFLB;SRT.,;
M.U '6ZI+<1LGD+G/6G"[,&F^=/@, 36'K]Y+Y%K(CE=ZY-6HXWN_#8W/\VTG
M/X4 )X:\1_VPUPLA&8W*KBN@FG2!-TAP*X'X?69$EZ^[[LI_G3[Z>ZUKQ%-I
ML,[1"$Y)]: .TM]1M[HXB?/.*LNZH,L:X+6=/NM$5;]+D^7&OS(.]:]S>RW?
MAJ.X1BKO&3F@#;DU6UC;:SX-6T=9$#J<@]*\]\-Z+>:AIDDDUV2^\X)J[X.U
M&=]0U&UFD+BW;:,_A0!V4]Q';)OD.%J.VO;>ZSY+9QUKSW6-3N+GQ8]H)2L6
M,X[5%+/=VFKV?D2L8RWSA>] 'I[,%7)Z"J2ZM:/+Y2R?-G&*P_%-S>/H<4MH
M'#E^0O7'%<U;EKJ B2Y^S2_WFH ].!!&12UGZ*ACTN)&G\\@?ZSUK0H S]3T
MN/4XU21W4#^Z:Q_^$+M/^>\W_?1_QKJ** .6_P"$+M/^>\W_ 'T?\:7_ (0N
MT_Y[S?\ ?1_QKJ** .7_ .$+M/\ GO-_WT?\:/\ A"[3_GO-_P!]'_&NHHH
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MUG?\(UK'F;O[5?&<XH [.BN=U31M0NXH%@OFB*+AB.]-TO1=1M)&:>_:4%<
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M.V@??%"JMZ@436EO<?ZZ)7^HH X/5YV\6S0P6H)CCD#\CT.?Z5L>)M'DN=%
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M^$C06-IDJZX;([UJWEL]AX9C@(PT<9KH(M.LX&W16Z*WJ!5?6+4W5HR*.HH
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ML!0!Q?BZ8W%]#HW.R9<$"I+7X>Z8M@$</OQZUUTEG;RSK-)"K2+T8CD5/TH
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M-+4%K*)8%(.<  U/0 A /49J/[/'OW!0#]*EHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M48A11161J%%%% !1110 4444 %%%% !1110 4444 %%%)F@!:*3-+0 4444
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M_P S11X#_P"09<_]=C_,T4 3^!O^18M_\]JZ2N;\#?\ (L6_^>U=)0 4444
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M+&O0: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *KW_P#QX7'_ %S/\JL57O\
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M&:WMXEC$BX.*XN*YO?#=\T$=G)/&HX('%>ATA53U4'\* . MK:Z\0ZY;ZC/
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M@ HHHH **** "J]__P >%Q_US/\ *K%5[_\ X\+C_KF?Y4 <YX#_ .09<_\
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M*>QKID4(@4=J2.-8DVJ,"GUO3@H(UC'E04445H4%%%% !1110 4444 %%%%
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M /CPN/\ KF?Y4 <YX#_Y!ES_ -=C_,T4> _^09<_]=C_ #-% $_@;_D6+?\
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MK;Z3;0 $1C=0!SMGI$]RX:4,HKIK.QCM(PJ@$^M6E4*,#I2TAA1110 4444
M%%%% !1110 A (P1FL?4]$CNAO3Y6'I6S151DXNZ)E%25F<%+:7=F_,9*CN:
M1+M<X<X-=U+!',N'7(K*NO#]M+S'& :Z(UHOXCGE1:^$P!*C=#3ZGF\-W2',
M<B@53>PO8>K$_05HG%[,S:DMT2T529YX_O!ORJ/[:PZ@T[$\QHT5G?;SZ&E%
MT[],T6#F1>D021E#T-0PQ16R!5P *2.&YF^ZQ&:M1:#>S\F0?C2]U;LI7>R*
M[W,:C[PS4$D\SK\B9'K70VWAM5(,X#56U6*"W A@7:P.#6-7$0IQNM1NG*UV
M8,%M)<R<YK?M-.2%02,GWJ2SM1#'G')YJW7!*<JFLS2%-(:J*O0 4ZJ.J:E%
MI=HT\GS!>PZUS?\ ;5Y>9E@$BH.<$&A(U.RHKG-'\0_:;H64L;B7KN(K5U+4
MH=/M7E=AP,XSR:+ 7J*P]#UQ=6 =%8 CH:VC(B_>=1]32 :\*.,%1^59\UH\
M#>9"QX["M-65AE6!^AI2,C!J913)<4PTO5?,_<S<,*VQTKC[N$P3+*G'.372
M:;<_:;8/GIQ5TIOX65"3V9<HHHK<T"BBB@ HHHH **** "BBB@ HHHH ****
M "D(!&"*6B@"M-90S#!11^%9D_A]&RRR$'T%;E%1*G&6Z)<4]SE6TBXB/R,[
M?C41@OXSQ$QKKZ.M9N@NC(]DNAR'FWZ]8#1]IOO^>%=88D/44WR(_P"[2]B^
MX>S?<Y7SKYND%&S4'_Y8D5U8A0=!3P .E'L'U8>S\SE5TRZE^_N7\:MP>'@>
M7E:N@HJE0BMQJG$I6^FPP?PAOJ*N!5484 ?2EHK5)+8M)(****8PIK1H_P!Y
M0?J*=10!GW&DPS]@OT%9DWA\KS'*Q_&NCHK.5*+Z$.$6<FVGWD7W59OQIF-0
M3_E@:Z^D*@]:CV"Z,GV7F<CY]\.L%+]IOC_RPKJC#&>U'D1_W:7L7W#V;[G*
M;[]^D!I1;7\G6)A75B-1T%/H]AW8>S\SEX]%FE/SNZ_C5^#08HL%G+?6MFBK
M5&"*5.*(8K:*(8"+^53445JE8L**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH P_$TC)IY(0-BO/M#UJY.N) 6.TOC&:]7N+:.YB*2KE:Y23P@L6L17=N%1%
M.2* .NB.8P:?3(QM0"GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5B^)'FATR2:')<= *VJCGA2XB,;C*F@#R'0;N[&M.54[G?Y^>E>O0*5B
M7/7%<YI'AM;+5+BX< JYROM73]J "BBB@ HHHH **** "BBB@ HHHH ****
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M^>:_]\TX0Q#_ )9I_P!\BGT4 -\M/[B_E2A0.@'Y4M% !1110 4444 %%%%
M!1110 4444 %%%% !24M% !11TK'U/51 /+CY8^E3*2BKL3:2NR_<WL%L#YC
M8K%N-;+$B!$;ZBJ20SWC;Y7.T]C5Z.TBC'W!FN=U)RVT,N:4MBBTEW<')@0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI+V8W<W+-5[I4%JFR  5/7T5.*C&Q\[6FYS;9:L]/GOY"D"Y(&:O?\(UJ/\
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M*J+FIW[&K1117HG(%%%% !1110 4444 %%%% !5>_P#^/"X_ZYG^56*KW_\
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M[T] )-8_Y!%U_P!<S6%X&X\/-G^\:Z6XA%Q;R0GHXQ572],33+/[.AR,YI=
M.2-C!/>7#Z9\LRM\^[UJ?P_J5_\ V^^GWA!VKGBM*]\+_:)C)#<M"2<G;WJW
MI>A)ITGFM)YDN,%SU-.ZL,V*CF8+&Q/I3R0HR3@5F7EPT[B*(9YYQ6<I61$G
M9%C0T,DQD[!C71RPI*N&%4]*LQ:V^".6YK0K6E&T;,N$;1U,BXT&VDRRJ=U4
M'T.Y3_58KIJ*'1@P=.+.4.GZFGI2?8]3/<5U> >HHVKZ5/L%W%[)'++I6HO]
M[&*L1:"S$><*Z*BFJ$05-&?;Z1;6_*KS5\* .*6BM5%+8M)+8****8PHHHH
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MD,"PIM45+7;0H^S6NYS5:G.]-@HHHK<R"BBB@ HHHH **** "BBB@ JO?_\
M'A<?]<S_ "JQ5>__ ./"X_ZYG^5 '.> _P#D&7/_ %V/\S11X#_Y!ES_ -=C
M_,T4 3^!O^18M_\ /:NDKF_ W_(L6_\ GM724 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A&>M1M!&W5:EHH
MX@*O]M.O;?79)!&JC"]JXX?\AQ_]^NU7[H^E*R%9!@"EHK(\0ZE+IEAYT(!;
M..:&[*YI3@ZDE".[->BN?\+ZS/J\$KSJ 5.!BN@HBU)70ZM*5*;A+=!1113,
MPHHHH **** "BBB@ HHHH *BEG2)<LP_.H+V]2V3KR>E83R37K[FR%]C5*-R
MXPOJ:%QK(SM13GU%46N+N<\.0*?';J@]?K4N!Z56B-4DMBK]FD;[[9IXM(QU
M6K%%%PNR(6T0_AH^SQ_W:EHH"Y%]GC_NTAMHC_#4U% 796-HO88IODSH<H^*
MMT47"[*Z7US ?G8L/:M.VU:.7"D$'WJF5!Z@5!):AN5)!]J+)B:3W.D5U<?*
M0:=7-6UY-:.%;[OJ:WX)TGCW*<^M0U8SE%HFHHHI$!1110 4444 %%%% !11
M10 444USM1B.PH =17&?\)/=_P#"5?V;M7RL9SWKL8SN0$]Q4QDI;&];#SHV
MYNJN*>E<7K/_ "-=A]:[0]*XO6?^1KL/K5&!VM%%% !1110 4444 %%%% !1
M110 4444 ,>))!AAD50GT>VEZ1@&M*BI<4]Q-)[G.R:!+_RR<+59M,OXNDM=
M728'H*S="/0CV:.2,-\G5B?PJ&:XN;="SDX'M79[%_NC\JP/%"J-,E( ''85
M/L/,7L_,S(9;F>(.A;!Z<5+Y%\_1R/PK6\-JIT.W)4$X]*U]J_W1^5'L/,/9
M^9RR:3?2]9:M1: __+5@U;^!Z4M4J$4-4XE"#2;6(?ZL9JZB*@PHQ3J*U44M
MBTDM@HHHIC"BBB@ HHHH **** "BBB@"C>:9!= DH-Q[U@W&@7$1+(XQZ5UE
M& >HH X26WN(%);/'M4=LLUVI:,G .*Z[5U7[#)\H^Z>U9/@M0VF3$@']X>H
M]S3 KP:'<S$%G&/>MRRT>&V +("WK6E@#H!2T@$  &!VI:** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *KW__ !X7'_7,_P JL57O_P#CPN/^N9_E0!SG@/\ Y!ES_P!=
MC_,T4> _^09<_P#78_S-% $_@;_D6+?_ #VKI*YOP-_R+%O_ )[5TE !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% '$C_D./\ []=JOW1]*XH?\AQ_]^NU7[H^E "US?C3_D#C_>KI*QO$
MEA-J.G>3#C=GO4S5XLZ,+)1K1;VN8?@.&-[6XW(#\U=A]FA_YYK6#X3TFXTN
M"99\98Y&*Z.IIJT5<TQU12KR<7H1?9X?^>8H^SP_\\Q4M%:6.3F?<B^SP_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 57O_ /CPN/\ KF?Y58JO?_\ 'A<?]<S_ "H YSP'_P @
MRY_Z['^9HH\!_P#(,N?^NQ_F:* )_ W_ "+%O_GM725S?@;_ )%BW_SVKI*
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MS_\ KT?\(A9_\]I?S_\ KUT-% '/?\(A9_\ /:7\_P#Z]'_"(6?_ #VE_/\
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MA9_\]I?S_P#KT?\ "(6?_/:7\_\ Z]=#10!SW_"(6?\ SVE_/_Z]'_"(6?\
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M%%% !1110 4444 %%%% !2-]VEI&^[0!Q7A;_D9-3_WO\*[:N)\+?\C)J?\
MO?X5VU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57O_P#CPN/^
MN9_E5BJ]_P#\>%Q_US/\J .<\!_\@RY_Z['^9HH\!_\ (,N?^NQ_F:* )_ W
M_(L6_P#GM725S?@;_D6+?_/:NDH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&BJ]G.)[=&!YQS5BNI.ZN;H****8!1110 4444 %%%% !1110 4444 %%%%
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MT@+9YJFTE=C;L@O-0BM$^8\]L5@S:G=W;$0MA?>H$22^G9W)"@Y K2CA2-<
M"N5RE/R1BVY>AG_8IY>93G-']E+Z5J44>SB'(C+^Q3Q\Q$"I(=3N[1PLS97V
MK0J.2%) 00*7(U\+#EML:=G?Q7: J>?>KE<<PET^?S4)*CM72V%VMU"I!^;'
M(K:G4OH]RX3OHRY1116QH%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 57O_ /CPN/\ KF?Y58JO?_\
M'A<?]<S_ "H YSP'_P @RY_Z['^9HH\!_P#(,N?^NQ_F:* )_ W_ "+%O_GM
M725S?@;_ )%BW_SVKI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYM6@9,J1C%<A#<#1O$[BX.R#'#&NAO/$=E#9M(DP+8RH]:IW!A%H20VBVT8
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MW363X*_Y!DW_ %T/\S6MJ_\ QX2?[IK)\%?\@R;_ *Z'^9H Z:BBB@ HHHH
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M_(L6_P#GM725S?@;_D6+?_/:NDH **** "BBB@ HHHH **** "BBB@ HHHH
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MVB/UH EHJ W4?8T@EDDXC&: )\@=Z8\RKTYJ2+3KZX/^K^6M2T\/)D--N!H
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M #-% $_@;_D6+?\ SVKI*YOP-_R+%O\ Y[5TE !1110 4444 %%%% !1110
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MQ_F:*/ ?_(,N?^NQ_F:* )_ W_(L6_\ GM725S?@;_D6+?\ SVKI* "BBB@
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MJ@5DZKIB6:H0!RV*F4E%79+=E<I&=F.$&:FM[&2=]T@(%:-K9PJ@8+SBK@
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M4G_/";_ODT?\)5)_SPF_[Y- '8T5QW_"52?\\)O^^32?\)5)_P \)O\ ODT
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M_P >%Q_US/\ *K%5[_\ X\+C_KF?Y4 <YX#_ .09<_\ 78_S-%'@/_D&7/\
MUV/\S10!/X&_Y%BW_P ]JZ2N;\#?\BQ;_P">U=)0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 444F0.] "T4W>O]X4>8G]X4KH=F.HIGF)_>%+O7
M^\*+H+,=129![TM,04444 %%%% !1110 444A( Y.* %KEO%VO+IUF(XF!D<
M[,?7BMK4M3@L;.29G7Y1G&:\[L8)?%'B"25\_9P0R@]*RJR:]U;L]' 4(R;K
M5/AB;'@S06 :]N@?,+[ESSP37=]*BMX5@A6-1C  J6JA%15CFQ6(E7J.;"BB
MBK.<**** "BBB@ HHHH ***3<OJ* %HI-Z^HHWKZB@!:*3>OJ*-Z^HH 6L'Q
M1IAU'3R!G* GBMW>OJ*:Q1U*DC!&#0!YOX+T23[9]J8'".1[=:]* P,57MK>
MWM5*Q *"<G%6-Z^HH 6BDWKZBC>OJ* %HI-Z^HHWKZB@!:*3>OJ* 0>AH 6B
MBB@ IKHKC# 'ZBG44 8E]H,4Q+H2&ZX%8DVG7ELW$9*^IKMJ:\:N,,,T <(9
MF0XD&*<+B,]ZZZ73+60<Q#-49= C8_( *8C!$B'H:=N'K6B_AJ4_=E J$^'+
MD?\ +:@"IN'K077UJU_PC]S_ ,]:4>'+D_\ +:@"D94'>FFXC'>M9/#<@^](
M#5N+0(E/S@&@#FQ+)(<1C-68=+N[EAO0A?:NJBTVUB^[$ :M*JH,*,47&9%C
MH<5OAVR6]#6NJA1@ #Z4M%( HHHH **** "BBB@ K%\0Q%[=".S9K:J"[@$\
M+*1VXJ)QYHM$R5U8P+"3?#].*MUD1%[*Y,3YP236LK!AD&N>#NK&47H+1115
MEC)8Q)&RGN*XG[%JFA7LCV$/FQS-EBW:NYI"H88--.P'#7MQKVJA86M@L88'
M*FM.YT>XM]/WV[.TX7[I)ZUTJQJGW1BG47"YQ)O-=>S6V-JI)&UOI^5;GAK2
MSI5B\; AG;<<UL>6H;..:=0V R4%HF ZD5P5U!K-GKPN;6U#H!U->@4TJ#U%
M"=@.'NKGQ%J*_9Y;)1&_#$=A^5&IZ!=0^&8[2UC+R*^[!KN0H'2E(S3Y@N<-
MY^NS::M@]J I3:3W_E71>']/:PTR*-P0XZYK5V+G.*=2;"X4444@"HYFVQ,?
M:I.E9M[<%V6*/G)P<5,G9$R=D2:-"LUV)64,ON*Z)H[92 8H^?\ 9%5-(M/L
MUJ-P^:N4\:ZC=6FKZ:D$I17?Y@._6K@_9PNSKP6&=:7(F=P+> C_ %,?_?(H
M^S0?\\8_^^14.FNTEFK,<FK=;IW1$ERNQ%]F@_YXQ_\ ?(H^S0?\\8_^^14M
M%!)%]F@_YXQ_]\BC[-!_SQC_ .^14M,DD6-<L0*&[!N-^S0?\\8_^^12&"W'
M6&/_ +Y%9]QJ?)5%/U%5#+<RGAR!7++%Q3M'4WC0D]7H;/EVO_/*/_OD4X06
M[=(H_P#OD5B>7<]?-HW74?\ RT)J/K;ZQ*]@NC-S[-!_SQC_ .^11]F@_P">
M,?\ WR*RH=39#MD4GWK5AG29001]*WIUX5-C*=*4=P^S0?\ /&/_ +Y%'V:#
M_GC'_P!\BI:*V,R+[-!_SQC_ .^11]F@_P">,?\ WR*K:AJUKIT)>:9%([$U
MYMKOQ:MX7:&W@9B.-RU<82EL)R2W/4OLT'_/&/\ [Y%'V:#_ )XQ_P#?(KY[
MN?B'J]RQ,,LL8-5D\<:\C9:[E(K=82H9.O!/<^C?LT'_ #QC_P"^11]F@_YX
MQ_\ ?(KPW3/BK<V<@^U1RRBO1_#_ (^L-:502L3=,,:RG1G'=&D9QEL=7]F@
M_P">,?\ WR*/L\'_ #QC_P"^13TD210R,&4]Q3JR*&K&B?<15^@Q3J** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ I&^[2TC?=H XKPM_R,FI_[W^%
M=M7$^%O^1DU/_>_PKMJ "BBB@ HHHH 1CM&:SI-42.0J2.*OR_ZLUR=Y_P ?
M+T ;7]KI_>%']KI_>%<]13 Z'^UT_O"C^UT_O"N>HH Z'^UT_O"C^UT_O"N>
MHH Z'^UT_O"C^UT_O"N>HH Z'^UT]11_:Z?WA7/44".A_M=/44?VNG]X5SU%
M '0_VNG]X4?VNG]X5SU% SH?[73^\*/[73^\*YZB@#H?[73^\*/[73^\*YZB
M@#H?[73^\*/[73^\*YZB@#H?[73U%']KI_>%<]10(Z:'4DE?:"*O@Y&:Y;3_
M /CXKJ4^X/I2&+1110 4444 %%%% !1110 57O\ _CPN/^N9_E5BJ]__ ,>%
MQ_US/\J .<\!_P#(,N?^NQ_F:*/ ?_(,N?\ KL?YFB@"?P-_R+%O_GM725S?
M@;_D6+?_ #VKI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"0!DU2NM06'(7
M#'VJ)U(P5Y%1BY.R+C.%&35274H(^-W-9;RSW+9#,HIZ6O=SNKCEB9R^!'0J
M,5\3)GU5R?W>#4)O+R3H!4PB0=%%."@=!6;]I+>1?N+9%4M=-U%)MN/\FKE%
M+V7=CY_(I[;BEW72]!5NBCV7F'/Y%87=Y'_"*E35)!_K,"GD ]J:8D/5132J
M+:0O<>Z+46IP/QNYJVDBN,J:Q'M03E?EI@,]NV0[,/2M(XF<?C1#HQE\+.AH
MK.M=163Y7&T^]: ((R#79"I&:O$YY0<79BU#<7,=K$9)#A14=_?1:?:23RL!
MM7.#WKPGQEXYN]7O'M[)WBC/=3Q713I2J.R,YS45=G>Z_P#$_3+$M%;3@RCC
M!QUKA+WXK:].Q%NL93L?\BN1CM"QWSMYC'DDU9$2+T4"O3IX&*7O'G5,=K:)
M:U#QAK^HQ,DJJ%;K@U<\/^/M5T15B*1B->,GK67M'I36B1NJ@UH\#2>MA1S.
MLH\C>A[#H'Q/TR_*Q7,X$Q[#%=[;W$=S"LL1RK=*^6)+0JWF0-Y;#H176^#?
M'=WI%XMM>,\L;$*"QX%<-?!N&J.JCBHU#W^BJUC>PW]LLT+AE('2K-<)U!11
M4<T\4"[I7"J.YH&DWL245%!<0W,8DAD5U/0BI: ::=F%4;S4X+4$,V&J#5=2
M%M'M7ECQQ6)#;27+^;,Q(ST-8U*K3Y8[F4I]$69=;NI#B  BHOMNIMSM%7$@
MC0<(*DP/2LN63W9%F]V9WVO4_P"Z*/M>I_W16C@>E&!Z4<K[ARON9WVO4_[@
MH^UZG_<%:.!Z48'I1RON'*^YG?:]3_N"E^UZE_=%:&!Z48'I1RON'*^YG?:]
M3_N"E^UZE_=%:&!1@>E'*^X<K[F=]KU/^X*/M>I_W!6C@>E&!Z4<K[ARON9W
MVO4_[@H^UZG_ '!6C@>E&T4<K[ARON9WVO4_[@IPU+4HN648J_@>E(44]11R
MR[ARON):Z\I;;.P!K:AF29-R'(KGI[*.1?E 4^M5K6ZFT^X"N2R54:DHNTAJ
M;CN==144$RSQ*ZGK4M=)L%%%% !1110 4444 )@>E+110 4444 %%%% !111
M0 4444 %%%% !1110 4444 9>J:8+I2Z#]X!QBL)9YK)]DPPHKL:K3V4,X.Y
M!GUK&=*[O'<SE"[NC$CO89!PU2^<GK2R^'RQS'+M^E0'P_/_ ,_)K.U1="??
M[$WG)ZT><GK4'_"/W'_/R:/^$?N/^?DTO?["][L3^<GK1YR>M0?\(_<?\_)H
M_P"$?N/^?DT>_P!@O+L3^<GK1YR>M0?\(_<?\_)K/U6RGTRU:8S%MO:CW^P7
MEV-?S4]:/.3UJA8Z3/>6D<XN"-XSBK'_  C]Q_S\FCW^P7EV)_.3UH\Y/6H/
M^$?N/^?DT?\ "/W'_/R:/?[!>78G\Y/6CSD]:@_X1^X_Y^31_P (_<?\_)H]
M_L%Y=B?SD]:8]W$@Y:H_^$?N/^?DU+'X><'+S[OK1^\?0/>[%&:^:9O+M^2:
MT-,TD[_.G!R>16C;:9! /N*6]:N@ # K2%)WO(J,'>[ # P*\V^(<JPZKILC
MG"JV3^M>E5YI\18A/JFFQ'^)L?SIU_@/8RBWUE7[/\C<T_QIHT-HJ//@BK7_
M  G.B?\ /Q638^"89;57++S5K_A!(/[R_E4IU;&TX9?S.[9<_P"$YT3_ )^*
M/^$YT3_GX/Z53_X06#^\M'_""0?WE_*G>J1R9?W9H1>,]'G;;'/ENU+-<O>O
MA#\AK%/AN"QF&-K'-;UM"(XP*XZE2=27(]B*D*$/>I7^8L5NJ#WJ; ]*K3ZA
M:6QQ-<(GU-1?VSIO_/Y%^=7&-EHCG<K[EZC J#[9;[0WG+@]#FI4=9%W(P(]
M13 ;)"KCFJP:2TDW+]VK$EU!%*L3RJKMT4]Z=(@=2#6<Z=]5N5&71[&C;3K/
M'N!K+\2>(+?0;!I9GVL0=OUJ&WNA928D;"YZFO%O'GB&;6-9DLT=O+B?MTKT
M<"W7T[')B$J6O0S]?\2ZAXEO'+,1%DCY35"&S2,9))/?-20Q+$@ %3!2QP!D
MFOI*5&,$?/UL1*H_(:%4=A^5&!Z"K/V&Z_YX/^5->UGC&7B8#WK6Z,+,K/$C
MC! _*JGDRVDHGMG<,O(&:T3$X3>5.T]Z9C/6IE",EJ7"K*#NCT'P%\06:1;#
M49 H48'KFO74<.BNO1AD5\J3J]M.EQ"2K*P)Q7N_PZ\1_P!M:-F1OG0A,$^G
M%>-BJ'LW='M8>LJD;G;4445QG0%%%% !1110 4444 %%%% !1110 4444 %%
M%% !2-]VEI&^[0!Q7A;_ )&34_\ >_PKMJXGPM_R,FI_[W^%=M0 4444 %%%
M% #)?]6:Y.\XN7-=7,0(SDUQ^J-CSV!Z*: ,'4];\B?[+;D&X(X!JC_:>M0$
M27$2K#U)]JBT5%O-1\^4996(&?K75301RQ%&4%2,4Q%?3M0CU&U\Z)LBFV\]
MR\[JX&T'BI+2TCLX"D0 7K@5BZ9=/)J$ZDG >@#I:*Y+6KJY_M!H89&7Z5I:
M9;W&G64DUQ<--GD9[4 ;=%<AMO-7O9/)N'B0#(Q6CI2W=I)Y,[/+D_>- &]1
M7.K>R_VK)'N.T'I4FK7<D,H"L1Q0!J7UR;:!G'89J+2;TWUF)CUSBJM^Q?1P
MQZE*C\,DC1L@=S0!NT5Q\BSWMQ*#?FW"MP">M.T.^D76Y+!K@SA%SO\ 6@#H
M;S4([5U1FPQZ5,DQDM?,3DXXKEO%-I+-?0[)BG%;%A');Z-\TA8A#S^% %O3
MIIYXW,X (; Q5VN?\+W+3VD[.<XD(Y^IJC)/=:QJ4UK!,T/E'[P[T ==17)0
M2W6DZFL$\S3+C)8U=UZ\D2*!HF*[QVH Z"BN)>TU!K,7?VQP,_=KH]&NVN8-
MK9+(,$^M &]I_P#Q\5U2?<'TKE=/_P"/BNJ3[@^E(8M%%% !1110 4444 %%
M%% !5>__ ./"X_ZYG^56*KW_ /QX7'_7,_RH YSP'_R#+G_KL?YFBCP'_P @
MRY_Z['^9HH G\#?\BQ;_ .>U=)7-^!O^18M_\]JZ2@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHIKMM0FANP&=J%X4PB'D\51BMRQWR=:09FNG)[&KO2O+NZLN:6QW
M6Y(V0@  Q4<]Q';QEY#@"I:XKQ/<RWMT+&)RFQP21WYK:*N9MV-&3QKID<A0
M[\@XZ5KV&J6^HQAX3P1T-5K71+,6B!X$9BHRQ%4M/T-]/U2:X$S>4W1.PI^Z
M+4WYIDAC+N<**JVNJ6]VTBQ')3K7/^([^2Z8Z=;DX<?ZQ>U4_"*/%)>QNY8J
M.IHY=+A?6QN7OBW3K&X\F4MO]J+3Q;IUW*L<98,3@9KF%FL5\4 7K(%QSNJ7
M7+C2S<VXL)8PY/1*KE1/,SL]0U.WTVV^T3'Y/:L;_A.-+SCY_P JQ_$IE7PG
M!YI.[S!G/X5JZ:NC'3X3)Y.[8,DBERJUQW=S7T[6[34SB G.,X-:6 17GEFR
MKXJG%E)NCQPJ]!UKT&//EKGKBE)6'%W*\UO_ !)U%6=/O&+"*0\TM9M_+]C/
MGCM6&M.7/$UTFN5G!_%+Q2Q,=E:/R3M<9KSBTMQ$F3]X\U)JMR^H>(;MG)(6
M3(S4PZ5]?@Z:4%(^;QU5\W(%.V.1PC?E4EJ US&#T)KOFOK32="CE-C'*V<9
M(KHJ5'!I)7N<=.FI7;=CSWRW'5&_*DVGT/Y5U5UXMMKBW:)=,B0L.H'2IM/M
MX;BQ,IB4$J>WM2]JTKR5A^S3=HNYQU5KJ#>N\?>7D5<F&)I .S&HR,C%:M*2
MLR(R<7='H/PK\3N2FE3/\[-P*]@KY?T"^_LCQ5#<;MJJ*]ZLO%^FO9Q,UU&&
M(YYKP,7%4YGT>%C.M"\5<Z:N9\9$C29L''R58_X2W2_^?J/\ZY_Q3XAL+O39
M$BN$9BN,"N*<X\KU/2PF&K*O%N+W-'P 2?#5N2<__JKJ+B7R8&?TKE_A]_R+
M5O\ Y[5N:Q)LL9 /2E!VIW,,P=L1/U9@<WM^[-RO45J*-J@>E4-,3]T'[D5H
M5E!:7/.BM+A1115E@>!FL/4O$MK93FW))D'I6CJ<AATVXD'54S7+>&+9-2(O
MIP')XPU-+J!<C\60I,J3;OG/'%=';W"7,(EC.5-4KW1K6[MVC6)$8C 8#I44
M*)H6DK%)-NP" Q[FC0!^HZY;:=,L4K?,PXQ3I=6ABM(YR3M<\5PU[#/?W)NI
MMR;#\H/<5LZD2OAVV(&2.@IV'8ZFTNX[J+>IXJ6>=+>%I7/RJ,FN"TZ\U#["
M\Z0/\IP%'>M^PO/[;@:W<^6ZCYA181&WBZT)+)NV XZ5HP:Y;7-E+<1DXB7+
M57-EI^CV#>>L9YZL*YO2H94L=;E*D1.I,?ICBBR8SLM)U*+5+);F(_*3WJ_7
MFWABXOCI"QQ1/L!SN%=1X?UN2^,L4\?EM&=HSWH:%8Z&BBBI *JWD FA/'-6
MJ*35U835R'0KLB1X7/W>!70UR%N?)U$X_B:NN7[H^E70?NV'3>EA:***V- H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "N;\7_\@B7Z5TE<WXO_ .01+]* -+0?^0+;?[M:59N@_P#(
M%MO]VM*@ HHHH **** "BBB@ HHHH *\^\<6TDVLZ8R*2%?GCZUZ#44MM!,R
MM)$K%>A(Z5$X\RL=.$Q'L*G/:Y!IBE;)0:N4@4*, 8%+5+1&$GS-L*0G I::
M_*TV28,I,E\X[ U;'2J?2^DSZU<[5Y=/=OS.Z?0\\\16T=YJL,4Q(4OCK6RG
M@K1<*<G.,_>K!\363WNJPHDQC._&16Q;^#[J-E<ZK*>!QFNJ^BU,.NP[7;:/
M3XH8X20H&.M:V@7"'2H]SC/UK(\56["TA@WG(7&ZL[1_"5Q/IZ2#4I%![ TK
M)QU'JGH2>([C/C/2U1N"><&N\KRR^TB32O&.FI)<M/N/5NU>ITI[((]3E_&T
MYM-$GG4X*BO#K=C<7<EPW)?FO9_B-G_A&+H#T_I7B^F_ZL>N*]3)X*\I>9P9
MI)\B1?J_HT:RZK;HWW2X!JA6EH7_ "&;7_KH*]Z?PL\*/Q(['Q#>6^E:C]G1
M3@+GI7-ZAJT=Q'M QQZ5UWBF_M(=5V2PHS;1R:XO6;NWN&3R8U7'7;7+05TF
MT=-=V;LS6O;&%/ EM<@?O&;!/Y5R%=Q?_P#).+3_ '_\*X>MJ#;3]695E9KT
M0R50T; ^E=-\+M0:VUF.RS\KN3C\:YMONGZ5H_#X,?'%F1]W)_F*RQB3@=.!
M;YK'TA1117A'KA1110 4444 %%%% !1110 4444 %%%% !1110 4C?=I:1ON
MT <5X6_Y&74_]ZNVKB?"W_(R:G_O?X5VK,JC+' H 6BJ<VH11CA@369<:PS9
M55Q[T ;<DR1C+&J$^KQ+D*>:PI+F60\N:B))ZTP+\^J329 /%9LX,T;@_P 0
MQ3J*!'&F4Z)JZB0'R>IP*T[OQ-:BV/E;M[#Y>.]:]Q9P7(_>1J3ZD5531K=7
MR44XZ#% ROH4]W<V9DN.^:S=(!_M2YX/WZZE(TC3:BA1Z"HX[2*-V=5 ).30
M(YR^!.NOQ6[=1&;3#&O4K4S6L;2^85&[UJ; QCM0!R>F:A'I]U)!,#E!Z5I6
M>K?;KH>3_JP<'(J]/ID$S[MBACU..M2V]G#;#"(H^E '+W<PL-5:24':S<8J
M/4]3BNKQ4C#<KZ5U5S8PW(&]%)]2*BCTJW3DQJ6]<4 4[P'^Q5_W*@T)GCT'
M*CG)K>:%&CV$#;C%)%;QQ1>6J@+Z4 </:R6]Y<7)O@WR-QBF^'U@7Q=,;<-Y
M6WC/XUU[:3 9-X51DY/'6I8M/MX9O,CC56/<"@#%\1-Y<\<A!VJ.:NVUPD^C
M$IGE#_*M&XM8[A"KJ#]:2&U2&+RU VXQB@# \)(6L+E2,9E/\S533[I=,UN[
M:X!VL>,"NLM[:.V4K&H4$Y.*BN-/@G.2B[O7% '-7MVFI:LL4(/(]*LZW&42
MR0CE>OZUN6^GP6YW!%W#^+%2S6\<Q4NH.WIF@#)E'_$G'%)X=SB;CO6P8$,>
MS QZ40P)#G8 ,^E &AI__'Q75)]P?2N5T[_CXKJD^X/I2&+1110 4444 %%%
M% !1110 57O_ /CPN/\ KF?Y58JO?_\ 'A<?]<S_ "H YSP'_P @RY_Z['^9
MHH\!_P#(,N?^NQ_F:* )_ W_ "+%O_GM725S?@;_ )%BW_SVKI* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGJ:&T!>HHHJ0"BBHYY1%$6/:ANPC.0;]0&.S5UZ_='TKF-&@,]Y)(PXSD5U
MZ4Z"T;'36EPHHHK<T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0!;T[_CXKJD^X/I7*Z?_ ,?%=4GW!]*0Q:*** "BBB@ HHHH **** "J]_\
M\>%Q_P!<S_*K%5[_ /X\+C_KF?Y4 <YX#_Y!ES_UV/\ ,T4> _\ D&7/_78_
MS-% $_@;_D6+?_/:NDKF_ W_ "+%O_GM724 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHHKJ225D;)6"BBBF,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KF_%_P#R")?I725S?B__ )!$OTH
MTM!_Y MM_NUI5FZ#_P @6V_W:TJ "BBB@ HHHH **** "BBB@ HHHH ****
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M5;N]57D8?CFO2E 50HZ 8%   P  /:EKS92<G=G<DDK(****D84444 %%%%
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M&7/_ %V/\S10!/X&_P"18M_\]JZ2N;\#?\BQ;_Y[5TE !1110 4444 %%%%
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M$Y<JT.C_ +3MO^>JT?VG;?\ /5:YT:5'CH:7^RH_0UE[6IV(YY=CH?[3MO\
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M8X).: -FBJL%_#/]UOUJUD'H: "BBB@ HHHH **** "BBB@ HHHH *YOQ?\
M\@B7Z5TE<WXO_P"01-]* -+0?^0+;?[M:59N@_\ (%MO]VM*@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BB@]* (GN8(SAY%7ZU&U]:[3^_3
MIZUR_B#1]9NYU:S90H/.:Q/^$;\3?WD_.L95))VL>E2P=&45)U$B#6IXF\86
M+!P5#<FO1X;ZU\H?OEKS.3P1KTMPL[;-Z]#5P>&_$P&-R?G6<)3BV[;G?B:.
M'K0A%55[JL>BK>6[MA9E)]*F!SR*X#3-!\007T<D[+Y8ZUWD*LL2ANM;PDY;
MH\C$T(4FE"7,244459RA1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %(WW:6D;[M '%>%O\ D9-3_P![_"NVKB?"W_(R:G_O
M?X5VU !1110 4444 %)M'I2T4 )M7THVKZ4M% ";5]*-J^E+10 FU?2C:OI2
MT4 )M7THVKZ4M% ";5]*-J^E+10 FU?2C:OI2T4 )M7THVKZ4M% ";5]*-J^
ME+10 FU?2C:OI2T4 )M7THVKZ4M% ";5]*-J^E+10 FT>E+110 4444 %%%%
M !1110 4444 %5[_ /X\+C_KF?Y58JO?_P#'A<?]<S_*@#G/ ?\ R#+G_KL?
MYFBCP'_R#+G_ *['^9HH G\#?\BQ;_Y[5TE<WX&_Y%BW_P ]JZ2@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1ONGZ5
MRE__ ,AB.NK;[I^E<I?_ /(8CK"OLC.IL:&<#)JE-K%A;OLEN$5O0U:F_P!0
M_P!*\_:SMK_Q$B76TJ<YR<4)7!'9#7M,8X%VA)J]%-'.F^-@R^HKGT\,:&K@
MJL>0>/G%;44<-A;8C7Y!Z4.P%JBLJUUZUNO/QE?)^]N.,T^TUF"\E:.-6X&<
M]J+,"^945@I;!/04^N#U+Q$R^([:)0X0-@C!YKK+K5X;2T6XD5MK=!0T%C0J
M%KJ%7VF0!O2L2T\76EY?):QPR[F_BP<?RI]S<68O0KH=^ZBP&]VS16=?ZO;Z
M;!OE!( [5D#QO8F14\B;YC@'!Q_*BS ZBBH+:[CNH/.C^[6)<^,+*WF:/RI'
M*G!VC/\ 2BP'15"]U"DJQ-( [=!533=8AU.,-&C+D=&JC?7%FFMV\<B$S'[I
MHL!OT54O]0AT^+S)>E8T7C*SEF\L03#W(./Y468'256OO^/8U+#,L\*R+T:H
MK[_CV-3+8E[$_A__ ):5NUA>'_\ EI6[6M'X$73^$****T+"LO7/^/,_2M2L
M_5H'GM&5.N#0!G>$?^0?+_UT/\S70UP&G2ZEIT<D2L0"Q/0U<_M34_[S?D:
M.SHKC/[5U/\ O-^1H_M74_[S?D: .SHKC/[5U/\ O-^1H_M74_[S?D: .SHK
MC/[5U/\ O-^1H_M74_[S?D: .SHKC/[5U/\ O-^1H_M74_[S?D: .SHKC/[5
MU/\ O-^1H_M74_[S?D: .SHKC/[5U/\ O-^1H_M74_[S?D: .SHKC/[5U/\
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MPFNATK4]273H@K-C'H: ._HKC/[5U/\ O-^1H_M74_[S?D: .SHKC/[5U/\
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M;5Q/A;_D9-3_ -[_  KMJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JO?_ /'A<?\ 7,_RJQ5>_P#^/"X_ZYG^5 '.> _^09<_]=C_ #-%'@/_
M )!ES_UV/\S10!/X&_Y%BW_SVKI*YOP-_P BQ;_Y[5TE !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY$7_ #S7\JDHH C\B+_GFOY4>1%_SS7\JDHH C\B+_GFOY4>1%_SS7\JDHH
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M6Y9T-%<JNI7C*" _/M5J\U:2RT47,@;<3B@#H**Y./5KN2-9 'P1GI5O3/$
MN+PV<B,KJ,DF@#:D0H=Z'!'I72:)J'GQB)C\RCFL'AE^M%A,;6]R#@,<4 =O
M134.44^HI'FCC&7=5^II#'T4R*5)EW(P8>H-/H **** "BBB@ I&^[2TC?=H
M XKPK_R,FI_[U=M7$^%?^1DU3_>_PKMJ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JO?\ _'A<?]<S_*K%5[__ (\+C_KF?Y4 <YX#_P"09<_]
M=C_,T4> _P#D&7/_ %V/\S10!/X&_P"18M_\]JZ2N;\#?\BQ;_Y[5TE !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 57O_\ CPN/^N9_E5BJ]_\ \>%Q_P!<S_*@#G/
M?_(,N?\ KL?YFBCP'_R#+G_KL?YFB@"?P-_R+%O_ )[5TE<WX&_Y%BW_ ,]J
MZ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10@.MTNZ-[IT-P>KC-/OO^/8TS2O^0=#^[\OC[OI3[[_ (]C6<MF3+8G\/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *KW__ !X7'_7,_P JL57O_P#CPN/^N9_E
M0!SG@/\ Y!ES_P!=C_,T4> _^09<_P#78_S-% $_@;_D6+?_ #VKI*YOP-_R
M+%O_ )[5TE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 C?=/TKE+_\ Y"\==6?NGZ5R>HD#5HR:PK[(RJ[%Z4$P,!U(
MKDX]"^T:H&G7*9YKJQ-'C[PI!)"#D$9I*5@N0V>F6UCGR5QFIKBVCN4V2#(I
MWGQ_WA1Y\?\ >%%PN.1%C0(O0# JO=Z?!>IMF7(J;SX_[PH\^/\ O"E=!<J6
MFD6ED<PIBKDD:RH58<$8I//C_O"CSX_[PIW"Y7M=,MK,DQ+C)R:+S3+:^4"9
M<XJQY\?]X4>?'_>%%PN5;/2;6Q/[E,59GMX[B,I(,J1BE\^/^\*//C_O"BX7
M,^'0+&!]Z(<U=M[2*VW>6N-W6G^?'_>%'GQ_WA1S!<I7>BV=[(7F3)-3V>GP
M6*%85P#4WGQ_WA1Y\?\ >%%PN,N;6*[CV2C(JG;:#96LOF1IA@<U?\^/^\*/
M/C_O"BX7) ,#%5K[_CV-2^?'_>%5[R5#;D!JF35A-Z%KP_\ \M*W:PO#_P#R
MTK=K:C\"+I_"%%%%:%A1110 4444 %%%% !1110 4444 %%%% !1110 4R;_
M %$G^Z?Y4^F3?ZB3_=/\J .%\-:=!>W=\9E)Q(<5U'_"/V/]PUA>#O\ CZOO
M^NIKLJ ,K_A'['^X:/\ A'['^X:U:* ,K_A'['^X:/\ A'['^X:U:* ,K_A'
M['^X:/\ A'[#^X:U:* ,K_A'['^X:/\ A'['^X:U:* ,F70;0QX1.>U<_=:?
M<6+$X^7VKMJCDA20890?K0!PRW /!!S4H8'O70W.A13DE6V_2LR7P\Z'Y9&-
M,12R/6D+@=ZL_P!B3YZM4L?AUG/S2,* ,QIQT4'-6+33KB]8$CY?>MZUT.*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JO?_ /'A<?\ 7,_RJQ5>_P#^/"X_ZYG^5 '.> _^09<_
M]=C_ #-%'@/_ )!ES_UV/\S10!/X&_Y%BW_SVKI*YOP-_P BQ;_Y[5TE !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>AI:Y&WUVYA(#H,>];UEJL-T -XW'M2 T**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *KW_P#QX7'_ %S/\JL57O\ _CPN/^N9_E0!SG@/_D&7/_78
M_P S11X#_P"09<_]=C_,T4 3^!O^18M_\]JZ2N;\#?\ (L6_^>U=)0 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9)C@ 9K+B\6Z;*X56;).*2BWL%TC=HIJ.)$#+T(R*=2&%%%% !1110!9LO\
M75K#I639?ZZM8=*[\-\!RUOB"BBBN@R"BBB@ HHHH **9)*L:Y8UFW&L1+\J
M'YJ:38U%O8U"0.M,,T:]7 KGY-2NY3A,8J(K<2??JN4T5/N=$UY"O_+1?SJ(
MZC"/XA6"+3/WB?SIXLT[DT<J'R1-C^TXO44X:E$>XK%^QQ^]'V*/U-'*@Y(F
M\M["W_+1?SJ43Q'I(OYUS)LQV)I1%-']PT<J%[-=SJ P/0YI:YI+V\AZXQ5R
M#65SB4\TN5B=-FS14,-S'.,H:FJ3,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***9)*L:EF/
M H ?1G'6L>ZUZWBRJM\PK)FUZZ<XB(Q0!U9FC7JX%1F\MQUF7\ZXU[J\E^\:
MB,<C_>)_.G8#LVU&W'_+5?SIG]J6_P#?7\ZXX6WJ3^=+]F'J?SH [)=2MS_R
MT7\ZE%[;M_RV7\ZX?[-Z$_G0(74_*3^= '=B>)NC@T\$'I7#K<7<7W35J+7+
MN,X<C% '7T5B6OB"!\+(WS5KQ3I,NY3UI 24444 %%%% !1110 4444 %%%%
M !3)O]1)_NG^5/IDW^HD_P!T_P J .0\'?\ 'U??]=3795QO@[_CZOO^NIKL
MJ "BBB@ HHHH **** "BBB@ HHHH **** ,O692EOM!^\*RM,0"WSWS6AKP)
MC0^E4M/.;85RS_B&,OC(M<9DT6Z93@A.#7&>'K5;VP26:Z4,>H)KL=?_ .0'
M=?[E<3X;T>2[T^.1<X/O6BV+6QU5AI<<4RR).KX/:N:@AFU'QG?6YE(11D#\
MZZO2],DL\[L]:YW1/^1^U#_=_P :$!9U3P_=06CRV]R58=,5H>&M1>XB^S2D
MM)$/F)[UJZE*D5B[,1@5S7A1&_M:[E_@;I1NA'6S)OC*FH-!D*74Z$\9JTQX
MYJCHXS?3$?WJR>DTR'\2.JI"0.M+VK'UJ\EMMHC[BNF4E%79M)V5S6WK_>%&
M]?[PKDDNM2==PQBG>?J?M6/M_(S]KY'27CK]BFY'W#_*N9\&$+;SY./WI_F:
M'EU)T93C##!JM9VUY8JPB &XY-/V_D'M/([;>O\ >%&]?[PKE//U/VH\_4_:
MCV_D'M/(ZO>O]X4;U_O"N4\_4_:CS]3]J/;^0>T\CJ]Z_P!X4;U_O"N4\_4_
M:CS]3]J/;^0>T\CJ]Z_WA1O7^\*Y3S]3]J//U/VH]OY![3R.KWK_ 'A1O7^\
M*Y3S]3]J//U/VH]OY![3R.KWK_>%&]?[PKE//U/VH\_4_:CV_D'M/(ZO>O\
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M)P13W&TI;G4 @C(.:6L[2[OSX]A/*CFM&H:L8-6=@HHI-RYQN&?K2$+1110
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M3S?\\11_PD\W_/$5M?V-9?\ /*C^QK+_ )Y4<T.P&+_PD\W_ #Q%'_"3S?\
M/$5M?V-9?\\J/[&LO^>5'-#L!B_\)/-_SQ%4K_6);W"LFT5T_P#8UE_SRK+U
M?288H]\*8P.:3<;:(#'A&(ABI:AMWS&!WJ:H$%%%% '&W6;W5S&Y^6-^E=6E
MK!Y2KY2XQZ5R^L(VFWZ7 4D2/SM%;BZQ!]F$GH.F>: "#1X[=YF1L>9U J&Z
MMUL+=G2)9']Q5&PU:YO);IAO"1GC(/-6[758KI3%,I#8_BXH R- D$EQ<.1L
M<-PH[U:NY[J>]DCD#11@9# UG,VV]:2S1E56^;CK4T,EU?7TGF2@1XSM;B@"
M;3=6>+4$M2V\.>I-==7 0A1XBM]B$8/)Q7?T %%%% #7&Y<5?\.2%9I5[9K.
ME<(F:UO#ELP,DC#KR* -ZYF,,)<#.*\]U_QE<H[0+%M[9%>C.BR+M89%8&J>
M$[&^5BL($AZ$TAF-H?B:X&FQ[DW'U-:/_"3S?\\15W3/#EM9V20RQ@LO4BKO
M]CV7_/*@#&_X2>;_ )XBC_A)YO\ GB*V?['LO^>5']CV7_/*@#&_X2>;_GB*
M/^$GF_YXBMG^Q[+_ )Y4?V/9?\\J ,7_ (2>;_GB*;)XFF,3CR1RIK<_L>R_
MYY4R71[(0N?*_A- '->!Y#+)>.1C,A-=O7%^#$"7%\JC@2&NTH **** "BBB
M@ HHHH **** "BBB@ HHHH *AN+=+B,JP%344-7 Y2ZTZ>SEWPAF7.:(M0QQ
M* IKJF4,,'H:S[C1[6;GR_FKGE1:U@9.#7PF<+N!NCBE-U"/XQ4&HZ1]EM9)
MDP HJGI-FU^,DC&*FU3L+W^Q<EU"-?N$,:@6.YOW V%5SU%;,&AVR<N@)K2B
M@CA&$&!35*4OB#DD]RI8:<EI&.[>M7Z**Z$DE9&J26B"L#Q!_K(ZWZP/$'^L
MCK.M\!-3X1EI_P >ZU/4%I_Q[K4]9QV)6P4444QA1110 4444 %4]39ELI-O
M]T_RJY4<\?FP.GJI% ')>!$0PWC'EO-//XUULT<<B_O%! ]17"6L\OA2ZDCD
MC=TE<M\BDU8O/%C:ALAM()XV)P2R&J:;8SL8%A\LB(+MSVJAJHDMK=C:6X9W
M'.!2:9:W<.G%9'!E8Y!K#C\1W&GWUPEY'+*H.%VJ:20BKX?=O[>470V7']TT
M>.X6N-5TR-21N;&1VZT_3D?5?%2ZHB,D6,888-.\;>9%J6FSHC,L;9.T9]:K
MJ/J,U/0IM/LDF6\E9MPXS6Y;W9N=%<'JBX)K$U/Q#_:=JEM#;S*^X9)4UNVU
MDUOHSY'S.N:3VU X^QU+4;75I1:VAE&*=<WFH76LPS7]L88U')-26.O+I&JR
M^;:S-QC*H?\ "I]0UD>(9!;P6\T988RRFJ Z2]*2:&3$<J4."*Y7PWX;DOK&
M60W<D?[P\ ^YKI6M9+7P\L)Y=4/2N>T#Q&-*LI89[:9FWD@A#[^U);: :/A:
M[E&HW=G(S,L)P"3UKL*Y#PM:2MJ-W>R A)CN4$<BNOJ9;B84444@"BBB@ JO
M<VRSISUJQ10G8#G9+>:V?A25H6X'1N*Z!T5QAAD53ETR%^549K55.X[F?YJ?
MWJ/.3^]3[C3C%'N&*FTS2?M>XM@XIJ<;V'S*]BD9\G"#)JU9:7/=2 R*57-=
M!;Z+:Q8)C&ZM%$6-<*,"K*(;2T2UB"*!QWJQ112 **** "JE_8K?0&)CC-6Z
M* /,=<\$/"6EMRTA/.*XV:QN+68)/&4.0.:]_(!&#61J/AVROSN>(%\YS0!R
M&C^%%O[#S!.R-CM3)M.U70Y=\)EF0'N:[S3; 6$1C&,=JMR1K*A5QD$8H YK
M0_%*7N(;G$<N<;:Z=6##(.0:X7Q)X=-FS7]@H0H.W6M3POK@OHOL\I/FQCYL
MT =/1110 4444 %%%% !1110 TNH[TGF+ZUF7$KB5@#WJ'S7]:Y7B;.UC=4;
MHV?,7UH\Q?6L;SG]:7SG]:7UKR#V)L>8OK1YB^M8_G/ZT><_K1]:\@]B;'F+
MZT>8OK6/YS^M'G/ZT?6O(/8FQYB^M'F+ZUC^<_K1YS^M'UKR#V)L>8OK1YB^
MM8_G/ZT><_K1]:\@]B;'F+ZT>8OK6/YS^M'G/ZT?6O(/8FQYB^M'F+ZUC^<_
MK1YS^M'UKR#V)L>8OK1YB^M8_G/ZT><_K1]:\@]B;'F+ZT>8OK6/YS^M'G/Z
MT?6O(/8FQYB>M'F+ZUC^<_K1YS^M'UKR#V)L>8OK1YB^M8_G/ZT><_K1]:\@
M]B;'F+ZT>8OK6/YS^M'G/ZT?6O(/8FQYB^M+YBGO6-YS^M/AE<RKD]Z%B;NU
M@='0V**.U%=9@%%%% !1110 4444 %%%% !1110 57O_ /CPN/\ KF?Y58JO
M?_\ 'A<?]<S_ "H YSP'_P @RY_Z['^9HH\!_P#(,N?^NQ_F:* )_ W_ "+%
MO_GM725S?@;_ )%BW_SVKI* "BBB@ HHHH :_P!QOI6--_K#6R_W&^E8TW^L
MKDQ70WHD=0W4ACMW<=0I-357O?\ CUD_W3_*N-;G0</8:CJ>JBY81\1N5&#3
MK/5=3O+F2P\K_5#.0>:O>$4*V]]E2,RG^=-T1"/$UZ=IP5_QKH;6NADKZ$ND
M:G=0Z@ME.N-YSS4^NZS<12QV]HH=F;:WM5-E;_A+K<X.,?X4S5 UEJJ2NI97
M?KZ4K*]QW=@NKG4-'B^U%"5'7)KH3J?_ !)?M?&_R]V*Q_%=Y'<:&882)&..
M%YJQ]ED_X1=3@Y\K[M)I-)L?5F9;7.HZK;-=JAY!Z'BH_!#3&YO1*N")*O\
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MW3_*@#D/!W_'U??]=3795QO@[_CZOO\ KJ:[*@ HHHH **** "BBB@ HHHH
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MM/\ ^?5/RKTCC.0_X32Y_P!FC_A-+G_9KK_[&T__ )]4_*C^QM/_ .?5/RH
MY#_A-+G_ &:/^$TN?]FNO_L;3_\ GU3\J/[&T_\ Y]4_*@#D/^$TN?\ 9H_X
M32Y_V:Z_^QM/_P"?5/RH_L;3_P#GU3\J .0_X32Y_P!FC_A-+G_9KK_[&T__
M )]4_*C^QM/_ .?5/RH Y#_A-+G_ &:/^$TN?]FNO_L;3_\ GU3\J/[&T_\
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M !1110 4444 %%%% !1110 5Q;_\CV_^[7:5Q;_\CV_^[0!V:_=%+2+]T4M
M!1110 4444 %%%% !1110 4444 %%%% !1110 4R;_42?[I_E3Z9-_J)/]T_
MRH Y#P=_Q]7W_74UV5<;X._X^K[_ *ZFNRH **** "BBB@ HHHH **** "BB
MB@ HHHH ***BFF2%"SL * )"0!DFJD^I6]N3O-8=[JLMRYCA4@=,BH8K"1_F
MDE)]C7/*LV[1,G4;^$TY/$-OG"DTQ?$,&>2?RJ%;*)1RH-*;2(_P"IYJG<5Y
MFC#K5K,< G-:".KJ"#7+2:=GE'V_2HXKFYL).=SKGO35:2^)#51K<Z^BJ=E?
MQW<8((#>E7*Z$TU=&B=PK \0?ZR.M^L#Q!_K(ZSK? 34^$9:?\>ZU/4%I_Q[
MK4]9QV)6QSFI^&XY;AKJW!\YCDU3_P"$>N[T^5>C]UT.#77T55V.Y5M;&*UL
MUMD'R 8K#O=!ECN_M%D/F]ZZ:BBX'.Z;X?"3&>Z'[S.1]:Z*BBANX#)8UEC*
M-T/6N9N= G@NWFLAC=P<^E=310G8#$TC119YDE!\PG-1:EH DF-Q;#]\QR37
M04478',6V@2S7B7%Z,LO QZ5KWNG+<0)&!PO2M"BBX&?:6'V>R,&*ATC2AI\
MUPX&/,.:UJ*+@9&OZ,FKV@B8=&S5C2M-CTVW$:#''-7Z*+@9&LZ+%J<0R/F4
MY'UK*&@W=RPBNA^Y'''I76447 IQV*0Z:;2/[NTJ*K:#I8TJUDB QN<M6K12
MN!FZMIJZA#@C+*.*KZ9I<D-B;><<5M44[@<FF@75I<2_9E'ERGYLU-I?AL6.
ML-?X^=A@FNFHHNPN8NL:*M_(EP,^=&/EK-_X1^YO61;Y08T8,,>M=911=@4[
MK3X;K3_LD@_=D 5SQT&\@S!;@>0>/PKK:*+@9>C:1'IEOL4').36I112 K7O
M^H-6?#_W9*K7O^HJSX?^[)4Q_B(E?&;=%%%=1L%%%% !7+^+-%^VVKS0K^^'
M2NHI&4.,,,B@#BO#/B'8QL;ML-'\JUVJL&&0<UQ^O^%S(WVFT8HZ_-A>]9FG
M>)+[2R(+NW? _C:@#T2BL6T\2Z?.@+W"(WIFKG]L:?C_ (^DH O4A( R:R;G
MQ%IT"$BYC)';-<QJ7BRYNR8+.W+YXW+0!J>)_$*6D#V\+?OB.,55\)Z,_F/?
M7*\R\BH-#\-37,ZWE\[$@_<>NXBB6&,(B@ =,4 .Z"EHHH **** "F-&K=13
MZ*+7 KM:1MVJ!['^Z*OT5G*E!]"U4DC"D3:Q4BF*H48  J>Y_P!<WUJ&O-DK
M.QUK5"$ C!I BJ, #%.HI#$"@= * H!R *6B@!-HSG KGM0T>>YO%D505#9K
MHJ*:;0FKD44"1HN%&0/2I< C%%%(8@4*, 8H"JO0 9I:* $VC.<"@@$8(XI:
M* $  & .*8\*.<E1^5244 -5%08  IKPI)]Y1^5244 ,$2 #Y1Q[4_ QC%%%
M #%C5"2H S2[5W;L#-.HH 1E5A@@&F+#&AR%'Y5)10 A (P:  .@I:* $V@'
M.!4T'^M7ZU%4L'^M7ZTX[H3V-H=**!THKUCA"BBB@ HHHH **** "BBB@ HH
MHH *KW__ !X7'_7,_P JL57O_P#CPN/^N9_E0!SG@/\ Y!ES_P!=C_,T4> _
M^09<_P#78_S-% $_@;_D6+?_ #VKI*YOP-_R+%O_ )[5TE !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 44UG5!ECBJ<VJVL0_U@S0!>HR*Y^;Q%MSY8#52D\07,
MAXBQ0!UFY?4?G1O7^\/SKBVU2Z?^$C\:8;ZZ/][\Z=@.WWK_ 'A^=&Y?4?G7
M$B]NA_>_.G+J=TO\)/XT6 [7-%<E'X@N8^L6:N0^(BQ_>*%HL!T-%4(=6M91
M_K!FKJ.KC*G-(!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5Q;_P#(]O\ [M=I7%O_ ,CV_P#NT =FOW12TB_=%+0 4444
M %%%% !1110 4444 %%%% !1110 4444 %,F_P!1)_NG^5/IDW^HD_W3_*@#
MD/!W_'U??]=3795QO@[_ (^K[_KJ:[*@ HHHH **** "BBB@ HHHH **** "
MBBB@!&8*I)[5S&JWCW5R;>,_+6YJ,WE6K^I%<[IT9D_?-R<USUI-OE1E4=WR
MEJUMEA0<<GK5FH;J;[/;/*!]T9KCF\6:M)=-%:V(D4=#1&.F@)';T5R=CKFN
M3W:1SZ=LC)Y;TJ&^\5:A%J4EI:V@E9*=F.QV5,EB652"*XX>*-7@(>\L!%"/
MO,>U=98W2WEI'.IR'&:&@:**L^FW09>$%=7;3">!7!ZC-8%]")8",<U/H%P6
M,D;'[O J*;Y9<I,'RRL;U8>O0O(4*#H*W*1D5OO*#]:Z)QYE8UDKJQQT<MS&
M@49X]J?]HNO?\JZOR(O^>:_E1Y$7_/-?RK'V#[F?LWW.4^T77O\ E2?:+KW_
M "KJVBA52Q1< 9Z5#;R6ER"8@C8.#Q1[%]P]F^YS?VBZ]_RH^T77O^5=7Y$7
M_/-?RH\B+_GFOY4>Q?</9ON<I]HNO?\ *C[1=>_Y5U?D1?\ /-?RH\B+_GFO
MY4>Q?</9ON<I]HNO?\J/M%U[_E75^1%_SS7\J/(B_P">:_E1[%]P]F^YRGVB
MZ]_RH^T77O\ E75^1%_SS7\J/(B_YYK^5'L7W#V;[G*?:+KW_*C[1=>_Y5U?
MD1?\\U_*CR(O^>:_E1[%]P]F^YRGVBZ]_P J/M%U[_E75^1%_P \U_*CR(O^
M>:_E1[%]P]F^YRGVBZ]_RJ*6_GB(#$C/M78>1%_SS7\JYKQ(BK<1;5 X[4>Q
M?</9ON5TNKEUW#.#[4[[1=>_Y5NZ1%&VG1DHI/TJ]Y$7_/-?RH]B^X>S?<Y3
M[1=>_P"5'VBZ]_RKJ_(B_P">:_E1Y$7_ #S7\J/8ON'LWW.4^T77O^5'VBZ]
M_P JZOR(O^>:_E1Y$7_/-?RH]B^X>S?<Y3[1=>_Y4?:+KW_*NK\B+_GFOY4>
M1%_SS7\J/8ON'LWW.4^T77O^5'VBZ]_RKJ_(B_YYK^5'D1?\\U_*CV+[A[-]
MSE/M%U[_ )4?:+KW_*NK\B+_ )YK^5'D1?\ /-?RH]B^X>S?<Y3[1=>_Y4GV
MBZ]_RKK/(B_YYK^5'D1?\\U_*CV+[A[-]SD)9+F1-IS^5;>A0O'&Y;O6IY$7
M_/-?RIX55^Z *J%+EE=L<86=Q:***V- HHHH **** "LZ^T6SU$'SX]V:T:*
M .,NO MKNW6\04U5_P"$,NAP-N*[VB@#B8/ T+.#<QAJZ"P\/6&GX,,6TUK4
M4 '08HHHH **** "BBB@ HHHH **** *<EIO<GUIGV&K]%9.C!EJI(H?8:/L
M-7Z*7L(#]K(H?8:/L-7Z*/80#VLBA]AH^PU?HH]A /:R*'V&C[#5^BCV$ ]K
M(H?8:/L-7Z*/80#VLBA]AH^PU?HH]A /:R*'V&C[#5^BCV$ ]K(H?8:/L-7Z
M*/80#VLBA]AH^PU?HH]A /:R*'V&C[#5^BCV$ ]K(H?8:/L-7Z*/80#VLBA]
MAH^PU?HH]A /:R*'V&G)9[7!]*NT4U1@@]I(****U,PHHHH **** "BBB@ H
MHHH **** "J]_P#\>%Q_US/\JL57O_\ CPN/^N9_E0!SG@/_ )!ES_UV/\S1
M1X#_ .09<_\ 78_S-% $_@;_ )%BW_SVKI*YOP-_R+%O_GM724 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)_6N[UO3(K^R?S&(VJ2,5R/A/1H))'E)(99"!^= 'H*G<N12TV-!&@4=J=0
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M>LO_ 'T?\:/^$(T__GK+_P!]'_&@#8_M>S_Y[Q_G1_:]G_SWC_.L?_A"-/\
M^>LO_?1_QH_X0C3_ /GK+_WT?\: -C^U[/\ Y[Q_G1_:]G_SWC_[ZK'_ .$(
MT_\ YZR_]]'_ !H_X0C3_P#GK+_WT?\ &@#8_M>S_P">\?\ WU7*I,EQXW9X
MV#+MZBM+_A"-/_YZR_\ ?1_QJWIWA>RTVZ^T1,Y?'>@#;7[HI:.@HH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6"?%FGAB,MP<4?\ "6:?_M_E0!O45@_\)9I_^W^5'_"6:?\ [?Y4 ;U%8/\
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MYA@'FNBGB83=MF8SHRCJ6Z***Z#(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *KW_ /QX7'_7,_RJQ5>__P"/"X_ZYG^5 '.> _\ D&7/_78_S-%'
M@/\ Y!ES_P!=C_,T4 3^!O\ D6+?_/:NDKF_ W_(L6_^>U=)0 4444 %%%%
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M&,5Q>M12Z7KT-ZB,T*#+*HZUIR>*XC9EU@D#,.!@UJU<T+UQ816UJQC  SG
M%<AH6J+::G>@JIRW?\*U--N;_4;1KB0L(PV-C#FHO#6F0S:C>F>$]>,CZ4]D
M!6UR:XUR(6L-N,;@=RCFJOBFQ\RXT6T?@X"G]:] @L+:W.8HPIKD_%D;MXDT
MHJA(#<D#IUH3!,CL;B30M2ELILBU5<*Y[FGZ8P?5@XZ%LBM?Q-HW]H61,.!*
M/F)KE?"1N3?E)E?]V^W)%&ZN!Z569J Q,&'4"M,G S67.?M&H)&O((K&IL9S
MV.FT\DV49/I5FH;5/+MT3T%35U1V-EL%%%%,84444 %9>N?\>9^E:E9>N?\
M'F?I0!2\(_\ (/E_ZZ'^9KH:Y[PC_P @^7_KH?YFNAH **** "BBB@ K-U#2
MH[I21\I]JTJ* .(GT^YM'.U"5]:A6< X?@UW4D22KAQD5FW.B6\H)2, T[B.
M<$BMT-.JY-X=N%.8W %4Y-/NXNI)^@H **@83IU1S^%-\R7_ )Y/^5 %FBJW
MFR?\\G_*CS)3TB?\J +-(3BHEBN).BL/PJS'I-W-_%CZB@"$RHO4U'YCR';$
MNZMF#PZXYE(:M:WTJV@ (C&Z@#GK+19KAPTP9173VMI';1A5 Z=:G "C I:0
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **8\L:
M??=5^IJ(WUH.MS$/^!B@"Q14 O;5NEQ$?HPJ575^58$>QH =1110 4444 %%
M%-WJ.K#\Z+@.HIGF)_?7\Z4.IZ,/SI7068ZBBBF 5S'B;_CXB^E=/7,>)O\
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M[22B.HHHKN.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO?\ _'A<?]<S
M_*K%5[__ (\+C_KF?Y4 <YX#_P"09<_]=C_,T4> _P#D&7/_ %V/\S10!/X&
M_P"18M_\]JZ2N;\#?\BQ;_Y[5TE !1110 4444 %%%% !1110 4444 %%%%
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M+=%5/MJ^E'VU?2CVL.X<DBW159;M6.,59JHR4MB6FMPHHHJA!1110 57O_\
MCPN/^N9_E5BJ]_\ \>%Q_P!<S_*@#G/ ?_(,N?\ KL?YFBCP'_R#+G_KL?YF
MB@"?P-_R+%O_ )[5TE<WX&_Y%BW_ ,]JZ2@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBN(Z HHHH **K7-];V@S-*J<XYJ:.1)4#(P8'N* '\T<T4V218D+.0%'<T
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M,1J *DHHK-))61;=PK,UO5$TJQ,[GOCBM.N-\9DM"5;[F1515V)Z(BA/B/4
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MH8FK*HJC@"G5ZL,-"*/+GC*DGH45M[A#E& -7;?6]>TU@UO=!<>W_P!>EI"
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M5G1M"GM;U[N\97F<<D5T5%/G=K"Y5<PKS19+CQ%;Z@,;(UP?TJSK.DIJ<2Y
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M*[=QEA.V"?J:I;7!#9(-=TMEEGNC*F>0HKJ=*O\ ^T+02[&7'!!%6Y$1T(<
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MD9<"GS!P>M; Z"F"%0>*DK>E3<$95)\S"BBBMC,**** "J]__P >%Q_US/\
M*K%5[_\ X\+C_KF?Y4 <YX#_ .09<_\ 78_S-%'@/_D&7/\ UV/\S10!/X&_
MY%BW_P ]JZ2N;\#?\BQ;_P">U=)0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (P
MRI%8,WR:B<UOUBZG$4E,P%<F+B^5270WP[]ZW<E'2N!\30+<:EL89&\?SKNH
MG#H,>E95[HD=W=><P.<YJ(26Y<ET(K7P]:B&)_+7.T51\6P+'8VT0'R[L8KJ
MHUV1JOH,50U;34U%(U8?=.::>NHFM#(T?0+"6SW/;H2:P?$&G6]EJMCY$:IF
M49Q7>V=L+6'RQTK.U/1([^YAE8',;;A34M0:T-B+_5)_NBLO79!'8R,>RUJ#
M"(!Z#%8NL0O?6%Q'&,MMQ6%36T>YK#N>-:E.LU^Y!JK4-[%+I^M/:SC#+4P.
M1FOM,-94HKL?)XJ+55ON;?AGB_)]!6YXAUM[>XC49^[7*Z;>&SG,F>HI^JWY
MOYE<G.!BB5/FJ79,:EJ=D.FU!KRXCW9^]71:I_R '^@_E7&QMLD5O0YK7NM8
M,]@;?/6G.&JL*$]'<QJ0\ TM5KR;RHNO)K5NRN9QBY.R-SP!IL6I:P_FQ!U6
M3G->[?\ ",:/_P ^,=>>?"/1&BCN;F=<;_F7]*]:KY[$M2FSZ6A4J4X)1;1D
M?\(QH_\ SXQT?\(QH_\ SXQUKT5S\L>QM]8K?S/[SF]5\.:3%I\C)9QAAWKG
M/ <:Q:Y?(@PH' KN]4B::PD1!\QKE?">D75CK%Y-,N$<<5E*/OJR/0H5W+"U
M(SEJ6]0_Y#2?2KZ_=%4-0_Y#2?2KZ_=%9Q^)GA1W8M%%%66%%%% $<Z>9!(G
M]Y2*X:,W'AB^,4<#RQNQ<[1QUKO:CDA24890?PII@<?>^)KJY188;.56?C<!
MTK6TK3)_[':"YE+NQSDUK1V<,;9"#\JL=*&^P'(WOA=X[6X>.3DCH.]5?"6D
M3V[B60D#T-=P1D8--5%3H *+A<X_Q<LR:A9S11-)LY.T5%>:[<7%C'$+.0,6
MP>*[1XD<Y90<>HI@M8@^_8,_2G<#&TZ!]*TJ2;:69OFVBN-;4;R?5Y)+JSEE
MASE4(Z5Z@5!7:1Q4/V2'/W%_*A,+F)H^MFXD2!;%X5/<BLOQGYZ7%G)%"\FU
M\G:*[%+>-#E5 /TI7B23[R@_44KZ@<3JVK7&KZ<+)+21&./FQ71VMM)!H(12
M1)Y>,^]:*VT2MN"C/TJ;M1<#C;37;NQ4VMQ;R2L!]\CK4>BP3:AJ#7+1-"$?
M.".M=A):Q2G+*/RJ1(U0850/H*=P.)\1O<6]_P";' \@W#H/>C4-5GU6T73Q
M:2+YB@%L=*[5HD?[R@_44Q+6)#D*,_2BX7*NB6ALM*AMVZJ*T***D HHHH C
MD@CE'S*#6?-I6XY1@M:E%--H#GI[*6W4GS,U9LM'FO(ED$N :M:E_J&^E:VA
M_P#(,BIPJ-SL$9-RL5;;P\L9!E8/6O#;10#"(!4U%;&@4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,AD#J>XKD[_2M/TVSF>=#YLB]1ZU/X/W?V>OEG]SV%-K0#H)+^&.=8F<!F/
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M8%+114 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N0\9Z)]LM%GA7]XK;B1UXYKKZCF57A96Q@@CFIG%25F;X>M*C44X]#
MD?!FN?:8&MYVQ(C;0#[5UTTT<";I&"@=S7E&LD>&_$,<L# QDEF"'/\ *IFU
M76/$DOE6KO'&>N]3TK"-7E7*]SUJ^7*M)5H.T'J>C6^L6=U+Y<,RNV<8%7ZY
M?PWX9.EJ)9]K39SD5U%;P<FM3R<1&G&=J;N@HIID0=74?C43W<2=77\ZHP)Z
MYCQ)X?75)XW QM':MEM5@7O^M1G6;?\ R: ':-8K8:='"!RO>M"LX:Q;G_\
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M=C_,T4 3^!O^18M_\]JZ2N;\#?\ (L6_^>U=)0 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#_Y!ES_UV/\ ,T4 3^!O^18M_P#/:NDKF_ W_(L6_P#GM724 %%%% !1110
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MM>LFFG9@8NIREY$0'O@TL481 *CU!2EPA/<U.I!&17E[U)-G;M!6%K-UJ_\
ML%D7S@MP*TJP/%D#SZ:@3/RMDX_"M5N0]C$T;0O[7:2YO))%(;Y0&.,5/?\
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M5']NZM_SZS_E709'H]%><?V[JW_/K/\ E1_;NK?\^L_Y4 >CU7O_ /CPN/\
MKF?Y5P']NZM_SZS_ )5'/KFJM!(K6LP!4@\4P.@\!_\ (,N?^NQ_F:*C^'Q+
M:/,2.3*<_F:*0%OP-_R+%O\ Y[5TE<WX&_Y%BW_SVKI* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(JQM0E1H6 8'BMG0_P#D&14J?\04?C-.BBBNHV"BBB@ HHHH **** "BBB@
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MQ_F:*/ ?_(,N?^NQ_F:* )_ W_(L6_\ GM725S?@;_D6+?\ SVKI* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $(!&*@DLX9?O+5
MBB@#.?1;-_O1U"WAZQ[1UKT4 <%-:QIXLCL /W3+DBNF7P]9=XZP;G_DH,/^
MY_A7:#I0!G)H=DG2.K$=A!']U:M44 (%"C %+110 4444 %%%% !1110 444
M4 %%%(2 ,F@!:,@=36?=:K!;@@."WI6/-K-S.=L<7'J*SE5C$AS2.F,B#JP_
M.HFNXEZL/SKE3'=3'+,Z_C3AITC=9G_.L_;2>R)]H^B.E^WP_P!X?G4BW,;=
M&'YUR_\ 9C?\]W_.FM82K]V9_P Z7M9]@YY=CKPZGHP_.EKCU:\M_N[GQZFK
MMOKLJ$+-&%'J:I5UUT&JBZG1T55MKZ&X4;7!/I5JMDT]C1.X5S'CO_D7S_O"
MNGKF/'?_ "+Y_P!X4P-C1?\ D#VO_7,5?JAHO_('M?\ KF*OT %%%% !0>E%
M% &)J.CO=7/FICI57^P[CU%=+163HQ;N0Z<6[G-?V'<^HH_L.Y]172T4O80%
M[.)S7]AW/J*/[#N?45TM%'L(![.)S7]AW/J*/[#N?45TM%'L(![.)S7]AW/J
M*/[#N?45TM%'L(![.)S7]AW/J*/[#N?45TM%'L(![.)S7]AW/J*/[#N?45TM
M%'L(![.)S7]AW/J*9-HUQ%"\A(^52:ZBJ]]_QXS_ .X?Y4>P@'LXG&Z+#-JL
M,CH?N.5YK5_L.Y]15;P+_P >5Q_UV/\ ,UUU'L(![.)S7]AW/J*/[#N?45TM
M%'L(![.)S7]AW/J*/[#N?45TM%'L(![.)S7]AW/J*/[#N?45TM%'L(![.)S7
M]AW/J*/[#N?45TM%'L(![.)S7]AW/J*/[#N?45TM%'L(![.)S7]AW/J*/[#N
M?45TM%'L(![.)S)T&=N#C%;MA;?9;58CVJS151IQB[HJ,$M4%%%%:%!1110
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M2>Z/^K9<#]:7Q!I5P^HP7T&,1<FNGV+NW;1N]:5E### $4<[O<.70XN^GO\
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MN?\ KL?YFBCP'_R#+G_KL?YFB@"?P-_R+%O_ )[5TE<WX&_Y%BW_ ,]JZ2@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .*N?\ DH,/^Y_A7:#I7%W/_)08?]S_  KM!TH 6BBB@ HHHH **** "BBB
M@ HHHH **** $9@JY/2N>U+5F9S# 2#G!(JSK=Z8HS"I^9A6;8VV%\U^6/K7
M/4FV^5&4Y-OE0R&P:0[Y\,:OQP)&/E&*)IH[>(R2':HZFN>G\2EY62SVR;3S
M2C!+82BD=+16#I_B**><6T[!9S_"*36/$*Z;+$@(S(>,U5BC?HKE_P#A)9EY
MD50OK6BFO6TVG2W,4@;RA\WM19A8UZ@EM8I1\RYK.T?7K;5AMC<%\9(%6;_4
M4LOO$"DU?1B:(7@GLWWPMA?05LZ7JJW $;YW^]5+>5;JV63@AA5"ZC:TF\^/
M.!6>M-W6Q.L'='8US'CO_D7S_O"MS3[D7%LASSCFL/QW_P B^?\ >%=:=U<V
M3NC8T7_D#VO_ %S%7ZH:+_R![7_KF*OTQA1110 4444 %%%% !1110 4444
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M>)ONCZ5T=<YXF^Z/I7HG(:&@_P#((AK3K,T'_D$0UIT %%%% !1110 4444
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MSN%%%%:$!1110 57O_\ CPN/^N9_E5BJ]_\ \>%Q_P!<S_*@#G/ ?_(,N?\
MKL?YFBCP'_R#+G_KL?YFB@"?P-_R+%O_ )[5TE<WX&_Y%BW_ ,]JZ2@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>__P"/"X_Z
MYG^56*KW_P#QX7'_ %S/\J .<\!_\@RY_P"NQ_F:*/ ?_(,N?^NQ_F:* )_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFO4-/MQ;6446.57%!MK8W0N#M\P=\U/O7^\/SH =12;E_O#\Z,CUH 6BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN1-HZ-&5K:Q@MEPD:@^H%.N;2.Z"B10=IR,BIZ:S!%)8@ >M%V R6!)8?*8
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MHHNPN8=_X=BO(($WE3"N 15.#PKB4-)=2.!SAC744478#8T$<:H.BC%.HHI
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%QTJI05KB4G<9J6L2#Q!;1AOEW8/-=B][%#;>=*V%KCM4MXAXEL_E'+<U?\
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M(:TZYC4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ JO?_\ 'A<?]<S_ "JQ5>__ ./"X_ZY
MG^5 '.> _P#D&7/_ %V/\S11X#_Y!ES_ -=C_,T4 3^!O^18M_\ /:NDKF_
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M1110 57O_P#CPN/^N9_E5BJ]_P#\>%Q_US/\J .<\!_\@RY_Z['^9HH\!_\
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M_0*>BP';45Q/_"2:W_T"GH_X236O^@4]%@.VJO??\>,_^X?Y5R/_  DFM?\
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M65AD$&N;EMP>5.#[4^SOI+:01R?=]32<>Q$H)ZHZ.F2RI$I9V  ]31%()4#
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M +A_E5BJ]]_QXS_[A_E0!S/@7_CRN?\ KL?YFNNKD? O_'E<_P#78_S-==0
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M*O!DO#5$;=%48M5MI/\ EH,U;219!E3FM%)/8QE"4=T/HHHJB0HHHH ****
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MN)J>YO(;10TS;0:JQ-R>D*@UF_V_I_\ SVJY;WD-T,Q-NQ185R0PHW45$UG
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MU>_C]*LQ>(9P?WI%(#JJ*QK?Q!;/@._-:<-S'.,H<T 34444 %%%% !1110
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M4*<,9!@_C7I;_=-<)XOTJYU.2W^SKN\N0%OSKGK.S3-::NF8MOINK/;KLO6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM)YUH>I;%(FKL."E3?9KN;F5P0:>FEQ_QJ#7-:=_=.KFIV][4:NJ;A]T4O\
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M[:UCMH]J+CUH ?#$(8E0=!4E%%(84444 %%%% !1110 4444 %%%% !1110
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MPL9]CI,-ET^<^IZU++8132;VZYSTJW3%EC9RBNI8=0#S1=[BLBM<:=#<.KL
M&48!QS2RV$<L2(W.SI5@S1K((RZAST7/-/HNPLB#[*GD^5VIMO91V^[;_%UJ
MS12NQE--/C2[-R/OXK$\0S7"W$2+;JT9^\Y'(KIZCE@CG7$BY%4I6=V)K0\]
MO[%]06*&W7S-KAL_C7H%FACLX4(P50 TR"QM[=LQ1A35FG*=]!1C;4****@H
MLVGWZUATK)M/OUK#I7=AOA.:MN%%%%=)B%%%% !5>_\ ^/"X_P"N9_E5BJ]_
M_P >%Q_US/\ *@#G/ ?_ "#+G_KL?YFBCP'_ ,@RY_Z['^9HH G\#?\ (L6_
M^>U=)7-^!O\ D6+?_/:NDH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\]JZ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]_QXS_[A_E2&<SX&_P"/*X_Z['^9KKJY'P-_QY7'_78_S-==0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5SWB;_ %/X5T-<]XF_U/X4 7?#W_(&AK4K+\/?\@:&M2@
MHHHH *0\C!I:* .1U_2&MYTOK48V'<]:N@ZPNHVBEC^\/7-:TL2S1LC $$8Y
MKBM1MIM"U(WL )B8XV]A6L7SKE>X'<453TZ^COK971@3CYAZ5<K-JP!1112
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!S/@;_CRN/\ KL?YFNNKD? W_'E<?]=C_,UUU !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7/>)O]3^%=#7/>)O]3^% %WP]_P @:&M2LOP]_P @:&M2@ HHHH ****
M"JU[:17MN8Y5R,<59HH X6WEG\/:F()"?*E;(P. *[6"=)XA(A!4^AJAK.F)
M?VCC'SXX(ZU@:'J4FFW9T^Z.V-!A6/4FMG[ZNMP.SHI%(90PZ$9I:Q ****
M"BBB@ HHHH *9)(L:Y8BG,P5"QZ 9KDKO5;B\UA(+9=T)X9AV-5&+D!"TE[K
M&KM%&2L<+Y^8=:[&-=D:CT%16MNL40.P!L<G%6*<I7T0!1114 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %5[_\ X\+C_KF?Y58JO?\ _'A<?]<S_*@#G/ ?_(,N?^NQ
M_F:*/ ?_ "#+G_KL?YFB@"?P-_R+%O\ Y[5TE<WX&_Y%BW_SVKI* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "J]_P#\>%Q_US/\JL57O_\ CPN/^N9_E0!SG@/_ )!ES_UV/\S11X#_
M .09<_\ 78_S-% $_@;_ )%BW_SVKI*YOP-_R+%O_GM724 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,11JB]%&*T;Y59 .50HP!@4M%%9@%%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 57O_ /CPN/\ KF?Y58JO?_\
M'A<?]<S_ "H YSP'_P @RY_Z['^9HH\!_P#(,N?^NQ_F:* )_ W_ "+%O_GM
M725S?@;_ )%BW_SVKI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** *6IVHNK8KCIS7'C=!*T;C'/%=[U&*PM7TCS?WL0 (I@8W45"]K;N<O"C
M'W%-W/ ^R13QWQ4RNI'44"&);0Q'*1*OT%/>-)%VNH9?0T[(]:3(]:   *
M, =J&( R::\BJ/6F112WLNQ 0/<4 /LX'O+M,#*@\UVL$0AB"#H*I:;IR6D7
M0;CUK1I#"J]]_P >,_\ N'^56*KWW_'C/_N'^5 ',^!?^/*Y_P"NQ_F:ZFX;
M9;NWH*Y7P+_QY7/_ %V/\S72:@2+23']V@#CY9#<79<\]JKZA?I8PY)&\CY1
MZU);#J?>N9\62-_:NFQ@_*SX/ZTQ#QK.JSC>EF2OK5S3==EED\J\C$39PH]:
MVX(4BA"(,+BJMQIUK)()"H\T?=.: ,N^UZX2]>VM(1*Z]13[+7+AKE(+N(1.
MW05F6TXL?%%PTL;?=QNQQWJ'5-02X\16K1HP('6@9W/6D9=RX-1VS%H%)ZFI
M:!$^ASF&Z=2>"<5UPZ5P]H2M\N.[5W"_='TH&+1112 **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ J.6,2(0?2I**35U8$['.X:VG*L, FKBL&&
M15N[LUN%/'S=C60RRVCX;)'L*\V4947KL=L9*HO,NT5#'<*_M]:FR#T-6I)[
M"::W.5\0:/+]L_M.U4M.HP%%9[:WX@,'V?\ LXX(QNKNJ,5:EW(L<KH>E7(B
M:ZN"XE*D;":9X/TVXL;O46GC*B20E<]ZZVBCF"QS?BC1/[0ME: ;95;=E>IJ
MYX?>[-H4NHBA3Y1GO6Q12OI8=M;G+>)=/N+N2 Q1EML@)Q]:Z6$%8(U/4* ?
MRJ2BAO0+!132Z@<D57DNOX5!)]JB4XQW*46]B2:8(I&>:X'XC0W#>'?.13][
MM7>VUE).X=_N]>:EUK1HM1TI[4J"H!(%:8:#E4526R)JS48N*W/FZTD,B8/4
M=:L5%J=C-HNKS0RJ0C.=O':I%8,,@U]A1FIQ/EL13<)G3>&[J*")A(X4YK)U
M:42:E*R-E2>*I*[+T-(22<FJ4+2<C-SO'E-#195BU2-W.%'>K_B.YBG">6P;
M!K !*G(I6<MU-#A>7,"G:/*-JI?/B(H.K# JRS!1DFDT;3YM<UNWCC4F-9,-
MQ4UJBA$TP])SF>M_"?36A\/07#C#&NG\3?ZG\*T-%TQ-)TY+5  J^E9_B;_4
M_A7S\Y<TKGO)61=\/?\ (&AK4K+\/?\ (&AK4J!A1110 4444 %%%% !1110
M 4444 %<KK.LN]Y';6J^9\VU\=JN:SKBV;&WC!,I'&WFI]-TRV*+=>5B23YB
M36D5RKF8'-ZEI4MA(-2@0^9_=%=/HVIQW]L &&]!\P]#6A-"DT11QD$5Q-U#
M/X>U-9(LB&5LL *I/VBL]P.ZHJM8WL=];K-&1@]LU9K%JP!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !5>_\ ^/"X_P"N9_E5BJ]__P >%Q_US/\
M*@#G/ ?_ "#+G_KL?YFBCP'_ ,@RY_Z['^9HH G\#?\ (L6_^>U=)7-^!O\
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M #-% $_@;_D6+?\ SVKI*YOP-_R+%O\ Y[5TE !1110 4444 %%%% !1110
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M<)GG%:EEH"Q$-*P?ZUM1Q)$NU% % PBC6*-47H*?112 **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "+%O_GM725S?@;_ )%BW_SVKI* "BBB@ HHHH **** "BBB@ HHHH ****
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M1FC- !129I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.3BO+M2U@Z%JK16;;D'J:WBO:JW4#U<$'H<TM8'A?4FU*V9V/..:WZQDN5V
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M1110 57O_P#CPN/^N9_E5BJ]_P#\>%Q_US/\J .<\!_\@RY_Z['^9HH\!_\
M(,N?^NQ_F:* )_ W_(L6_P#GM725S?@;_D6+?_/:NDH **** "BBB@ HHHH
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MS#*&D!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M (J/_GY'Y?\ UZ .THKB_P#BH_\ GY'Y?_7H_P"*C_Y^1^7_ ->@#M**XO\
MXJ/_ )^1^7_UZ/\ BH_^?D?E_P#7H [2BN+_ .*C_P"?D?E_]>C_ (J/_GY'
MY?\ UZ .THKB_P#BH_\ GY'Y?_7H_P"*C_Y^1^7_ ->@#M**XO\ XJ/_ )^1
M^7_UZ/\ BH_^?D?E_P#7H [2BN+_ .*C_P"?D?E_]>C_ (J/_GY'Y?\ UZ .
MTHKB_P#BH_\ GY'Y?_7H_P"*C_Y^1^7_ ->@#M**XO\ XJ/_ )^1^7_UZ/\
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MXO\ XJ/_ )^1^7_UZ/\ BH_^?D?E_P#7H [2BN+_ .*C_P"?D?E_]>C/B/\
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M7^T;7_GLM']HVO\ SV6N:_X1R^_OK1_PCE]_?6CDAW Z7^T;7_GLM']HVO\
MSV6N:_X1R^_OK1_PCE]_?6CDAW Z1]2M5C9O-7@9K'MO%EI)<>7+(B<XJA+X
M<OA$YWKT-<@GA:_N[[Y,#DCD5<*<&G=@>N0W,-PNZ)PP]JEK%T'2[C3H DS
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ML7^Z*-B_W13J* &[%_NBC8O]T4ZB@!NQ?[HHV+_=%.HH ;L7^Z*-B_W13J*
M&[%_NBC8G]T?E3J* &[%_NBJ5ZH'0"K]4;ZLJWP%T_B,ZBBBO-.P**** "J.
MI:E%IT DE8+DX&?6KU<?XN^=8ED^X)!C/U%5!7=A2=D5M=UV[DT><-'L0CAA
MZ5N>%I=WA^WD9LC;DDU4UZWM3X6<_+GRQW]JL>&]D?AJ(XR@0YK1VY-.Y"OS
M!>Z](LWEV:"4T[3->-S,T5R CCC%8@O8+JZ/V*,QL"1GWK/LTEBUG=)(&+/3
MY%8.9G:ZKJ\>FQ%W( ]ZR#XHG1D>2-1"W(;VJ/Q7$LL 5AD<4:E9P_V-;#9_
MRSI14;*XVW<GF\3R#$D**T!. ];MK?Q7-MYH8<#)]JYBWM(1X8C&WO5O0I$B
ML+EI!E%[4I15M 3=]26[\03"Y:*TC$A7DU-IFN_:I/*G 24GA:P?M45Q>RBS
MC,;$<M5+3DDB\20*\@?)SQ5<BL+F=SM]4U2+38U+L S<*#W-8DOB>XMHC+<1
M*D8[U7\4#S+JW$OW1(,9^M3^*X;0^&'^[G:._M4QBM+]1MO4Z&TO4N;%;G(V
M%<YK(NO$$OG%+-!*!26?R^$3Y?:'BN6\/0W4ULTHE"ON(YHC!:L3D]$=MIFL
MI>ED<@2+P1[UK5PVEZ9/%J/F"X4Y;+ &NYJ9I)Z%1;>X4445!04444 %3Q6S
M2<D<5!6S;?ZI?I6U&"G+4SJ2<5H11V2KR35E8U4< 4ZBNZ,(QV.9R;W"BBBK
M)"N>\2_ZEOI70USWB7_4M]*TH_&C.K\#,:V_U"_2I:BMO]0OTJ6NI[G(M@K(
M&C)_;K:AN.XC&*UZ*5AIV,&[\.QW&HPW(<C8<D#O5F_TA+O;R1AL\5JT4K(?
M,S*O-*%T(U+':JXQ5ZUMDMK=8E'"U/13L*YD7^C)=WBW.2'48&*NM:+)9^0_
M/&,FK5%%AW9RQ\-M;N?)GD(/;)JSI_AQ()O.ED9VSD!CG%=!12Y4/F8=!111
M3)"JW_,3BJS5;_F)Q52$SN+7_CW6IJAM?^/=:FKA>YW+8XSQ]_J;?ZUH># /
M[$''>IO$>B2ZPD2QN%V=<U9T+37TNP%O(P8YZBL%%^TN>E.M!X-4T];FG@>E
M&!Z4M%;'G"8'I1@>E+10 F!Z48'I2T4 4M1M!=6K1XY-<>Z/:3,CC S@5WM9
MNH:7'=(2%&[UIH#F@P89%! 88/2FW%E<63D$%@/04Q9P>""/K0(P=0T-EO&O
M+=FWG^$56:POK\B*<.B="0:ZS<#W%+0!@7>B :7%;1DG8<YJA#8W\*E%5L?6
MNNHH YW3]!VW!GG9F8\X;G%2ZII4CW0O(6;>HP%!XK=HH Y8:9=:A-&;D,@B
M.1SUJ[J&E-Y>^!FW#L#6Y10!RT>FW-Y/&;@,BQ^_6NEAB6&,(O04_('>HVF"
M].?I0!(2 ,FH"6N)!'&,\\T^&WGO'VJ&4'U%=)IND); ,X!;UH FTBR%I;8(
MY/-:-'08HI#"BBB@ HHHH **** "BBB@ HHHH **** "FNH9"I[BG44 <9J=
MB]G<;U!VGDU#'(''7FNRN;:.YC*NN<UR]]H\MLY>/[OH*8B"J]Y:)=P-&W<8
M!I5F9>'5@?<5*'![B@#E%TR\TW,=OOD7.<DU/9Z&\]RMQ<LP93D FNFS10!@
M:EI4GVIKN!F+G^$&JL>EW-]=1RW(9/+Z#/6NIHH Y_4=$X$D&0^<\52DTNZO
MG5Y@R[!@#/6NMHH Y34[*VCM8$DE,;J>,=S63K*--I[ R-OQPN>M=CJ&EQ7J
MC*C<#D&J<.ACS0;@AE':@"[HJE=(M@>H6K]1*8X8PBXP.@IF^24[8U;ZXH =
M+*!\HZFM70M/8R"XD'44:=HC,PDFP>^*Z2.-8DV(, 4#' 8&*6BBD 4444 %
M%%% !1110 4444 '44P11J<JB@^PI]% !1110!GZC:^:@91RM9]O,5^1^#6^
M0",&LZ\T_?EH\ UQ5Z,N;G@=-*HK<LA@Y&:*I"22 [7!/X582=7]JQC43T9H
MXM"SPK/"T;_=/6N/GT:[TN]DN+(/)N_ASP*[/(/0TM:J5B&CB%TS4-8N%-ZC
MQ)T(!XK0UG03/#8Q19(@:NGHI\S%RH@MX=ENJ,.V.:Y:^T&:UU%;BS#'>V7Q
M7844D[#:N>>WNCZC)K+7GE,X(^Z>E:EA_:BW,:O;E8P>:ZZBFY"Y1%Z<TM-+
M*.XJ&2Y"\ 9^E9RFH[EJ+9,SA1DFJ9W74H1>5-.2*:Z;C('N*UK6S2!>GS>M
M3&$JS\ARDJ:\R6VB\J%5[@5-117I122LCC;N[A3616'04ZBG814DLE;G-5)+
M1U^Z,UK4=:QE0A(TC5DC"9&7J*;6S+"C*2163* LA KDJTN0Z(3YAE%%%8EA
M3)94AB:1SA5&2:?5/58C/ID\2L%++@$T+<"BWB2R#9$RE/6M*VNX;R+=$^X5
MYU (=*@6*[MGN,'[R#(KK_#MQ;W%K(;=-@'4>E:S@DKHB,FQ;%+<:_<,ERSR
MD<QD\#K6A>ZG;6(Q+(%;L*YC1_\ D=K[_<_QINKC[5XMM8)>8F'*GOTH<;RU
M"^AMCQ-8!E#SJ"QP*TI+V&.V\\L GK7)>*-'LK?[(T,:H=XK2O\ _D6V'L/Y
M4.,=&@NRT_B6P'W9E./O>U7K'4K;4(P\,@8'TKF-(TBTELYWDB!)6G>'U%MJ
M7D1_+&.U#C&SL";ZG1WVJVM@56:4*S?='K52+Q%9M)L>4#-9/B.ZLX[R'SX3
M,0> M<YKUS;M##);VS0L9!R1[BG&FF)RL=UXCE/_  CUQ)&Q'RY!%0^&W,OA
MB)I'/*'+$^U,U@Y\',3_ ,\A_*D\.?\ (H)_US/\JFWN?,?VB?04MUCE\FX:
M7YSG)Z<U/<:[96TC1R3!6'&*Q/!?^IN/^NS?S-4IK.*[UZ42KN >FXKF=PN[
M:'2V_B"SGN!#YHWGH*TI;B.*$RNV$ SFN.U?3[>RO5F@C"N%ZU=UBXD&GVB
MG;(N&_6DX)VL',^I?_X26Q+9$R^7ZU=L-3MM1#&WD#A>N*Q+'0[!])):-2<$
MYS5;P0BQSZ@B_=5\"AQC9M F[ZG8T445F6%%%% %BT +\BM4(N/NBLNT^_6L
M.E=V&^$YJVXW8O\ =%&Q?[HIU%=)B-V+_=%&Q?[HIU% #=B_W11L7^Z*=10
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MT4_:,.5&/JNEF]0#!IUUIIFLHH<'Y5Q6M12YF.R,>/2]NE+;8/!HL])$5I-
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MQ/\ >0&@#AC+(GWABD^U+W-=LVGVK=8EJ(Z5:'_EBM,#C_M2>M)]J7L:Z_\
MLBU_YY+3AI-H/^6*T <>)G;[HS3UBO)/N1YKL1IUJO2%:E6VA3[J 47 Y*+1
MKR4_O(R![&M6U\/0IAG+9K< Q2TK@116\<*X51^52T44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4A4,,$ _A2T4 9UUH\%UG/'T%8UQX?>,
MDPAC^-=510!P[6-_#UBXJ(M,GWU KNFC1_O+FHFL;9NL0- '$?:0.M+]J3UK
MLCI=F?\ EBM1G2+3_GDM.X'(_:D]:3[3G[M=@-(M!_RR6I%TRT7I"M CCE^T
M/]Q,U,FFW\Q_U7%=>MG OW8P*E5%7H,4#.;MO#H8@S;@:VK;38;8#:,_45<H
MI ( !T%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $4MNDH
MP0/RK/FTI1RA;-:M%95*,)_$BXU)1V.?-M=Q'Y4R/>D\V=?O*!70$ ]:88(V
MZJ*YWA&OAD;+$7^)&%]LQ]ZG"]C]:US9P'_EF*8;"#^X*GZO675#]K3?0R_M
ML?\ >I#>IV-:G]G0_P!P4X6$ _Y9BE["MW0_:T^QD?:F/W>:-US)]U :VA:0
M#I&*D$2+T6J6%F_BD+V\5LC$2QN)?]8I'T-78-+C3!).?>M&BM886G'5ZF<J
M\F-2-4& !^5.HHKI2L8A1110 4444 %%%% #7^Z:QI_]:U;+_=-8T_\ K6KD
MQ6R-Z.Y'1117&= 56OX6FLI43.XKQ5FBA <0D6NVT/V:.RC>/IN89/\ *M?P
MUI,FFPS&0$/*=Q'I7045;FVK$J-CF]-TJX@\3W5XZ8B=< _G5;Q!;#^V8;BW
MYNU7Y$[&NMK&U?1Y;^42PR^7(!@-Z4U+WKL''0XW7I]6F>T%_"(U\P8P:Z^:
MTEN-!\E%RQ X_"J,'AF[:97O;KSU4Y /:NH1 B!1V&*<YJRL**?4R--L9;>S
M>-UP2N*K:?ID\&IF9TPN.M=%14<S*L<=K.E:@M_%/9PB7!R=U4M5TW6-5BC2
M6T1-KACM'O\ 2N^HJE4:$X)F/J%C-/X;-HJYD\L+BC1K&6U\/+:R+B0(1C\*
MV**GF=K#MK<Y[PUID^GQS"9-NZ0L/S-,32KA=6DG*?*S9!KI**.=WN'*C UC
M39[J0&-,\5)?VD9TJ-)CB1$PH]ZVZK7MK]J@9 <,1@'TH4M@:.+BEUB&Q,4<
M(-O_ 'L\U;\#*X:],@PQ;FI/^$8U+[HOSLS]VNAT[3TL(MJ@;B/F([UI*2M9
M$).Y=HHHK$T"BBB@"S:??K6'2LFT^_6L.E=V&^$YJVX4445TF(4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!"<"J$S[WS5N=]JU0[TP'Q-M85H Y%9G>
MKUN^4I 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% $4[[5QZU0J>X?<V/2H*8BW;/QBK-9\3;7%
M7U.1FD,6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ,BDR/6JDLA#5'YS4 :&1ZTF1ZU0\YJ
M/-:@"_D>M&1ZU0\YJ/.:@"_D>M&1ZU0\YJ/.:@"_D>M&1ZU0\UJ/.:@"_D>M
M&1ZU0\YJ/-:@!]P^YL>E04I.3FDIB"IK=\/BH:4'!H TLCUHR/6J'FM1YS4A
ME_(]:,CUJAYS4><U %_(]:,CUJAYS4>:U %_(]:,CUJAYS4><U %_(]:,CUJ
MAYS4><U %_(]:7(]:S_.:G1RL7 H O44@Z4M !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113)#A: '9'K1D>M4/
M-;-'FM0!?R/6C(]:H><U'G-0!?R/6C(]:H><U'FM0!?R/6C(]:H><U'G-0!?
MR/6C(]:H><U'G-0!?R/6FR.%7.:I><U(9"PP: &L<L32444Q!G%7H'!0"J-.
M5RO2@#2R/6DR/6J'G-1YS4AE_(]:7(]:S_.:CSFH OY'K1D>M4/.:CSFH OY
M'K1D>M4/.:CSFH OY'K1D>M4/.:CSFH OY'K2UG^<U6+=RPYH L4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;P_I5I>6 N)XU>21>2:VFT[S])%I,.J@'\JYQ++7M/DDBM57R>B9H$1V_\
MH'C6&RM^(&&2!T[4GB%O[%OXYDX\ULG%:6BZ+=?;5O\ 4% N%Z8]*F\5:')K
M$,8B7+)TH X^_+F]_MM6.W&*UM.?^W;NVGZ^0:M1^&KD^%_L,B_O=V:N>$]"
MFT=9A,N-QXH&9_BV$3SJIZ;Q_.IM9TJSM]"%Q% JRK&"&%7M:TFYO)PT2@C<
M#^M6M6T^:[T4VT8S(4 Q0(7PN[2:!;LQR2*V*S- LY;#1X;>88D4<UIT %6K
M;I56K5MTH M4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO)[Z[O/,R%1_E]ZY3Q"\^G:T88,B/T KO-"M%@L4D PTBY- C5HHHH ****
M"K5MTJK5JVZ4 6J***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;O<&4,5R<X%68M*@BN5G50&4=A5^B@"I>V$5Z%$@''3BB&PCBMO(SE?>K=%
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M[T44 'V5/>C[*GO110 ?94]Z/LJ>]%% !]E3WH^RI[T44 'V5/>C[*GO110
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M ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>cbio-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-04T15:52:13.4116896+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : e2a5eda4d98d48aba04c2fa8e195e2fb -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:cbio="http://www.catalystbiosciences.com/20201231" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.catalystbiosciences.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.catalystbiosciences.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100060 - Statement - Consolidated Statements of Stockholders&apos; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNatureOfOperations" id="Role_DisclosureNatureOfOperations">
        <link:definition>100080 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLiquidity" id="Role_DisclosureLiquidity">
        <link:definition>100090 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100110 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstruments" id="Role_DisclosureFinancialInstruments">
        <link:definition>100120 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureOtherAccruedLiabilities" id="Role_DisclosureOtherAccruedLiabilities">
        <link:definition>100130 - Disclosure - Other Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100140 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedParties" id="Role_DisclosureRelatedParties">
        <link:definition>100150 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100160 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100170 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100180 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborations" id="Role_DisclosureCollaborations">
        <link:definition>100190 - Disclosure - Collaborations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureInterestAndOtherIncomeNet" id="Role_DisclosureInterestAndOtherIncomeNet">
        <link:definition>100200 - Disclosure - Interest and Other Income, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100210 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>100220 - Disclosure - Net Loss per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEvent" id="Role_DisclosureSubsequentEvent">
        <link:definition>100230 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100240 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100250 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsTables" id="Role_DisclosureFinancialInstrumentsTables">
        <link:definition>100260 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureOtherAccruedLiabilitiesTables" id="Role_DisclosureOtherAccruedLiabilitiesTables">
        <link:definition>100270 - Disclosure - Other Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100280 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100290 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100300 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureInterestAndOtherIncomeNetTables" id="Role_DisclosureInterestAndOtherIncomeNetTables">
        <link:definition>100310 - Disclosure - Interest and Other Income, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100320 - Disclosure - Stockholders&apos; Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>100330 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail" id="Role_DisclosureNatureOfOperationsAdditionalInformationDetail">
        <link:definition>100340 - Disclosure - Nature of Operations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail" id="Role_DisclosureLiquidityAdditionalInformationDetail">
        <link:definition>100350 - Disclosure - Liquidity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail" id="Role_DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail">
        <link:definition>100370 - Disclosure - Assets and Liabilities Measured at Fair Value (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail" id="Role_DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail">
        <link:definition>100380 - Disclosure - Assets and Liabilities Measured at Fair Value - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail" id="Role_DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail">
        <link:definition>100390 - Disclosure - Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail" id="Role_DisclosureFinancialInstrumentsAdditionalInformationDetail">
        <link:definition>100400 - Disclosure - Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail" id="Role_DisclosureScheduleOfOtherAccruedLiabilitiesDetail">
        <link:definition>100410 - Disclosure - Schedule of Other Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100420 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail" id="Role_DisclosureRelatedPartiesAdditionalInformationDetail">
        <link:definition>100430 - Disclosure - Related Parties - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" id="Role_DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail">
        <link:definition>100450 - Disclosure - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" id="Role_DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail">
        <link:definition>100460 - Disclosure - Schedule of Maturity of Operating Lease Liabilities - (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2" id="Role_DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2">
        <link:definition>100470 - Disclosure - Schedule of Maturity of Operating Lease Liabilities - (Detail)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails" id="Role_DisclosureScheduleOfSupplementalCashFlowInformationDetails">
        <link:definition>100480 - Disclosure - Schedule of Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100490 - Disclosure - Stock Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail" id="Role_DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail">
        <link:definition>100500 - Disclosure - Summary of Option Activity Under Company&apos;s Equity Incentive Plans (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail" id="Role_DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail">
        <link:definition>100510 - Disclosure - Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail" id="Role_DisclosureSummaryOfStockBasedCompensationRecognizedDetail">
        <link:definition>100520 - Disclosure - Summary of Stock-Based Compensation Recognized (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail" id="Role_DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail">
        <link:definition>100530 - Disclosure - Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail" id="Role_DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail">
        <link:definition>100540 - Disclosure - Reconciliation of Statutory Federal Income Tax (benefit) Rate to Company&apos;s Effective Tax Rate (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail" id="Role_DisclosureComponentsOfCompanySDeferredTaxAssetsDetail">
        <link:definition>100550 - Disclosure - Components of the Company&apos;s Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100560 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail" id="Role_DisclosureUnrecognizedTaxBenefitDetail">
        <link:definition>100570 - Disclosure - Unrecognized tax benefit (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail" id="Role_DisclosureCollaborationsAdditionalInformationDetail">
        <link:definition>100580 - Disclosure - Collaborations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail" id="Role_DisclosureDetailOfInterestAndOtherIncomeNetDetail">
        <link:definition>100590 - Disclosure - Detail of Interest and Other Income, Net (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100600 - Disclosure - Stockholders&apos; Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfWarrantActivityDetail" id="Role_DisclosureSummaryOfWarrantActivityDetail">
        <link:definition>100610 - Disclosure - Summary of Warrant Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetail" id="Role_DisclosureBasicAndDilutedNetLossPerCommonShareDetail">
        <link:definition>100620 - Disclosure - Basic and Diluted Net Loss Per Common Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" id="Role_DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail">
        <link:definition>100630 - Disclosure - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail" id="Role_DisclosureSubsequentEventAdditionalInformationDetail">
        <link:definition>100640 - Disclosure - Subsequent Event - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="cbio_InterestAndOtherIncomeExpenseNet" name="InterestAndOtherIncomeExpenseNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_LicenseRevenueMember" name="LicenseRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CollaborationRevenueMember" name="CollaborationRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CostOfLicenseMember" name="CostOfLicenseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CostOfCollaborationMember" name="CostOfCollaborationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" name="StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" name="StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_PaymentsToAcquireShortTermAndLongInvestments" name="PaymentsToAcquireShortTermAndLongInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" name="ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" name="ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet" name="NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" name="NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock" name="CostOfLicenseAndCollaborationRevenuePolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" name="AccruedResearchAndDevelopmentExpensesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_ConcentrationRiskCreditRiskPolicyTextBlock" name="ConcentrationRiskCreditRiskPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" name="SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_LiquidityAbstract" name="LiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CostOfCollaborationRevenue" name="CostOfCollaborationRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_LongTermInvestmentsMember" name="LongTermInvestmentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_FederalAgencySecuritiesMember" name="FederalAgencySecuritiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_AccruedManufacturingExpensesCurrent" name="AccruedManufacturingExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_AccruedClinicalExpensesCurrent" name="AccruedClinicalExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_AccruedAndOtherCurrentLiabilities" name="AccruedAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_ClinicalTrials" name="ClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cbio_ClinicalTrialsPaid" name="ClinicalTrialsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cbio_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_AGCBiologicsIncMember" name="AGCBiologicsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CatalentIndianaLLCMember" name="CatalentIndianaLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" name="MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_DalcinonacogAlfaMember" name="DalcinonacogAlfaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" name="UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_SublicenseFee" name="SublicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_TotalTransactionExpensesRelatedToCollaboration" name="TotalTransactionExpensesRelatedToCollaboration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" name="MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_MosaicBiosciencesIncMember" name="MosaicBiosciencesIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_BiogenCollaborationMember" name="BiogenCollaborationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_IntravitrealAntiComplementFactor3Member" name="IntravitrealAntiComplementFactor3Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_LesseeOperatingLeaseRenewalTermDescription" name="LesseeOperatingLeaseRenewalTermDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" name="TwoThousandEighteenOmnibusIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" name="TwoThousandEighteenEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedInPeriodIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriodIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_EffectiveIncomeTaxRateReconciliationDerecognition" name="EffectiveIncomeTaxRateReconciliationDerecognition" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" name="DeferredTaxAssetsFixedAssetsAndIntangibles" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_IncomeTaxLineItems" name="IncomeTaxLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_IncomeTaxTable" name="IncomeTaxTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_OperatingLossCarryforwardsWithIndefiniteLife" name="OperatingLossCarryforwardsWithIndefiniteLife" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" name="DeferredTaxAssetsStateNetOperatingLossCarryForwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" name="ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_MaximumAmountOfTaxOffsetPerYear" name="MaximumAmountOfTaxOffsetPerYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_RequiredMinimumTaxableIncome" name="RequiredMinimumTaxableIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_MilestoneContingentCashPaymentsObligation" name="MilestoneContingentCashPaymentsObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_CollaborationAgreementsAbstract" name="CollaborationAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_PfizerIncMember" name="PfizerIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_IsuAbxisMember" name="IsuAbxisMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_AmendedAndRestatedLicenseAgreementMember" name="AmendedAndRestatedLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_BiogenMember" name="BiogenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_LicenseAndCollaborationAgreementMember" name="LicenseAndCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_ExclusiveLicenseMember" name="ExclusiveLicenseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" name="TransferOfExclusiveLicenseAndRelatedKnowHowMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" name="ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_RegulatoryAndDevelopmentMilestonePayment" name="RegulatoryAndDevelopmentMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_CommercialMilestonePayments" name="CommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_ResearchServicesAgreementTerm" name="ResearchServicesAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_ResearchServicesAgreementOptionToExtend" name="ResearchServicesAgreementOptionToExtend" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_DevelopmentMilestonesPaymentReceivable" name="DevelopmentMilestonesPaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_FirmCommitmentUnderwrittenPublicOfferingShares" name="FirmCommitmentUnderwrittenPublicOfferingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable" name="NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_UnderwritingCommissionsAndOfferingExpensesPayable" name="UnderwritingCommissionsAndOfferingExpensesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_StockholdersEquityDisclosureLineItems" name="StockholdersEquityDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_StockholdersEquityDisclosureTable" name="StockholdersEquityDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" name="ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_ClassOfWarrantOrRightForfeitedDuringPeriod" name="ClassOfWarrantOrRightForfeitedDuringPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited" name="ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued" name="ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised" name="ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_UnderwritingDiscountsAndOfferingExpenses" name="UnderwritingDiscountsAndOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_UnderwritersOverallotmentOptionMember" name="UnderwritersOverallotmentOptionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>cbio-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-04T15:52:13.4116896+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : e2a5eda4d98d48aba04c2fa8e195e2fb -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="cbio-20201231.xsd#TemplateLink" roleURI="http://www.catalystbiosciences.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="cbio-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="cbio-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_InterestAndOtherIncomeExpenseNet" xlink:type="locator" xlink:label="cbio_InterestAndOtherIncomeExpenseNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="cbio_InterestAndOtherIncomeExpenseNet" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="cbio-20201231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="cbio-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:type="locator" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_PaymentsToAcquireShortTermAndLongInvestments" xlink:type="locator" xlink:label="cbio_PaymentsToAcquireShortTermAndLongInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="cbio_PaymentsToAcquireShortTermAndLongInvestments" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10170.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureScheduleOfOtherAccruedLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail">
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AccruedAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="cbio_AccruedAndOtherCurrentLiabilities" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AccruedClinicalExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedClinicalExpensesCurrent" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AccruedManufacturingExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedManufacturingExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="cbio_AccruedManufacturingExpensesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="cbio_AccruedClinicalExpensesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="cbio_AccruedAndOtherCurrentLiabilities" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2" xlink:href="cbio-20201231.xsd#Role_DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_EffectiveIncomeTaxRateReconciliationDerecognition" xlink:type="locator" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationDerecognition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cbio_EffectiveIncomeTaxRateReconciliationDerecognition" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureComponentsOfCompanySDeferredTaxAssetsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:type="locator" xlink:label="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureDetailOfInterestAndOtherIncomeNetDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_InterestAndOtherIncomeExpenseNet" xlink:type="locator" xlink:label="cbio_InterestAndOtherIncomeExpenseNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cbio_InterestAndOtherIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cbio_InterestAndOtherIncomeExpenseNet" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cbio_InterestAndOtherIncomeExpenseNet" xlink:to="us-gaap_OtherNonoperatingExpense" order="10030.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>cbio-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-04T15:52:13.4116896+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : e2a5eda4d98d48aba04c2fa8e195e2fb -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="cbio-20201231.xsd#TemplateLink" roleURI="http://www.catalystbiosciences.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="cbio-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_InterestAndOtherIncomeExpenseNet" xlink:type="locator" xlink:label="cbio_InterestAndOtherIncomeExpenseNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CostOfCollaborationMember" xlink:type="locator" xlink:label="cbio_CostOfCollaborationMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CostOfLicenseMember" xlink:type="locator" xlink:label="cbio_CostOfLicenseMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CollaborationRevenueMember" xlink:type="locator" xlink:label="cbio_CollaborationRevenueMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LicenseRevenueMember" xlink:type="locator" xlink:label="cbio_LicenseRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10080.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_LicenseRevenueMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CollaborationRevenueMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CostOfLicenseMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CostOfCollaborationMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_InterestAndOtherIncomeExpenseNet" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10810.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="cbio-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CostOfCollaborationRevenue" xlink:type="locator" xlink:label="cbio_CostOfCollaborationRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:type="locator" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cbio_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LeasePracticalExpedientsPackage" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cbio_CostOfCollaborationRevenue" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10790.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LongTermInvestmentsMember" xlink:type="locator" xlink:label="cbio_LongTermInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="cbio_LongTermInvestmentsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LongTermInvestmentsMember" xlink:type="locator" xlink:label="cbio_LongTermInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_FederalAgencySecuritiesMember" xlink:type="locator" xlink:label="cbio_FederalAgencySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="cbio_FederalAgencySecuritiesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="cbio_LongTermInvestmentsMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="11190.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClinicalTrialsPaid" xlink:type="locator" xlink:label="cbio_ClinicalTrialsPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClinicalTrials" xlink:type="locator" xlink:label="cbio_ClinicalTrials" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_DalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_DalcinonacogAlfaMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CatalentIndianaLLCMember" xlink:type="locator" xlink:label="cbio_CatalentIndianaLLCMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AGCBiologicsIncMember" xlink:type="locator" xlink:label="cbio_AGCBiologicsIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_CommitmentsAndContingenciesDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_AGCBiologicsIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_CatalentIndianaLLCMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_DalcinonacogAlfaMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_ClinicalTrials" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ContractualObligation" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_ClinicalTrialsPaid" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureRelatedPartiesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" xlink:type="locator" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_SublicenseFee" xlink:type="locator" xlink:label="cbio_SublicenseFee" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" xlink:type="locator" xlink:label="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_TotalTransactionExpensesRelatedToCollaboration" xlink:type="locator" xlink:label="cbio_TotalTransactionExpensesRelatedToCollaboration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_IntravitrealAntiComplementFactor3Member" xlink:type="locator" xlink:label="cbio_IntravitrealAntiComplementFactor3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_BiogenCollaborationMember" xlink:type="locator" xlink:label="cbio_BiogenCollaborationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MosaicBiosciencesIncMember" xlink:type="locator" xlink:label="cbio_MosaicBiosciencesIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cbio_MosaicBiosciencesIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cbio_BiogenCollaborationMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_IntravitrealAntiComplementFactor3Member" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="cbio_TotalTransactionExpensesRelatedToCollaboration" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="cbio_SublicenseFee" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="10940.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:type="locator" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10930.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureSummaryOfStockBasedCompensationRecognizedDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_RequiredMinimumTaxableIncome" xlink:type="locator" xlink:label="cbio_RequiredMinimumTaxableIncome" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MaximumAmountOfTaxOffsetPerYear" xlink:type="locator" xlink:label="cbio_MaximumAmountOfTaxOffsetPerYear" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:type="locator" xlink:label="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:type="locator" xlink:label="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_OperatingLossCarryforwardsWithIndefiniteLife" xlink:type="locator" xlink:label="cbio_OperatingLossCarryforwardsWithIndefiniteLife" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="cbio_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_IncomeTaxTable" xlink:type="locator" xlink:label="cbio_IncomeTaxTable" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_IncomeTaxLineItems" xlink:type="locator" xlink:label="cbio_IncomeTaxLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_IncomeTaxTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_CA" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_OperatingLossCarryforwardsExpirationYear" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_OperatingLossCarryforwardsWithIndefiniteLife" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_MaximumAmountOfTaxOffsetPerYear" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_RequiredMinimumTaxableIncome" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="11160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureCollaborationsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_DevelopmentMilestonesPaymentReceivable" xlink:type="locator" xlink:label="cbio_DevelopmentMilestonesPaymentReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ResearchServicesAgreementOptionToExtend" xlink:type="locator" xlink:label="cbio_ResearchServicesAgreementOptionToExtend" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ResearchServicesAgreementTerm" xlink:type="locator" xlink:label="cbio_ResearchServicesAgreementTerm" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CommercialMilestonePayments" xlink:type="locator" xlink:label="cbio_CommercialMilestonePayments" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_RegulatoryAndDevelopmentMilestonePayment" xlink:type="locator" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MilestonePayments" xlink:type="locator" xlink:label="cbio_MilestonePayments" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MilestoneContingentCashPaymentsObligation" xlink:type="locator" xlink:label="cbio_MilestoneContingentCashPaymentsObligation" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" xlink:type="locator" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CollaborationRevenueMember" xlink:type="locator" xlink:label="cbio_CollaborationRevenueMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" xlink:type="locator" xlink:label="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LicenseRevenueMember" xlink:type="locator" xlink:label="cbio_LicenseRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ExclusiveLicenseMember" xlink:type="locator" xlink:label="cbio_ExclusiveLicenseMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="cbio_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_BiogenMember" xlink:type="locator" xlink:label="cbio_BiogenMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AmendedAndRestatedLicenseAgreementMember" xlink:type="locator" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_IsuAbxisMember" xlink:type="locator" xlink:label="cbio_IsuAbxisMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_PfizerIncMember" xlink:type="locator" xlink:label="cbio_PfizerIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_PfizerIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TransactionTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_CollaborativeArrangementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_RangeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_IsuAbxisMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_AmendedAndRestatedLicenseAgreementMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_BiogenMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_LicenseAndCollaborationAgreementMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_ExclusiveLicenseMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_ProductOrServiceAxis" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_LicenseRevenueMember" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_ExclusiveLicenseMember" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CollaborationRevenueMember" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_MilestoneContingentCashPaymentsObligation" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_MilestonePayments" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_RegulatoryAndDevelopmentMilestonePayment" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_CommercialMilestonePayments" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_ResearchServicesAgreementTerm" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_ResearchServicesAgreementOptionToExtend" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_DevelopmentMilestonesPaymentReceivable" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20201231.xsd#cbio_UnderwritingCommissionsAndOfferingExpensesPayable" xlink:type="locator" xlink:label="cbio_UnderwritingCommissionsAndOfferingExpensesPayable" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable" xlink:type="locator" xlink:label="cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_FirmCommitmentUnderwrittenPublicOfferingShares" xlink:type="locator" xlink:label="cbio_FirmCommitmentUnderwrittenPublicOfferingShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_StockholdersEquityDisclosureTable" xlink:type="locator" xlink:label="cbio_StockholdersEquityDisclosureTable" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_StockholdersEquityDisclosureLineItems" xlink:type="locator" xlink:label="cbio_StockholdersEquityDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_StockholdersEquityDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_StockholdersEquityDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_StockholdersEquityDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_FirmCommitmentUnderwrittenPublicOfferingShares" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_SharePrice" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_UnderwritingCommissionsAndOfferingExpensesPayable" order="10460.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CommonStockWarrantsMember" xlink:type="locator" xlink:label="cbio_CommonStockWarrantsMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="cbio_OptionsToPurchaseCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cbio_OptionsToPurchaseCommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cbio_CommonStockWarrantsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureSubsequentEventAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20201231.xsd#cbio_UnderwritingDiscountsAndOfferingExpenses" xlink:type="locator" xlink:label="cbio_UnderwritingDiscountsAndOfferingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_UnderwritersOverallotmentOptionMember" xlink:type="locator" xlink:label="cbio_UnderwritersOverallotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_UnderwritersOverallotmentOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cbio_UnderwritingDiscountsAndOfferingExpenses" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>cbio-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-04T15:52:13.4116896+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : e2a5eda4d98d48aba04c2fa8e195e2fb -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies (Note 7)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, 5,000,000 shares authorized; zero shares issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 100,000,000 shares authorized; 22,097,820 and 12,040,835 shares issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_InterestAndOtherIncomeExpenseNet" xlink:type="locator" xlink:label="cbio_InterestAndOtherIncomeExpenseNet" />
    <link:label xml:lang="en-US" xlink:label="cbio_InterestAndOtherIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest and other income (expense), net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_InterestAndOtherIncomeExpenseNet" xlink:to="cbio_InterestAndOtherIncomeExpenseNet_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LicenseRevenueMember" xlink:type="locator" xlink:label="cbio_LicenseRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_LicenseRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License revenue member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_LicenseRevenueMember" xlink:to="cbio_LicenseRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_LicenseRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LicenseRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Revenue [Member]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CollaborationRevenueMember" xlink:type="locator" xlink:label="cbio_CollaborationRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CollaborationRevenueMember" xlink:to="cbio_CollaborationRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CostOfLicenseMember" xlink:type="locator" xlink:label="cbio_CostOfLicenseMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of license member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CostOfLicenseMember" xlink:to="cbio_CostOfLicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of license</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of License [Member]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CostOfCollaborationMember" xlink:type="locator" xlink:label="cbio_CostOfCollaborationMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfCollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of collaboration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CostOfCollaborationMember" xlink:to="cbio_CostOfCollaborationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfCollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfCollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Collaboration [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and collaboration revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of license and collaboration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Goods And Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_InterestAndOtherIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_InterestAndOtherIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income Expense Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used to compute net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Change [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (loss) gain on available-for-sale debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" />
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period from ESPP purchases and stock options exercised value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" xlink:to="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" />
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period from ESPP purchases and stock options exercised shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" xlink:to="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from ESPP purchases and stock option exercises</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period From E S P P Purchases And Stock Options Exercised Value</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from ESPP purchases and stock option exercises, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period From E S P P Purchases And Stock Options Exercised Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for public offering, net of issuance costs of $4,559</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for public offering, net of issuance costs, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs of issuance of common stock for public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:type="locator" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease in operating lease liability and right-of-use asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:to="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_PaymentsToAcquireShortTermAndLongInvestments" xlink:type="locator" xlink:label="cbio_PaymentsToAcquireShortTermAndLongInvestments" />
    <link:label xml:lang="en-US" xlink:label="cbio_PaymentsToAcquireShortTermAndLongInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments to acquire short term and long investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_PaymentsToAcquireShortTermAndLongInvestments" xlink:to="cbio_PaymentsToAcquireShortTermAndLongInvestments_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock for secondary public offering, net of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" />
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock from ESPP purchases and stock option exercises.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet" xlink:type="locator" xlink:label="cbio_NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet" />
    <link:label xml:lang="en-US" xlink:label="cbio_NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash or part non cash right-of-use asset and operating lease liability recorded upon the adoption, net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet" xlink:to="cbio_NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" xlink:type="locator" xlink:label="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets obtained in exchange for operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" xlink:to="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and other accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability and right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liability And Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Maturity And Collection Of Shortterm Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_PaymentsToAcquireShortTermAndLongInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of short-term and long-term investments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_PaymentsToAcquireShortTermAndLongInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Short Term And Long Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows provided by investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock For Public Offering Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from ESPP purchase and stock option exercises</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock From E S P P Purchases And Stock Option Exercises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of Non-Cash Investing and Financing Activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset and operating lease liability recorded upon the adoption of ASC 842</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Or Part Non Cash Right Of Use Asset And Operating Lease Liability Recorded Upon Adoption Net</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Or Part Non Cash Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:type="locator" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:to="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidation Basis Of Accounting [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments All Other Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Income And Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncomeTextBlock" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncomeTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncomeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and Other Income, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncomeTextBlock" xlink:to="us-gaap_InterestAndOtherIncomeTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncomeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Pronouncements Recently Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock" xlink:type="locator" xlink:label="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of license and collaboration revenue policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock" xlink:to="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of License and Collaboration Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of License And Collaboration Revenue Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:type="locator" xlink:label="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:to="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Policy [Text Block]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:type="locator" xlink:label="cbio_ConcentrationRiskCreditRiskPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cbio_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration Risk Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:to="cbio_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="locator" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable, net and Allowance for Doubtful Accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Receivables Trade And Other Accounts Receivable Allowance For Doubtful Accounts Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" xlink:type="locator" xlink:label="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of present value assumptions of lease payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" xlink:to="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Present Value Assumptions Of Lease Payments Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturity of Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Flow Supplemental Disclosures Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Option Activity Under Company&apos;s Equity Incentive Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Federal Income Tax Rate to Company&apos;s Effective Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of the Company&apos;s Deferred Tax Assets (Liabilities)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Detail of Interest and Other Income, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Other Nonoperating Income Expense Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Warrant Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and Diluted Net Loss Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive Security not Included In Diluted per Share Calculations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LiquidityAbstract" xlink:type="locator" xlink:label="cbio_LiquidityAbstract" />
    <link:label xml:lang="en-US" xlink:label="cbio_LiquidityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_LiquidityAbstract" xlink:to="cbio_LiquidityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_LiquidityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cbio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="cbio_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AS 2016-02</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201602 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software Intangible Asset [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:type="locator" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasePracticalExpedientsPackage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease practical expedients</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePracticalExpedientsPackage" xlink:to="us-gaap_LeasePracticalExpedientsPackage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasePracticalExpedientsPackage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Practical Expedients Package</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CostOfCollaborationRevenue" xlink:type="locator" xlink:label="cbio_CostOfCollaborationRevenue" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfCollaborationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of collaboration revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CostOfCollaborationRevenue" xlink:to="cbio_CostOfCollaborationRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfCollaborationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of collaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfCollaborationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Collaboration Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Gross Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Agency Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LongTermInvestmentsMember" xlink:type="locator" xlink:label="cbio_LongTermInvestmentsMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_LongTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_LongTermInvestmentsMember" xlink:to="cbio_LongTermInvestmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_LongTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LongTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale, debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_FederalAgencySecuritiesMember" xlink:type="locator" xlink:label="cbio_FederalAgencySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_FederalAgencySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal agency securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_FederalAgencySecuritiesMember" xlink:to="cbio_FederalAgencySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_FederalAgencySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Agency Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_FederalAgencySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Agency Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LongTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-Term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Material realized gains or losses on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Gross Realized Gain Loss Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale debt securities current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale-debt securities noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Noncurrent</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AccruedManufacturingExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedManufacturingExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedManufacturingExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued manufacturing expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AccruedManufacturingExpensesCurrent" xlink:to="cbio_AccruedManufacturingExpensesCurrent_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AccruedClinicalExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedClinicalExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedClinicalExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AccruedClinicalExpensesCurrent" xlink:to="cbio_AccruedClinicalExpensesCurrent_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AccruedAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="cbio_AccruedAndOtherCurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AccruedAndOtherCurrentLiabilities" xlink:to="cbio_AccruedAndOtherCurrentLiabilities_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional and consulting services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedManufacturingExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedManufacturingExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Manufacturing Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedClinicalExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedClinicalExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued And Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other accrued liabilities</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClinicalTrials" xlink:type="locator" xlink:label="cbio_ClinicalTrials" />
    <link:label xml:lang="en-US" xlink:label="cbio_ClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trials.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ClinicalTrials" xlink:to="cbio_ClinicalTrials_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClinicalTrialsPaid" xlink:type="locator" xlink:label="cbio_ClinicalTrialsPaid" />
    <link:label xml:lang="en-US" xlink:label="cbio_ClinicalTrialsPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trials paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ClinicalTrialsPaid" xlink:to="cbio_ClinicalTrialsPaid_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_CommitmentsAndContingenciesDisclosureLineItems_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="cbio_CommitmentsAndContingenciesDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AGCBiologicsIncMember" xlink:type="locator" xlink:label="cbio_AGCBiologicsIncMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_AGCBiologicsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">AGC Biologics Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AGCBiologicsIncMember" xlink:to="cbio_AGCBiologicsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_AGCBiologicsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AGC Biologics, Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AGCBiologicsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A G C Biologics Inc [Member]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CatalentIndianaLLCMember" xlink:type="locator" xlink:label="cbio_CatalentIndianaLLCMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_CatalentIndianaLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Catalent Indiana, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CatalentIndianaLLCMember" xlink:to="cbio_CatalentIndianaLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CatalentIndianaLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Catalent Indiana, LLC.</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CatalentIndianaLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Catalent Indiana L L C [Member]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marzeptacog alfa activated and dalcinonacog alfa.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" xlink:to="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marzeptacog Alfa Activated and Dalcinonacog Alfa</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marzeptacog Alfa Activated And Dalcinonacog Alfa [Member]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_DalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_DalcinonacogAlfaMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_DalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dalcinonacog alfa.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_DalcinonacogAlfaMember" xlink:to="cbio_DalcinonacogAlfaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_DalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dalcinonacog alfa.</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_DalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dalcinonacog Alfa [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical trials</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trials</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual obligation payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClinicalTrialsPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical trials paid</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClinicalTrialsPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trials Paid</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" xlink:type="locator" xlink:label="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" />
    <link:label xml:lang="en-US" xlink:label="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee reveived from license and collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" xlink:to="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_SublicenseFee" xlink:type="locator" xlink:label="cbio_SublicenseFee" />
    <link:label xml:lang="en-US" xlink:label="cbio_SublicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublicense fee entitled to pay.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_SublicenseFee" xlink:to="cbio_SublicenseFee_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_TotalTransactionExpensesRelatedToCollaboration" xlink:type="locator" xlink:label="cbio_TotalTransactionExpensesRelatedToCollaboration" />
    <link:label xml:lang="en-US" xlink:label="cbio_TotalTransactionExpensesRelatedToCollaboration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Total transaction expenses related to collaboration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_TotalTransactionExpensesRelatedToCollaboration" xlink:to="cbio_TotalTransactionExpensesRelatedToCollaboration_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" xlink:type="locator" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" />
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment .</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" xlink:to="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MosaicBiosciencesIncMember" xlink:type="locator" xlink:label="cbio_MosaicBiosciencesIncMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_MosaicBiosciencesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Mosaic Biosciences, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MosaicBiosciencesIncMember" xlink:to="cbio_MosaicBiosciencesIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_MosaicBiosciencesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mosaic</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MosaicBiosciencesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Mosaic Biosciences Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_BiogenCollaborationMember" xlink:type="locator" xlink:label="cbio_BiogenCollaborationMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenCollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Biogen collaboration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_BiogenCollaborationMember" xlink:to="cbio_BiogenCollaborationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenCollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biogen Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenCollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Biogen Collaboration [Member]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_IntravitrealAntiComplementFactor3Member" xlink:type="locator" xlink:label="cbio_IntravitrealAntiComplementFactor3Member" />
    <link:label xml:lang="en-US" xlink:label="cbio_IntravitrealAntiComplementFactor3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Intravitreal anti-complement factor 3.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_IntravitrealAntiComplementFactor3Member" xlink:to="cbio_IntravitrealAntiComplementFactor3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_IntravitrealAntiComplementFactor3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intravitreal Anti-Complement Factor 3</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IntravitrealAntiComplementFactor3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intravitreal Anti Complement Factor3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses related to collaboration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_TotalTransactionExpensesRelatedToCollaboration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses related to collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_TotalTransactionExpensesRelatedToCollaboration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Total Transaction Expenses Related To Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fee received from collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee Reveived From License And Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SublicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment related to collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SublicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublicense Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Payment Related To Regulatory And Clinical Development Events</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Related To Regulatory And Clinical Development Events</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Research And Development Expense</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LesseeOperatingLeaseRenewalTermDescription" xlink:type="locator" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription" />
    <link:label xml:lang="en-US" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease renewal term description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_LesseeOperatingLeaseRenewalTermDescription" xlink:to="cbio_LesseeOperatingLeaseRenewalTermDescription_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease renewal term description</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease not yet commenced description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Lease Not Yet Commenced Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term of contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total undiscounted lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for leases that were included in operating cash outflows</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:type="locator" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen omnibus incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:to="cbio_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Omnibus Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Omnibus Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:to="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in number of shares of common stock reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Underlying Outstanding Options, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Underlying Outstanding Options, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Exercisable- December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available to be granted - December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Exercise Price, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Exercise Price, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Exercisable - December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years), Outstanding Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Exercisable - December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedInPeriodIntrinsicValue" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedInPeriodIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options canceled and forfeited in period intrinsic value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedInPeriodIntrinsicValue" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedInPeriodIntrinsicValue_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriodIntrinsicValue" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriodIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options expiration in period intrinsic value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriodIntrinsicValue" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriodIntrinsicValue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Additional General Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options canceled/forfeited</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Canceled And Forfeited In Period Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options expired</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Expiration In Period Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable - December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" />
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value assumptions Black-Scholes method used.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" />
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black-Scholes Method Used [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average fair value of stock options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock issued to certain board members in lieu of cash compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issued For Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized employee stock based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized employee stock based compensation expense, period for recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock available for future grant</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares remaining outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fair market value of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum employee subscription rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock authorized for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock stock issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Or Sale Of Equity</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:label xml:lang="en-US" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, permanent differences.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_EffectiveIncomeTaxRateReconciliationDerecognition" xlink:type="locator" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationDerecognition" />
    <link:label xml:lang="en-US" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationDerecognition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation derecognition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_EffectiveIncomeTaxRateReconciliationDerecognition" xlink:to="cbio_EffectiveIncomeTaxRateReconciliationDerecognition_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax at statutory federal rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">State Tax (benefit)&#8212;net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationDerecognition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Derecognition due to Sec. 382 and 383 limitations</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationDerecognition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Derecognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:type="locator" xlink:label="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" />
    <link:label xml:lang="en-US" xlink:label="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets fixed assets and intangibles.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:to="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carry forwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carry forwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed and intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Fixed Assets And Intangibles</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_IncomeTaxLineItems" xlink:type="locator" xlink:label="cbio_IncomeTaxLineItems" />
    <link:label xml:lang="en-US" xlink:label="cbio_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_IncomeTaxLineItems_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_IncomeTaxTable" xlink:type="locator" xlink:label="cbio_IncomeTaxTable" />
    <link:label xml:lang="en-US" xlink:label="cbio_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_IncomeTaxTable" xlink:to="cbio_IncomeTaxTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Income Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State Income Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CALIFORNIA</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowances And Reserves Period Increase Decrease</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="cbio_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="cbio_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_OperatingLossCarryforwardsExpirationYear" xlink:to="cbio_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_OperatingLossCarryforwardsWithIndefiniteLife" xlink:type="locator" xlink:label="cbio_OperatingLossCarryforwardsWithIndefiniteLife" />
    <link:label xml:lang="en-US" xlink:label="cbio_OperatingLossCarryforwardsWithIndefiniteLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards with indefinite life.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_OperatingLossCarryforwardsWithIndefiniteLife" xlink:to="cbio_OperatingLossCarryforwardsWithIndefiniteLife_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_OperatingLossCarryforwardsWithIndefiniteLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards having indefinite life</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_OperatingLossCarryforwardsWithIndefiniteLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards With Indefinite Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards available to offset future federal tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit carryforward, expire period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Date</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:type="locator" xlink:label="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" />
    <link:label xml:lang="en-US" xlink:label="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets state net operating loss carry forwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:to="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward, derecognized</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets State Net Operating Loss Carry Forwards</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:type="locator" xlink:label="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" />
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credit carry forwards derecognized.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:to="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross federal R&amp;D tax credit-related deferred tax assets derecognized</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credit Carry Forwards Derecognized</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MaximumAmountOfTaxOffsetPerYear" xlink:type="locator" xlink:label="cbio_MaximumAmountOfTaxOffsetPerYear" />
    <link:label xml:lang="en-US" xlink:label="cbio_MaximumAmountOfTaxOffsetPerYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of tax offset per year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MaximumAmountOfTaxOffsetPerYear" xlink:to="cbio_MaximumAmountOfTaxOffsetPerYear_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_RequiredMinimumTaxableIncome" xlink:type="locator" xlink:label="cbio_RequiredMinimumTaxableIncome" />
    <link:label xml:lang="en-US" xlink:label="cbio_RequiredMinimumTaxableIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum taxable income required to support realizing the company&apos;s.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_RequiredMinimumTaxableIncome" xlink:to="cbio_RequiredMinimumTaxableIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_MaximumAmountOfTaxOffsetPerYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount of tax offset per year</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MaximumAmountOfTaxOffsetPerYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Of Tax Offset Per Year</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RequiredMinimumTaxableIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Required Minimum Taxable Income</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RequiredMinimumTaxableIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Required Minimum Taxable Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits increase (decrease) resulting from tax positions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase/(Decrease) of unrecognized tax benefits taken in prior years</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase/(Decrease) of unrecognized tax benefits related to current year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax-related penalties or interest recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Penalties And Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liability For Uncertain Tax Positions Current</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MilestonePayments" xlink:type="locator" xlink:label="cbio_MilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MilestonePayments" xlink:to="cbio_MilestonePayments_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MilestoneContingentCashPaymentsObligation" xlink:type="locator" xlink:label="cbio_MilestoneContingentCashPaymentsObligation" />
    <link:label xml:lang="en-US" xlink:label="cbio_MilestoneContingentCashPaymentsObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone contingent cash payments obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MilestoneContingentCashPaymentsObligation" xlink:to="cbio_MilestoneContingentCashPaymentsObligation_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CollaborationAgreementsAbstract" xlink:type="locator" xlink:label="cbio_CollaborationAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CollaborationAgreementsAbstract" xlink:to="cbio_CollaborationAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition Multiple Deliverable Arrangements [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Multiple Deliverable Arrangements [Table]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_PfizerIncMember" xlink:type="locator" xlink:label="cbio_PfizerIncMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pfizer Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_PfizerIncMember" xlink:to="cbio_PfizerIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pfizer Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pfizer Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_IsuAbxisMember" xlink:type="locator" xlink:label="cbio_IsuAbxisMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_IsuAbxisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ISU Abxis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_IsuAbxisMember" xlink:to="cbio_IsuAbxisMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_IsuAbxisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ISU Abxis</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IsuAbxisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Isu Abxis [Member]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AmendedAndRestatedLicenseAgreementMember" xlink:type="locator" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AmendedAndRestatedLicenseAgreementMember" xlink:to="cbio_AmendedAndRestatedLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended And Restated License Agreement [Member]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_BiogenMember" xlink:type="locator" xlink:label="cbio_BiogenMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Biogen.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_BiogenMember" xlink:to="cbio_BiogenMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biogen</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Biogen [Member]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="cbio_LicenseAndCollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and Collaboration Agreement (the &#8220;Biogen Agreement&#8221;), .</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_LicenseAndCollaborationAgreementMember" xlink:to="cbio_LicenseAndCollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Collaboration Agreement (the &#8220;Biogen Agreement&#8221;)</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ExclusiveLicenseMember" xlink:type="locator" xlink:label="cbio_ExclusiveLicenseMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_ExclusiveLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exclusive license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ExclusiveLicenseMember" xlink:to="cbio_ExclusiveLicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_ExclusiveLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exclusive License</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ExclusiveLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exclusive License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ExclusiveLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exclusive License</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" xlink:type="locator" xlink:label="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Transfer of Exclusive License and Related Know-How.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" xlink:to="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer of Exclusive License and Related Know-How</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfer Of Exclusive License And Related Know How [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" xlink:type="locator" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" xlink:to="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursable Out Of Pocket And Personnel Costs Incurred Related To Research Services [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition Multiple Deliverable Arrangements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Multiple Deliverable Arrangements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MilestoneContingentCashPaymentsObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contingent cash payments upon achievement of certain clinical, regulatory and commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MilestoneContingentCashPaymentsObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Contingent Cash Payments Obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_RegulatoryAndDevelopmentMilestonePayment" xlink:type="locator" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory and development milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_RegulatoryAndDevelopmentMilestonePayment" xlink:to="cbio_RegulatoryAndDevelopmentMilestonePayment_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CommercialMilestonePayments" xlink:type="locator" xlink:label="cbio_CommercialMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CommercialMilestonePayments" xlink:to="cbio_CommercialMilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory and development milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory And Development Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone Payments</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ResearchServicesAgreementTerm" xlink:type="locator" xlink:label="cbio_ResearchServicesAgreementTerm" />
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchServicesAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ResearchServicesAgreementTerm" xlink:to="cbio_ResearchServicesAgreementTerm_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ResearchServicesAgreementOptionToExtend" xlink:type="locator" xlink:label="cbio_ResearchServicesAgreementOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchServicesAgreementOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research services agreement option to extend.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ResearchServicesAgreementOptionToExtend" xlink:to="cbio_ResearchServicesAgreementOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchServicesAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research services</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchServicesAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Services Agreement Term</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchServicesAgreementOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research services option to extend</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchServicesAgreementOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Services Agreement Option To Extend</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_DevelopmentMilestonesPaymentReceivable" xlink:type="locator" xlink:label="cbio_DevelopmentMilestonesPaymentReceivable" />
    <link:label xml:lang="en-US" xlink:label="cbio_DevelopmentMilestonesPaymentReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones payment Receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_DevelopmentMilestonesPaymentReceivable" xlink:to="cbio_DevelopmentMilestonesPaymentReceivable_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up-front payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From License Fees Received</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_DevelopmentMilestonesPaymentReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and sales milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_DevelopmentMilestonesPaymentReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones Payment Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Nonoperating Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Miscellaneous income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_InterestAndOtherIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total interest and other income, net</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_FirmCommitmentUnderwrittenPublicOfferingShares" xlink:type="locator" xlink:label="cbio_FirmCommitmentUnderwrittenPublicOfferingShares" />
    <link:label xml:lang="en-US" xlink:label="cbio_FirmCommitmentUnderwrittenPublicOfferingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Firm commitment underwritten public offering shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_FirmCommitmentUnderwrittenPublicOfferingShares" xlink:to="cbio_FirmCommitmentUnderwrittenPublicOfferingShares_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable" xlink:type="locator" xlink:label="cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable" />
    <link:label xml:lang="en-US" xlink:label="cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from sale of common stock, after deducting underwriting commissions and offering expenses payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable" xlink:to="cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_UnderwritingCommissionsAndOfferingExpensesPayable" xlink:type="locator" xlink:label="cbio_UnderwritingCommissionsAndOfferingExpensesPayable" />
    <link:label xml:lang="en-US" xlink:label="cbio_UnderwritingCommissionsAndOfferingExpensesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting commissions and offering expenses payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_UnderwritingCommissionsAndOfferingExpensesPayable" xlink:to="cbio_UnderwritingCommissionsAndOfferingExpensesPayable_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_StockholdersEquityDisclosureLineItems" xlink:type="locator" xlink:label="cbio_StockholdersEquityDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="cbio_StockholdersEquityDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders equity disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_StockholdersEquityDisclosureLineItems_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_StockholdersEquityDisclosureTable" xlink:type="locator" xlink:label="cbio_StockholdersEquityDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="cbio_StockholdersEquityDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders equity disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_StockholdersEquityDisclosureTable" xlink:to="cbio_StockholdersEquityDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_StockholdersEquityDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockholdersEquityDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Overallotment Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockholdersEquityDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockholdersEquityDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_FirmCommitmentUnderwrittenPublicOfferingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Firm commitment underwritten public offering shares</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_FirmCommitmentUnderwrittenPublicOfferingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Firm Commitment Underwritten Public Offering Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of stock, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price, per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from sale of common stock after deducting underwriting commissions and offering expenses payable</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Sale Of Common Stock After Deducting Underwriting Commissions And Offering Expenses Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UnderwritingCommissionsAndOfferingExpensesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts, commissions and offering expenses payable</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UnderwritingCommissionsAndOfferingExpensesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Commissions And Offering Expenses Payable</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" xlink:type="locator" xlink:label="cbio_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" />
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, warrants issued during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" xlink:to="cbio_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator" xlink:label="cbio_ClassOfWarrantOrRightExercisedDuringPeriod" />
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, exercised during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="cbio_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClassOfWarrantOrRightForfeitedDuringPeriod" xlink:type="locator" xlink:label="cbio_ClassOfWarrantOrRightForfeitedDuringPeriod" />
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightForfeitedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, forfeited during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ClassOfWarrantOrRightForfeitedDuringPeriod" xlink:to="cbio_ClassOfWarrantOrRightForfeitedDuringPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Note Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Underlying Warrants, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Warrants, Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Warrants Issued During Period</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Warrants, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercised During Period</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightForfeitedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Warrants, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightForfeitedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Forfeited During Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Underlying Warrants, Outstanding</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited" xlink:type="locator" xlink:label="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited" />
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right weighted average exercise price per warrants or right forfeited.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited" xlink:to="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued" xlink:type="locator" xlink:label="cbio_ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued" />
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right exercise price per warrant or right, issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued" xlink:to="cbio_ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued_lbl" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised" xlink:type="locator" xlink:label="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised" />
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right weighted average exercise price per warrants or right exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised" xlink:to="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Warrants Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Per Warrant Or Right Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Exercised, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Weighted Average Exercise Price Per Warrants Or Right Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Forfeited, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Weighted Average Exercise Price Per Warrants Or Right Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Warrants Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of shares used in computing net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share, basic and diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="cbio_OptionsToPurchaseCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_OptionsToPurchaseCommonStockMember" xlink:to="cbio_OptionsToPurchaseCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options To Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CommonStockWarrantsMember" xlink:type="locator" xlink:label="cbio_CommonStockWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CommonStockWarrantsMember" xlink:to="cbio_CommonStockWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti dilutive securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_UnderwritingDiscountsAndOfferingExpenses" xlink:type="locator" xlink:label="cbio_UnderwritingDiscountsAndOfferingExpenses" />
    <link:label xml:lang="en-US" xlink:label="cbio_UnderwritingDiscountsAndOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and offering expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_UnderwritingDiscountsAndOfferingExpenses" xlink:to="cbio_UnderwritingDiscountsAndOfferingExpenses_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="cbio-20201231.xsd#cbio_UnderwritersOverallotmentOptionMember" xlink:type="locator" xlink:label="cbio_UnderwritersOverallotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_UnderwritersOverallotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriters overallotment option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_UnderwritersOverallotmentOptionMember" xlink:to="cbio_UnderwritersOverallotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_UnderwritersOverallotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters&apos; overallotment option</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UnderwritersOverallotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwriters Overallotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UnderwritingDiscountsAndOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UnderwritingDiscountsAndOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts And Offering Expenses</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>cbio-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-04T15:52:13.4126890+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : e2a5eda4d98d48aba04c2fa8e195e2fb -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/role/TemplateLink" xlink:href="cbio-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cbio-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="cbio-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="cbio-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="cbio-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_InterestAndOtherIncomeExpenseNet" xlink:type="locator" xlink:label="cbio_InterestAndOtherIncomeExpenseNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CostOfCollaborationMember" xlink:type="locator" xlink:label="cbio_CostOfCollaborationMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CostOfLicenseMember" xlink:type="locator" xlink:label="cbio_CostOfLicenseMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CollaborationRevenueMember" xlink:type="locator" xlink:label="cbio_CollaborationRevenueMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LicenseRevenueMember" xlink:type="locator" xlink:label="cbio_LicenseRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_LicenseRevenueMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CollaborationRevenueMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CostOfLicenseMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CostOfCollaborationMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_InterestAndOtherIncomeExpenseNet" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="cbio-20201231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="cbio-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="cbio-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="cbio-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="cbio-20201231.xsd#cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" xlink:type="locator" xlink:label="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet" xlink:type="locator" xlink:label="cbio_NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_PaymentsToAcquireShortTermAndLongInvestments" xlink:type="locator" xlink:label="cbio_PaymentsToAcquireShortTermAndLongInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:type="locator" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="cbio_PaymentsToAcquireShortTermAndLongInvestments" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="cbio_NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNatureOfOperations" xlink:href="cbio-20201231.xsd#Role_DisclosureNatureOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNatureOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLiquidity" xlink:href="cbio-20201231.xsd#Role_DisclosureLiquidity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLiquidity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:type="locator" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LiquidationBasisOfAccountingTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="cbio-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="cbio-20201231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstruments" xlink:href="cbio-20201231.xsd#Role_DisclosureFinancialInstruments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstruments">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureOtherAccruedLiabilities" xlink:href="cbio-20201231.xsd#Role_DisclosureOtherAccruedLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureOtherAccruedLiabilities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="cbio-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedParties" xlink:href="cbio-20201231.xsd#Role_DisclosureRelatedParties" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedParties">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeases" xlink:href="cbio-20201231.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="cbio-20201231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="cbio-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborations" xlink:href="cbio-20201231.xsd#Role_DisclosureCollaborations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureInterestAndOtherIncomeNet" xlink:href="cbio-20201231.xsd#Role_DisclosureInterestAndOtherIncomeNet" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureInterestAndOtherIncomeNet">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncomeTextBlock" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncomeTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncomeTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="cbio-20201231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:href="cbio-20201231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEvent" xlink:href="cbio-20201231.xsd#Role_DisclosureSubsequentEvent" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEvent">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cbio-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="locator" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:type="locator" xlink:label="cbio_ConcentrationRiskCreditRiskPolicyTextBlock" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:type="locator" xlink:label="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock" xlink:type="locator" xlink:label="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cbio_ConcentrationRiskCreditRiskPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="cbio-20201231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsTables" xlink:href="cbio-20201231.xsd#Role_DisclosureFinancialInstrumentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureOtherAccruedLiabilitiesTables" xlink:href="cbio-20201231.xsd#Role_DisclosureOtherAccruedLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureOtherAccruedLiabilitiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesTables" xlink:href="cbio-20201231.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" xlink:type="locator" xlink:label="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="cbio-20201231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="cbio-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureInterestAndOtherIncomeNetTables" xlink:href="cbio-20201231.xsd#Role_DisclosureInterestAndOtherIncomeNetTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureInterestAndOtherIncomeNetTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="cbio-20201231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:href="cbio-20201231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureNatureOfOperationsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureLiquidityAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LiquidityAbstract" xlink:type="locator" xlink:label="cbio_LiquidityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_LiquidityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_LiquidityAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_LiquidityAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CostOfCollaborationRevenue" xlink:type="locator" xlink:label="cbio_CostOfCollaborationRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:type="locator" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cbio_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="cbio_SummaryOfSignificantAccountingPoliciesLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LeasePracticalExpedientsPackage" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cbio_CostOfCollaborationRevenue" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LongTermInvestmentsMember" xlink:type="locator" xlink:label="cbio_LongTermInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="cbio_LongTermInvestmentsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LongTermInvestmentsMember" xlink:type="locator" xlink:label="cbio_LongTermInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_FederalAgencySecuritiesMember" xlink:type="locator" xlink:label="cbio_FederalAgencySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="cbio_FederalAgencySecuritiesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="cbio_LongTermInvestmentsMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10060.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureScheduleOfOtherAccruedLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AccruedAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="cbio_AccruedAndOtherCurrentLiabilities" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AccruedClinicalExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedClinicalExpensesCurrent" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AccruedManufacturingExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedManufacturingExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cbio_AccruedManufacturingExpensesCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cbio_AccruedClinicalExpensesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cbio_AccruedAndOtherCurrentLiabilities" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClinicalTrialsPaid" xlink:type="locator" xlink:label="cbio_ClinicalTrialsPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClinicalTrials" xlink:type="locator" xlink:label="cbio_ClinicalTrials" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_DalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_DalcinonacogAlfaMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CatalentIndianaLLCMember" xlink:type="locator" xlink:label="cbio_CatalentIndianaLLCMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AGCBiologicsIncMember" xlink:type="locator" xlink:label="cbio_AGCBiologicsIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="cbio_CommitmentsAndContingenciesDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_AGCBiologicsIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_CatalentIndianaLLCMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_DalcinonacogAlfaMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="cbio_CommitmentsAndContingenciesDisclosureLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_ClinicalTrials" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ContractualObligation" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_ClinicalTrialsPaid" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureRelatedPartiesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" xlink:type="locator" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_SublicenseFee" xlink:type="locator" xlink:label="cbio_SublicenseFee" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" xlink:type="locator" xlink:label="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_TotalTransactionExpensesRelatedToCollaboration" xlink:type="locator" xlink:label="cbio_TotalTransactionExpensesRelatedToCollaboration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_IntravitrealAntiComplementFactor3Member" xlink:type="locator" xlink:label="cbio_IntravitrealAntiComplementFactor3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_BiogenCollaborationMember" xlink:type="locator" xlink:label="cbio_BiogenCollaborationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MosaicBiosciencesIncMember" xlink:type="locator" xlink:label="cbio_MosaicBiosciencesIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cbio_MosaicBiosciencesIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cbio_BiogenCollaborationMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_IntravitrealAntiComplementFactor3Member" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="cbio_TotalTransactionExpensesRelatedToCollaboration" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="cbio_SublicenseFee" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LesseeOperatingLeaseRenewalTermDescription" xlink:type="locator" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="cbio_LesseeOperatingLeaseRenewalTermDescription" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails" xlink:href="cbio-20201231.xsd#Role_DisclosureScheduleOfSupplementalCashFlowInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:type="locator" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_li0l2" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriodIntrinsicValue" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriodIntrinsicValue" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedInPeriodIntrinsicValue" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedInPeriodIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="13410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="13510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="13710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="13810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedInPeriodIntrinsicValue" order="13910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriodIntrinsicValue" order="14010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedInPeriodIntrinsicValue" order="14210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" order="14410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureSummaryOfStockBasedCompensationRecognizedDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_EffectiveIncomeTaxRateReconciliationDerecognition" xlink:type="locator" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationDerecognition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cbio_EffectiveIncomeTaxRateReconciliationDerecognition" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureComponentsOfCompanySDeferredTaxAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:type="locator" xlink:label="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_RequiredMinimumTaxableIncome" xlink:type="locator" xlink:label="cbio_RequiredMinimumTaxableIncome" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MaximumAmountOfTaxOffsetPerYear" xlink:type="locator" xlink:label="cbio_MaximumAmountOfTaxOffsetPerYear" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:type="locator" xlink:label="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:type="locator" xlink:label="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_OperatingLossCarryforwardsWithIndefiniteLife" xlink:type="locator" xlink:label="cbio_OperatingLossCarryforwardsWithIndefiniteLife" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="cbio_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_IncomeTaxLineItems" xlink:type="locator" xlink:label="cbio_IncomeTaxLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_IncomeTaxTable" xlink:type="locator" xlink:label="cbio_IncomeTaxTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cbio_IncomeTaxTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_CA" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxTable" xlink:to="cbio_IncomeTaxLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_OperatingLossCarryforwardsExpirationYear" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_OperatingLossCarryforwardsWithIndefiniteLife" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_MaximumAmountOfTaxOffsetPerYear" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_RequiredMinimumTaxableIncome" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureUnrecognizedTaxBenefitDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_li0l2" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureCollaborationsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_DevelopmentMilestonesPaymentReceivable" xlink:type="locator" xlink:label="cbio_DevelopmentMilestonesPaymentReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ResearchServicesAgreementOptionToExtend" xlink:type="locator" xlink:label="cbio_ResearchServicesAgreementOptionToExtend" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ResearchServicesAgreementTerm" xlink:type="locator" xlink:label="cbio_ResearchServicesAgreementTerm" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CommercialMilestonePayments" xlink:type="locator" xlink:label="cbio_CommercialMilestonePayments" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_RegulatoryAndDevelopmentMilestonePayment" xlink:type="locator" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MilestonePayments" xlink:type="locator" xlink:label="cbio_MilestonePayments" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_MilestoneContingentCashPaymentsObligation" xlink:type="locator" xlink:label="cbio_MilestoneContingentCashPaymentsObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" xlink:type="locator" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CollaborationRevenueMember" xlink:type="locator" xlink:label="cbio_CollaborationRevenueMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" xlink:type="locator" xlink:label="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LicenseRevenueMember" xlink:type="locator" xlink:label="cbio_LicenseRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ExclusiveLicenseMember" xlink:type="locator" xlink:label="cbio_ExclusiveLicenseMember_li0l2" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ExclusiveLicenseMember" xlink:type="locator" xlink:label="cbio_ExclusiveLicenseMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="cbio_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_BiogenMember" xlink:type="locator" xlink:label="cbio_BiogenMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_AmendedAndRestatedLicenseAgreementMember" xlink:type="locator" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_IsuAbxisMember" xlink:type="locator" xlink:label="cbio_IsuAbxisMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_PfizerIncMember" xlink:type="locator" xlink:label="cbio_PfizerIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CollaborationAgreementsAbstract" xlink:type="locator" xlink:label="cbio_CollaborationAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CollaborationAgreementsAbstract" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_PfizerIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TransactionTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_CollaborativeArrangementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_IsuAbxisMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_AmendedAndRestatedLicenseAgreementMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_BiogenMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_LicenseAndCollaborationAgreementMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_ExclusiveLicenseMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_ExclusiveLicenseMember_li0l2" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_LicenseRevenueMember" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_ExclusiveLicenseMember" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CollaborationRevenueMember" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_MilestoneContingentCashPaymentsObligation" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_MilestonePayments" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_RegulatoryAndDevelopmentMilestonePayment" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_CommercialMilestonePayments" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_ResearchServicesAgreementTerm" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_ResearchServicesAgreementOptionToExtend" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_DevelopmentMilestonesPaymentReceivable" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureDetailOfInterestAndOtherIncomeNetDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail">
    <link:loc xlink:href="cbio-20201231.xsd#cbio_InterestAndOtherIncomeExpenseNet" xlink:type="locator" xlink:label="cbio_InterestAndOtherIncomeExpenseNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="cbio_InterestAndOtherIncomeExpenseNet" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20201231.xsd#cbio_UnderwritingCommissionsAndOfferingExpensesPayable" xlink:type="locator" xlink:label="cbio_UnderwritingCommissionsAndOfferingExpensesPayable" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable" xlink:type="locator" xlink:label="cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_FirmCommitmentUnderwrittenPublicOfferingShares" xlink:type="locator" xlink:label="cbio_FirmCommitmentUnderwrittenPublicOfferingShares" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_StockholdersEquityDisclosureLineItems" xlink:type="locator" xlink:label="cbio_StockholdersEquityDisclosureLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_StockholdersEquityDisclosureTable" xlink:type="locator" xlink:label="cbio_StockholdersEquityDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="cbio_StockholdersEquityDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureTable" xlink:to="cbio_StockholdersEquityDisclosureLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_FirmCommitmentUnderwrittenPublicOfferingShares" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_SharePrice" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_UnderwritingCommissionsAndOfferingExpensesPayable" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfWarrantActivityDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureSummaryOfWarrantActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfWarrantActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_li0l2" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited" xlink:type="locator" xlink:label="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised" xlink:type="locator" xlink:label="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued" xlink:type="locator" xlink:label="cbio_ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_li0l2" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClassOfWarrantOrRightForfeitedDuringPeriod" xlink:type="locator" xlink:label="cbio_ClassOfWarrantOrRightForfeitedDuringPeriod" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator" xlink:label="cbio_ClassOfWarrantOrRightExercisedDuringPeriod" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" xlink:type="locator" xlink:label="cbio_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="cbio_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="cbio_ClassOfWarrantOrRightExercisedDuringPeriod" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="cbio_ClassOfWarrantOrRightForfeitedDuringPeriod" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_li0l2" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="cbio_ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_li0l2" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureBasicAndDilutedNetLossPerCommonShareDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_CommonStockWarrantsMember" xlink:type="locator" xlink:label="cbio_CommonStockWarrantsMember" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="cbio_OptionsToPurchaseCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cbio_OptionsToPurchaseCommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cbio_CommonStockWarrantsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail" xlink:href="cbio-20201231.xsd#Role_DisclosureSubsequentEventAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20201231.xsd#cbio_UnderwritingDiscountsAndOfferingExpenses" xlink:type="locator" xlink:label="cbio_UnderwritingDiscountsAndOfferingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="cbio-20201231.xsd#cbio_UnderwritersOverallotmentOptionMember" xlink:type="locator" xlink:label="cbio_UnderwritersOverallotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_UnderwritersOverallotmentOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cbio_UnderwritingDiscountsAndOfferingExpenses" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>cbio-10k_20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cbio="http://www.catalystbiosciences.com/20201231"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cbio-20201231.xsd" xlink:type="simple"/>
    <context id="C_0001124105_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_20210225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2021-02-25</instant>
        </period>
    </context>
    <context id="C_0001124105_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0001124105_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCostOfLicenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CostOfLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CostOfCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cbio:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cbio:FederalAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cbio:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cbio:FederalAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:AGCBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioCatalentIndianaLLCMember_srtProductOrServiceAxis_cbioDalcinonacogAlfaMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:CatalentIndianaLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:DalcinonacogAlfaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:IntravitrealAntiComplementFactor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:IntravitrealAntiComplementFactor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_cbioBiogenCollaborationMember_20200110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:IntravitrealAntiComplementFactor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:BiogenCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-10</instant>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:IntravitrealAntiComplementFactor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_20200716_20200717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2020-07-16</startDate>
            <endDate>2020-07-17</endDate>
        </period>
    </context>
    <context id="C_0001124105_20200717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2020-07-17</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20200611_20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="C_0001124105_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613_20180613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-13</startDate>
            <endDate>2018-06-13</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-13</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20071231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629_20200629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-29</instant>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioPfizerIncMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_us-gaapCollaborativeArrangementMember_20161208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-08</instant>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioPfizerIncMember_us-gaapTransactionTypeAxis_us-gaapCollaborativeArrangementMember_20180201_20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioPfizerIncMember_us-gaapTransactionTypeAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioLicenseAndCollaborationAgreementMember_20191218_20191218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-18</startDate>
            <endDate>2019-12-18</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioTransferOfExclusiveLicenseAndRelatedKnowHowMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:LicenseRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbio:TransferOfExclusiveLicenseAndRelatedKnowHowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioExclusiveLicenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbio:ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200228_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-28</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200228_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-28</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_0001124105_20200228_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2020-02-28</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200629_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0001124105_20200629_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtStatementScenarioAxis_srtScenarioForecastMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioUnderwritersOverallotmentOptionMember_srtStatementScenarioAxis_srtScenarioForecastMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:UnderwritersOverallotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtStatementScenarioAxis_srtScenarioForecastMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_cbioSegment">
        <measure>cbio:Segment</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001124105_20200101_20201231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001124105_20200101_20201231" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001124105_20200101_20201231" id="F_000007">0001124105</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001124105_20200101_20201231" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:LeasePracticalExpedientsPackage
      contextRef="C_0001124105_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101_20201231"
      id="F_000265">true</us-gaap:LeasePracticalExpedientsPackage>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231"
      id="F_000268">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231"
      id="F_000270">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:TaxCreditCarryforwardExpirationDate
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_000471">2040-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <cbio:ResearchServicesAgreementOptionToExtend
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioLicenseAndCollaborationAgreementMember_20191218_20191218"
      id="F_000502">P12M</cbio:ResearchServicesAgreementOptionToExtend>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001124105_20201231"
      id="F_000069"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001124105_20191231"
      id="F_000070"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001124105_20201231"
      id="F_000071"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001124105_20191231"
      id="F_000072"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001124105_20180101_20181231" id="F_000394">P8Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001124105_20190101_20191231" id="F_000395">P8Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001124105_20200101_20201231" id="F_000396">P7Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0001124105_20200101_20201231" id="F_000397">P7Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_000404">P5Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      id="F_000405">P5Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <dei:DocumentType contextRef="C_0001124105_20200101_20201231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001124105_20200101_20201231" id="F_000032">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001124105_20200101_20201231" id="F_000002">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001124105_20200101_20201231" id="F_000003">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001124105_20200101_20201231" id="F_000033">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001124105_20200101_20201231" id="F_000022">000-51173</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001124105_20200101_20201231" id="F_000006">Catalyst Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001124105_20200101_20201231" id="F_000023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001124105_20200101_20201231" id="F_000024">56-2020050</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001124105_20200101_20201231" id="F_000025">611 Gateway Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001124105_20200101_20201231" id="F_000026">Suite 710</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001124105_20200101_20201231" id="F_000027">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001124105_20200101_20201231" id="F_000028">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001124105_20200101_20201231" id="F_000029">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001124105_20200101_20201231" id="F_000030">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001124105_20200101_20201231" id="F_000031">871-0761</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001124105_20200101_20201231" id="F_000020">Common stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001124105_20200101_20201231" id="F_000005">CBIO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001124105_20200101_20201231" id="F_000021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001124105_20200101_20201231" id="F_000009">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001124105_20200101_20201231" id="F_000011">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001124105_20200101_20201231" id="F_000010">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001124105_20200101_20201231" id="F_000019">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001124105_20200101_20201231" id="F_000012">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001124105_20200101_20201231" id="F_000014">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001124105_20200101_20201231" id="F_000015">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001124105_20200101_20201231" id="F_000018">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001124105_20200101_20201231" id="F_000013">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001124105_20210225"
      decimals="INF"
      id="F_000016"
      unitRef="U_xbrlishares">31331027</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityPublicFloat
      contextRef="C_0001124105_20200630"
      decimals="0"
      id="F_000017"
      unitRef="U_iso4217USD">128362589</dei:EntityPublicFloat>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000034"
      unitRef="U_iso4217USD">30360000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">15369000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">48994000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">61496000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">3313000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">15000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">6843000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">4201000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">89510000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">96066000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">2543000</us-gaap:LongTermInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">528000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">257000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">1832000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">1927000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">433000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">304000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">94846000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">98554000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">5931000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">4279000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">2476000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">2106000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">1983000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">15000000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">6743000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">7031000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">663000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">483000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">17796000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">28899000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">981000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">1319000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">18777000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">30218000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000085"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001124105_20191231"
      decimals="INF"
      id="F_000086"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000087"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001124105_20191231"
      decimals="INF"
      id="F_000088"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000089"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001124105_20191231"
      decimals="INF"
      id="F_000090"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000091"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001124105_20191231"
      decimals="INF"
      id="F_000092"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000093"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001124105_20191231"
      decimals="INF"
      id="F_000094"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000095"
      unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001124105_20191231"
      decimals="INF"
      id="F_000096"
      unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000097"
      unitRef="U_xbrlishares">22097820</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000099"
      unitRef="U_xbrlishares">22097820</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001124105_20191231"
      decimals="INF"
      id="F_000098"
      unitRef="U_xbrlishares">12040835</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001124105_20191231"
      decimals="INF"
      id="F_000100"
      unitRef="U_xbrlishares">12040835</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">22000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">12000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">390803000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">326810000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">5000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">34000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000079"
      unitRef="U_iso4217USD">-314761000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000080"
      unitRef="U_iso4217USD">-258520000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">76069000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">68336000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">94846000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">98554000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">15100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">5848000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">20948000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCostOfLicenseMember_20200101_20201231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">3102000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20200101_20201231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">6061000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">52975000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">43859000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">16180000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">13418000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">78318000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">57277000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">-57370000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">-57277000</us-gaap:OperatingIncomeLoss>
    <cbio:InterestAndOtherIncomeExpenseNet
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">1129000</cbio:InterestAndOtherIncomeExpenseNet>
    <cbio:InterestAndOtherIncomeExpenseNet
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">2099000</cbio:InterestAndOtherIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">-56241000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">-55178000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001124105_20200101_20201231"
      decimals="2"
      id="F_000118"
      unitRef="U_iso4217USD_xbrlishares">-2.93</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001124105_20190101_20191231"
      decimals="2"
      id="F_000119"
      unitRef="U_iso4217USD_xbrlishares">-4.60</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001124105_20200101_20201231"
      decimals="0"
      id="F_000120"
      unitRef="U_xbrlishares">19179299</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001124105_20190101_20191231"
      decimals="0"
      id="F_000121"
      unitRef="U_xbrlishares">12004489</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">-56241000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">-55178000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">-29000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">38000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">-56270000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">-55140000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="INF"
      id="F_000128"
      unitRef="U_xbrlishares">11954528</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">323279000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">-4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">-203342000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20181231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">119945000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000134"
      unitRef="U_xbrlishares">24235</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">3204000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">3204000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000137"
      unitRef="U_xbrlishares">62072</cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares>
    <cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">327000</cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue>
    <cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">327000</cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">38000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">38000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">-55178000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">-55178000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000144"
      unitRef="U_xbrlishares">12040835</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">326810000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">-258520000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">68336000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000150"
      unitRef="U_xbrlishares">51056</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">3627000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">3627000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000153"
      unitRef="U_xbrlishares">82853</cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares>
    <cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">435000</cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue>
    <cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">435000</cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">4559000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000156"
      unitRef="U_xbrlishares">9923076</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">10000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">59931000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">59941000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">-29000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">-29000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">-56241000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">-56241000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000164"
      unitRef="U_xbrlishares">22097820</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">390803000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">-314761000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">76069000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">-56241000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">-55178000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">3627000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">3204000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">138000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">146000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">-11687000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">15000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">3043000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">490000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">1652000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">3031000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">82000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">5599000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">67000</cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset>
    <cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">75000</cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">-13017000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">15000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">-55048000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">-43613000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">107565000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">157433000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <cbio:PaymentsToAcquireShortTermAndLongInvestments
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">97635000</cbio:PaymentsToAcquireShortTermAndLongInvestments>
    <cbio:PaymentsToAcquireShortTermAndLongInvestments
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">129977000</cbio:PaymentsToAcquireShortTermAndLongInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">267000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">64000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">9663000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">27392000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <cbio:ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">59941000</cbio:ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts>
    <cbio:ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">435000</cbio:ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises>
    <cbio:ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">327000</cbio:ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">60376000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">327000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">14991000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">-15894000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">15369000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001124105_20181231"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">31263000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">30360000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">15369000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <cbio:NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">2052000</cbio:NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet>
    <cbio:NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">476000</cbio:NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities>
    <us-gaap:NatureOfOperations contextRef="C_0001124105_20200101_20201231" id="F_000212">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p id="NOTES_TO_CONSOLIDATED" style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Nature of Operations&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Catalyst Biosciences, Inc. and its subsidiary (the &#x201c;Company&#x201d; or &#x201c;Catalyst&#x201d;) is a &lt;span style="color:#000000;"&gt;fully integrated research and clinical development biopharmaceutical company with expertise in protease engineering, discovery, translational research, clinical development, and manufacturing. The Company is focused on advancing its protease product candidates in the fields of hemostasis and complement regulation.&lt;/span&gt; &lt;span style="color:#000000;"&gt;The Company is located in South San Francisco, California and operates in&lt;/span&gt; one segment. &lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000261"
      unitRef="U_cbioSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:LiquidationBasisOfAccountingTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000213">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Liquidity&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had a net loss of $56.2 million for the year ended December 31, 2020 and an accumulated deficit of $314.8 million as of December 31, 2020. The Company expects to continue to incur losses for the next several years. As of December 31, 2020, the Company had $81.9 million of cash, cash equivalents and investments. Its primary uses of cash are to fund operating expenses, including research and development expenditures and general and administrative expenditures. Based on the current status of its research and development plans, the Company believes that its existing cash, cash equivalents and investments as of December 31, 2020 will be sufficient to fund its cash requirements for at least the next 12 months from the date of the filing of this report. If, at any time, the Company&#x2019;s prospects for financing its research and development programs decline, the Company may decide to reduce research and development expenses by delaying, discontinuing or reducing its funding of one or more of its research or development programs. Alternatively, the Company might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The Company will continue to evaluate the impact of the COVID-19 pandemic on our business, operations, and cash requirements. For recent financing, see Note 16.&lt;/p&gt;</us-gaap:LiquidationBasisOfAccountingTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20200101_20201231"
      decimals="-5"
      id="F_000264"
      unitRef="U_iso4217USD">-56200000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001124105_20201231"
      decimals="-5"
      id="F_000262"
      unitRef="U_iso4217USD">-314800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_0001124105_20201231"
      decimals="-5"
      id="F_000263"
      unitRef="U_iso4217USD">81900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000214">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Summary of Significant Accounting Policies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation. The Company&#x2019;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;). &#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, operating lease right-of-use assets and liabilities, accrued expenses, income taxes and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounting Pronouncements Recently Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-18,&#160;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606 (&#x201c;ASU 2018-18&#x201d;). The amended guidance precludes presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The new guidance is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2018-18 as of January 1, 2020. The adoption of ASU 2018-18 did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement (&#x201c;ASU 2018-13&#x201d;). The &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;guidance removes, modifies, and adds certain disclosure requirements for fair value measurements. Entities no longer have to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The guidance is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2018-13 as of January 1, 2020. The adoption of ASU 2018-13 did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;New Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13,&lt;span style="font-style:italic;"&gt;&#160;&lt;/span&gt;Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to adopt ASU 2016-13&#160;and related updates&#160;as of January 1, 2023.&#160;The Company will assess the impact of adoption of this standard on its consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued&#160;ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;span style="font-style:italic;"&gt;. &lt;/span&gt;The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes.&#160;ASU 2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning January 1, 2021. The adoption of this standard will not have a material impact on the Company&#x2019;s consolidated financial statements&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invests its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;span style="font-style:normal;"&gt; &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;span style="font-style:normal;"&gt; &#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;span style="font-style:normal;"&gt; &#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, which are three years for computer equipment and software, and three to seven years for furniture and leasehold improvements.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Investments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invests its excess cash in investment grade, short to intermediate-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#x201c;available-for-sale&#x201d; and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation as of each consolidated balance sheet date. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value determined to be other-than-temporary, if any, on available-for-sale debt securities are included in interest and other income, net. The cost of securities sold is based on the specific-identification method. Interest on short-term investments is included in interest and other income, net.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;License and Collaboration Arrangements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.21%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may enter into collaboration arrangements that fall under the scope Collaborative Arrangements (Topic 808). The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808 to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. The accounting for some of the activities under collaboration arrangements may be analogized to ASC 606 for distinct units of account that are reflective of a vendor-customer relationship.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 606, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when the Company satisfies each performance obligation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues attributed to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of each arrangement that contain development milestones, the Company evaluates whether the development milestones included are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not generally considered probable of being achieved until those approvals are received.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the end of each reporting period, the Company re-evaluates the probability of achievement of any development milestones, and if necessary, adjusts its estimate of the transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For research and development services, the Company elected the practical expedient to recognize revenue as the research and development services are invoiced.&#160;&#160;As the Company has a right to consideration from the &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;collaboration agreement with Biogen, in an amount that corresponds directly with the value of the Company&#x2019;s performance completed to date for the research services, the Company recognized revenue related to the research services as invoiced, in line with the practical expedient in ASC 606-10-55-18.&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price is allocated to each performance obligation on a relative stand-alone selling price (&#x201c;SSP&#x201d;) basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the timing of recognition and the SSP for each performance obligation identified in the contract.&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The SSP for licenses are calculated using the residual approach if the Company has not yet established a price for such license and the license has not previously been sold on a standalone basis.&#160;Otherwise, selling prices for licenses are determined using an income approach model and include key assumptions such as: development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success. To estimate the SSP for research and development services, the Company uses a cost-plus margin approach. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cost of License and Collaboration Revenue&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of license revenue includes sublicense fees paid or payable to Mosaic Biosciences, Inc. (&#x201c;Mosaic&#x201d;), incurred in the period, under the terms of the Mosaic collaboration agreement, and fees for patent development and protection paid or payable to other third-party vendors corresponding to the recognition of license revenue from the Company&#x2019;s collaboration agreement with Biogen International GmbH (&#x201c;Biogen&#x201d;). See&lt;span style="color:#000000;"&gt; Notes 8 and 12. Cost of license revenue does not include any allocated overhead costs.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of collaboration revenue includes fees for research and development services paid or payable to Mosaic and other third-party vendors and personnel cost, incurred in the period pertaining to the Biogen Agreement. See&lt;span style="color:#000000;"&gt; Notes 8 and 12. Cost of collaboration revenue does not include any allocated overhead costs.&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, and consulting costs, as well as allocations of facilities and other overhead costs. Under the Company&#x2019;s collaboration agreement with Biogen, certain specific expenditures are reimbursed by third parties. During the year ended December 31, 2020, $5.4 million of research and development expense was recorded as cost of collaboration revenue related to the collaboration agreement with Biogen signed in December 2019.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accrued Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses include estimated costs of research and development activities conducted by external service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in other accrued liabilities in the consolidated balance sheet and within research and development expense in the consolidated statement of operations. These costs are a significant component of the research and development expenses. The Company records accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these external service providers.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, investments and accounts receivable. The Company&#x2019;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company believes that it has established guidelines for investment of its excess cash that maintain safety and liquidity through its policies on high quality of investment and investment duration. The Company is exposed to credit risk in the event of default by the institutions holding the cash and cash equivalents to the extent beyond the amount insured by the federal depository insurance corporation. The Company&#x2019;s accounts receivable as of December 31, 2020 of $3.3 million as well as its total license and collaboration revenue of $20.9 million for the year ended December 31, 2020 is from one party, see Note 12.&#160;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounts Receivable, net and Allowance for Doubtful Accounts&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under the arrangements. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time balances are past due, the Company&#x2019;s previous loss history, the customer&#x2019;s current ability to pay its obligations to the Company and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are determined to be uncollectible. For the years ended December 31, 2020 and 2019, there were no allowance for doubtful accounts deemed necessary.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes are computed using the liability method. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company follows the authoritative guidance on accounting for uncertainty in income taxes. This guidance prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company&#x2019;s income tax returns. This interpretation also provides guidance on accounting for interest and penalties and associated with tax positions, accounting for income taxes in interim periods and income tax disclosures.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s policy is to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant and recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the Black-Scholes option-pricing valuation model to estimate the grant-date fair value of stock-based awards. The determination of fair value for stock-based awards on the date of grant using an option-pricing model requires management to make certain assumptions regarding a number of variables. The Company elected to account for forfeitures when they occur. As such, the Company recognizes stock-based compensation expense, over their requisite service period, based on the vesting provisions of the individual grants.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has elected to combine lease and non-lease components as a single component. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the consolidated balance sheet as right-of-use assets, operating lease liabilities, current and operating lease liabilities, non-current. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Share&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss of the Company for all periods presented.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000228">
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation. The Company&#x2019;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;). &#160;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001124105_20200101_20201231" id="F_000229">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, operating lease right-of-use assets and liabilities, accrued expenses, income taxes and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000230">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounting Pronouncements Recently Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-18,&#160;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606 (&#x201c;ASU 2018-18&#x201d;). The amended guidance precludes presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The new guidance is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2018-18 as of January 1, 2020. The adoption of ASU 2018-18 did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement (&#x201c;ASU 2018-13&#x201d;). The &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;guidance removes, modifies, and adds certain disclosure requirements for fair value measurements. Entities no longer have to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The guidance is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2018-13 as of January 1, 2020. The adoption of ASU 2018-13 did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;New Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13,&lt;span style="font-style:italic;"&gt;&#160;&lt;/span&gt;Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to adopt ASU 2016-13&#160;and related updates&#160;as of January 1, 2023.&#160;The Company will assess the impact of adoption of this standard on its consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued&#160;ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;span style="font-style:italic;"&gt;. &lt;/span&gt;The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes.&#160;ASU 2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning January 1, 2021. The adoption of this standard will not have a material impact on the Company&#x2019;s consolidated financial statements&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invests its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="C_0001124105_20200101_20201231" id="F_000232">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;span style="font-style:normal;"&gt; &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;span style="font-style:normal;"&gt; &#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;span style="font-style:normal;"&gt; &#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/p&gt;
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000233">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, which are three years for computer equipment and software, and three to seven years for furniture and leasehold improvements.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001124105_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231"
      id="F_000266">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001124105_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20200101_20201231"
      id="F_000267">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231"
      id="F_000269">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231"
      id="F_000271">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:MarketableSecuritiesPolicy contextRef="C_0001124105_20200101_20201231" id="F_000234">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Investments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invests its excess cash in investment grade, short to intermediate-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#x201c;available-for-sale&#x201d; and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation as of each consolidated balance sheet date. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value determined to be other-than-temporary, if any, on available-for-sale debt securities are included in interest and other income, net. The cost of securities sold is based on the specific-identification method. Interest on short-term investments is included in interest and other income, net.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000235">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;License and Collaboration Arrangements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.21%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may enter into collaboration arrangements that fall under the scope Collaborative Arrangements (Topic 808). The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808 to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. The accounting for some of the activities under collaboration arrangements may be analogized to ASC 606 for distinct units of account that are reflective of a vendor-customer relationship.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 606, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when the Company satisfies each performance obligation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues attributed to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of each arrangement that contain development milestones, the Company evaluates whether the development milestones included are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not generally considered probable of being achieved until those approvals are received.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the end of each reporting period, the Company re-evaluates the probability of achievement of any development milestones, and if necessary, adjusts its estimate of the transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For research and development services, the Company elected the practical expedient to recognize revenue as the research and development services are invoiced.&#160;&#160;As the Company has a right to consideration from the &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;collaboration agreement with Biogen, in an amount that corresponds directly with the value of the Company&#x2019;s performance completed to date for the research services, the Company recognized revenue related to the research services as invoiced, in line with the practical expedient in ASC 606-10-55-18.&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price is allocated to each performance obligation on a relative stand-alone selling price (&#x201c;SSP&#x201d;) basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the timing of recognition and the SSP for each performance obligation identified in the contract.&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The SSP for licenses are calculated using the residual approach if the Company has not yet established a price for such license and the license has not previously been sold on a standalone basis.&#160;Otherwise, selling prices for licenses are determined using an income approach model and include key assumptions such as: development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success. To estimate the SSP for research and development services, the Company uses a cost-plus margin approach. &lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <cbio:CostOfLicenseAndCollaborationRevenuePolicyTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000236">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cost of License and Collaboration Revenue&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of license revenue includes sublicense fees paid or payable to Mosaic Biosciences, Inc. (&#x201c;Mosaic&#x201d;), incurred in the period, under the terms of the Mosaic collaboration agreement, and fees for patent development and protection paid or payable to other third-party vendors corresponding to the recognition of license revenue from the Company&#x2019;s collaboration agreement with Biogen International GmbH (&#x201c;Biogen&#x201d;). See&lt;span style="color:#000000;"&gt; Notes 8 and 12. Cost of license revenue does not include any allocated overhead costs.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of collaboration revenue includes fees for research and development services paid or payable to Mosaic and other third-party vendors and personnel cost, incurred in the period pertaining to the Biogen Agreement. See&lt;span style="color:#000000;"&gt; Notes 8 and 12. Cost of collaboration revenue does not include any allocated overhead costs.&lt;/span&gt;&lt;/p&gt;</cbio:CostOfLicenseAndCollaborationRevenuePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001124105_20200101_20201231" id="F_000237">
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, and consulting costs, as well as allocations of facilities and other overhead costs. Under the Company&#x2019;s collaboration agreement with Biogen, certain specific expenditures are reimbursed by third parties. During the year ended December 31, 2020, $5.4 million of research and development expense was recorded as cost of collaboration revenue related to the collaboration agreement with Biogen signed in December 2019.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <cbio:CostOfCollaborationRevenue
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-5"
      id="F_000272"
      unitRef="U_iso4217USD">5400000</cbio:CostOfCollaborationRevenue>
    <cbio:AccruedResearchAndDevelopmentExpensesPolicyTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000238">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accrued Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses include estimated costs of research and development activities conducted by external service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in other accrued liabilities in the consolidated balance sheet and within research and development expense in the consolidated statement of operations. These costs are a significant component of the research and development expenses. The Company records accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these external service providers.&lt;/p&gt;
</cbio:AccruedResearchAndDevelopmentExpensesPolicyTextBlock>
    <cbio:ConcentrationRiskCreditRiskPolicyTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000239">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, investments and accounts receivable. The Company&#x2019;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company believes that it has established guidelines for investment of its excess cash that maintain safety and liquidity through its policies on high quality of investment and investment duration. The Company is exposed to credit risk in the event of default by the institutions holding the cash and cash equivalents to the extent beyond the amount insured by the federal depository insurance corporation. The Company&#x2019;s accounts receivable as of December 31, 2020 of $3.3 million as well as its total license and collaboration revenue of $20.9 million for the year ended December 31, 2020 is from one party, see Note 12.&#160;&lt;/p&gt;</cbio:ConcentrationRiskCreditRiskPolicyTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="C_0001124105_20201231"
      decimals="-5"
      id="F_000273"
      unitRef="U_iso4217USD">3300000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_20200101_20201231"
      decimals="-5"
      id="F_000274"
      unitRef="U_iso4217USD">20900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="C_0001124105_20200101_20201231" id="F_000240">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounts Receivable, net and Allowance for Doubtful Accounts&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under the arrangements. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time balances are past due, the Company&#x2019;s previous loss history, the customer&#x2019;s current ability to pay its obligations to the Company and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are determined to be uncollectible. For the years ended December 31, 2020 and 2019, there were no allowance for doubtful accounts deemed necessary.&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000241">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes are computed using the liability method. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company follows the authoritative guidance on accounting for uncertainty in income taxes. This guidance prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company&#x2019;s income tax returns. This interpretation also provides guidance on accounting for interest and penalties and associated with tax positions, accounting for income taxes in interim periods and income tax disclosures.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s policy is to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001124105_20200101_20201231" id="F_000242">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant and recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the Black-Scholes option-pricing valuation model to estimate the grant-date fair value of stock-based awards. The determination of fair value for stock-based awards on the date of grant using an option-pricing model requires management to make certain assumptions regarding a number of variables. The Company elected to account for forfeitures when they occur. As such, the Company recognizes stock-based compensation expense, over their requisite service period, based on the vesting provisions of the individual grants.&lt;/p&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000243">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has elected to combine lease and non-lease components as a single component. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the consolidated balance sheet as right-of-use assets, operating lease liabilities, current and operating lease liabilities, non-current. &lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000244">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Share&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss of the Company for all periods presented.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000215">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For a description of the fair value hierarchy and fair value methodology, see &#x201c;&lt;span style="font-style:italic;"&gt;Note 3 &#x2013; Summary of Significant Accounting Policies&lt;/span&gt;&#x201d;. As of December 31, 2020 and 2019, the Company&#x2019;s highly liquid money market funds included within cash equivalents and U.S. government agency securities are valued using Level&#160;1 inputs. The Company classifies its federal agency securities as Level 2. There were no transfers in or out of Level 1 and Level 2 during the periods presented. U.S. government agency securities are bonds issued by the U.S. government and are fully backed by the U.S. government. Given the frequency at which U.S. government agency securities trade and the accessibility of observable, quoted prices for such assets in active markets, they are recognized as Level 1 assets. Federal agency securities are bonds and notes issued by government-sponsored enterprises, including Fannie Mae, Freddie Mac and the Federal Home Loan Bank. Since Federal agency securities typically do not trade as U.S. government agency securities and no exchange exists to price such investments, they are recognized as Level 2 assets. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present the fair value hierarchy for assets measured at fair value on a recurring basis as of December 31, 2020 and 2019 &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,197&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Included in cash and cash equivalents on accompanying consolidated balance sheet.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. $2.5 million of U.S. government agency securities are included in long-term investments on the accompanying consolidated balance sheets due to the maturity being more than 12 months.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,490&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,490&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,006&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,006&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,859&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,006&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Included in cash and cash equivalents on accompanying consolidated balance sheet.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. &#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-0.43%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000245">
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present the fair value hierarchy for assets measured at fair value on a recurring basis as of December 31, 2020 and 2019 &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,197&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Included in cash and cash equivalents on accompanying consolidated balance sheet.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. $2.5 million of U.S. government agency securities are included in long-term investments on the accompanying consolidated balance sheets due to the maturity being more than 12 months.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,490&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,490&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,006&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,006&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,859&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,006&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Included in cash and cash equivalents on accompanying consolidated balance sheet.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. &#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-0.43%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">30360000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">30360000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">37837000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">37837000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">13700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">13700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">68197000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">13700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000283"
      unitRef="U_iso4217USD">81897000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20201231"
      decimals="-5"
      id="F_000284"
      unitRef="U_iso4217USD">2500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">15369000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000286"
      unitRef="U_iso4217USD">15369000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000287"
      unitRef="U_iso4217USD">51490000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000288"
      unitRef="U_iso4217USD">51490000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231"
      decimals="-3"
      id="F_000289"
      unitRef="U_iso4217USD">10006000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231"
      decimals="-3"
      id="F_000290"
      unitRef="U_iso4217USD">10006000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">66859000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231"
      decimals="-3"
      id="F_000292"
      unitRef="U_iso4217USD">10006000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217USD">76865000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000216">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Financial Instruments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents and investments (debt securities) which are classified as available-for-sale securities, consisted of the following &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,835&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,697&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,892&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,994&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,543&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,467&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,490&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,995&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,006&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,831&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,496&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There have been no material realized gains or losses on available-for-sale debt securities for the periods presented. As of December 31, 2020, the remaining contractual maturities of $49.0 million of available-for-sale debt securities was less than one year and $2.5 million of available-for-sale debt securities were less than two years. &lt;/p&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000246">
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents and investments (debt securities) which are classified as available-for-sale securities, consisted of the following &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,835&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,697&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,892&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,994&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,543&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,467&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,490&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,995&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,006&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,831&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,496&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000294"
      unitRef="U_iso4217USD">30360000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000301"
      unitRef="U_iso4217USD">30360000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000295"
      unitRef="U_iso4217USD">37835000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000298"
      unitRef="U_iso4217USD">2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000302"
      unitRef="U_iso4217USD">37837000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231"
      decimals="-3"
      id="F_000296"
      unitRef="U_iso4217USD">13697000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231"
      decimals="-3"
      id="F_000299"
      unitRef="U_iso4217USD">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231"
      decimals="-3"
      id="F_000303"
      unitRef="U_iso4217USD">13700000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000297"
      unitRef="U_iso4217USD">81892000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000300"
      unitRef="U_iso4217USD">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000304"
      unitRef="U_iso4217USD">81897000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231"
      decimals="-3"
      id="F_000305"
      unitRef="U_iso4217USD">30360000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231"
      decimals="-3"
      id="F_000306"
      unitRef="U_iso4217USD">48994000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20201231"
      decimals="-3"
      id="F_000307"
      unitRef="U_iso4217USD">2543000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000308"
      unitRef="U_iso4217USD">81897000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000309"
      unitRef="U_iso4217USD">15369000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000316"
      unitRef="U_iso4217USD">15369000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000310"
      unitRef="U_iso4217USD">51467000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000313"
      unitRef="U_iso4217USD">23000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000317"
      unitRef="U_iso4217USD">51490000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20191231"
      decimals="-3"
      id="F_000311"
      unitRef="U_iso4217USD">9995000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20191231"
      decimals="-3"
      id="F_000314"
      unitRef="U_iso4217USD">11000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20191231"
      decimals="-3"
      id="F_000318"
      unitRef="U_iso4217USD">10006000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000312"
      unitRef="U_iso4217USD">76831000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000315"
      unitRef="U_iso4217USD">34000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000319"
      unitRef="U_iso4217USD">76865000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20191231"
      decimals="-3"
      id="F_000320"
      unitRef="U_iso4217USD">15369000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231"
      decimals="-3"
      id="F_000321"
      unitRef="U_iso4217USD">61496000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000322"
      unitRef="U_iso4217USD">76865000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000323"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001124105_20201231"
      decimals="-5"
      id="F_000324"
      unitRef="U_iso4217USD">49000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_0001124105_20201231"
      decimals="-5"
      id="F_000325"
      unitRef="U_iso4217USD">2500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000217">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Other Accrued Liabilities &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accrued liabilities consisted of the following &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional and consulting services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,979&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,320&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;435&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;235&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,031&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000247">
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accrued liabilities consisted of the following &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional and consulting services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,979&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,320&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;435&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;235&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,031&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">3979000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">2026000</us-gaap:AccruedProfessionalFeesCurrent>
    <cbio:AccruedManufacturingExpensesCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">2238000</cbio:AccruedManufacturingExpensesCurrent>
    <cbio:AccruedManufacturingExpensesCurrent
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000329"
      unitRef="U_iso4217USD">4320000</cbio:AccruedManufacturingExpensesCurrent>
    <cbio:AccruedClinicalExpensesCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000330"
      unitRef="U_iso4217USD">291000</cbio:AccruedClinicalExpensesCurrent>
    <cbio:AccruedClinicalExpensesCurrent
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000331"
      unitRef="U_iso4217USD">435000</cbio:AccruedClinicalExpensesCurrent>
    <cbio:AccruedAndOtherCurrentLiabilities
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000332"
      unitRef="U_iso4217USD">235000</cbio:AccruedAndOtherCurrentLiabilities>
    <cbio:AccruedAndOtherCurrentLiabilities
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000333"
      unitRef="U_iso4217USD">250000</cbio:AccruedAndOtherCurrentLiabilities>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000334"
      unitRef="U_iso4217USD">6743000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000335"
      unitRef="U_iso4217USD">7031000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000218">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Commitments and Contingencies &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Manufacturing Agreements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 20, 2016, the Company signed a development and manufacturing services agreement with AGC Biologics, Inc. (&#x201c;AGC&#x201d;), formerly known as CMC ICOS Biologics, Inc., pursuant to which AGC will conduct manufacturing development of agreed upon product candidates. The Company has firm work orders with AGC to manufacture MarzAA and DalcA to support its clinical trials totaling $11.2 million and the payment obligations remaining at the year ended December 31, 2020 was $2.3 million.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 9, 2019, the Company and Catalent Indiana, LLC (&#x201c;Catalent&#x201d;) signed a clinical supply services agreement, effective October 4, 2019, pursuant to which Catalent will conduct drug product development of agreed upon product candidates. The Company had firm work orders with Catalent to manufacture DalcA to support its clinical trial totaling $0.5 million and all outstanding amounts were paid during the year ended December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, potential trial participants and business operations. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national, and international markets. The COVID-19 pandemic may disrupt the operations of the Company&#x2019;s manufacturers or disrupt supply logistics, which could impact the timing of deliveries and potentially increase expenses under our agreements. All required MarzAA supplies for the MAA-304 and MAA-202 studies have been manufactured.&lt;/p&gt;
</us-gaap:CommitmentsDisclosureTextBlock>
    <cbio:ClinicalTrials
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_20201231"
      decimals="-5"
      id="F_000336"
      unitRef="U_iso4217USD">11200000</cbio:ClinicalTrials>
    <us-gaap:ContractualObligation
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_20201231"
      decimals="-5"
      id="F_000337"
      unitRef="U_iso4217USD">2300000</us-gaap:ContractualObligation>
    <cbio:ClinicalTrials
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioCatalentIndianaLLCMember_srtProductOrServiceAxis_cbioDalcinonacogAlfaMember_20201231"
      decimals="-5"
      id="F_000338"
      unitRef="U_iso4217USD">500000</cbio:ClinicalTrials>
    <cbio:ClinicalTrialsPaid
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioCatalentIndianaLLCMember_srtProductOrServiceAxis_cbioDalcinonacogAlfaMember_20201231"
      decimals="-5"
      id="F_000339"
      unitRef="U_iso4217USD">500000</cbio:ClinicalTrialsPaid>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000219">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Related Parties&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 24, 2017, the Company announced a strategic research collaboration with Mosaic to develop intravitreal anti-complement factor 3 (C3) products for the treatment of dry Age-related Macular Degeneration (AMD) and other retinal diseases. Dr. Usman, the Company&#x2019;s Chief Executive Officer and a member of the Company&#x2019;s board of directors, and Mr. Lawlor, a member of the Company&#x2019;s board of directors, were also members of the board of directors of Mosaic. On December 21, 2018, the Company amended its collaboration agreement with Mosaic to, among other things, include certain additional products. Pursuant to the Mosaic collaboration agreement, as amended, the Company and Mosaic co-funded certain research. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 18, 2019, the Company entered into the second amendment to the Mosaic collaboration agreement following completion of the co-funded research. Pursuant to the second amendment, any future services provided by Mosaic will be performed on a fee-for-service basis. In connection with the Biogen Agreement, the Company received a $15.0 million upfront license fee on January 10, 2020, see Note 12. The Company paid Mosaic a $3.0 million sublicense fee and recorded such payment as cost of license revenue for the year ended December 31, 2020. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 8, 2020, the Company entered into a subsequent amendment to the Mosaic collaboration agreement. As part of this amendment, the Company paid a one-time $0.8 million cash payment to Mosaic, and Mosaic is eligible to receive up to $4.0 million in potential future milestone payments related to regulatory and clinical development events for CB 2782-PEG and an additional anti-complement product candidate in lieu of the Company&#x2019;s obligations to pay Mosaic a double-digit percentage of funds the Company receives from Biogen or any other amounts the Company receives related to sublicense fees, research and development payments, or any other research, regulatory, clinical or commercial milestones and royalties on any other development candidates. The Company now owns one hundred percent of all future payment streams related to these product candidates.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The one-time $0.8 million cash payment was recorded to research and development expenses for the year ended December 31, 2020.&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June 30, 2020, Mosaic was no longer a related party. Total expense related to the collaboration with Mosaic were $1.6 million for the year ended December 31, 2020, of which expense recognized while Mosaic was a related party were $1.3 million, and $1.1 million for the year ended December 31, 2019. The amount incurred in 2020 is fully reimbursable under the Biogen Agreement, see Note 12.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cbio:UpfrontFeeReveivedFromLicenseAndCollaborationAgreement
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_cbioBiogenCollaborationMember_20200110"
      decimals="-5"
      id="F_000343"
      unitRef="U_iso4217USD">15000000.0</cbio:UpfrontFeeReveivedFromLicenseAndCollaborationAgreement>
    <cbio:SublicenseFee
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200101_20201231"
      decimals="-5"
      id="F_000344"
      unitRef="U_iso4217USD">3000000.0</cbio:SublicenseFee>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508"
      decimals="-5"
      id="F_000345"
      unitRef="U_iso4217USD">800000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <cbio:MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents
      contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508"
      decimals="-5"
      id="F_000346"
      unitRef="U_iso4217USD">4000000.0</cbio:MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200101_20201231"
      decimals="-5"
      id="F_000347"
      unitRef="U_iso4217USD">800000</us-gaap:OtherResearchAndDevelopmentExpense>
    <cbio:TotalTransactionExpensesRelatedToCollaboration
      contextRef="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231"
      decimals="-5"
      id="F_000342"
      unitRef="U_iso4217USD">1600000</cbio:TotalTransactionExpensesRelatedToCollaboration>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231"
      decimals="-5"
      id="F_000340"
      unitRef="U_iso4217USD">1300000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231"
      decimals="-5"
      id="F_000341"
      unitRef="U_iso4217USD">1100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000220">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Leases&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases office space for its corporate headquarters, located in South San Francisco, CA. The lease term is through April 30, 2023 and there are no stated renewal options. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not the remaining lease term. The lease includes non-lease components (&lt;span style="font-style:italic;"&gt;e.g.&lt;/span&gt;, common area maintenance) that are paid separately from rent based on actual costs incurred and therefore were not included in the right-of-use asset and lease liability but are reflected as an expense in the period incurred.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 17, 2020, the Company entered into an amendment to the existing lease agreement to lease additional office space for an aggregated undiscounted future monthly payment of $0.5 million. This amendment is treated as a separate lease with a lease term of 2.6 years and commenced during the fourth quarter of 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December 31, 2020 and 2019, the Company&#x2019;s operating lease expense was $0.7 million and $0.6 million, respectively. The present value assumptions used in calculating the present value of the lease payments were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.33 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.33 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of&#160;December&#160;31, 2020 were as follows&#160;&lt;span style="font-style:italic;"&gt;(in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;739&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;762&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. The Company did not incur significant variable lease costs for the years ended December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information for the years ended December 31, 2020 and 2019 related to operating leases was as follows&#160;&lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for leases that were included in operating cash&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; outflows&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;562&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseExpirationDate1 contextRef="C_0001124105_20200101_20201231" id="F_000348">2023-04-30</us-gaap:LeaseExpirationDate1>
    <cbio:LesseeOperatingLeaseRenewalTermDescription contextRef="C_0001124105_20200101_20201231" id="F_000349">no stated renewal options</cbio:LesseeOperatingLeaseRenewalTermDescription>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001124105_20200717"
      decimals="-5"
      id="F_000352"
      unitRef="U_iso4217USD">500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="C_0001124105_20200717" id="F_000351">P2Y7M6D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedDescription contextRef="C_0001124105_20200716_20200717" id="F_000350">commenced during the fourth quarter of 2020.</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedDescription>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001124105_20200101_20201231"
      decimals="-5"
      id="F_000353"
      unitRef="U_iso4217USD">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001124105_20190101_20191231"
      decimals="-5"
      id="F_000354"
      unitRef="U_iso4217USD">600000</us-gaap:OperatingLeaseExpense>
    <cbio:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000248">The present value assumptions used in calculating the present value of the lease payments were as follows:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.33 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.33 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</cbio:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001124105_20201231" id="F_000355">P2Y3M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001124105_20191231" id="F_000356">P3Y3M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001124105_20201231"
      decimals="3"
      id="F_000357"
      unitRef="U_xbrlipure">0.057</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001124105_20191231"
      decimals="3"
      id="F_000358"
      unitRef="U_xbrlipure">0.060</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000249">
&lt;p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of&#160;December&#160;31, 2020 were as follows&#160;&lt;span style="font-style:italic;"&gt;(in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;739&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;762&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000359"
      unitRef="U_iso4217USD">739000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000360"
      unitRef="U_iso4217USD">762000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000361"
      unitRef="U_iso4217USD">259000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000362"
      unitRef="U_iso4217USD">1760000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000363"
      unitRef="U_iso4217USD">116000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000364"
      unitRef="U_iso4217USD">1644000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000250">
&lt;p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. The Company did not incur significant variable lease costs for the years ended December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information for the years ended December 31, 2020 and 2019 related to operating leases was as follows&#160;&lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for leases that were included in operating cash&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; outflows&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;562&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000365"
      unitRef="U_iso4217USD">602000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000366"
      unitRef="U_iso4217USD">562000</us-gaap:OperatingLeasePayments>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000221">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Stock Based Compensation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;2018 Omnibus Incentive Plan &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, stockholders of the Company approved the Company&#x2019;s 2018 Omnibus Incentive Plan (the &#x201c;2018 Plan&#x201d;). The 2018 Plan had previously been approved by the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) and the Compensation Committee of the Board, subject to stockholder approval. The 2018 Plan became effective on June 13, 2018. On June 11, 2020, the stockholders of the Company approved an amendment previously approved by the Board to increase the number of shares of common stock reserved for issuance under the 2018 Plan by 1,300,000 to a total of 2,800,000 shares. The amendment became effective immediately upon stockholder approval. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity under the Company&#x2019;s equity incentive plans and related information:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&#160;of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Underlying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,361,977&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000394"&gt;8.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,294&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;450,900&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,219&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(182,722&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,395&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;96.49&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,577,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000395"&gt;8.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,350&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,091,250&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44,605&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(250,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,355,615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.59&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000396"&gt;7.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable &#x2014; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,113,791&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000397"&gt;7.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;823&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available to be granted &#x2014; December 31,&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,255,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Valuation Assumptions&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited history as a public company and limited number of sales of its common stock, the Company estimated its volatility considering a number of factors including the use of the volatility of comparable public companies. The expected term of options granted under the Plan, all of which qualify as &#x201c;plain vanilla&#x201d; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#x2019;s limited operating history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of employee stock options was estimated using the following&#160;weighted-average assumptions for the&#160;years ended&#160;December&#160;31, 2020&#160;and 2019:&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee Stock Options:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000404"&gt;5.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000405"&gt;5.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average fair value of stock options&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation recognized was as follows &lt;span style="font-style:italic;"&gt;(in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,052&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; (1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,140&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,152&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Included in general and administrative stock-based compensation for the years ended December 31, 2020 and 2019 is $0.3 million and $0.2 million in expense related to 51,056 shares and 24,235 shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.19%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, 1,255,302 shares of common stock were available for future grant and 2,355,615 options to purchase shares of common stock were outstanding.&#160;&lt;span style="color:#000000;"&gt;As of December 31, 2020, the Company had unrecognized employee stock-based compensation expense of $6.5 million, related to unvested stock option awards, which is expected to be recognized&lt;/span&gt; over an estimated weighted-average period of 2.63 years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, the Company&#x2019;s stockholders approved the 2018 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The ESPP had previously been approved by the Board and the Compensation Committee of the Board, subject to stockholder approval which became effective as of June 13, 2018. Under the ESPP, employees meeting certain specific employment qualifications are eligible to participate and can purchase shares of common stock semi-annually on February 9&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;th&lt;/sup&gt; and August 9&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;th&lt;/sup&gt; of each year, through payroll deductions. The purchase price is 85% of the lower of the fair market value of the stock at the commencement or end of the offering period. The ESPP permits eligible employees to purchase shares of common stock through payroll deductions for up to 15% of qualified compensation.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s ESPP is subject to an Evergreen provision which shares may be added to the pool as needed. As of December 31, 2020, a total of 359,545 shares of common stock may be granted in accordance with the terms of the ESPP as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December 31, 2020, a total of 38,248 shares of common stock for $0.2 million have been issued to employees participating in the two ESPP purchases of 2020 and 300,444 shares are available for issuance under the ESPP as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense for the ESPP was $0.1 million and $0.1 million for the years ended December 31, 2020 and 2019, respectively, and is included in total stock-based compensation recognized.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20200611_20200611"
      decimals="INF"
      id="F_000367"
      unitRef="U_xbrlishares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20200611"
      decimals="INF"
      id="F_000368"
      unitRef="U_xbrlishares">2800000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000251">
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity under the Company&#x2019;s equity incentive plans and related information:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&#160;of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Underlying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,361,977&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000394"&gt;8.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,294&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;450,900&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,219&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(182,722&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,395&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;96.49&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,577,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000395"&gt;8.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,350&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,091,250&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44,605&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(250,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,355,615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.59&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000396"&gt;7.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable &#x2014; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,113,791&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000397"&gt;7.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;823&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available to be granted &#x2014; December 31,&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,255,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001124105_20181231"
      decimals="INF"
      id="F_000369"
      unitRef="U_xbrlishares">1361977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001124105_20181231"
      decimals="2"
      id="F_000382"
      unitRef="U_iso4217USD_xbrlishares">12.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001124105_20181231"
      decimals="-3"
      id="F_000398"
      unitRef="U_iso4217USD">2294000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001124105_20190101_20191231"
      decimals="INF"
      id="F_000370"
      unitRef="U_xbrlishares">450900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20190101_20191231"
      decimals="2"
      id="F_000383"
      unitRef="U_iso4217USD_xbrlishares">7.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001124105_20190101_20191231"
      decimals="INF"
      id="F_000371"
      unitRef="U_xbrlishares">41219</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20190101_20191231"
      decimals="2"
      id="F_000384"
      unitRef="U_iso4217USD_xbrlishares">4.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000399"
      unitRef="U_iso4217USD">159000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001124105_20190101_20191231"
      decimals="INF"
      id="F_000372"
      unitRef="U_xbrlishares">182722</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20190101_20191231"
      decimals="2"
      id="F_000385"
      unitRef="U_iso4217USD_xbrlishares">8.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_0001124105_20190101_20191231"
      decimals="INF"
      id="F_000373"
      unitRef="U_xbrlishares">11395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20190101_20191231"
      decimals="2"
      id="F_000386"
      unitRef="U_iso4217USD_xbrlishares">96.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001124105_20191231"
      decimals="INF"
      id="F_000374"
      unitRef="U_xbrlishares">1577541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001124105_20191231"
      decimals="2"
      id="F_000387"
      unitRef="U_iso4217USD_xbrlishares">10.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000400"
      unitRef="U_iso4217USD">1350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000375"
      unitRef="U_xbrlishares">1091250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20200101_20201231"
      decimals="2"
      id="F_000388"
      unitRef="U_iso4217USD_xbrlishares">6.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000376"
      unitRef="U_xbrlishares">44605</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20200101_20201231"
      decimals="2"
      id="F_000389"
      unitRef="U_iso4217USD_xbrlishares">5.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000401"
      unitRef="U_iso4217USD">116000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000377"
      unitRef="U_xbrlishares">250641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20200101_20201231"
      decimals="2"
      id="F_000390"
      unitRef="U_iso4217USD_xbrlishares">10.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000378"
      unitRef="U_xbrlishares">17930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20200101_20201231"
      decimals="2"
      id="F_000391"
      unitRef="U_iso4217USD_xbrlishares">51.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000379"
      unitRef="U_xbrlishares">2355615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001124105_20201231"
      decimals="2"
      id="F_000392"
      unitRef="U_iso4217USD_xbrlishares">8.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000402"
      unitRef="U_iso4217USD">1337000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000380"
      unitRef="U_xbrlishares">1113791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001124105_20201231"
      decimals="2"
      id="F_000393"
      unitRef="U_iso4217USD_xbrlishares">10.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000403"
      unitRef="U_iso4217USD">823000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000381"
      unitRef="U_xbrlishares">1255302</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000252">The fair value of employee stock options was estimated using the following&#160;weighted-average assumptions for the&#160;years ended&#160;December&#160;31, 2020&#160;and 2019:
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee Stock Options:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000404"&gt;5.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000405"&gt;5.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average fair value of stock options&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="4"
      id="F_000406"
      unitRef="U_xbrlipure">0.0091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="4"
      id="F_000407"
      unitRef="U_xbrlipure">0.0235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="2"
      id="F_000408"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="2"
      id="F_000409"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="4"
      id="F_000410"
      unitRef="U_xbrlipure">1.1336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="4"
      id="F_000411"
      unitRef="U_xbrlipure">0.9081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="2"
      id="F_000412"
      unitRef="U_iso4217USD_xbrlishares">5.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="2"
      id="F_000413"
      unitRef="U_iso4217USD_xbrlishares">5.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000253">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation recognized was as follows &lt;span style="font-style:italic;"&gt;(in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,052&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; (1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,140&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,152&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Included in general and administrative stock-based compensation for the years ended December 31, 2020 and 2019 is $0.3 million and $0.2 million in expense related to 51,056 shares and 24,235 shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000414"
      unitRef="U_iso4217USD">1487000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000415"
      unitRef="U_iso4217USD">1052000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000416"
      unitRef="U_iso4217USD">2140000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000417"
      unitRef="U_iso4217USD">2152000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000418"
      unitRef="U_iso4217USD">3627000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000419"
      unitRef="U_iso4217USD">3204000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-5"
      id="F_000422"
      unitRef="U_iso4217USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-5"
      id="F_000423"
      unitRef="U_iso4217USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000420"
      unitRef="U_xbrlishares">51056</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_0001124105_20190101_20191231"
      decimals="INF"
      id="F_000421"
      unitRef="U_xbrlishares">24235</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000426"
      unitRef="U_xbrlishares">1255302</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000427"
      unitRef="U_xbrlishares">2355615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231"
      decimals="-5"
      id="F_000424"
      unitRef="U_iso4217USD">6500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_000425">P2Y7M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613_20180613"
      decimals="INF"
      id="F_000428"
      unitRef="U_xbrlipure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613"
      decimals="INF"
      id="F_000429"
      unitRef="U_xbrlipure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231"
      decimals="INF"
      id="F_000431"
      unitRef="U_xbrlishares">359545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000432"
      unitRef="U_xbrlishares">38248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="-5"
      id="F_000433"
      unitRef="U_iso4217USD">200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231"
      decimals="INF"
      id="F_000430"
      unitRef="U_xbrlishares">300444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="-5"
      id="F_000434"
      unitRef="U_iso4217USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="-5"
      id="F_000435"
      unitRef="U_iso4217USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000222">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Income Taxes &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has incurred cumulative net operating losses since inception and, consequently, has not recorded any income tax expense for the years ended December 31, 2020 and 2019 due to its net operating loss position. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reconciliation of the federal statutory income tax rate to the Company&#x2019;s effective tax rate for the years ended December 31, 2020 and 2019 are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax at statutory federal rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State Tax (benefit)&#x2014;net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-0.06&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.58&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-12.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-11.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derecognition due to Sec. 382 and 383 limitations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-12.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.38&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&#x2019;s deferred tax assets as of December 31, 2020 and 2019 consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,095&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;936&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carry forwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,392&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credit carry forwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,789&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,945&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed and intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,396&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,283&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based on the available objective evidence at December 31, 2020, the Company does not believe it is more likely than not that the net deferred tax assets will be realizable. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets at December 31, 2020 and 2019. The net valuation allowance decreased by approximately $6.9 million and increased by approximately $17.2 million during the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, after consideration of certain limitations (see below), the Company had approximately $140.4 million federal and $8.0 million state net operating loss carryforwards (&#x201c;NOL&#x201d;) available to reduce future taxable income which, if unused, will begin to expire in 2037 for federal and 2032 for state tax purposes. The federal net operating loss carryforward includes $132.9 million that have an indefinite life.&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company also had tax credit carry forwards available to offset future tax liabilities of approximately $5.0 million for federal and $6.8 million for state. If unused, the federal credit will begin to expire in 2040 and the state tax credit does not expire. &#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the Company experiences a greater than 50 percent aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carryforwards are subject to annual limitation under Section 382 of the Internal Revenue Code (California has similar provisions). The annual limitation is determined by multiplying the value of the Company's stock at the time of such ownership change by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company determined that ownership changes occurred December 31, 2007, August 20, 2015, April 13, 2017, February 15, 2018, and February 18, 2020. Approximately $156.3 million and $70.8 million of the NOLs will expire unutilized for federal and California purposes, respectively. The Company has derecognized NOL related deferred tax assets in the tax affected amounts of $32.8 million and $0 for federal and California purposes, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All of the federal R&amp;amp;D credits could expire unutilized, whereas none of the California R&amp;amp;D credits are subject to expiration. Approximately $15.2 million of gross federal R&amp;amp;D credit-related deferred tax assets were derecognized due to the Section 383 limitation. The ability of the Company to use its remaining NOL carryforwards may be further limited if the Company experiences a Section 382 ownership change as a result of future changes in its stock ownership. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 27, 2020, the &#x201c;Coronavirus Aid, Relief and Economic Security (CARES) Act&#x201d; (the &#x201c;Act&#x201d;) was signed into law. The Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll taxes, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company analyzed the provisions of the Act and determined there was no significant impact to its 2020 tax provision.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 29, 2020, the California Governor signed Assembly Bill 85 (&#x201c;A.B. 85&#x201d;), which now becomes California law. A.B. 85, which includes several tax measures, provides for a three-year suspension of the use of net operating losses for medium and large businesses and a three-year cap on the use of business incentive tax credits to offset no more than $5 million of tax per year. Generally, A.B. 85 suspends the use of net operating losses for taxable years 2020, 2021, and 2022 for taxpayers with taxable income of $1 million or &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;more. Since the Company is not expected to generate California source taxable income of more than $1 million, no material impact is anticipated at this time.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 27, 2020, the &#x201c;Consolidated Appropriations Act, 2021&#x201d; (the &#x201c;CAA&#x201d;) was signed into law. The CAA includes provisions meant to clarify and modify certain items put forth in CARES Act, while providing aid to businesses affected by the pandemic.&#160;&#160;The CAA allows deductions for expenses paid for by Paycheck Protection Program (&#x201c;PPP&#x201d;) and Economic Injury Disaster Loan (&#x201c;EIDL&#x201d;) Program, clarifies forgiveness of EIDL advances, and other business provisions.&#160;&#160;The Company analyzed the provisions of the CAA and determined there was no significant impact to its 2020 tax provision.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounting for Uncertainty in Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company only recognizes tax benefits if it is more likely than not that they will be sustained upon audit by the relevant tax authority based upon their technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had approximately $3.0 million and $1.9 million of unrecognized tax benefits as of December 31, 2020 and 2019, respectively. As the Company has a full valuation allowance on its deferred tax assets, the unrecognized tax benefits have reduced the deferred tax assets and the valuation allowance in the same amount. The Company does not expect the amount of unrecognized tax benefits to materially change in the next twelve months.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning Balance at January&#160;1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits taken&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; in prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;253&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending Balance at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits taken&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; in prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(295&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending Balance at December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,955&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest and penalties related to unrecognized tax benefits would be included as income tax expense in the Company&#x2019;s consolidated statements of operations. As of December 31, 2020 and 2019, the Company had not recognized any tax-related penalties or interest in its consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files income tax returns in the United States federal, California, Kansas, Missouri and New Jersey state jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. As of December 31, 2020 and 2019, the Company had no uncertain tax positions which affected its financial position as its results of operations or its cash flow, and will continue to evaluate for uncertain tax positions in the future. The Company is subject to United States federal and state income tax examinations by authorities for all tax years due to accumulated net operating losses that are being carried forward for tax purposes.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000254">
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reconciliation of the federal statutory income tax rate to the Company&#x2019;s effective tax rate for the years ended December 31, 2020 and 2019 are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax at statutory federal rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State Tax (benefit)&#x2014;net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-0.06&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.58&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-12.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-11.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derecognition due to Sec. 382 and 383 limitations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-12.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.38&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000436"
      unitRef="U_xbrlipure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001124105_20190101_20191231"
      decimals="INF"
      id="F_000437"
      unitRef="U_xbrlipure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001124105_20200101_20201231"
      decimals="4"
      id="F_000438"
      unitRef="U_xbrlipure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001124105_20190101_20191231"
      decimals="4"
      id="F_000439"
      unitRef="U_xbrlipure">0.0006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <cbio:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="C_0001124105_20200101_20201231"
      decimals="4"
      id="F_000440"
      unitRef="U_xbrlipure">-0.0058</cbio:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <cbio:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="C_0001124105_20190101_20191231"
      decimals="4"
      id="F_000441"
      unitRef="U_xbrlipure">-0.0043</cbio:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001124105_20200101_20201231"
      decimals="4"
      id="F_000442"
      unitRef="U_xbrlipure">0.1226</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001124105_20190101_20191231"
      decimals="4"
      id="F_000443"
      unitRef="U_xbrlipure">0.1120</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <cbio:EffectiveIncomeTaxRateReconciliationDerecognition
      contextRef="C_0001124105_20200101_20201231"
      decimals="4"
      id="F_000444"
      unitRef="U_xbrlipure">-0.4455</cbio:EffectiveIncomeTaxRateReconciliationDerecognition>
    <cbio:EffectiveIncomeTaxRateReconciliationDerecognition
      contextRef="C_0001124105_20190101_20191231"
      decimals="4"
      id="F_000445"
      unitRef="U_xbrlipure">0.0000</cbio:EffectiveIncomeTaxRateReconciliationDerecognition>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001124105_20200101_20201231"
      decimals="4"
      id="F_000446"
      unitRef="U_xbrlipure">0.1225</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001124105_20190101_20191231"
      decimals="4"
      id="F_000447"
      unitRef="U_xbrlipure">-0.3120</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_0001124105_20200101_20201231"
      decimals="4"
      id="F_000448"
      unitRef="U_xbrlipure">-0.0038</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_0001124105_20190101_20191231"
      decimals="4"
      id="F_000449"
      unitRef="U_xbrlipure">-0.0063</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001124105_20200101_20201231"
      decimals="4"
      id="F_000450"
      unitRef="U_xbrlipure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001124105_20190101_20191231"
      decimals="4"
      id="F_000451"
      unitRef="U_xbrlipure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000255">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&#x2019;s deferred tax assets as of December 31, 2020 and 2019 consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,095&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;936&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carry forwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,392&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credit carry forwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,789&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,945&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed and intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,396&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,283&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000452"
      unitRef="U_iso4217USD">1095000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000453"
      unitRef="U_iso4217USD">936000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000454"
      unitRef="U_iso4217USD">29505000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000455"
      unitRef="U_iso4217USD">34392000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000456"
      unitRef="U_iso4217USD">7789000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000457"
      unitRef="U_iso4217USD">9945000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <cbio:DeferredTaxAssetsFixedAssetsAndIntangibles
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000458"
      unitRef="U_iso4217USD">7000</cbio:DeferredTaxAssetsFixedAssetsAndIntangibles>
    <cbio:DeferredTaxAssetsFixedAssetsAndIntangibles
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000459"
      unitRef="U_iso4217USD">10000</cbio:DeferredTaxAssetsFixedAssetsAndIntangibles>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000460"
      unitRef="U_iso4217USD">38396000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000461"
      unitRef="U_iso4217USD">45283000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="C_0001124105_20200101_20201231"
      decimals="-5"
      id="F_000462"
      unitRef="U_iso4217USD">-6900000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="C_0001124105_20190101_20191231"
      decimals="-5"
      id="F_000463"
      unitRef="U_iso4217USD">17200000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000464"
      unitRef="U_iso4217USD">140400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231"
      decimals="-5"
      id="F_000465"
      unitRef="U_iso4217USD">8000000.0</us-gaap:OperatingLossCarryforwards>
    <cbio:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_000466">2037</cbio:OperatingLossCarryforwardsExpirationYear>
    <cbio:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231"
      id="F_000467">2032</cbio:OperatingLossCarryforwardsExpirationYear>
    <cbio:OperatingLossCarryforwardsWithIndefiniteLife
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000468"
      unitRef="U_iso4217USD">132900000</cbio:OperatingLossCarryforwardsWithIndefiniteLife>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000469"
      unitRef="U_iso4217USD">5000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231"
      decimals="-5"
      id="F_000470"
      unitRef="U_iso4217USD">6800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20071231"
      decimals="-5"
      id="F_000472"
      unitRef="U_iso4217USD">156300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20201231"
      decimals="-5"
      id="F_000473"
      unitRef="U_iso4217USD">70800000</us-gaap:OperatingLossCarryforwards>
    <cbio:DeferredTaxAssetsStateNetOperatingLossCarryForwards
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000474"
      unitRef="U_iso4217USD">32800000</cbio:DeferredTaxAssetsStateNetOperatingLossCarryForwards>
    <cbio:DeferredTaxAssetsStateNetOperatingLossCarryForwards
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20201231"
      decimals="-6"
      id="F_000475"
      unitRef="U_iso4217USD">0</cbio:DeferredTaxAssetsStateNetOperatingLossCarryForwards>
    <cbio:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized
      contextRef="C_0001124105_20200101_20201231"
      decimals="-5"
      id="F_000476"
      unitRef="U_iso4217USD">15200000</cbio:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized>
    <cbio:MaximumAmountOfTaxOffsetPerYear
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629_20200629"
      decimals="-6"
      id="F_000477"
      unitRef="U_iso4217USD">5000000</cbio:MaximumAmountOfTaxOffsetPerYear>
    <cbio:RequiredMinimumTaxableIncome
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629"
      decimals="-6"
      id="F_000478"
      unitRef="U_iso4217USD">1000000</cbio:RequiredMinimumTaxableIncome>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001124105_20201231"
      decimals="-5"
      id="F_000479"
      unitRef="U_iso4217USD">3000000.0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001124105_20191231"
      decimals="-5"
      id="F_000480"
      unitRef="U_iso4217USD">1900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000256">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning Balance at January&#160;1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits taken&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; in prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;253&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending Balance at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits taken&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; in prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(295&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending Balance at December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,955&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001124105_20181231"
      decimals="-3"
      id="F_000481"
      unitRef="U_iso4217USD">1573000</us-gaap:UnrecognizedTaxBenefits>
    <cbio:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000482"
      unitRef="U_iso4217USD">45000</cbio:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000483"
      unitRef="U_iso4217USD">253000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000484"
      unitRef="U_iso4217USD">1871000</us-gaap:UnrecognizedTaxBenefits>
    <cbio:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000485"
      unitRef="U_iso4217USD">-295000</cbio:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000486"
      unitRef="U_iso4217USD">1379000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000487"
      unitRef="U_iso4217USD">2955000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000488"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_0001124105_20191231"
      decimals="INF"
      id="F_000489"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000490"
      unitRef="U_iso4217USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="C_0001124105_20191231"
      decimals="INF"
      id="F_000491"
      unitRef="U_iso4217USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000223">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Collaborations&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Pfizer&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.2pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the termination agreement entered into on December 8, 2016, in connection with the termination of a prior license and development agreement, Pfizer granted the Company an exclusive license to Pfizer&#x2019;s proprietary rights for manufacturing materials and processes that apply to Factor VIIa variants, CB 813a and marzeptacog alfa (activated) - MarzAA. Pfizer also transferred to the Company the IND application and documentation related to the development, manufacturing and testing of the Factor VIIa products as well as &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;letter-spacing:-0.2pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the orphan drug designation&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The Company agreed to make contingent cash payments to Pfizer in an aggregate amount up to &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.5&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million, payable upon the achievement of&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; certain&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; clinical, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;regulatory&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and commercial milestones. Following commercialization of any covered product, Pfizer w&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ill&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; also receive a single-digit royalty on net product sales on a country-by-country basis for a predefined royalty term. In February 2018, the Company paid Pfizer a $&lt;/span&gt;1.0&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million milestone payment based on the dosing of the first patient in &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;its &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Phase 2 study&lt;/span&gt;&lt;span style="color:#000000;"&gt;; the amount was recorded as a research and development expens&lt;/span&gt;&lt;span style="color:#000000;"&gt;e&lt;/span&gt;&lt;span style="color:#000000;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;"&gt; payments were made to Pfizer &lt;/span&gt;&lt;span style="color:#000000;"&gt;in &lt;/span&gt;&lt;span style="color:#000000;"&gt;the year ended&lt;/span&gt;&lt;span style="color:#000000;"&gt; December 31, 20&lt;/span&gt;&lt;span style="color:#000000;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;ISU Abxis&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2018, the Company entered into an amended and restated license agreement with ISU Abxis (the &#x201c;A&amp;amp;R ISU Abxis Agreement&#x201d;), which amended and restated its previous license and collaboration agreement with ISU Abxis previously entered into in September 2013, as subsequently amended in October 2014 and December 2016 &lt;span style="color:#000000;"&gt;(the &#x201c;Original ISU Abxis Agreement&#x201d;)&lt;/span&gt;. Under the A&amp;amp;R ISU Abxis Agreement, &lt;span style="color:#000000;"&gt;ISU Abxis will receive commercialization rights in South Korea to the Company&#x2019;s engineered Factor IX dalcinonacog alfa - DalcA and the Company will receive clinical development and commercialization rights in the rest of world (excluding South Korea) and manufacturing development and manufacturing rights worldwide (including South Korea)&lt;/span&gt;. &lt;span style="color:#000000;"&gt;The &lt;/span&gt;A&amp;amp;R ISU Abxis Agreement &lt;span style="color:#000000;"&gt;eliminates the profit-sharing arrangement in the Original ISU Abxis Agreement and&lt;/span&gt; p&lt;span style="color:#000000;"&gt;rovides for a low single-digit royalty payment to ISU Abxis, on a country-by-country basis, for net product sales of DalcA by the Company or its affiliates in each country other than South Korea. Pursuant to the A&amp;amp;R &lt;/span&gt;ISU Abxis Agreement&lt;span style="color:#000000;"&gt;, the Company will also pay up to an aggregate of&lt;/span&gt; &lt;span style="color:#000000;"&gt;$19.5 million in milestone payments to ISU Abxis, including $2.5&#160;million in regulatory and development milestone payments and up to $17.0&#160;million in commercial milestone payments, if the applicable milestones are met. As of December 31, 2020, no milestones have been met.&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Biogen&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 18, 2019, the Company and Biogen International GmbH (&#x201c;Biogen&#x201d;) entered into a License and Collaboration Agreement (the &#x201c;Biogen Agreement&#x201d;), under which the Company granted Biogen a worldwide, royalty-bearing, exclusive, with the right to sublicense, license (&#x201c;Exclusive License&#x201d;) to develop and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders. Pursuant to the Biogen Agreement, the Company will perform certain pre-clinical and manufacturing activities (&#x201c;Research Services&#x201d;), and Biogen will be solely responsible for funding the pre-clinical and manufacturing activities and performing IND-enabling activities, worldwide clinical development, and commercialization. The Company will provide the Research Services over a term of &lt;span style="color:#000000;"&gt;thirty months&lt;/span&gt; with Biogen having the option to extend the term for two additional &lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:F_000502"&gt;twelve-month&lt;/span&gt;&lt;/span&gt; periods.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Biogen Agreement, the Company received an up-front payment for the transfer of the Exclusive License (inclusive of certain know-how) of &lt;span style="color:#000000;"&gt;$15.0&lt;/span&gt; million in January 2020. The Company is eligible to receive development milestones and sales milestones of up to $340.0 million. In addition, the Company is eligible to receive royalties in the range of single-digit to low double-digit percentage rates of annual net sales on a product-by-product and country-by-country basis. The Company will also receive reimbursements for costs associated with the performance of the Research Services.&lt;span style="color:#000000;"&gt;   &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the performance obligations under the Biogen Agreement were the Exclusive License and the Research Services. For the Exclusive License, the Company used the residual approach in determining the standalone selling price, or SSP, which includes the upfront payments, milestones and royalties. For the Research Services, the Company used the historical pricing approach for determining the SSP, which includes the reimbursement of personnel and out-of-pocket costs.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Biogen Agreement will continue on a product-by-product and country-by-country basis until the tenth anniversary of the first commercial sale of the first product in a country, unless terminated earlier by either party as specified under the agreement. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December 31, 2020, the Company recognized the $15.0 million in license revenue upon the transfer of the Exclusive License and the related know-how, and $0.1 million in license revenue for reimbursable out-of-pocket costs incurred.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December 31, 2020, the Company recorded $5.8 million in collaboration revenue for reimbursable out-of-pocket and personnel costs incurred related to research services.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <cbio:MilestoneContingentCashPaymentsObligation
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioPfizerIncMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_us-gaapCollaborativeArrangementMember_20161208"
      decimals="-5"
      id="F_000492"
      unitRef="U_iso4217USD">17500000</cbio:MilestoneContingentCashPaymentsObligation>
    <cbio:MilestonePayments
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioPfizerIncMember_us-gaapTransactionTypeAxis_us-gaapCollaborativeArrangementMember_20180201_20180228"
      decimals="-5"
      id="F_000493"
      unitRef="U_iso4217USD">1000000.0</cbio:MilestonePayments>
    <cbio:MilestonePayments
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioPfizerIncMember_us-gaapTransactionTypeAxis_us-gaapCollaborativeArrangementMember_20200101_20201231"
      decimals="-6"
      id="F_000494"
      unitRef="U_iso4217USD">0</cbio:MilestonePayments>
    <cbio:MilestonePayments
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231"
      decimals="-5"
      id="F_000496"
      unitRef="U_iso4217USD">19500000</cbio:MilestonePayments>
    <cbio:RegulatoryAndDevelopmentMilestonePayment
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231"
      decimals="-5"
      id="F_000498"
      unitRef="U_iso4217USD">2500000</cbio:RegulatoryAndDevelopmentMilestonePayment>
    <cbio:CommercialMilestonePayments
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231"
      decimals="-5"
      id="F_000500"
      unitRef="U_iso4217USD">17000000.0</cbio:CommercialMilestonePayments>
    <cbio:MilestonePayments
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20200101_20201231"
      decimals="-6"
      id="F_000495"
      unitRef="U_iso4217USD">0</cbio:MilestonePayments>
    <cbio:RegulatoryAndDevelopmentMilestonePayment
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20200101_20201231"
      decimals="-6"
      id="F_000497"
      unitRef="U_iso4217USD">0</cbio:RegulatoryAndDevelopmentMilestonePayment>
    <cbio:CommercialMilestonePayments
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20200101_20201231"
      decimals="-6"
      id="F_000499"
      unitRef="U_iso4217USD">0</cbio:CommercialMilestonePayments>
    <cbio:ResearchServicesAgreementTerm
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioLicenseAndCollaborationAgreementMember_20191218_20191218"
      id="F_000501">P30M</cbio:ResearchServicesAgreementTerm>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131"
      decimals="-5"
      id="F_000503"
      unitRef="U_iso4217USD">15000000.0</us-gaap:ProceedsFromLicenseFeesReceived>
    <cbio:DevelopmentMilestonesPaymentReceivable
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131"
      decimals="-5"
      id="F_000504"
      unitRef="U_iso4217USD">340000000.0</cbio:DevelopmentMilestonesPaymentReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioTransferOfExclusiveLicenseAndRelatedKnowHowMember_20200101_20201231"
      decimals="-5"
      id="F_000505"
      unitRef="U_iso4217USD">15000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioExclusiveLicenseMember_20200101_20201231"
      decimals="-5"
      id="F_000506"
      unitRef="U_iso4217USD">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20200101_20201231"
      decimals="-5"
      id="F_000507"
      unitRef="U_iso4217USD">5800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InterestAndOtherIncomeTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000224">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Interest and Other Income, Net &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table shows the detail of interest and other income, net for the years ended December 31, 2020 and 2019 &lt;span style="font-style:italic;"&gt;(in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,145&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Miscellaneous income (expense)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;659&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total interest and other income, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,099&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"&gt;&#160;&lt;/p&gt;</us-gaap:InterestAndOtherIncomeTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000257">
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table shows the detail of interest and other income, net for the years ended December 31, 2020 and 2019 &lt;span style="font-style:italic;"&gt;(in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,145&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Miscellaneous income (expense)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;659&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total interest and other income, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,099&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000508"
      unitRef="U_iso4217USD">561000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000509"
      unitRef="U_iso4217USD">2145000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000510"
      unitRef="U_iso4217USD">659000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000511"
      unitRef="U_iso4217USD">-39000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000512"
      unitRef="U_iso4217USD">91000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000513"
      unitRef="U_iso4217USD">7000</us-gaap:OtherNonoperatingExpense>
    <cbio:InterestAndOtherIncomeExpenseNet
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000514"
      unitRef="U_iso4217USD">1129000</cbio:InterestAndOtherIncomeExpenseNet>
    <cbio:InterestAndOtherIncomeExpenseNet
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000515"
      unitRef="U_iso4217USD">2099000</cbio:InterestAndOtherIncomeExpenseNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000225">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Stockholders&#x2019; Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2020,&lt;span style="font-style:italic;"&gt; &lt;/span&gt;the Company completed an underwritten public offering of 5,307,692 shares of its common stock (including 692,307 shares sold pursuant to the exercise of the underwriters&#x2019; overallotment option)&#160;at a price of $6.50 per share. The net proceeds to the Company, after deducting $2.5 million in underwriting discounts and commissions and offering expenses payable by the Company, were approximately $32.0 million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2020, the Company completed an underwritten public offering of 4,615,384 shares of its common stock at a price of $6.50 per share. The net proceeds to the Company, after deducting $2.0 million in underwriting discounts and commissions and offering expenses payable by the Company, were approximately $28.0 million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had issued and outstanding common stock warrants as follows:&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Underlying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155.73&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;499.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,857&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53.61&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,772&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;392.70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <cbio:FirmCommitmentUnderwrittenPublicOfferingShares
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200228_20200229"
      decimals="INF"
      id="F_000516"
      unitRef="U_xbrlishares">5307692</cbio:FirmCommitmentUnderwrittenPublicOfferingShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200228_20200229"
      decimals="INF"
      id="F_000517"
      unitRef="U_xbrlishares">692307</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200229"
      decimals="2"
      id="F_000518"
      unitRef="U_iso4217USD_xbrlishares">6.50</us-gaap:SharePrice>
    <cbio:UnderwritingCommissionsAndOfferingExpensesPayable
      contextRef="C_0001124105_20200228_20200229"
      decimals="-5"
      id="F_000520"
      unitRef="U_iso4217USD">2500000</cbio:UnderwritingCommissionsAndOfferingExpensesPayable>
    <cbio:NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable
      contextRef="C_0001124105_20200228_20200229"
      decimals="-5"
      id="F_000519"
      unitRef="U_iso4217USD">32000000.0</cbio:NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable>
    <cbio:FirmCommitmentUnderwrittenPublicOfferingShares
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200629_20200630"
      decimals="INF"
      id="F_000521"
      unitRef="U_xbrlishares">4615384</cbio:FirmCommitmentUnderwrittenPublicOfferingShares>
    <us-gaap:SharePrice
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630"
      decimals="2"
      id="F_000522"
      unitRef="U_iso4217USD_xbrlishares">6.50</us-gaap:SharePrice>
    <cbio:UnderwritingCommissionsAndOfferingExpensesPayable
      contextRef="C_0001124105_20200629_20200630"
      decimals="-5"
      id="F_000524"
      unitRef="U_iso4217USD">2000000.0</cbio:UnderwritingCommissionsAndOfferingExpensesPayable>
    <cbio:NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable
      contextRef="C_0001124105_20200629_20200630"
      decimals="-5"
      id="F_000523"
      unitRef="U_iso4217USD">28000000.0</cbio:NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000258">
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had issued and outstanding common stock warrants as follows:&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Underlying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155.73&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;499.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,857&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53.61&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,772&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;392.70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001124105_20181231"
      decimals="INF"
      id="F_000525"
      unitRef="U_xbrlishares">10194</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001124105_20181231"
      decimals="INF"
      id="F_000530"
      unitRef="U_iso4217USD_xbrlishares">155.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cbio:ClassOfWarrantOrRightForfeitedDuringPeriod
      contextRef="C_0001124105_20190101_20191231"
      decimals="INF"
      id="F_000526"
      unitRef="U_xbrlishares">2337</cbio:ClassOfWarrantOrRightForfeitedDuringPeriod>
    <cbio:ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited
      contextRef="C_0001124105_20190101_20191231"
      decimals="INF"
      id="F_000531"
      unitRef="U_iso4217USD_xbrlishares">499.50</cbio:ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001124105_20191231"
      decimals="INF"
      id="F_000527"
      unitRef="U_xbrlishares">7857</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001124105_20191231"
      decimals="INF"
      id="F_000532"
      unitRef="U_iso4217USD_xbrlishares">53.61</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cbio:ClassOfWarrantOrRightForfeitedDuringPeriod
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000528"
      unitRef="U_xbrlishares">7772</cbio:ClassOfWarrantOrRightForfeitedDuringPeriod>
    <cbio:ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000533"
      unitRef="U_iso4217USD_xbrlishares">49.91</cbio:ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000529"
      unitRef="U_xbrlishares">85</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000534"
      unitRef="U_iso4217USD_xbrlishares">392.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000226">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the computation of the basic and diluted net loss per common share during the years ended December 31, 2020 and 2019 &lt;span style="font-style:italic;"&gt;(in thousands, except share and per share data)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(56,241&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(55,178&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average number of shares used in&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; computing net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,179,299&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,004,489&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.93&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,355,615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,577,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,857&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,355,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,585,398&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000259">
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the computation of the basic and diluted net loss per common share during the years ended December 31, 2020 and 2019 &lt;span style="font-style:italic;"&gt;(in thousands, except share and per share data)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(56,241&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(55,178&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average number of shares used in&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; computing net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,179,299&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,004,489&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.93&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000535"
      unitRef="U_iso4217USD">-56241000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001124105_20190101_20191231"
      decimals="-3"
      id="F_000536"
      unitRef="U_iso4217USD">-55178000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001124105_20200101_20201231"
      decimals="0"
      id="F_000537"
      unitRef="U_xbrlishares">19179299</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001124105_20190101_20191231"
      decimals="0"
      id="F_000538"
      unitRef="U_xbrlishares">12004489</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001124105_20200101_20201231"
      decimals="2"
      id="F_000539"
      unitRef="U_iso4217USD_xbrlishares">-2.93</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001124105_20190101_20191231"
      decimals="2"
      id="F_000540"
      unitRef="U_iso4217USD_xbrlishares">-4.60</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000260">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,355,615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,577,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,857&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,355,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,585,398&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000541"
      unitRef="U_xbrlishares">2355615</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000542"
      unitRef="U_xbrlishares">1577541</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20200101_20201231"
      decimals="INF"
      id="F_000543"
      unitRef="U_xbrlishares">85</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20190101_20191231"
      decimals="INF"
      id="F_000544"
      unitRef="U_xbrlishares">7857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000545"
      unitRef="U_xbrlishares">2355700</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_20190101_20191231"
      decimals="INF"
      id="F_000546"
      unitRef="U_xbrlishares">1585398</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001124105_20200101_20201231" id="F_000227">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Subsequent Event&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the first quarter of 2021, we sold an aggregate of 9,185,000 registered shares of common stock (including 485,000 shares sold pursuant to the exercise of the underwriters&#x2019; overallotment option) at a price of $5.75 per share. The net proceeds, after deducting $3.5 million underwriting discounts and offering expenses, were approximately $49.3 million. &lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001124105_srtStatementScenarioAxis_srtScenarioForecastMember_20210331"
      decimals="INF"
      id="F_000547"
      unitRef="U_xbrlishares">9185000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioUnderwritersOverallotmentOptionMember_srtStatementScenarioAxis_srtScenarioForecastMember_20210331"
      decimals="INF"
      id="F_000548"
      unitRef="U_xbrlishares">485000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001124105_srtStatementScenarioAxis_srtScenarioForecastMember_20210331"
      decimals="INF"
      id="F_000549"
      unitRef="U_iso4217USD_xbrlishares">5.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001124105_srtStatementScenarioAxis_srtScenarioForecastMember_20210101_20210331"
      decimals="-5"
      id="F_000550"
      unitRef="U_iso4217USD">3500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cbio:UnderwritingDiscountsAndOfferingExpenses
      contextRef="C_0001124105_srtStatementScenarioAxis_srtScenarioForecastMember_20210101_20210331"
      decimals="-5"
      id="F_000551"
      unitRef="U_iso4217USD">49300000</cbio:UnderwritingDiscountsAndOfferingExpenses>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_000276"
          xlink:label="F_000276"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000286"
          xlink:label="F_000286"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000275"
          xlink:label="F_000275"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000285"
          xlink:label="F_000285"
          xlink:type="locator"/>
        <link:footnote id="FNT_000000" xlink:label="FNT_000000" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in cash and cash equivalents on accompanying consolidated balance sheet.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000276"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000286"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000275"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000285"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000290"
          xlink:label="F_000290"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000289"
          xlink:label="F_000289"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000287"
          xlink:label="F_000287"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000288"
          xlink:label="F_000288"
          xlink:type="locator"/>
        <link:footnote id="FNT_000002" xlink:label="FNT_000002" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000290"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000289"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000287"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000288"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000277"
          xlink:label="F_000277"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000280"
          xlink:label="F_000280"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000278"
          xlink:label="F_000278"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000279"
          xlink:label="F_000279"
          xlink:type="locator"/>
        <link:footnote id="FNT_000001" xlink:label="FNT_000001" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. $2.5 million of U.S. government agency securities are included in long-term investments on the accompanying consolidated balance sheets due to the maturity being more than 12 months.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000277"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000280"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000278"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000279"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000416"
          xlink:label="F_000416"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000417"
          xlink:label="F_000417"
          xlink:type="locator"/>
        <link:footnote id="FNT_000003" xlink:label="FNT_000003" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><xhtml:span style="Background-color:#auto;text-decoration:none;"/><xhtml:span style="color:#000000;">Included in general and administrative stock-based compensation for the years ended December 31, 2020 and 2019 is $0.3 million and $0.2 million in expense related to 51,056 shares and 24,235 shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000416"
          xlink:to="FNT_000003"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000417"
          xlink:to="FNT_000003"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779170233576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 25, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CBIO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Catalyst Biosciences, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001124105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,331,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,362,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2020050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">611 Gateway Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">871-0761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779173535016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 30,360<span></span>
</td>
<td class="nump">$ 15,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">48,994<span></span>
</td>
<td class="nump">61,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">3,313<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">6,843<span></span>
</td>
<td class="nump">4,201<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">89,510<span></span>
</td>
<td class="nump">96,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">2,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">1,832<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">94,846<span></span>
</td>
<td class="nump">98,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,931<span></span>
</td>
<td class="nump">4,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation</a></td>
<td class="nump">2,476<span></span>
</td>
<td class="nump">2,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,983<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">6,743<span></span>
</td>
<td class="nump">7,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">17,796<span></span>
</td>
<td class="nump">28,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">981<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">18,777<span></span>
</td>
<td class="nump">30,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 5,000,000 shares authorized; zero shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 100,000,000 shares authorized; 22,097,820 and 12,040,835 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">390,803<span></span>
</td>
<td class="nump">326,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(314,761)<span></span>
</td>
<td class="num">(258,520)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">76,069<span></span>
</td>
<td class="nump">68,336<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 94,846<span></span>
</td>
<td class="nump">$ 98,554<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779173352728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">22,097,820<span></span>
</td>
<td class="nump">12,040,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">22,097,820<span></span>
</td>
<td class="nump">12,040,835<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779173430872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="nump">$ 20,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">52,975<span></span>
</td>
<td class="nump">$ 43,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,180<span></span>
</td>
<td class="nump">13,418<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">78,318<span></span>
</td>
<td class="nump">57,277<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(57,370)<span></span>
</td>
<td class="num">(57,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_InterestAndOtherIncomeExpenseNet', window );">Interest and other income, net</a></td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">2,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (56,241)<span></span>
</td>
<td class="num">$ (55,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (2.93)<span></span>
</td>
<td class="num">$ (4.60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used to compute net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="nump">19,179,299<span></span>
</td>
<td class="nump">12,004,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_LicenseRevenueMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="nump">$ 15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember', window );">Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="nump">5,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_CostOfLicenseMember', window );">Cost of license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of license and collaboration</a></td>
<td class="nump">3,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_CostOfCollaborationMember', window );">Cost of collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of license and collaboration</a></td>
<td class="nump">$ 6,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_InterestAndOtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and other income (expense), net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_InterestAndOtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_CostOfLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_CostOfLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_CostOfCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_CostOfCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779169715192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (56,241)<span></span>
</td>
<td class="num">$ (55,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale debt securities</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (56,270)<span></span>
</td>
<td class="num">$ (55,140)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779174587016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 119,945<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 323,279<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (203,342)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,954,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue', window );">Issuance of common stock from ESPP purchases and stock option exercises</a></td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares', window );">Issuance of common stock from ESPP purchases and stock option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale debt securities</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(55,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,178)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">68,336<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">326,810<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="num">(258,520)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,040,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue', window );">Issuance of common stock from ESPP purchases and stock option exercises</a></td>
<td class="nump">435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares', window );">Issuance of common stock from ESPP purchases and stock option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for public offering, net of issuance costs of $4,559</a></td>
<td class="nump">59,941<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">59,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,923,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale debt securities</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(56,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,241)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 76,069<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 390,803<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">$ (314,761)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,097,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period from ESPP purchases and stock options exercised shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period from ESPP purchases and stock options exercised value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779167452584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement Of Stockholders Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs of issuance of common stock for public offering</a></td>
<td class="nump">$ 4,559<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779174351224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (56,241)<span></span>
</td>
<td class="num">$ (55,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,627<span></span>
</td>
<td class="nump">3,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">11,687<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="num">(3,043)<span></span>
</td>
<td class="num">(490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,652<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued compensation and other accrued liabilities</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">5,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset', window );">Operating lease liability and right-of-use asset</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(13,017)<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(55,048)<span></span>
</td>
<td class="num">(43,613)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from maturities of short-term investments</a></td>
<td class="nump">107,565<span></span>
</td>
<td class="nump">157,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_PaymentsToAcquireShortTermAndLongInvestments', window );">Purchase of short-term and long-term investments</a></td>
<td class="num">(97,635)<span></span>
</td>
<td class="num">(129,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of property and equipment</a></td>
<td class="num">(267)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows provided by investing activities</a></td>
<td class="nump">9,663<span></span>
</td>
<td class="nump">27,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts', window );">Issuance of common stock for public offering, net of issuance costs</a></td>
<td class="nump">59,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises', window );">Issuance of common stock from ESPP purchase and stock option exercises</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
<td class="nump">60,376<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">14,991<span></span>
</td>
<td class="num">(15,894)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">15,369<span></span>
</td>
<td class="nump">31,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">30,360<span></span>
</td>
<td class="nump">15,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet', window );">Right-of-use asset and operating lease liability recorded upon the adoption of ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">$ 476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease in operating lease liability and right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash or part non cash right-of-use asset and operating lease liability recorded upon the adoption, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets obtained in exchange for operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_PaymentsToAcquireShortTermAndLongInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire short term and long investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_PaymentsToAcquireShortTermAndLongInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock for secondary public offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock from ESPP purchases and stock option exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779169437624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p id="NOTES_TO_CONSOLIDATED" style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of Operations</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. and its subsidiary (the &#8220;Company&#8221; or &#8220;Catalyst&#8221;) is a <span style="color:#000000;">fully integrated research and clinical development biopharmaceutical company with expertise in protease engineering, discovery, translational research, clinical development, and manufacturing. The Company is focused on advancing its protease product candidates in the fields of hemostasis and complement regulation.</span> <span style="color:#000000;">The Company is located in South San Francisco, California and operates in</span> one segment. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779167476888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidationBasisOfAccountingTextBlock', window );">Liquidity</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Liquidity<span style="font-weight:normal;"> </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had a net loss of $56.2 million for the year ended December 31, 2020 and an accumulated deficit of $314.8 million as of December 31, 2020. The Company expects to continue to incur losses for the next several years. As of December 31, 2020, the Company had $81.9 million of cash, cash equivalents and investments. Its primary uses of cash are to fund operating expenses, including research and development expenditures and general and administrative expenditures. Based on the current status of its research and development plans, the Company believes that its existing cash, cash equivalents and investments as of December 31, 2020 will be sufficient to fund its cash requirements for at least the next 12 months from the date of the filing of this report. If, at any time, the Company&#8217;s prospects for financing its research and development programs decline, the Company may decide to reduce research and development expenses by delaying, discontinuing or reducing its funding of one or more of its research or development programs. Alternatively, the Company might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The Company will continue to evaluate the impact of the COVID-19 pandemic on our business, operations, and cash requirements. For recent financing, see Note 16.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidationBasisOfAccountingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the liquidation basis of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=35686142<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiquidationBasisOfAccountingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779177554568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation. The Company&#8217;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). &#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, operating lease right-of-use assets and liabilities, accrued expenses, income taxes and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Pronouncements Recently Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-18,&#160;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606 (&#8220;ASU 2018-18&#8221;). The amended guidance precludes presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The new guidance is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2018-18 as of January 1, 2020. The adoption of ASU 2018-18 did not have a material impact on the Company&#8217;s consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement (&#8220;ASU 2018-13&#8221;). The </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">guidance removes, modifies, and adds certain disclosure requirements for fair value measurements. Entities no longer have to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The guidance is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2018-13 as of January 1, 2020. The adoption of ASU 2018-13 did not have a material impact on the Company&#8217;s consolidated financial statements. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,<span style="font-style:italic;">&#160;</span>Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to adopt ASU 2016-13&#160;and related updates&#160;as of January 1, 2023.&#160;The Company will assess the impact of adoption of this standard on its consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued&#160;ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes<span style="font-style:italic;">. </span>The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes.&#160;ASU 2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning January 1, 2021. The adoption of this standard will not have a material impact on the Company&#8217;s consolidated financial statements<span style="color:#000000;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 1<span style="font-style:normal;"> &#8211; Quoted prices in active markets for identical assets or liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 2<span style="font-style:normal;"> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 3<span style="font-style:normal;"> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></p>

<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, which are three years for computer equipment and software, and three to seven years for furniture and leasehold improvements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash in investment grade, short to intermediate-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#8220;available-for-sale&#8221; and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation as of each consolidated balance sheet date. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value determined to be other-than-temporary, if any, on available-for-sale debt securities are included in interest and other income, net. The cost of securities sold is based on the specific-identification method. Interest on short-term investments is included in interest and other income, net.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Collaboration Arrangements </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.21%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may enter into collaboration arrangements that fall under the scope Collaborative Arrangements (Topic 808). The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808 to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. The accounting for some of the activities under collaboration arrangements may be analogized to ASC 606 for distinct units of account that are reflective of a vendor-customer relationship.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when the Company satisfies each performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues attributed to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that contain development milestones, the Company evaluates whether the development milestones included are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not generally considered probable of being achieved until those approvals are received.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the end of each reporting period, the Company re-evaluates the probability of achievement of any development milestones, and if necessary, adjusts its estimate of the transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For research and development services, the Company elected the practical expedient to recognize revenue as the research and development services are invoiced.&#160;&#160;As the Company has a right to consideration from the </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaboration agreement with Biogen, in an amount that corresponds directly with the value of the Company&#8217;s performance completed to date for the research services, the Company recognized revenue related to the research services as invoiced, in line with the practical expedient in ASC 606-10-55-18.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is allocated to each performance obligation on a relative stand-alone selling price (&#8220;SSP&#8221;) basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the timing of recognition and the SSP for each performance obligation identified in the contract.&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SSP for licenses are calculated using the residual approach if the Company has not yet established a price for such license and the license has not previously been sold on a standalone basis.&#160;Otherwise, selling prices for licenses are determined using an income approach model and include key assumptions such as: development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success. To estimate the SSP for research and development services, the Company uses a cost-plus margin approach. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of License and Collaboration Revenue</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license revenue includes sublicense fees paid or payable to Mosaic Biosciences, Inc. (&#8220;Mosaic&#8221;), incurred in the period, under the terms of the Mosaic collaboration agreement, and fees for patent development and protection paid or payable to other third-party vendors corresponding to the recognition of license revenue from the Company&#8217;s collaboration agreement with Biogen International GmbH (&#8220;Biogen&#8221;). See<span style="color:#000000;"> Notes 8 and 12. Cost of license revenue does not include any allocated overhead costs.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of collaboration revenue includes fees for research and development services paid or payable to Mosaic and other third-party vendors and personnel cost, incurred in the period pertaining to the Biogen Agreement. See<span style="color:#000000;"> Notes 8 and 12. Cost of collaboration revenue does not include any allocated overhead costs.</span></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, and consulting costs, as well as allocations of facilities and other overhead costs. Under the Company&#8217;s collaboration agreement with Biogen, certain specific expenditures are reimbursed by third parties. During the year ended December 31, 2020, $5.4 million of research and development expense was recorded as cost of collaboration revenue related to the collaboration agreement with Biogen signed in December 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses include estimated costs of research and development activities conducted by external service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in other accrued liabilities in the consolidated balance sheet and within research and development expense in the consolidated statement of operations. These costs are a significant component of the research and development expenses. The Company records accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these external service providers.</p>

<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, investments and accounts receivable. The Company&#8217;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company believes that it has established guidelines for investment of its excess cash that maintain safety and liquidity through its policies on high quality of investment and investment duration. The Company is exposed to credit risk in the event of default by the institutions holding the cash and cash equivalents to the extent beyond the amount insured by the federal depository insurance corporation. The Company&#8217;s accounts receivable as of December 31, 2020 of $3.3 million as well as its total license and collaboration revenue of $20.9 million for the year ended December 31, 2020 is from one party, see Note 12.&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounts Receivable, net and Allowance for Doubtful Accounts</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under the arrangements. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time balances are past due, the Company&#8217;s previous loss history, the customer&#8217;s current ability to pay its obligations to the Company and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are determined to be uncollectible. For the years ended December 31, 2020 and 2019, there were no allowance for doubtful accounts deemed necessary.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are computed using the liability method. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the authoritative guidance on accounting for uncertainty in income taxes. This guidance prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company&#8217;s income tax returns. This interpretation also provides guidance on accounting for interest and penalties and associated with tax positions, accounting for income taxes in interim periods and income tax disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant and recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option-pricing valuation model to estimate the grant-date fair value of stock-based awards. The determination of fair value for stock-based awards on the date of grant using an option-pricing model requires management to make certain assumptions regarding a number of variables. The Company elected to account for forfeitures when they occur. As such, the Company recognizes stock-based compensation expense, over their requisite service period, based on the vesting provisions of the individual grants.</p>

<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected to combine lease and non-lease components as a single component. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the consolidated balance sheet as right-of-use assets, operating lease liabilities, current and operating lease liabilities, non-current. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss of the Company for all periods presented.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779183461064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value Measurements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a description of the fair value hierarchy and fair value methodology, see &#8220;<span style="font-style:italic;">Note 3 &#8211; Summary of Significant Accounting Policies</span>&#8221;. As of December 31, 2020 and 2019, the Company&#8217;s highly liquid money market funds included within cash equivalents and U.S. government agency securities are valued using Level&#160;1 inputs. The Company classifies its federal agency securities as Level 2. There were no transfers in or out of Level 1 and Level 2 during the periods presented. U.S. government agency securities are bonds issued by the U.S. government and are fully backed by the U.S. government. Given the frequency at which U.S. government agency securities trade and the accessibility of observable, quoted prices for such assets in active markets, they are recognized as Level 1 assets. Federal agency securities are bonds and notes issued by government-sponsored enterprises, including Fannie Mae, Freddie Mac and the Federal Home Loan Bank. Since Federal agency securities typically do not trade as U.S. government agency securities and no exchange exists to price such investments, they are recognized as Level 2 assets. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present the fair value hierarchy for assets measured at fair value on a recurring basis as of December 31, 2020 and 2019 <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,197</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. $2.5 million of U.S. government agency securities are included in long-term investments on the accompanying consolidated balance sheets due to the maturity being more than 12 months.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,369</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,369</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,490</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,490</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,859</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,865</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. &#160;</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-0.43%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779169548872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Instruments</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents and investments (debt securities) which are classified as available-for-sale securities, consisted of the following <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,835</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,837</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,697</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,892</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,897</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,994</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,543</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,369</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,369</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,467</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,490</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,995</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,831</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,865</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,369</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,496</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,865</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no material realized gains or losses on available-for-sale debt securities for the periods presented. As of December 31, 2020, the remaining contractual maturities of $49.0 million of available-for-sale debt securities was less than one year and $2.5 million of available-for-sale debt securities were less than two years. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779169508824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Other Accrued Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Other Accrued Liabilities </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities consisted of the following <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional and consulting services</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,979</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,238</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,320</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">435</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other accrued liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,743</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,031</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779174337928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing Agreements</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 20, 2016, the Company signed a development and manufacturing services agreement with AGC Biologics, Inc. (&#8220;AGC&#8221;), formerly known as CMC ICOS Biologics, Inc., pursuant to which AGC will conduct manufacturing development of agreed upon product candidates. The Company has firm work orders with AGC to manufacture MarzAA and DalcA to support its clinical trials totaling $11.2 million and the payment obligations remaining at the year ended December 31, 2020 was $2.3 million.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 9, 2019, the Company and Catalent Indiana, LLC (&#8220;Catalent&#8221;) signed a clinical supply services agreement, effective October 4, 2019, pursuant to which Catalent will conduct drug product development of agreed upon product candidates. The Company had firm work orders with Catalent to manufacture DalcA to support its clinical trial totaling $0.5 million and all outstanding amounts were paid during the year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, potential trial participants and business operations. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national, and international markets. The COVID-19 pandemic may disrupt the operations of the Company&#8217;s manufacturers or disrupt supply logistics, which could impact the timing of deliveries and potentially increase expenses under our agreements. All required MarzAA supplies for the MAA-304 and MAA-202 studies have been manufactured.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779167467336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Related Parties</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 24, 2017, the Company announced a strategic research collaboration with Mosaic to develop intravitreal anti-complement factor 3 (C3) products for the treatment of dry Age-related Macular Degeneration (AMD) and other retinal diseases. Dr. Usman, the Company&#8217;s Chief Executive Officer and a member of the Company&#8217;s board of directors, and Mr. Lawlor, a member of the Company&#8217;s board of directors, were also members of the board of directors of Mosaic. On December 21, 2018, the Company amended its collaboration agreement with Mosaic to, among other things, include certain additional products. Pursuant to the Mosaic collaboration agreement, as amended, the Company and Mosaic co-funded certain research. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 18, 2019, the Company entered into the second amendment to the Mosaic collaboration agreement following completion of the co-funded research. Pursuant to the second amendment, any future services provided by Mosaic will be performed on a fee-for-service basis. In connection with the Biogen Agreement, the Company received a $15.0 million upfront license fee on January 10, 2020, see Note 12. The Company paid Mosaic a $3.0 million sublicense fee and recorded such payment as cost of license revenue for the year ended December 31, 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 8, 2020, the Company entered into a subsequent amendment to the Mosaic collaboration agreement. As part of this amendment, the Company paid a one-time $0.8 million cash payment to Mosaic, and Mosaic is eligible to receive up to $4.0 million in potential future milestone payments related to regulatory and clinical development events for CB 2782-PEG and an additional anti-complement product candidate in lieu of the Company&#8217;s obligations to pay Mosaic a double-digit percentage of funds the Company receives from Biogen or any other amounts the Company receives related to sublicense fees, research and development payments, or any other research, regulatory, clinical or commercial milestones and royalties on any other development candidates. The Company now owns one hundred percent of all future payment streams related to these product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The one-time $0.8 million cash payment was recorded to research and development expenses for the year ended December 31, 2020.<span style="color:#000000;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2020, Mosaic was no longer a related party. Total expense related to the collaboration with Mosaic were $1.6 million for the year ended December 31, 2020, of which expense recognized while Mosaic was a related party were $1.3 million, and $1.1 million for the year ended December 31, 2019. The amount incurred in 2020 is fully reimbursable under the Biogen Agreement, see Note 12.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779171193528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space for its corporate headquarters, located in South San Francisco, CA. The lease term is through April 30, 2023 and there are no stated renewal options. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not the remaining lease term. The lease includes non-lease components (<span style="font-style:italic;">e.g.</span>, common area maintenance) that are paid separately from rent based on actual costs incurred and therefore were not included in the right-of-use asset and lease liability but are reflected as an expense in the period incurred.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 17, 2020, the Company entered into an amendment to the existing lease agreement to lease additional office space for an aggregated undiscounted future monthly payment of $0.5 million. This amendment is treated as a separate lease with a lease term of 2.6 years and commenced during the fourth quarter of 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2020 and 2019, the Company&#8217;s operating lease expense was $0.7 million and $0.6 million, respectively. The present value assumptions used in calculating the present value of the lease payments were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.33 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.33 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity of the Company&#8217;s operating lease liabilities as of&#160;December&#160;31, 2020 were as follows&#160;<span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Undiscounted lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">762</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,760</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(116</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. The Company did not incur significant variable lease costs for the years ended December 31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information for the years ended December 31, 2020 and 2019 related to operating leases was as follows&#160;<span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for leases that were included in operating cash</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; outflows</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">602</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">562</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779183229080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock Based Compensation</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2018 Omnibus Incentive Plan </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, stockholders of the Company approved the Company&#8217;s 2018 Omnibus Incentive Plan (the &#8220;2018 Plan&#8221;). The 2018 Plan had previously been approved by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and the Compensation Committee of the Board, subject to stockholder approval. The 2018 Plan became effective on June 13, 2018. On June 11, 2020, the stockholders of the Company approved an amendment previously approved by the Board to increase the number of shares of common stock reserved for issuance under the 2018 Plan by 1,300,000 to a total of 2,800,000 shares. The amendment became effective immediately upon stockholder approval. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under the Company&#8217;s equity incentive plans and related information:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2018</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,361,977</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.04</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000394">8.71</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,294</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450,900</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,219</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.57</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(182,722</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.36</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,395</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96.49</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,577,541</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000395">8.15</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,350</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,091,250</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.26</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,605</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.04</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(250,641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,930</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51.12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,355,615</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.59</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000396">7.96</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,337</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable &#8212; December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,113,791</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000397">7.14</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">823</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available to be granted &#8212; December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,255,302</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Valuation Assumptions</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited history as a public company and limited number of sales of its common stock, the Company estimated its volatility considering a number of factors including the use of the volatility of comparable public companies. The expected term of options granted under the Plan, all of which qualify as &#8220;plain vanilla&#8221; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#8217;s limited operating history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of employee stock options was estimated using the following&#160;weighted-average assumptions for the&#160;years ended&#160;December&#160;31, 2020&#160;and 2019:<span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Options:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000404">5.81</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000405">5.98</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.91</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113.36</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90.81</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average fair value of stock options</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation recognized was as follows <span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,052</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,140</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,152</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Included in general and administrative stock-based compensation for the years ended December 31, 2020 and 2019 is $0.3 million and $0.2 million in expense related to 51,056 shares and 24,235 shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.19%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, 1,255,302 shares of common stock were available for future grant and 2,355,615 options to purchase shares of common stock were outstanding.&#160;<span style="color:#000000;">As of December 31, 2020, the Company had unrecognized employee stock-based compensation expense of $6.5 million, related to unvested stock option awards, which is expected to be recognized</span> over an estimated weighted-average period of 2.63 years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company&#8217;s stockholders approved the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP had previously been approved by the Board and the Compensation Committee of the Board, subject to stockholder approval which became effective as of June 13, 2018. Under the ESPP, employees meeting certain specific employment qualifications are eligible to participate and can purchase shares of common stock semi-annually on February 9<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> and August 9<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> of each year, through payroll deductions. The purchase price is 85% of the lower of the fair market value of the stock at the commencement or end of the offering period. The ESPP permits eligible employees to purchase shares of common stock through payroll deductions for up to 15% of qualified compensation.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s ESPP is subject to an Evergreen provision which shares may be added to the pool as needed. As of December 31, 2020, a total of 359,545 shares of common stock may be granted in accordance with the terms of the ESPP as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, a total of 38,248 shares of common stock for $0.2 million have been issued to employees participating in the two ESPP purchases of 2020 and 300,444 shares are available for issuance under the ESPP as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for the ESPP was $0.1 million and $0.1 million for the years ended December 31, 2020 and 2019, respectively, and is included in total stock-based compensation recognized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779174667352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred cumulative net operating losses since inception and, consequently, has not recorded any income tax expense for the years ended December 31, 2020 and 2019 due to its net operating loss position. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate for the years ended December 31, 2020 and 2019 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax at statutory federal rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State Tax (benefit)&#8212;net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-0.06</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.58</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.43</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-12.26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-11.20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition due to Sec. 382 and 383 limitations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.55</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-12.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.38</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.63</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets as of December 31, 2020 and 2019 consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,095</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">936</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carry forwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,505</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,392</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carry forwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,789</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,945</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed and intangible assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,396</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,283</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the available objective evidence at December 31, 2020, the Company does not believe it is more likely than not that the net deferred tax assets will be realizable. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets at December 31, 2020 and 2019. The net valuation allowance decreased by approximately $6.9 million and increased by approximately $17.2 million during the years ended December 31, 2020 and 2019, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, after consideration of certain limitations (see below), the Company had approximately $140.4 million federal and $8.0 million state net operating loss carryforwards (&#8220;NOL&#8221;) available to reduce future taxable income which, if unused, will begin to expire in 2037 for federal and 2032 for state tax purposes. The federal net operating loss carryforward includes $132.9 million that have an indefinite life.&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company also had tax credit carry forwards available to offset future tax liabilities of approximately $5.0 million for federal and $6.8 million for state. If unused, the federal credit will begin to expire in 2040 and the state tax credit does not expire. &#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Company experiences a greater than 50 percent aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carryforwards are subject to annual limitation under Section 382 of the Internal Revenue Code (California has similar provisions). The annual limitation is determined by multiplying the value of the Company's stock at the time of such ownership change by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company determined that ownership changes occurred December 31, 2007, August 20, 2015, April 13, 2017, February 15, 2018, and February 18, 2020. Approximately $156.3 million and $70.8 million of the NOLs will expire unutilized for federal and California purposes, respectively. The Company has derecognized NOL related deferred tax assets in the tax affected amounts of $32.8 million and $0 for federal and California purposes, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the federal R&amp;D credits could expire unutilized, whereas none of the California R&amp;D credits are subject to expiration. Approximately $15.2 million of gross federal R&amp;D credit-related deferred tax assets were derecognized due to the Section 383 limitation. The ability of the Company to use its remaining NOL carryforwards may be further limited if the Company experiences a Section 382 ownership change as a result of future changes in its stock ownership. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 27, 2020, the &#8220;Coronavirus Aid, Relief and Economic Security (CARES) Act&#8221; (the &#8220;Act&#8221;) was signed into law. The Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll taxes, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company analyzed the provisions of the Act and determined there was no significant impact to its 2020 tax provision.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 29, 2020, the California Governor signed Assembly Bill 85 (&#8220;A.B. 85&#8221;), which now becomes California law. A.B. 85, which includes several tax measures, provides for a three-year suspension of the use of net operating losses for medium and large businesses and a three-year cap on the use of business incentive tax credits to offset no more than $5 million of tax per year. Generally, A.B. 85 suspends the use of net operating losses for taxable years 2020, 2021, and 2022 for taxpayers with taxable income of $1 million or </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more. Since the Company is not expected to generate California source taxable income of more than $1 million, no material impact is anticipated at this time.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 27, 2020, the &#8220;Consolidated Appropriations Act, 2021&#8221; (the &#8220;CAA&#8221;) was signed into law. The CAA includes provisions meant to clarify and modify certain items put forth in CARES Act, while providing aid to businesses affected by the pandemic.&#160;&#160;The CAA allows deductions for expenses paid for by Paycheck Protection Program (&#8220;PPP&#8221;) and Economic Injury Disaster Loan (&#8220;EIDL&#8221;) Program, clarifies forgiveness of EIDL advances, and other business provisions.&#160;&#160;The Company analyzed the provisions of the CAA and determined there was no significant impact to its 2020 tax provision.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting for Uncertainty in Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company only recognizes tax benefits if it is more likely than not that they will be sustained upon audit by the relevant tax authority based upon their technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had approximately $3.0 million and $1.9 million of unrecognized tax benefits as of December 31, 2020 and 2019, respectively. As the Company has a full valuation allowance on its deferred tax assets, the unrecognized tax benefits have reduced the deferred tax assets and the valuation allowance in the same amount. The Company does not expect the amount of unrecognized tax benefits to materially change in the next twelve months.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Beginning Balance at January&#160;1, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,573</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits taken</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; in prior years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related to current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">253</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ending Balance at December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,871</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits taken</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; in prior years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(295</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related to current year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,379</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ending Balance at December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2,955</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and penalties related to unrecognized tax benefits would be included as income tax expense in the Company&#8217;s consolidated statements of operations. As of December 31, 2020 and 2019, the Company had not recognized any tax-related penalties or interest in its consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the United States federal, California, Kansas, Missouri and New Jersey state jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. As of December 31, 2020 and 2019, the Company had no uncertain tax positions which affected its financial position as its results of operations or its cash flow, and will continue to evaluate for uncertain tax positions in the future. The Company is subject to United States federal and state income tax examinations by authorities for all tax years due to accumulated net operating losses that are being carried forward for tax purposes.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779169524456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaborations</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pfizer</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.2pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the termination agreement entered into on December 8, 2016, in connection with the termination of a prior license and development agreement, Pfizer granted the Company an exclusive license to Pfizer&#8217;s proprietary rights for manufacturing materials and processes that apply to Factor VIIa variants, CB 813a and marzeptacog alfa (activated) - MarzAA. Pfizer also transferred to the Company the IND application and documentation related to the development, manufacturing and testing of the Factor VIIa products as well as </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;letter-spacing:-0.2pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the orphan drug designation</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Company agreed to make contingent cash payments to Pfizer in an aggregate amount up to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.5</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, payable upon the achievement of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> certain</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and commercial milestones. Following commercialization of any covered product, Pfizer w</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ill</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> also receive a single-digit royalty on net product sales on a country-by-country basis for a predefined royalty term. In February 2018, the Company paid Pfizer a $</span>1.0<span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million milestone payment based on the dosing of the first patient in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 2 study</span><span style="color:#000000;">; the amount was recorded as a research and development expens</span><span style="color:#000000;">e</span><span style="color:#000000;">. </span><span style="color:#000000;">No</span><span style="color:#000000;"> payments were made to Pfizer </span><span style="color:#000000;">in </span><span style="color:#000000;">the year ended</span><span style="color:#000000;"> December 31, 20</span><span style="color:#000000;">20</span><span style="color:#000000;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ISU Abxis</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, the Company entered into an amended and restated license agreement with ISU Abxis (the &#8220;A&amp;R ISU Abxis Agreement&#8221;), which amended and restated its previous license and collaboration agreement with ISU Abxis previously entered into in September 2013, as subsequently amended in October 2014 and December 2016 <span style="color:#000000;">(the &#8220;Original ISU Abxis Agreement&#8221;)</span>. Under the A&amp;R ISU Abxis Agreement, <span style="color:#000000;">ISU Abxis will receive commercialization rights in South Korea to the Company&#8217;s engineered Factor IX dalcinonacog alfa - DalcA and the Company will receive clinical development and commercialization rights in the rest of world (excluding South Korea) and manufacturing development and manufacturing rights worldwide (including South Korea)</span>. <span style="color:#000000;">The </span>A&amp;R ISU Abxis Agreement <span style="color:#000000;">eliminates the profit-sharing arrangement in the Original ISU Abxis Agreement and</span> p<span style="color:#000000;">rovides for a low single-digit royalty payment to ISU Abxis, on a country-by-country basis, for net product sales of DalcA by the Company or its affiliates in each country other than South Korea. Pursuant to the A&amp;R </span>ISU Abxis Agreement<span style="color:#000000;">, the Company will also pay up to an aggregate of</span> <span style="color:#000000;">$19.5 million in milestone payments to ISU Abxis, including $2.5&#160;million in regulatory and development milestone payments and up to $17.0&#160;million in commercial milestone payments, if the applicable milestones are met. As of December 31, 2020, no milestones have been met.</span><span style="letter-spacing:-0.2pt;"> </span>&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Biogen</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 18, 2019, the Company and Biogen International GmbH (&#8220;Biogen&#8221;) entered into a License and Collaboration Agreement (the &#8220;Biogen Agreement&#8221;), under which the Company granted Biogen a worldwide, royalty-bearing, exclusive, with the right to sublicense, license (&#8220;Exclusive License&#8221;) to develop and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders. Pursuant to the Biogen Agreement, the Company will perform certain pre-clinical and manufacturing activities (&#8220;Research Services&#8221;), and Biogen will be solely responsible for funding the pre-clinical and manufacturing activities and performing IND-enabling activities, worldwide clinical development, and commercialization. The Company will provide the Research Services over a term of <span style="color:#000000;">thirty months</span> with Biogen having the option to extend the term for two additional <span style="color:#000000;"><span style="-sec-ix-hidden:F_000502">twelve-month</span></span> periods.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Biogen Agreement, the Company received an up-front payment for the transfer of the Exclusive License (inclusive of certain know-how) of <span style="color:#000000;">$15.0</span> million in January 2020. The Company is eligible to receive development milestones and sales milestones of up to $340.0 million. In addition, the Company is eligible to receive royalties in the range of single-digit to low double-digit percentage rates of annual net sales on a product-by-product and country-by-country basis. The Company will also receive reimbursements for costs associated with the performance of the Research Services.<span style="color:#000000;">   </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the performance obligations under the Biogen Agreement were the Exclusive License and the Research Services. For the Exclusive License, the Company used the residual approach in determining the standalone selling price, or SSP, which includes the upfront payments, milestones and royalties. For the Research Services, the Company used the historical pricing approach for determining the SSP, which includes the reimbursement of personnel and out-of-pocket costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Biogen Agreement will continue on a product-by-product and country-by-country basis until the tenth anniversary of the first commercial sale of the first product in a country, unless terminated earlier by either party as specified under the agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, the Company recognized the $15.0 million in license revenue upon the transfer of the Exclusive License and the related know-how, and $0.1 million in license revenue for reimbursable out-of-pocket costs incurred.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, the Company recorded $5.8 million in collaboration revenue for reimbursable out-of-pocket and personnel costs incurred related to research services.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779168857880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest and Other Income, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income And Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncomeTextBlock', window );">Interest and Other Income, Net</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Interest and Other Income, Net </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows the detail of interest and other income, net for the years ended December 31, 2020 and 2019 <span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">561</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Miscellaneous income (expense)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">659</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other income, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,129</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,099</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for interest and other income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779167469560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14.</span></p></td>
<td valign="top">
<p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020,<span style="font-style:italic;"> </span>the Company completed an underwritten public offering of 5,307,692 shares of its common stock (including 692,307 shares sold pursuant to the exercise of the underwriters&#8217; overallotment option)&#160;at a price of $6.50 per share. The net proceeds to the Company, after deducting $2.5 million in underwriting discounts and commissions and offering expenses payable by the Company, were approximately $32.0 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, the Company completed an underwritten public offering of 4,615,384 shares of its common stock at a price of $6.50 per share. The net proceeds to the Company, after deducting $2.0 million in underwriting discounts and commissions and offering expenses payable by the Company, were approximately $28.0 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had issued and outstanding common stock warrants as follows:</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2018</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,194</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155.73</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,337</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499.50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,857</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53.61</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,772</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.91</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">392.70</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779167180632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss per Share Attributable to Common Stockholders</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per common share during the years ended December 31, 2020 and 2019 <span style="font-style:italic;">(in thousands, except share and per share data)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,241</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,178</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of shares used in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; computing net loss per share, basic and diluted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,179,299</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,004,489</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.93</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,355,615</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,577,541</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,857</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,355,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,585,398</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779181844616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subsequent Event</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2021, we sold an aggregate of 9,185,000 registered shares of common stock (including 485,000 shares sold pursuant to the exercise of the underwriters&#8217; overallotment option) at a price of $5.75 per share. The net proceeds, after deducting $3.5 million underwriting discounts and offering expenses, were approximately $49.3 million. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779174251240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation. The Company&#8217;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). &#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, operating lease right-of-use assets and liabilities, accrued expenses, income taxes and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Recently Adopted</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Pronouncements Recently Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-18,&#160;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606 (&#8220;ASU 2018-18&#8221;). The amended guidance precludes presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The new guidance is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2018-18 as of January 1, 2020. The adoption of ASU 2018-18 did not have a material impact on the Company&#8217;s consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement (&#8220;ASU 2018-13&#8221;). The </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">guidance removes, modifies, and adds certain disclosure requirements for fair value measurements. Entities no longer have to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The guidance is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2018-13 as of January 1, 2020. The adoption of ASU 2018-13 did not have a material impact on the Company&#8217;s consolidated financial statements. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,<span style="font-style:italic;">&#160;</span>Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to adopt ASU 2016-13&#160;and related updates&#160;as of January 1, 2023.&#160;The Company will assess the impact of adoption of this standard on its consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued&#160;ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes<span style="font-style:italic;">. </span>The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes.&#160;ASU 2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning January 1, 2021. The adoption of this standard will not have a material impact on the Company&#8217;s consolidated financial statements<span style="color:#000000;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 1<span style="font-style:normal;"> &#8211; Quoted prices in active markets for identical assets or liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 2<span style="font-style:normal;"> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 3<span style="font-style:normal;"> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, which are three years for computer equipment and software, and three to seven years for furniture and leasehold improvements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash in investment grade, short to intermediate-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#8220;available-for-sale&#8221; and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation as of each consolidated balance sheet date. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value determined to be other-than-temporary, if any, on available-for-sale debt securities are included in interest and other income, net. The cost of securities sold is based on the specific-identification method. Interest on short-term investments is included in interest and other income, net.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Collaboration Arrangements </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.21%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may enter into collaboration arrangements that fall under the scope Collaborative Arrangements (Topic 808). The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808 to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. The accounting for some of the activities under collaboration arrangements may be analogized to ASC 606 for distinct units of account that are reflective of a vendor-customer relationship.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when the Company satisfies each performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues attributed to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that contain development milestones, the Company evaluates whether the development milestones included are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not generally considered probable of being achieved until those approvals are received.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the end of each reporting period, the Company re-evaluates the probability of achievement of any development milestones, and if necessary, adjusts its estimate of the transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For research and development services, the Company elected the practical expedient to recognize revenue as the research and development services are invoiced.&#160;&#160;As the Company has a right to consideration from the </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaboration agreement with Biogen, in an amount that corresponds directly with the value of the Company&#8217;s performance completed to date for the research services, the Company recognized revenue related to the research services as invoiced, in line with the practical expedient in ASC 606-10-55-18.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is allocated to each performance obligation on a relative stand-alone selling price (&#8220;SSP&#8221;) basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the timing of recognition and the SSP for each performance obligation identified in the contract.&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SSP for licenses are calculated using the residual approach if the Company has not yet established a price for such license and the license has not previously been sold on a standalone basis.&#160;Otherwise, selling prices for licenses are determined using an income approach model and include key assumptions such as: development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success. To estimate the SSP for research and development services, the Company uses a cost-plus margin approach. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock', window );">Cost of License and Collaboration Revenue</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of License and Collaboration Revenue</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license revenue includes sublicense fees paid or payable to Mosaic Biosciences, Inc. (&#8220;Mosaic&#8221;), incurred in the period, under the terms of the Mosaic collaboration agreement, and fees for patent development and protection paid or payable to other third-party vendors corresponding to the recognition of license revenue from the Company&#8217;s collaboration agreement with Biogen International GmbH (&#8220;Biogen&#8221;). See<span style="color:#000000;"> Notes 8 and 12. Cost of license revenue does not include any allocated overhead costs.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of collaboration revenue includes fees for research and development services paid or payable to Mosaic and other third-party vendors and personnel cost, incurred in the period pertaining to the Biogen Agreement. See<span style="color:#000000;"> Notes 8 and 12. Cost of collaboration revenue does not include any allocated overhead costs.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, and consulting costs, as well as allocations of facilities and other overhead costs. Under the Company&#8217;s collaboration agreement with Biogen, certain specific expenditures are reimbursed by third parties. During the year ended December 31, 2020, $5.4 million of research and development expense was recorded as cost of collaboration revenue related to the collaboration agreement with Biogen signed in December 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock', window );">Accrued Research and Development Expenses</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses include estimated costs of research and development activities conducted by external service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in other accrued liabilities in the consolidated balance sheet and within research and development expense in the consolidated statement of operations. These costs are a significant component of the research and development expenses. The Company records accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these external service providers.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ConcentrationRiskCreditRiskPolicyTextBlock', window );">Concentration Risk Credit Risk</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, investments and accounts receivable. The Company&#8217;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company believes that it has established guidelines for investment of its excess cash that maintain safety and liquidity through its policies on high quality of investment and investment duration. The Company is exposed to credit risk in the event of default by the institutions holding the cash and cash equivalents to the extent beyond the amount insured by the federal depository insurance corporation. The Company&#8217;s accounts receivable as of December 31, 2020 of $3.3 million as well as its total license and collaboration revenue of $20.9 million for the year ended December 31, 2020 is from one party, see Note 12.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable, net and Allowance for Doubtful Accounts</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounts Receivable, net and Allowance for Doubtful Accounts</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under the arrangements. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time balances are past due, the Company&#8217;s previous loss history, the customer&#8217;s current ability to pay its obligations to the Company and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are determined to be uncollectible. For the years ended December 31, 2020 and 2019, there were no allowance for doubtful accounts deemed necessary.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are computed using the liability method. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the authoritative guidance on accounting for uncertainty in income taxes. This guidance prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company&#8217;s income tax returns. This interpretation also provides guidance on accounting for interest and penalties and associated with tax positions, accounting for income taxes in interim periods and income tax disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant and recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option-pricing valuation model to estimate the grant-date fair value of stock-based awards. The determination of fair value for stock-based awards on the date of grant using an option-pricing model requires management to make certain assumptions regarding a number of variables. The Company elected to account for forfeitures when they occur. As such, the Company recognizes stock-based compensation expense, over their requisite service period, based on the vesting provisions of the individual grants.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected to combine lease and non-lease components as a single component. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the consolidated balance sheet as right-of-use assets, operating lease liabilities, current and operating lease liabilities, non-current. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss of the Company for all periods presented.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ConcentrationRiskCreditRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk Credit Risk</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ConcentrationRiskCreditRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of license and collaboration revenue policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779179874808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present the fair value hierarchy for assets measured at fair value on a recurring basis as of December 31, 2020 and 2019 <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,197</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. $2.5 million of U.S. government agency securities are included in long-term investments on the accompanying consolidated balance sheets due to the maturity being more than 12 months.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,369</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,369</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,490</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,490</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,859</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,865</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. &#160;</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-0.43%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779170449240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents and investments (debt securities) which are classified as available-for-sale securities, consisted of the following <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,835</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,837</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,697</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,892</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,897</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,994</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,543</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,369</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,369</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,467</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,490</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,995</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,831</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,865</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,369</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,496</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,865</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779173419128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accrued Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities consisted of the following <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional and consulting services</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,979</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,238</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,320</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">435</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other accrued liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,743</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,031</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779167469560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock', window );">Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments</a></td>
<td class="text">The present value assumptions used in calculating the present value of the lease payments were as follows:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.33 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.33 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity of the Company&#8217;s operating lease liabilities as of&#160;December&#160;31, 2020 were as follows&#160;<span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Undiscounted lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">762</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,760</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(116</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. The Company did not incur significant variable lease costs for the years ended December 31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information for the years ended December 31, 2020 and 2019 related to operating leases was as follows&#160;<span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for leases that were included in operating cash</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; outflows</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">602</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">562</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of present value assumptions of lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779168762504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity Under Company's Equity Incentive Plans</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under the Company&#8217;s equity incentive plans and related information:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2018</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,361,977</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.04</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000394">8.71</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,294</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450,900</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,219</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.57</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(182,722</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.36</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,395</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96.49</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,577,541</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000395">8.15</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,350</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,091,250</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.26</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,605</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.04</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(250,641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,930</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51.12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,355,615</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.59</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000396">7.96</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,337</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable &#8212; December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,113,791</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000397">7.14</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">823</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available to be granted &#8212; December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,255,302</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options</a></td>
<td class="text">The fair value of employee stock options was estimated using the following&#160;weighted-average assumptions for the&#160;years ended&#160;December&#160;31, 2020&#160;and 2019:
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Options:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000404">5.81</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000405">5.98</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.91</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113.36</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90.81</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average fair value of stock options</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Recognized</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation recognized was as follows <span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,052</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,140</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,152</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Included in general and administrative stock-based compensation for the years ended December 31, 2020 and 2019 is $0.3 million and $0.2 million in expense related to 51,056 shares and 24,235 shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779167496776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Income Tax Rate to Company's Effective Tax Rate</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate for the years ended December 31, 2020 and 2019 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax at statutory federal rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State Tax (benefit)&#8212;net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-0.06</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.58</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.43</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-12.26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-11.20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition due to Sec. 382 and 383 limitations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.55</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-12.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.38</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.63</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Company's Deferred Tax Assets (Liabilities)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets as of December 31, 2020 and 2019 consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,095</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">936</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carry forwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,505</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,392</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carry forwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,789</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,945</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed and intangible assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,396</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,283</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Unrecognized Tax Benefits</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Beginning Balance at January&#160;1, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,573</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits taken</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; in prior years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related to current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">253</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ending Balance at December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,871</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits taken</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; in prior years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(295</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related to current year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,379</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ending Balance at December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2,955</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779167443480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest and Other Income, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income And Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Detail of Interest and Other Income, Net</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows the detail of interest and other income, net for the years ended December 31, 2020 and 2019 <span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">561</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Miscellaneous income (expense)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">659</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other income, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,129</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,099</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779169080360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Activity</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had issued and outstanding common stock warrants as follows:</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2018</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,194</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155.73</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,337</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499.50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,857</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53.61</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,772</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.91</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">392.70</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779167556536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Loss Per Common Share</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per common share during the years ended December 31, 2020 and 2019 <span style="font-style:italic;">(in thousands, except share and per share data)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,241</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,178</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of shares used in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; computing net loss per share, basic and diluted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,179,299</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,004,489</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.93</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-dilutive Security not Included In Diluted per Share Calculations</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,355,615</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,577,541</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,857</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,355,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,585,398</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779167258056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779174380984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_LiquidityAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 314,761<span></span>
</td>
<td class="nump">$ 258,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">81,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 56,241<span></span>
</td>
<td class="nump">$ 55,178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779177440888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="nump">20,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CostOfCollaborationRevenue', window );">Cost of collaboration revenue</a></td>
<td class="nump">$ 5,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">AS 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientsPackage', window );">Lease practical expedients</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_CostOfCollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of collaboration revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_CostOfCollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientsPackage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL77916155-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL77916155-209984<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientsPackage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779170654760">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 81,897<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 76,865<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">30,360<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Agency Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,837<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">51,490<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Federal Agency Securities | Short-Term Investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">10,006<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68,197<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">66,859<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 | Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">30,360<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 | U.S. Government Agency Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,837<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">51,490<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,006<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 | Federal Agency Securities | Short-Term Investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 10,006<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in cash and cash equivalents on accompanying consolidated balance sheet.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. $2.5 million of U.S. government agency securities are included in long-term investments on the accompanying consolidated balance sheets due to the maturity being more than 12 months.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779168795816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=cbio_LongTermInvestmentsMember', window );">Long Term Investments | U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, debt securities</a></td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=cbio_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=cbio_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779170978440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 81,892<span></span>
</td>
<td class="nump">$ 76,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">81,897<span></span>
</td>
<td class="nump">76,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">30,360<span></span>
</td>
<td class="nump">15,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">30,360<span></span>
</td>
<td class="nump">15,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">37,835<span></span>
</td>
<td class="nump">51,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">37,837<span></span>
</td>
<td class="nump">51,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">30,360<span></span>
</td>
<td class="nump">15,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">48,994<span></span>
</td>
<td class="nump">61,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=cbio_LongTermInvestmentsMember', window );">Long-Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=cbio_FederalAgencySecuritiesMember', window );">Federal Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">13,697<span></span>
</td>
<td class="nump">9,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 13,700<span></span>
</td>
<td class="nump">$ 10,006<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=cbio_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=cbio_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cbio_FederalAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cbio_FederalAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779167428472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet', window );">Material realized gains or losses on available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale debt securities current</a></td>
<td class="nump">49,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available-for-sale-debt securities noncurrent</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779177605512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Other Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional and consulting services</a></td>
<td class="nump">$ 3,979<span></span>
</td>
<td class="nump">$ 2,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AccruedManufacturingExpensesCurrent', window );">Manufacturing</a></td>
<td class="nump">2,238<span></span>
</td>
<td class="nump">4,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AccruedClinicalExpensesCurrent', window );">Clinical</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AccruedAndOtherCurrentLiabilities', window );">Other</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Total other accrued liabilities</a></td>
<td class="nump">$ 6,743<span></span>
</td>
<td class="nump">$ 7,031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_AccruedAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_AccruedAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_AccruedClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_AccruedClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_AccruedManufacturingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued manufacturing expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_AccruedManufacturingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779170461528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_AGCBiologicsIncMember', window );">AGC Biologics, Inc | Marzeptacog Alfa Activated and Dalcinonacog Alfa</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ClinicalTrials', window );">Clinical trials</a></td>
<td class="nump">$ 11.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation payments</a></td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_CatalentIndianaLLCMember', window );">Catalent Indiana, LLC. | Dalcinonacog alfa.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ClinicalTrials', window );">Clinical trials</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ClinicalTrialsPaid', window );">Clinical trials paid</a></td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ClinicalTrialsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical trials paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ClinicalTrialsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_AGCBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_AGCBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_CatalentIndianaLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_CatalentIndianaLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_DalcinonacogAlfaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_DalcinonacogAlfaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779169826984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Additional Information (Detail) - Mosaic - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses related to collaboration</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_MosaicBiosciencesIncMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents', window );">Milestone Payment Related To Regulatory And Clinical Development Events</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_MosaicBiosciencesIncMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_MosaicBiosciencesIncMember', window );">Intravitreal Anti-Complement Factor 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SublicenseFee', window );">Payment related to collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_MosaicBiosciencesIncMember', window );">Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_TotalTransactionExpensesRelatedToCollaboration', window );">Expenses related to collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_MosaicBiosciencesIncMember', window );">Collaboration Agreement | Intravitreal Anti-Complement Factor 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses related to collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_MosaicBiosciencesIncMember', window );">Biogen Collaboration | Intravitreal Anti-Complement Factor 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement', window );">Upfront license fee received from collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_SublicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublicense fee entitled to pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_SublicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_TotalTransactionExpensesRelatedToCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total transaction expenses related to collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_TotalTransactionExpensesRelatedToCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fee reveived from license and collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_MosaicBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_MosaicBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_IntravitrealAntiComplementFactor3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_IntravitrealAntiComplementFactor3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cbio_BiogenCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cbio_BiogenCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779174308520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 17, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_LesseeOperatingLeaseRenewalTermDescription', window );">Lessee operating lease renewal term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">no stated renewal options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription', window );">Operating lease not yet commenced description</a></td>
<td class="text">commenced during the fourth quarter of 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term of contract</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 1,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_LesseeOperatingLeaseRenewalTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease renewal term description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_LesseeOperatingLeaseRenewalTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease that has not yet commenced. Including, but not limited to, nature of involvement with construction or design of underlying asset for lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779174211752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">2 years 3 months 29 days<span></span>
</td>
<td class="text">3 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779177297336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Maturity of Operating Lease Liabilities - (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 17, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">1,760<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 1,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779168873448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for leases that were included in operating cash outflows</a></td>
<td class="nump">$ 602<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779171021576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 11, 2020</div></th>
<th class="th"><div>Jun. 13, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable', window );"><strong>Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,255,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares remaining outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,355,615<span></span>
</td>
<td class="nump">1,577,541<span></span>
</td>
<td class="nump">1,361,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,627<span></span>
</td>
<td class="nump">$ 3,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable', window );"><strong>Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized employee stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized employee stock based compensation expense, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbio_TwoThousandEighteenOmnibusIncentivePlanMember', window );">2018 Omnibus Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable', window );"><strong>Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Increase in number of shares of common stock reserved for issuance</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable', window );"><strong>Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee subscription rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common stock authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of common stock stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable', window );"><strong>Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of fair market value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cbio_TwoThousandEighteenOmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cbio_TwoThousandEighteenOmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779166021272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Option Activity Under Company's Equity Incentive Plans (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares Underlying Outstanding Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Beginning Balance</a></td>
<td class="nump">1,577,541<span></span>
</td>
<td class="nump">1,361,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares Underlying Outstanding Options, Options granted</a></td>
<td class="nump">1,091,250<span></span>
</td>
<td class="nump">450,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares Underlying Outstanding Options, Options exercised</a></td>
<td class="num">(44,605)<span></span>
</td>
<td class="num">(41,219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares Underlying Outstanding Options, Options forfeited</a></td>
<td class="num">(250,641)<span></span>
</td>
<td class="num">(182,722)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Shares Underlying Outstanding Options, Options expired</a></td>
<td class="num">(17,930)<span></span>
</td>
<td class="num">(11,395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Ending Balance</a></td>
<td class="nump">2,355,615<span></span>
</td>
<td class="nump">1,577,541<span></span>
</td>
<td class="nump">1,361,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares Underlying Outstanding Options, Exercisable- December 31, 2020</a></td>
<td class="nump">1,113,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available to be granted - December 31, 2020</a></td>
<td class="nump">1,255,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 10.85<span></span>
</td>
<td class="nump">$ 12.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options granted</a></td>
<td class="nump">6.26<span></span>
</td>
<td class="nump">7.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options exercised</a></td>
<td class="nump">5.04<span></span>
</td>
<td class="nump">4.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options forfeited</a></td>
<td class="nump">10.32<span></span>
</td>
<td class="nump">8.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options expired</a></td>
<td class="nump">51.12<span></span>
</td>
<td class="nump">96.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Ending Balance</a></td>
<td class="nump">8.59<span></span>
</td>
<td class="nump">$ 10.85<span></span>
</td>
<td class="nump">$ 12.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable - December 31, 2020</a></td>
<td class="nump">$ 10.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (Years), Outstanding Balance</a></td>
<td class="text">7 years 11 months 15 days<span></span>
</td>
<td class="text">8 years 1 month 24 days<span></span>
</td>
<td class="text">8 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable - December 31, 2020</a></td>
<td class="text">7 years 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 1,350<span></span>
</td>
<td class="nump">$ 2,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Options exercised</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">1,337<span></span>
</td>
<td class="nump">$ 1,350<span></span>
</td>
<td class="nump">$ 2,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable - December 31, 2020</a></td>
<td class="nump">$ 823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779170740472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail) - Employee Stock Option - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 9 months 21 days<span></span>
</td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.91%<span></span>
</td>
<td class="nump">2.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">113.36%<span></span>
</td>
<td class="nump">90.81%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of stock options granted</a></td>
<td class="nump">$ 5.20<span></span>
</td>
<td class="nump">$ 5.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions Black-Scholes method used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779170233528">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock-Based Compensation Recognized (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,627<span></span>
</td>
<td class="nump">$ 3,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,487<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2,140<span></span>
</td>
<td class="nump">$ 2,152<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Included in general and administrative stock-based compensation for the years ended December 31, 2020 and 2019 is $0.3 million and $0.2 million in expense related to 51,056 shares and 24,235 shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779174358168">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares of common stock issued to certain board members in lieu of cash compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,056<span></span>
</td>
<td class="nump">24,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,627<span></span>
</td>
<td class="nump">$ 3,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,140<span></span>
</td>
<td class="nump">2,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative | Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Included in general and administrative stock-based compensation for the years ended December 31, 2020 and 2019 is $0.3 million and $0.2 million in expense related to 51,056 shares and 24,235 shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779167521304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reconciliation of Statutory Federal Income Tax (benefit) Rate to Company's Effective Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at statutory federal rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State Tax (benefit)&#8212;net of federal benefit</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="num">(0.06%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="nump">0.58%<span></span>
</td>
<td class="nump">0.43%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(12.26%)<span></span>
</td>
<td class="num">(11.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_EffectiveIncomeTaxRateReconciliationDerecognition', window );">Derecognition due to Sec. 382 and 383 limitations</a></td>
<td class="nump">44.55%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(12.25%)<span></span>
</td>
<td class="nump">31.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">0.38%<span></span>
</td>
<td class="nump">0.63%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_EffectiveIncomeTaxRateReconciliationDerecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation derecognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_EffectiveIncomeTaxRateReconciliationDerecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779169713720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Components of the Company's Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">$ 1,095<span></span>
</td>
<td class="nump">$ 936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">29,505<span></span>
</td>
<td class="nump">34,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carry forwards</a></td>
<td class="nump">7,789<span></span>
</td>
<td class="nump">9,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_DeferredTaxAssetsFixedAssetsAndIntangibles', window );">Fixed and intangible assets</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (38,396)<span></span>
</td>
<td class="num">$ (45,283)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_DeferredTaxAssetsFixedAssetsAndIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets fixed assets and intangibles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_DeferredTaxAssetsFixedAssetsAndIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779171504328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease', window );">Increase (decrease) in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,900,000)<span></span>
</td>
<td class="nump">$ 17,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized', window );">Gross federal R&amp;D tax credit-related deferred tax assets derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,955,000<span></span>
</td>
<td class="nump">1,871,000<span></span>
</td>
<td class="nump">$ 1,573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Tax-related penalties or interest recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_OperatingLossCarryforwardsWithIndefiniteLife', window );">Net operating loss carryforwards having indefinite life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to offset future federal tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Credit carryforward, expire period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards', window );">Net operating loss carryforward, derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to offset future federal tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA', window );">CALIFORNIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards', window );">Net operating loss carryforward, derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_MaximumAmountOfTaxOffsetPerYear', window );">Maximum amount of tax offset per year</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_RequiredMinimumTaxableIncome', window );">Required Minimum Taxable Income</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets state net operating loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_MaximumAmountOfTaxOffsetPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of tax offset per year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_MaximumAmountOfTaxOffsetPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_OperatingLossCarryforwardsWithIndefiniteLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards with indefinite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_OperatingLossCarryforwardsWithIndefiniteLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_RequiredMinimumTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum taxable income required to support realizing the company's.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_RequiredMinimumTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credit carry forwards derecognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779169015160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unrecognized tax benefit (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning Balance</a></td>
<td class="nump">$ 1,871<span></span>
</td>
<td class="nump">$ 1,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions', window );">Increase/(Decrease) of unrecognized tax benefits taken in prior years</a></td>
<td class="num">(295)<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase/(Decrease) of unrecognized tax benefits related to current year</a></td>
<td class="nump">1,379<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">$ 2,955<span></span>
</td>
<td class="nump">$ 1,871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits increase (decrease) resulting from tax positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779165515288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 18, 2019</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 08, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_LicenseRevenueMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_LicenseRevenueMember', window );">License | Transfer of Exclusive License and Related Know-How</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_ExclusiveLicenseMember', window );">Exclusive License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember', window );">Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember', window );">Collaboration | Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_PfizerIncMember', window );">Pfizer Inc | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_MilestonePayments', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_PfizerIncMember', window );">Pfizer Inc | Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_MilestoneContingentCashPaymentsObligation', window );">Contingent cash payments upon achievement of certain clinical, regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_IsuAbxisMember', window );">ISU Abxis | Amended and Restated License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_RegulatoryAndDevelopmentMilestonePayment', window );">Regulatory and development milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_IsuAbxisMember', window );">ISU Abxis | Amended and Restated License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_MilestonePayments', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommercialMilestonePayments', window );">Commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_BiogenMember', window );">Biogen | License and Collaboration Agreement (the &#8220;Biogen Agreement&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ResearchServicesAgreementTerm', window );">Research services</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ResearchServicesAgreementOptionToExtend', window );">Research services option to extend</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_BiogenMember', window );">Biogen | Exclusive License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Up-front payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_BiogenMember', window );">Biogen | Exclusive License | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_DevelopmentMilestonesPaymentReceivable', window );">Development and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_CommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_CommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_DevelopmentMilestonesPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestones payment Receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_DevelopmentMilestonesPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_MilestoneContingentCashPaymentsObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone contingent cash payments obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_MilestoneContingentCashPaymentsObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_RegulatoryAndDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory and development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_RegulatoryAndDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ResearchServicesAgreementOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research services agreement option to extend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ResearchServicesAgreementOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ResearchServicesAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ResearchServicesAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_ExclusiveLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_ExclusiveLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_IsuAbxisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_IsuAbxisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=cbio_AmendedAndRestatedLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=cbio_AmendedAndRestatedLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_BiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_BiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=cbio_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=cbio_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=cbio_ExclusiveLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=cbio_ExclusiveLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779177584120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Detail of Interest and Other Income, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income And Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">$ 561<span></span>
</td>
<td class="nump">$ 2,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Miscellaneous income (expense)</a></td>
<td class="nump">659<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_InterestAndOtherIncomeExpenseNet', window );">Total interest and other income, net</a></td>
<td class="nump">$ 1,129<span></span>
</td>
<td class="nump">$ 2,099<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_InterestAndOtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and other income (expense), net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_InterestAndOtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779203527320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockholdersEquityDisclosureLineItems', window );"><strong>Stockholders Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable', window );">Net proceeds from sale of common stock after deducting underwriting commissions and offering expenses payable</a></td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="nump">$ 32.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_UnderwritingCommissionsAndOfferingExpensesPayable', window );">Underwriting discounts, commissions and offering expenses payable</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockholdersEquityDisclosureLineItems', window );"><strong>Stockholders Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_FirmCommitmentUnderwrittenPublicOfferingShares', window );">Firm commitment underwritten public offering shares</a></td>
<td class="nump">4,615,384<span></span>
</td>
<td class="nump">5,307,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,923,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock price, per share</a></td>
<td class="nump">$ 6.50<span></span>
</td>
<td class="nump">$ 6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Overallotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockholdersEquityDisclosureLineItems', window );"><strong>Stockholders Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_FirmCommitmentUnderwrittenPublicOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Firm commitment underwritten public offering shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_FirmCommitmentUnderwrittenPublicOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from sale of common stock, after deducting underwriting commissions and offering expenses payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_StockholdersEquityDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_StockholdersEquityDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_UnderwritingCommissionsAndOfferingExpensesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting commissions and offering expenses payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_UnderwritingCommissionsAndOfferingExpensesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779177596632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Warrant Activity (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants And Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares Underlying Warrants, Outstanding</a></td>
<td class="nump">7,857<span></span>
</td>
<td class="nump">10,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ClassOfWarrantOrRightForfeitedDuringPeriod', window );">Number of Shares Underlying Warrants, Forfeited</a></td>
<td class="num">(7,772)<span></span>
</td>
<td class="num">(2,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares Underlying Warrants, Outstanding</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">7,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 53.61<span></span>
</td>
<td class="nump">$ 155.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited', window );">Warrants Forfeited, Weighted Average Exercise Price</a></td>
<td class="nump">49.91<span></span>
</td>
<td class="nump">499.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 392.70<span></span>
</td>
<td class="nump">$ 53.61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ClassOfWarrantOrRightForfeitedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, forfeited during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ClassOfWarrantOrRightForfeitedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right weighted average exercise price per warrants or right forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779168990648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Common Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (56,241)<span></span>
</td>
<td class="num">$ (55,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of shares used in computing net loss per share, basic and diluted</a></td>
<td class="nump">19,179,299<span></span>
</td>
<td class="nump">12,004,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (2.93)<span></span>
</td>
<td class="num">$ (4.60)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779167291592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Anti-dilutive Security not Included In Diluted per Share Calculations (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="nump">2,355,700<span></span>
</td>
<td class="nump">1,585,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_OptionsToPurchaseCommonStockMember', window );">Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="nump">2,355,615<span></span>
</td>
<td class="nump">1,577,541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">7,857<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139779170220760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,097,820<span></span>
</td>
<td class="nump">12,040,835<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">9,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="nump">$ 5.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_UnderwritingDiscountsAndOfferingExpenses', window );">Underwriting discounts and offering expenses</a></td>
<td class="nump">$ 49.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_UnderwritersOverallotmentOptionMember', window );">Underwriters' overallotment option | Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_UnderwritingDiscountsAndOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts and offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_UnderwritingDiscountsAndOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_UnderwritersOverallotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_UnderwritersOverallotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?02*. #=)!IN:WL/XCI&)2A09?<4]^L"Z"X2:I..\@^@8+9H6^&"=6W%J@S
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M'&TC*U2SI(>1P4P6J<BC,]2$A\*/W97_(U0,6.7J 14<.O(>ZY,5J5G^P]
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M>@'\?^!<71_T!NTHN_D74$L#!!0    ( "]H9%(^J:(<O (  /\&   8
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&ULC55=;]HP%/TK5]$>6FDT'WRDK0 )
MZ*956M>JM-O#M >37(A5QV:V@6Z_?M=.R"@#M)?$'_><>\]Q?-/?*/UB"D0+
MKZ609A 4UBZOP]!D!9;,7*@E2MJ9*UTR2U.]",U2(\L]J!1A$D6]L&1<!L.^
M7WO0P[Y:6<$E/F@PJ[)D^M<8A=H,@CC8+CSR16'=0CCL+]D"IVB?EP^:9F'#
MDO,2I>%*@L;Y(!C%UY/4Q?N KQPW9F<,3LE,J1<WN<T'0>0*0H&9=0R,7FN<
MH!".B,KX67,&34H'W!UOV3]Z[:1EQ@Q.E/C&<UL,@LL <IRSE;"/:O,):SU=
MQY<I8?P3-E5L2AFSE;&JK,$T+[FLWNRU]F$'$/>. )(:D.P#.D< [1K0]D*K
MRKRL&V;9L*_5!K2+)C8W\-YX-*GATIWBU&K:Y82SPXF21@F>,XLY3"V]Z(BL
M 36'B2KIPRC<B:T1/BMCH 7/TQLX>W<.[X!+>"K4RC"9FWYHJ1;'&&9UWG&5
M-SF2-T[@3DE;&/@@<\S?$H0DHE&2;)6,DY.,-YA=0#M^#TF41 <*FOPW/+XZ
M44Z[,;;M^=I'^!HOX7X.MS)3)<)(YGNNUAO?1S-C-7W2/TYD[C29.SYSYTCF
M+W3W!9W6H4.ID#V/=!=\/6QU>TDG[H?K7:L.A77C]+()>U-8MRFL>]*2>UN@
MANR- ;PRX,P5?'Y]0GVO2=([J?Y94C,3_#=]SA4I+*B7@>L8:\8%FPEL4?-K
M&2:0[OO,@L%LI;GE>-"Q*EMWUXKD:L^N?V/:1ZQ*&Q7I215/RC*Q9]6Q,TT/
MGFD:[15Y**P;=Z*]0L.=7E*B7O@6:ZB4E;3596Q6FRX^\LUK;WU,W;UJQG]I
MJE_#'=,++@T(G!-E=)&2<[IJM]7$JJ7O6#-EJ?_Y84%_*-0N@/;G2MGMQ"5H
M_GG#/U!+ P04    "  O:&12143H#\8$   '%   &    'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;+U8:V^C.!3]*U8TTK924[!Y9I1&FJ:-MM(^HNET][,#
M3K *.&,[36=__=J$0@!#JLQNOR0\SKT^OM><8YCN&7\6"2$2O&9I+FY&B93;
MSY8EHH1D6%RS+<G5G37C&9;JE&\LL>4$QT50EEK(MGTKPS0?S:;%M26?3=E.
MIC0G2P[$+LLP_W%+4K:_&<'1VX6O=)-(?<&:3;=X0QZ)?-HNN3JSJBPQS4@N
M*,L!)^N;T1?X>8&*@ +Q%R5[<70,]%16C#WKDX?X9F1K1B0ED=0IL/I[(7.2
MICJ3XO&]3#JJQM2!Q\=OV1?%Y-5D5EB0.4O_IK%,;D;A",1DC7>I_,KVOY)R
M0I[.%[%4%+]@7V+M$8AV0K*L#%8,,IH?_O%K68BC .CT!* R +TWP"D#G%8
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M$X)CPC5 W5\S)M].](>7ZMO?[%]02P,$%     @ +VAD4HP("*A" @  LP0
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MU(3:H%4;6+7!B-KOD-&94$Z/US,C.].D[>EV'D8DP->+T[D?7&(A7JY:L5?
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M"$E9WVO6#UJ4]FIP)[06N1T>&4V9- +P?2^$?GDP"[2WR[?_ U!+ P04
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MLJ /!!I_@/R9IMJUAD_0?7)FOP%02P,$%     @ +VAD4IW9)29B!   \ D
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M0DHI@7-#X&H<8PJ.$+!J-T"!*;23.(G1,0G]16[XL#P%+.]:Y'W#]H!&G(T
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MW:?RUM!NU*)DHD!EA59@<'7>OXA/+\=>/RA\%KBUG37X3)9:W_O-^^R\'_F
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MLV\\K065.VH!1F!6WQ[C</B6 4*%\<#":#!SD,!)X,ZG4^>5$X2>/W9FWC3
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MSFGV8=V#8C'ITY8BC4DR4[A:* ?;]Q5P  U;EUJU</ =48*"F(V/C2ND:+Y
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MM #O4X4&'FYH@_:+^M7_ 5!+ P04    "  O:&12)6EN6HT"  "Y!0  &0
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M!\INP/5:2G,T+,'T?J[_!5!+ P04    "  O:&126.S$R;P#  "*"   &0
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MTES3W>3K'JQJ_+39*DNSRR\K^EA [0SH?*>H@OV#(Q@^/U9_ U!+ P04
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MRD;Q#"?3\W"RQX7PMWL1'<BL0EWX86+ I^H4-^P.\^JRD^DO]V[8W3)=<&E
M8$ZA,?4>@.X&2+>PJO:BW2A+(\!_EC1S43L'LN=*V?W")1BF^.HG4$L#!!0
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MBLD'KY'A/_C6[)"D,0GYO!F(?<P"E@OX\2&2@ ^AV3?M@5F%>P5+_'MG0,K
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M,V+>X:3:.O=A5Z#V.?Q+"?3@+MCK2X1<W!9@Q$"CYW R<P^(3@)E#H,=PCV
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MX;T&S5T6U"^89I8^E;Q?2%K@#&?0?;'6TB?&7=R8QI0Z+0W=AQO-<)2T#]D
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MXCOK])RK]MR^BF$7=J%[:B_GVZ5']Z6.:C:#EJ*"&$58A*QT\5$W 24=P]%
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MQ!JW=O@ _+ZVP WY@ O$=^%^_T]02P,$%     @ +VAD4@Z_"7\6!   PPH
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M=@.NYU*:W<0&Z+Y99O\ 4$L#!!0    ( "]H9%*>(=KFD (  &P%   9
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MGYK::57"@Q58%X6TFQO09CT+!^'VPT>URAU_B.;32J[@$=RGZL'2+NI0,E5
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M8@>+9JPT&\77MI677.G!8)>%GL0@C(&^SSE7NXTAZ&;[Y"]02P,$%     @
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M,SP')@NXYZ*Q6$#?!!?Q6&X7^+WRG@5W,WQM:I;C(J0A-:B?,5P^E@A;)6@
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M;N_B]L&JVM]_&V7I-O7+DCY?4#L#.M\JZF#WX +T'T3+?P!02P,$%     @
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MN-3TYKWC-7&NHX.Z#[.TU^@F,YB=>PK ^ "WWVB-)\<33(]+^0=02P,$%
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M %Q?"*&?3\PG@>H3T/@_4$L#!!0    ( "]H9%(S$ FO<@(  ,$%   9
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;)5476_:,!3]*U:TAU8:) 1(MRI$
M@K)J?4!"1>T>ICV8Y$*L.C:S;Z#=K]^U QE; 6D\$'_<>\[QL>]-=]J\V!(
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M\[19*)SYK9>,E2 TDX(HR,?>=' [2ZR],_C)8*?WQL1FLI+RV4Z^96.O;X&
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MH_<'V9WL97?&#1/*K#20;S?H2:XMU.;[$=Z+CO?B:/P%+G"&-;.:4W&P+BW
MR .XD_N<)TF89M'S =I^1]L_3HOA:3QG*V16<\&KMED:^NI3<$A&"YC$.SK2
ML'=8QF4GX_*X##P( @FQ[B6GDIZ3FYLBQ YX4V**)0Z/Y'K0L0W^:XV''>_P
M7VL\W$]N'/8/)W?4T8[^AA:+R\M#W*.]_MJGCG;N+?<$X FMN#1$P *]XG"
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M D\%4_6"I-3 /M.Z:1:%PJJ#T_?OWJ%M@PYAPU;8\!_"7-UX_EAA8DVX4ZI
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M=X4;9GC]@[(!^'TEI7F>V NC_4,Q_P-02P,$%     @ +VAD4G8M]*Q( @
MN 4  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N>&ULE51A:]LP$/TKAV&P
MP18[=M*N)0FD"6.##D+#V@]C'Q3[$HO*EB>=F^;?[R0[)BU)R+[8.NG>T[TG
MG49;;9YMCDCP6JC2CH.<J+H-0YOF6 C;TQ66O++6IA#$H=F$MC(H,@\J5!A'
MT558"%D&DY&?6YC)2->D9(D+ [8N"F%V=ZCT=AST@_W$@]SDY";"R:@2&UPB
M_:H6AJ.P8\ED@:65N@2#ZW$P[=_.!B[?)SQ*W-J#,3@E*ZV?7? C&P>1*P@5
MIN08!/]><(9*.2(NXV_+&71;.N#A>,_^S6MG+2MA<:;5D\PH'P=? \AP+6I%
M#WK['5L]0\>7:F7]%[9M;A1 6EO210OF"@I9-G_QVOIP (B')P!Q"X@O!20M
M(/%"F\J\K+D@,1D9O07CLIG-#;PW'LUJ9.E.<4F&5R7C:+)L3@_T&A8&+98$
MCT+5"%/+!ULYJRW4%C.0)<R$2FLE2):;=]D,OT=V$Q9BQV=,%C[.D814GT8A
M<9ENLS!M2[IK2HI/E#3'M =)_S/$41P=@<\NAO=OWL)#-J=S*.X<BCU?<H+O
M'JU%A+FTJ=*V-@B_IRM+AB_@GS/T24>?>/K!"?HG?]$P^R)>T'#?<&NXYG,6
M*^\HH2F.F7B>-H8="F,A@4*7E%N(;R 3.WO,S_-,R45,;[0/.NV#_].>L<FZ
MYEME!.$QT>?YAKWKZ,,QA>=A5[WH/:R1$Q[TE7O3?@JSD=P/"M=,%/6NN4=-
M\TXT >G*M]I*$S>N'^;\M*)Q";R^UIKV@>O>[K&>_ -02P,$%     @ +VAD
M4MEQT2N7 @  [08  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULC57?
M;]HP$/Y7K*@/K;227R1A58C4@J9M:C54VNUAVH-)#F+5L3/;@?+?SW;2"(U
M^T+N;'_W?7<^SNF.BQ=9 BCT6E$FITZI5'WCNC(OH<)RQ&M@>F?-1865=L7&
ME;4 7%A01=W \V*WPH0Y66K7%B)+>:,H8; 02#95A<7^#BC?31W?>5MX))M2
MF04W2VN\@26HYWHAM.?V40I2 9.$,R1@/75N_9O9Q)RW!WX2V,D#&YE,5IR_
M&.=;,74\(P@HY,I$P/JSA1E0:@)I&7^[F$Y/:8"']EOT+S9WG<L*2YAQ^HL4
MJIPZ$P<5L,8-58]\]Q6Z?"(3+^=4VE^TZ\YZ#LH;J7C5@;6"BK#VBU^[.AP
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M9Y$W D$5L&[J6B"5R#(!"V9*N*0BPY7L'HO+^O$2+>/"G,![N%LOX?CH!(Z
M2_A6JL8PF9LDM!26(P^S/H1Y%T)\((11##=*VM+ 9YEC_C=!2'H&4?%.U#Q^
MDW&)V2F,1^\@CN+HE8 6_PT??7HCG/&0X['G&Q_@^UJCIO3)+5PCO3BXYFS#
M!;<<#:S8DTNX@66#\/-B8ZRFE_WK#:^3P>O$>YT<\.H+6#.> Y4/A/-LP);,
M0HL:J6:9:"C=KGAJ"#!S(&KV@@K_:BD[GU/OTTV(AW0:Q4GXL)_=?VW.IL\V
MG9AP[\E6J+>^DPUDJI&V*_1P.@R+"]\C+\[G-$2ZGG^FZ2;0#=-;+@U)+X@R
M.OUP%H#NNKK;6%7[QM@H2VWFER4-0M3.@.X+I>QNXQP,HS7] U!+ P04
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MCFW20'R_RC)^?)$)JLOYZ;]02P,$%     @ +VAD4OF2VDQ  P   0D  !D
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M3M#$\N62:_<E^VYM')"\T2CK#FP\J)EH__2AVX@C0#(] 4@[0/H2,#X!R#I
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M SY?"Z&?+_*O\]4O2M/_ %!+ P04    "  O:&12B/11C:@"   '!P  &0
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M<XN95%7WK"9&%JX!K:3!=N:&&?YP0-D W%]+:?83^X'F%S;Y"U!+ P04
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M1#MKL'^8[7G+IN#P?R+Z"U!+ P04    "  O:&12EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( "]H9%*\E//^A04
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M<F]P<R]A<' N>&UL4$L! A0#%     @ +VAD4@>3_T#N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ +VAD
M4IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    "  O:&12?LD>@]$%  #!&   &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ +VAD
M4LY,G;7"!0  XA8  !@              ("!% X  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( "]H9%(HH7G>P (  $4)   8
M      " @0P4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M"  O:&12B85TGA8$  #6#@  &               @($"%P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ +VAD4CZIHAR\ @  _P8  !@
M             ("!3AL  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( "]H9%)%1.@/Q@0   <4   8              " @4 >  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  O:&12C @(J$("  "S
M!   &               @($\(P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ +VAD4HGI+9H !@  :18  !@              ("!M"4
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "]H9%)7\O/*
M$ ,  'X&   8              " @>HK  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    "  O:&12G=DE)F($  #P"0  &0
M@($P+P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( "]H
M9%*"M^%U9AD  .)-   9              " @<DS  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ +VAD4APD#45 !   .@L  !D
M         ("!9DT  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    "  O:&12,C*E$_X#  #E"0  &0              @('=40  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( "]H9%*QS02&@P(  '0%
M   9              " @1)6  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ +VAD4FRF074S!0  ! P  !D              ("!S%@
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  O:&125E"W
MY- %  #)#@  &0              @($V7@  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( "]H9%)C\O8H+04  %P,   9
M  " @3UD  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M+VAD4H_<TAA'"0  *Q@  !D              ("!H6D  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    "  O:&12TVRHURT-   R)   &0
M            @($?<P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( "]H9%+[[-WZS @  %T7   9              " @8.   !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ +VAD4B5I;EJ- @
MN04  !D              ("!AHD  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    "  O:&1241AKQUD#  !+!P  &0              @(%*
MC   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( "]H9%)8
M[,3)O ,  (H(   9              " @=J/  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ +VAD4HJBRV?( @  T04  !D
M     ("!S9,  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M"  O:&121L_T(IL:   75P  &0              @(',E@  >&PO=V]R:W-H
M965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( "]H9%(.OPE_%@0  ,,*   9
M              " @9ZQ  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L!
M A0#%     @ +VAD4M2SPWR- P  OP@  !D              ("!Z[4  'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  O:&12GB':YI "
M  !L!0  &0              @(&ON0  >&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;%!+ 0(4 Q0    ( "]H9%(6GW2$& 0  !\*   9              "
M@7:\  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ +VAD
M4BFT<Q&6!0  70T  !D              ("!Q<   'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    "  O:&125#G3[:,$  "X"P  &0
M        @(&2Q@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( "]H9%()Y-:IE (  *D%   9              " @6S+  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ +VAD4J4[.GBV @  YP4
M !D              ("!-\X  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    "  O:&12$J2H_0$$   <"0  &0              @($DT0
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( "]H9%+#S]2(
M%0(  &@$   9              " @5S5  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ +VAD4MY*GD>0 @  0@8  !D
M ("!J-<  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  O
M:&12CWV )[P#  !Q$   &0              @(%OV@  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( "]H9%+>H"XZ& 4  '<9   9
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M  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ +VAD4GE
MR(F> @  \08  !D              ("!-NT  'AL+W=O<FMS:&5E=',O<VAE
M970T,BYX;6Q02P$"% ,4    "  O:&12MA%G*J,"  #G!@  &0
M    @($+\   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M "]H9%)@BIM;F ,  .4-   9              " @>7R  !X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ +VAD4OG[+Y/U @  7 @  !D
M             ("!M/8  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    "  O:&12=BWTK$@"  "X!0  &0              @('@^0  >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( "]H9%+9<=$KEP(
M .T&   9              " @5_\  !X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ +VAD4G2%ZN!S @  9@4  !D              ("!
M+?\  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  O:&12
M?KK"*J\$  "2$@  &0              @('7 0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( "]H9%+QS\\P+@4  *@7   9
M      " @;T& 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ +VAD4OF2VDQ  P   0D  !D              ("!(@P! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  O:&12M!)0%94#   <"P
M&0              @(&9#P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( "]H9%+N+KM&PP,  "@,   9              " @643 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ +VAD4K_VPIY-
M P  %0L  !D              ("!7Q<! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    "  O:&12-LO-=Z8"   3!P  &0
M@('C&@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( "]H
M9%*4$T'0F 0  /82   9              " @< = 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ +VAD4O:)XU"\ @  3 <  !D
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M=#8Q+GAM;%!+ 0(4 Q0    ( "]H9%(VBF:]O@(  ,X&   9
M  " @:PT 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
M+VAD4O),9NC/ @  IP@  !D              ("!H3<! 'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    "  O:&12#NDER2L#  #'"0  &0
M            @(&G.@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( "]H9%+2C8Y@3P(  %P,   -              "  0D^ 0!X;"]S
M='EL97,N>&UL4$L! A0#%     @ +VAD4I>*NQS     $P(   L
M     ( !@T ! %]R96QS+RYR96QS4$L! A0#%     @ +VAD4KR4\_Z%!0
M>BH   \              ( !;$$! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( "]H9%+22;QM$0(  !<F   :              "  1Y' 0!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( "]H9%+ B&UTZ0$  'XE
M   3              "  6=) 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0  !( $@ KQ,  (%+ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>128</ContextCount>
  <ElementCount>347</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNatureOfOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLiquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Other Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureOtherAccruedLiabilities</Role>
      <ShortName>Other Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborations</Role>
      <ShortName>Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Interest and Other Income, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureInterestAndOtherIncomeNet</Role>
      <ShortName>Interest and Other Income, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Net Loss per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstruments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Other Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureOtherAccruedLiabilitiesTables</Role>
      <ShortName>Other Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureOtherAccruedLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Interest and Other Income, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureInterestAndOtherIncomeNetTables</Role>
      <ShortName>Interest and Other Income, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureInterestAndOtherIncomeNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Nature of Operations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail</Role>
      <ShortName>Nature of Operations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Liquidity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail</Role>
      <ShortName>Liquidity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Assets and Liabilities Measured at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Assets and Liabilities Measured at Fair Value - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail</Role>
      <ShortName>Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Schedule of Other Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail</Role>
      <ShortName>Schedule of Other Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Related Parties - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail</Role>
      <ShortName>Related Parties - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail</Role>
      <ShortName>Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Schedule of Maturity of Operating Lease Liabilities - (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Schedule of Maturity of Operating Lease Liabilities - (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Schedule of Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails</Role>
      <ShortName>Schedule of Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Stock Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Summary of Option Activity Under Company's Equity Incentive Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail</Role>
      <ShortName>Summary of Option Activity Under Company's Equity Incentive Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail</Role>
      <ShortName>Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Summary of Stock-Based Compensation Recognized (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail</Role>
      <ShortName>Summary of Stock-Based Compensation Recognized (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail</Role>
      <ShortName>Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Reconciliation of Statutory Federal Income Tax (benefit) Rate to Company's Effective Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail</Role>
      <ShortName>Reconciliation of Statutory Federal Income Tax (benefit) Rate to Company's Effective Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Components of the Company's Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail</Role>
      <ShortName>Components of the Company's Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Unrecognized tax benefit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail</Role>
      <ShortName>Unrecognized tax benefit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Collaborations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail</Role>
      <ShortName>Collaborations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Detail of Interest and Other Income, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail</Role>
      <ShortName>Detail of Interest and Other Income, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Summary of Warrant Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfWarrantActivityDetail</Role>
      <ShortName>Summary of Warrant Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Basic and Diluted Net Loss Per Common Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetail</Role>
      <ShortName>Basic and Diluted Net Loss Per Common Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail</Role>
      <ShortName>Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="cbio-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Subsequent Event - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail</Role>
      <ShortName>Subsequent Event - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="cbio-10k_20201231.htm">cbio-10k_20201231.htm</File>
    <File>cbio-20201231.xsd</File>
    <File>cbio-20201231_cal.xml</File>
    <File>cbio-20201231_def.xml</File>
    <File>cbio-20201231_lab.xml</File>
    <File>cbio-20201231_pre.xml</File>
    <File>cbio-ex108_383.htm</File>
    <File>cbio-ex231_10.htm</File>
    <File>cbio-ex311_9.htm</File>
    <File>cbio-ex312_151.htm</File>
    <File>cbio-ex321_12.htm</File>
    <File>cbio-ex322_152.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g2g5bnvu5o20000001.jpg</File>
    <File>g2g5bnvu5o20000002.jpg</File>
    <File>g2g5bnvu5o20000003.jpg</File>
    <File>g2g5bnvu5o20000004.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cbio-10k_20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 128,
   "dts": {
    "calculationLink": {
     "local": [
      "cbio-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cbio-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cbio-10k_20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cbio-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cbio-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cbio-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 468,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 14,
    "http://www.catalystbiosciences.com/20201231": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 19
   },
   "keyCustom": 47,
   "keyStandard": 300,
   "memberCustom": 26,
   "memberStandard": 28,
   "nsprefix": "cbio",
   "nsuri": "http://www.catalystbiosciences.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiquidationBasisOfAccountingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Liquidity",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLiquidity",
     "shortName": "Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiquidationBasisOfAccountingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Fair Value Measurements",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Financial Instruments",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Other Accrued Liabilities",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureOtherAccruedLiabilities",
     "shortName": "Other Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Commitments and Contingencies",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Related Parties",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Leases",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Stock Based Compensation",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "Stock Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Income Taxes",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Collaborations",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborations",
     "shortName": "Collaborations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestAndOtherIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Interest and Other Income, Net",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureInterestAndOtherIncomeNet",
     "shortName": "Interest and Other Income, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestAndOtherIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Stockholders' Equity",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Net Loss per Share Attributable to Common Stockholders",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders",
     "shortName": "Net Loss per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Subsequent Event",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Other Accrued Liabilities (Tables)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureOtherAccruedLiabilitiesTables",
     "shortName": "Other Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbio:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Leases (Tables)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbio:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Stock Based Compensation (Tables)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InterestAndOtherIncomeTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Interest and Other Income, Net (Tables)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureInterestAndOtherIncomeNetTables",
     "shortName": "Interest and Other Income, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InterestAndOtherIncomeTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "shortName": "Net Loss per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_cbioSegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Nature of Operations - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail",
     "shortName": "Nature of Operations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_cbioSegment",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Liquidity - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
     "shortName": "Liquidity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LiquidationBasisOfAccountingTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "cbio:ConcentrationRiskCreditRiskPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cbio:ConcentrationRiskCreditRiskPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Assets and Liabilities Measured at Fair Value (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
     "shortName": "Assets and Liabilities Measured at Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Assets and Liabilities Measured at Fair Value - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
     "shortName": "Assets and Liabilities Measured at Fair Value - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail",
     "shortName": "Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Financial Instruments - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
     "shortName": "Financial Instruments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Schedule of Other Accrued Liabilities (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail",
     "shortName": "Schedule of Other Accrued Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "cbio:ClinicalTrials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "cbio:ClinicalTrials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Related Parties - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
     "shortName": "Related Parties - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseExpirationDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseExpirationDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail",
     "shortName": "Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Schedule of Maturity of Operating Lease Liabilities - (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail",
     "shortName": "Schedule of Maturity of Operating Lease Liabilities - (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Schedule of Supplemental Cash Flow Information (Details)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails",
     "shortName": "Schedule of Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Stock Based Compensation - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Summary of Option Activity Under Company's Equity Incentive Plans (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail",
     "shortName": "Summary of Option Activity Under Company's Equity Incentive Plans (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail",
     "shortName": "Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Summary of Stock-Based Compensation Recognized (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail",
     "shortName": "Summary of Stock-Based Compensation Recognized (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail",
     "shortName": "Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Reconciliation of Statutory Federal Income Tax (benefit) Rate to Company's Effective Tax Rate (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail",
     "shortName": "Reconciliation of Statutory Federal Income Tax (benefit) Rate to Company's Effective Tax Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Components of the Company's Deferred Tax Assets (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail",
     "shortName": "Components of the Company's Deferred Tax Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Unrecognized tax benefit (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail",
     "shortName": "Unrecognized tax benefit (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "cbio:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Collaborations - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
     "shortName": "Collaborations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioTransferOfExclusiveLicenseAndRelatedKnowHowMember_20200101_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:InterestAndOtherIncomeTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestIncomeExpenseNonoperatingNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Detail of Interest and Other Income, Net (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail",
     "shortName": "Detail of Interest and Other Income, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:InterestAndOtherIncomeTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestIncomeExpenseNonoperatingNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200629_20200630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "cbio:NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200629_20200630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "cbio:NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Summary of Warrant Activity (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfWarrantActivityDetail",
     "shortName": "Summary of Warrant Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20181231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Basic and Diluted Net Loss Per Common Share (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetail",
     "shortName": "Basic and Diluted Net Loss Per Common Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail",
     "shortName": "Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Subsequent Event - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail",
     "shortName": "Subsequent Event - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_srtStatementScenarioAxis_srtScenarioForecastMember_20210331",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Nature of Operations",
     "role": "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNatureOfOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20201231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 58,
   "tag": {
    "cbio_AGCBiologicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AGC Biologics Inc.",
        "label": "A G C Biologics Inc [Member]",
        "terseLabel": "AGC Biologics, Inc"
       }
      }
     },
     "localname": "AGCBiologicsIncMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_AccruedAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued and other current liabilities.",
        "label": "Accrued And Other Current Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccruedAndOtherCurrentLiabilities",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_AccruedClinicalExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical expenses current.",
        "label": "Accrued Clinical Expenses Current",
        "terseLabel": "Clinical"
       }
      }
     },
     "localname": "AccruedClinicalExpensesCurrent",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_AccruedManufacturingExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued manufacturing expenses current.",
        "label": "Accrued Manufacturing Expenses Current",
        "terseLabel": "Manufacturing"
       }
      }
     },
     "localname": "AccruedManufacturingExpensesCurrent",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses Policy [Text Block]",
        "terseLabel": "Accrued Research and Development Expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesPolicyTextBlock",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbio_AmendedAndRestatedLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and restated license agreement.",
        "label": "Amended And Restated License Agreement [Member]",
        "terseLabel": "Amended and Restated License Agreement"
       }
      }
     },
     "localname": "AmendedAndRestatedLicenseAgreementMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_BiogenCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen collaboration.",
        "label": "Biogen Collaboration [Member]",
        "terseLabel": "Biogen Collaboration"
       }
      }
     },
     "localname": "BiogenCollaborationMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_BiogenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen.",
        "label": "Biogen [Member]",
        "terseLabel": "Biogen"
       }
      }
     },
     "localname": "BiogenMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_CatalentIndianaLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Catalent Indiana, LLC.",
        "label": "Catalent Indiana L L C [Member]",
        "terseLabel": "Catalent Indiana, LLC."
       }
      }
     },
     "localname": "CatalentIndianaLLCMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right exercise price per warrant or right, issued.",
        "label": "Class Of Warrant Or Right Exercise Price Per Warrant Or Right Issued",
        "terseLabel": "Warrants Issued, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfWarrantActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "cbio_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, exercised during period.",
        "label": "Class Of Warrant Or Right Exercised During Period",
        "negatedLabel": "Number of Shares Underlying Warrants, Exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfWarrantActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "cbio_ClassOfWarrantOrRightForfeitedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, forfeited during period.",
        "label": "Class Of Warrant Or Right Forfeited During Period",
        "negatedLabel": "Number of Shares Underlying Warrants, Forfeited"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightForfeitedDuringPeriod",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfWarrantActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "cbio_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, warrants issued during period.",
        "label": "Class Of Warrant Or Right Warrants Issued During Period",
        "terseLabel": "Number of Shares Underlying Warrants, Issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWarrantsIssuedDuringPeriod",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfWarrantActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right weighted average exercise price per warrants or right exercised.",
        "label": "Class Of Warrant Or Right Weighted Average Exercise Price Per Warrants Or Right Exercised",
        "terseLabel": "Warrants Exercised, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfWarrantActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "cbio_ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right weighted average exercise price per warrants or right forfeited.",
        "label": "Class Of Warrant Or Right Weighted Average Exercise Price Per Warrants Or Right Forfeited",
        "terseLabel": "Warrants Forfeited, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfWarrantActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "cbio_ClinicalTrials": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trials.",
        "label": "Clinical Trials",
        "terseLabel": "Clinical trials"
       }
      }
     },
     "localname": "ClinicalTrials",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ClinicalTrialsPaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trials paid.",
        "label": "Clinical Trials Paid",
        "terseLabel": "Clinical trials paid"
       }
      }
     },
     "localname": "ClinicalTrialsPaid",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_CollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreements.",
        "label": "Collaboration Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAgreementsAbstract",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "xbrltype": "stringItemType"
    },
    "cbio_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue member.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration",
        "verboseLabel": "Collaboration"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_CommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestone payments.",
        "label": "Commercial Milestone Payments",
        "terseLabel": "Commercial milestone payments"
       }
      }
     },
     "localname": "CommercialMilestonePayments",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_CommitmentsAndContingenciesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "terseLabel": "Commitments And Contingencies Disclosure [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_CommitmentsAndContingenciesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "terseLabel": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_ConcentrationRiskCreditRiskPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk Credit Risk",
        "label": "Concentration Risk Credit Risk Policy [Text Block]",
        "terseLabel": "Concentration Risk Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRiskPolicyTextBlock",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbio_CostOfCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of collaboration.",
        "label": "Cost Of Collaboration [Member]",
        "terseLabel": "Cost of collaboration"
       }
      }
     },
     "localname": "CostOfCollaborationMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_CostOfCollaborationRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of collaboration revenue.",
        "label": "Cost Of Collaboration Revenue",
        "terseLabel": "Cost of collaboration revenue"
       }
      }
     },
     "localname": "CostOfCollaborationRevenue",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of license and collaboration revenue policy.",
        "label": "Cost Of License And Collaboration Revenue Policy [Text Block]",
        "terseLabel": "Cost of License and Collaboration Revenue"
       }
      }
     },
     "localname": "CostOfLicenseAndCollaborationRevenuePolicyTextBlock",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbio_CostOfLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of license member.",
        "label": "Cost Of License [Member]",
        "terseLabel": "Cost of license"
       }
      }
     },
     "localname": "CostOfLicenseMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_DalcinonacogAlfaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dalcinonacog alfa.",
        "label": "Dalcinonacog Alfa [Member]",
        "terseLabel": "Dalcinonacog alfa."
       }
      }
     },
     "localname": "DalcinonacogAlfaMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_DeferredTaxAssetsFixedAssetsAndIntangibles": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets fixed assets and intangibles.",
        "label": "Deferred Tax Assets Fixed Assets And Intangibles",
        "terseLabel": "Fixed and intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsFixedAssetsAndIntangibles",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets state net operating loss carry forwards.",
        "label": "Deferred Tax Assets State Net Operating Loss Carry Forwards",
        "terseLabel": "Net operating loss carryforward, derecognized"
       }
      }
     },
     "localname": "DeferredTaxAssetsStateNetOperatingLossCarryForwards",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_DevelopmentMilestonesPaymentReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones payment Receivable.",
        "label": "Development Milestones Payment Receivable",
        "terseLabel": "Development and sales milestone payments"
       }
      }
     },
     "localname": "DevelopmentMilestonesPaymentReceivable",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_EffectiveIncomeTaxRateReconciliationDerecognition": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation derecognition.",
        "label": "Effective Income Tax Rate Reconciliation Derecognition",
        "negatedLabel": "Derecognition due to Sec. 382 and 383 limitations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDerecognition",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation, permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Differences",
        "negatedLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "cbio_ExclusiveLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive license.",
        "label": "Exclusive License [Member]",
        "terseLabel": "Exclusive License",
        "verboseLabel": "Exclusive License"
       }
      }
     },
     "localname": "ExclusiveLicenseMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_FederalAgencySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal agency securities.",
        "label": "Federal Agency Securities [Member]",
        "terseLabel": "Federal Agency Securities"
       }
      }
     },
     "localname": "FederalAgencySecuritiesMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_FirmCommitmentUnderwrittenPublicOfferingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Firm commitment underwritten public offering shares.",
        "label": "Firm Commitment Underwritten Public Offering Shares",
        "terseLabel": "Firm commitment underwritten public offering shares"
       }
      }
     },
     "localname": "FirmCommitmentUnderwrittenPublicOfferingShares",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "cbio_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax.",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease in operating lease liability and right-of-use asset.",
        "label": "Increase Decrease In Operating Lease Liability And Right Of Use Asset",
        "terseLabel": "Operating lease liability and right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_InterestAndOtherIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and other income (expense), net.",
        "label": "Interest And Other Income Expense Net",
        "terseLabel": "Interest and other income, net",
        "totalLabel": "Total interest and other income, net"
       }
      }
     },
     "localname": "InterestAndOtherIncomeExpenseNet",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_IntravitrealAntiComplementFactor3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intravitreal anti-complement factor 3.",
        "label": "Intravitreal Anti Complement Factor3 [Member]",
        "terseLabel": "Intravitreal Anti-Complement Factor 3"
       }
      }
     },
     "localname": "IntravitrealAntiComplementFactor3Member",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_IsuAbxisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISU Abxis.",
        "label": "Isu Abxis [Member]",
        "terseLabel": "ISU Abxis"
       }
      }
     },
     "localname": "IsuAbxisMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_LesseeOperatingLeaseRenewalTermDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease renewal term description.",
        "label": "Lessee Operating Lease Renewal Term Description",
        "terseLabel": "Lessee operating lease renewal term description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTermDescription",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_LicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and Collaboration Agreement (the \u201cBiogen Agreement\u201d), .",
        "label": "License And Collaboration Agreement [Member]",
        "terseLabel": "License and Collaboration Agreement (the \u201cBiogen Agreement\u201d)"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_LicenseRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License revenue member.",
        "label": "License Revenue [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseRevenueMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_LiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity [Abstract]"
       }
      }
     },
     "localname": "LiquidityAbstract",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "xbrltype": "stringItemType"
    },
    "cbio_LongTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term investments.",
        "label": "Long Term Investments [Member]",
        "terseLabel": "Long Term Investments",
        "verboseLabel": "Long-Term Investments"
       }
      }
     },
     "localname": "LongTermInvestmentsMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marzeptacog alfa activated and dalcinonacog alfa.",
        "label": "Marzeptacog Alfa Activated And Dalcinonacog Alfa [Member]",
        "terseLabel": "Marzeptacog Alfa Activated and Dalcinonacog Alfa"
       }
      }
     },
     "localname": "MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_MaximumAmountOfTaxOffsetPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of tax offset per year.",
        "label": "Maximum Amount Of Tax Offset Per Year",
        "terseLabel": "Maximum amount of tax offset per year"
       }
      }
     },
     "localname": "MaximumAmountOfTaxOffsetPerYear",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_MilestoneContingentCashPaymentsObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone contingent cash payments obligation.",
        "label": "Milestone Contingent Cash Payments Obligation",
        "verboseLabel": "Contingent cash payments upon achievement of certain clinical, regulatory and commercial milestones"
       }
      }
     },
     "localname": "MilestoneContingentCashPaymentsObligation",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment .",
        "label": "Milestone Payment Related To Regulatory And Clinical Development Events",
        "terseLabel": "Milestone Payment Related To Regulatory And Clinical Development Events"
       }
      }
     },
     "localname": "MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_MilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_MosaicBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mosaic Biosciences, Inc.",
        "label": "Mosaic Biosciences Inc [Member]",
        "terseLabel": "Mosaic"
       }
      }
     },
     "localname": "MosaicBiosciencesIncMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from sale of common stock, after deducting underwriting commissions and offering expenses payable.",
        "label": "Net Proceeds From Sale Of Common Stock After Deducting Underwriting Commissions And Offering Expenses Payable",
        "terseLabel": "Net proceeds from sale of common stock after deducting underwriting commissions and offering expenses payable"
       }
      }
     },
     "localname": "NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash or part non cash right-of-use asset and operating lease liability recorded upon the adoption, net.",
        "label": "Non Cash Or Part Non Cash Right Of Use Asset And Operating Lease Liability Recorded Upon Adoption Net",
        "terseLabel": "Right-of-use asset and operating lease liability recorded upon the adoption of ASC 842"
       }
      }
     },
     "localname": "NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets obtained in exchange for operating lease liabilities.",
        "label": "Non Cash Or Part Non Cash Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "cbio_OperatingLossCarryforwardsWithIndefiniteLife": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards with indefinite life.",
        "label": "Operating Loss Carryforwards With Indefinite Life",
        "terseLabel": "Net operating loss carryforwards having indefinite life"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsWithIndefiniteLife",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock.",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options To Purchase Common Stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_PaymentsToAcquireShortTermAndLongInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to acquire short term and long investments.",
        "label": "Payments To Acquire Short Term And Long Investments",
        "negatedLabel": "Purchase of short-term and long-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermAndLongInvestments",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_PfizerIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Inc.",
        "label": "Pfizer Inc [Member]",
        "terseLabel": "Pfizer Inc"
       }
      }
     },
     "localname": "PfizerIncMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock for secondary public offering, net of issuance costs.",
        "label": "Proceeds From Issuance Of Common Stock For Public Offering Net Of Issuance Costs",
        "terseLabel": "Issuance of common stock for public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock from ESPP purchases and stock option exercises.",
        "label": "Proceeds From Issuance Of Common Stock From E S P P Purchases And Stock Option Exercises",
        "terseLabel": "Issuance of common stock from ESPP purchase and stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_RegulatoryAndDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory and development milestone payment.",
        "label": "Regulatory And Development Milestone Payment",
        "terseLabel": "Regulatory and development milestone payment"
       }
      }
     },
     "localname": "RegulatoryAndDevelopmentMilestonePayment",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services.",
        "label": "Reimbursable Out Of Pocket And Personnel Costs Incurred Related To Research Services [Member]",
        "terseLabel": "Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services"
       }
      }
     },
     "localname": "ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_RequiredMinimumTaxableIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum taxable income required to support realizing the company's.",
        "label": "Required Minimum Taxable Income",
        "terseLabel": "Required Minimum Taxable Income"
       }
      }
     },
     "localname": "RequiredMinimumTaxableIncome",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credit carry forwards derecognized.",
        "label": "Research And Development Tax Credit Carry Forwards Derecognized",
        "terseLabel": "Gross federal R&amp;D tax credit-related deferred tax assets derecognized"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ResearchServicesAgreementOptionToExtend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research services agreement option to extend.",
        "label": "Research Services Agreement Option To Extend",
        "terseLabel": "Research services option to extend"
       }
      }
     },
     "localname": "ResearchServicesAgreementOptionToExtend",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cbio_ResearchServicesAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research services.",
        "label": "Research Services Agreement Term",
        "terseLabel": "Research services"
       }
      }
     },
     "localname": "ResearchServicesAgreementTerm",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions Black-Scholes method used.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black-Scholes Method Used [Table]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Table]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Table]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedInPeriodIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options canceled and forfeited in period intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Canceled And Forfeited In Period Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options canceled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedInPeriodIntrinsicValue",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriodIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options expiration in period intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expiration In Period Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriodIntrinsicValue",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period from ESPP purchases and stock options exercised shares.",
        "label": "Stock Issued During Period From E S P P Purchases And Stock Options Exercised Shares",
        "terseLabel": "Issuance of common stock from ESPP purchases and stock option exercises, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period from ESPP purchases and stock options exercised value.",
        "label": "Stock Issued During Period From E S P P Purchases And Stock Options Exercised Value",
        "terseLabel": "Issuance of common stock from ESPP purchases and stock option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_StockholdersEquityDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders equity disclosure.",
        "label": "Stockholders Equity Disclosure [Line Items]",
        "terseLabel": "Stockholders Equity Disclosure [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityDisclosureLineItems",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_StockholdersEquityDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders equity disclosure.",
        "label": "Stockholders Equity Disclosure [Table]",
        "terseLabel": "Stockholders Equity Disclosure [Table]"
       }
      }
     },
     "localname": "StockholdersEquityDisclosureTable",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_SublicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense fee entitled to pay.",
        "label": "Sublicense Fee",
        "terseLabel": "Payment related to collaboration"
       }
      }
     },
     "localname": "SublicenseFee",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of present value assumptions of lease payments.",
        "label": "Summary Of Present Value Assumptions Of Lease Payments Table [Text Block]",
        "terseLabel": "Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments"
       }
      }
     },
     "localname": "SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbio_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_TotalTransactionExpensesRelatedToCollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total transaction expenses related to collaboration.",
        "label": "Total Transaction Expenses Related To Collaboration",
        "terseLabel": "Expenses related to collaboration"
       }
      }
     },
     "localname": "TotalTransactionExpensesRelatedToCollaboration",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer of Exclusive License and Related Know-How.",
        "label": "Transfer Of Exclusive License And Related Know How [Member]",
        "terseLabel": "Transfer of Exclusive License and Related Know-How"
       }
      }
     },
     "localname": "TransferOfExclusiveLicenseAndRelatedKnowHowMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen employee stock purchase plan.",
        "label": "Two Thousand Eighteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2018 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_TwoThousandEighteenOmnibusIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen omnibus incentive plan.",
        "label": "Two Thousand Eighteen Omnibus Incentive Plan [Member]",
        "terseLabel": "2018 Omnibus Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenOmnibusIncentivePlanMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_UnderwritersOverallotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters overallotment option.",
        "label": "Underwriters Overallotment Option [Member]",
        "terseLabel": "Underwriters' overallotment option"
       }
      }
     },
     "localname": "UnderwritersOverallotmentOptionMember",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_UnderwritingCommissionsAndOfferingExpensesPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting commissions and offering expenses payable.",
        "label": "Underwriting Commissions And Offering Expenses Payable",
        "terseLabel": "Underwriting discounts, commissions and offering expenses payable"
       }
      }
     },
     "localname": "UnderwritingCommissionsAndOfferingExpensesPayable",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_UnderwritingDiscountsAndOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts and offering expenses.",
        "label": "Underwriting Discounts And Offering Expenses",
        "terseLabel": "Underwriting discounts and offering expenses"
       }
      }
     },
     "localname": "UnderwritingDiscountsAndOfferingExpenses",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits increase (decrease) resulting from tax positions.",
        "label": "Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions",
        "terseLabel": "Increase/(Decrease) of unrecognized tax benefits taken in prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fee reveived from license and collaboration agreement.",
        "label": "Upfront Fee Reveived From License And Collaboration Agreement",
        "terseLabel": "Upfront license fee received from collaboration agreement"
       }
      }
     },
     "localname": "UpfrontFeeReveivedFromLicenseAndCollaborationAgreement",
     "nsuri": "http://www.catalystbiosciences.com/20201231",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r40",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r204",
      "r206",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r373",
      "r415",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r204",
      "r206",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r373",
      "r415",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r138",
      "r191",
      "r192",
      "r374",
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r138",
      "r191",
      "r192",
      "r374",
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r194",
      "r204",
      "r206",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r373",
      "r415",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r194",
      "r204",
      "r206",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r373",
      "r415",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Forecast [Member]",
        "terseLabel": "Scenario Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r184",
      "r205",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "CALIFORNIA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "AS 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]",
        "terseLabel": "Other Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureOtherAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r141",
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Gross Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r16",
      "r141",
      "r142"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10230.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r34"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r34"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Professional and consulting services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r43",
      "r44",
      "r45",
      "r407",
      "r425",
      "r429"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r42",
      "r45",
      "r46",
      "r82",
      "r83",
      "r84",
      "r293",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r243"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r240",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r88",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r273",
      "r274",
      "r275",
      "r276",
      "r376",
      "r377",
      "r378",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r207",
      "r209",
      "r246",
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r185",
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Issuance costs of issuance of common stock for public offering"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r209",
      "r233",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r77",
      "r127",
      "r130",
      "r136",
      "r157",
      "r289",
      "r294",
      "r306",
      "r392",
      "r406"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r39",
      "r77",
      "r157",
      "r289",
      "r294",
      "r306"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available For Sale Securities",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available For Sale Securities Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r145",
      "r147",
      "r169",
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Available-for-sale, debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r146",
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available For Sale Securities Debt Securities Current",
        "terseLabel": "Available-for-sale debt securities current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r146",
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Available For Sale Securities Debt Securities Noncurrent",
        "terseLabel": "Available-for-sale-debt securities noncurrent"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.",
        "label": "Available For Sale Securities Gross Realized Gain Loss Net",
        "terseLabel": "Material realized gains or losses on available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesGrossRealizedGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available For Sale Securities [Text Block]",
        "terseLabel": "Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r210",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r27",
      "r69"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10210.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r70",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash Cash Equivalents And Short Term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r63",
      "r69",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r63",
      "r307"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r75",
      "r77",
      "r98",
      "r99",
      "r100",
      "r103",
      "r105",
      "r111",
      "r112",
      "r113",
      "r157",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "periodEndLabel": "Warrants Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Warrants Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfWarrantActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Outstanding",
        "periodEndLabel": "Number of Shares Underlying Warrants, Outstanding",
        "periodStartLabel": "Number of Shares Underlying Warrants, Outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfWarrantActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r284",
      "r285",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r183",
      "r397",
      "r411"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "verboseLabel": "Common Stock, Capital Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value, 100,000,000 shares authorized; 22,097,820 and 12,040,835 shares issued and outstanding at December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r48",
      "r50",
      "r51",
      "r54",
      "r399",
      "r413"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r174",
      "r176",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software Intangible Asset [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation payments"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r56",
      "r374"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost Of Goods And Services Sold",
        "terseLabel": "Cost of license and collaboration"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Net deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r268",
      "r269",
      "r270"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Tax credit carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals",
        "terseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r67",
      "r126"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal Income Tax"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted",
        "verboseLabel": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r255",
      "r278"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "negatedLabel": "Tax at statutory federal rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r255",
      "r278"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r255",
      "r278"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r255",
      "r278"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "negatedLabel": "State Tax (benefit)\u2014net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r255",
      "r278"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits",
        "negatedLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Unrecognized employee stock based compensation expense, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized employee stock based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r86",
      "r93",
      "r95",
      "r110",
      "r161",
      "r185",
      "r187",
      "r240",
      "r241",
      "r242",
      "r275",
      "r276",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value Assets Measured On Recurring Basis [Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r298",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r299",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r195",
      "r196",
      "r201",
      "r203",
      "r299",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r195",
      "r196",
      "r201",
      "r203",
      "r299",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r299",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r72",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r151",
      "r152",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r177",
      "r178",
      "r375",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r174",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10070.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r256",
      "r262",
      "r267",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination Penalties And Interest Accrued",
        "terseLabel": "Tax-related penalties or interest recognized"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r72",
      "r253",
      "r254",
      "r262",
      "r263",
      "r266",
      "r271",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued compensation and other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncomeTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for interest and other income.",
        "label": "Interest And Other Income [Text Block]",
        "terseLabel": "Interest and Other Income, Net"
       }
      }
     },
     "localname": "InterestAndOtherIncomeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureInterestAndOtherIncomeNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail": {
       "order": 10010.0,
       "parentTag": "cbio_InterestAndOtherIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income Expense Nonoperating Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Debt And Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in CCYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeasePracticalExpedientsPackage": {
     "auth_ref": [
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.",
        "label": "Lease Practical Expedients Package",
        "terseLabel": "Lease practical expedients"
       }
      }
     },
     "localname": "LeasePracticalExpedientsPackage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease that has not yet commenced. Including, but not limited to, nature of involvement with construction or design of underlying asset for lease.",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Description",
        "terseLabel": "Operating lease not yet commenced description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "terseLabel": "Total undiscounted lease payments",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Operating lease term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r77",
      "r131",
      "r157",
      "r290",
      "r294",
      "r295",
      "r306"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r77",
      "r157",
      "r306",
      "r393",
      "r409"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r77",
      "r157",
      "r290",
      "r294",
      "r295",
      "r306"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as current.",
        "label": "Liability For Uncertain Tax Positions Current",
        "verboseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiquidationBasisOfAccountingTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the liquidation basis of accounting.",
        "label": "Liquidation Basis Of Accounting [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidationBasisOfAccountingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r114",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNatureOfOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash flows provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash flows provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r63",
      "r65",
      "r68"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash flows used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r47",
      "r49",
      "r53",
      "r68",
      "r77",
      "r85",
      "r89",
      "r90",
      "r91",
      "r92",
      "r94",
      "r95",
      "r101",
      "r127",
      "r129",
      "r132",
      "r135",
      "r137",
      "r157",
      "r306",
      "r398",
      "r412"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92",
      "r96",
      "r97",
      "r102",
      "r105",
      "r127",
      "r129",
      "r132",
      "r135",
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Basic",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Accounting Pronouncements Recently Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing And Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-Cash Investing and Financing Activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10040.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r127",
      "r129",
      "r132",
      "r135",
      "r137"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Total operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liability, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r321",
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Cash paid for leases that were included in operating cash outflows"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r326",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r34"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other accrued liabilities",
        "totalLabel": "Total other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets, noncurrent"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Change [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r41",
      "r43"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized (loss) gain on available-for-sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income And Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail": {
       "order": 10030.0,
       "parentTag": "cbio_InterestAndOtherIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail": {
       "order": 10020.0,
       "parentTag": "cbio_InterestAndOtherIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Miscellaneous income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Other Research And Development Expense",
        "terseLabel": "Other Research and Development Expense"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "Overallotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments To Acquire Investments",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r210",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 shares authorized; zero shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10240.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds From Issuance Or Sale Of Equity",
        "terseLabel": "Proceeds from Issuance"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds From License Fees Received",
        "terseLabel": "Up-front payments received"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds From Sale Maturity And Collection Of Shortterm Investments",
        "terseLabel": "Proceeds from maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r47",
      "r49",
      "r62",
      "r77",
      "r85",
      "r94",
      "r95",
      "r127",
      "r129",
      "r132",
      "r135",
      "r137",
      "r157",
      "r288",
      "r291",
      "r292",
      "r296",
      "r297",
      "r306",
      "r400"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r180",
      "r410"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r29",
      "r72",
      "r180",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r23",
      "r72",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables Trade And Other Accounts Receivable Allowance For Doubtful Accounts Policy",
        "terseLabel": "Accounts Receivable, net and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r202",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction Expenses From Transactions With Related Party",
        "terseLabel": "Expenses related to collaboration"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r202",
      "r333",
      "r336",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r331",
      "r332",
      "r334",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r249",
      "r448"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r72",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r187",
      "r243",
      "r408",
      "r424",
      "r429"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r86",
      "r93",
      "r95",
      "r161",
      "r240",
      "r241",
      "r242",
      "r275",
      "r276",
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r124",
      "r125",
      "r128",
      "r133",
      "r134",
      "r138",
      "r139",
      "r140",
      "r190",
      "r191",
      "r374"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10030.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "License and collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Recognition Multiple Deliverable Arrangements [Line Items]",
        "terseLabel": "Revenue Recognition Multiple Deliverable Arrangements [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.",
        "label": "Revenue Recognition Multiple Deliverable Arrangements [Table]",
        "terseLabel": "Revenue Recognition Multiple Deliverable Arrangements [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Sale of stock price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Other Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureOtherAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Anti-dilutive Security not Included In Diluted per Share Calculations"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r149",
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule Of Available For Sale Securities [Table]",
        "terseLabel": "Schedule Of Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule Of Cash Flow Supplemental Disclosures Table [Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Components of the Company's Deferred Tax Assets (Liabilities)"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Basic and Diluted Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Reconciliation of Federal Income Tax Rate to Company's Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r209",
      "r232",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r209",
      "r232",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule Of Other Nonoperating Income Expense Table [Text Block]",
        "terseLabel": "Detail of Interest and Other Income, Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureInterestAndOtherIncomeNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r78",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r210",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r214",
      "r221",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Option Activity Under Company's Equity Incentive Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r188",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]",
        "terseLabel": "Summary of Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r261",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Additional General Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee subscription rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Number of common stock authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Shares available to be granted - December 31, 2020",
        "verboseLabel": "Number of common stock available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Exercisable- December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercisable - December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r216",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Shares Underlying Outstanding Options, Ending Balance",
        "periodStartLabel": "Number of Shares Underlying Outstanding Options, Beginning Balance",
        "terseLabel": "Shares remaining outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease",
        "verboseLabel": "Increase in number of shares of common stock reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward",
        "terseLabel": "Number of Shares Underlying Outstanding Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted- Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period",
        "terseLabel": "Number of common stock stock issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r208",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r72",
      "r210",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Common stock price, per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r227",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "verboseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable - December 31, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable - December 31, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Outstanding Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Percentage of fair market value of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r12",
      "r394",
      "r395",
      "r405"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10220.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r441",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short Term Investments [Member]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State Income Tax"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r75",
      "r77",
      "r98",
      "r99",
      "r100",
      "r103",
      "r105",
      "r111",
      "r112",
      "r113",
      "r157",
      "r185",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r38",
      "r82",
      "r83",
      "r84",
      "r86",
      "r93",
      "r95",
      "r110",
      "r161",
      "r185",
      "r187",
      "r240",
      "r241",
      "r242",
      "r275",
      "r276",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r110",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period Shares Issued For Services",
        "terseLabel": "Number of shares of common stock issued to certain board members in lieu of cash compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r185",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock for public offering, net of issuance costs, shares",
        "verboseLabel": "Issuance of stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r185",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Shares Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r185",
      "r187",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r185",
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock for public offering, net of issuance costs of $4,559"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r20",
      "r21",
      "r77",
      "r144",
      "r157",
      "r306"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r187",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r314",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r339",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Tax credit carryforwards available to offset future federal tax liabilities"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardExpirationDate": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of the tax credit carryforward, in CCYY-MM-DD format.",
        "label": "Tax Credit Carryforward Expiration Date",
        "terseLabel": "Credit carryforward, expire period"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r151",
      "r152",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r88",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r273",
      "r274",
      "r275",
      "r276",
      "r376",
      "r377",
      "r378",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r195",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "U S Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency Securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r195",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "U S Government Sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Federal Agency Securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r252",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Unrecognized tax benefit"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Increase/(Decrease) of unrecognized tax benefits related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves.",
        "label": "Valuation Allowances And Reserves Period Increase Decrease",
        "terseLabel": "Increase (decrease) in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants And Rights Note Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Shares used to compute net loss per share attributable to common stockholders, basic and diluted",
        "verboseLabel": "Weighted-average number of shares used in computing net loss per share, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetail",
      "http://www.catalystbiosciences.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=35686142"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5144-111524"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r449": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r450": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r451": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r452": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r453": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r454": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r455": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r456": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0001564590-21-010823-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-010823-xbrl.zip
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M1W$3K0'('U(9(-/C@V^AP1/V'=A9NE_4M(8-0T,!!5S\BX\B9OM]T(U[S/H
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M5\ 3N) VNM& R8@+99U(9#\J4%_KU)0V2[_/8M21X85OGFEV.:M]T\ZWCS+
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MCN#8IT/VUOQIKUZ_T 0GDX9(+< QVU,95E7#;(6YU:2'@&*Q5,VPCZ(%M5#
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MT?A$^M4&[.(JX53H/!6TII(5'1LL28HJX6=(B/F88)E)'89FT+&L$"@"G@D
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M-!_9B ;"()L;#O)*SA!IJ8,5,1" '76R#,4:5>74\*E"#RJR*:VNW(J*6#1
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MRKE<%OL;AIQJ[9&[G)*5=>]@:B<<RG!^E7PF/.U24.CI >X0^<S5^=V RG5
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MQ+H%%9FES"*&$YUMM!X+3SI,M19.NA^(U%R(H-'E[G LV=8AK=Y-^0,9O:)
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MW]7:I0A4]"8"COXMD''9K,2>X]I]I<SZE01='XF42[[\U>&77__E&[+(5^X
M8 V:[#7-XK-M]BC&?Z-=]N5M5SF.Z]]ZQ><0  >Z3G^[E>7SJSIWR/H\.GSR
MQ5U8GQN,O5,2;25=+YKT;UK&(?/R5A=EXL:*49 7/BW&;R\;KO@\B*?PAT^G
MOIF+BS?[OI[R9">W[,?@WM%/!T"'J='%J5?.JDL7*0]=2Y3+4#UB5 GC0<@P
M##;"%&9<Q)4,2_HIK]IA?U??0U/Y0:0JQ\>'7SS^2Z)>#D0$A"7^<M-[_!-*
M^5OKTC^IE/]5Z[.7\G=,RM_M4_Z[2WEAX.N5$#TP0)X6*$4H;@;?(*10*&A8
M$)("* A)(OQU+\?W<GPOQ_=R?"_'?V\Y?C*Y0GWQZ>/102A%9J$L/*@:?!X@
M&0&'P""7RJ\3WK=D@A<QEPAO^=,GC/-P>K!=%6W9[N,\N^ !?WK-L8_SW ?-
M<;=/^1_E 02&//X'1W(\ 5EA*/M':NU;(C I,I/NDP(9WEO^=T)^WVV;Z-/+
M[[WE?Q_D]]T^Y;^S_'[^;@G)/6#!LU!^632_G* @-:[SKB96T/W["NHO#A\]
MV6[E[P7UCASAO:#>"^J]H/Z-@OK4;&N>AL= !:PR2K,^?M#E[L!HOH]9TV[,
M_PJ_ ?281JYZJ>?5/CQS]QW73Z\U]N&9^Z U[O8I_YVUQ@M +^M*Z$(\Y";B
M_29+WT@A2):2?(7I/UI'\%<TOP5=-%-W-9M-0&ZI=O8B]HX=OKV(W8O8O8C]
MK1$4M4"'T?)"VAI3X"G5G8=%QM&4;"](=_*([07I7I#N!>EO%*0_KE!'&4C?
MH]YB(C,CX:JTH,I371OK48@!C%SEIN7JMA'JO4B]8X=M+U+W(G4O4G^C2-6"
M9.V+83'12(PJ>\>4F9X]D,_WXMC+SMT\57O9N9>=>]GY&V6G,K+WFOVPO R-
M-_.XZ^;%?]_0>/-#LW&[1'V1-(UK/PKYA0Q%^0]_VZQ^=7<-P;Z\MS?/)B(R
M>WAT))WV/'V9XFA(Q?ZT=G2$SF<%_7B,4U4PS^Y9-3[TA%[XCA%Z'>I/0.C<
MC5HY>=SF:JSL6:-U)K2#O<?('STQ&!-E,,$"LW\I"_UMVEL(N:E".X5.0NNT
MLK-_:J%6=MXU;<=\/MHY-7V8O35Y,-K&N7?<9>PR-"%H>+.D"YKVB9991.1O
M6%D\1FC9B[=,,KY>@-^3_J _ '$H?8^^> F *OH29XZ9LM$R#FRV_W[\U>$7
MS!\X!WDZ/0<62[>LA:%"_4K#0QE.*H];I:7-#_EAKEW1P4)C>NO6.]@=D8E%
MT5O%^49?N8U?FDPJ*1*HGSWS\\&DO"RYU>:ZF#.98)55;N6IP-L"+;&E/0!-
MN5D?C-8'^I],/U0*#0=XZ+@O&M.QV+-XJ] V,N*0.WZ")5\6Y<0&5]#"'1[9
MNH4IVT9DPD^BBQCXB@//K;5Z!\63\D'>S QTSRC/OKA7E&?O%>)_F-B^37.F
M/V(< .3<QM"X?1>GGV+!:LQDOM]'Q"[]HPG]W#>_1;.X'KI3,$/9CY7T)^Z+
M[4A4\TO(U&'YHJI#KNQ9OWE@X"3GI''1&@-9.=)FQJ T2DA+E5*UC!C"3,&D
M#]]4,]$("\EE3X1-,FYZ^T2&SYV"JU6YFBM3&UHQ#,I3E6'YS3)4N)P&!*^M
M #<OI3&>"ED64U,Q&6TQG3*#Y$I:.(%DUAXKM79@';^H.]K:?]0D# YM]% %
M?@JFOKX.Z@ML&WU)S!U IDI(^^\/HR\78 )/E%A\/#8?) 2T7FL>Q:\=4G_^
MA_>AD6/4Q_C]S1IA FJSY6"H1%<WZ:<<H=7Z;9335MFHQV0.,YR3J%.XXC3X
M/$8<QG%QC34]"R6=49OBGW@\W # -0B=QX39_(-MUU4HB746>,+(96T]U[:Y
MR;7G7JRA#_CMGJ]MQ# HH?V..K70;YGP#4E7+_A^\#2X!X"U],=[S=RPU^7$
M#0+>\^$VULHRZ[MO_/OQ%]'A[Y;3ID9O8S%\P$RL:\+DLC0WS\1KQ,*.C)A2
M03=FV^G%>O3X*+U90Q>Z8+HT92HO83R*Z#(1&J;)XLF+)?39W>S_)6]&&_2Z
M&YDT?-^M_="^DI^*1AI2<U-KOJS;HASS1K5H"^R"^I2/8C[E?K=SY4T^3>JA
MTU5M(\Z+Z [?2MEN5V4D4G3@R85EG:K-BYE: RT<H6O)C'_S7+D"I\ZE"K2(
MW$EYH3:^)&]UK>U(]&W1Z:?5/@ _\;AH9_[4TXK\^]'ADZ!<N+MX>]-!?YP>
M\ZAIATQD0/],06B:NEU#=2O! 8MZ!O@V&[V-[ O8(BEU$<[4&_;9>XRL!'E%
M:OC*"X"SZ_%;HW=5*\#WS91^F"Q<3M#V$..$PJCH(G+;)I[ZC*0F?$,22%8F
M&?;:%E]ZG?-DY^+9PSAJW<"IO+'5SF[%G!9+M\(V[3#;ZBNA->N+#ESN*??%
M'(=I1NWVKGH8]L/L-/Z>-O<>.*OE4JB'N9M[&_51P:/GW"0H!_OQ@6-:XWG9
MSOCP);$J)7\5=3JK!>!DS?VF9554L *YZ5W7C%6)NW?@1)5F]8$D/S4Y\]00
MR,WA0/0D<034\D"OEI7V&)55">W27CJ:C9)8(%+6EMJDC\2_RO3>S- \I*RC
M-@-T2#JZ7:Q7F<9^*BW8I!%Z)<T3;8?JQG>X\W/WK*S<2::NN/>M?-MK;UQ3
MOZ+0-:Y9B+:. EZC;B6*#,LW;KIR9=V2&F<4^6@!AZZS4&FTW&JST[(:KI>V
MH:VKRLTE^F:[K V^5A5]/"N7&N?NN7;<RTA7GG];-:2_Q"P+++XI'8ALUF]O
M[_4);^A94 >PX:4E!!HZ3+3SQ*GP[B9TQGE_$815V6&A60=+V!9=WPIMO>4\
M+2YMXAR/IM-(!X 3#[KJ?*_1!#E!#;Z)I7W;[V?,)U<;_?KV(J%QFT]@C+7%
MB+@'!I\1%*.=87T,QAZZ8\@]3.F($ZU&?U\GPV .:&XZ652K5,3!:%E'C2GZ
MHA'F+9Q94I7U"!'BOAS@2,%3BS\NR:0MQQPNORK*N:IJWXE..BE.?906*'EN
M2Z6Q2K^F42\0>Z&03?.O0LO-T3H6"&A4%#8*Y--S&F-T_Y487V<KW7EVI"+I
MB\.'C]^?-GZ_@?%QK^SOF2B_'9#@EC/6,?Z?WB#_S^\MT3:C%Y]L)%O#GH/.
MXL;X>/_(2?ORFP_,@=_I([D5G["E.9QOY/;/L[,BM@/_IJN2_2G0.^\U^G='
MRMP.CG.[">^%S!T0,G?N0)[TW:4_A8BX1]"G/<!O#_#; _Q^(\#OA_JJSGX@
M.52V;WU<EO]XP;V"L]=OD'2MDC;KC=/^B>2XQG:7>GG6)RM.O?FN?FY9MO7$
M>:\PZ7P4]18\8<?RJ4*S^:NS<L3N),<?PCO/^%M12]HP<,ZZ^X 8O>OXZZ^_
M]NEX_T$!![WFH+@CFY&6KVM2<A%-A\0KHDD1?NK#HZ,GTIDLS)8;J;8E$\F.
M''W?OPL120Y*+)!"EC#@QA*$N66,2D):1J+\W\Z+ZA?Z;:4-G8N6?/.J+"0P
MQH$)I#Y#+_##[&SE4^;),-ZS-9IQ+ ]J+ GG*Z+H&6BPNOE*!WQB +RP>1\*
M^;QGF*8O=P_3M.>,O -46W\BPVE/178?#*>[?<I_9\-).M=[D^G%\[.G)]"V
M7'W;+@H%'' @O):L&Z#34>_&*51]VS.;8D.KK@[47-!*7ZCV\:H<F_VP02!\
M6YO*&U2,S\;8V6Z!Q:)X98WO\Y@6=>,$DO?H*%N[HMES$^_US%[/[/7,7L_\
M[GKF=3V>.:]F2)K/RU%39 ^8PJS\I5L4HX.W[ZYGG^>D>49ENW1CSBD'I[@X
MT/_\%XGQJA[//:2+6^BRQDKU#PU^Q>B8B_^.?<G(ZP/BC!3*I '@M:]BM)@Z
M]M&]KCG,GOM11W ZS5<'=-J+9R?B71]_E?QD3-XO^;E0>.JNTE3-@=WKI+U.
MVNNDO4[:ZZ3?6R=]]_SE":/&!99EB+^+Y_]\_L.+D].[$#)F@!3];\V0P5M&
MCY-P,0._[Z(^V2NOO?*Z3\IK$PEQ#U381Y_4)T)OW*.;\[LW !L"2#/>M@\R
MR3W<N584?8"]6ZE4G)/-/:O%MZ[Z9;UP 9XL<&J%W?+OF'OETA<);80&WZ\J
M0U"0_QI]?R-HF'6ML&#P1KG5.L'JE^[/13AXEU%.>]C=IQS)'G9WLR2.Q_$^
M:"]9Z#&PU_@BLJ>N<B_._I6CU&+#RZ!?W>!CW.1./,V'0"1?656GK_?PQ$-@
MC#$UD&<G<_KAO'R7AVC8V;\.7HRS*<E.KLG0NH[^2QX>'3\>>LE%4=73,CNY
M0E43OG%Q31Y2.\M>-4M.SI!'=E6NFF[AJW@O7CT]BVMXGW=-O71Y]KIK6T:.
MD))A",>TH07"$UEIO"PG$Q*]SXMV15.:N/D5YA//HIB/N@4]KS>5>+BG%]_3
MULQ0S9Y,41DA0HSOR_ 6>(XQ4N7:N;=,V2'<.:B,F=1SUXX]%T,4E1R5!_I]
MKM;)9G2LN,:?JTM$(?)_M<7"&>\.*=TI2OVX &C%I5R!KJ=N2KHT*.*[I#-=
M>33-P/"X=->>^!__1O+V^*&DR5"K>ND.LT&8U>5\/:;MN%RC8O4@G%A;S]>.
M#O.Z(AG^U>-OWK.*7P$&1 /D".EP2+<7S^7?_WAX<6BOV9A=2#^&2R/D %BL
M+>"A5E:4_O?<->4@A"CZX>'>0MA;"'L+86\A?!P+@9PDIXWGUX/FPD^DW-$]
MK;&BY"%O+3SPDA^XT@=Z,2@>5FHLF%\7E8;W_+/W/Y7Y$ZQD5MO:_3D$Y#T"
M;'_Z(-W'+DO8!^GN2Y#N;M^<WSE(MW6';E8O&Y3(RB(V4&5ZX^NSVZF>GHY1
MSK(!]=+7+N,UJ8YQMG3+53EA&H/EBER=)@]8#WI<HG@$H?A>=I\MX41C4_/<
M"&$R VKL;W<PF?8G5)UW.TK_Z57G'IRQ!V?LN)H[69)HX@A/&W-'K:YK)91]
M9")9Z#A)FS323MIH<1#C$68<B9$RC*-DV3_/3LZ_/WCH%0A"INVL6-"7?A8J
MMS8)AA67I&"^5,RX9*[FS/R''WY[0DJ-A\C4D#06J#FAM:&QM^.9FW3*4SMR
MQKWNX1G'=Q&>L=<H=^RN[37*7J/L-<IO13>0YR$TL=D#GHEC%O57R]EJ!IK
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M45GZ\.A3@>CKP-=I9?R"RU6W=FGQXC):SF0-;BX,O[V8D!M0DHU0CG_CC?J
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M&>,M+*Q*#3GUK_']@@T]/+K[L*';2]!/N)!WA6_)I"[\&:NBQ072ZY;*/U0
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MRGE:=%S\/Y603$F?4ND@%)\M7]EIUTH.17$I@S2K0O$Q:8IK@1!Y& NV+9Q
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MUC]"/' I(I< +1;.HB>T-FJS@X#QE\*3%#-5M;"!:N&6:Q:M_UZ?"-72EDI
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MM=[Z2Z/HZ#G:(+%# Q[4':\,[0*J+G/!)82> J[)LU8B5%$TODD9Q\> *)3
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M,R%'^_!\%LKD85;6UU2K? >HX/.D,X%;<(X<+<3P?-#P&SE1.DFS1B(7CMT
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M@CAC(29G_'Y_B'SW)$/JC(HVA"S)-B4?J6@\D[#/\P:B,2'*&V!KI6M$1_-
M*'\L_/!3PT6$%?)[)*PLERRT8@#,X7D[?6B?.?-143X8X/QYP((B<Z!5KAX
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MG43T(%1;.DR<KM"P=*POA'2,I=[FTU4M7-;U;O=;8?4E?,0&MTJG*60\Q@7
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MPV_=^)",!;%3>MS5')=$7+Z44$3@WZ0'>HXS_\#&&6&'R8<)N.!R+X?XXXC
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M-3]?J]&&E#9&@T4C?MYD3:ZR</CAK4DJN2=K<HTGYR*MR5=Y53PP*G%.]H1
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M%VMFE-U6BQED Y ^$8P 6QW2RV!N]D)_R*B5$&:T!?,H6@ <#W<C]WY.87^
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MXP[!^O.!DY])N<.6#3*)N\8]I'MA'K!RCMS0'-RSC9$$'.M0O$042IX-H8B
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MWH3GG2)&62*])1P 6M85378+X1C-EHQX'V7$V0S0R@!LO;F9B4@<U3$LO#*
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M-&PQ^_S1U>CU!!O#3[EORP/:%LH.PC\ZMCGX<.A@AF/Z)$/D1W%B3Y$JRMK
MJ0@@@5\-=?BW946\OB6*(%)AXQ_AE%3X<^OV55XP8HB(0\MV*K*M^!6!4UI:
MI 6/^W-RE0Y9W>$%=[+U*#(!VPB^.C#$@?K3F4%R(""7^ Z:K(UD=D8Z=<J#
MS2$6W0@B8"17\)$=W+3WB&,4T'C@#Q(-#GR43OC,E+P.R'MRL>IX0V/EZ%5:
MIC14L#Q2CPIT[_")02B'/6[YV)B4&BA,^A FP-)EGEUBX_],!+9C%"."Y<EW
M2O&LOOX",=T8,2<$.@30YN&,,"8EF:3?J_42+ 8]74Q1[6X'#><GQT88WA>W
M.H:TJQKL'H)?$2DXI230J.H:X:'UG!$C14O7F[J83F.A+]XY1P>>.?ANQ\C^
MI' G*JV"/K<LF]X5VQJAUHX"1WC,5,W2/J 2/+I^ 0$PRNEH0\A?&1QC7\7[
M5CN_Q(CLDH.O@[A-DYL''W@8-DB^_NJCCUY9^V>N IKV7__PV?VKQ0YA-63+
M__4/?S"_T;TD@*@%*H35XBL'%@'34I]\G,'E7WU$WWOU$9HVV/&]5Y2+![K'
MR><S7HN5.'&# C(S)@PAU?SK)Q]_>O\G?8P;4KDB.%U?,DH,^2&(K3@-'#EO
M#5FH1*(,T(I"KZP)=TD1P19=7KG[Q=L&X0]=YH61E2.F=&+%">X+K"FLCP<_
M*[MN8*.+?CLH6_X);]%@=K@I'C,%4V0_R+L.\L$:LT>,OL3],RCZ_#W2T_3=
M_,C?X.1$0)DB\=RTCB]X(A W5IW]X_559Z_P+)XI;'Q8#4%'$[1 @UIQ!ZZ)
MJH$):$8TQ7.(C^<R)U%<934.!CL'BK/)!@DXX;/&7_TF]LI8DR#:K9B: Q.T
M@_GY900[B&GA)S>!$3=2@PJ*^2SR:H#+O%]\%]1:>!AT6M<5?(D#CRC>)2T$
M$4G;<^)+?\1KDK6%W^%_:6W>S3V*5DB\3]J9\?-%$(W3BR;.[]"&JSZQ11&G
M-LH98@A&[ARN])]--32U/%QBR3:U/*26A]3R<.DM#R\T6,$:I:;PJY2FI(V3
M-D[:^&JTL8UQHK"&D$DVME5II*\MVOX+D=>32K]*D4PJ/:GTI-(O7:6OF<''
MUP_CSBQA1B+NC?F.AJ2@KU+ DH)."CHIZ$M7T'G?X_B[<$-1.T_W6%;8%KIW
M;8?MVA5LQN>?)@U\=1*4-'#2P$D#7[H&[IQ[C!BHB!$+.1)I[-W3DVD[['QO
M)?5RC@EVB1-T,6ZV3RK].D4RJ?2DTI-*OW25GA<\FTNC8'=*U1MQIYU0N6G'
M:5+.5RM<23DGY9R4\Z4KYUW^Z+ IW76]H"6(8GY9VW*FW,Y&LX>_ZB 6]2\G
M/7Z=<ICT>-+C28]?OAYGUG <$,>!K5Y'_[3W U$8JLIABSB"O&*+=G]<[)NV
M7S=5V23M?)W2E;1STLY).U^Z=L81EMY91*ZR7K=YU[>#C/@SR 1HXVC8&_ZW
MV ]+\*QU\M;W\FGF9-P1N*_RNL9I29I/-@.3Y7^S\R[P(*SP7X 7FY3^Q0EM
M4OI)Z2>E?^E*WX#@H.(6(!R?8<'Q<QIR[+=:R60<\.;@?@-HH6^FX0\UB;2!
MB\@,ZM A-M'W:WB4EN;\*<$D*#F/.F>[(:C-O-N&U!5\@+]%Z$.8MH(O;L@0
M[V"_^P4"]51TBSW^_[]^_,?[/RA"0X;7(?LF8#$(FK0MP=IJ=[U6D;-QO=J
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M";?'(6@@H,XY]]<[S',VE2L&\N!\HGUNA4UL5M:DU@_E:L!3\;1M?/,L\O"
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MB?_:JBL?&GW][4/,1\\))U>W8(Z"NA?5R>1C7->4QDW.(H:\X7X@=Y3*HL@
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MF=;M0[=?0#?CIY#.A*GGS,8-+,9ELZ^@)&AA$>\7_Z%3DS%1^-A FJ6B")@
MY\WRC1G)QTYC,,@EM\=DE!1$W85*B&#9SVR4CVA-BY3IA(JG9E:'LFM:/^ :
MD(*P/0N=A/#P#COIG?>@-ZWF&<?/H@$[=0:A&HA6"UM5#2;N?GOLN!L$)]\C
M<#BW*SW I'Z*:BPH1VU3P_./OQ2U3X5E%> M>*LM*#F?%-$'+S2[$4\Q9*,Y
M8_+0^4J977#B%)#G\% ZHJ'0AN*(9U34"3A;FEQA*!X9",82*W]O9!U..>KQ
M:B%;M73HB2U\0PEU[?J9)\XS&KE6K8G[?3O*\:'"WM@-F6DI<5'^<=Q[*Y+K
M&P2QU-FA)RW>#Y-:< "#S6J\@U.7&AVOZ$Q1[VX,H;1M(I#O$&^^FZYJ6",\
MIPY(]8.&(K6LW88XK=!);DO+L%4E^=0@V($=>C54.B+)/J,?]H[E,:AS^T31
MR]E7LM!PVC(8+F_D,WPR2/LFYZ%GLXCQPU ,&(D_FXQY@ S[;*2Y<+U+#,6I
M6Y1\1'@1OQ]1=Z,MJ:\G'N<D/KKQ,NB?KK0,.KVP%Z/?+G,(T4X#^Y8ZG21Y
MQ[3YX@0:B^;X>K?O?/8^;G<8*2&DL44=MB)L6C:Q/FR0P-D,LV!! ?L.?;_B
M*4;'+CK\TCQH[SJVU)R?X=K'E 6>T9TSBO+V!OA\<+XF!!S*A74TD2E=9:$G
MU.=$ZJE\!MH :IB3W)YBDPDLQ>*I:4'K>MH2;;/F=+KOUK%CGF=R^8@/C!Y6
MN!O<!N<S)C*0$A54:)Y""SH8-LVJ3N4M)[!%N/E6X'I/4ID>Y74B-).'E@BQ
MRW>.'Z0W3,[T6^G;DDJJWG#BX2)\/SE/(:\257?;!J*_G<ZI:M]RO+/SZPT2
MO'UN/($*UB=E&LTT>F43FV7*E#3U'0L5DUP]7PSP?I>,+HS0="37@9DU#!X7
MFR$GG%L7-U=)4E-ZIGU:OG)S(?E<9<@ADG95=EM&C1%%F$>0#*!CX1%D:BG4
MC.:)><Z1\LQT%="+3S06W$R/]%O;-,#U"!INF!(9;$XH97""('JDA.!;S84D
M#ZG]J(WB"<?+Z!]Q;AXWW.?Y6\7/&]J3.>]30#P9J+R=NN!W0XQZ.T)TD?P(
MS30?FG+%Z1&[#W%:?6QB14/2I\R)IE(6G^:Y9E)L+MD(+!0I*\RZ"$C,K$W(
M)#,5K)H)F)XS/"^J, :<%=O4K2E@NS(Z"9)Q9_$:WK<FR*UFK_Z;#B#VE,EN
M4?M":/B+9S#C3)7#6V!M$&T3O_./W[_]+M/><,8.6PEL,EDO>1[IOKI?_*=R
M'?_M_L=[5BKRR5%AD-XX<@NB^H@J-[0(>+RD2SO2U81:J^M)!5G#32W69 _>
MX(#WB)FZ0B'XH7O7[4!7@_,!*QZ7]J]$<H9OF84!2.65ZD*</8]Q94;=K(Z:
M.P6S0G\[SN5I;9Q'B7@UXVXQ</T&IL%B2IU96']=T2X4:;":OQ1S/A(SD_:F
M*5?*%8DI*&?3OSK7K5D%&69C;23;;1O9GBL7VCHZ5TG\T:9I^IX:_-0+X KP
M3CO<<?(>'F.ED_>>]XU W?@O!%.)U3EA8/1>$RZRK&OTU7E*AR\=3_9-O0CZ
MTC1U1T ;7+H*!<O>+H\ANIM7%*'0C _<SG<B/'?\5"@BBR$W9-GWCZ'>K*JX
MKP?4\4'WV'X';L+(J8=>*$9#+D[J=#\Y ^,H4<!20!RYV9\OF'ME@^ZC OR!
MK EUB2SBDW([TCJ'8%='[4B ;(=)V8X[2W+&RM?.$P^^176$_"D7*/HP3Q*M
M<GA!V8-9]U]6+GQ+WM2(WS=4QEC\UYLW%NE(EX>^*>NZ:KBS@CQTW4[RTND]
M]-K$# .+JK6@VU&6NDE^?T;R*Q4U&H3OQN=C:H^RQ0,:/5B]/%N\Z=H<48R^
MS;'FCK_!%_O?#OXIUO#_S<$P9I%ICXXJW$(VG&:Y\CI?Y;;7J)O_JB5>F#M>
MQ$.#! HL.]_\+T.\X ^[.=YP*+!$TX;!&94J36!WWB*S@@T4?[D]08VQR887
MR1Y=22$LP1-8^=*_#AKG,?"3P@W@\_N**3XO^C)NY<\WY=,\_Q&7+@A@XKDC
M;Q[LAJ1_##Y&^J2%Y2D1>3\J8IS)STWT,OF"'YM^6U>D$A"I7PSSL-FB\HAC
MJX7VGX^\2S3Q,Q!4OLUZTAGT)FRZ7C6JDM@BL*9*/;T7PSN$"LP@U9I0NHD6
M+"I>3</*2ON/?S0!*R(_)$SE8SWZKS[@TE<-)%XT^X=))9/!I1F_:6F]L3K+
MYS=59[E417&999?O?8SSR- :[/(%W 5J$.#YT[+^^U S!D68XODY8!B"%5M;
M+ [;=[ZL")\L[K\+M!Y<5AWGI&(:@_G(:J@I24XM2MS,2MX?N6*&9+U;_"ZT
M*"^=F:WY/;V0PHQ@VQSU1$H37A_ST*G78"ZFZ57M;ULTEBRE(F>A:^HIP+S?
M9UP'[LLJ<A"E=^TEA9MK2H@&0V,)>#VJB&UR"N,1)KEY.YG)UZ8YP4:"T=LN
MWGJ<O)/\<-0[ )942<P8BL\ 54W-@6,,&%\Q:I=GOS',HE.!(J(P&Q6:*',9
M7S D]S)RDN&PTY.L7,')370KZO$8@;;/4?!$;9Y#;2L=$B/*I_2&W#O,;OF:
MB&,:A"O<T]F5<7]*>)BA0JK FNQ;S[&)@M-NJ!?>1O#R@!(+%DJ?8"\"RZ!S
M%\R-)(5J0_=3'TWNE_/S:U(V-AG*"G0_]),:4,.6WJ.=\6#%J"V;$J_@(?(H
M',Y<5-IOYZ\^3"=^S*5IF3M*9]Z4VQYRUM'*8XM3\SB1^:5^.*H,$]K;T,VX
MD0P7*?W(&.L9?NG:I-4,][O=U)E,W)B@D2T4-5J"F WU.C_ :2?3P^,4'@^+
MF;!D<!1SPD;\?<(C"A,81QU<9WHXM862]95 A4,/89^AH\5(&V:<4@KFS+NF
M31CC;W'ZA/JR$/23 !_\+9^SHCYN&94WI?@%:J>2XQ.&-'7=LE%+1A@D/E='
M&<V#EK:0_L1<OEH ]R0^?G"L":N8PT(2!48^G0*YH9,634HM)4>KT-J3I;'0
MINTM%F.>U=)H3KLYO4VVK-:'C"HI,]+D3%J\5L#:Z6#3"R^&R"#PI2 )F5:
ME7+6X C+D:?APLTUWV/0[K!WA%%,L)<2!_%\MSH?15\?W[J\939&QN0S0 "D
MTLM=I+&:J+#+8_C23LSPTH0#*W$Z KRA2P"K12D*"73U[LS35[L-H=F8$9KG
M.[!$WQ5F=7<[Q,-%0*.;*>B_>4;J%I:]CI5N1W@=5M1AM6&!"N>1E!A,@,R
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M?L2;$TD&A^?P""IV=F3+OB0YSOZ-%>"@&_8*B!X!$'"/%D1@F%SH7:=(';%
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M]MEU:@WNZ5*2?-*W=G>6?9ODX14*CE'1]VP7Y,2W(P^(2"0X36#9<21V_RW
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M(E:*F#ZK HD U/&_RL@Y3,3>ST&[;@97VI85!7%=_RKVYJ7Q?,[VA'MQN&Z
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MW,75I@13LP/8;9I1YGNF<B4!$>(3:3SG2'C@_3NXI6!%IFB5$H2ER!/ZWFS
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MJ75];>7&.K5ZIW#O%.Z=PION%&:76#T:U\2TC39F)I&@2/8>G(,] &+\,VI
M8?&<N)]>)OTYO.SJ$RQN)]'U3+MGVCW3WG2FW8+2SMGUV6AEQ.CFB'3$E6^G
MR[TP@;O:<^?;25T]=^ZY<\^=-YT[2_>J[,)DB<L"X%!9/FVJVJTVX;U>O;V4
MUW/NGG/WG/LV<&ZXGFF*F:+_<4"6$RAL]"%:Y(O:MY%!1Y2,)H[(0[RP?0P
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M#V82N\U]>G+Z^(@!6].XG,<[ O -QNS,&HB&V,;%+$Y>:S7A^O-L1YL J,G
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M65R7)07?[K:[72 M-I\'!>?VA7X&:JQS:S#V@4@I&6^(EI\D3/<"2"%A!HY
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M$$X^,LP(%5!TP07 (8\&2U_/1+<(M>K5S7=?D-1^-^4ZH@'&15F2F2R:T>&
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M'V1HG^B>\0AZ@;-%+%OXH1,'><UX5?%$ 0+_76=C#Q(B?L<,!>(3UHZ]&R^
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M#=VOSKG9NM"-:QS&Y#[+17N-KZ+MMBWE]99PG+,V/$LNRM#S@TM['KW^-9J
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M-]:MGTL3W,*@#I]($TX6EB57CJH]8/QT<"&?GFJ5 Y<V\*HG)NP2US02<.)
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M]EM"OC:ZM?&5&A#8KU7[W6:5R@DU2#Q4^:Q1HACD ;^=9L@8BP?1\^?'OB6
M?NIU*?<\%*KKE215(K#=I6A+UO2X6N?#M= K@0]9?V)U:8UB$(YVF1<?U V
MO3*2)';!W848/E-NMJH"M(K4?&2;7;.K;S._MHX?W@/)F5G.1PD7Y[UN=FPY
MLQ3Q/"$E18!"&B>T]D38*4D6\P[];<<1%KLDA\'[9HS#J#2R=!22\<M^I3$G
M^;R1>^]J8Z#F73$5J_%Q6O@:@B -T,\D4/PLGTTN\LJJ?,T*@$\SA/<W*GB/
M4"8V3U?9V$.[:PWSHK%-B:]-*I2.&KN[B,<?2*N2("B7*LD(CB=<N\^WU\D@
M.)^K$)6WV</@0%$=JJB C7Z9)7VS"Z#&\3@OR%B[2(JZ='"OS),D^UV<S(A/
ME0MN5*>JVMSY4,-BMTI9JBU[28IHEL_A,X1"EZ!JV7:W"H2B#X&I>QBEV=J3
MJ*@7SO&I#>.B5D^MEE:9>91,%>ID92:9=M'X&BBYFIR3QDM5B 7PT'G1%6P2
MKU.T.(TX\K>1>'4UPJZ(""3BV.CT=;"VM[!D17G(4VEY^,<5SXV![3G-@H*P
M_Y"MAO(R04G<8X.M1'X6(A'GY^C]6[$S_]%@[^'A@*8>E43]XL=I1!3N>!?(
MO>:3/%X8X)%H+/SM/IF+LXL1]C323''OP<^,# *4$\UIX(MXET.G")..^;L_
M'@X?',*_+F_3-"%3B6?&3! !YP*ZB22<T?1^/!@>AB$>]VK;+E."$39%(.$\
M)_D]1Y*1YEHA(%%:(=S(>/KQWJ/A@7W#%L&RG;;K2AN5T6X;$;A><,S&[Q>=
MU+W!_;W#P<'#>^LHJ'6P]X>'NY]XL/O-V-T?.5@$9Z2+,E!:NX]Y_Z%_WW8=
M\U,S*KP7IR/I.&30/COY4TF"R&'WP>#^H_T;,!5Z"D__.4Q%3(HO08!?C+-T
M$N"/!_O7D]PF]RC8&"*WSI@LM]I:@,LT;8:$2P9@YEIC153Q30 1$M9<)=$Z
MG>Z'3*IA]!1_(RHV"GN3KTF+XJ%)12VY,Z<G,@X9MZ3+X?[PD26"L&!9W\^=
M0B,'XJ.W*KM MT$0%.G14T"33>22#?R[>  &?3<%.A&R9^(MG6F,^0](-<9U
M&\M%7<?%H4C&#)_4:*O\XX/[PWOAY:C8XK1[YS(YW!QND%BY3:T!'4$"JD/@
M>AC83KK*..I+,BDQ#Z'9K!'!,&Z _^;\-R1V<39>"?+S-"C]54%C^K!PEL/[
MP_U&FLR/AX?!7Z9!?E^Y+L&/OR=Y0+X2-EVN!!%;E"_:YGA<SVM)@!#\+\G>
M.=B[Y_-WKAB)'?^<[L()0+ 2+]C=42IB]84I*]LQ/.40G"S\X9Z_34,;R?>=
M,24#IKW!E]+>6\\BD:X?Z_-2'#1DYAX6%I(J+K['KZ(S=C;AUL<#'VUS/'!C
M6,MFPL?^9A2.4A#MZ2HU>)K3@X+VMH'#Q%]%#B%4P/0L*T7"_%@YH%?A5US/
MPFD2"82-YIS;X,N@PX6S/FV\1(5*F.?'6H,"PK"K!.[<,"GL51<'@9MEFI*F
MP/D?3:!-EH'6-*?=L3_B]<S2Z6_\[Z3F%$:4ZXI&O7Y5@^YDQ 9K"E9U7@,P
M@9@DL7%.U+])T=S-/3PKON%/H,'/)3AUY= &O+I -(1>\D5<J*M^[L]T$W_"
M6IX'RE&C!"=ZHPK5UE3B/%^K!UK=$56E)#VE,;7\B2Y'IHK\(DBZ"3-92_JW
MG**H.S0C<8$U1?7(JIF<?]_*<_[#A4 \*,_<U6O>O&IDM6+D,JQ<0;'*CE2K
MV&^%"=&-LI9D)66#O<"7[('74@W.!Y9Q[ 8'%6]7E7P,H\@7-8YS8G*_FW7'
M*+D7R7Q$Q\%*;S5+BLF.U#E<<(8'U+QJ)Y_N+,C4,)4M!RI1EY *& A^M]6_
MZA9HGZ?Z#7U6^(T7\Y:A?8&,/&+3,2:#J!!=$D6K, 97TL2Q*BTV<1GCM<NR
MU[EY$H%<8!RI 9*TX9)(T^'5B=Z?TT:R*R*Z,5?>&^=7FMJ2-"D]?O A!&_I
MBJ<F.7_?ZQAVI*L'XD&T;.@2'(-#/EWRGM_:KN#3POBOE;;]YTN:XUPXZ[42
M9VL$CEWQ>H;>$CSB#FE6*?"W^ =A:VLL0Y>68;U]1*=26S'XS&^O,DV]$BT^
M.1#T911E3@)>J5S:YJ]>OP=!40?P[V^Z=9.<IHW[*1XBN93PRPJN.+RT,X1[
M%>#I=+7X#+-M2Z5 QH3%)L!>DS:>8",H0&>!N8B3R=6<U96Y_'@0B,SF4:M
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MV$+N_O5SZE_60D^MN^G*:S]7%9=7_Y5%WW5J^<.U6KFLQ>OW*Z+U*?_O9YW
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MZ""@!-FYE26M2'6ETNV<I3\:<AWY!:JB8X[N]5=;R ]OS"?"WD+!U==&VI_
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MIQEMKQG0\-4MYBR-A0E=)+PP=S,7!6D@!<V%/7CV<7TH7TFW@7]BFJ=)+CS
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M2"<X-A_$^2 0YO=S<PCS>V>Z/\SG\$S[C;RX[.V5^(+6RE"^OL">??CB6-@
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M/%)T/@3"450'"ENZ5MDQ)/5]VT%Y\.R"^9+?",6+^Z%TD'*_2813EY<#DW'
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M M/58.]%FC_4HD<1"A1,J2HQ)J8-'<_T+ <^%*9V=UC9<HVF=VG-J!C-7_:
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M8OOB <>9C]6VC!E*BD<#$624Y#TDW]HXZGIU_;F0;SX/A84YYQ_ *Z'PSCZ
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MBG;C8;S%]QY\_.4 %;">'V-J1X?*0TQ'FG=UHT<_1%='A6ND\_,DT S'"A#
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M&\J[0?++UG=]0DL;4F'7&W7%)J.^XDC3T*BMHT#JEMHY5G3/^W"A#M*7 A/
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MH9H=&"#YSDZST$L2BB$#=?-%^RJRK'38C.XW=7='KB:'P(?-,PB![QK!WMB
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MP,20BW16I/H&-KTMX^9>.LGH218VBHJW]D>@^-'D3QWMV1=TDHX:$9ZY0-S
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M18K^>89/?S% "=A/ZW%Q_K6:Y'8W0F)7JM\8@SX*OB,O56533<>-02QL-*/
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MMX:>:CV^JG\F^VY]G,@9I&].]V;#.,"I\+BBFF&)*%;=5M*J%-*>5^L;X5G
M46LX$>NN.\B>YP7?T>)6<BK_K/=;OM[Y.L_".OM:%('G])"5^<-@6WQS\4&C
MYW1 \E@&9RHX4LB8A3R<6<98B#K\7-=?-496Y,)N>N^CO>0+.]<]^/8W;@#:
M( ]GE=<(A$2 4*,D;^Z;ZI0OYOPY'8> U9T07T#3X5/OPF#R!PP1CA\WOG-;
M7-]L/,N=.0O],N\+2O0&=.AMID+OI 9M:T>-MCL7F9UOGHM_R5W=$@!8NLAV
M!:C[@H=</_#A>2H^C6]">-:C?&WV7;7@I<D6G$8PN>:2@$2W4;U^E#F)$K7
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M&!4>CGZ[ M.3P-*W&X/.B[1JK/B\%L$S6.O6^Y:0I':+@@:,%WK"\#)MWFC
M<4(*Z6A"\0(N;E94Y"2#%14I.-;O*O%"[3^4<4JI'24!V^JE6[!(FF ,Z-/&
M.NV7+H9:T+=R]-Y%ETP=IZ6IV/!E#49,I-#I?70-1JG[&@U8J+1>>VF/+IF0
M_?_*1PFG;GT3(=YQFI?L0:^WQ$MY6\C@M#_:.1PH9=I9V/#C\CIWS,E5J';H
M*(5S4[&\45+Y)17*+-=B589?);%O-L6B7<WCD]%Z>K+^,I8_F3U#M2L3JUQ6
MN2> VF*5VSNHRDUS:A:JW#:K7*I[9E^GD%/+*R$#0.44DB;ORFQU>G$LYD(B
M0%R\HJ(!0TN:(=RE<4%*[X]1Z+G3)!2EC-YJ[8YE]LA;K1&_@$+\K&JK;-A@
MN9VE^-9;5Z^[<W*4Z6VL"Y/OG^@AP%1'!(@+$P6J,##5;4%UE3O+>Z6ZZG66
M,M7UYM2QH[>Q+DR^?YISW%Y55N! EV.J72@NI]M(YW2[C6Q6?67Y%:C-;CF]
M^"*LWR>E4^F3LO1Z\@<+NXW&SWN[;K?^\IS6C5:\*#C1B[6PI.BR<A)8/40A
M6LG3UJT]RQ<&-?JK:B?\+,L,!$ED^4[TR_7RPH*'T9\7<^TO'4"CU3IB#B^-
MQ)T_B_45RE=?CYVW.%R1^T8P;_%(*:7$TA9[C<$*P;JXM,6,MF<U^AG/>:;B
M&*>;7WP2IJ;<\ST,@P%HTLL"D$S*KM_C [%&AL]%^8[^3@^B;LEVV1ZF2_4;
M+ZAZM)DWHU!L[2.,ZN&[\+Z)#S"6IV4-6.;6<\H]R.VKU_WV<&\.9$[:NI2D
MK4NP6EKTXBALM1 !XN+U$0T8E&7"AL=&AD=OO5JB<PR/?PLK?/@>[&9O]%H<
ML*:VAZAX26A$(<C HBK2'\<6)QIQ((,-?7_*LB##A6LW&E!UUXX)L86SF86S
M5EGWA1;.4[BT3_=J&Z?5I>-3(5F@@\S68D?+L1%0[3$3>BD7[(4A?_SGV-%I
MX,0!I(-8.8?JUC//N"FV4?.3B1/$^N]%N\>L]7M\'8'<SEK?R)FXCN.),W+P
MF.U&GS8X*+/7ACN9)JJA(O81BV+V^M!$BZHK@;T^)P,5>WW6P^_GS0VB2A^T
MI091,<W_W0\;/GHCNW[OY/HQS6I[,7;]4-Q?OQS?Z[/,&G*"!"\<M1J7$^Y2
MKJ!%-\V>"=Z]61,DMHF(>H>6P7F11M/6V<='=Q[M!<JS-J@VMZ=6]&7-+*G#
M^9-ZG0X9?](B<VHA"1Q)<Z@=-%WC4M5+^)A*=2^6%9_8JM[ XL(*<RL(5-MH
MW]M/PDD\\6E\:T5/=U[P_3Z93CW9F]WRL%J+%T1)*/;7M/=<JPC <4JHSMA8
M5C\JMP[.^MU'I8;8V,T=5$(@^RX'?N2B(&'#>UN$L>7ZAGP-_G*F W'\9,4&
M2!F\/C9<W_821[4SQH=/X+, F6P77QI%9DIB5_E\$ ZPB7Y.$AH1:!-W[-J6
M;()<>KT=1'$DQ[=^ _#&.?="+\J*88, &6.0(%A(I=Z1939;+=@(GH6.T#B8
M/0A$LCOZCD4D= V):RXB\;(U?GN-X2%Z&O.IIYJ<T'NA=)&Y9L9Y]C<D&$GD
MU5?U"@>, .__2UU]UO6\UR]E]5G7'QN!2UW]8[<V5V<G2K?A+D@<BDS+$,PM
ML->C4&"OW6RT5TC)Q178P\M,QKN2QRVKRWKT( J7H&-&H:3.F%&.#@&QDJUM
M>>+8-/'@LBD'@SE,+<>M?'Q43;:5F'#5:E:!9X,KAK%9!1*TKH]4X/E0L6\R
M>868.&5,+1!YS/70N1HR04>V_2AFY^0I'9@LLE,2!O%%4=M2_:\1)#'FQ1!L
MACTG@G36.;!4+X5Q)0/R5;!;Z]E"G&.^68YY=WF.>5JU8+.$VT6W\WK-_16?
MY&+79ZZ3EW,C7^1B<F1R9'(\*#GV]D".YE"38[65<)D<NWNLS'R&Y'A)UZH.
MVL:U5:G.F5^S^C3&2SG"C^0SOJC+(+=X[>;^R0K%&]CT3KKK]W$9R]!#%LY-
MG(]/M<SM62VS.[2L^K UZM<[+3&J6^UFJSZV.RV["Z]HML97^G)'NMI*=>'&
MTG<PMKSPL>J2A]E<>,NCZ.92'U;W5:IB,U=J<%L,IO,4;\7?MZDJW5IO5N[X
M'&,49K-1Z$ [1RGBPN]C1;<;X$9R>Q^#V!A2FHRBP&4SDVIF9<]RG%EO[LS6
MNRZU8.KZ[M8&,]K,/3\P/DU\=Y1$QGL?S7CWFS ^>[#%%C@D=YWF<:R-][[Q
M/XDO\%K=H 8S L2?8*%%&,WT>#:LZ30,ON&ENSF-GY>MU\_X!?QDJ_E*?@Y_
M*W\V7_VB[EAFOS:>+,>8AN*;&R21]VR,A/#S-X^>Y[[\36"%#@[WK1L*.PY@
M[,5WRC^G[Y-W"-.'I!L:?YBX<2Q$.FGY'5B/9/1_\$2\9UA8&CT@RYL=_$C8
MP%B&&(_A2SC_0*^NV:[)CS6,3^EO])U&==%UK76'%\#3?4?>6"VLT>SRJ.6
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MFD;B.OW'*T.9G7T8Z-71ZM/T>HWA!CV4]F[EGNR98U\W#7KD>[])! 9'/W4
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M"RN,#%$J$F2TS9J!WA7Y1#35##<R_KZQ =FJU,\F%[K3'\Z>].X_B1L_XY@
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M)8-?WXE1F%CALS'<\?)C_*2N/LJAW"2/213O[YDP#6'!JJ.BPKT6!LGC$RS
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M=$"&/3 L7]$3;3=3Q+Y;_5J%S\GBJ$@P'M[T OH.78T@^UBQ5.);DDO3%1.
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M2<Q5Y]C))-9?]IE)K*( %M28#.)R^FDA6ESRDU6>EJ)$:R.:E2":-V,WA-9
M36$$ ]9WO!=9YU54KXRK6HM>*5P6T>.B&.FBX<0K2W8FF5L)F2XVN6M/O%@*
M^I1Q3-=*('J89U:(Z \0M].01>/CSBZ&:4;#2"K(W'+SHCXHMM:1=3:Q9X8M
MNVN)UK%QF?E)X]G\JNL+*_?I<V='SK >&7BVH@E'U_>Q+B!JX',[,&%,0*]=
ME.I+669UP\E89!'R=JO9:[4[YDFMB47(K5KKQ.CKC9.FT6SU3FLF;]5EK3]P
M)A-K($,U5/5Q\;0-*[6]5IU-JZU4GDU>+(W.O/N_N()Z?NW?.>?^8*'B7.6^
M(D:AZ=F*Y#DA'U)^)R3=;(1K11R9Y05Z(IV0")2FPZ0]5$HNHCST;1_N\G=?
M^MGA(;B0)_&:_G12J^HKA;9[<^EN(S^(XF+NHA.A*!,>EW-]\KGL%B0PWZ0Z
MO)>I22\::&JM"MHF4(YN7$]==@Z9>9QL&2J21X%Q(B23I<G39FB3-U:8Y ![
M@EF$<1':2<US,%L0Z@78+R9Y% Q,WI(&=K(6/@^QTZ> P^*6-88;]<'R@X\'
MIBFI)BO+V<(M)L]8L-'($0W)+N%ZN/6?5U<&BVD(?NO95];6ZH8L?F_X_^&C
MT(!  FQFWV#OT;EX1A/Y@9U@5ZW_=+O59%:BR[5D4%Q6UYON@8;-9J_/DZZM
M85(!V?+ \ )YY#>9Z%C6Z$T)69F9I>P>%0@3'==!S4X)IHUU\T7]TQ<P,?AO
M:I(78!X+MP3*V0:E4^(V*.MX(,M<&*W9Y!U3,T]:G;YYTN"-]DFO9[3@KV:_
M;ED]G6NG"TW6J@I1.0VH2G,57)2>/\**]98?/<%RQGQ/P>S$D5!DI#,]XU!G
M6[(R]P\>R]<3:G,1](R,L<334@6-M@++\J?]P./"W]$(KU%LKO^EV'C6#\JG
MRS)]1]@FA!><I7PZ S;=QERZZ8%&%S*W)$P*_% T]^7^R/##\34\7;3@PA=(
M%E^Y9MSW%ZZ]PV!,]NCRP[CU6OQK'+X]X-3EA![&(Y[M)KPHL$O;"FLM3:^U
MEQ3G/ZWF[<(HQ=1)SR-8+2(&3+IB0*@]L'G<L]'KJS;N&*=0;EB.+?J(5%33
M)J#P$#;Q_+%B Q,>HND-P<\3X-8P41-!E5V*BO@"QTDOL/\S\>G!!IC8W));
MB2.9>N\OBDT3EIEB(Y*A@ _Q% 8S!@N S@X_L>PG[!SKC0T'.R2[ F:+J<L"
M Z%W# F8*9NLG_3&)_&?V%;'3GI[CH IO"_:\B3/PHBLRJY<=LE[/I:+QP"N
M/0UABW992:C"4A.XMNFIYYN>Q-CLR,3LPHBT$?"+_]"769.<'C7*B%+2<B9=
MO(GS%;=:BDV*Y069.+!O^P&(%I &+P373+$%@NBY8D.Z'0 YF0XCB:Q<13Z=
MQH!A7+/S.=OC!KNOX::C'^]6B\;CHCO\'"0B=Z]7>0M?Y:)J+C%GKUI_J3?*
MLM2794RW5MI5 C5PG;>K]#I9)\'0"_;@&QI6!K=:B3$+UN?L92AJHN4R=T'"
M5AK:S/;F*O>L=E55L=7+5F@46K9NAE?WO[%N#Y;!434KO,HV/YUS4J8P:<03
MAD+8A0+%) T!C:9 <PIE"V@ZI==42]3N?_^IWOY\E_FUF]PVVXT]]V5HJL#C
M>K:]*)B"N,WL]LGBL23W.C.3@T5_ST=A2HAZ!6U&$/4"_D<D$Q^2\<"E-V;H
MQ1<VQ-NS-&RQI6LU2XT;'WQ0%V*!)>2(EU*5_282+_#N)42L+'_YY ZQ/9[X
MQ/-!1PSF(UF\""CX#\_GQ@R$GNX"<!=FP04Q8\C[ZE_,,AS3!M&;P/4G[!R^
MZZ9-[1(IFQY*'%=.[UE,14[S8Y0=, /1V Y,B6.Q]V+W0IP9R$S@0[R/D,7M
M9]\S_6O\#O'0%QMLR7N9 3?[X)1+2\F/F%Y\Y1(>+G\&=VRQW<.#I!]MWX;U
M/S#D+L3$'">$629D..-X0&RT]+6BBW"2L, @6,T/HQ)O&"0E?5UE>1Q5$<_,
M";[ZL;S$+4[3GJHRW</H]T5O.IEFQ W0&,EC98:1:$R:X5&5S6[$)3R(*9!#
MGZ4DJ<Q+L8@T@08QT#H%P:;0TG+^KM^!L]/:BV-X%42"&MNBC/BLKM2=7=>Z
MBS7Y-ZF[4TIGXD0MB1-?:0G:R4$=TP#-SHG1@AFQG"SE#8C>GB+Z78HZP1S/
M)RIEEAF[X44!U-9SB"VWSC(4GV!O<S%6#C/P$KE.UB9_LU:;(O]9:AS>C/2?
MYL D<PS)@QM3!E2PE;.(F.46.(+B$U!2Y)8->;@P-[.R00IF\Y@TU4["W/5I
M>'H4BJ<@XG6.4VWLA)JKY/'F&MQ$8XB6UCW.7:$W\C")_,R$"6"0+9QR3.#!
M5]M[6EC!L)S(P4T&.=!DCMI,EC[:=SEQ)HZ@R$0+,$6_#'N_LO=Q#"RO2*+=
M&<B!?<N$^%,9DID8)AM1Q^_+ 17DN04)+61'F62_Q7<:DUBODD0U)STNHJO*
M)">N,LF_$R$B>C%!U(L1B4H*322SO$B3Z>(9I1.&&V,_:2[,Y9C^II^V]9/;
MBU_$KS*R@0';)V=UC)="4>5"1% C^  _ 'U#B';">#N;6>",=;^?9VZW0#=B
M,G,P'Q'-DB\GQ!EQ'V4CV9=&1.4D#=KG VB1HB=SW1-:W"4X_#WWGX$:P81)
M&9$1+^MQ%G@.=\88WH\\-[#12<'9]B-9$4#&P*L.01Y]$Q/ 7ZZNST^X"X[/
M]&653+R?AT=4\@&)Z9P=22P9-HM1SDV;X8XN"!QN%R*G5MDNF$O4;]:T&7]
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MZK18/]YC*VE\E.0[3@HHYH:!Z <07X0O]%PA+=FB_KK>3O[H9+V!J^O+9>[
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M-)4I#,9V)E4XM<;;6. OC4XGKP0SJ0P5)9"VF8OFP"H'A#OJ072TG: ((^B
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ME"]IQ;R!*6]6M-,VF?)22.*'[>$2!78NCXDC2:&$$T-62F"PT#!%S.O+=*Z
M10&WF.VNG<E5(B)(1T;^-\Z]P_RYJ00[08W*?!J>2GL@"FQQ*,93]4K$3'LT
MN=X*E?LI"2_G/=3]\?.H/=3U3Z/7YQIHSY3\N19V[*8ODM(SA])G\M,WQ9QJ
M2^OQ:1UP2CL5O=.A>D"E$$#U\AG(EJO"';+E;X&79,N+L^7M ]CR):#3*[9<
MK]1JC4JC3;:\' )(B3E*LN5ZGV@*;?6I;+5IJT\E7M)6W_$Z7ZMM]2UTQ.;.
M^;]RNG]3]$2?[/)]T:N=.FW?E4*Z*!-'4<:0>3X>7I)Y)O.<;YX;M5V:YR6
M2-8\-ZHMJO-7#NG*RZZ9*O"T=24>,7:LN#1M<A97"MSA6Q85IVK-K8I)<:JN
M&]H"6;"?^3TW(]\.;1Y<_#2=R.+6I>\-SR:5EN9K6:E6R:[8NE7WMFMR450*
MB6:X8_9B!,QVF1'C.EY@"Z4&3V*&XR#08WL6_ !Z#'TNJY)?NTK6C;(#\>P
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M$,"2+<0'3^:,)UL9\0ZWW,C&W>8DO0?1E7MSP"V!/36Z^"C3<]V8H>)2?+0
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M=J#0:NNTH%B,YV$0 G]9D<F'0*Q<_([@N+**'C6%*!O'"(HK(=-PFTT)+YA
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MS#CR7ER,J=.TV,#U/&LL.#\(AP[\\?\#4$L#!!0    ( "]H9%(A>P8^;A4
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MKC=-I][B+.(OY- F4\JHEN9$_:%>,E\3-H546U_ZFQB;Q#Q![!'[57]><B*
MB.ZH!'8 4H9I8<?RG :(,6?%>,'34#$;^@K[Z8%,D5ZBG@>A0/E"MK_D[I)P
M2<%J$NM@36#.R?3KD5JI]D(U_@X2'H/>0I!, VGE::5O=$K 9$A!4JE(7,9
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M*36;@8DI($VB4]=>]RUVL']1=1_C-)N>J;Z/@=Z%G[H:@)UN:3PI5UEC8R.
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M=VD\C>#?/L1&";J;(\9#^F?\7 59.7IFLN,0#A]1N)XT8U!SE+'D43"4169
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M[9]#65;[&)7C1RK'NW^E<OQ+&[7B94_\(4]V>T2T\F:TJ!]AX5;:)D'7 M_
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MQ0:?(<(LN4041C4_#-0B9P^4!GD?_4DX4UX[L&(KR\>&X5$F0&(+C2X --3
M:]6.E\9R3F-T\[VLMWWW2L4 3(ZECAQY&K2_I* ;6JF''EU1V]LD-/OB)HI_
MC1ZU7N-KDQJ9B=)-VE."$-A+C@"6+,.(H[JP-1.%AG08.$1(1:=D!BIN0+ +
MY6G#IQQN#^@ZV1IYDA8Y#\GR%7GW'B5;UF[ @7$!*'F&@7B3"7PZ[QJ:>EP
M5,*S>M\U<)Z ,AU;K(@V3UQOSS B%'#&]A:W9 V4'O3KO_21L"P.TDW22W47
MRHZ6=HE5AB#C'$,HZ**!$M947:"(U-^.], Q?BWJ>RA(&059<]88@=NA4?A\
MN9[?PA@FS[3(RT\9SO.S0Y81+S"9$8<HC7X&W4'96TV'G!B69!C&)*@)UO$S
M]5[5A0T,:F!2\0*,&1#<ILYGC9*,-ER';7T)17;!9DW"1TS$(SM)\@<?,6T@
MQK^EW0+TBZEY8#HB-=*5$!ZR8XEH@,G6U:91R@?6K%\Y%XG]E2HC:^:@6>!K
MLAQ:YP:'O6'Z:HP+S6-7?B/6AY?RR_],8$9/.%^NZ>FF\7L938H.S*&7@]=
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M^=@>KH[CZ^=07<HD-P(@!(MU90G8I>:G[0\K1+RAF1J*\^4?7FJ_L>\5:\3
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MWJ7)PX$V2B'1/7F&E*EAY5E#JK;=?4VX^&GN^QF3'147 4 A \!<"+K#XE*
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MP*_$J2+:UN) RC$V8LFWCJMT<PZ?(<)[ZG[U\"QYG2M*UPY;]@PL#=B6H9<
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M[?VGCH:H_H L*GXE/Y0_(O]YB'+XI_\#4$L#!!0    ( "]H9%+K:E1"BT0
M +PF!0 5    8V)I;RTR,#(P,3(S,5]P<F4N>&UL[7U;<]RXDN;[1NQ_T'I>
M9F+7MB1?VNXX/1-E73S:(ZL4DGQZSKYT4"2JBF,640V2957_^DV0+()5Q0L
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M*OWUEX/?__DN_NVSSY\_OXW_-OO5P"WZ12![]O:_OMT^V@NTM%[#4L$NL.D
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MWHTH-1#+#,</(XZB6IR!]\L(GJAYQ\#[/((G8?IG^)V->H+O.L@0&W6&D#>
M 3<JB2:>(H;CJ"\$784,NE%;-/(E9T">CVI#XDF!P3?JD+:>FAC&H[KA><1D
M>(UJI>&+-H-R5#.<P0\99.]&A2(0^\)@TZ!(^M1PX"E6$X+A7AR4>A?;5<6S
MSF>[I!=BRH0SA=L)7(QIG_+8(]VL*P$W[;%1@3)!)-VH@'NQAA"=6N2:E!--
MM83Z)YG*6=;Q,KBV7(^.!E> 1ROOJ).K!\Y#;NQBT-,N!ERK-P1Y5%++7THD
M<='JG52JYEI'B+6]0$[DH?B1OH@+N7P< :IC+X)N>A&(K-$0A%%:-E1&]A1]
MVCM1L\.D5LE"0PJN/?SS,5H!&%0]6EZ^@9@",2,XA+XDG-VJM-LCMOE&^US#
MO^7G+D5>*O@\R]=*:S!M[U71,C[RP706#YX5EA2>DHI1QI++6DHNJUBJH03[
M-2UA77N:AQ(/* *DM$K0&A38JR+A4B8/#ZG>F4"53&LUB:X $[Q!</4G:]=&
MQ>]V]-W83BL>IJ%*?R'G'L'&3*HZ-S2:E#.A)2<X8_^@IO7DIT6<>(V3%\^
M*J9D$DPYJ; VU8S<%5KYU<WS/+%#=]W()E4QVEBNOE=>3O7EZE5LDJ&8D'K0
M;R+$AF*#MKD2RO7P$&S97,L#*0.V]/O>6:V'G&HU'+[[)-MNP,07Y*.9&P8
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M86$SW;/MJ'U9-P9#>[0)6D([YRQC):#-#G;2+98/5-\ORA]RBU5?1P\27ZS
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M-^3'31^_$JMWPF#[7PE,<N@)MV;W->"=FMW7G&5:WR>>2FBE&.DOK"=\Z8N
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MS+C[GT3&"AO&LRY.4X N9J&R:\+4F@Y3>!C*545J=%7%#V%?>]G-S"D:]?R
M4S)I,+$($$[G6>V9)41Q5LN<]42:/[6N-[KM_7[V48CZ%;&<CK_.7WB@$PN+
M%Z>8RPX,;Q*U%LO3)2G]2(#%2+'B. G3E08W/<F8^":W7J"EP&>Z)"U_MTL5
MJ1]NBJU"NE1Z7->$OZ8XZKK*#-%.;YV49ZA>ZW*<KA4IZG\8T<++1RCDI2Y
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M1?B^/M33SQ-0S<UG$@QP*))DV#"C5@W@.>_SB11'YH]7K+"R<83_N 2@B.W
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MG:NC<^71N=>[@]"=89!N=Q2/??CC_P%02P,$%     @ +VAD4MDMZ,QB P
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MDJ(NA4$Y%Y:9+M3(\N;5=!\^#3D:@G2$^IR]3*E84+*@Y&&4'+Y62NXLMQ[
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M+,7?,P"'?]\'RZ7LFC[T-^0?_-\:>S_L?'!<\O\D<N;E_['D+U!+ P04
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MQ!0EM2$Z@0S3Z=SNCH'B !!+S0Q-$GK#O4)?M&GA' -GH$N)L9E+^$B8*$O
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M8[/7ZY)Q+*X87<"0"2)2ANY/%@N6XB9_?*D8UA18]9'PJ0%B1FF\;0%6:K;
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M7MGE'_]P=.]=\RN'[+C-9[*.VWR0^PM02P,$%     @ +VAD4HP?!]ZP2P$
M+ ," !8   !G,F<U8FYV=35O,C P,# P,#$N:G!G[+QG6%/?MB^\$ &EB@(B
M78IT4(H@+10! 9%.Z$B3$@'IH49%BJ%$0$"*@" =@DB3KG2E20V]A-X)-4!(
M+O]]]MYGGWWON?>_[_-^./=YS\KS^[+6>N:<8\PYQ_B-L<8,88PP!US35--0
M XB(B("G%S^ , FH %=(2<E(2:Z0D9%=O7J%G)*.BI*"@O+6]1LT=*Q,[&RL
M3"PL'-PBO!R<0EPL+'Q2_$)W[TE(2+#S/I"7%I,3$9<0^Z,1HJM7KU)24#)2
M43&*W6:Y+?8O7X3O .T5XE6R#&(B3N 2+1$Q+1&A#6 ' "(2HK]<P%\OHDO$
METE(R:Y<):>X>*'J&G")B)CXTF5B$I++ER^>!E\\!R[3DER_?4^)](:>#1FG
M!YW8J[A/5[B4RW_0ZP_L<HO;>KZ^2LYPD_$6$\\=7CY^ 0G)^U+2#V14'JJJ
MJ3_2T#0P-#(&FYB:V=D[/'-T<G;Q\O;Q]8/Z!X2^"0N/B'P+CT]XGYB4_"$E
M-3OG<VY>?D%AT=>*RJKJFF^U=2VM;>T=G5T_?PT.#8^,HL;&)^;1"XM+RRNK
M:^N8O?V#PZ-C[,GI'W(1 <1$?[O^EW+17LAUZ?)EXLMD?\A%=,GOCQ=H+Y/<
MOD=Z74F/S,;C!J?8JRMTRG&?RG]<Y1+7WZ6W]1P@9^"6F.?!_"':7R3[<X*]
M_K^2[.^"_;M<$P E,='%Y!'3 B#@^)0O^R7Y?^/_%[@E%$6I(W@^K-^Y*I@X
MJ,"%]3,?[8MSD-OR92PT?E/0=8Q,T"4 [UQ1YQZP1<B*3CALS_@S 4"6G3L1
MKST9Z5+'B+9Z0E\Z1<D1 %?1"O=XC\Q2G]YCG<$FNPH"$#_8?'@ ^I!%D^]4
M)(,L=<@>TP@,%FLGI]8HNUN+/<]N];6)TJI-O0L;+7E)C+5]*>\+7V[@7XCA
M:O\M;J+UUF"GK3/.I.DN-M]A[MQ67F9!.V,^W3'@$<#^$? [ ">Z6+-6"C+$
MN&[FUT]E57=25&9,Q8[4YN&,=@_QH?<+]D[8=+N55X0567OI%ZMGV2HUJF@J
M?N9/J5![K%2^1'3?*C.HK \_&I3]P"*AS^? ]?OWY0,P#;H,+G,S+/_^X+W:
M.KT$.M?7(+;$_K5,-F_9C5SX<DN@I!WBWB(EV2(?\2A?T9'?Z&E8MJ6YYE?E
M!8'O&(N;D2&BJZ<\9^/F9OT%?1&47UB>'F\ILD6I^OLF8^K5&QJU(%LR*T^F
M7C#Y]J_!-^1,%P2M*9RN%DO63[>LD',]%>^T2 4&$ZR'N(87AF(&)8=>/W12
MXMI8,_/9DXJ0<SR/6S!&[7"FKFG $F"]KZ&+I^!!,W#,P;E*B_7NN[Y21]=X
M\JYQN6 ^XOSLAM2%A>KT^"]5O\N0GZQ/7)FIFG_595[!J0W@K+:HJE?=%'^&
M]6D#OG1@$#J3T3GD>H7ISN+)[+::3-4+Z]TFH5 'G&R!T ,"8&;BVEFF"1Q.
M+,EI86ZVSMQHC!TRRO!.4A7Z=%OH'M9HAQ):\1ACB9CP7E.QBU 9T?9W;]\H
M(_^!IG 8/>A57O:BG1A%"3(2*[QA HZ*(9';6S:UD0DL!=S*:M)<G+DE.ELQ
MLJJ[N:7GK2<,SJZW+%>XJ7*(-RPN$P#6YPS&#!-4A\-<>+..5N?S"Y47(&5;
M0-<EW&\^>EHS3?+[UA[W \FQWT2J=+K_3T*OI_VVKU76=0'-UYCJ\<<SD3IK
MBG02YN/; ST]U#)/C:L\V,A&V?#;:-+')-HG.$A-UB4XWY\"<%#2+?@S;YCW
M[1B=RO=V9[;P\LK9$PK+8"=BES_9Q!^@;/67.D*-'].(NGG ATH,"  7+XZT
MN@#(AO/]*93T*N\YB<P]&B/Q"FUW'A4I)0#L1\T[NJ0C='J*)'\2MTZKAJN_
MY#Q4Y/GB*;#YV(S';AC>@VI>F!$]WM!D/^0_R+K*EPT'_@P$D#GB/^RXX]+%
MHN%5ACZP$U)M_!:@92/>[\ 2SU)![=)K,-B\R$PSB/S+#)&XJN"5:JP/VPE
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M^.REPM-=]O#*63KL'KK50(/MTAX+5Z*<8V.@9,T/!.G$+VXMK=>M%7V/2@@
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M$'WEJ;>]#B=AM%V@%)48AV((6-/$$AG26,U;.GL5VU^L6-_G=E$B:CLB/OA
MLW\L$D-V/'L=;U7B97.)&E$J1(IFH/2ZB;%XQQ57ND?GEXOW"E]5GPWT>+K\
M!K))\#E\0B1RCSX?3/WU(B2)OKXZ9"OO'N%:I)%\XV7B05.*\A)WANDY8RD#
M1;EOY!0>P%=!T"L&VE>\]5TV@M\MQ.L_68BM&$>U2>47D:\MU&!;*?(M)^R7
MV7N[FCV>*I[Y4OOI$AU)9,?*9>O EJX2[_D3FF6!V-=R#O(H^Q,KPH_]6)";
M">).49PQEW#DO)QY5,>UR@@ZJU'L&51 A&<RC5_?6^ZIW(L4!D.#:>@\IQ#5
MXFD]/+]X?31_L-%&W3-37Y+L-MFEC?I2,<E"?OKBW;EKS.Y<HAA.PKGD1_NH
M&F>+TUAM-ED;05>:@1[*LR)J6A'W8_[?%VA]L8.5L/TINRPIN1;O/C!&?'^;
M\Y70?("WWW' YF@&QTNGB W/M<4=K[K(S5Z!).A'O.EU!0?T;6'%3&^_FX>.
M-HLUBABX2$Z3WPKCXA)PL;PJZXP#D"]!AR<XH(WSMV\;@2?<"K]@U"=.T@*P
M=MU+G 4-V MXI@8WH+^ ?OT^MJL%QK?H=RQ/AIE[WZYN#,-<)<+"8*A.\,(Y
M\,XQ#@A7/XD-QIJV$.V',QXV"+Q.K<8!Z+L4&"P.0+R%-5Z K1S@E7G:,1\U
MIB&88H-)9,?G'TY)?M^$^Q!&!9H4M5O&]-X-7L<!OV+! >?NX #X',8AXENM
M[C:6$USZ;*[G,,&?>@SO5?^"YC<*?B).#6:UT!"_(T;,7?@#EE])*$:9=J&3
ML0--,)%E!RI=TQ]P_$:"Q6)#+.K.GUHD5SP&$.K[M+6Y[4CB0ZH>'JM(U!][
M#/QNJ9+^6JI_27[JAY-$YGA';4B6U-B8_+7B_X)LJ56 X;6QO1:R<;NV*71C
M[?=(7?[:F7\Y@?&Z>>A^=EI.H?)@7EK1QW#!RU5297T=*?+IAMQV.ZQ//C\U
M#_YJ]E-EC_WM:8H11!\X"$L4$='JZ>[0M/"] (7''WM>^A/9P\5")\S*C^@T
MQ'3 /$%L 8X&NSK.$+D\)HX2WD1%S;@$5WEJ_++(]F&PLCC *VZF7]!=T.V)
M(IN^1.MI:KJ6I^I&PPY'5)9]9PIS!G0O&^2)L>_B57B-BG2A,/H+#F"=-3TZ
M"CF,VXU+R[4Z<JEY]+1,26$S/^0L?\<02THR\>P_OJ7+/_9TR[=)JWA^^EES
M"B61+&%RIHG^U-RD(M3Y8M?I-&B:D]GWX'<<H(H=13^8])$^OL<#DEH:XYE_
MC&Q].R8."G:*U]NZ$EVN;$_CFL/!=,)O,I*YYB(NF3H)V>^PLZVC%"?._8 V
MOS<Z+IR1)>,@[TITI$8$_^I1V+3.N XU!C>5QX5U%YSM<O.=V%2DV@K-SIF'
M"BEX15^R!QVXK1F/QB[P$,I&=0^55O+,'7>2PPPJ/JQ6VU8]+3]*3'=5RYFF
MW/&U.@4BPZ]_C3F>HL#M0GXT/PY@X0O! >O?<,"JC4G#:4I#Z=>-SUGN^*OW
M$Z=DH#T5!BRKX,H?@R<-,V<$V!U6Q#HP/8 [O)7BD-S-$UL/RU!%@55KBD=+
MP313TCL%B17=6E^!CAX/X8R%$PZ]&'IG$KH"UN<5<GWPM\?:AU?#]4(UKEBU
M?]80;0$<GGG)(Q%KW!X'J^GL!K?(OR&R[B_Y,!E,K\_>&L9H"MZ(^>9B6!*N
M]S@<3+QIB+=O_9F7IH4#GUIPL%7A (;5*Q7!D]0!YT9%AQ]RA9\!W.P"O?2A
M"PTA]>SAF.B*RLK'._RO UT<H"GH2 096*M?)22MG8^/CR+FXDVWLR42U%GZ
M7^$TM39VWK91C1.=HHBMX-T9@<]8T$"6 &12BV8;M*CF>!0'(/;RKY:"_?(?
MK2PK-(D4L0B5(1NP]VZ#=L9UU;VS)JU=(J">IWH(3Y9L T+(Q(>42I64Z"Z2
M.!UG)YX!W*5R<  ;0AD'.,$$%!$4AS>JB0ZQ5TW@'(&E[YV=1I):V1LB-GL=
M*]4=%S;8=S0#-2J+@I7&82/=$].E!"NS^./[IB<#!XS1X(!^64UT%!X:"5XF
M>,%83%*$ S.-K"._:NJW'A2%LK;=]LV<<X,I#A>:U=86!4-?J9A'ED0G4["@
MJL*'%C.CG0M2O&\ 6A\[":)&\?+J GI,^B-R=_](,_U A/)M,!W53N3G@B;-
M <$9Z^D[V1,MCA=6"[AB$N>W*""WZ&\(YKK1(>_[G2@#STP)WT_='R;UNTC_
MKOCH<FO=XP32I)'X3"L&G1#6;<@HOZ'@1K7&^\-PQR@#UK,:Y]I9SOI*6*\-
MM3;0TPP,]98,!G9G13^] ,OW<,5<BR,Z.<4#WAK/$=PB6SU2GAYS8?!2,U+&
M%M_K-2CC)&S&V%N"7DA=@8CO^5=_MA&[4"QWL^ZFZKK)P.F!Z4]1=S\C[*/-
MIK5Y#.\.[HUK\&AT<F?W;VI'23!4V=B0)9:ZC*)>+82YI)+[JA&1H*#2U:.U
MW,MZ*9XA^J=3Y)\):+@9+K('.29_JJBX-K@\R\]4I$ N-Q"*C9Y)DB-S'$LZ
MBVQ-<;#EW85"GG"PM8MAG0A6;G9B)='Y9TY2!2#"7+>6GK5%1A[IP(,:EBK<
M7+&5%"?GQC+T(.4>QA\KBBH4KEVF/B,C%9AI;/WQ:]1$ZT$_65&W8Y5\&6"E
M+OO]AHPA,2D*U5)0F*5GIME585OVE0S%V&B5$:\72%A(A.%J39LW);4>"W.%
MI1FJ/IOSD.]57=>6;S(]FW/:S6>(Y60+E4PA/O#8CM[KH;>E:M!H(]7GM^$4
MA!CN::Z,@%CSC*:E\2GYT["9.SJKA(FHWK="$41?A9,M)B52=J_XF<@B)Y<1
M+<PWAV0[$R TW?$1=S]O<\^]E[FN0Z]Q4]8"8D(_X*3X)5YY**7\C6;L8R(>
M:>;+*/I-)Q#C[.3$"Y81Z@L$7^4H=@H?]PNV#$J0D*46T-N<M\>.SEIO9BR$
MT>K6OMA1&TJIK/3=#)8GXH*JI\F%MG824Y9&6 /;IB_F4%MY>*YN@EW5JJ7,
MGES% 91[E<[G[UW$2]XK]F//38HRK,1U7K$QV+S5:=29/A;88<B%+5!0?(UM
MW#^X_P+ZVH'UZ<IA/U'"^@T0(C_D>F?\,_RI\"7>Y6. M:=EXT%SE<\R#4QI
M1FA SX4M*5"RKSADT[5]T2W(?UA7[NGY;E3!R"RRFE*:B?9SP^%%%AS@44>>
M XE3#@BSYG%:URKW=;JWIFM%V%;:=\BG"]IKP@$6@GJP#@>\X'$]BMM=Q4BF
MM^26Y\7P\QR39=HG-JLE@0;-1^*UE>C\=YY9TD];$<+1^'-[[>SWXI\1VWD-
M)#B@@SH>6[N"E:N9D5$I&7FZ5%K_G*/BM1G"YZ66RY$4')J1>(M$;[ ]1^;<
M<:6D+/ ,3@A>2I#' :8:..!^&SH0?_8UFTRW*)9&OGJHA&59Z5SK4BH-'QWG
M-V/RON41%WS0-*F2EGT'YFY.-:8&^Q!=\A:O/^*\-/$:K::Q8:L0ZZ_M<W.F
M+KQHX7:ZQJPZK_3N&<5"G6$)</K7"N$#VE%^5:&B;M[#3F_.G_Y78MCC;4ZU
M;0C+L>SKV,5D$\)C%^4#Y0+& O9DWO5M?G0]VZ82W8OA'-HLL"TSO6CTJ3]D
MA5W0K,-$[(2[).I3/6W,P49$FJ%0JV.M7P+6N8Y)O8DN7) X^"85^5N")5-R
MV%+J^MP6_(MVJ=*Z#2/B;,9)RI6*'=TE7O&]0MUBY/=G_AYW2W,J$0&FCFLK
M/&K629?ZG7,SJH:=VGDYC,RFF4*]R0#WPK!4.'YW+@C.T=VYI)I%37+U3H+S
MRE[!X!9^LCR[41X5'5>GHL/N3+<-93CU9$T*O2JVNC!U9I*%)=1#AQ5&@;E.
MU@9G#GQ:O'+[NU(!%NOI(+IV9\L*9UO59OEO;C)MK." ?!V?"R<G=MCZ);P8
M[O&P"A *[#QWVFVJE)Q?:W?FDO) =Y9J2?A<[Z/MIWW=JJS]1!R(!AIK'YKZ
MH:7P&=8A-N^*TYD*=. 3ZTZ4T%S3B:9TTE?9,O>X6YWF#\2D$KD';?,VMI*M
M>,WT'YF]R!,5\@/A*3K?!/YI7I9_F]>R#ZG!S)2;M>--YW)WO4_YP[S*'CPC
MI:XQ@X;= HRA-[-:J)[)%34_IY0#+N?L$C3#&K.061@T#N!#IN,UI^J"ZB$*
M:[I@W$)%$+BP=7Y-BFX'!Y1<V:[]9G?08HNWT:ZN0MNQ9T^VJ/"'!V_$3.2.
M0444^P7S239 $S'\!B<I!UU?5E;L- _[";UD,Q,-I6N+01X*O7,%HGC+"KH8
M;T>NK[30XQ9_.]?RJGX;J?BC.I>B/5,2*X^I@.'2<5X])UZ*W62*6^BP@B8$
M)*]6(*7&B/:=X&"RJ$D:T4X:@JQZW,U0WH_@GI1!N611W-YE[J8XJ8!S0X)H
MFY*QA^#1Q#R\;AM;T',VI"M :+XNM@P&EIW (/0C,N)&>F>KF'O/J9\3^45D
MV(.IO+2SW(IGV^[UOYN=%CR\$?Q,]*!0!K\&EO-]1[3Y8-06*I]'H-&#/'1A
M=X.7Q.5R/VA=^M(JC5W6JHY+,5.MO2_T_C_QN;\7^T,Y=1/(CP6*_O#KNDS_
MJ' \#K@*+<Q_FO1_V5#D/RLL^5\-;EH='!!Q;'J0:UWD;(=GLC*\ /U]%?7_
M:OR).H+_/>%46IJ_5-GS#Q?0&/LQN I.K=^?QA5DTHJVOE^FK;PG@@-*O\%6
M-D''W[3ZIV6>G0_0>DU>HV)OHOQ#3,#R_([B(C>7K7#57'!7VMVH[ S'#ZG!
MW),2K_\3KCC%6O[BNHG>0A@KK/:K+\U1TA[/OT#WF_^N\5L6L.8P+1R%L,?K
MOJE#-:)$C/#W0OLK)_:@WCK>VJZ%[B#F7)?'SFIF(#=$G<=O:5KI2S'?K'F^
M*<G*_A]Y7E15B&FOXK__D6-;I4-7$0\U[=_)-5/O8U[HXFTNU3+].REM\A*>
M@3=J+@ZH>_^]9# FU";3OQC&J[\U+2@C&ZD'C_T$H6THZZ5U!6L7W6FD$K$8
M8EK,8GPV-?7O9.?][;.8X)#_,ZN-<R7BV9?81P9<?'\G?2XM2;(IQCC(*KO^
M[V6OA;L=D.N[L/VOP!B:]HM8/-U'@6$UK!W?WUBO?%3N\Y]O4I7HI=\AY_S
M^K]1AOZS0U(MK>.P4:FGQ9-2SB3#:I;+!:09!'7QTIB$L!&\>W,<-C>@:> V
MU*1[8#\Y"75Q5+W:*/?F<=%^,ME7;O$VD\&RVT$\W^SF*^-8 A6FV'S*TJ3/
M4,MKC IN7&;QEMMFM(@L3XDNJCPB#L8!S>)RL:2:IE^%]U&=]HP*:++=9#)Q
M+OJ"C8UODYN02)X!D=)0-Y)U[=T-<Y61#>5>N#M9-Z'8&^%V1#Y@DEJU5NN\
M (7,TI=-4463C^J\?<R@Y^6X  TZ_6R]7&6EN).3,#DUGBGHAAGB86?3E?#=
MO,]4)4Q<H6\\B0$#KOSP#(N<UFU]HS9QEJ=/0I?.[J;7C]QP:C^8,Y:US:H-
M"P8J9!V1Z)7&G>ZK(<;%[A0$]_R$:O#0'BF,W_K8SE('2 5G\!9EW<F1S5)R
M)S:Y?^LUS>$[3^*:/QCTK,TQ4HK>ZO&;::XP<WVGY#6^GJ!V9I(K+* D\^N;
M^S$B'Z<%Y2^>F[JM6F>"9Y 4\HI,(VO5+%EODMDK7=*,RX1KNJL_Z+3P1;=\
MFZ7*)-EPNN&2&J8SA#G)YSD_Q%1GA.T]KR^K#H:JG;^59O%,?$==;SW.).O1
M0;E(OY%!RM6,L.+D" ^@/S4'4ET/SVT<@HS9&[5F00657Y,9_QU&Y4I*^S .
MH9F##-LNE@>*SK$\?.++JVXTA[E!@6>M_B8S' "3!2$_2N"=.1FRP),3*H)!
M=6W!#8TFW?)C%;@S=;=8*WJ*Y:<XY;Q$U18&YC!1/XT1GGP+EJML7DQJ9\NH
M>W! XR=DQ FI,.A@5V<F^B0SC2C1TIX)!5^4B92F^8^ED/^[!M=OYN$'C]^>
M&@&4LL")(_Z(&$3'_EPWHUX)?Q@\8"QKQ7T'SCO$G*FU3?W_M*Z4<\C1UW:V
M+[?Y-LW%5JKRZH1;E>^BKDB[@_EWJ==<7"(G#-(I0\]0KUNX\=F (7S^S+;F
M(?MJ2^'?$@" ,'E>8T#66WW'[*_ZEG^JOF4M%/$2*K0<R!B:6W]N?YI[ MHJ
M)>Z>BI"]:=XSLVV9Z4JJ1J2?A>%'IE<[ET9D?8D38MV2M#<P@#7UD4%<D;.3
M>M^2+E4QNHN*MMB[Z()I_$-/T>WB .XN1H%S:^'@X!H*(B4$/1L<>]&__!SM
M@<D#,_>^X7ZBLVIH;L3=FV=LA.RBY<W>$.T60DY31K8++<_1.;E6]E\=Y9'C
MS6,2?6I)?$O9R4 ^Z&H5D@MZYI/>1K@*+$@7/JQ&1+0X*G43G9&U:O]F-$8O
M1F9<F *M9<JLQ0[/X/(%W@%$_:-9C<9"A05"JE2]YSTGWIO/C!/"U_7A(#"B
M2PG/_(A#!F"7XB(.Z!!JP $?\;9C/_=K-!L.N':Z8:L#T^.,Q?_]!@K# 0\1
M."!9]RI2"7OO/&PNZC .^(0$^9?"*=$-S>::Y3NU58JF\72'N36U:*4%P_@G
MX=SR 0^\BEE?4@OU>G'@@,BF9ARPUX\#5K772PD0]:=&G"E(W497/D^^W1"D
MXR,-=Y!//H$.>%GDA'$TCHV) 6_Y0X\J" _'WKE]%,'PYO-U'#>'C>]VCBFC
M[NK4Q2KTIXI!:WQ[TP84! &\KNH!^=73\&8X-[WS.CB]K3>O*[E 06R$7IMJ
M]F%-@ER)+K$[5:4]M=XV6([E;2RO/VWH=D=/:^/3[F(UG#!/<3Z?YR$.T+EZ
M"!.0IN*38G"S_CJ12B/'/N7O](@8;L*=A(;9%:!AS:Z3E^?C;,1\K-B?J3K.
M(:E+%F&O+J%=M:&<&+"K!T#4$_0)U%F" :/,A!JHIE9OK>H*:W:?)[OA.V\N
MR;\A354KCP/8^N[B@$)GK(V)7][ZD>USZ'[8W85')DU@_B/BG2U*_%8X]C>L
MS\#BM>JEAG;=,$KFN="C5!(]H@[+TB)'O(DQHAKB0^L>(PP=/V B>C,1#1,P
M#J4='1.^MGU>1X%XBS1+PEQHR>,@3$(DQVI,Q\6'*<:K<>JRV22MGU_G?KZ=
M7\6M:<S-=YU?@A6Y>#V!-"J"Z@8JB9NC448\W<TR?&\[OES^4I1$FY-3:OIJ
M]O*877V+C<3 -'.0/64H/!/:YT-IY4)[5%#H[GKJ :I7FS#T^1 \WQ"=GS&Q
M%E<?E#TA_=HH:-@VU!PLX@'L\E&Z]2DAFR/9DRL>=QQXO2*%=WZ$(XC\!Y3$
MK:W3<H25GQM["8\>C-(,SMQARGNDH53@J1OMA@/40O1'%I&Q@1M7=S*>&CUX
M):6^MC'H>WN&Y'OD].YQ[HSD)@.)Z5[& G>X0(LFF,J+?Y^MVC!H1C_XI4*0
M#SE%UR@<NA ")D:3+[>.G%T@N 5VM=,T<OU<1ZA:551?7U6AF"GP4?-*[T 4
M'JH-]R)?P)[;LAL?J8]"5][ZEXHEZSB,#K+&.*,J;HVD?"1R_BH%AB3CF10/
M$IODPZ]O('\N^#Q"D]4>R0@D14]BE)#8:-JF.A6K/+.P#;,YRGN$D'8J@EE6
ME"*0^%B3DM'/,E27)=M+%3F:Z+"_)=2\&4BV;_7 U^=:MIOQDU$?"OW<61((
M>[D%9 KMSB+4O2I^X"?!EED6:I^HLZHP^[2+X':XM[TT<]C"]_>7)#:7"-5*
M.R&Y!PX%K9@PI7RW"D7DR49^01IW&UN73>C+3BQ'Q7V4I_<CDH:029O-Q,R.
M+/EK&YQ-!&@)Q*EJ4*A+EWO^JLNF@CXK$(GN)]*U1YDW[@^YV_!,D2*ZE1PT
ML4=KQB;P7'WKF%/[O18QIP2J5*!7,7RIA0$&_1"D^Q-RGSM)B3YE35Y,T:-M
M)L6D7B'NZ92%6=W#!&/@Y@8RCDE7HTZ&F6[;)--NA=W+JX-2;&A'_09#3HZD
MZ],+.HLLS#[O"\%HNY3QKSZ2**J#CWG8!^FM!;<(9L:H71&V\9895I,^^>9V
M3+21TR]U9=OHV'TE Y^15$96T/>XN_H_'\68+2K;JFAP]M3*S[@2&KN4?8!9
MNA$KC=G!O\D0G:1&OY\G$US#GN)=#[*]%TNJJEG[Q%=L[B5XFW8,!ZR7P/A-
M2DPEW.1,Z>7SU\'(4)XB4[':/O&;,VV5!6T;IK0-*TF)>'.>" =02U-[X;4,
M6Y<Z7D[B!=B=0M61O1[PW5(1<?_&%M#3)-5^W7",A(TVEF<F\;$<7VW,CD31
M\P-($N^PC7-#B,Z13Z[#)<5R-7T*Y>F50V)@E\0TN)ZVIDKO]!B_K:ANW*E7
ML'GYX&\^0Y3EQW<KK<HWIVN7=.%05^;3P[O7\T['0-XV/\TFT-S0\KFXKFF=
M1#["8Q&9;D@OD?Y$C/6",N DLQ@80%9;0O(^(O9J:/*K+58F)O+,S.]=K.WT
M(Q$OUA8BS]Z?SHJ!&>QL^1U1^V-S"TR,/T75NMY@(;]%>V,BNY[-2H<$L7'9
M[.5=CH?%[J:\<F2 JX.7#K)6]RY1W*I%>9"$WT<<\*E:IR*H(*46R9YK;[NP
MZ"E&_%'21U/?A!\Y^SH)&+ZF1*<E^_0^M30Q7 V:B SKCO*B;%"DJXBVN?7"
M [&<3&87($>)+&5\_8#18H=_S%;LA!-9FT0?M8!-]>**8@M8F68GNHT4&$U!
M>^( U@"[(P08^P)*L<"!>>.MB:WIP/@#6FA3!!E+DPE#C?%=W1UF!#>38MVK
MMN1"Y7XOFU2W<!GJL*;S\ICB]R[@)7<\9PDM&$LIWUK7KG[.D?CEJDBH/Q7\
MDE.E!+AP=7+VW8M).S&-.W13M33,;PE6L==0ME$+YI"3'.ZV_<SK]%KM[>OP
M^RE97C+]SL9F3EUR5>[ORW,/.;K 2-[H)J_'.B,\M6S;*WV5;+'C_CT>80'/
M,]=B!F2A$-(G;(VB=_#'Z:Q/%2*,HFG'7226= C6)ZKK2?%)^[+ HEU F5)S
M6;C[?'0OE5&C>=^*T4,I>B0\N(RDY\FAD*2<9>>](IKM,<+U'D?X!2_EC'7A
MF&+()&M,L:PX==7U"M#-?2J"7=$KH>&RU.\7UDQ@Y&O;[:ZW/V5$Y+18*0FJ
ML1\^5A@[[OU$#'A3:Q[KJN  ^+'I,:8!(;]?@&=G\'[#P2&LU9=GU*<H50\Z
M"GL\?'7'K-=EA6ED/#/8:8XTZ!H.<*>C/-)<)>S >"*/F^)T7]IN;MQP>>#W
MQ69I7[">$.V]4*?;J!/KZG)[V7Y'>*?O_AH6?RC:@[QWL0&Q"[&85^5@U55.
M0L_[ WC+AT*/$4K7+#R_>:7B_HH=EA-MJ5KC^21NT5(F0!CYGLKGV@<OHU%>
MP<)S5.4N\M5VW!X)E+,%:(Y&<97XA5PUFVLQ$$VG-PK),8($)2EN:8HH)G9E
MX27%B@\BI%*IM1&+%@FT^/,I. 5].4?UZGF !])Z[M5&*E*D^81K2Q5D63&L
M&C-0.,/Z6MQ'"([2FN-K[I%8^ZP\%Y-D@HI,P!L\FLC"1I5XE03WR^E"S5:4
M2O-;(12I>KW;D)T<*25^FT1P:VD28G'GGF[7T.'E%."[S1(R#QW(<-O71EF4
M1J['<CQU*+$@?W:3Z,NLKV3O/ZM5Z ]1CUF_76PG4U#]G VL[V%YM((#7,JX
METI@!UG;4O$W<("KZ?=>!=V2_Y2F65G7!,,I"6ZH %23ZU[<:;9VY;VU%)5D
M3F;/MINUU(("KM5::3H^:0O<C1[*)ZS&'K8:3I9;I=8/1G,.OGCI(M^IG<,5
MY1CS#>]_]7?_=57S9Z]J\.H&BD<;_AP/D C[DGL\ET,/.1I9V$'XU05Z6]J1
MGC4LJ] :J, [3NQ#V,K"[5RG]C2%1WII=/< SEVJ(R W1Z\M!U)!HQ':)DYE
MEU*8.*5;,R0(G2,L6*KT'-'SQ2+$>L&$IHHZ5%BR?EZAHCREK-8Q!%TLAX13
M,@DSXV"L+/(D\47!$-5]QFE$W/9<!!SUY7N<A#TFS%/R,32);@ C%YF9_Z2"
M^Y*M=',HJ-%7 (/W,EA'<0#V<QL.D"Z0F<=+"KR[T<"Q([1604,SYN$4<^D>
M\Z0")O/!GI$YM:X<<C\V62^>Y]:(S48':S+KWOJHKT3LPFA-QNHL'^KJL-VC
M\KGK)+5[A[G]A?4L:)W6F0SQNMI0HG/I7QKN6[0U\9V;,59R%'X==B-/?\J3
M%-[[2HK>[>ZL.JN'A%G@7>.(O61RT*=]79.;J).YD *S-]R"G7<+Q%&?0=%/
M)T4PK& Z6UYJ5\.UU]G,W9_\,+F#/!LII?Z/7K"%"]$1IU&KJO27SK O+GIR
M6P0;QLQPGU(T3^@_8T>]JK@()IN%A/D.L5,W5'N,);F!6D'(H$+,-2Q'3YKA
MY8_*'#,6.("]SJ6D3)E(:=1\ F;)U#3M>-A_ACN"'NTP.=W'FVM[@72%(VY[
M1D#=E!KC5#[J-/[8D^XA96DEPM\L;E<0;;G N31;?7^3N9@?6S8P 2GW<.*F
MSBBUO[)69D78X_6C:V&$K1\=P%C/+4J#2U[A +E;$6^=L%6%9I5(;*QS_IW<
M'NM\V*F-<*.$[,QU*<9!(?2(T&W6!+X'2Y3H8&!)PA3!0Z&$G.G)?(M2M;>_
M)/?Z\]CIA_ F(9GY3]>1K6MT9B]W'ON<JE$6^6S"/"@3(BDN.)MAR%I!5&A0
MD8'V5!JP6?93+=-[].[-U_-7HO#[-S=?<=1CAZU7W:;F:U5M2(.--<)6M5<-
MP(&"^:>[G:9D_7IM!A]&56(%JQL"2^N<&IT9M>$=#SO>R)T[4B.B130P%@9X
M"5A:6L]_I57[<*5OYC0YS" 7N=EW%WD2-,RWQ\DZ4M!ZF-C7+3!9PV/ZF9EY
M+(ECN'0I,54M6XG25_0;%(REAKT$KUX$;ZWC@## RKJZ+"!MX41:?T:>7T_%
MA3FZ'4.#=U%]#K#UC(=QWYSZB*P,) 1:S!]=4VQE91S?! 7EQDGY9:[>E&"P
M*?[,6+ZLIMB!L2+LPFCC%[WFNR,M@S<0A2:]5+][RP7X(]& [>8V66DRD%TN
M82Z4C*O;E3E_G>.*=H^22ME(Z=HWOM2+4RHUCT/AM9R$[44>,,O<JQ8UKF]F
MG\QM?BDQ:"#? Q.-HU7.2TQ9V5ZXQ(O:(=PR"3)/&X=4:WD8YU>W63)LZ%7[
M@AF:[0*EJ#W3')S2=Q0[KHZ3G@A(,VM[%A:^JN>'5)2ORKZ!\XI1R%]AEG4"
M4^. I2?(@Q,7T&@=L=VY5==+4\KL<-#[IXZ4](PPKGA-Y&Q4WK3AM.GDC<&I
MA.;FR-+^,T&P)7+8>L1NX0VTY%ASP]ZLZLGYW+$'"H^V@S'OIB*LNP>]A-)7
M85;8WE(]J<&6C,\<]A('1_U$"5Z<^-7L^M7A%VF;.[QTXWN\&VR5O8Y$";D<
MG68\/:-G<$/ **'S4U1-'6_5P@9?<PP$FFN0W\UY/*(7Z;?> CSSD:J!8"07
M3HBOQM99G6\S3L/K8O%=JG(:#]J)V'2=*:+YRNPG>&CVGA!WGM32_:#BLZP8
MOP@D=?;7R_1T%GH/OP>^P'YG_.M[Z 8ZY5_4_S*T04.4L/GZA0K"X"T! LN(
MW[DOWV-8+N& Y%'7T%)/,MI%(X/,BBQYYS3C;!W>*F*\&1^\5P,C@PA7#\?5
M"@?'#I+E\ZHHK.GR[4Y)JDQ_]CRE3/^MT5=B?[-K03DS:2S,+$/"S"%%[4M]
M=.[\A),2G-1DQLK@ZN!&QE)!OT3W*8$6HXB%BI>(^!YC-A%+B1K*PR?5>AM7
M@J>^#33GD MOJ#\/!K8+7S2L.^. HR.[D_,?^(),M]4$*0[:MH76/'XZ/;WX
MT^/;.[6$7_I>SQ.($(@,(IZ/H:TH#^%I)N*OXOB23%POB-\,$)Y3"\V-:%_@
MV2#$NF%O2P3;8Y+O;FD'L^!)['ZDP&9<$%CY0=B'<?"IH+M3/%0VO%.;"W7J
MV9UUS"IAZ#\TSCTR H*R(''J0S<V8KAOT3]XF/!P+UNP@72-@3>6/3YK(D_X
MS9L^.M87J@; -@YXR<PW],VI*TQ /=$F?4?IGFD:'_[HQ+89U#(+HJ2B4JWR
M>%]J!+%'BA$3$IJ\P +(I@F>E$'$MM82T SJ$\N=! <(>A/H0<K5/]?DT'/L
M"!+@S1^JA6.A-K]Y(BGC#M-V'@__K?C]Z[7PO7CRN7S-$2<R <,WH\IW1YY
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M_4WY67_(3J^(I?8-"VOU+W[%8A3HN^"UG_,J(HZ\<4 ;=V%J,;:K$0?P+?:
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MT"1*? ?!\O "FBHX 9K(  4*TC0:1;SA3'NMT*HF<YO<[VR-75@YK8@)77E
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MUO62;(]+^Z9JA&_Y_<\A>AYTT)O[JK97^53OL+0XZ;G.LMK4102*?,ET(79
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M4"@/W!V,BUNV'NG@O2O_AB@TE!__RTWUW]Q4>_SO$Y>1T+-S0$G?.2 -ME^
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MP62&XW,79*FU3(1G:7U%J+_E-7W1F>N\WK2$WS,E>S<?R=<VNB6:[-1L/:.
M3ESG(;&"+5>"65:-%$I0KS=WY25R=E7P-;T2R]]"VYNO^:6_=&^($+*_U4 O
MAUL.D"S@Y?/Y[% \Z,FA']ZQ],*3K3;2>EXP=%^UW%9J2$UL+KO"WP)DP@C8
MX"GQD,56A<^+7],3JOLET?YP$]I5O-'$-=@@#DC4KKVYLIVV%-VO2=8(;!_'
M:V-&#@:-PP6*)WJ!)7?&B_<YQEZ51-+'&-"PWWFW0 -8[QEV.^-6KJNJ'!9$
M5\,7MX(YWC!0.B%7#"1RV_HH;?5[K/8TG!Z>H>U!7Z)+KGN-M9DZMYIAK=\[
M%''-P*&W,=U[""U4@/0HC#<!D=>>9?OHT1ZT\!U%)4#B'/"\;!"]ARBQ# 3O
MB'\O\H&RXK37G2XQ;GV-C0LHP(^EX!3E:W Q>5,;,[=C>F!-DSZO7])$FSU8
M,^W(Q$RV)HY2.20\X9[<E7A JF$IR^(L\?-=?V#6JYL&=;D14M(9)A_L-?0K
M*S]'!,64.IF$MKIB*>/RUAFY<FD0%B2@<O4Y_-3)&:DS7+2L>KCID8V[OM-Q
MPIZ8OKE6G"SK%R*R9/_1O/]@'#K;U3_88)@&B?LLW*B'VM9\J,?5"22:25?[
M6J#[%.:GJZ,)T>CKU(]KA-9&7S)<_G$[3I96,:S"?:3Y6TCFA>9S )RIR;&K
M8J,M[1P0BY-IQNOZV/]_;FO\;_'XUJG"*+N]_?@T.Z47  1Z(UL=+W_^9'>4
M][#U2,7'9Y0^"9NNUIE"_T:J<%A347=N]KH\^HR3Y/:ISON'HI)CJO+ W4I>
ME:ROV?4R52EB0[ @]\?R-#JT_P*2_R> I.YU(R:*>N[*YEA.V..!*<&EI&83
MQ;84,GMC)>,/3G7&4#2+THZQ)BS^:7+UER@V=>%)%8+BHWQ?/@\N/RXL9P2<
M3ARYD+0BZ+I#[:DBGZ"?P-%'^HI38PR8C38']:#KS4MG4)WW>-L"&NZ#([EA
M>%\"1\4I2W%F^TVI[<74KL:??K8:L;8JTGUDN2.F,IZ/&-PEU9C:GGLF?C\)
MBK7<>J"@]9.^L_UM*B4+&W;0*XLJ]G%?L4?J=5?EBATJC<,:[&$U55GC ]B<
MKP;Z3*ZE[FC2?B2"G_L+,TQLXZL>C5]RBM%-]Z:.@\:,8-X]_:J5VLY[3H!7
M,3=8DY.!/WSU$\ X1?N.)<Z<X[=^A9%COBYG]=D_+F%-%-VN_'1]09.TC!"!
MG#VAMVR &UI^"+[FK=VRM!>TH*UA,;]'KWXK%UB[/GLE)O%)W<O[C/+LL^_-
MWIM  T1,!3845=5D1"/:9-Y.NY@&>XUW3'N)%GE["L=?SMKVY(Z*'^IP/O["
M\$+!3\AL(N,CBC_=[''$RQKS<#,@'%=2;)4,%VG-8Y[3 X40.-0R##D3TB$<
MG3=0]9ZW_456==ZW6Z W#R#I*]IYI35?3DVI)^#=\IZ]U5A!K1'1]FPDY[=M
M<O8=D -?/YZ!"R$#*U_?.D6">>$U!R*M^N02FBMPN*(?L[W$B/@=Q)>%F3LA
M\PO(I""]H'#46J!%J<M!\7NT(,MF7[)3-6COZ!PP5M1C=>"Z$Y98[1 \RE?U
MLG!X[$TSW7Y_&M3*]"VXJ7)3-][ML@]/;H:4D5;:"A@B6FE-D:,^PXQE["PR
MJOC&Y]*PPDHXV$GP>#!CV.ITA=4DC,%I%?+=[<P,2@<IO">ZI/HQKV:YL;MU
M5##71B]AT-J[XY%U6;O3LM:1Q5U; :2#H:#_VZBR;;.:%/[B1;A<T.-82/NV
M0RJ2]?Z5>VO 3VH#4SPHB0.$Q<@]XJ>M6E.A<'4PIQ^9AN!W#&+\( G:DC13
M]U_0$V,8#/R4RR<3,H[32XZP8$+F1R[L5WYHBVFW&:C00C*^9[CTECS;ASRT
MQ'Y6]AN%U#-MTNE0D"#+1HN4''JM0;+@+-!V(1Y#N7B)TK]RS8P*8]\3%>K&
M/JUP#G (H+E\F6\V::/C27)KZ\S^GOC]YWEEU$=^OE&%IM6,VY$N.2C3%L97
MO&TWQH&+1B7A?G/\9C.+4OI7O?3O(I>T;)-RTN=2;W8YO'1'N2OEUASF^SZ?
MM\5;^SD"LXO"&2,+0F.53W0M, <\W?&20SXQX6W/BRG=B[7>1+\<$,ES4Z.E
M.'P=<;_5X?:UHZ)F.AOR]BK:P\/$,C;D'6N+D*TAV*]Z3&.7KZ3Q98.S;-G$
MZ%\P-/[NPET\-\?HD?N@,M,M%<K+CAVU=RVFOA9H>N=F2/*]U-&Q?4D;:=>J
M45./(0_'AP^*LT^'OLSD](NV.[K\^M8D\C[:E,3?4F1N[):9YTH[;R<%K](X
M"<@),NAK/T^+F0U-KPPER+R*8$N5);MN&YFUKG+SU-'E'O"U"I#SD+;=D0DW
M+_V0JW1H2ME]X1+B#H0.?12TG3M,5IU_=VX[ JSMI^9$ (WLUU]_O","$4=P
M<#L'LS,<]7AS1K>;BL[/,QGL=W^:<4?\J@%FJP!YAEQ7D7X3*;S[A2.Z$)71
M"=90>;:J?;T#AFS$C:,G#7Q(,&IA_B#Z\$Z$^9NSV<\7&#H/$&X(6JS(64DR
MMERMKN&+13 -K?NJN/"%POKYHZ/]G=/=U 53JJ"^*+4](FY5&<V9! E^@E%"
M28B"&PW&(,[(BL\!YIC\8BE;].1&<'75R(M8_=,"H;@33?(OODK?/FCA\C-0
MOX288>FA<Y#^!E7T%B?^CI?CX64@+4GUFQ<W]TN8D*!= U=0&D'-+'D>=$R+
M:-X(3Z.D0]\;! <*WK'BO..A<VF?0>0=)EFNK DKVNSE<?$95GV2)$#V.+K8
M'L]^#HCY30U5$HU'%?HR$?5)==@Y8 /=O"\D"VP2,4"MR3T9WGRA)-"SW+*:
MYE2-J@>SV/:O-UVY:6KWI.,&;%?%Z^?D3Z3WDHPT40.!'I\#$.> LX04;)1D
M#J;I\P_3(CGNKW1KLM=+L<U!^XT2_.!G@YQ-.J;9P?G'?5!T$31D;-D\'/7A
ML<VH9F_:9RH'Y373T>CY:');,]; Y=%YE/3' %V:;?XH1?7:$KKO$A%)N>W)
M&YTO;8(*ZT0<LIW'A2]8MIVX,N9V;(FBECQ:OCO*#81H *=Q.ZTGSW%TST$6
M[WP_6'EVI5VZ(58BITM$4#LYT#KP%\03+!(?AAH[\U;&YY&$8UC+I4"D9B>*
M_+Q78HR'&"ZF8C[(5M7T<XPBT*H?-O+IRW^FU\QADSZ@<U+."C&&1=B$F-RK
MTKM.6OC[6.F<]SE]Z&D'\V\S1EWC#UTMAJ*[ B3\%-%G#03^;V.;7,;B_+VO
MHD2^Q\%Q"-&ZX8HSR/Q^3\E4].:IO(P16.T[U8;IR#F@[0I"RM R$_=&WHNI
M]/19O?+-Z"%43<]SU2%?<>Q#9;QB3JM+]JR GC+U'28 5*J?7&-^6O&'$3)4
M@#\S:8+KZ30U&^#[NYA F?AD-!0X7?V#7TXK9KS[50[G2V?U^^!BVW5[3+U:
M*02Q.?W0,J+(J7WOT2 "M7;(RHFS]8%D$ZV3"4VS.WP7 *\P+LC! #Y?'LQT
M(.[)K"Y\1GQ;$)G4QQ8BK;2S7Z(ZKQ^Z58$(,V.JKXA02*3C,:1Y<9>RD=01
M+XP-3OB2246Y077(5T@U'9R("S6)[JTU!WF63+:!;^"E23_L5%?5/EZFC%)%
M[*91I?%%X;)7B%]&W:@4'*[1MQ$!V[2+*LM5++0YTKMUUKG :T.2@%-A!U$*
M%W^>TMPYV1:9'(/AV-NBYU@45EK]V?0"J83NF]S<?;=V,I:VGGK#5S)GK<_E
M+).FB([GP]>R30E-<B6!%[;/5*6L'H^01!!TT: ;S150M),M:(*4+#UFT9'!
M=$(:DHFSS;4S0H8YXO7]8^6N_S@'*$8V/H2F%S53GP,Z?3$[9VZ@7_UDO3L?
M9F>'FG>ZH)'N,S0R;!+6>)T0:J^:<T"!)IFD:S'1(/LC1O?\!-HU)Q\[!\ 0
M]G^>*>U_^OM##H?</^9E2ZG\F\LVXM^0.R*[&SP]]NO8=^AL"1\(XRG9Z_OG
MSOL*4>J),D2;S-HAJ_PK]:JTK6A&"9*^5I+=Y_L,O9^/CB''\T,#]67NVGV$
M9PA'("=,Y&K8?<"6(8HRTC%]S<E(-N#&PT4/Z0WM)G.&<+=U\XSQDP9:H,7:
M9.'OF,)%R?^2#NYO_"&%-$2YTWD.N%!<\*=32O#]C8*NT.[OQ'3_7%:*SC_2
MSQ5-_Z<T2+%_=K;^_>"L\6\'Y@#)OY'0Z>S_E9;NTU^C8?\S?<B:[G]D&79_
M 9ZQ/',5VZ,ZLB76T6#[C[!]T6TCE9Q8O0 Z]HJ@T%C4?3:!;Q9J[28VVL-'
MJV; ^)8U\JX^N4#/SI8  W0T8'*"H7=C-]1"%*65?Q(J$IIN];_)HK+/D6,B
M^:@ [:C**Y8N5C7^,CG<-S[4>*Q[=@G \YV>I#1OFS^]+@PI!6%C30]6E;=V
MC^3WNW9%BAI=:^ZS=I_V@#A3C *^=&E3AI75A[Y*N>DF2QK%C@-&I][-OPA[
M@A:JQ_I3+W$NK7IPQJH$)CWK6Z+S!M=&1VATU)V_UF;7O@VR8#4HO'/YVN7;
M-WP8.^HP">_][OBDB#+0?XUU^9WPZN;7S"+30,V(BMC::&NT/66+[&&=ZX/2
M506U-P# =WH:K:>Y=R4[I]@OMQOQ=@#'WC=(>[EQ]G0D7HM3FDSI%.?>RVM&
M7\(@SR[>QD_B(1D9Q?H%%=I0+\I@KNWYI@5>9*N1Z)?;/M(R/)]=V<&CE389
M&=J?4A:W32SI"^4-B LC-B)%KE5"M-#M,'GC<D[RN\;P/E"DK=PU=PS' QZE
M?GM=EF!E^>=?D\J];Z73;"<4]0Z[L@CJW9Z=4!1G>61]HN/.RCA0T?EH8ER>
MVCOB'& TDI%:D5+KL"EH3>D X0M]HR>]$UPAK> HNJ,>HL\M+@[JJN+)9N@2
MP+HSIS/P*9NDYZZBW!.R#%"*E\'3.79)9(G%PO9Y$\BWEI>XYCW[!BOR<K>X
M>WK\Y#?1W=WVE!Z$&QK7H/UL5#W-':ET@;[BEPKO&>GPKCMG42,WC/=U?7Y/
MRZY?L."2^=L  (#YPO?LWP21?"1Z&/U0D<DRM_PUS:E>,I):<>0<Q!\&6&Q&
M&^"$" &BYX#?>; ,ON&@:%.)+8%B81NV+^+ZUR9 Q:X5FF2FLZ&N'\ZT6536
M.\0=[YP#]._VZE5P!_(E>P2^HJ*.+,JMR2=^XEM"3X:$?0SY*TZ%JT.>J+*M
M7!IR;::R-;I7WIEKJ.BP5[6F8KTLWN<]E!$@)))*92MS&T9_8,RS'4NWQTZ5
M&M_H6>A!*SKF'C(Z#XR]6*_RZ)DNC(<DJ9HX)&/5=TYDD1=5*.5>UQ'<TN",
M YFC='JJEQ..=6Y_?L5,.9.RH0<#=,>UUCU%M7DW)#RHQ$.=7;["&CUL2<^^
M5B5JA;_XHJ(4FDDRK#.L2<K"K3BTST=:-L2OC1I1MF"T!L ;[>"%:'YRX[A?
MPZ[CUM#G'Z%ROU.YF<6A>]CE3.OL(_3F(GQKP;U%=HRF48470DY0X@O@EI82
M+5GF7R JW[OV8DDLM*0?F=\G@$?KGD:RR8:EZUP#D$K  "TC4DSH+3LH6',0
M#3??87Y_PAB! [4^.RQQ#7MD)+I*!;[3ZP=)_ZN,%JJ4IG@V^MPJ_36PY1Q0
MP<<[B]X)VK*BELOX_HWDHS/R.&DM+XU,GN9M1UG'NYL* ))L*Q-/:X6ZT1<C
M*Z61!Y<I7WZ-J]58,1K^Z[:%$J8CHJ[O\'MIA!UH;Y;;8Z_8[O^05OMSFFUZ
MU9]6 VBB_.:(WW%)X.R'"]S)N!F32Y2;:0VI1ZO02!]/YM>,.CI6!U+W_*]6
M&O6^-6+5D/=&XN^.0U<%N<].0 N*?[@V346).2[C&9!GR>$$\_;_JJKB8133
M<3,9:*(F=0FOM;BO7P1M20DE!.Y"9]-_)WS[P[4-NCD98_&O+O]\EX5$A @/
M!>W2Q1'.J+ %>LT4+VL:$DCR:W9/CRU31Z.WF!_M^5\#E_\O]MX[KLELVQN/
MHJ(440'I1 6DA"(@O80B77J)=!&0$HKT3E2:= $!Z;T34.E=Z45ZDR*8T*NA
M1 *$\(OGW)EQ[GOO/3/O[]P[Y[XS?SQ_Y)/][+7W?O9>:^VUOFLM)W ?)J??
MNOS!*2!(C.SD_'?0GNSWBHD__L(-M\&$OK0="Y%C6\+$LW0:SFO&JIWW@;6=
M BYQ1SZLJ0&E% 5[ 5V]=?VH$&[YB44*'EP+1B\&9.YZ4LX#*  7 &LF[F &
MVIC%W/UU;Q'_LSIY6QQP;V(Y"DBLSS\T_/V9D'T@H"EJ(@/YP"Q<XUI\4#AK
MPK&7P%LY'2LV2>L&/JN+_<X]QO00+$<+*<QY W<*@*%+/*3P+R *'X>K7PM*
M"@"_/JZC?"MG(RZG7Z:O5&E%(D M:=UQ&S^51W9_- 3GCS:__SK/>+\D':S;
M8 ]7&[UBDOB; 6@7O6D[1V&+7&YH>-S0A&#*]W(AY?#?AR/[>1O_9$S_[<D.
M?T:NV?\,9]/X70 Z&M$?8&OQ*3\BVJ2N_=9)Z/Y;<4U(\4^)H3,);?Z.7.-(
M_PG+]O?[SI*O([(."[*QN7M]>, JYE7((]YGZ>/C_X=B/AH0: N)L*@4<:IB
M40O,HWH<T8(Q$CH%[!-5XUE0I"'N"B; #6G\Q&;O01O1X?WCX1YQ\XE&DQ^R
M_YD,L!+*4%BR=>E$DQ-'MJM5FK-;3_TMZ]_:?M;_#13R?^/S&^&;+8BM_J:R
M(M=)\HYKKZ4N*!"12:)7,Z:/'$_.<8&_[IX"(@6N?Y-Q5G$WRB[";[>UEOTK
ME?C/T(<72#_^.&3Y9+2S_5^W<59YX])5YQQ6<%*>C[]QR8SBN18/9OC7OWJX
M/PPR+O5R9'QKQI\H:6+U8VP+7J3]^(.Y@5#<)Y&M&/;C*($__J"/W:3_WS@:
MNWV!2#SY;H.-#8A:>?X"3N9ZQL$AK/-=9<F&DD!X4-0Z(:<G\0V1G 3C@'2)
M@; PMB*VO^I _A')Y[^3H.S;D)08KK1)IDH<B/>TB-@%<0##:3G+J^#;3(SP
M",B])U6Y=:^,H[P>K<KMUH'2MBA5[H_;H7TTG2Q%>].^I<>[O['IF$K)SRU[
M'K:"54*>@-M P.F 'J8,M-,"TQQ\U6"KN:7 KWI.2'%O^&B\7EMC!2I#:2UR
M?!<M8%TFXG]K#0[/?\55)K[R2IXNPF+27$Y9N\#!#1HD^J;(7\$'OPSZR><I
M4\HV-*QIS4V-F!IM/RBJ-4Y^KWW@HG *R!!KZ89%.JJ3ZF4W,KF::9,KQRVE
ME@[*9->*P<*..$<"K;EO$6(RJ,MZVS2JQK;TED=T$V[34PH(L.GD[91<3K\5
M;_H<PH5?CY@W_Z%TT$%+R$CPJ"?LZCY6[%0TJ0I'9- ]P&1O0WT>W([,5EWL
MB;B:JA>3)R+=SW4UM;B57\-1SW5,4^ZQ]1^M-/S_52[^:;Y]-V'*=1B)KR13
MK;W,$MBKYN!A5#IZP).L%5YN*^F[+E?*RNET$)WG/1='VU%D)!] U'CF$!*=
M]&BS*4+2JBH>P7U2B9-?HM TH?GZ%ZK^GX&J-VYI+3^D#SGQ:=DON_6#PF$J
M'8$[=T*6^N$4T"@[=H!7=YKO'Z'*5) 7&H]X0CY)=3C<O@E9]9XT-#';<3/Z
M8-&V#7!!][L]_%)@PJ' +>@<=$E9[+4)(<H;DZ#$@R8T!S@>;QZ4#>IAS'-F
MI]^\>3'SD;#ON2+K3H$OR%623.><([D(TT[97$W'HPWY!DWWMX.!K9KQYQ;+
MIEHQK!_JHT,<<A.6-Q8?*B04,&T8^Q<4RN:M[7X>>,\,3?=);X5/1F.^FOAY
M&$7+5[[FJG]SN7WKW,J1GNN"N#%T<-E&2^/#<*6DPDTD@_*&08N?\L,YG2@]
ML!2AXT03%%& #3/?. %%[8P'124B_!@'1JPM7.,_!@N1N%1Z0PQ1$T@RC/P]
M$U?_Q_[+B/3T^/GPV'1*83BW%T98^-%T7$/-LE?J@>8GS))#WF B9;=[5Z;
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M_5;C3[$36G^OMS3]D:"P[8$U4O'6U?9GFO)GPW9;KF-&'@C85&[)RE:F4\\
MN@V9_=T>B$;IYO4P &6<*L>LNZ95=,="M#&)+B5KZE;FYK?45N^5?Z#N$L:"
M>!#/XY!!-YY094R4"T5@!2SS[R?KA=VH3^:+>/*$[X[/\5C&I?VU#,W:)M"+
M>"G"L>7ZQ1QU,C&%>"^T,'()0JZVM^QO3.+X(F-72!V']@F*Q@9LM6S$G@)N
MZA\T7Q]"@^)<O ID[W:55+M@-XROFLO)4>M2$PQ!DEZT=\*%I7D"T7<^V6B5
MB-3L ,&FQ=.8B<?C.>9DZ4J$QPVU\'DZJ#?+7!)#?H@CXY +4V<M %)D*\DX
MXF8U[V=.L2E6;2O<R)759L_2Z&T'H@BXW+@+*MC8GXG(39N<=3X%6(TK:X;K
M)<XYPXA(M#V]=V^W^>]?T-XONXX#S1-ZUFV?4PCA+*"_H@:=N?N96&6XCT%R
M0,SO%.#SV*M(@!2H/J[!@LYU*5REK8@2Y(6S&^S$Y*+XXJEEOKWR3M<MQRKZ
M.2I!06+LMZR C8^DL6\56F\VZ(]!)CZ18;V;;L^W>I,6FEU((KI +3P(AJOF
M>_HH#>=YN6Y0PQ?=IC\F+>JJ4,EIQG,XV2*#+S? ::N8TZ+I)^W*?9D6R*IS
M+3J9]YCLGK36E.&X!EF*N2)##3.0? ^+CLZ8I/GD3ZUK>GDDK/%YWRG]Y$N'
MV/"Z%V.C 0KX#IJ(+M-,A50'39,500I8-ZTL>OUIQZK\#*72O^J&"=?DV.D8
MT9O#O1P#8(M^5?C#-;Z-T[K8F)EYF[=F^AW<%Y0U9<+UN3J%Q(/(F9FF&YQF
MI4)UD;W$US@29,8JI+IGFNB3@F>@3QB?_E[<_?_T\]^87Y*R!0&^K(KDTKT)
M>$&QK+=/R9]J1L5N%Q[(HJ7,^SE-O<WQ$G%=2Y6C^<F8U8%RVU>@ ?H+@)KA
MO+2E#65DKOM0H8[<^[.ED%ZDT[5RS9X,_:"VSB !BO^P*GK5@&O*[_&__9GC
M#4HC86T&'J$W@[FD+4#$U]6YONU"<XCU[I;(.T_18^JU2N0UHC8/FW]0%(SG
ML1R#I+!!L?+CDU/ !)R!_/V1X+-"O^H.5G([]KV>VH>3)2\^6H_EL8$^YW2W
M+545C4<L06^[OOJ'.?]_GDY2L2?L_@3@V/Y=MX+3!^R&6EAA3\<<=WLO;VQE
M_("N)(.G#=#[4VJT/JFKGKO@M.]9N@<)PET/.3HHM4NTO)6J[[.-!K\-DY:C
MT'O\[(_VEORSO2RO,&#I4?3QQ@L!ZOOXB]32F1<?!L0@YGC=;;X-N(></T"7
M$/R0.,.M%#KVO-)BA"^-2-OCE;85ZP\-OX>B.R*B#W<<CX_&)S1UT<GS [A=
M_Q+90ZI99Q@*_CW$7)+K%  SB,;H_2UL__KW;#O&EA1^CVOV6AHE_VKYJY;5
MKGX$:D/9GI48\2J7N+@X U>=WB;]$F75["R95PP+%*^_F[0+_TI0\KM,J=EA
M_X=[E]F<0*)X;31>B4W!W4HOUT9ZP)"I.+LQ $=U.0NORC:8'F^59*)@[70M
MUS8"U),[+VKW6LU&*"TP5HV*G_>4ZU616W:1O=,VH,SKW<+4DAT&BMCZP^_F
M?[ -0/SKCSQC.8.T99'+"\]Q%/;*57ZS,^[<S_MYHN<7N?S[X+M_.1/_V<[$
M/\/SG]3G9.3-P>1B]+RXY=[4[D$>CWSJ\L:O<U [?JTOFAX?X[67,O*?ZG::
M+!->DH=3LI=4?.A: &F5+5S29\P[!1"'G@)6K[0<')P"X I8;KSXS)0Y!<S/
MXZJ\["FG3C*"<:8?%W##^"Z%%KT3?]4 B*K-P#TCQDL&V-'X4J7FWQN#*YW
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M8T)Y7MP]!;S1GU:ZUBRT_8%UMRP#,1B<]W;8H:!.-=:X2(/:E?X4$&F4P_%
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M[]8IX.O0*8!H%3=IVH,72>]%3@%O,_9P0)3Z?]D>7#6YZP]&$1S3G + B%/
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M^&(5P+59$*.>[PG[L*!3G?ZX08,D;Y[#L^=]6< 7X_V -JH-4!QEW6S.:)'
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M!F:YZ8M592S,INZ+$$G W)^>B7^8__8\A@ST=2ETMXD&J]!DDERZ0-;UTE@
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M.TEV+8:<G*6%A%N_@O&Y_M$^B?]L_'L^B_;C7=<SB;@?96])&'9MMNM#AZ\
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MS_ENOF=_E,#>XB((9>FD6BA>-J:61' P($IWQR65V4[VH\^UC(.<&\6D45<
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M'#DM3I!@HEL7<,]H)1?@9'9"%^3[K!Q^\39!B.]HYW)SC80EZCO46]H*SOG
MTI<IU.K!I&=);\WN\^>8%UFHNM:C=E&ZKW[!M1?2NP%0+G#9P5[@9?620K)-
M;1*K6R<W6ESE>EYCJ60^2FE%W76FU*[VQ@DPVF"Q-4)T68Q8M-#]D*]CI_0Q
M90B.THT.>W):^N3VIKM##8*4$6/5..8J'IH1+1C-O227)*L9E\:4U]>"N )H
M6_TX_@:7QM\\-/[%FM X^7/BN@;.TK:IB\^AWFS/,TXFAG7<U"O C5.L$!:?
M3;\X!9?_+@#&5;53_O/S>\*6IF;RU"&T^'\)^BM5Q0O+VS-L!B\O^/;A6LTS
MSS#J=KO/KP!/EHR146"Z8R(L%32;1Z%D*J/.K\]= 18KC"ZDZ+!@*IC1],.T
M_W ZU<MLL362/V;[-V8S7H+=&)C,.U*MMIQXJDK].M80^@4P;BN^063S+R&,
M,956F@G/!(LGXZR<9&>P9L7]OZK2>-;_K4YL>D?*%6-D6GLSS\>)-836R<Q#
MK>![0<E*&[W80[*3PAZ26?7E!1D?-"I?IW]=;UKR]I?.50-JS:TGM3T;TTHY
M"Q&!I*IJXMH<!WBM%:C>UOV<V;DN.\97,1XQ3QC7SK75I0!J(^S)BL,E)89M
ME0U/[KX69+IMGG'P(/Y\,7C?>6I59V%9Y/W46V(I:U5QZGW_AN<"@0W"Q(DB
MK4H')\[7\'I.H%Z:*!NA;1[KIH=C5X *6^8?4L^GNC: 0QL9)#QT1)6I>H>4
M($48X13#Z][;PG%.QWR-*U'7Y9:C2"1RI^>DK!E\6NIBN"-3M(VE .HC.[/*
MHQR[-&UP6=*OU%2K:,(E_?2;UG7CJV?1!D^SN:,?\-%GS"D1^U;.89>C'=%P
MUVFY5%*QUO^0%3^GR91 S<UAEJQVF8Y(QSU9QD8((](M\[VM*%U5GU>%(*$+
M>=8Q\>DA4(R,0>=8\_7:F*=Y7?H-=[:N5M=#BL2\^B\_K.96RZ!IH0 D(^+L
M@*!CWEK0=K6R-C"LC8V?OVK'R= /95.Z57V7Y-[VMI<%97<0?6\Z%)P[BKYK
MD8^J.FKGGG\U.N^S,464G7)@* 4P!5/=6W2WMF$8CL&W;( SV0MV:"%E@A\C
M84%9(^LU<O/49=@=3/'\%4KN0+7X'NIB_+%.+"3FD!7Q%<#+GE/ALN'IEH_J
M^B8@^GCB.!EEQQ#X3N<9L)"Y=I ".A(*6 &9+16GW^_-;A!PD#B]&2.]D+,W
MTW(0E<O2SGEM#C7 \81CGZ'J@JPK9>%-;(U#2]=(O3PK7NQ!NC\'6C^_[:&\
M25W ESR:B-<22R2D@[C3UDTL]Z:.WW[@J>?,?-SX-!2PY,V,W$6S+ LG;X,+
MD@;>$J[9"'^C7!<!-F6% A"B#"CBH\XP\*D"RD8/+Z4[9QV6^X;%S]N'VCIL
MA?5% 8 (-GH$T\KR _4JH+3MS^%"42%\KF,_/NQ)Q,+I,F&O #CO1^)# <#W
M2(&V"]C-;;U<]-G00'4,/+0@AZR')>42W(0E.O_3N7E=1=ROZ@R[UTX+-S*(
M'[:($C0A#>-A]XTE0-45'F7EF3B"(DZ3I=K(];;$'6]5)Q@X8=AX_KFHUC@]
M_7HD>,@RXYH9<:[.V[O^P(%=7VJC35H!H1]A!=]L+(#F8/,7;B02D<!A+!!E
MRZ#1,4^P6@F.%@7]62YVY1>:J+?-,SS6HK1C;T?V<I[;A[^@:]%\#KJ[$E9Y
M"&W0O?$!Z1WG8HJ:S!L6IX8$BM):I5'4"VP=&EC?SN$]K%(6<9 )0Q/8+>LN
M-_F[PL<R+Q)NV/L&DTVIBM.:B/EYFQ1(G1I*=G W)B(FF.W[1&Y"NQ21C= H
M1,+PCM*XY?=]6T=E)_TQ%8)'2V($<^[2 UN4>UDUS^1'\*BBPV.\+JWIJ% ,
MZQU"D8E.^*LJ'"GU4T*Q]9%3T(E00.<!2=!.@T(V?[)O\J>HN&!-T:R:@@:\
M%4(*WYY\5!XOG)HUVJ \RO17FSY'6A(D.RUE/+@'2KNODG[Y=L I/<^W<G(8
MRX#:4 DMDT+[8?!^<V!W5F3?6K894S7]P4]M!^S#=E1RRQGVX7&I]:^'W?[#
MY3'Z,.6!>FM6W-*3;,/-6#T@OA4C*\4Q63_J_K<CE'SGUL+R%C" MV0I*]I/
M3G!]V]"%%&<]J:O-*K+R*0PQKW#!OV5WDK$.]L4MB@JJ&RCU($2E&Y%7'? C
M;C_Z3 <%CUIF$*MW^MZQN^=N3L,PX+[[4KV+WD)-FASD8$@345LYNKN;&$"1
MI=-#0WR=K8,4Y\?Y9)M"YP%IW60PG^8HU/SY%T&FYVBVAXN!9^<+J?9U>W#;
M?2J>KU_GUSH7:O@VL7M]GS;8"3$86'UN-M[NU$.4LPBR%J</V#9R0/9^.V_$
MLEUUK6&^;%,'IA$9AB9Y+AI!LCW/N%!K3[/Q\/#NA+N\[WK'<+EU?>\@*ZL#
MCLE&;"SBW>.E8[TS+#B.,VYS$J%!8"(#L-#\P9@+\T6,4Z6HWS%TQB,C]-EZ
M=^B7=0^\T/A:.W+WQXL="\KI$*=W#!3M@C^#FRSQ_%!@Q*P5VJUHZ_17@\:&
MR++[0_$##JA)N);6>\0%'=%FB(D)A<YDC%?9"5_Q_UR6@^;^KVND/SF%TW[7
MG[5A%%&-#H2);7_$N&PZ_]6*8?"?.[1.BQ"96C4?/J@['_J;_*S_IZ[V_B^.
MHC/LII#\<[_@#NUF+-+Y_'.JC<<?J3;_\ZDV_P='\2)V3T1_"WPH)L/?Z ]L
MN0+D_3=DO=IH L$X=F[L%ST+GBKX,_^%+(TBZ1:(E0_,8S-<<^:_DO=::#A%
MF/PQ=T&Z+>5O6\#OK"4VP@MNKWO0Y7HEZ^]/VPDW6''&_G9$]-];W-6"$3O4
MF/+B//@3.\RL#-B9Z'G@!'<I+/B'<Z9_U"B WLVIC.>[Z/M 4H@5(-3! =X"
M!1L)9_>-F$QH18HKCP; \/\/^KS_3XVKZ?\'4$L#!!0    ( "]H9%+@1YTJ
M1"$! "VZ 0 6    9S)G-6)N=G4U;S(P,# P,# R+FIP9^R\95A=S98N.G&"
M!H)[<'?WA.#!W0,D05: X,Y"@KLGN+L$=PGN[N[N[NOR?:?[[-WGW.<^O<_M
M[OW=VYD\[Z]1S+=&S5%#JFH59 :R KR4D9"6 *"@H( /SW\ 9!X0 Q#AX1'@
MX1 1$!!>O$!$0L%"14%&1L''?(6.14Q 2D),0$1$1LE,0T;.2$%$1,M#Q\C*
MQLG)24K#)\3++LC,P<G^QTN@7KQX@8*,@H>*BL?^FN@U^S_\0%H!#$18-(04
M&"AR !H#"@8#"M(!D ( %!S4GP_P+P\4- PL'#P"X@LDY.<&52\!:"@8&&A8
M&#@X6-AGJ?NS'(#%@,-\S?8&_I62(0*Y-1:[5V0Z(L7;LE_8RJ,GE!Q&-MXO
MD'!P\? )J*AI:.GH.;FX>7CY^,7>B4M(2DG+J*BJJ6MH:FD;?_STV<34S-S6
MSM[!T<G9Q>>;KY]_0&!05'1,;%S\]Q\)&9E9V3FY>?D%Y1655=4UM77U;>T=
MG5W=/;U]8^,3DU/3,[-SJVOK&YM;VSN[>Z=GYQ>75]<WMW=_Z 4%P$#]Z_-_
MJQ?&LU[0L+ PL A_Z 4%[?A' PQ8N-=L\)AOE! ,K5^1LWLA8KV-3"_[]8*"
M0_D$V\AF% F'DG.5ZO0/U?[4[-^GF/?_D6;_4[&_Z34'H,! /7\\& Q !+B^
MH\WP1/J-_Q80C%:\\2G5V>-AE60DI(B-M7VY@RH).L75!>5UC+4:,_EUB%KK
M3I5"@->)RW='$. .HR ;'[J,B$2<C52\;4U36?3-0MJIXO(B4W+(-(IUV0O8
MN_6@WA.+D^:3Q0K+_HS5IH+X#E11K1OG-=)]*C*6[<'72;(/DM/7U;T?D%-$
M[!C$1$^G:O) ZE,UF&^-(EL_D /32!$<;\<@ -)4Z3<(L/&I' *4>'\/-YDJ
MV2P;,ZG]YD7.+"$!ZL^X"5Y#^('5#X\,@&T8IJSD\BHCEKZ<L9T?[P9M8EH!
MQWJIL_<572\O'_+P9[HZ,R2$9+Q!_5RI)* X[:*KDU[$4$(8-AC]O-J9!H\C
MWCL-[YOH)[%I@^.$ER0-J\3J^YJC.'N',7VZ)6I?&5SJ1/Q3SQA*'^VL=O5,
MY"L]:8L:2C%VKN25MY[P9NQA$RQ: BMU<E_ 9R*7[<";PF@'B;[!A\4XE!6%
MPY8YUQP_(,35L.YPQYN$6D='?^55\.L. O@"EDJJAUPZA!#@YK(NS.!:3L=!
M5<*!5PV?9D01#E5#NV)TA7U1"G?$D6MP1Y@S6N^49V8MA*HT9K!G(S)HRX-L
M[XH@ZVJK:Y<&B6\^A4&@-<$WY\?:&VM7_G;TJ/VF^H]KWTFFQ97&+T-%U!:O
M"+-239;F4^AW7TM( ZYC4*9%A>&8.U,AZNYOL<A6?!*D!!4R=&LU[?'TPD4Y
M1 DFE!D82C;)?!:41Z#$C5J"[1 W35-5//FKQ_A6GM32[F*3' KMKA%?&T9L
MG(@#VAEEX%7F$9Z#IPD?QUR15>WJ:T6]#BIOM4CTMY503%BJ&KBLVET?4\1#
M$92[/*DRR@@[GTC5Y^RE8%QLG[#33?)G#?*Y:^AH21<YH2R#Z$KV">(<D-(^
M1HNB991MG<K[6\Y_FDA7&4?@C'0J??NCNCN_K>,*_]E @-F,'UAE U[K7_M<
M,!32H(-H?^,O!O242_ MRA($F':$ ".A9LN:&*L@@4EB \.'0@X-"! Q>/SH
M"'Y$G+8"&;$($[Q?[L0=REP.,J*^,<QSB^=FZJ5QN0?H4SOFSZDS42,$WS4$
MW 6UG5C<CC=*PN"TM1P-KYF7!E@1JIS"=7S;9G<V/N'%@K(X^":,$K;Q>$MC
M>&-4>*/P)*'#<K?#D'_*%5%Q0O*#H 1Q\ZFV1*<-?,8^"YY^(TKR:\WJ%M #
MUX/:+"# ^A;+=?=YJ<,ISX,G<\LBURHW!#@]Q[U?OQWQ<\=&OPN  (ND?8VD
M':EG)/40P&VZ4>PI0^1:\JP4X93FP;^D99F33$AD=?LA:!\"Z!'>J4N&NVDP
M%?G+E4=D&F/^W+\H-@"(G!2$P[HOL#?K+XZM2_3Z-J+&%&'G]'WS]\_8:MX^
MG!W)B_#'JY\,%:;31JT**QQW24-7NXFLY]DQ,3'ARC.W1AEX<*CL08"7:Y.5
MO47S<O-;*/ L21XQB-&M'O0_K%[)-4;42UD3ONH1CIV]J='DY_9E/(W<*D-L
M;KPNQ?[Y(VWB=2SO)[<0C9].I=+16B?U 1H<](5AKE#1HL/4?@*/MHH8F8(5
M/:X)\]&K1W58))8]B2&'&KU/:L-B3$OQ3I1RI^_]:SOMN<&87*9JZM9$!4)8
M2+"V4Z'Y9G.>K"_43>>/0J:KS&HX]A+@;XW9!BD_(1J&6>LVQZ\WX9RM(!?B
M'2ZVA'_@$XEU9)7&&BF*B&7[V<,PYL?19C^,9F"*%NQDW'_&S6V.2BA9-\WR
MU&U6,4AOL,V+ASWGI@@!PH,-KL%=Y<V$X)Z9ELM?$" ;6D $SLGFNCW?SBI$
M\RM;6<58G0'^3?/:WI4L(1_2&_RY@=QCC4PG[]V#"]D?T<>P%.>E<*':KK[*
M-EIUU%X)<QI^EWI?K6I"8FB.>Z003K,GW=@*37W<.\!D3[R]9!Y<A_QR20X$
M'U^^2Z-],Z)2Q6!:4KF[]@.&3NP7R80N.M.)8\CG\9*HH=/^>;Y61H]#E[6?
MGU#X,2(-!'0ER!J=IC.XX5QS_3Z[AJ/-]FW$?=Q(+49!1Y\(XW*MV!6  #L2
M519,]BV8 6O^KN(OY^IXE;3X4Q]\2T7V&_X0-OFTQNVB^ZW2PQMLT6 AGCV:
MM!.D^&7(UG:U63>A29A?>U_NA_)H!A%OIL4<TBK@"R)=*!"_HSH9F.WN/T<Z
M/62,+-1:6;_>A0#I2,#U_G[MP9?LNIA5"MV$4R;'#IZYRW.<R,;&-=Z)"^Q=
MTI=')*1HY71D4E]!O97]M0?VM,S9P8.:26SOUSE?)\8MP4X=%7N,E&5XLV//
MHX HI?-V^/W&AE%ZG/'W]7IN\H(  BW@JX@S!)@JD>R8>_ @:]*)J3K#HT5(
MVO(BJ5BUL+=?I/HL^#Z5T6>IUBJ Y'5MM(H%_PN9=KS;ZM1&.=F3YL^X-:P;
MAPP-) ]J+*0[&CAS[4O=K[@:TVSX.F'8[<*1S.LWA.W+2^.3+"-_TM67^MKK
M80OV!_QZ_[@S),XA=2J<FX$:5^[Y8V@*'WM<QTW&D9"+D'9;[(#MUL@+P^F5
MVL2A/5RUZ6;4E'P=_AQH<C]Y1% \<Z^5J: ;:W'\@_9./@IM1A#P&W\MW![_
M?9@HO'D[QM=(\/I+;*SS0V$?U]\'%U<$K]N3IEH(\/E[.&%#Z,'E"T4B=KY?
MA?Q4%08@A].DJ(\H[B>VVB3<Y3@>5+5SK&$V5>DG6_W#TP]G=9JJVZ=84%-N
M[]04T#+RH,1> G<:R?\S=(PV4T" 'BCPDDA?X_:_QHVW^ <DU,]=@YN^SVFD
M7GX2-GJ.!F#^:ZM7X![H_<=Q_5=6$("4#=PLDHR(GI$. 91([S-O-7S^-<^\
M#@!/2#[M/*FM/%$^O^9R^G[K&T*NFPAA(TW-Y(R'=V-#!_>P6:G^VW6XCZ7*
M-\_SBOPYWDQ+/,4J=#UA6BBZU_>"Q[#<>D2"(4"IZ,L;DFZQ24[Q5YKSO;;X
MK_M+A2=;G#.=3!2^]=L;FV 9-U Y'5CE[\3#1?1;D*>^5SFZM-#1_E#SJO^K
M*PK8%UKH\]APFX8R;75-N0--")6I^=UFF \T81P28AMM"?*OE)<-KC/'I9'K
M@6B;$CV4TU9K<M!,MK(@&^Z>3+::' %%C@0]G79]FHFXT0,'61KI,+KK%I2#
M3[?%S 2"SZ.RH0'EGK'G(M2+*4:.+<A+I%JXUF3_^IYW@NI%B$5KFK@>2,:=
M5#EJ<$,+"8QY42IU W+FO%.-Z.F,XSB+UG<VR3)/6)R918GB2/E($70E@FIJ
MEFXF;<D7\3"TM.7'$7Z33LI=[D$Z5/9W4<%^^>6%\R4Q.U]Q9)93(I6J0Z?S
MIZK!K7@'*J\E_.F0]4C1<(>I0X_%S(56/&C%U+[&EU8UM81^^(21^NDG5T_W
M2JY;S8[1]*P#_)<%PJPG[\9TFZX2$J^3&C\X7J696*6;?]U+4'W5M2<_@HB0
M+:(U87%QR.YL$D$[(XJ_)U6*X7VL/K(IK!JMPRH8HF0-+@390'&6+[#QPF!I
M(BGSU3<R%MA2?&58$A0QOW+!SL)$8<\EKP4CW!"HULD>RB'!\DD%;*2Z7*0!
M )JW'\+POPD)B;\,SACGP0WZ'/G/1JE]_M30\O0---N(_6P@@S7WE6P(H> -
MK3H(X-!H\O[9L(I3'QT5'A$U*IRFG\034Z]!77;#MTBSSZ9D]SQK?!%-2MQ$
M*Y_#D]0.QZ9;5V.N>-0<D]%L*85&#1I/(1J;_JVM%?%D981,>F07(M>Z/L6)
M[U&DW3&*%5,9GX;2^/Y;F GRDR,O3EERL[AL36C$-ZHFU2?VQ<.S6]Z=5$2'
M=/I:%FM,)@H!\[^<&4V=&#HE+0SS]W$_=!.5]VS'=P*NGV--,COK+=B1[8;A
M,O"*Y RZYAA1J8IVKSS1\"4A@'[)C4([!)AQ,=72K.I(JAN6V7PP6^G-KK,0
MDP__:JG/-GV2ACRE3W*R'<0XN-C(9%47,/,-&M5HOP5=(M&0:X%'1IV*4:T^
M89/IZ%(.1]G0V6+!'B_?\G+06,. ?FU/JUONV6$@P:J.F\1-JWA+?2\L#).<
M:O:LC,RN\).X'_!,.$M]X<1]='0ET-"30$LAX&G83W!9I1B$+0'@0?NQF68$
MB6(IB0._\=>!N@5_Y_<*K?DH>6DV%I%L.2+K#B\*<7%BZ! D=RPHV&J'BNK=
MXO3()CTHSAT+B\->UE]8SOMEP/"F\J@H2AQ>KEYY1Q1+9AYYABPR[P*_MF@1
M/W8(-'TG%A 63!YKCY*;1T%>"/X\XQ/YZ;E<\(A_H)_$ NP*!G-G!7!<91V,
M)[Y[B?05/;\JB'95+E(BLC2#%CI5_)DX3KT\J=<".?4J$S[R"V/$I@69RB$>
MZ5B1DB@B  -\4!X5!R0I7PX^55."KV,(_.^YN_GNL6L>[PQ."E458:U_H8CL
M9;R# /:B^;09GB\])1!["@YS9]GZM>:C]XR>&W$^-WJ#0H'Q+M+GL1,ZZSEV
M>AT44_%%3>$*%^-Q!AJ;X?=IM^9.&D,_,\)A*8EBAR4;#4A7U% F11GI@V52
M>,<H7Q#0T^Y@?5#)2X/O)9#QI12W%Q)#"?(TFZ)O#1;X^J:'G&K]XID'2LY.
M&A=4\/."@G./%KILO$BZM[R&9HGJ>29%"9B^A@!J*&9/>U#/X_D'STNAT"Q_
M%A ,J7H(@?GNE8Q-M</*_;N65773-%B MLT3(2W[+Y!G_,9O_,9O_,9O_,9O
M_,9O_)5 7YWNBI-JS#0Q@$VA;&,^Z(S0 0&PD0.[(LUHCL9_2 DI9 /&>R*8
ME[=66R#9%OJ%LID&J-:"EI.R!R4(\(;TP:^J3^F]I 8$0";M)+W @  ](,D'
M1C 6>.2YS'Y=;!.CB/!;^%OX6_A;^%OX6_A;^%\G+,B>H?>6WH$#')=(3QV#
M[0?U":6. ]6MDFZ-O9:K7%7?Q%%J6 QAP5NIZ)JTMZ"@DDKCJN3>J:[3"*EJ
M6$@9BF,I0OT]%!<7NDU 5!W/F8)NE+GY67@0"?WP@_0AY?5WGSM%>)SB4P:]
M:)6DF<5;]?EF\1ET;-DG')$@D1T*"! Q52=#%[ ' 5:-;S*?O$5N44TA@&_X
M6O@=(@38X"I1#@)^"W\+?PM_"_^_*SRP$'1=F^_/.UQM9J)( BA(5_7GLZCF
MS"*"=QOGO=,:C(E=-1+=6$ZJI:>8UZ\",*:7FO0CVOX\T4;/$+A>71/EK$E/
MUDM3!=@^<9X2.('%H\0-KP+A9[K!Q6ZW@L/6@M%2-F=LGX6W:AZ,U^C<WA3U
M4J]O2,AT-4\.J;Q4$L<"_NNA]3.4JL6+\D.>KB6C4Y<IC*/H"7?Q&N+#CJ+8
M"R)ILI6IR>XVN<]X6F-;2\KP#F1\7(OF^@QC=@:HTH_Q]A:499(!ZVCL<K8I
MT*==Q87[$,"P.4*6,)-7B'N]"D:PZZYK6[X>!,I+H-,HJ#*_<6QSB0^DM"JG
MGHGW84"/(3CR8#([><Q]GZSZPB2BJ\.1"!QJ/\*HCW'"]^,E3HV/]3I<*+3@
MUOXJ=X65Y1A59^/ GSUHU],>-/EZHBLQVN,/IY-7JG8B$LY%;-"!:NPFUDE>
M0>&HZU @@GV1Z,0EP-"I&&HS3W2/ @X%K)](3W)RUVA$/@9CP/Q)OYNZBO:S
M[ @WK@A<#_.Y08Y"9^1"!"E+_;IZD)/UK*&5$10Q(DP.XO&@]EMRQ-09IA5-
M780=X?";K 0MXAP6'QN:+MCU[!^K,LQ[T,^\8?'WF.H1W/D.9Y5?HO"+%'U:
M.TA(XDI7![XGU'GQ\B)-PL3?@]3<@[R,QUH6"V,;><OGW#5$@\D61D=/SK(#
M)W#V!7$/;VEN449U38V.JV(&[Y,B;I7;:.%S6F!^_]1,^<=1%D E(X@6^&>A
M9'^UQ0^MN(#I8?\IU-(&BHCMHD16>CQGTI[6XK7RP.&0D,#T: ):*+Q_MK@)
M(BGM;7A^&BH9=![P <I+5AS+[]]NR+Z/4_6CCI- "F*7/A3%2V$ZA?4@'<VJ
M912<(C36OQ7:WW9MR+>RW*S[OB6-5T'JLBMHO:8Q?>F/V'TP$I4GDFQ3V?&/
M;/YB,Q6AVCNBUD<0:*C"7L FJ:HY2CRG-9O^CVZ2?YZ".P*O*IA#@(N7E0^)
M#PQ!4Q>NH<BJ"6W;<)F\:$V$"QKCF#WD(0UVV!M@7,[%FNJ:/6%UN>++01C>
M8U0G_?..:PNXPBQ7":UE7NRQ!3>J28OBC1^EAS(9<63P)<&KPDE,G*!D\6',
MI) K&+Z28R7[>(GDB4UM\C>D,L#M?GL*4>TI=<:5^KGDJX(CQMMN[;*UU!=Z
M-^HZ3D>Y02K\<08L@L;["B??"!;N!@K3!B+U+/A,R% ^%]ULS7?$G<^&8^A*
M<L1:,1@BP A>I4E2J6C/5TU.?*6#ROH"#=)X=Y)3O(;:U0=5!@X3JU)8URES
M$YJ^2-QW#5P-7-> O56H#1_S1)5<C<O.-;,"4QU62 36%OBD_"@A:0XZ5:3X
M-0U<OH0 !U7GQ0"62J8899"GI^8ZY:F>VG9[DT._'.@6KLQ+Q7F669XM50;8
MV,D69]X+8A_XRE $]M<^<#&<H,3I!>2V[6K)/%2A>I4T[!ZISU4;[KFRJ*4Y
MPA"@Z[U.*CK\A.Z9RG:WSA_R8((R*KGT<"" 1"WK4JLQ7ROORB.J9,YNO$OQ
MW+Q6Q\?()@%%.'Z&:@-?#ZJ/"S@3)F6)J9N:VLN^57I >(TH=$J8/\/M"#P7
M=MTJ!'BQYT&%22PH=E_A=TYJ82Y^,MRAHBN-U W0388DD:9W M87ZBDUZ?I.
M'M<'\4N:\98'%!^-*FC_<((IN6MTB)4! ?Y:FFX9]28W8D6,KKZ;A43N(X1<
M<V;\2[[I-UK*8T?S@V'$]SPA<5W6M]-4JZD!_$/I:TYIM1%<C8=>I-?",2BK
M7!8$U^\:N:=_5EH]4(8W"HG+I=]X0 "#^C/&-1I2Y].VZ2(WU9]!8'2J4:A/
MH6=H?!3$]-=>%S>5"@C!<8J4M&,"I&\&@:_#)\&:4C7!#9]YAT;00$$3%X5-
MY*?%5J]--T@RBUV80T]?*=6?.M?\F#S(LBEH6;PN)@TF4);+?I,G$;R5N9KX
MF #KG.*[.BC9@0LO0"NM=C]F['LWK>GQ<I]$_[AZ;ON^]LNTSBJ3BMBH(&MD
M\65-RLL*Z!5,=X8H_S7YGTL4@!3)9/9,&=KW(8X$8,.^!7V/ &[4[PHS4X1A
MW>].U44BT+UX,=B55EOB2'35H^H0C%%$5G^2/'!&QBZ:/7)'T'7C"$[?U2?6
MB#M:8LBWT17P=!J$X;M\'E5.U]##/)'%UQ6ZS2VK%K+MY;Z- ;=?OI9[G27L
M,3]1@5#7Y'Y*98S(;09,1[3S#H%&W=1 .(4K^SFQHE8,-DGNXZ*D J,R[:#R
M.R)E1;)_U*,5+R,Y>1B\!+'IY)%3D?4L>9<9A>;$4KR),P*PCY?@3L9,^?DY
M X-_^.FF9,YY\NO(FAX<&M<$OLT"><+)_8M'P]Z$ %B"*IOO.%VE60^?:L,5
M9 X;%4K:TTS/%GH\;%A]ZKC.JQX/YD(/:E3*S"@M.D;@S&DSOGO_4T[>TZG)
M_E3#-_H*!P@C4M7%&OGB+X8!,%R'8/0'TD>?+_;(*QE[;[K GJH&Z _$)-%&
M]3GI>/>RH7UXMG@0@*#MM"6\Q#(K6GZL)@OIZUD>GY7AH6B?A\ IEO9P$.,A
MF4!:]0^)XZMRJ-)WIS/(*\FB:-ZO].%@!!U_]M,:!L)@2C:Y/I5AG")X?<;Q
MM]75V1)T3$.GNK&& !3?2(]X+DK.U\;R1PYG\BCY?G7+Q_:Z\8RQB*PRL0NB
ME;46E6Q\1<?#KCGUOMXHJY3F0^F<(&E$442(*:CXJ:8\X 0@79;Z>R"ZFN&J
M3ZB C*^E7%TG2%$?\,("BY:[\*46D7X^FE^'"3I=O;E8I&2+)]171.^_2$,Y
M#DJA##)*$*_TJGX86T_-MJT6%FH:>Q"L_Q1BQ/U$A\YWI\' EB!-H%439QSW
MF5A.7#0<?&//&4^"&Z2EER+!Q]A->09JYP+?HAJ ISM2[S!*K6[,( !Y".GV
M5*/8'R=4)Z\?W:2?(PP!D/N_UN/_51"%34)B*#IA\<N:MO_F:'!A*K]-^54A
M&W!,17E@9&0$5S%G=G8L?R5=)0[?UP]\'\3E1Q4*CPT KBJ[_]O19X8A81JG
M+&TM"/!)NS<P&P)H2AKNZJ4&<'VW$Z(&U84O&L2X)-P.JTY03W+AE](8#5-\
M]J3;IJ$.HLWYAV9G83W/@S^CR/Z:R".B&GU#)KC'IOWIC^.V([Z .\PZ0WSE
M2=7":?647*[(R6M-8>YJ/<=6,Z=4GKCFKQ3-<.9N;\F<*)1@+]^$#Z@9^)^+
MY=]0(TNV9YEM\C]5^G$B/G"M(+YT2V\K78, 3_4+$."'*GBZYJ)$;"TG(\[%
M/C8* KPJ]"4)$K=W.+M]0@G2-79/XX4 GB,(\6[T$""R 'RW 4[^\J#AJ0=R
M(:[;I=YXF%'G:2N])<B% "62MU/'G2]P2#&</#1X58TZ($"K+^" SE3ZS8V2
M&L.+""-DQ5Z(P6M,F,X<EV!.W"72/4RC%4J47FC8Y<A-R82Z;B4_O;*=LZR0
MI<7EE(FT/7XNKH;8JR92RDW*^IH69J%1]]<#E<-ZIGCDK4: Z1/&E/V\L77N
M?%&DC[>LE_[\6MY#*?R"Y&./PY.LOLE*"\FLDXDL2"=8>M.HLP(?;WM?%'_P
M9+GCE,ZA7!0W^GY4/WV5(;W4B7=NX>58P?=/^+L3ZD00 +>R[H,=@?T,(]MU
M7)D'[KX1L<=6;[/F4;#4B\L#$>T/'W;U29S=[.H_!JA2=OJ/$(5OZ@>?BFD0
M./K'M;$TV3B\1'\S?:<AAN"_YM/)P_^K>QBSX-Z8KY3T)K@(;.:4HZH24RVL
M><$K9 HS*DRXJVCVA!L& ?H?+]9=,?G6R7]NW_B7L@2\-\N5O<*.-C2@C'+N
ML@W:?WCE8B5(;$9N/*!*%BX6K6N9?@K3Z:"=%2?Y_IOP69FW/R-'MXNHO3[7
M^.MIM]=,P]&!42+L@F%O2CE/3()63GI^P,=<:S ON^M$"/&K+Y6N&^#IS$K%
MW[U3[-CW,_)_ %FMEOH?2$1P:1E),YL(^+!N"OD"MMPUPDS3]C>7>)AKM.]]
MKK]TJC*["\?ND @'?CP13CM+8Z?\X!/F3UX[*+E&7<P3X)=JAAB$G20YOD7&
MC>K0S#?\0.82=]0L-;Q%"Q-Y(_14<O\( 7:UFT5.L[?]/_O-RYU-?=[\,<):
M5.JSO'?<LOP4&WEJ_"3Q[&\72'M48$(GJUR;+&]+670%!UBE\+ E@FA?%A0=
M8+]AE >P]TG1'C"H*@N+S!FJ/ >44I:V,F[L5V+L](R50C"F:&?LK@N;>4\/
MXK[<?8XJ^D@D38L0;G@L.@ !@IK)@];[QRR6';H67ZLLCS64I[LAT^JG&ED]
M0C<[)>?&J2=8'!S8#+07NT( _UPYJ]9?QB+[9*8M[Q41 FY 3Q*$(M?[<\VO
M 3=BQPBTEVN-%>U+I(WA766SWPVNV8D'PWS*2L5N<CV8W#BK5Y+'N=L0<FAA
M.@#*%6CI'3@7D_9EF'ZF-O/Z;ZY&^L821^;H_L(H!"&%!<MDW#M@AR+AT\N2
MS*YF'@)&285Q%?LA5BDBLC1QTB!]RC"&UUDZ/2A1X&*8)":G1P5[ILF)86N;
MC\YXF\G^U WH@!-7U?QPM1XS8X:@M_#M'S\&C&]-04A5:PQ[NB00X!U:08<;
M= !CNHFA):=+Y[2U#]7J?:.[SRAR:ND<N3$:_&)WXZ-[V)9'1%:*/<'"8L^0
M6]_ +DUASX@*0_=<,"/^8[NSE1>H)!96:GY#5#36M^%I:6CCJ^&^G9>SD\R9
MCP,&>[](G:;+)YD8Y(-EQ@TK?$55%=$$4K9*QO#^*,U5]*8X36R@\WIIJO@;
M[]<T@C3DQX<2OSR;SBOT[SXCCFEHZ-W--.Z.&J;&O-6>L8KH*B,)&W32E!M)
MT1-C_ZS5!"Q [9 $),6E2=6LSKTS_YVVMX!3$:$V/&B)$ F+:0GH$BQ]:A*'
M ,@\;29/>CG/CM%:GT8<<-07.94/7V-PI1PGMS/5"SX*88%%BO[5\G)9K :'
MW[NRND#X+;S,O5$M 2W,',U-85HG3%5L8XX1+RK.B$(=]F9]=1US30GJV_/T
M3WUA7],N'@JI@X"K0I; )_R*\J YSGJU4 =/<@BP/S[\[(R1V/IUAJ2/+#J=
M8K&@=CW83TN\BG?8M6;$R.4'$)D0]?VG&L>":&$FW C7'PG?CAB5-^"2F%_.
MDDB>EW*W_+"T)\P?%Z",7;3=D>;2_^?M^Z?T#8'N>XH_Z(WUS:MJC ICCQB-
M<)H6QWQ^RWX8)EU"N@KVK0X_#,Z[%=E[\V2_%^/WOU7%(;]4*X@ =CFFK\L8
M;HJ<H8RS\RUW[]N)'(AW8'QN M<<I[@^5_BVC!;/>/FTDVJOT4DS=I11IF3]
M'UB76K*P7?5$L27E4$^.Y!?[5K))<UJ823>#4V3QJ0<!:V-39L%=!,+UUOW+
MHG#_)X[Q!RZ0+1P$2'H77N=6-?Q% T8<L&\6/.4J#;2GS:[ =&8K@3_U&;2_
M2L7DY'5C0TMIVQZ2M<;H<#/!NRRER/#D+X6Y\>YOG]NHB6\VB>E1_:*;4F6U
MAAMD]QS6=35[<V_31$,(!_2:I$KH@X + T0W:7ZUM/))[&POA)X]]E87HYK2
M)_J=4='CG+F&!8SN'R0C"A,:84JB)%7%;M*CER)H@Z89ZX?LU'SA(>O37!N5
M2J)PYDY."Y*ELU7U99&?5+QV$_I+U4_ P0\LV4X>4X0KP:YX JD]_?:7G8!C
M_5$>YS#JH#/;S)*Z\+>@VS:SK-H?6['!4MN,"K9ZT^&"]B0M!+.:'[5]XHS8
MZFL)@+T'TG79<)0!8X:MN1Z;'04%:WUO83HGLU9GLM1G5UY"]E17^BK#4PBF
M$P)@P%>93ZFSPGIUX<^X=66>:(1#@%52S]FE3*$2FVR)/^80/RW,%,WI\#>*
M)G>9:87(TI[[81*$\_S29BI3[1K_S8J&L-7/"8+\1<Z*'G6EKS,\!5J FYKW
M)]-SG3N)F,TJ_>]/@X9/IP.^-(H7,@W&_]CT[3[&A:^3H05RVS=O>[>B*(8'
MO8;H8A01JK3<%$XFLT.X]VK$^D5S,5S0BP4?%$XRB:H:-U*V%C0"GP<T\3D!
M(]PA&/*[BGLI5?'JE^G;IRK?E67"X=4:UO<H<1:3X(:+$N'GR5Q]4[@Z*?:<
MMFX;/SEYW4TG.!5VOKI)5#S/THO(1?2\*O%X;B1$NJ;@5]E$CRPNFWTV 0VK
M:]+B4KF,)4A_6+>2')Y? ]\H$P1<&KQR.F]/*/4_.CA8B36)Y4YGA1J>2EVU
M(KUQ?#ORH<S:=HOLMJ]SXLE^XT(1H4:DDQ19:CX%V4^X&!"9RC-?QA!D<\[6
MG?]E11OWKBT:()J.4!)%LR&0H$BG#++XQS)S:$\M3V(YU]SV%F140EE<1^2G
M6-[%GON,6E)_#US^KH*:^!>)FFC.3Q2[^CL%&&_S6F&@(SK_)4.&$="9/+S0
M8P;U^P'D)R*-H&TA8Y5$C8FMQN1 $TLA7]?E(#?J%-H@WIR6!,21[2_FB#2G
M)3I/6$O)$."-3NG]5274^H3&3PC0ECC>LL-@#P$\IL)O5%P<'^$L6X[GQC'^
MGZ0C".%*^NW/KM1*'@*D%4\_WFN+K,KM+E]@UT. %I HB9"X*_H#79/ DW>-
MP?7A'ROM/+G@$?7]I\=BP.D2^T#D).?B^ YI$;Q<E?GO[M-_<]85HY,%=J?U
M>V!!BOQ\0-\2_@#E/ C8IBTU_'M*TK^QI:&39#3Y_STE^._(/ 5=@JY(_\8X
M^F_(@-,]AAGPW^DI^7<JPG3G_2;]3?J;]#?I;]+_<M+"M!-__XU3^"JBUPI1
M_G:A,T@7?_>J:;W55&2MYU(VK>9S[/?-[*]0PA-0I2 +[.1*AY,\S74\17IS
MVBS6_V6]#3JN,/]-UN[8DBZK:JCMI7#L>4I+D5SQWKC>0,?1%]H+XL*E!X75
MV%.N#!U95ZY&&9MWYF@*Z[KQ_\[1R*'X_]WW(5TY2LD;?"RT;QU>T%YYH%O-
M<Q-;D^:L*Z$,Q-"K28-]R/'DJ__+V<YOTM^DOTG_XT@+$_13N?/SVLV@<1P_
ML H)3!?\FX2^YH%MA0$=9:&IP[;7F@(%/E)T_J(3^&)*P,B/$XN=)/I)<F I
MIXHVXU].$?V_1./;Z2=9W,=FGC.NP\LUG)8SS9;#TY;(-'2K0W'BO'_ZG5]_
M%<#+/N5#@$6NM644"+"1I@N>Y@,GN[YOV4M]'-=G.AE^DH'K?K2-OQU!J/YG
MK:+^9T(C0!L"]!I!@)JN)XFFYK\9#2?4X6->9M4_OX=_%?2")T7N<QIU5E,?
M8I##[[99SDO-XA]5($ ]J+,9_WD016LA0(D-!. 'KOK^ I=V_H?C%-G@EM'@
MZF:Y9[IF^N_-QE.HI0K+X2_0P[\(\%GN<B& W72P&P<$B/*RA@"ZFT_VA^P0
MH !\+>=4TRYR2XM+>CEDL"U*,OO/.@;PGPG]UR (0!7\M$QX2W#5%<=Y?T;^
MJ(ETRF"B<*-S?\V\7,TSF,)/ %RC3:BH37:I^: ;)]C_TR^$^:N W>!2X6FW
M%.?&Y'D,H=>?ZOH?]N<^00!5"'"4<&KE!SY39!;93VH9\A0J_PO$S_\XT.%[
M4W 0T8=$BV(L++2;69X/DX5QXG^V_...,Q$LJKC/%:/&O32F\75WZE8AC>+.
M:Z%?3.<^KR,)+\<\KN]?E&RW"2-6C!R,R0;$Z73A?S:,H(7Q#!<]K0E 3[2G
M:H/?P*]=2_+ <?+F?E7< 2]?![O55 3  ZU7V6GH:&:-H%6.9C$;B^@2R1Y0
M]4EIAZO0IZFI"Z:F7CS8U-A01\QVHAUE50V5"=9!9W"8&ZSQ4'XF=9?!CU%Y
M$0Q1DEQQY^/V4MSJ3/0KM5T1LV^&LO:&N_J^?UYL\]\:JLT3!Y4]C?WSWU?D
M.X<88D]3P])/[A[CYC'U?ZXX:*]R#J,Z^715)/;WI@@X"%80>;SU%"A<#JQ'
M(1PEWEKQ-/X%WSC]B_\R)W2ME^4H\&4]+\(X3="%+(NO-B.&E\WPU_9\$98S
M+J'N-@B +I4ECOS.>MJ:$VK$S(-RS#X$66 FR_8!J@Z[4)^OZ(%[XD)W<1=7
M@3YW0,(A\@:M*GT% @1$%7>XZ%<B-3L4A;"^N>"$VK-39D!0[+-![.&L_*>G
M'/\A"1[+^J+NKC!>\OH766IL#W\?/7'G^"Y\F1E-R=G9EFR 8U7"K_G]7,<Z
M.]O,CX=S_73=;:]T3;?7N1$(PR^-]8C_97<X?:00)1^//"X(.#E^I2WRK=&1
M>+)$G8](BFT\9?+0(;IX,$LEO:_>&]4YMPM1[<-X"7 ;DFU[@3WGQ"W&\XVS
M%UT]^"X!6,SX<X%I7=!BS;ERF$9N?,C*4GXTK'#^;BHF7Z:HSLA$O<A,+$%2
M>UI]Y^LU!MT%,YPP7T;\HV[>L_/[R=4VZR80=K1H,F6YG;#;I4ED"&+1&F-Y
M0&?4]HNT98S+_GF2\OVYF-L)(XE9IJ0IS?$7+,/^4+>-*F0O].:'DJ, G-)"
MDJJ(924$2,T3.5XIL35H)O#WRJY78V@6C'"WUC7Q=D//O?%I[W>WY^Q_'1N-
M'/)!.=??)V=;6;VB^I?**RZEMTE6]NX'+FUZ.CU?HSNZ1WBYF)RM MQ>00#$
MJ92[ZDAG_J;:A=;(L8949',;$ EQ55.$VU&MB#\VEZD$JQK9435SK+.,9=*Z
M25V%.%;O)RDC,\H/>9F4*9,#=C[]1)KGE.^&Y0;@!%]*2)(WJG0F/ [5%8M3
MZG1^4_95D. K_5#%R!D@@U+KB4V2:V&OWLZO&&RE;C/223\>HSSZJE>0C4B:
MT>SI'$J6:%3VJ405?*U)<-X@@K0G3#G)7.(F:OGZ&]M9AI#(HYJL4F5J:_UC
MM.9"SY1M$N<7)Z+)(D;"C9!2EO9C#J?\3ML^G/#U:Y)\Q<2&3Q;%UB^%?3N-
MG:+65<#H1V.O'>M^2'#; ]-\N6[\0=ORLJ'*SH,7P7$T^"I:;V.(G',9/*BK
M&.1DXY*L;BA&U&+_B.^*II]5]09^2>;SE@J=R*>[FJP)+*,MOA\+@/K(Z P8
M/YBY&;CF[:50^;3'69Y*M KZ\D=.3#ZJW>O+[H*6>U*+2S\-6UB!G)-7&JMI
MH+<PW6&"$DME5EB$">=T9@2G-#BH%D!U!F$*3:9N0E-'7,D$G^J-SK1[-W&%
M=$(FAKXY$^WV[5KR:J16JNY)#!Y.[.]DI-4WUI1_&[1E[\3;&W JL4L<)6;*
M*NG=H82*;BTR==-*6Y A]U>K<:2!$E/W/47-T67E@Z<F>\*6QPRNC U4HZ!R
M:HBF')5-97[G9C_7NI:J;[""*C\L9R&ALQ_CA1R!/]SD>$5P%)]?/4^X8T)1
M3C#53**Z,3;)G*/*AE&(M11ZP6F:(\OX]=V8S"J&A"S)9#@$>.'OWSC,<J\]
M#\[9ZV*-:<:V-9-GNTD.K:>G97Y=%_C)6SR*>X/]@DO[7G.\<L"]^HR68]PY
M*V.^7-LG1KG!!3>O:!_5569BV2+T@J,F@Z#"V1V4.__C:%O*2+]DVTNN3?JL
M*H^NL^3C!:.2YO%:$SS/.W?E!8['$9UBS?)ISD$)1^^A*[ILA<8\9ZQ%OFR'
M[[&:/!]'T\7%K:U1BQN&!8.)I-B'%H&\HBH&(8GEX8I:Z0S2+O^@% U0[$"I
M978! \%ZIPMJ40[?I:S3 M'+08TO]CK$,NQ7&DI#F?EBJKN##)4',OGP!PEU
M9LFJG@/P3OA"ILZ85(L4!2R%1$CG"OA.80M.W1)!Q&\\!I%];*!6Y8\@@*\]
MP44]:8 @$\5P?I&+;2W\*CH^0NZVCB!G1MIF96,(#C6[K=*2L(E444EZC)_*
MB,^O[ ("3O6I.Z8L]6CGJ=Z7&+VIC<U5^ON=!,0Q783)\DMT"&J?M\HVHJ.5
M-'BN(I7DY;N:L-7[E2HFC,\9CS _7HJ]KY_BO&>(J:EK"*++NL_KCI:-TZBJ
M(A6T<-W1RR@SZ%PB#;.BN]0QI+:NK.$J1AE=>%?>MCI:SWK\+IWV0>87?I>V
M^$)44":X:+?>Y,%C21P>W&S>E!I8*7L;1R@G\R++V+-@(<$\::Y>^\6$MUMQ
M84+8/L&1 U)F'2]6P=Y^'1Y[RLI670L)Z4W6D?4>O0+L^:J.R#4XK?#*H/XJ
M?M](J/38/;E>=\>L8=ICL-WZ,,4TZET0M^.'@C^<R!:&4\: FV+<FKLT?%)$
M.47<+53K^GFNQ+>"<YV,VD*-4&:=2P<AB:!TV^+=N*_S@]:N6-8+X(+/@B)C
MZ<$="5R=*^7!2EY'+^8H4(= 7/(6^EUA6:^J1K,JWAVH44D83L##CN]'C7 >
M8LYWX*K,['U>VZW8$D]MT(.[*LO=]22<KTT;EMLJL#MDUEQ\"/25[4Y0-V _
MI.#/^!_Z%24:8)DZCC-RUR<WEK.UJEG*J9[608 @]8/PYT\M]LY,>O"MMBZ5
MNF"8M6/9"$51\)^#L:%2F'!"(XQ5/9Q?$I>3Q4>]/E-@N^T=_S4CB![YGUKI
M]9PR5R;@! JM8S2IWGZXYBK5USIU>+R:G8'QI1D0R4M# </?.%CA[*N8U_O@
MU$CV(MR$6[4UI> 9U_@:!4)GA !P1DX\<G(<[=P_/7FP%[JGN5K^3)J@-CY,
M_W@0/S&7MKSK2DFD"MZ*5;7'WHTE.J6\.GNWAZ\E13:"@'$RWU%<:/:Y;_/<
MVNHLY-)P7V_1*=Q/JQ(]X$R;[E9KX*.[M?[BWQ*Q#TZ%&O5CC#@@Y<1^J'-F
MD$>="#$$Z.'^XQK[$C?=)-/>SMED)SP)IX NF;W-4B30.(A[##FYV84H.1.&
M5&8G$/B8I &5OBUU"HLHA;'8EI6R.&@O3-&,PT]Y/+2MG!^NW8^J=8^SW>C(
MW;DZ/85E5DQ5-E :?(G/M5DEACL[D"B\+60]U=!WCEZ6*"0KJZ$KP'U^'(7J
M\K&$/'#A0E%.'LDVGJ?RTQ;G;G?T+(,>44U@HZ1SKAY3DU?(3[WA.MN@A5%[
MTD,A;@&?T.YCJ'W=+I\O7(/Z$$ QV?%M1\$=6BR-;ZZ[B&;]6#9O+[/G%396
MH<)<?N]]>;W!] _[GQ>/P;G8Q[^H(8!![<$^<L?<P)Q:D=%$Z1SE%UK#A,42
MYFW^Y9 Q(DN_\6.H\8=S/=[\VO8X@28T06+>OLR8)[S""HVVNX6YJDKO?=,4
M#F\LHYI]_R\[)&QZ+4Q-/:W$%:TEZWD]V;Y)V;CXQ\0(H;EX@_+(BU'U,*V#
M-LHW/BH37"^8*ITTOIB@'+$S%!?(8OM%8E702UJ&V!SN@61&8HK-M.PYVH=>
M-JT/W#FPOCY%RS3,DP05O4N3^EKB UVOTU][4+11%_$04,?5L>^XNR8D,S6M
M8,#Z[CXX:.PT4:C9%^5-(,J\YMTT)4,?:]YXO0Y'?0X!1S+E-$/<CA^Q08?V
M=U PHI&.VT/#""98>VS$_KHE3E:@YZ&A=IBBK/".$H03;AD\PF3+_^,>-^Q#
M@DB\BZ?U1<[M+NV$C>55RX"T2BG=F*),[VSQQ9'#9.]->">[V;0TZ*-B;VI2
M9 2#AO[DN&R%@ <H4%AS>F+Z5:&9PJ?<=FO;P8$S>".7<'.GN;,07;.CFC,<
M []O6;D:)N5'+N(-/RPR(IO/R8QO@N+2*B! ."'X;JNE+X>/;+W84=)X,+YC
M"-SALCB42-54E0!?FWH4AX^-E]BQ_OY'W]MK+0.ZMP#;<I,A:(K?^\:[D^1V
M=A.\R.VQS55<3*P@>=)8SO40_I52D7*8[)4^J)"'KT]#&ARY7\ :0B=!5-Q?
M[PX!*+(K.*IBF.R I+1S8 =50?=P\W+  Q$WF ,Y_+7.P'$* XLL"=E4D;)]
MB^E+%'B$^.N2^$ E\Q?<<W5=/\.48B4IHQP$S!DB1JOTWD[K63"HQ ]0?OIH
MK/X@7J0WKRMF:)0['/-X+ /"1O^\/2_K'+A20%^0 %)SO2@;4](-[4I<PV-*
ML"YL8 ^=Y^@^*R9%,3_;JV;:A@ E@=5EE[DHXMN]M)6S7*R-E8M2O=),!SQO
M)X^J4%44:Y)RXV$B$C402A@\ZM"1P#V.FL__XP\!WG)-C_I&QPKT#Y^3<&/X
M@L2UM#PD^=:*/U]+2WETJ=CYD_)OY77;K[^@T- \[/O9<XMP,[J>>FO[YVWD
M>T4MZUWH=ULBL8;]]+&;))^CJKL5!&E7TYG?S3?O;*ITS*4DVD6"N'^IU2[Y
M !K:%5U7:U_;^QD:A">CUPIYCRH)O=NW0F7IK@N$<6*/&]FO-A[ZLJ'NM@HP
MD_E+8I(OZLFSZ"8S"L5M*@\.:_)AEZ@FK(ZS:D:+VV%Y&=O),Q.U3JF_9[C>
MFRX!'A9!4$6'#&I@Y*5A"W?+>>) % 2:A%V5#G[A8LNKXZ]Y1!\*24 I28\9
MC05<S-UZVN;1,IPQZ<N.UPDNGS/1\C_&LUX8]ER4\-]W$<265$\MU[,B('G(
M6Z=J[U5:4*-2SZ[7Q&9)"I1/MNEI)1Z"%$,E--W:3WH+.^7+<Y$%9'N&X130
MZ:N82[&KAF7]U!*P8]'4_,2-;Q(UHZ7&OT5@G\]Z*K9SIKQJXDG (GO<\6N_
M46=NEB\L3?P@+"L5S#/MHZ->L@A':SGD@F=7QOQJ3B A!6O*\C+83/\@9Y.7
M4 ,[DB7 ?O=ROA"9E"P@R1>.KWM;O1'Y*6/_\?QA\).F_KSFS;QBU-ZG0,'V
M<[;K$@UERUB&OFF7BBHE[U*=N!>SID5F3=O!*V(4OV#(ST3?)'G8EZT^VML'
M$+$?)'#X:\N&8YN>M W%ETFUWZB>@2A^3=E4#2ZE]2CSZ<:0-";,L5L7X[6Y
M]1Y/;"=A[<C8T^5Q@<Q R:%82OI>F_^IRP#.TYT-$O'B-;7(L;YA"CG6^L%:
M^N1CT5JCS(S+-_$4>_R*\)+M#9N-)['E^;W?G$U.L*<T@IW0=< HH'$S?I\O
M@?-6%)DNTQ6910'$>.R1$6_2$/Y'?:LR<<G@3M\GF_@#&QLK,GIB!.'[@TZC
M5NF7+U#]F0@4^YTN-'X6"</MZCA'K+TXB ]RSB2QL$\\I_UZTM&6X;51_"R&
M^FM!&-B2HFRBR'\N76H50( L-RVI;(-(+.SA$CB79.?4<";JL4;Q3Z7OLC-0
M8!LDWT3J?<>][R8IYK0VCC^:J*?^L1LS'4JI5T[^\\(P(3UGWX$_.\:155>R
MRO]M*X9N37BC%--!O,)X+I,S6^M98H1P1EGN6]O\W@J>?/V7N</UW(U&!2G8
M#6J*:70KZ,;ZKBO+KT#\ZI[54_PL<ZN8%<YUAKU[O-C3>ZQZ.@\"IL>4)JG]
M_1Q$*6_RA'$7WN#Z*'U,X+02EL?W%"JL3@QA/:O?N@XC"%+IZ!J.7^0+?^44
MKS/)-#6O./[I9[DEE1U<[8.XBZ3O4UL]7+G9V6T$_8GKI!7.\F[_:L,OP9%F
MX]<28D13/&TS6W)HJPL8A+W?SW<'Y20*#$OBF5(6^[*2!348W*9UK@3J5P6U
M"H8+]S!NK-Y;)8@%;B <!1U]MY30_X%7@@GVMZ#.%CK@3_K9R_ QQ@C5=E6/
MMS_!RJ))/D0YGS;OE_[]'=X2]]C*Z*%=L!064,3N+@\:YX0 MP@ZX&FJ)[4-
M8?:3C3O5.!!SMM#P]U;H(_DE]_V11JZLP0RS<,&:J$6$;[P:1M9>22C3\M1L
M=F2W)9>W23-:TAH)F^7C&^;[/#7J!*Z#)A97@:VWQKWXI8QU+;43;BIF+$'J
M.E+&(O7B[_.W<YQ*($#[$FOE=(+3 /A3 O4O::*/X=J_;E+M382C4;-<J1J=
MH<(-8;UDD9+Y4_J4)B_W_(/-LT5 ^*;U=B;@%Q+>'*1WY6FEXT0:'&O%QMH_
MA>7C<V]7HZG?IXC(?$R82,$YJ8J95C_3)0XB-.M:@K,PJU^,R\WM=B0:+:C?
M*&3M*?F$('=>NTC,GI#7E!#[XY>;8-S(/H^*OAS99-;01J1UN*'^CTW)K=MF
M;>=D'@O\A_U^G;X)#YJN.W/O,NY/'W=<U"% Z(/FG?X@CP+9TN ORL=64"Z&
MC)IY=[Q#\WHBJCIG7G^B:4MC=%<*?5C7;.7\JVV#X3,X>8?)5&A3=E/MUZ\@
M0&FM%?N;'9!(6PI!19G(G';R@(HYNUM'I>=AR1R?<<QG.HS6E4.RM?)BWC:2
MOI1% UMMUICMPP*K40=2?;V\'XU:Z]7C5+%1?3,//;FEVI<$9S-4>@AKNL?.
M,6$;F[H7>V8K3_,ZV6EE+89"B1,[5:70N\J[[,79=4%VNET]\K:JC:\*AMU7
MBR7&5OM[38M^"+G^4?/Q-]> <G95]!XS& LV/3[8@$).X(J"T_=YAK*0,P[J
MCJ=*,&-VI"=V)@.2#%'>J0GG+_2>\/A97+I+G.V=LZ!8.G2GO!@T.*T.Q?43
M+ZG(\H&A]&2'7QE_(MQS&-4UF.TGS[SU]5L/.5<7IEX6L\^=-XL[H*J+>^\K
MEJJ]$[,GJ!T\?U(VB*>BR4/5LF[=+-!<5W_2%-M!8ECCGF.4F0K>5]I5NF%1
M&5NO68A\WP/#&5KIUSU5;<^DOMRNC>I;=?BCSD]<S7;6=C\AUWUE&67/ ?X*
M09/RXU+V)P"-8ZS\VUI^7D.VX^=0DQ?\83*#LWHB([,C=GEN')GOE1]+TDAY
M/Q,S^)\L5M4$<14N2FK5&3#3<6>]OT%X6"NZ(3UTC)NK_F[B7.P=&SJ3:AF;
MNDJ,(-G4T%0^^;'6^Y!20.TS+>)6E=*5QVB?]FZ!]LS@\)PK%=Y]_<Y2/.>#
M0<YNO2"&^1SC+M;/VJ6RWN3V76U]NF;^U':G8P6MM64E\Q2L$X=D +3?7QSR
M%:AC2FU5?6+P&YM?G1,S;CC(QR%?GK9J>IOT<?=H\=JTYH6XZBS#E^_+<#<*
M<HGM4]..7W^81&]1!:[#5UPB^OLVD\WK=B1:,*M2"[P*?VIRT,>$ )%&_8]]
MO3>!.8E-+RS7(8".^>HTJ9)66T7<ZRXK23LS?GI>ISYDM<]BIPQ*W'>,#FP\
MQ\S+_?3\:T6]&4O:3IA" @IV81]2.2HL\ 13P 0;E8GQI^&!%]U?&M4C&630
M;7N>JL8>9!OKRT]F9)5[2O:*]F=L.U5\?'+?6+F6JXESJ;R\JHJ,-K9892+O
M-)S8#MLZ+@H+;XB>+_[L9',WQA+ @!/U48=N:"PT<E]/TM]-8+76+H!YN?='
M'X)#I-<VOA#H^\^ZRKJ;;!@M\BRD>PWS%9*JRH_9ASBEDLW+UM\R5@^6@M6J
M(8"S55>]7H+3\=M00RA+G>O,^V5N!M :7&AS\@IRL*MFA_4+15^20U4WF[<W
MU^WONY'0*2](N<P?9.W!, OLK)_.7T78+I6'9"TBM^QME8<HEWYZU!R:J JL
M3/5+,)@=FC7Q,E:_6"MQ,OFE#3(]U360L&2F(4S^GL) 85">L+^:$LXHHZG3
M4=+J8E1_C+2/XS@'5T&Y@X^+5C1#-C%I$XJS^C"T.:84^[$ 3%_6I?MV"?FT
MJGR. YFAHL:8A/VK2#$I1CH/"?7X&HIJ,[SDNL*I>.LI>NC%/*$RE8X&FLS5
MQJOA5873[8?0.X,)L/92HL<89GQGW_$=T27FE3T%J?\/G4L>RP>,3&H?<F3P
M$J,SYL=MX2JQU=B),[.:J<[^ $KZQ/"ZDJ'[IS<<X&GZ%6%B <G<_;!4=ZV@
M1P_SK6^;*NC")NY*T[P2*>1$!7-LA%*5/AT\CDO4C;XQJ0MM5+!A[@SHG34I
M1#AELNG.D8N9VS8^(1[VKK_NW/U:"@T6]EF:[2TQEO&VE[)O0N:XPJ)1?;^]
M?'%M2<V%WUV'/8M@?NK3 /9JYW+!3)!F:4I\(JMS;?%_:R9\*CZ\J=W\XME(
MU8<?EW<87CV[UZB/+4?%%C<T3^)_+L*4$!1,$#R=+DLOU5O=RMUB? R-[%+S
M0RREKQ[]0G539?OA!.;+:Z:*9>@F_<:YR2F14%PY"C@#LK-NF*,@33[. IU;
MS=-(N?&6<[*;S"^%%NDZ[Y!RDY1$#UCA[+4-OETTL9%%D@UVB D;TE#>32%T
MV*!V>;_IX:&)O-%P?2#UQ::7-ER)7H( WY5S$0+RJ:MK-ISCO<$;CA/-Q<IR
M63KB:[(-QZ_TWQH.'[W&W(@<5IH/*EZ5)F'!,3^38-\K475=*[R1[^KN(+C*
MYJZAOHU\>N?0Q2=<-<\YL2DPJV51UPF?1(&L5WT]D[\VWX*2*)4JCDDU)^Q(
MQMN]K>=7;$^UW0X65HDWK1/Q*E(( ,_,>42BQH:PONBW,5:*$)+&+G2$ )1U
MX/W(IRK,RG1Y[>.)O%R"6(K<]G%C@U;P&=V\NYQ=U: 3^I.X@%5^25SC@>3I
MIST7)_!*]^ASCJB9^$_=IW+:[NRP.MSG&>[?A+I+N.(_3PTFT%'(_N5.$#7*
M,WA0";5H)E^:K5WNOLP$CM4M$5N=*D_(]<L,J/Y<<VN0VE=_]^>O\.C09;2S
M"Y8[<\P<<6V)*$VEMSP%';:OEW$=Q5OOE4E$D*[N3JW\KZ) ^NR)RC&8 ;*6
MUX?ZXW_KA8V'  2(^&)P'+ZM]\EVB7'<LHJ!=KTJW!4>-F2]R79M;5-"FM@)
MGW:-?.,@)-EAIL0_QZ CU^VU+.M%IXAJ@Y[EM4QE:(LC-?'I?)*&Z)RMKI/S
MEX]XMB^5A3H-;U1$FWXV1KGNG%8Y=$>G,$39Y0YEQ$55/4E:\%\\)B:E-L$?
MGM/?>,%ZT(Q'V"FG><36K.V?FV1^GW[\N&TT*6?U'&9.X;(GV"S]N.$2*<+$
MJ>NR]@A*&JSN,Z]H>P1JT%ID* O$595TFJ#9LWG$^V1&Y2I$9,<$9<T^9HRM
M\:Y;)9IUF8=E@@IWM9,(DA\"-GZB]+F:S#6]EL#ZO]A[RZ"XVC9=M!.2D* A
MH7$+[A#<"21 &G=IW*61X Z!($GC3AIW;;QQ27 /TM"XN[L%V7EGINJ;JG-.
MU=2N;[YW3NW]XZI:/]9:===ZGN=>U^V/IC0-O[J,%UMSZ69_H7?G0&JH_Z13
MFK??M0/E)#=H7JZ47HYGT6WD1F]%^-[2BT1UU[>\5D+ER;15)M"<7M-5QEU/
M-+BTN#G@SF[OVSK1"@\?7WITN=[8%5:.9_[1QND0J"#=U\+4LE@#6*@(9PWL
MBZJ37R--"(JG_"41P<&%U=K+U(A<,RW33,.(]S(A1IYHUC?0!G= 0TWB*^X6
M693PLKZPREA^?> *F6Y<\O#RK@:&8H3+JEM>FRH#6""<6[7*T<ME9.<%Q@M:
M@%"<1BK81KG&>\SJYW5@[2>;CLP88M(L(MZ>LJC2K:2JOKP8'BZR>(?[%A?-
MU"P'M]VB <E42W_O1#F'*R=Q_*W)&_/B'0+#AE@^8L#=CLA[VKK6EQ4-CHE4
MPO<:K#.:=65S'WBIHG6SAD<73\IB-^4#5V4A6";4*3((QV+V F%H%>18>(&:
MIP66VI";-KNHB"+-$?"EGH]? Y:9:E+:''<U,PU//%G=5JI!'-/'D()GNN,D
M<7N'(L6%1D9XF/8/<I&NS[!=&=Z)AQ0U:(9;GR @AFORZHRRKIYQC6ZU-\DS
M05[EM[11;K9^HV1*7Q.^H0'E.AL3<SRQJ'=^VK57=!.EWB=L\PY=5<LU(;,#
M[$P7- )$5A)I,.D4%;GL[]"#N]LUC KPX7D#?I2M+<VULZY65-JCDB]!\UVV
M2,W>T9GV<,Y^*"X*R.8^'A;^RG[SNZ:LFCUS#]V*^#4)C\-ESVF)F.!?-,+P
M9BMC. -NG:3E=?'=&<L[.SC .3T5N<!<48^L86*#J_GD(0-277A[!$#=M2E_
MGMA2*WHJA-U2=X+,*O3O^W/,ZESN$_*6':X);,5W,\YYGVZDN')\\?L1L['9
MIS&;O@KTED D#DC6U*:Y#9 8AW@Y:\B^THB#[-WGNQ80ACHJ&;@] -"^M_YY
M\\U?8SV!$,.) UVM,/GQA*<=6-^?HP/I%F*\.<+&KJF'ZO4(AOCU1QQ(-:+4
MQS]9&F# VI6+<\34[SG2FB,+A\/2Q"QJHOKOS5Y[.%W-R/$>Y#'T-S"W,/D\
M>6OG\6B8%DT\38ZN[2O"ZG[(K<@.\].:*:T?4#RHIJ2%CCV[(<S*\II4L#<[
M37RQ6R5,3E^[>,)?,]62=@%&71XLOB9<ZH]Z_U>_D=W=U*/[[^Y_=I?:+XJI
M#2?ES7+>493!*W:>TML' '<H.6,_8N4P^S92N$?\9//^ZMYU0L>_)YSR?-"?
M^<>Q?9)W8>ZS88ZWT6NGD>>:@K?Z^'(D,U+!1.0L%.Z*S;-AUK-F+K]Y=;&?
M%]%.7+KQWJJXDM<&N#;?#@>K>\%^'97-<W=8'"QQ2E]'/E-\9I-Q08& Z^78
MG+ Z,@UW;?DS[TJEBIO\IE^<!\Z\.RMX*H30UP7W]Z\A$X1X-$@7#@ZZY*Q=
M%E_J7/<&?NRCV= C&42*D!8HD(K6<WY\)O&LT-]H5XAMMB_W8_EKLJ^SF06#
M(KH^Z1]B>C#XGX9PW^[0\0K,P/G6MV]@DCBO-K(T&*_;1OP#'1C,&ZH3PKYF
M8'1.*-"]O^K>QY5^0CG9J( II4 RDK]_TC!WN /AD!\]M+M5$EV+,7DV3"H.
MEDV0PI#5)U9L85*LR=YW+?BN!&J(^C!Y3@I*+A5@H]Q4&C'BMKY)S*&BVQ@>
M\WVK=&P0X.WO">P*]Q28N1)8J;,[NZ@=\>O^3(@7$^6EOJTT(X#(=7!(UBA7
MFF8J.)1%7?M_#UTR/"<T/!_YLRPZ?'Q\E_>\2.J&*"_/T*CN1@X,:W<O6RU,
M5XKV@X^;HKO$9VE>OSKYDR8U^P=H@XIHG5CX%643V*WJ+,M"*DL(#>I88QM'
MY[;,CM(CM[3VIG[Y=E?X"+(VNG];&XN5G%PC %R4*#BOHJNVF7]S7HP4!U<O
M+^+^,G>E.]\]:/"Y!Y8SIVDW*MO,-NF^9[=4#)^P@6J!61;5\K.A+&,BG[+_
M>SO,H7T^/@QHJ\7?(?$*<$NM"KA\ -R<#WF8KCP=#HC@UH9*?QP>Z2E&56F)
MEWD(RZ*BKX^"XL]B9*@_LV[?TX^>\V!#?%_'"BI[ K-1;ELI,#/,7=A)R6(0
MJN*C?[7#=/P#P+?6GWEE=0PAZ/.1A]OE 6!U*N^_J\C%B#;C&D5N!9.75QA3
MX'P )*JD0P9=V92TKT)+Z!"EBK4['BJC,D5E<?)7<A3K26HM[L83@">4W2WH
M\J.E+E^?:'YB-<+)=+)Z'!7<S.NPW/+6*)SI>XA9-$Y^G=5_A(X"#\8P=RWJ
M&B+,(AI+,-*AUC4'06,V@RMK5Y"\Z]*+2WZ^GXVE'QYIU?BC;8.E?LU((CI7
M<V.7HGTA^=FU'K Q32?.2()P?:2L5WH:05%!GR4+5P_53Y;)^K4KK;SN)M7[
M8YE,FEN6ENP$H7.F$HFIXF0O#?*-LD_'MQQC!.].YN:&T8]Z)8#38+"$J6WB
MQ7&I(U5[<22S#9,Z7+6@^T#(A6G\"A@(92R-D%?P[N!KI?(@V=!1;G=J>CL$
MZ7K591\=J8'/(99 !U1T<E1Q^" 9I)X:.Y%:5K#$QJ+2S"\[!A[LH<OZ03NV
M[8<V5C/[TVU#KBCT3?Y/JAN4FI3U.:RYN7F&^ X<Q<_/GDOH]LE@!H'HA-#*
M<ZI'LL0XA#1:7'#.S[^+F!3HQ=2'XQ=-%BDMNS'G8;CRPAJBLJX@BB,TQI8O
M<1:]) 5Y(TINA<?/(Q0.-YL;=0S1UFG0@%.CB@+0RCB85Z4<KJR*LN,H&<,M
M\[[P?2!_V[\EAS0++_>*"-KQ<"KQM&OAR.>:.4*GLU./>2TI=(2SWF/+IC;D
MD'*6ICETU)+<4@OW_C3_789.C2@LS6&26F ?G%0)1[$FC'85=.BS"GTO*[.,
M4/S@]%*SL:8RD 7-$N/Y\I3RT[VWFE8E:38)8@Q.3",%2LN: HM7FC=*B3\M
MTLS8#8>(YK@US_S1K+VDCIH'D_@!ZP:VKPJ06DI2:IV3-L,?2MGP#[)5D6=-
M^N AN/W**^GYK]MZ%5>0 MP$A[)):O^)0+X' /-^85&P5_Q$]IZ&+/Z.<)_>
M\.B9+MNK\;T+QR<&FV09< N(&,8X;THY0NR*X9!6^PD*)$6GZ9@DY!6I;MTO
M$F'E>+&(4U-OK^JYD;X=O?:B0LI^YX:\MC*O-H.%YU-,5%PA7(BIOP7$2W_^
MH3M8H*N+C5A+H2)*O@(Z1F_QL?N1/8*M\X6K ^TKK)PBM2MDC::]0A.L,!<^
MLGDKN$Q*B2T"MSH1C#=*Z@&6%&Y/SN3%)R:IA$;T2 IY3S0RYZDZ)0E[Q9 H
MAWN^&EG)N;+._S!%F&2@Z;QN9E=R?$4I7S<!Y\54H\6U!:A'/=(M-QQNM&&1
M^59Z&0-K']7]T'&,'ES:_*'2MRB-@J-Q.QQ:>H^-2.JPRY9S=SKB#EWHM"?;
M: 0S:WA]HTW_6B>98J]@T^_F94O@)2_T:3"ZBRC<X0 =[LQ]*S"V5N]I5%]?
MB^.D2@THZX>^ >>2.GH';:G!9.5,<26/RE(R[2':E[+SYL:G)/;ER[JBEJIU
MK>DZFA]QU-DY(5Y0482BO?<.17<&!UT-=>)3V'2FB635/JVF8L!RBA(NO'^V
MCS9PN8[OUC_]O$Y*-C5>3VTT?IF0CAXA0^-_="G7W.I=OY$^(R/HP(#&$[H\
M&3FI^JY;.E:QFLRAK!4ZOJL!MS?E*!YMN9:W]A%TX _MCCR5-29SZ)W7XH'S
ML3$H10X36$2^_:P+U\^N=J6=2.%57TD;0QF56>H>*6; %\.FZ6$OC@-'C5[K
M\^)+YA8U=4TQJP5+69<D$][C(Y!V9U<%]:EWP74T9N;UY/[,"SU$>=G?%%5!
M_!72>&%V;(/D+.V)7HHE8EE8535QEDZUG,PA.4</ +FV-DAG(D1'>[TY%0NV
M:U6B#2W6Z]MYWS'FN.XXLN:_;&#]K-^*K/=$EM/2U@&NMCS@=G0T"K.6?^-V
M*#"ORZ/"?$[7]'QY6\;J&M\E@IV<5#&R']TB0HA@5ZLPNRK.R=VB$@JMPOAG
ME<'\[Z+$AD!Y1_.USC W60DB6"?[LPC#(%*,PB,O=-!N+BYR&+$'IF\Q+YN"
M=Y463U-R;2;PP#9#]UQWI0,/.#VN]7 TFPN4CQR^-G.XV?-\I]"6Z(\7%/^:
MB0O);C;!_69 /8XRWT^"K1;%,?LGB"F%";6@#O;/MD9[5TUC_1, 7N<32 *W
M0]%.:$QF'RTJ_*JC*XF"&?E:=NR2U.FW].*U]0-@LE J*ES$]%/VZM#';[L,
MO6^OM7(]='\2B)%_,Z-2<)$9HL')D 54+QWB]"S/ ]_\.,WMD/UC@O/\#\@*
M_:=:[L'EMXD<OWT<UB"SNYUL_FN5_K.K_C3O*!9GH,+_ ^3['P+\ Y=9XI@9
MN8]D2R>C7PSXCQ:>YQVO'?>1"#U?;Z_H)4/5#OR_U$$!O,'%V?L:&.A&3%9_
M4Y;-?R?^;T7+?Q'_!U>TO Z(&U%^3("16PG R45AKHA_TR11XVV)_JWP0Z#_
M[%FEB/^JX&;C?>>8?IVE;7B:]HU&&_JM8 "5W)TQ5ES=((T]\M%P75BS:9D@
MA#%78^\-T;U%54C RA4O7C&YV);>P>+&FJ58"V31I#;PR0O\C]!G $Q5(R\,
MP'&8TM?6-Z/K>#::74C?_=6-V]W19N%5<O[.CP0OGCBO)B>?@F$A4<9%LS7\
M;J.]$2CHB1*!A]!A^R6DR&J?(1K'SW I$]<ZNP$7S:-1_.7V"O$4YE3HL'C+
MH;[OWU[C\G<#**<\L<=3WSPP6[AL,!OA3,%[/"A&$3ZC:WRH[;B5<>>US%..
M 5G@2ME'G3:[[3DW1 E<X#^:7O11&S5:B*%-0GOR3)+37^@TXYE'(.K#L3HL
MHM>!;@+U9=RQ7+[RRCASIIO A9_6_W6XY4D)(27VK2 7'CFL_>-.@\"=%9JN
M[+%T3*D1V*#[A'+I%W4M2\]Y6XC[C*+]&:0@06UCQL/X['&9!_\*UN@<>P)\
M3<RM- ))^?X=19$4U9MXO)%P*/AO'S/WSP +>C=)SP5'*+M]P/5QI3\%BU<S
M:N7\9Y1\=="K)^%.HHY0P."5<9:_E8$"? &7&V+,C[MR7JY?9OJ#K\1NF90Z
MA\(&75Q-7_3?%Y3L2,89K8,Y1$;U.77N'[+&M4U_)!,5$!Z#V;J$+ED@ #S
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M\,UW1F1.NL97@Z\PK"/?LWH:%@"'BX?39%XT3>MM)V"X6DOG$K+8=Z5$$3P
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M)<OS8$SOWU^<L7H>#4,HX0*YF\^2G/.,XE,B!/-1"HHK4"FC?B*R+V.)C<.
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M4$KL[M.7-'BWTX==SA=>$7?MO3""].A9A]^W)S;#"2*PQ,@;M5DYS&(C;B9
MJH8"J5KST2V'J5@&:[)MB!0M9:^&;-XU;XU=6X8)#:@+.7;R1TS[>W,V/VQ-
MX1)I9($67<B$6JJSP3>[/X90] .@OJV_^0&@1Y*?QT-XJBLD6?I8.C,6O<7K
M:?FMU_N?E$T&N&.(G^4+PZC:E.35V0N>0\AN)=M_?_W,/RU8LMGU8W%VTO+*
M)^9VR)O<,Z.KA3>WLK;M'4AZ9J']LRBZ'+-+DVJ&^X#ANN9NXA%.:6-!"-5U
M0.(;1$]!GBO/OS%992\5C?*#E<H*V(8%)ID-B.?1*K^A>-=<U_@^Z-K18-&
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MV2,]=L/.$B4IB-=U>FS44:&&>\+!;9+Q LG(/JFL7%CR*YW\Z^2*TJ.2Y0<
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MSTS3.EI<7_85O*IX;4(T/IY\//NGK&&$U@J$4D</BG1F16H] &LO.KF1%!5
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M/2"<@UN.15QZPF6OZEEC#, WAGS+.+"XL*T0ZY?FSW]\X_L/_E.!Q8P!:&,
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M6O>Q[YY 'F@1L_5.T7#MFO",D.R1DQASFI>0+S>8WO.L,+9E138\G943=CS
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MGD_Z.-3PI37D-I@2=@Q )+NY"0HA*]9/&#,#<!P_-:I9W<54ZVEQNKY6%?(
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MWD?D]QI2V;<F,KC>[LJ"^;>W!%P#,8!@4WL,0"H- [C]6'4*NB^3LQ"9/^8
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MYYNU93SJUWFM?F_DW\@+NJP12-/=:!ROL=M5>XVSY>J=833;@&;7$&^ZF&"
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MQZ(1;+GU!*_^/]8^+,).\/*FM_+ "\N 1.S))B<Z\L,Q-$.3O9H&T\S^K$<
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MP!%$<\'U*J@ Y<XE"A;,T#_RSA"#7!G.,;BF=79R7<:X2!?>.5.?%AY^"EP
M;;+01B@QI*(XN<KMFJ EN<)=H?*>Y4ZJKORQ]'/>;(/:^)R\T 9OFQ=)^+IV
M_2=8)/F.DE95-I'>(,'\?(1 L3!XA^R+S<#B=@>RMS)@"WX7ZSR@,91<WT.9
MLEV^BHQ84&*$$@-;<C&O$F/B%9?P8S[5Z(;K98CCD1EUJ;I6I;$BF<6]LH?T
M-.[8;:ZXU04'@P=GD_5 E*MJ,\&RZJR^, 2W/E=OLAW]_A@"7S@S/^%MJY8
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M$T%C@" KP"OG?]'5)$W\-U!+ P04    "  O:&12:)R^1SR" @#,0P, %@
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MP>M'_(9Z[Z,M;%EHPYL/=,EK:<.HZ,1/M'T XO\7C%50Q5D,-RLUA>O_UKG
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MD_#W<E1Y^:S'5B@JF:PUZE3D!#2O8A)MK-<O1G6RO?;#W)%VRPEZC^C1]V#
MTJ]-PGSC0HM_D$O;DK8[-2Z0.:EBF'!%,G16F3(V85\]2W*DDK/9,BGL1Z<_
MF]Z.6[4=,6) JJ7*3=O3X9'MS$'64W2/!UQ?CH(?ZH2=P=EP9;S?,\1Q\M7,
M=>5[ F-3KLQO[>]JZDA.1R@T,OF1?ATRMK<:KL:2!?WH,/T>M=%9;S *?WE^
M+<S2LE-Q W"(44)SZCY&2 FKWKE0XQ>2,">Z5AIT#H,%GO'G'JQW<ZT3Z1J7
MR:[ U][3'BP\532F,E9$RVD5T)5JPH7*:>J32-..P3Z[GOGK"!:[^=.EF 3P
MU@'JFH</HE/[+CZ^,\L\?.HHG_\M9O,3UWE J91:;.\H/<^*[_@-H"DPC)8C
MQ2E'DI3/K&HZ"3=2I_^Y4 N)7>S)26T=$0K3@E$IC'YPL289AS#JK=L6W[_G
M1P[L?G.UMCYZ*A6]HYY?*_<R+$(,J59SR4>PG= F*IX>I\JY/9%0P8LXL$Z<
M%ASE$PSHCS="P4]V,.['N4*,VVJ<%BS-9)[KN!IM^U(;?'LS+2M!NYJN/7J@
MV F3RE9$DU/4T^LP)TF^O[*C,H53W/,P<UECK+'S*<4J.5!3_#*<TF\D*1#-
M<VZXE&I%&J:%U^\YQ;R,@V$404;XA(>-QATNZ%5=>5!BDQV#_I.!#.Y<.JO=
M4][S:+9T3@_J2OJRNW4WY5B82F95)XB&DQ Q7:Q7-3Y@/9BR4S=QQ!71/<F
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MC_']_??9&Z_?LJ#W#N8HW0 8>I$_SK2!38M2KVO"!NJ+;Y5^;1K&-X!P@K\
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MBD_X\R=#\\OO8C)D)?WN.+!CZ./=:KM+WJ;Q+S]86G2%%ST!;3. D9AC<&=
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M M:S7S!0\;0_')8$(9M]6':*P+6V0SNFQ=D1(Z;BK;'M?DE9_&32D1-/V[C
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MS; A^A'3+@*7?):*#<[\HGQ>.:E/WQT'+]>: W6&=D\]-:/%E3H^<?,1KOD
M#\J&FD1PZ<V4J8E%@MG)((-1WYR"I"F".^("\)KM+4@[6J<:LHY?IP1/3[A:
MZBY^8VF[6X#/RQWHD28%$7$,N*R[#(RA#%SXMM=FT#?+]2\VS.(./5FG*$'N
M6!F.[L8_T;1D_$'0KU95$?PYPC*8>$'M0<&&7B_%]A86^OQ1MU1_O/G1YW.%
MA3[=RKU*4\&,\Y^:_%'*=^B]B]CMZS6CC:G,_,J4A2?S&#]6C'*L>N!"1 F,
M>/Z"_?;<#NPC\Y*QO_P' 8#$2#5@"^\[U]61ONG1W7J'S2OWQXP+*Y3LD!,8
MY>4;:%)2916:B Z@:2#B_.O3D]X"39S#1Y<[>:/?3,S'^G@^72/'*!E&^R1)
M%^VKC(?0;PEZ\F2RM6GY-$C0,__M=AY&W(-RZ]I&PM"6]?S;R=7PI2E0""<,
MM/-6T(@UR1PMN#/9+Q5^G<+['%2B&M*<J9>!)QQ-4@7R/C5W&L)2C\=(Y^)
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M#L,@GKV!;$^6ZKP9=,,Q3_&=+;A*@.G!2O> 8->/;RN:QIP&*Z=?,;BXP2B
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M:6F?>[BIEYR2&Z6QK\3S7/H15<I3[^)$U<;/UCG-U\Y%^G->;J<(88&O]/<
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MU_!O1PRC_;*+.]]:=?1H7E$&)ROS"OP^U.%'EKY,L*H05CBN,D*FL"$I$/S
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MDDOO 5_F]O0%*_.X)L\((%XJ4&AE*W]$J"Q?+]!6Q^"-X_.$=U.%EH@C_X]
MEL^\CLTS%&HTP$8+IX4P^;1WUP*/=R.DK1&,>;YL9WS.^]-,,,[FGX=J_G?3
M;^*2E__694L)A>^W4,G]_]49'QJ_%D_SM&=7W&%<=T@RAM@2@9._C'"C5%I
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M1[T2S$8NXU^1&5N$R(T?WJL]]LX5[U'\3TT'.1<5/N5+)12$IP..'%\^)1E
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MAW_*.D@=.-2\":1Y&.DAEZF3TZ]>6"FL-Q&._"9Q5Y<H _G+[B-@RCH2://
M'CY-P]"H=H9KHM5B!=<R$<+$$(8M&46@.^O5Q*>7U['%P]T(D.,DV%?8+LHH
M<%R4Z DM8VXF*6^UT!1K.__T84%<.'6$TE@=I_EL.3NY,4/X!.SDI/ORUW)D
M)_,BUUNJB- >?X?/F%/[P*@\YO1EO4;&\1>:ZHG!:H&G7"KG7V72_#<]RA=U
M+G)E-69(J)V80@D4G!7+23!/8S?X+FMT9Z:>G#"F]FIJ/HSV\NQ?MIEBB-\T
ME^PO&5QL#=BX87N O<BW;EQ][B9_$,/_.H)FOD.S[!_B>E8\]>L?*+D'M-[A
M+FB^6'6X). 2N6CO:K;^#W69_T_9R_??A(BE?BML(2\]@MJJA]<CSZ8PG!8L
M-US.LC%T&%FOG1:F?5W\['4]HT?]N>C*V_>'')0O)VX;[79$^ '3N=7W@'KF
M5LGODN>;]<4W6T@JH*&[Q;HSL@RRA:3EO)-L#)G_HF>TU]N%/. A2S%^O;?4
MXJC""0C,N,0GS"T2DN1T9^4G$%V+'UC_O;_@[YZA]%?,J(\PRUPU[>LZ;*@'
M7@$Q&;#%8/%F8QX_3 &/918HS4]Q!^3@U\J/LI(+7/$^A6NSW4[IM7T.&%;4
M[VW<M9Z6*[6>Y)Q I%/B5Y&F_-*<_DUU-_6HY41WR^N;3T4S00Y%6O#=U]>&
MKTU/2U.73N:^7E:AQSGJG>KH?S^GG4\U,CV^H#\M[;W2]A8B5JWR$!NP+@/L
M"DEJM2P/.,1@@6VM)G=$!V=?)ZJK )WGN8M<T9T8J&(SNYK*&!LA=N8GN"']
MGM'6MA;\3;"B#RX#CP3\C7FY.':N9CZ%FD))M478A(($ND6.+FAO741&F^S,
M.7U8OE5N4/1@[%!<V=UX!A6G<J-4]>BX8N9CPQI%0O9&\J2;[SRSX#:0$ALE
M<S5;6U>,CALHK.MZ3>., "*KONK$#\^)\E$<4H)<._;A%&_38JM.U+K-*"I-
MK;776VX@Q<[B#EU>5=R<^@TF[Q,6_?IMPE H[1IALGO^: MJWC!6:YUU,O&
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MD.@;*M NCIV2$",5L.KXW?(Z?-0##&IBL^;QD937?E!N= G_H.4 G>]R2G5
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M.;;:.(S=CN:1U.P(5]*S:I;6^RBMV:@Y92@Y>0=:$+:S +&L=?N95K;O/]I
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M6QE-4G6()21;=O9)E^VA_F"K7)7$)*XP+PJ8I)<;L$:A=!N)#IWK\F8Q37Q
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M;CFT:\N5"?U.$_SHB2L74AW$?I_II K?_[5U4Q4@J7P+YQPRLE@,\^>#]-P
MM "KMMSWMW2A\5@>*AWLX:,_Y.7Y;ADN3WBW-TX'W%Z;"*_#-MUK@.@I+C@
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MN@PP23X3& 7/"YZQ?%X;69QK.V_94KFD"B6,*:F+9A2(XW>JUM=^%/.%>;#
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ME5&O5Q4%M)%1+KOO6G58UZUR?'XJ39>#ADG =R!K<&NNNH3C<R1^=E4%J^5
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M"/&).G#.:,A,6"&C:V,X56'2A1_W5#W.]G*7,M/([=VW2BWGH/"VAZCJW.O
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MC]U5+T<?:M1@ /+OB]<V$I7+E!Z>](^D$O,,M]G1!O2P:)D4PI5=MB .?3^
M@[IB;E"_;K,9]J,"0X=73Z8L?!X,BU5H7*QAY[I1 =]B#65;ID"H/0YX5,9:
M-Y=79Z-IHY9$BF;#<_768D]>&9[Q4S#FS0:8\\*((#OQVCX?NO=A!L0%Q$\+
M2,B[9()U!^'P V_O!L\;MT]#&PJM*K^M[70:K&AT,R0:XN-KBP'A5P!66=>9
M")M'UY<?UUX!?#05\W5Y8,V= CR)KMFR/#M)3SLWAWQ?*NWJ>"8T2'>J04"5
MK'&8;:!Y[NER"S>!8IW.6-9]767_!:"U++8M^6;R2;5MW\-!G(';'+%M)VXB
M4G /<4C^JVD$++-.FYI%SP*(6A74@]K%'UJ1$'<O5U!+CV:F&R>"Z8-I\) C
MI.S!I2COY5!QK>T;YT,1HYI:3RX?;)"U9%D2ZECC^@H%10?=*;3?U[9S[;'I
M,'SP+"LAD2!MX98%[VJONL_02 M/C;.1Z:3*26ATX?-$S/2X/HBDK0H6010\
MO(&A B^VN#_#(F:#8[_CGJ'@!ZP((7[4DVE_!U_+YBM I(EX8!VB,H)8 /14
M_N&WW4WKQY4,NH3'D$L=C2TCCU^!C>1W\9'C%Z&,L'MW7V"L,UEFWCY_W[("
MO53S)( ,\)P7R3#> -.QGRRWQ%.]--CK@X!B0@&17SY<>I8N248_/-\S^)J3
MY?_H)QU: MJ<*"^*7P&$QWX6,OZ7%A-\78QVY2IQY31+2?:20">S8G\8[_!&
MPPCW*2"4V<.(1&K4[VTYS]EP0+?J4:!]S6U%A*-.6+/OSH"0 E,F[9NG_ND(
M'B(EFJRR YC!9HIQV(-MM]W)RN8..*=GZ]Y=SPZ :Y4F.-?ZITQL%TC 0Y(^
M J&^C'0E[='],O3D(Q'&J+(6&4,^_; L5GLE;:>-GS]M&F=#L++N).ZW-)(W
M.VX1!Q$2$DR3:D'W#KO\&#$_M@S9VB^ AHI6:H'FJ%9R79=W=%'9I!W:K]2H
ME<4$2V<-GU4%<?W6K=]')_VV< !4YS\V9!@ @.'? OI$RG+)U2_[5ADQJ75:
M. H#\?N@'RVLWBR#Z??Z7G9M>65S+#GJ6#_-]-)\TL5F;K0K5"Z*F9D5"NJY
M>^=3=Y[,/&/R@#@IG'/]\@J@C12&/3,A<QFPMM+#&S+5X,?.%:Q-">?2KU!/
MV4J)]S040KT9W7Z\<P68U!# 2N[DZ".^1\DFSNHP\ASVW'ILP ?+T&[<:S1R
M*R7DG -WLD[3_/.3G?ROQ$)DS-ARJ/NMPA-JJ:Y]>DB[2L/AYS3](V]QF3&R
M:[V&QU+7[F],9LG366.\J -0P_3+FI N4WO I8%TDN\8DQF,6MM.7*',$0TH
MAH!.C<,MWBDWN7APH$O9.N^>@#)=P%1Z%?3&$I&R%,!?DN?%ST'.9,(@JGB_
MMYQ/K:3U[Q2'#]GW4%=^\516W>";G[TE#N8@!09SD0M5@G9CE:WY;FVO<Z6&
M(USH)RM7!>UE[V=5P4W]I \*/WW*P<0$#FP(MNGHG]PFY]_237#AU@35QR\P
MTH"?C5KO:<3TB#_DO#6MP(@>T#K^ YNZ1]H 'X+T>'NY74!M(Z_3(^:";@9_
MWIP7P5X4!&OZ#"$%GKOOD\Z_"I10D?I5:<G9VCOA85(H8=N+\^ I*Q;D>&:'
MF<UHKEOA^!)]R95.='IJM([[[$]ZM<19557XD25FZ$[IKPM>1J^O>#8X(>51
M_/^O>/ZW/+?_;,$<K9D!RRRQHYO/3FED8&JA:O+2)1MS.&*47/&![QJ1KSPM
M_J=]HMJ"8<O<LPCR5:O>]0 64:I]'%<@V?2+E7MTL9M6K]3"S,89CS*Q=\4E
M8CN>3$?KKEI79Q=(YK?2^QBF*MV<! 4E%TH6M/<G?9^'"P^U<VX_W!#%STJ*
ME:0YH> ;'.D&F*;>!3!^$A$7.VQP&-^+!>O$W6^C652Z,:3<U,Z1*AR:/SV<
M$T+S]:G1EBA^SJ?]' LU4G. ]\B#95*\!^(FFY8W=&#77H@Z2T9M?AP?<N>6
MLYOP#FAZ$QO6KJ!@5X!6>;XLY"EK6N.R&(M1^88N]82;P=YG&QWP#;:,5D/(
M-?G:-PGW[ ?=*\ OFN5E3P5:$-W3(;XF@W^16;NR4%> 0_V,\QT=@\T>\,GW
M*HP!=.&RX*QAZ@?3;NKPX#/.@4L/5NJ)!,C>9ZLW Y!66>>+T=SK3:B-LV)]
M[$.SC/-='7"E+7@E=!@S_??XY[N/OYGIK$)^10]=I%BA)9^&O\"W8VEV<&U5
MRT[T+,31)NNRKPK=(&;)0]=\=!F %<C<H\;+>73%:#SG:)-]V?^79/#<H^;+
M^>MF X^.B.O!FQL&)_-5$(MK_ [,PQ;XG1![^4#H"G"RC!C^G91]]FSLT@-&
M(S!P+.6*?[)<!6D5*T +7GCL)G'+7K?EV<V:\Y\Z@.4KP!PM$KP"';ZFHS/2
MPQ,WB;_]68(6-!VR$C-,?=^:'UROL];<AE8?A -OM8Z'>;[P%RY5W7U\T5R^
MC-\4D3S? ,&SX:L/TTXC @BI#1^_0MF*;3V0R/5E-I[MOZ<^A6,DB0#(/SFM
M/B6;HU_^*7<%\!CS0/>Z.;YMEC9T/V"F,)-:G$CI43A:EX1_K? =M>/2?_NF
M7.(6AUYG@PD+X>->0&P#R\,F?H^LY]CGGM*UCF%*7%[\AMH4!:0B'D63B9,?
MJ^W+7Y1< 62ZAF-.O\\H;*]3F!$=Y@9HUE4XVW.STU)WA&)I[&R0V#.<&70S
MU]QH "UR'^<B>?"%VX>P7O\4'#,0O2EI!QFY)2(N+9%!FG#^9M)?T'MCSLQD
M>24JJ_&'RBYLNJ;X0>!M&%(SKZE1M?6!&@['X)@(Y/N9;G+\_$LY"J@8:,(C
M\X-C79!UU_ECJ@V=ZGI@*L=-2_5(F.)%M,D5X-F&* ED)\X;1KT3=P:S@YAJ
MH4>]?NC/:=2'UR^WIK5,P 8V4ZA/CG3 %:];5F8L,?$O'P1<]CTY?XP_96MW
M!3 =_RUK[.]9#79BNR_[V,_I?T(J=5LF-'[-_Z^_YK\H"?@7\0F:>,IJ?P4P
MTX8,W$1K93WH>0[X%UE'E(1Z)U9^%3V!T SRBW$2_YIQ'']1'5<1@Q!S[=]F
MWR\&NK[:-&;Z"N!J57$<M*R5?!=^&Q[Y&TG2,6_R(NVP-7,A5&5<T21M1.%H
MV@N**BDVF)Y-BB0!%NM5'7($?;YV0J*!=+Y(<XQHUH9K?C+T#35Y<CK O0!6
MU7]7N/SR"^2]<6WQ!^\T3.6]3,D8@FYQ2NL$%);;,)'61"INIC/T+:EM?C '
M*&[_4X?30RK:)B12M\N,1:B615S?%W3ZK6WVI3L.PTR#0]9G(Q]I>V_6XA/E
MRTT\1ZU".OP[GU\K4+L_^EE<6OI*)%:+)R[WZR:G<?9E5QHW23?6%WPY9WF<
M6(6=7DZK88X$42V+PJ+#V$;V9VFU%>W!6.E>:@FG34NYV5,ITEHU&.7#)1-K
M3BF>[,F*R704A13[V4@<17Q*B^[:,Q;:V%[AE>F1>3XWP:+NHLPPJ>]/4+E#
MKCTP,H$Y6T'-&5H!S-F\9#8?>?=[W.QWV^>:C10+"*SKO=:?"2#"D^/).+YF
MY&JC]N.'X270.Z9@/@&&Y.(N5[/Y!N_Q><]'$4]O*^\7LL'9&I][VEY&TC,3
M.D>C_(7(27L/OZX,ER U=MX;J5$&RFJ_OUXENU&B!)@_M!.ZV.[ **624WHH
MHJPSXFQ7U$4Z+;-W.8UV.?L<7]'&M<&9_>],S3;H+"(\Y-)I]#XRAZ[Q,%2/
MYC*3G2@OK#*EL\2Z^9>(4O.OZ:(.->:)GFGU,S_J)+"0N/TA(]6!\08Y+D0Q
MM).>I>&MOP=0XZN _<$)&P'@702)'P\B;XU8WNB>2/TV(Y>.PV2;'<>#FZ=*
MG&HDHB(W-?W8'CTZ:RU!WLW3S<&LO(OEQBG-.7[KC9@4D:$?<+F9%H6 "'=Q
M&Q%1X) =\ ?1/K_\4N3N)9XV_LP4U(=&(7.-X"*;\K7CZD!3N0,TTZ!@!EN1
M#R #69",UGI=7%YR1N%<Y;#1%@;P=BA@X0I0+2R-YJR02\A=\)\^;@HG7;_]
M_]/D<C43#WQFTIZQMYJQLI/]QT_PMN[(LZS(_[L0O-+Y%^"%(?# G'YP+/61
M.)4<9(8(X\NQ3.LII<S/Y9^L0:KIS.4YZNJK'++_6*SPO]!Y(@;Y'_;+'T;4
M5Y_EK^FAU^?SP(42YLVP]=?Z<?.W'I7!:9JV+JNKNRY%I@0^PV?MCX\@1_(.
MU9/O$;MTC^"$J>6G(^_IVD>F5Q_N2'3=$=HBY?FX<&_J@_S#OIJSQ=!>E/Y!
MD\) MU@U*:<4C)KDY8^L0'7ZM_SYHSC<Y,QO;"F1)R>="WUJC8WUR$8QMM3@
M(Q G<^[(?;1@UOWX_<2X3G_8:O8IU#WL1-R!8O^']&V7*\#K(5<28O !:\_B
MZ  A!B2G?5WAGKJ^^2X"5V:6\=$L["C)#4:I,#0_E!7^W#B?(>G+^>/7K)MZ
MJ1?KG?6H]#.MVJKX%G>"!6#=7.&[:B<)#Z%RO4W>H*EV]QA%JO'IG;[9B$RM
MBM'9'MV(25Z&Z;#4,=5":=?'4 3\:4^_35KXO."TH_CKQRI@%-ZH=_L/5PKB
M;CM2M9T.;Z4C@A /OS[;%9E>-JX-_8?!!P+V+*;TBYGS=2<F:B-\]F<OZ\Z:
M-C1;4Q:JZTP(L,^J1(+,]-=?^#KI>N<9O8F.U)F]5J*0O)N>G@OIHVFNK$TS
M^]$]K\OXJ3?PO8*?R]8B*.Z\DOK@NB4V?H_J$6I1-K*BW8N7?$U[Q!I3;LH1
M\P&@QP)58H-2>5[$TQU6WX"QGS\K4ANBPJCAI&8F?ANO1K:>K]Z%#[LX;.1'
MR\+X"'?I";;860M[9,.:XJ\]!>T><[GJ)^A&G%?!)EM_#U&1GT+S=P*)E'6(
M_^6-**FNNXJ9?0!6X)LG(5G:VD Q6WYN-'!+O/14PA831R]CL?@G2Y+G]&U_
MBF __YE]^< ,S2%J&(-#>D>_B,KH-?3I;U&'<)-VXD S;24';!Z^<_H>-&HJ
M:EIN3'S*22(AM2&'LYKAA:FB?CN/F<'M'.&I]?0+]^V[020T9 &;#C]FJOS4
MC4,!XNK*_H!S$!-K=M12G)\Z#Q&@/=R$1 E[3C$+VDOD9(E1^0SY# &;VQ!K
M[&\+ L9;V3_>^AI&F;PX9F9[8W+JG?*1.$!1.GI#K_2]L");$NG-<F'?]>5]
M1>",M#=S!5?A:G-<D)<O$-VT5G6^\Q,H> Z4<NG3!W ETF2_]O'W;6_Y&HD4
MV9_L<6,@E?5:SA^K0@:2T=TN;%GI'<16%G?JZG!Z$VONP*PK.3JF_B;G[D-L
MDDQ<P;]UB/J"DT-6'.!TVE2IJY\23\W$7[B5IYV-114 G:ROUDT*+0/V]-D_
MR^  D49!EU+U'KN6A\5^:!%3"2W$W7?"3PI\%F_2'W8%(,G+21J1\Z55MRO"
M1ZKZ("]WLOL4?]QU?^[H4T5)  &Y8>=R74<(HRE9<XZ_7>G=(,'Q)C*7[X_Q
MW]D3,J8-OB9BDGSJ^+-8*C7(]>:-4J@@(_5SZ>7\HT J:XB'LD-M+E%J//8Z
MX^V K()S)N$_U,GVD%K\5UTX0Q%P)OV;74@^PMLF+-YJSJ^Z2$ZD3-;4C8-\
M7QC%F\DDLGUPTJNGTV<;GWW%#7^F^B5WK"14JI+F1-TFL[)*5DL=0$JY-L:[
MX7Q' A,Z&R= G!<5'MWY<B[*"^FDW4$_:X.?I/YABNGUBG&1S'*VM'KPDUL(
M1@]R44R$N#-:#GG34UCP\%IFWNI\RWV["? I7UG.4UU2#PJ@=W@OKS]8TEMS
M2Y.::4UMB_5Q4YJ?"J&(35DE0E<+B*YUE92?!'!]WOIOOKSF_WEGBG_QW.#[
MD]KM:G&])'F%8&J$05N;OWR%=ZP]?_J44@JN(')OBRS3:HPIW::84#*RD0DK
M*B!*PHI)BTW,(D]7:Z5;SSROMCIBB5>*DVG6!S)+Y+F+UHW0\VY1//P&N^A3
M4--LQLUUVV0GD/TS,'JR'E\!&M'S[6L"5#PWNI<IM([>!@0T^DR2L[> GIH#
MD6>M::U+WOJ<D[VQ#Q:>,'SHXYP\$4UV#BU?Z;J8D\R@/@I\>"_^]7Z*+N%9
M7(=V^JS0^Z]2G#G&B=<Y(Z]K8'O(-3?(8NB[&LSC-CO,;#NKL^"N [G.2'7=
M/.>;7S6]6-,V Y?E8E4GUG:T/FII I!_T?*>%"WXP@3CER*W2=SXDF93JR!L
M'LB?E4^/B0G4.;L4"9>];I/ZC\=B=J+6R3Q&?!]MVM!K^G"-S;W?0^M?VCU:
M3%MJ_8NN]AFN ,I/SO)/5-=B(06Q%R/G!9B!.ZBTFULSN\G2[<% )*05;'+1
MIO4*#[U<%/\X7;>IR,0I/9;<A-3^\B74=1:$L/Q78MK^7IID%W(Q*@*!+;T+
M5(:C<?O"TB%\,CN&*,HHCAH&<.AQP,>B0'Y\\T,?MS^0:#'>MD6F-[&M/W@I
M.IR#J$+$ZMZ;6;32:JR8#E/IFD,Y[TFU^G.1.0X][].J&H&S:SUX9N UBQB<
M]W_;Y8Y"/* /,R+"SP5H5I1'] LS?OZAL9H5U3LC)EZ%C L9$2@)%VKE/>1S
M$LPCJ-=4%0<H778C+I?8#^5+CT '1!B29PQC9W$0T\DK@%.ILB@1I,(64B?Y
M!VJ\>Z[N/8'WK][;//P,(IYT *\47IK7?Q@X_IEQT79>G+AC<.X]#1E3/4>O
M$?M_SU2+HBSGJWKG\T+&3!S9M!L,0EEZ9'DNLF5^>L;U7LQ/)'""%5B6K@#E
MI4WBU.-CLUGUH2#?=^*;64Y7@.NOD9LV/Y3UQ8F\;P=7A*!7)A,#KU#P=6)7
M(N5-.JJO3]@OPGW7&2\[FP^ 2&7)LO?>C*DMASQ'!=EG9&=(365QJE;:OUU8
M+^2ZK%L?//P..?1%B"[>B4V\;*L9I,--UF1 S+VAT2]X"M(!+=SN,HY3&4<K
M0Q7O+6HBYGAKOY3<&\!/ZX!U,N=F^?,'ES>^FRL22:1\"@%MXTC-*)'93\S]
MVNM6K:4PUIZ5<T#D6LT=L9 M8NJ3A/*L^JNNWKCGK;45^]H$*$*D\E\"C_\W
M'A12%A,J#RW5ITJ38E(A:L3EON>4=# 6VCD;C&M"ONF R^!7@&;$\)#VV6V"
MS?F_CI4L\_?F3QT[!'X[0D5N,K?\@+E4*6_24/4_X;D(=+\XR#Z[^^-L0Y\5
M/5&P*T/Z($;Z5P!?R\O6ALO3,5GTC,+X9Q8IECE3]MD5#@T5>8<Y\7)@Y+5.
MG]1KTU.-0"*-<AG0EZJ2$J)_S7D^I_W! T@])/Y9,M]I"'CFVB@*'QO2-7IT
MX<HSH4G^_<?Q*1HDP_,:0/^R8\L[F(5HA3F.MRV1O.%N>XIV?>I6Z%--I(93
M,4DT4X[+U,C9QLG0,H/?Z:5K-X$[.VNM'W>Z_K#3/>K.RL,?Y<]&OFRT80X&
MR.JE>H5OE2\+O]G007DAG2DKRC3VB\,MFTAELLP11*&?@\19K?\@S#%NKIQ[
M*EY?4])SS'XIL@W>^/>+G'\!UTMA/D$ 6&EI7&DT]+<K<9M?/&5=TXK=T%2-
M 3J(%&#"]PA_=>G)T=@>G#2_SCE&RX^[V-&9FJ;\W&H<;_&^%YG.HNW!5)(4
M7@#509-949L+8):/"ND_^-^E^OY3>#N9JDJ@E5#;2:_61\,5Q&BG9[AH;>HU
M%+VA36WM]6STL=E!4N*F=FGTAH0DS-2W2 8=1:W]WIO89O'W1#&1")%_0XRT
M),J8J@-Z0E5EZH62G,S)WE)1/D@*+C=OEH214B&B#PL9S]3B?,UI_[7*_@D%
M(=)LA!IK>;(GJ_-Y>%PL&'\VH%E+0^J_^PJA?PO.B=IQ/_<U0#.)?KQC\Y_!
MF[]K>UAQ(/]25T)=L6]+<YO^9Z;[/O#K#?L?/IUGB'#MJI(:<^?XJN? QD0G
MSUB*L$5,'8[/%"9+>BHQ41VQK05%DCH5J@&L%B1:\>1D1.J,KKK:T_1.IE"&
M45N:J"[Z)"-40=8476T;SBCY!XRC^1.IY0R\0ANA=Q%RL9K\='G*BDXZ<@$R
MR GZ^W(*OO(N,F*,CS["%94"[,P52#268]T/W]]8B:<854E1C(YXX+YD'DZD
MK'_KVK 5ZV'&[A+?6?"))L?WEN.CC,OZC&6;_$9T=YFN -/@KW60FU> +O3W
M R2: T0I??^=NV1W!IWU+LN+B2Z0DKB#\U4'LAF5$PV8>V[PY\[<,&;W/$!Y
M57BS6*SJS7O#*?0?[MHY!P*5UE'^W[M%/R#5M>RW5GS+F^5Y#F2UQHO!=/ZL
MG,RN0&+Z&MM="N-DXFQ[+EO)[F(1<8"]%5EFW7/RC%0\:1CT>_0L:D[?.UH?
MD3/O 7PS<".J>_6_U#O;/^]L%!=2^TVF,^4'JN>B\U2#^YM?'8<^[FKTD#BP
MT^57&HDG[ZL'%QRV5#0I;1UIQ_)?>."JDTS+CV]:%FE"XXCO>\:F,@*3KP!W
M(A*;5+W-ZI6R9C]-2CX7-^R;G^'%GMR>@%G:&Z5_ZQ>+[[3B1]0R)!N'MM?M
M2J39TD9(" 7KJ9KLFJ>PR-/5M1[D=[-][@V?9'ZDN N,R.42QZ1L@ULO=7Z\
M61D8]3T:J@<3NCED%PH_BJ:_H>*GPB5M[XW;>\NR7TVEDK*'6X-HEF7$*'[!
MPO:+@Z/&_H7=B"I_C;'T09&CU:O6>NZ"HC'WLHF7IDG?,: ]'SKJ7\.!VA4*
M3(PU9?J/W$*M^:,QV5]P,B&#_B!JM2O0XZ?3EFLZ 8'#C(8;=KYA].C.H_7C
M>IRW?^10TY@2FP2>%,>2ERT@:BA4/ER\*?R%Z(8<ET23WMV5121\B5_..(O9
M\<FWHB5NM;,TPE<O6GX.003?KS^-G >^9>4Z"CE?F^\3BI4$4=/+1V[Q-XGS
M6RM3S9?[=5$W41M'(H>^!L0P_)QM_7:=*TZ18(WNTK4WA6,<JDPT=-$F"7I8
MJ=^?^50$S\H&*COUQ6L!Z(1KYARBR%VGE<;[>DBIS9EB@=':.O8__*[K;P^Z
MF];:D3?\J24<4>7;B V/BJ)O3TN2$1OY_._#E+ US,.]:H&DC364Y@;]M6/U
MC8D_R-YW/;J8APBZ85;:2DQ#>M3/US(F$ZX W] )YFS7%5=D#XW6(8* S425
M&O"OOKV:JCFO1E,AE5Z$)X.TKF F<!K W=@C)3M $8LJO@W6,6W@,EJ Z*GM
MIT#7:2!NK'/\%KOURS<>FPY!N8:X@QRLN+^%++I;D-*7:Y=JIZ;?UNFO "[7
MGGT6A2FO -2:WPZ08V9Z]@$M"^MGE_70S;]K!(C)KAV7VSSHMU,"XP#4#/B@
M@AKOA./GJHSTVP8Z#1P'<1Y_072:#MDE*]Q6P'5,IT+H3F$EV.3B>+VU*1]#
M\R*VZ^62XS/RH<6&D85HYX ?.JP?="G5@Q(I5%E"!)OQK9<S@VPE.]U1RRH$
M$J+G&\7#^]TL>PTB-FE#X$4_)'CF"D!VG]A5$7_FN>7/J>EXHQ'@QSF8^#;=
M&7=.531^4OI!<:%,M%8#!PFPST.9_$QGV^"[79S=.]=*AN.OT(#G4;G(5472
M8CF/Y8+5!;X1@HOU[C7N+Y '@D7HN2H[67Y0W&U;_?XL="TN3GVB*BV^SW;C
M8D[BX'('+LV&>*+?1I+O>9J!,-DZ#[LHC1Y^)7@1:B=Y+<8S;MVOWEM<.,H_
M@5+I2P_%+> \M4:D(99"R]YCU"Z.'%X^WQ*.F/*ZWF=H@C0RQ^T=@*V%+Q0G
M(^T7J4:^K!^5'@62CYVUUBF"50^S!Y 7!;_E*/V?D4/V'U['!RJZE*.W3SWH
M*N9)PM3<84XCA1EPD-;E=U@VFYG32'U=]+PGF0BQAEC AM:I&51/M[C;*3.Z
M7][&H_12U G%&Y\CS5-1._ (56"^%?]65.=E'!@[U]GK)3ZDX%4(PQS% @]2
M6YNGA(5\<(PRI\N7(=OW4!2,HAB\%51C]CCL#HNFKL+N<+T^@QNT3W:%!D_1
MJ]66[/0BWE[R"YX''#HY8SNG-5;6 6!9 (D4?]Q9S)/E[5X='>@YPK7U,*6N
MJ+L"6/L+H@5D5.M_]1L:_Y1K*L?.PO=+K)HO7K=,V^>:R!]MQ ('9T,HB93U
M+$2OZ9J$-E> 1[A=9P=3FERWHAV@[6/8Y*05H._#=9POGSU]<>K,^-JEP&Y_
MRBASJKX]2Y']APET=*QJHA06*AXVLLU]DC-L[&_BE8>K$A]#J),$]7WWP,/V
MU4O-6+!'A/7LN\W7<&3,BQW04GH*MR!-]6O[6^',<E#4O7@?LP&BZ5@Y:1*H
M>ISS1@TN9[!^*N8Q4N.0 ]?U/B-!@L"KSAJ7&9"WKXQV!KFV UC'5$>^U;I8
MH'/063%%@YC+(I"5)V"1450+/P&VT>MS?'*)H<&VGQ+BBL_C6.-F+>\MF[X]
MP#M.>!- *)NL?S,M*1$63OP,\C9Y;E[A_81(GQE/4)VS#<4M\9-;N/:K*$(=
M*XD['"W<:3%DHZE'@:]I:Y$'8)&7&6#R!I="%B7=XT,MNA/C.ZT1:1N:;?5Z
MAP\3*V3#*ZHUJ0,EB6,=FI_&*O'_U'8 I<9_RX1E<?I8>8LTEUM06/?#1K&]
M"CV=A:/H&&*,:9MWJ"^\UA 75+)KV?7^^(*T/V.U2ZE:A*T>)C4$^$R[Y9,R
MTW)O]V7@27--4//?EQ2U,2\:;]WYA)7A33%:U*JP.?0:O1K07NOFQ"Q?")UL
MM.Y+ M_=48W6>-00[3$ ')&H>%O)42C?/4.&5)?ZH;3C-1H8K>5@ ^<*JS;'
M8[5[%LI83 ^*WSK5I?U\LPED4]?^M/Q'!',J.7QICSI:'>@L)7%:;@KUKNG7
MULB)F-!$0_0\];M/F:0_#>2J][&/6XI3WA2LZU-M9\9MG=)=Z;-[ITY8M%YM
M9EKO-!0[>%>38<5$W!37#3.WZ3LN@I\G]@+A_>3T!<=]U\^4!??2;($9.=;1
MU@GI+IZ?^ 6*9TT-O]=?NN"X F_VSC/BA#[_M*47WEQ7:*#(.=7=;AL1=Z>R
M"H2OK-QX>P8 [.Z>O]?$$U^:%&=,9*BI;2LX+1K#+D&:M2 7\!JU54<1O:93
M+9B4>.?)5]_U\N4BQ3MBRT^P5*=MF>Q< 6\YT<!"2+9A;V%<$20 (PLJ,1Q-
M>QO*Q,?F6&NQ(?7BKYWI_>N/6DL],6I[8H5""<O]--7MO>?-)N;$NI;:QMBW
M7Q X,2*;RYH"MWZ-W/L0P^TNQZ/"&XRK3$@E#'&+=9T202=,!FF[6\PT&[%E
M>YKNB6NA@+75DB8A[:!3OLG;EEU]T'SG4OPJDBS<Z"U1RIO ^-P- FOR4><Z
M/#P;I8J('/Q.?^*HHO0L_^>KSW,S;T,!"IH!"D'K\T-[=<F^3/L$T0&BE'@I
MQ8\G_<<U]F'* SR?T@Z'/<L=Q%TGU5?K_7&6XIQ%^^XRYM#CY>##:(A#19^3
M8E'GLOYCP<:-A'SL%.N56N# 6L66 5/]<GV-TJK:/D^/M0;,S,TBS"=^0)L;
M&1TWFL'!4(A1/V+QSM6U0VEG-G72+8V"14$3A6#=)C:EV)O-_R@$PQ#*A!,O
M2#54[^+V[0L-)*_ICQ*-E/4SZ',I(<>Z/4U#=)M<3C6@4-<BB=OFF#>;K"]X
MINEB%&7([T6]DJ'S3S]X$OR==BDZ>'91P]D>R?9.^DC>52/J-NN0Z"*>-1/<
MZEL6P[-]N*(6%<T50)O2'H7]'HR2U$$=WRO<B9[$.'2=+S%4(X;L;B-$+"A#
M=&_=)"%2EL.\$7:7,?-/_YG@GQ^9BQ 1BMY[(PGLTMO0B<AW,1DVG2QR2SU%
M<@[,RPM$;^?AD@H'WLI@W'0[)C)49Z9\SK8E_)W$)"!ZMJ[.%=?Z\*?'INEX
M><8\D1:+FQ9ZGG-EK1^Q>K#8&[A<. DJSXL8KRB,<A\;^Y;WCD-0'ZR)!5_?
M?0H"UKU/:S9>V9!OC.NP_$F[B(=+2_R4\1,<P_Y<&E(@#<Q9OX_C;]TNF(#(
MM^9H*Y0CU8TA+HYS$_+!EWDJPOQL>Q_V)OU19%RTF@^X&+&5TNU(EX GJ:.!
MZ8WNE'5][=<RL)A"#LVG;/0:!?CU'Y-/+9@C&=M(S= GD[+#KH<D@3.XR?EG
M)ZHR8SNVPP8[-U1<WVFHU*4KT OJ%__:UE89WRBTOH3$40%VER!(.;B@A/6>
MG UY<1TYN-$G=/;ZN"Y/Z)W>()9SS8PR,E53/4LWQ5N.8 RZLM_#T%0W+?E5
M #B>]4Y<>=PXB -Y?9D28U%-S=!XJVDL/U4<AFG4+7D+ QL--S%<3KM^#KU7
M-0LEVQ%]R5+?EVL_P&3F3QWI?\1&R0.\(S)\:H82E3\5Q[<?&QA4A0Z^/,'5
M?\>GK/ F>BS#"P#]_^H:[SQ+L2L\Z1<)K&\E8?="70'>#2]<^G: /T^*Q(\%
M9R98U@BLVT N";;X+CWN&CJW[$#U( ,8DN<,B=1[GS3%KP"W#U.N ,(WJ7<B
MK5KV/BEA"Z&UW-RN\QTB2*N5XS7%Q> WDO(?TP*<UQ9(%QV", : N12=+K,2
M7)H*;_)IILMP(N*UL[4B1DF 7:&K]B]E&+-J^_VSH/K8&M1IY&.DTQP'F=C*
M;]:D2)Y^#]CGKL,L[ !@KTDP?1S<(2'<M$("W#I(J.*ZH@FT$BAP#DI@[-KR
M+SRSE2!NXWFQUG/.!IC#B9C#L8_RQ-E$?TAA8@Y'C!>-);Z8?+ 2'3%Z*[8
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M;G9]-?-EY[5EJYJS6!E)RTYL'SI*G/KWT!9BH@T9 (%_54(QN'F+_9Q^#S)
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M/][%F[%1;3W]WOQA\V?L<N>SUX/8BG]E6H8I6_!#>ID=9JXG,Z\!."KP&3N
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MB3,W:+F!M*T&QZN"V!<$>&Y]S)JRIM[@S!?1A%DI2W(U=9B:CEL25^/7W>/
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MYY>P+I^_OB-$<G].]H0#QL]'RRY1QO:YBQ]T_ +0^^H"(-QVJ?09U2YC2R\
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M*D\;(F(2F"=W0VN"G0;O=]"X<(K(7:7;H53+,C:N9C/;YEF<J[GLZ:B?MC0
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MTV9XLCCSU/W7,><9I9;S?@U) >_,Y( .!C]IZ-Z?#^:_<6DS/WZG49.:X[=
MA3"SG15")W!UR &=]#E1S%45H*I8D\ =6']Y.=K$?%X(5A&=6ILYAC$VJ IA
MR,:IX%^D5E2X9CU0A8^&M W1FJL6Y9/CW>-J&IS+^-<CYYN7;=?SBW12P3U3
MLV>)O#S-P.55L]6KK^ _17%Z6 =CO?]Z!7#W9<G,A"Z2-X]TP_=YYW@-JQ)5
MO)Y+$&;"=AFM:B?83V,EHG'L\'!.%WVI@> 7AQF_^J_?A7I6MC_KU^#R#&Q5
ME:YW=@]L8DS ^\Q%4ZM$4H9/5NBKOJ;A _0SRQ&B(#XRD+^?[ H,%3-+]CX&
MJ+YI7D8\"!HZ_3F.*_3@\N!U7V'])U]118 0M/1P3>_'WES_V0A/74UW&0-*
M!3,_WZ3>CR$XB>0,IK7Y./'C/%BLW9?#TF"5<D5G[%K:IB]._:O:R'L%^/C:
M^[G2C2O,F_]$\#$&V8R3+LM'3[E\W*XG3V8(6OS7]&;F04_7B\01R>F,;GE%
M&DJ<1<S.,Y;#.5P6[4OWLH_YK4X"T9DFA"F^<GR38S\@%MOLC.;\$?66D.1/
M&X^?M-H+:7)Z%?4Z+A@R >_GD:V#62C!]4=IJ>%KJ:9C@)<U$\)@D4NZ&D<P
M[VVP>4"E;=0F'VNX9@:<@+M"3[?_*)3P<_YY 65QY,D(E/46867ZR?)TZM-K
M37_<KB\WTY?N3/S,YF3PT&E,^GS5G?56C7;4@HE/7S$P?_+KP(,#7A5S3.GQ
M5N4H9@R@?GKK0_OQDS3S7J=PXF<K(+-*@AH&CA5%G=,/KEX*H)'LW5_^1XQS
M[J>@BQ??NBCOY<5/UA=1#?/:2'/HOE0GG^-#916'ULHRC,%1*]18/!SO/ZL0
MD1@/:"!4M?^A259#[7M4B=9LS*PAGDFZ?*L;8T-LP?B*[L':F>C#1=2*D^7A
M$^4"V25K"2)0 ,]KQ_66G2*B+Q^%G-1&*</RBG\.P"*B@2Y(5=32FOI=E"MM
M/"A=K<K?G_W!"HSS0-BB[W8^8:XEBO@G\?Q/._-]DC?N&@^FI&S%WZ^*Y690
M( NN  D%D7!0H.,A=@X933S>"WOERQ(-XV7\UZWL\RD80%_^THQ<7OG)0'[A
M?)-8(]EBK_ 'NBV BWEH7AES+-30D1^!G46TG\N6-K'@V#(Q/--<G515G \9
MYC/SXW@A9XM@4SR@M2D($G[[A2^[F,J$H@7VXP7[,R!GSG@+7<1+6;C%+!-V
MCTK(D)IF2"V0OLP%3WAHU*W[-Q:B1HRMKMIE'S)!H21GRYM,<P5P1E__Q6LP
MN(([F>'[PM?CR7QM'PO(S2.@JE8.UP+@(O^-*96H:>94D]3I"L# U'PV,E8]
M*2X_6R(^;U)]/9\1>:@D2AI6M.G@!GT,*5[?F;T5Q5PK1>O#9NN8$3 ?>:_V
MSJ_>U/0+5X-%]HZ/<838 IB7VJ6[A5"PCJU"X\\TV&&EDWFUG*5(@VT_TN[8
M!^2E\S77'I/#&%J0G4]#H"^^$%(X=?MZOKV:/D!=,UUY.>V5LI%-J,*L#7A+
MK0Z)K-:\7\56,&NCI7_AO]ZS-"=LJ7R/E89N)$(\\IP51+M=UM6Q#6J"(&T#
M<C<\8G763@,>[8Q/?6/8@]Q"-@"+%'(@,HSR]\QP>XV.XWS:@+D^S9=\9AWD
M%,XLY!?+ET:Y7<A%X?KGUS* 2LSXRQ>%&/8?RN5R+'GTEZW<?V&S0F@#3:U>
ME-'>XWF2#^FFPNQ5G&E)Q_[<<5XIWIV7.-F<I(GJKMIA+O(>8N3O[B[19%C3
M1"BZ[\Z>0JPZ SP$2+']4&Z:MR,\%R]-D^Y> 4+.KP!;($3)2(CF8++.5-F8
M)W8G1NYZ;GD0LOA5@? X!J5CQX &#;N?:R,Q ZE>HR4SHD'(?1.E&E<ZT4L$
M+>/?=!72.[7DMQ*Z+[E?A R9,?<,IU8G6ZQ:(^<0Q;U)0O";G\F=9.5FG98<
MDS&O4S0U1SW^=LI(]?6'KGO]\O_E9'$8_>]3Y;1D-[0&G6A)T9:NF8N3C1*S
MM0"**67.K[0Z1H**QD<Z!VE7@%EOCO+.=@^P=&4.OL23_"]"A'%H-?[/M_6E
MR*GK;#/P5UQP%2_EWE"=@06V)U-'SBM/(LB#!?B8$S/ED[-K8CVX._LM@R >
M/90KS)KO9'ZQ;DB0M)I)[S UIBCU/@A+[5A10R3T%"C9Z'9QB_-42X(YG9-*
MG\8<FCZ.]<4'4UA7":7LW>%Q"PXCB,/+LAT5WTYH?:O2_%1RJ-I LQ[B3P8:
M(V /HP"V6%EX?G?]$(Y$<68SWC(FSY!A>=+O W=[3L7U_&M1W50JX<\YPZ_
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MI]";G=/+_C/!MYZOA;O'3B *-66:S#.0$^)=(803B-*C?2C&'=&-EO%P?)[
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M\6]L?)'W2Y*?R-[]'APVHI7E#5VX LPP);E%:SR%F^<VVO"G<GY7P]H-[MT
M?M(:S6="0E7WN*R$94;A2,.J%W=V8NYH-Z/4>K;NL_%YD<$>OV>I]-JN>C0
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MGTU[+ERL".)CWU[6_1X<C,UI]_&:5"[S_%.6ET7OBQ.T^E@4$1U]E$C*M7!
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MT/WM2#?DE7:D+4=T(XJY*:JP>O."%1-\9'!7_M7GQC9CA7=.CC\G.@D;^>A
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M,\1!E%;V)MB,IY!O),7;1!\,DV?BUD<E%9P8I7D+L2ZE=&F(>N5JZGC0T:
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M/I'KTZJ,W-G6C!K&2 )7_2OQ&& RW-MM-SCQT"X'%OVF\I,^569EKG&&O:V
M<]C;IRC;VHYN?KJ:#4%*#=KO<N/JFFTYDF1#^B-3[2T37N'AG^ @B#-3N4@T
MNX>&3LN;.+P_[9EN^QC65:Q/DVMPB%*S6/-BE;60L#0]8=LP'70]MN&K*YC<
MOU08%E6;R&^8,DO5Y2B]5RZC/:B*.A'\C8XK=5J&EV^@1C+R=L-D<WBN^P:)
MZE\[^U<9JZ<)'M9>BW@+S>$(]QB/N=E%B:_R\9 23XPK#U>YY"8C3R,&X :^
M:5H+C,+ 7+^"MM)"!B/>'T0' !]D#U'CTH=UH='JGX%F=I8?O5D#_$J=Y"=
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M^^=2/Y";F'0N^_YSCI#[<P7Z1##^#YJ4_MFD5/'K8YMX^:IBJQ=/RMV+9-!
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MJOWHN9[F+T2K.!WVJCZDWE[#U\*ME*\SODA73?*,>' C3790A.HGW*X25PE
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M=EI10(N6'$GH+W2^8.<]61!?@UIU_8KV9$[B>DO]_)/$9JW_Q5B%TAW>AU\
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M"YFQ1<"TV_;"WU5E&IV\L<>^*C<3Z>DR/<UU)R;4[UC4*//8R%$JRH"46GR
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M>6A,\4W1?[Y9?SH6--S1U&.NFMU)<8T)>89*Z.)#@^AK:R\V,-E@$5,UUZ7
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M8@ N*;^<5Z_T*T17X^+)'_L9U0U_MAS^N9KH_P6!WCI R@FZG6*4]SR(-U4
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MAN%>6>'J]7:)L=96$8N>V?$ "80MAVF0H6W=<*R+_:*1<*/YX$ M96I7N(B
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M.5UUO5(8Z*'57D\C+JP82VM-;0?WL[3*2K7G+6</]H;A &=Z(VDB1XK["FW
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MG3[=3IW.7E="6HO-<SA*\GL7"]!6]L*A0@>TLKNB;^#48U%MPM.NTZ4\JS.
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M1I5GG3[J718AH^7S8#DBTYUB4;]5T5F^WK*Q86'-8$ZSNQG;/;[ST&V>ZJU
M*@LMV;*&VG0+$2/Y+;-L:-H:P3&;V#:AH%,E FT<0]0'[K\B<<P3S437XI"R
MX=JZJQM/X;A">8$%,F&5L5!>SE4TUCOJ;-M0^^"3N^ILF<.AS7='N_OJ_%(?
MP&!E$9X>QO)EV)//7;(9;"8,F>-J^J,^,5 NM/%=C0K:-:8S@.I&<:D^_=4G
M=G(OK45/KXO#FY+Z2>"B3G0NCV3J:_@Y+BG)$T_D%J5AW]8W2&Z0.20M;[[G
MU&C)YY474=?@F?%QN,F]56M#O\R5ESD]\RZ:S%HC:T7!6GU3QQRKY%V,MHZD
M%,R;KE^I6ZO$YM@0D2KA[;Q4L["?G4TU#._L8F"9/ ,$R(R_P@>%MPF3"KDZ
M:ATHB0DT"PR^/\$N>:_)\K)A<US9%]C;'+A!1E>2FGSA7.4:YRB<1#S[<=TS
MU;[?JSS@'[>[_SM(OSEL[B@7"='E*@$)=7V<ZCL"MB<'PLU5,;G5AR@R651T
M=K7:LO)$P0[2D>L0A3]Y[W<<<64*_R &TO^:(MS^'0-,L.1>AQ@?M7L>K72N
M+:3/$=?TC@H_C[R1*;UVL^91AKTZ5^"W'<3L/#]_CQ9X67 &>&KC3[_"A91%
MO3^))C<_I4Q8LO\M,F]27?8?%.<@/T/'%-Z,X-H;I;#&3_W%\7SR;23UFU[%
MV68I+I]"IFY\:T5Z L9B.VQ3D7Y :L>D$7U2F2M=02EF*(O,Z)]G,OK"A'!2
M\R:^F)**"#\88)Z;=MT5HO5?(OJB*[2F(.3]TQ#86+H!NJ9$0[U1*[GG2#0K
M.3!+2W4"VY[L;*[:O]([.BG"_&W+'[+W4!9D;74(J0[D.JRA<'X?5-NWK/QQ
M;@<9$[6LU+63M](K6RMT.G2S@/E^$KI>7*#@.@TZKC1G[_V?RI0K#_T/1);^
MK2++6,Y%RN!$(G B)_Z:R'6FCR_. +B\2;@D:#=.HN,A9%=_2K966.XO2LWZ
M]U+%L30&?=1%YU9PF+'E+1"=ILE['-X:_KT-]?]$PKO<47I5;G_ .',/J;VA
M3M0Y:0@-EJ1.FZXT;M>)O_K/<N  W*CS6-7C"7@V-;%3S!W1X'QL58YYI%'7
M9:Z;@+AS[9]V3N]_/N&S);%C2M58R2 _!A3HZ9A0:4QU=P8=93 Y)#^84#;^
MXQ22Q=N(8($Y_Y&$53V9A;Q!1\"KA%4E9:3V-BQ.LOC"J3*2[K<L1%-R"ST%
MBJJ:F@[<$3Q.?F]G7Q80$0:+ULC:]^Z6,CE!%L584[=^!;QP 8!Y[VX>.Z;X
MX8 R8@POB!T3'0=[N2C&Y*5-<!P'$Y9U?)8Q]G! @69+UL%3UDE^T-';L]J=
MZ\(N,+2 [S]Q6%0]?L8>[^.OIQ*K_2M%(L^+_(]JF?$S2SI[F,E"R<.!>S:\
M@O9XY9Z=: A8B-##(,==FSA/TP"$/G]BA]^J?\\6)]@D#C:TC?CW[;7PUYM8
MS>C42S_*CU<RA^2?Z=[V?P3YYL:.X=UV:X/HU0:NP%\\.7_97P:T/(AELM%=
M'Q?S0KP*6ZM\FB2S54;N7A[4'2S^"L5[!EA<$#A:TJL> GY>F3/HV==T>N\L
M(TG67<,'6PA\=I)W*O;908J77JH1KNS^R8]AF+" .BY@5D/JG=?%6BO%,3WL
MXR;K$AOC_L98,H #1$^,SVI(-4+%C[/K)EVQZ!G@RO)ANM6T:8]$#IDCB&JQ
M"V:*[)_LD^/0S,W3HEGFS3_)#;ZU7,FFU)+Y)$['B?Y#EY3MU+2)UWQMB,Z#
MIUA&P?0FF$3M?O(P815K,K4D46-!*71;T:V XW5?R%7IN *[;%H' L\&(-XK
ML/:H3Y2L/AW29IHF5*782=S?<6%!(R=#FS",U2*/XPN4@0F$7F@TO'@&D/:F
M=M-/E0IH9I[!5>MB @>=$JELC%13):'JUG)B*D>VX*[<0C/LUP4)FT'EP'>/
MS%<) /;DR2A<%V3]NR&V\JU/)3R2[6L ;5D'+EG[0M9?SUM9(D:T%Y9]?-QU
M!@@D[MQLC6$*GK],)*M8'GCK]5[J<\HI%2\).Y,,H3, /6"=/8M;R3K!>,E1
M=4:4VZ9Z4W?9HU:LF5_1.LG49Z_,J8ATJJ\!#F@!6R]/<XS623\/Q[I\(_30
M6:%?BTUGB9TUK5!2R"&3 K$-=2)\OF69B+A:8E'\KKFH!I'WD]:,&@ ML-?:
M[ FW,5.@(];\=3&,;BW;TQH),#2R]KS=G"@5[+#;M63 *R;]E9VQ]+0.;;PJ
M[G?+#LLMPD+'%BS*'<>F)+Q.(U=8:KZ":78?Z$Q_4"'=>7JSIN7)1[[[-UI'
M,I@]%!B_LT2'(F %17VGH=>KO]J?ZM\.HG9P5Q\1/? ^>A-\BZM4ZC'2H:2G
M':OQ52*7$89V>A;"T?_R-1#/'SX0Z-DE)E E^FJ9=A";N A%H1K#Z6S>#NP3
M(0%FN;4;NV5\HG8+&JVSQ3>C=E+3K(WCTIJU"4^ O04J7ZE8WV4E'P)XQAM4
MRZ#(9FV"4JZ_LKWQ+_ISBAV#8(.Y-/9+>9[C1A?=*^> 1<] ?G/MYE$=G[)4
M:LB8#SL0KVN9>4N$SP>;A()YK[?I>X)(M$8J<C!A_<5;/?Y+BQ%:^)V?:"V&
MB=*,5MC41CGVR-Q[VGG&4>N'GQH^KB$PPI^%OR(=-/)7FA_G#%C2TWIT@V&C
MHB<Z3M7B.7!QYM0+P3P/]N3%,9\"Z,*#A$R94@J-)HW>C"B4=N%Q0(,B4>F9
MJEQ0@CXC?.9"L)LQ:RR&P[4TAQ[PQ3N=UNV12W'Y$J.R@D,#UJ?UL1RJ[EY'
M2-(-:::4MGS[!FC6S;:V!(5P\V8'_AWCDD>V+L6E<:PT%T_U\%)FHR1$U^YH
MBE='[/?>LFZS/_A\"JX^T#OE'%FO [70L6A#;_;K37..\HO)TGS#?!7V4+AT
M!MCB. -,4JP:3E.B75Q%\42'RZJ)DG8J8LKMY.B.KLD'S+OTM"G.((6_:HY<
MPWI$ D3QHF9\KNU_$.K9*HG_SN/R>.72^@L9MKG0TW(?:J][(^M( ;M$?3RC
M/FIEO1$?X'A^>XVV6M8.:4=[&URM&"LK,UG%P&!@8_CJ&?6+N62Q9W[Y3JG?
MD!P.'3T7FN]69=A'.;_=#[G$%BQR3'$&8"EYM?KRU*X9_O9[=[I<NB6';K2(
M)/LN\MW%GSKDX!6&V%9.8/=)L"B1*DP1_?SO[REYZ>MC*0R??8-%CD845\%"
M##VQ/[ZOG@':#&%NX75.F7*WHO1LH"8ARZ;*<-1JC):R4X!EVN7>"G\,!0U,
MH:H[LDZ) !^TM*F2>Y#RLBE(SD+01G;5N(O%1(8EEE;/'_JL1*,T_1-$P4JR
MR]%)2F_?\XTEG1YMSNTE?UMD8=JB,G&D;T;5*KIQM0V<;JPK5J8)3(@VR#4T
M1HF#2$,S+#Z(E=HW#*^H>!2QI3!DQ.[@A09YVC37'_%%P9@%7256!WQAWXH1
M%!N7CD)93D"<(#+'O7F-;_;L2KT=2'DJ!]T5>C6PJP@_ /][#KG.5^T&*1NX
M:&A\ADH<IOX1 7?2V\YL7?VPN CRU#TAX(./J$U8.Q#-CT**]#9JTR8ZD,ZL
M5U2X;&S<)9ZCD01A6[2(\JD<$@:_!.;':OF[9L_\0*]\GV+96G".*^ +CPLL
M6HVU8EXR_&%/><=L8"BR/#?^]%L&M>RRS/U\(V,L%D7)X;(HP+X"TC(?<76M
M9&VM,QFX,EOM(RO2B6A69'S#/^;>PPRSON4CF37Y)H;#)ER/EGU9OU6^ &9F
M2!+YU2 1/(? ND@/H<'Y;TN#@W@6J?K-1N<20?KF-W/M0B@GSP Y#S#708]9
M+!.)-,>R6-V^&1\L:,I@^KH<[)OY/DQ"SP#:VOPTA;(\;M3VGDY7NME,:KQS
MR.6.F]I.)Z'2'G#,:/:1[SKV<;MB&>3 <>[ _)NPP(:?7<4#K=OIRD9/^V-Z
MX(3W#^HI95:*"C>/5USNJ]8V#(=U:O.\JWY"J[_FI-+4FB&J>FF*8A5:YR+G
MU :<5!)A51!2"/O>@D(0M CUL=6#1!1JG[]5#I^VC 1ZP;P!^F6N*5"DL7<.
MB=YOYF#_HK^-&(OSZ@#:Z1MZ^KR?_7,+67)_FR*G+["<BATO*Q*])%I6(!3!
M/(^O,LNG*,FG8I4@+]K,(8) M*2,.TT' 72E_E D87&BJ/*Z.+D&P'[$4 6)
M7ZKB;+R.P!I1!K\MN3D\C+^4ST&>3WP98!//A6>?W]OM*:3 $OWD4@Y!'O"S
M$-[\V&/1ER$,5QXG U Z-O?I@%1$.@0 OM_J>#XVI6E%G5CDD.'A1B?O@GS!
MW+]SQE^\<%1W P?*<DBW,7 *&'?$+P<!\56,]YAU%4B486XOTKIWAS"9"I>#
MN1T*[S*:*H^APZ%+'2=D -H+SVOJ-%P_JV5-<VN)B!.2P=I:KNUEN<L$:!,T
M@P34QJ_MO^\/:1C#O+!04L0U%@F8\TL _!;I5W9Y& !V&V]5Z0NYL(@BBP]+
MH#V>?6'DE0PBW0/TG/_PA9%[E]B?D-$1O00"4+]Y^7&<+- O@W[BNC!^[N3A
M_P+/<__/D+(CUYH"D/-HG%KMUG1QR<^_F*<^C_699F."?RD5SX#.>*QH>MX9
M0'T X 'C,5O%#+&K<3C21H?"VIG&.8V;UOA%(B8=JS>,IDDP+QM&.4+&:UNW
M=99:ZABM9L%*^C';V^0HO*)*+>^M%Q=J[IR;_7NA36+X#RGX-PNF/!5E>1;J
M A^<L@7(ON?K6)<H'X!)&U8@]SK>+QXDVX5D^N:UZ Z_#>>Z=Q/>]9TOB<=$
M_D6/\[/H(\Q\3=+,R.L9K:WR5Q>G@E,A-?'J1<7[.4J:.4GR$??O>3UWII+6
MK]Y#TN@]I3.["TIJ'(^ O)KA;)36%%G6/8@T_%0(S$Y%!_.OTNA>=W**V(Y%
MPM]A?'Y<5Q!PV58E%P0%SFP_DE&2LZ3K<G_,'&Y4IVOK'JT]MR610YXX:BYB
M7U[N(3Z8N6V *DM_F<,;1J+J'VHB*F0"GA5@ 3U4,O%>,UVHWUIN5CCB5QR4
MH,LA][1UN#MJ8MK*6Q0V!!O_WE[^04>L<.VU 6LMIOHEB8>#: /<)-9CNOS!
M+4N,K9!2;_J#BX'V= 4^Q0.VLVH!=Y(8,A(=L)C\K4]WR*HYRF(F"C9-J\)%
M2D*V;TN(Q7T9?WYZ:IRV!0DW8 MA_&:TE23K"P]D^6+U!Y=&Y[,RX6R:P]<*
M]/@%?"S+:G]_%X$,[#NJQKJU*- M(H%,J%_0UN#&;-F/M0WDS#/)QQT?C$VT
MHA:O8;LRWE\FF="^Z(4UPTXJ/^:(;[GU/FW9E"FSI&TA"\TV/QH-E7M9>8<S
MB=)P*E7:G8@M?S0W6V/8]8;)AG6CA39AX/#S]75K+_>]F8>T8C>?^?C2PPTC
M24M[-J[JK9ENV*1M"'>0?AF3HDE^I$^10-(=6J'<QIIXL-#W"K7S=>'6T,U*
MS3KT]&1=_9,K35ZQ1<N&IU)3 J@&XGM&PNYR=4W%FOPH[24*175R>97JYO8C
MXT@F>=[-4$Q#JWRQ.G^Z5NJ-%*\D3,'WV00RC")SF!XZY=6,X(L4B<D/S+"+
MAO09SV&EKX58[DW9U2QLDNZ=<B+$+RK&4]=VR?=<Z6><N^7!+6?8UU$^<'M0
M;>#"9^V[;$J2,E[88"F576[;3<8,#YO.7A+* _TXRBE3MNX$$(%UN.4$U"V4
MW6E)XWWIG<Y)I1GX_4BW#8(I#W;!VP<ROCFD1Y,I([IK0M.M@Y(3&KX7%M3B
MR$D*!K>O?2%PG^:,'1<MO!N"\,2;RA.;MD_8^+Y6[BS5\X0,7Z15MHQ.M'8O
MJ5X]BXSI>FO6X?KV^UZ]H-3I)JTKK8>^*,M0-GD%4.LP\AH),)Y4-"I)(0;V
MFP>H.A=TZ7B9:S*>(YSK[U<:_S]37AW0-X?X:N *O  '#O0Z?^HF75VE)/5&
M,)W=;4"9]],+@O[T@-E'?#-HK&Y4O+7GW*:I3T$RU*%>C&F1T=$[QIH6$J*9
M0TR#U:-IK<)^GL9'A#,23]]@.3[])@(?SPUFB_W$'MJ'/]_-DUF?0(;JOC=X
M6;(#2<]UH;@Z0G/4PE5NK/9CCS2AY;"_/H(+[\D-RH=!;Z/U#5$3;(W;*0IN
M!::YP=Q!=L8_3EV[/F4L4CL:)MI,K%S:!QYRX=,]DG6M_9$>9[*V9N"RL^1R
MWR$/0"5-W 0&>#%Q9RTX^5:'"TY;E)TRC9YVX93]A;Y8)9#&6N[#B]$Y54N.
MVH)"_P:0_E'@ Y2X*9XMMH!TU+_%<M3=C+56*E=DY] FE"T,N4#)SG &J/&'
M]B1GF0WDN15RGW#ED#Z4D7?=)]3N\O0*@5JA<^#S]_7QDGVI'\,!)0&6U$L0
M%@;OV0AG=OAD[Z#!-')$X<H=!P:\)W%M'^ VOD+*GO<!KG+CCG! I<]]:BQU
M@B+1F"Z-UE,8LGVDVI]4OYGK0EM!!M0>R@*X*4,,/U(/_Z'@CL?848;2)KQ]
M\'A"P<JZD>F;".PZN""-,JZQ56\G^F5R"0,3"J^3KVVPLG(# 6 YW0/5A0L!
M0;1+><")M:]1Z_P\L']SH/6OI9C_ [J$(+!.TCCB"1@! YAMM?SEWF7M0!2(
M/NI.Q]44M>&4VI[>?MZWD@V<)@M,D5WZ1S)"7.&>N*&5\S\SJ.3;D@K:YP:S
MGDO#R<>]%N?%GLO/#:; %7LNGRL''U>L,JXBN S_8,9=MKLE:#@7WLY_T_)]
MT-G'_P502P,$%     @ +VAD4HP?!]ZP2P$ + ," !8   !G,F<U8FYV=35O
M,C P,# P,#0N:G!G[+QG6%/?MB^\$ &EB@(B78IT4(H@+10! 9%.Z$B3$@'I
MH49%BJ%$0$"*@" =@DB3KG2E20V]A-X)-4!(+O]]]MYGGWWON?>_[_-^./=Y
MS\KS^[+6>N:<8\PYQ_B-L<8,88PP!US35--0 XB(B("G%S^ , FH %=(2<E(
M2:Z0D9%=O7J%G)*.BI*"@O+6]1LT=*Q,[&RL3"PL'-PBO!R<0EPL+'Q2_$)W
M[TE(2+#S/I"7%I,3$9<0^Z,1HJM7KU)24#)243&*W6:Y+?8O7X3O .T5XE6R
M#&(B3N 2+1$Q+1&A#6 ' "(2HK]<P%\OHDO$ETE(R:Y<):>X>*'J&G")B)CX
MTF5B$I++ER^>!E\\!R[3DER_?4^)](:>#1FG!YW8J[A/5[B4RW_0ZP_L<HO;
M>KZ^2LYPD_$6$\\=7CY^ 0G)^U+2#V14'JJJJ3_2T#0P-#(&FYB:V=D[/'-T
M<G;Q\O;Q]8/Z!X2^"0N/B'P+CT]XGYB4_"$E-3OG<VY>?D%AT=>*RJKJFF^U
M=2VM;>T=G5T_?PT.#8^,HL;&)^;1"XM+RRNK:^N8O?V#PZ-C[,GI'W(1 <1$
M?[O^EW+17LAUZ?)EXLMD?\A%=,GOCQ=H+Y/<OD=Z74F/S,;C!J?8JRMTRG&?
MRG]<Y1+7WZ6W]1P@9^"6F.?!_"':7R3[<X*]_K^2[.^"_;M<$P E,='%Y!'3
M B#@^)0O^R7Y?^/_%[@E%$6I(W@^K-^Y*I@XJ,"%]3,?[8MSD-OR92PT?E/0
M=8Q,T"4 [UQ1YQZP1<B*3CALS_@S 4"6G3L1KST9Z5+'B+9Z0E\Z1<D1 %?1
M"O=XC\Q2G]YCG<$FNPH"$#_8?'@ ^I!%D^]4)(,L=<@>TP@,%FLGI]8HNUN+
M/<]N];6)TJI-O0L;+7E)C+5]*>\+7V[@7XCA:O\M;J+UUF"GK3/.I.DN-M]A
M[MQ67F9!.V,^W3'@$<#^$? [ ">Z6+-6"C+$N&[FUT]E57=25&9,Q8[4YN&,
M=@_QH?<+]D[8=+N55X0567OI%ZMGV2HUJF@J?N9/J5![K%2^1'3?*C.HK \_
M&I3]P"*AS^? ]?OWY0,P#;H,+G,S+/_^X+W:.KT$.M?7(+;$_K5,-F_9C5SX
M<DN@I!WBWB(EV2(?\2A?T9'?Z&E8MJ6YYE?E!8'O&(N;D2&BJZ<\9^/F9OT%
M?1&47UB>'F\ILD6I^OLF8^K5&QJU(%LR*T^F7C#Y]J_!-^1,%P2M*9RN%DO6
M3[>LD',]%>^T2 4&$ZR'N(87AF(&)8=>/W12XMI8,_/9DXJ0<SR/6S!&[7"F
MKFG $F"]KZ&+I^!!,W#,P;E*B_7NN[Y21]=X\JYQN6 ^XOSLAM2%A>KT^"]5
MO\N0GZQ/7)FIFG_595[!J0W@K+:HJE?=%'^&]6D#OG1@$#J3T3GD>H7ISN+)
M[+::3-4+Z]TFH5 'G&R!T ,"8&;BVEFF"1Q.+,EI86ZVSMQHC!TRRO!.4A7Z
M=%OH'M9HAQ):\1ACB9CP7E.QBU 9T?9W;]\H(_^!IG 8/>A57O:BG1A%"3(2
M*[QA HZ*(9';6S:UD0DL!=S*:M)<G+DE.ELQLJJ[N:7GK2<,SJZW+%>XJ7*(
M-RPN$P#6YPS&#!-4A\-<>+..5N?S"Y47(&5;0-<EW&\^>EHS3?+[UA[W \FQ
MWT2J=+K_3T*OI_VVKU76=0'-UYCJ\<<SD3IKBG02YN/; ST]U#)/C:L\V,A&
MV?#;:-+')-HG.$A-UB4XWY\"<%#2+?@S;YCW[1B=RO=V9[;P\LK9$PK+8"=B
MES_9Q!^@;/67.D*-'].(NGG ATH,"  7+XZTN@#(AO/]*93T*N\YB<P]&B/Q
M"FUW'A4I)0#L1\T[NJ0C='J*)'\2MTZKAJN_Y#Q4Y/GB*;#YV(S';AC>@VI>
MF!$]WM!D/^0_R+K*EPT'_@P$D#GB/^RXX]+%HN%5ACZP$U)M_!:@92/>[\ 2
MSU)![=)K,-B\R$PSB/S+#)&XJN"5:JP/VPE 7%F\*ZBF>5ZLC@"\\=MB=]]/
M<X\[KD>-3D3@0MV:-Z(N=&,M$R1^8?:J>,]]8!N*-/T=S[W.:T[(5W"WCP@
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MK% 5E1?$LYN4X%G#<*0O6]AU0],B1*T>SD=4WA&G5L@49L0(4!)9S#3.L=-
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MMIDGMT!SDE4F?\V?_?DODR9U-3C8! %H-#>**H9UGI>=#1-5_0N?-DF?-!(
M-@RLV4R7 !3JY#[;F,7LW#P[S*4Y?7^J>_G]GQ2 _F]N;&0]I_A" V+NQTY$
M$V!<J,VIT:_\7%C7??9<B[^Z?6MF M"9FW_N[;YD:>39)$4 $%HZIZNSO[YY
MB1Z;$@#+)SW-Y\L@E$H4<N@'.V;##W]*  30&Y6[ZKB :0+0U/RK"<9/  (0
M_7OR#?WG$]:B/>L%V?#3A>5+M3"63MG5E"@>E9CO8#U#2=DMF5%14=U4Z4&E
M@;-1Z<C"00\WE,S=BO>":GK@&I5^W#U8CAER6OF:/3=N4XKF5[4/U8U'J*.F
MCSY4]:%)"P B5\:=S#GU,\QYR.UN20"BWF*[=#YMZS+%*X$ZXN.$*G]J>F>#
MI72ZG&FVO8],(_YKPQZ9CGCUK#4&T1SGD,>H2P[1]G<9OY=)?^A%T]#2^4D[
M?C\"4';SC6H+)KM;@YKM2]'/IP(R!!&_+9]BQ$XBW%C*%&J+VC7%8_@ZY^V?
MSLMXE?('.1V8@ZB=JY/0H JN]*<5!9)=T-;6+\Z8W.GL1/T7W:D[2'?AS87K
M%IKEGZ0OHR07(-^LE97C!:\R+_W8:/>U7=,[$C9U>O%4$'7:9N[6B]@5QB4'
M/([K\EJ\JZO3+#F,8MT]NJ,ML_;AQ=XED, FQ.*&.PU#CS@]/3P5X=7; ",
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M1<$Z =BC3#N?:/S[H7?9O]6#&A[\6X7H^W\[4">X ,,>5%Z$6S&XXB(DN(,
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MBN^EU$U]9?/C^-O]IR/Y[CY356U-1,R("9F&SC*41Q,V#E#PJ]I7]A-Y+^
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M@JQZW,U0WH_@GI1!N611W-YE[J8XJ8!S0X)HFY*QA^#1Q#R\;AM;T',VI"M
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M7=$KH>&RU.\7UDQ@Y&O;[:ZW/V5$Y+18*0FJL1\^5A@[[OU$#'A3:Q[KJN
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MT)O[JK97^53OL+0XZ;G.LMK4102*?,ET(79 9U.BT4JT%6\=::@6KBD]O%9
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MM7+>$6-]!#$L1]U,>?H/'ZM1#\R4E5+8 OVZ$*HQN8V5_1NF*<2-8J6%-Z!
MH@SY6);)53_Q,9:\?6RT@X!L63V4EGO@MRD=[-9T$QN9"-MB22?C^ZP^D>;
M<'DA&^#Z29]B'A'&K3@2ISCX1CT]OZ;O4^UM/R>#I.BV,ZCLMR13EU;L9'/"
M,U(*&JO-*\(7UBOT0:\7F)(1H5OSHI7A5I=[EL@D/?O\*W_9@JE]E>?Y#'('
M\)(T/R_?JJ=%4?G>E&5%R#O!.;'SG@X= U:5#^T2Y18KU;T(GD6JJ<PX5-<$
MPD&*'U"A50LK3Z#8@ 'VU_FH6@C<%5B%L*3X*DUG%J:"F-%:-8UYM<V3191^
MB&OJ%D.:V)=927TLS85^W%B'>].5H=M-=95):*[$+HJ;@/<1*TFKQ<MTM /J
M:>_8R &'/WL\J=K-:<SLFEC*AP[LQ8O<+F^_WP1LO?[!<.ETK**[T&@53AM"
MP+;( >NH=W;WTZXG\747$]@]4PWTZP:D1./&\\5BM;^7LGXN26Z1>52%%5*#
MW..'Y$U^57-8(+4A*<QHF&R#4@L*:]"*AE,F)-[K\DW)2K#>?&!*%5R9>M,N
M]I=(,1L?C0D-C\%VWVB !&RA01=+K8%IQ$MX524='FK%7+KD@%PP?;/%9OQS
M@,<6>$57NE<,N(='(<*S<2DL4W6<^<-Z#SXX_])GD#KI)Z_R]#"5(*0<5I7"
M?ZZPFBPZG/&]K-FR[!C 05H/QR2RORGF]<H8*]5VKN3ZZI%XGG:\G?1K<KQZ
MNZQC7J<)TU1SHDF>IV5@QHA52PS?AU8;PO7O+$CKP-#1[6IF"^;#PJ;@IU'+
MVS/:,<'\@=+&@P'21DE;WT1=>OO5+''6FB,'_&+=1>.<\=_%=OMCP4:C1*45
M;0N= G<%2/6N+*A]8DP9B3"BS)2<K%6PF;COA!L4[*@'6ARFD&M719P#F(.=
M3G1!P4Y([@A?C49@V9UU(;SN^M#:H8>FE)#Q4VQ-Z]W'/0#=_H,SR391/H]<
M$XX!>+V&W)J1V[P1;_4[@D!G=DN[ZV0[IV4?4]0#_$8Q-K?-$,^-0*UMO$B\
MV=OL25WO+@;PLR'IYT%(5V,](LPZ#M<76C\^80O]%20$_N723P#6SCD"SP$M
MIND48S"Q$IJM!&&.8$=U&Y*<C)IF&MSHA@*6]4NF[:&328_[;,-,VQN3"+AT
MI#LD)=-=:)8&($2JC4QC**%2Q15FK</O2MPRZF-:+.C])?J )=1[!/>NY#KY
MCZ/JJ^,I'XMDMLQ4_="02*KO=?KAF4_<+G/=^BG]30W@1VKR*,*?VY9P;82M
MK+ZT-B5+<W+A-<!ZPU3F78%BD8U[XH HFL/.^&SS&J%R(16XOSCBS[9VZ-C5
M2;6K;4."<BU683%7K1[F/P<,]R:/K2D4YK5FV7K0[2TB+[W^R:).KC)'H%S7
M$ SE',SMZLOM7+*7^=QWD$_@-4\8NK?/8T['&+1:P^)N?1V_>G$LD, Y[CEZ
M.(\:[)@GN7RIHB@+U)6)]6@[!5^!#-C>6O/P<.FDCWG&Z=3KN;)FHM\B"1SR
MA11.I'T/UJ4:?J7;1Y/GB*)J[?I^XZ5)H'12@' SVLTXRKQ5(B-OO2T75.QF
M1H?=CIR/M:Q([*XEX;HB@RF)WAP]!^RU")[.Z4?B-0<6,!VU.;C$9R K-ETZ
M)K'KL3PD*)N"I-?C38-;#DCE#'U\A]WT?ZOH7,RDSP$QZBMG2P2W)?^;_<4'
M6UK%)2PCLKTZ8P6>1P1YR=2CQ.,QN*]8DIC;LJVIIOVZFG>-H1@Z:Z%V:5X[
M@>ONIAL44RB,.,:E[H'0!JS<.']7'R$?"SX)[IGGPSYC^5!;0VC?+^C1B,O,
M?2QEJGWZU!-N9<YXE0*2/ND-1K$(N23]VL8WTJ1D6Y8P#/A#27$E_:;#DBW_
MXIP#V'6D&=:,/;4G[.#&Z-+:.4ZF"Q0>SKP0 QEM$NYBO=Z )T"C]=F7D4#:
MNIRW'<X)C,K[-O5S5QA!E]=C!6?T?N(+^^R1*8@.)MPV&906H8RSO5R#V=KG
M'U@$$'17]#&=V9[OVF!RBJ)S8&883^56@4"Z(?BUVKY,8.5CEB*E1J LL ^W
MSAG7DA@<ROL%F)MNI[GN_8RZ!=TDRS1^5.(Q+U!XO23P,!F9#.ZNK@$N:44T
MUIDZ>,>_!KV<567UFO-B!-,8V_?]&@>GN(%N5="W9>I$/=5[P\?M@BJ38;$=
M-,4%6U&<UH2H^@S[WQ]VX,):37Z;>:;>?&>M6F2]\Q',!/$Z?ZD].^0H8;,>
MC6"9LDE@&UP>5<XPK]%Q!DLXADM9NLTKT7:-#BKUPQ\S)VV^&,6SBWQ293?F
M09&-BK$5&4.:J*O8?\)'I,6!O];E-5*T/21H.- _U_GH"1<Q%2?:RODS7)VP
MCV'> 9">2L.L1-,Z_^*5*O!.P0G9(*&7((7J8RXD_.CQ=(2],5?%WD-_"C#_
M!0KOL7U?L*X;!U]\N<:C#8OJ."NI7*#?8E.R!W5=O;@PM)==.]+PVLV>XY;A
M3VUY%+07THB!YT+R5_4Z1.4X;(!C-2+IA7:B*(54SN%3P../5"YK!E)/GB\=
MVBVO!Z-[MEBBF0:$I:TF32I3BEYK<I)&LP@9I5+ONN65CW6;+YDZA"X4^EEK
M&8MMT8MW_C1[8)+:#CJ^CB3,$70'U+-6PDW6>Y%2Z,OH6?:ZVB'?!]4&>##'
M^QWA4/#'DDQ3(JH#[IPYVZWX,Q)AW3?H1NY^R8=__W>NY!R  N5/*YY->[,R
MI4-_]CB> TQ#"<'FC_7[ZNCP$<0O\& <NJJ[#W2U,J=1]ZU'?]22!R[#P_XG
M+J9[5<6$'/!1(5OE@>/! R+V-03NUUJ?UAVG"B9!&YI_WV'&"_W/)!37=TUY
MZ&>N!>N==NYU2GV\H3.B6JK+P#&G7^T+QL2N'O+Y.-?6?;:..9)W>8GE#98\
M6'6;P_3=?)Z8^SRS7]C8CT(5-GH)$$#Q40)^4"@/W!V,BUNV'NG@O2O_AB@T
ME!__RTWUW]Q4>_SO$Y>1T+-S0$G?.2 -ME^ ',.+Y.(2Z%\.7\JV>-FYU#2C
MYFIAUQ%OTVO,GDJGHFO3=7,Z54S?$5-(^$T:;+9SQE=W#@C61R.VB3; [ ZA
MTM8&3C;0 ,[SJVM3YQI_OA+W]@>>;Z3-2MA.^Q-P>V#18A<UO-[A7!DGH<*3
MT< ^>W77,?+CPTE;CTVED"N?P+G\9N4&\'N8?59NS$%'\GV0V%30H45_/VG/
M+9U4N;*$AU<K+BO(!)9TLK4S*2V2:L6J>6Z_G_>#?B<^R2L(ZM617AFSO)2<
ME/N!B+4I=B9_OIMK4.I1UE3''OZ;!L]WK:V//"3]%50TMOZ<4;;"G:SRP8?B
MKSJN:Y38RAD-+I8)=0*<'V)CJ=8,FJYAPC!CP9$!?M7/KP\I-;QNA$0,X17G
M01?7$Q,(MZOJFLMCG_3W!E4-Q"%=9@(>5IX#KLW@A8=OC^V?IE;)]MZR>/OH
M8?1+9Y^Q\C6)P/4ZM<J3:_=6F8F/>V,]"='66>S:**@&1_UX=5UJC_+R/I*\
MTGLYV9+U2\[DA#RAA.9RQ84/"Y-?['VI"Y1IY;RN/91T,D@E+[8(_?Y6E9[U
MU;=:]VUUR+>1BM4#>][U%O-:J==7]GN\!$/=BE717\M7C4I2I0[9%'R\7IK,
MW=(0ZZL$J&&]NRX?G .H9GCSDE0C(Q1-+N@VB9B"417&HC#E%V\DV2ZJLBK<
MYZ-H/ZE"S$=3K^G/3E3?6.N^;_!.6UFZ$\\WV,2.,]HS&=AR=&T^OCQQD^/%
M.8"67&,TX&&Q#'<RA,=^J%4B[*EL&H4^4B/;PI/59\*?8\;\<8[IQ(2)@F%0
MZ;?([]13WF./+;$Z$^.<3;D9,Q3C8[:ZST/8IZZ.8QPJY_W\#Y<WM"NCQE3!
MZVROCON&5]90 >+1H3S5L[?P&EYO27Y%/*'&@Q_9;31Q&_SPFF/1RJ&HHS=Z
MRN%QL>9,N^\YACS:H?)44EQ@?Y)@K72"$%_8+SH'@'#;>VUPAIJJP?W)L.(6
MVIH$K0"ZFL6K@,E!\&+HHS.GN)/1E1;5IY68ZWDFOMN]ZM).!G7"#N> 2X9
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MP(^EX!3E:W Q>5,;,[=C>F!-DSZO7])$FSU8,^W(Q$RV)HY2.20\X9[<E7A
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M]0Z[L@CJW9Z=4!1G>61]HN/.RCA0T?EH8ER>VCOB'& TDI%:D5+KL"EH3>D
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MVNQW3]/DW"_F$6L176ZF@?+K0R,+%!?;>,XHK7X&?=I6O/XN5HJ.S#3/DS5
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MESOZY<*L#>[$"#H0"*P,8PWC'2V#%]1"F53?\]4QQXR\*P@JT<*6F-O6%NO
M/QY(*(=]\07M7-AH-RB? JI'L;WOB3%*)4ILS[C&N0]-J*Z,,!H((8T+ K[(
M1[G5G:15L9BS'8-M_"XOA^TV@,,'F==KO%V=VM4Y(Y3*%4<%0/8&/=QP4U_[
M(RUX<(G"@IQFAQ8<Q;=$V8;)00I4ASA/)+P)#P\4?M(%\+_UKE22LQ0U^*U$
M&!FOS1OT2!8H8YOSO)QMKW#UWMLQ)DD%+G75[-H,0LSR0OMT8,+(E!Q1)C.?
MB$AIOR'2K3,1WO?(%6,@/$/7ESKTQBUUEJN8,#([L]A4WEN5<CD9UD&7IJ(?
MUDO*)ZAD:EN]T+ +=[R*E0I7:+PNF#!OT[#:,W!F'QGRO#0W<Z+TNF! >+(W
M4U5V8T<SFZV@2[:M]XUJ^17F:B?,I(]5R8="ZR[-ZL.X/LXS: +API+@$B56
MECK7MSK%U=EH^4C*I008E8%"W):WKU-QF4Y.K%+^AQU_^09BP33:#^G&1@E=
M(]6XP788>_1W^'ZT;G;CL1$FR^8AD^%%O65YC2ZG]S2,V06H@O8'5<<(*S>'
MZCWP+)'2.9P &:&^;%J7K%QDYLKF6)58,2A]1SV<RY??#G[K:U)7=WI53TU[
MFM,-*B[$K$$<KC*A$\RA@XJW54@&28]UC!1PZTO@%[!NGAA3/]C^1BCQN&[T
MJSPLSU4W L'AO!1;(5B@)<#43^5*\1L2[_XAEI:!Z9]2,D[^FX,4,K*4L;VQ
M[-ML@]O%2>/%D=?*/U:Q=5/HV*N(N^&9,@.;%P!9E?&?1NRG:''DJ,6Y&^-:
M=W*E0OB$,LNMAK86*IN2+[[BN/'^; 8"=KD-\9G%?HR GZ3[T[K-T=_MFGO4
MFY":]!2F]2?"<C+I#4W]>#6@-NK+;W5'_J6#_+-T$,IXI*J<:].%]:6HBS(E
M:*:P\7(^3$7)ZRWX?O?\B=7 %_</R/H[E4WP!^TK';K?="SYPU'I107ZF,1C
M%5UWW7-O6A-Z!&#("S4Y&S4OC=?>5?3F0 -H3"2@T%;PY?TM4YFH/0V;]K*N
MLX+ONVR'QYNI;*X?Z7Z<L'=VN,KW+(,)'.]SK=TL@2FIQJT@!ME&&NKIKQ.?
MWOQXL*W)]%B]S:FS/XD+)X]S6\;QQU>!&0[YZ)D48YZE)[TO@9&@M0L\@S;S
MF!4$(< M5TJA]C1&'^"5LI)S"KU^N93T9WDUE9/S(F*W*[GA"H:$5%/KWM<\
M5115B3<?CS"]&# E<'?:,%%!-%A68*+-'5K<Q> YNP+#LCN:G1%<DJU;'A56
MKR_.C([4P2XVOO,\5O6J6!;H-)2LO8O:+]$.4H=.A5\U"%)^U93H:H?5K(M=
M:(\Q3&B5S].QBG(R"<G"J"@&2 ??KHJ2O:L\\#$S7=Y3H!NK/<1J@QQ_&%'Y
MT#Z.(*NX7KV#QJXROB)]1,E*;HJNB)J:FJ9TB2C^R9".MP.49C0GK' #_6D9
MS27)Q=\)MP>TJX![^5-))FUVK'#BG/XY1Y,9X75?L?<3/0"A+*]Y":M5O0D[
M,C"HMT?1&\:4Y+IKK'7]J@4R%5&=DP$WPV A5YB'F<.K!B8UY)W]H(-8*D>2
M^2OM?&UT7<VF,:^NSE=Y\SR[FHOQLPOC^U@&P*IZF604MP0WFG/MO^&GSGM)
ML:KF#"*ZU*N[P( 6*EN@'GI5/;HOP82TN&J(,;Y&'7MWSE]'@U#=-@>%1,#%
M@45&K'.1-62]63ONU0*G  *6]79STIMGU#4[\,W/&F$>?Z.YH/F]\EPB*)BT
M:/]Q8Z_G&&*"E0JARBNNM""H,L&9Y$677BO2X0T)%^?)ZT>LA1ETD;?7R<L!
M<,(;)E8NUW.^1%,*],I_(E%.?:*3'E]1AE7U,U41U$MPOK=+(L9+N-OAJE=@
MD/= +>Y S9N2;21/6-<$E4'D=HEIG-NNYS9K] UO>G0IE]JP(]9_(OK@<:T.
M.-*]A1@K(9"JO>[!&\^7/T8BYM;O'()3#@2C,1DC9?SA[3I/-N]EL03G%HRG
MAR =2=9>>BHK+E1%&E!T/\EQET*70;[L@*>]7P\R*L-6=5=-N$X!,;9[)VW8
MD@'<U;..Z(<MGC-E8'XC5TOVA^LN_-65YO3VDCIVGC&-P'PH'.:UHEH8,J<A
M LHH4%X6MURXV"A=P-(HZB)'>Z>]W3\-)(C6&^SB/AJ[/WQICTVBP]YSTGCX
MJVONZ+ZA)[:QI/'%ZTXQB+&H\K6"G,2T?04&Y8$G1<71\556JJC,#(S"(@V.
M'[L1&H=3?C6/QHQ/85G=1)F[+\Z6*0$CG6)A/5HIN!;:[(SC#D>9]5- PS!:
M8MP?>0("XUE<C(_F=X:"YT"JUCRSIGE6&_.[/+;@[_B*HTOEUX&T:(G>#()]
M<?7WM*K5<"1SU)9'9X#[O,&V)!/&1TV5>.OE3"Y?QVB?1B;^(M-,-\'M*J'I
M:+_ 9W?<%[$(D4.6 \$O-K4ZY\81V@=M#V-A1$=$8R4JY#1="(6!H1(987T9
M4W)!?UI3,0Q,I\KW96/1/G49O_2;<*T=SYJ45_R\3),7FNC>U]/70P*_WJZ-
MMDLD\!S4X U#B.,Y']/(*6!2 >=V)7D%SD:E12H3:'5BZXTK)ZT.S?RL;@DE
M48OY0BE%MF*BBSJ6"S#=.??.U'_GD2G_N9.%=/06;62RZ=K>C'!WS$4LM(US
M6X#G#"9*9JCZS'0;O>@D]_FZD=1')\MN"R-!!BZQ!U=73210$Z_G&&.70=:(
MA*LOS37JL"49&/.BW@2#M"+FXGO&$E&7BDUN8T)Y7MP]!;S1GU:ZUBRT_8%U
MMRP#,1B<]W;8H:!.-=:X2(/:E?X4$&F4P_% @7:F)BO5DO93%0<=2U$KYG$G
M%ZSS=5-?CJ+^!PGHL+@3PN\.QF 9"?)$QH[<6M>4&I!P,G%ZXNA+@SQ(,^^.
MDH$P!1M,[Y"U@R)A\@D# [V*+[/VIM[(@XGFJD0K2BZ-^F\'4]AJ%LB[KO/X
M:/J3P[IM'0_(=LM@[3N7&J',"CD?*7!<QF2MEN 9\FKAB[!X,\\ G,+@L9?I
M"5%E]/'L"<D2;H5,>WJ_GT!]!'XK#&3MT5F[YTXZ;X0N T)2/M1?KIV,N)VA
M"9F5W^W+6#*)$[S/=V;2IL/W%%"0X@.DVIZ\=9LE<>6R\,9<XRR%,41$J45N
M;']G5.<5$W4Y9*AIP92RX,7(588 J;?[+P].0,TH5FS<FF3L*8 #*>Y6NF80
MJ/$A9Z;P.;CE%O<%'PCT"\U5'+"OZEE7,MF2L?"KA.N"D56?EML$=YP;R_-7
MDCU!J@':.Q*50J#Z.U.@#6-(ARK?P$?]'GM'>M4:PD?/TOU*"!&#V,@W?M B
M3 ,N?W#M!&K[+G'R87E>!+L,6#.ENH;35Q"%#AH,CMQJO\095Y$UE_F%((K?
MR#CBDM4.]0>RWIC9=V42H)%F:EAWW/>BB1;X@U,R8'X*B,T2.O%K09<6J:E5
M6<R[& Q%6 _9N(NJAR5++(U]JQF2WY6C-Z1F&[CL,O*&$W?#U/ 3S,I6,&;0
MOL9&]9D:F+MJ&C/?+HH+N$7WX&%"K]QBI<7"ISU](=JNYVACYCXWDCLFFTN4
M=SI:.'28/U,7M26YULB4='#LNJ[T'LT_-D"1-%-G:/+9# TZ>DM_=&1_*.>M
MZ@EKV^)#KG0\7YX5=]^Y+G;2 *F%7#<[3SLMEE;G.ENX#B_4E*-L]?A##;#_
MB5$4*&8[OXY?5>]W(-.?C)^F*@FPAO*DW<."X[Y#_,O&*^G_R$D+N/;D@M(F
MZ%,S'49[4V]^.M$):4/8G>O*6-7C"T:50$7#/L^R'W.RBI\"KFZ9(,,*_U;$
M"% .Y.N8.;ASF#X'"6SY6K!+\$N HUUZ\-O*O^/^VB1&?Y?A_J^<(_\HYTC9
M/ *"C9+%-<T?0:[^$&U0GMD).^L?,O 0?]&YN>Z#W["FM_T\]?2R$' ZW8S!
MYE%DNDE*A@C<@".'7>XG%WPW')Y5^>Q&383"-1*.J.>Y-^[<B B82 A+F=>"
MVY-88UDSVSRY%T9OZH_7$-)T2S9!E9='YG8)SK>K,%L55ZG+::>F-%AP/ E[
M)\\L288Z:6RV,]"YB,L$[A3=0C6'7LZLV5D;@H]4[[ -2*/AWAQI!M%>X$;E
M2(%*R"S? _/TVV$ZER/NZ!R46J(\0F(=15P+SR4-; )WX+T<YB(*"'?ZHE;3
M:W61K('[- YR;6LO:4)N'@[NE1A$A>:OKX;"K!A:"SZ3I7.<4)SD;J?-/=O,
M>EQ:!9IZ,+U6'0JU(FH[ZS=F\KS0Q--0=HQUKVS_DV7<\<?+4),P96>UM?7+
MJ;1+4%E>K%BNTB-.DU8FN\OW?!<$!--R/]E<J12\WN-(1Q^OMEPV+)N:7/&P
MZ(-87I'>@>J[,?/=KUPC%OMF^F\PX+:)W=!'(YD*A"( O*QRT%352=6-,^-X
M$M>@:)N=O:5[1L%,WQ05OIHQ??84<"P*K+HPQ[(B@MXPV->*6&)XO72QS\T9
ME&+M\,6:F^G:O3:2@JQB ZN0?3BM$O-HZ:,:FPOT^5Z4>7)$SBKQ$F=:N?8$
MBI(*/7V4QHTDT!':;[;?CSEA#&7#+CR7$#P?BMM]Z@7W9B^N4.YY9\PFY$'I
M KX_M-\/A'WS2W4_QGW[N*<!)%X-T1!:40O9DJM)\AKP\YYHHO!1^MS0I+")
ML"BMO!Q F58.ZVXJQ.L+#:> U=N5MF(OF.IK8B]!7)W9]1@S1\(KX^CCD<-(
M,.F-L)5V+HIN!AH1[?D DW*J0'$P"<[7VXB8363VS"F 5A74*LH=[O8MA4Z;
MOK;3(\XP?C*\P\<@=6Q&<:'53")>TB!4D#=;_D5[+]'5Y\WC\?8(X\L#7[?<
MC^QX!V,](E8R.JO9RN1$Y/3YW[;R>5ASQ.-B"M9MKW^;$'F*0Y54:JD6N J^
MBD\*MT=PG1W0Y&I./.=P6?K[1[ #QO*_E9?ZHEU8P-YKT#.K&?@(3FG>A95=
M>"Q:62U:%F1UUTG$J'ES81*N-X8U1>QD?GZP.JT^E5L7D?.6GN3(Q:2@" -5
MFJ!SV\IN\(XB6]-_ZRN)FN5FX!1A+%/U?M)A]DH7.=X@0<:=3WYM<8OYZV=;
M%^ EU[58NI))ZL@7Q%\[W$<]M65J&X^-IBUXG!K<]U)7]N J4&O[FP\>1FI2
M99[-*Q/]E*13O*Z@DE9Y9[A 23NAFJBW!3416=2_/+<VU,]Z\)IV//M-1!Z5
M9P/=WP[IQVB,W#[XG4#!-SM&V2O*#[_$Z''>516Z_^S+N\HHZMQS?&5/7""K
M^>NJ)8+M^(V:&Q$.)+;VMN^NK1@U"S8;GA3!N9EK#=_]_)!MC'.AEOC 8R6L
M18YQQ'[/>)92F&UWZD&)68&!C7LXU/SLA[.Q,CQ2Z@:YXCS9Q'O^=U?]QQ[4
M)::N3,*APS)%=V?4G[A^&5&UD\.K#YK4!9$6$1&49@_ZOY23-J;,*-9P>@V"
M%PS'-&GCHELWKQ5<\E7BJTH+*LN@BK<Y>R\]C*.?0J=ZIH&=.?XEGO4%_TO'
MY97K8SS.::\G/K*.E;IYCE##J=^;YYM?(O9PYA0PGX6C7#=SH91)#N$:!%$F
MU*.-U:"^T:^MRPM:*C9;5@;F<2=DJ)QCR3Z<[]8IX.O0*8!H%3=IVH,72>]%
M3@%O,_9P0)3Z?]D>7#6YZP]&$1S3G + B%/ N</@L".?7S?Y\5UC&.O"*0
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M N?VG(:<4-X)G"V3HXL$IXV9Q>H>J :=.T8GNJY%222=>H$M;3A&;F#9R&T
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M17';2JGUS86W[@+-!AT&XZ0^1@F'&>>5=&LR^E< 0KIVNJ.110PZ5 QAB@K
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MVJ;O&S'7'.<S*/A;$[6-A:JNF?JI3J3.>=HXUJ;\U%[6F:DJ#2#[L5+VP&A
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M1B:$+@VAE9U.IYX*1JZSE'KN8FG(6 QEN]^YP'E 7 JV6DXN?EM5XZ)B["=
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M^KS_3XVKZ?\'4$L! A0#%     @ +VAD4HK!*W!)$0, U.\I !4
M     ( !     &-B:6\M,3!K7S(P,C Q,C,Q+FAT;5!+ 0(4 Q0    ( "]H
M9%(A>P8^;A4  -?R   1              "  7P1 P!C8FEO+3(P,C Q,C,Q
M+GAS9%!+ 0(4 Q0    ( "]H9%(1&KWJ1 T  *^U   5              "
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M#P0 8V)I;RUE>#$P.%\S.#,N:'1M4$L! A0#%     @ +VAD4MDMZ,QB P
M^@X  !$              ( !P#0$ &-B:6\M97@R,S%?,3 N:'1M4$L! A0#
M%     @ +VAD4K4&.!^="   (D4  !               ( !43@$ &-B:6\M
M97@S,3%?.2YH=&U02P$"% ,4    "  O:&12>ZX.L)$(  "71   $@
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M"0!G,F<U8FYV=35O,C P,# P,#0N:G!G4$L%!@     0 !  &@0  &"/"@
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
